"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT05166161","A Long-Term Safety Study of PTC923 in Participants With Phenylketonuria",,"Not yet recruiting","No Results Available","Phenylketonuria","Drug: PTC923","Number of Treatment-Emergent Adverse Events (TEAEs)|Change From Baseline in Dietary Phe/Protein Consumption at Week 26, Measured During Phe Tolerance Assessment Period|Change From Baseline in Quality of Life (QOL) Using Phenylketonuria-Quality of Life (PKU-QOL) Questionnaire at Months 8, 14, 20, 26, 32, and 38|Change From Baseline in QOL Using the European Quality of Life - 5 Dimensions (EQ-5D) at Months 8, 14, 20, 26, 32, and 38","PTC Therapeutics","All","Child, Adult, Older Adult","Phase 3","200","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PTC923-MD-004-PKU|2021-000497-28","January 28, 2022","February 7, 2025","February 7, 2025","December 21, 2021",,"December 21, 2021","University of Colorado and the Children's Hospital CO, Aurora, Colorado, United States|UF College of Medicine, Department of Pediatrics Division of Genetics and Metabolism, Gainesville, Florida, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|Boston Children's Hospital, Boston, Massachusetts, United States|Icahn School of Medicine at Mount Sinai (ISMMS), New York, New York, United States|UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|Children's Medical Center Dallas, Dallas, Texas, United States|University of Texas Health Science Center of Texas, Houston, Texas, United States|University of Utah, Division of Medical Genetics (pediatric and adult clinic), Salt Lake City, Utah, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Children's Hospital at Westmead, Westmead, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|PARC Clinical Research, Adelaide, South Australia, Australia|Hospital Presidente Vargas, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital de clinicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo, Ribeirão Preto, São Paulo, Brazil|Metabolics and Genetics in Calgary (MAGIC) Clinic, Ltd., Calgary, Alberta, Canada|The Hospital for Sick Children University of Toronto Adult Clinic: The Fred A Litwin Family Centre in Genetic Medicine University Health Network & Mt. Sinai Hospital, Toronto, Ontario, Canada|Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark|Bretonneau Hospital - CHRU de Tours, Tours, Centre-Val De Loire, France|CHRU de Tours- Hôpital Pédiatrique de Clocheville, Tours, Centre-Val De Loire, France|Pediatric Surgery Center, Tbilisi, Georgia|University Children's Hospital Hamburg Eppendorf (Kinder-UKE), Hamburg, Germany|Universitätsklinikum Münster, Münster, Germany|Policlinico Umberto I, Rome, Lazio, Italy|Division of Inherited Metabolic Diseases, Azienda Ospedaliera-Università Padova, Padua, Veneto, Italy|PanAmerican Clinical Research, Guadalajara, Jalisco, Mexico|Grupo Médico Camino SC, Benito Juarez, Mexico City, Mexico|UMCG Beatrix Children's Hospital, Groningen, Netherlands|Centro Hospitalar Universitário Do Porto, Epe, Porto, Douro Litoral, Portugal|CENTRO HOSPITALAR UNIVERSITÁRIO LISBOA NORTE Hospital de Santa Maria,, Lisboa, Estremadura, Portugal|CENTRO HOSPITALAR UNIVERSITÁRIO LISBOA NORTE Hospital de Santa Maria, Lisboa, Estremadura, Portugal|Hospital Sant Joan de Déu, Barcelona, Esplugues De Llobregat, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hacettepe University Medical Faculty, Altındağ, Ankara, Turkey|Gazi University Medical Faculty, Yenimahalle, Ankara, Turkey|Istanbul University, Fatih, Istanbul, Turkey|Ege University Faculty of Medicine Children Hospital, Bornova, Izmir, Turkey|Cukurova Üniversity Balcali Hospital Health Application and Research Center, Adana, Turkey|Birmingham Children's Hospital NHS Foundation Trust, Birmingham, United Kingdom|Great Ormond Street Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT05166161"
2,"NCT05099640","A Study of PTC923 in Participants With Phenylketonuria",,"Recruiting","No Results Available","Phenylketonuria","Drug: PTC923|Drug: Placebo","Change From Baseline in Phe Levels at Part 2 Weeks 5 and 6|Percentage of Participants With Baseline Phe Levels ≥600 micromoles (μmol)/liter (L) who Achieved Phe Levels <600 μmol/L at the End of the Double-Blind Treatment Period|Change From Baseline in Mean Blood Phe Levels at Each PTC923 Dose Level (Average of the Each 2-Week Period in Part 2)","PTC Therapeutics","All","Child, Adult, Older Adult","Phase 3","178","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PTC923-MD-003-PKU|2021-000474-29","September 30, 2021","February 9, 2023","February 9, 2023","October 29, 2021",,"October 29, 2021","University of Colorado and the Children's Hospital CO, Aurora, Colorado, United States|UF College of Medicine, Department of Pediatrics Division of Genetics and Metabolism, Gainesville, Florida, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|Boston Children's Hospital, Boston, Massachusetts, United States|Icahn School of Medicine at Mount Sinai (ISMMS), New York, New York, United States|UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|Children's Medical Center Dallas, Dallas, Texas, United States|University of Texas Health Science Center of Texas, Houston, Texas, United States|University of Utah, Division of Medical Genetics (pediatric and adult clinic), Salt Lake City, Utah, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Children's Hospital at Westmead, Westmead, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|PARC Clinical Research, Adelaide, South Australia, Australia|Hospital Presidente Vargas, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital de clinicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo, Ribeirão Preto, São Paulo, Brazil|Metabolics and Genetics in Calgary (MAGIC) Clinic, Ltd., Calgary, Alberta, Canada|The Hospital for Sick Children University of Toronto, Adult Clinic: The Fred A Litwin Family Centre in Genetic Medicine University Health Network & Mt. Sinai Hospital, Toronto, Ontario, Canada|Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark|Bretonneau Hospital - CHRU de Tours, Tours, Centre-Val De Loire, France|CHRU de Tours- Hôpital Pédiatrique de Clocheville, Tours, Centre-Val De Loire, France|Pediatric Surgery Center, Tbilisi, Georgia|University Children's Hospital Hamburg Eppendorf (Kinder-UKE), Hamburg, Germany|Universitätsklinikum Münster, Münster, Germany|Policlinico Umberto I, Rome, Lazio, Italy|Division of Inherited Metabolic Diseases, Azienda Ospedaliera-Università Padova, Padua, Veneto, Italy|PanAmerican Clinical Research, Guadalajara, Jalisco, Mexico|Grupo Médico Camino SC, Benito Juarez, Mexico City, Mexico|UMCG Beatrix Children's Hospital, Groningen, Netherlands|Centro Hospitalar Universitário Do Porto, Epe, Porto, Douro Litoral, Portugal|CENTRO HOSPITALAR UNIVERSITÁRIO LISBOA NORTE Hospital de Santa Maria,, Lisboa, Estremadura, Portugal|CENTRO HOSPITALAR UNIVERSITÁRIO LISBOA NORTE Hospital de Santa Maria, Lisboa, Estremadura, Portugal|Hospital Sant Joan de Déu, Barcelona, Esplugues De Llobregat, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hacettepe University Medical Faculty, Altındağ, Ankara, Turkey|Gazi University Medical Faculty, Yenimahalle, Ankara, Turkey|Istanbul University, Fatih, Istanbul, Turkey|Ege University Faculty of Medicine Children Hospital, Bornova, Izmir, Turkey|Cukurova Üniversity Balcali Hospital Health Application and Research Center, Adana, Turkey|Birmingham Children's Hospital NHS Foundation Trust, Birmingham, United Kingdom|Great Ormond Street Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT05099640"
3,"NCT03761069","Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias",,"Recruiting","No Results Available","Leukemia, Myeloid, Acute|AML","Drug: PTC299","Number of Participants Who Discontinued Study Drug Due to Adverse Event (AE)|Time to Maximum Plasma Concentration (Tmax) of both PTC299 and O-desmethyl PTC299 when PTC299 is Given as Tablet with Food|Maximum Plasma Concentration (Cmax) of both PTC299 and O-desmethyl PTC299 when PTC299 is Given as Tablet with Food|Area Under the Concentration-Time Curve (AUC) of both PTC299 and O-desmethyl PTC299 when PTC299 is Given as Tablet with Food|Half-life (t1/2) of both PTC299 and O-desmethyl PTC299 when PTC299 is Given as Tablet with Food|Estimate t1/2 of of both PTC299 and O-desmethyl PTC299 During 14-Day Washout Period|Apparent Clearance (CL/F) of both PTC299 and O-desmethyl PTC299 when PTC299 is Given as Tablet with Food|Apparent Volume of Distribution (Vz/F) of both PTC299 and O-desmethyl PTC299 when PTC299 is Given as Tablet with Food|Accumulation Ratio (R) of both PTC299 and O-desmethyl PTC299 when PTC299 is Given as Tablet with Food|Percentage of Participants Achieving Response Rate/Overall Response Rate Utilizing International Working Group (IWG) Response Criteria for AML","PTC Therapeutics","All","18 Years and older   (Adult, Older Adult)","Phase 1","39","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PTC299-HEM-001-LEU","October 29, 2018","April 30, 2022","May 31, 2022","December 3, 2018",,"December 9, 2021","Rocky Mountain Cancer Center, Aurora, Colorado, United States|Yale University, New Haven, Connecticut, United States|Henry Ford Health System, Detroit, Michigan, United States|Rutgers, Cancer Institute of NJ, New Brunswick, New Jersey, United States|Columbia, New York, New York, United States|University of Rochester MC, Rochester, New York, United States|Duke Cancer Center, Durham, North Carolina, United States|Gabrail Cancer Center, Canton, Ohio, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Rhode Island, Miriam Hospital, Providence, Rhode Island, United States|SCRI Tennessee Oncology, Nashville, Tennessee, United States|Texas Oncology, P.A., Austin, Texas, United States|Texas Oncology, P.A., Fort Worth, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|Texas Oncology, P.A. - San Antonio Medical Center, San Antonio, Texas, United States|Swedish Cancer Institute, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT03761069"
4,"NCT03761095","A Study of PTC596 (Unesbulin) in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS)",,"Recruiting","No Results Available","Leiomyosarcoma","Drug: PTC596|Drug: Dacarbazine","MTD and RP2D of PTC596 in Combination With Dacarbazine|Number of Participants With Adverse Events|Objective Response Rate (ORR) (Percentage of Participants With Objective Response) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)|Time to Response as Determined by the Investigator Using RECIST v1.1|Duration of Response (DOR)|Progression-Free Survival (PFS)|Best Overall Response Rate (Disease Control Rate) (Percentage of Participants With Best Overall Response)|Overall Survival (OS)|Maximum Observed Plasma Concentration (Cmax) of PTC596, Dacarbazine, and Inactive Metabolite of Dacarbazine (5-amino-imidazole-4-carboxamide [AIC])|Time to Reach Maximum Plasma Concentration (Tmax) of PTC596, Dacarbazine, and Inactive Metabolite of Dacarbazine (AIC)|Area Under the Plasma Concentration-Time Curve (AUC) of PTC596, Dacarbazine, and Inactive Metabolite of Dacarbazine (AIC)|Half-Life (t1/2) of PTC596, Dacarbazine, and Inactive Metabolite of Dacarbazine (AIC)|Apparent Clearance (CL/F) of PTC596, Dacarbazine, and Inactive Metabolite of Dacarbazine (AIC)|Apparent Volume of Distribution (Vz/F) of PTC596, Dacarbazine, and Inactive Metabolite of Dacarbazine (AIC)|Accumulation Ratio (R) of PTC596, Dacarbazine, and Inactive Metabolite of Dacarbazine (AIC)","PTC Therapeutics","All","18 Years and older   (Adult, Older Adult)","Phase 1","27","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PTC596-ONC-007-LMS","March 13, 2019","December 29, 2021","December 29, 2021","December 3, 2018",,"November 8, 2021","Mayo Clinic Florida, Jacksonville, Florida, United States|John Hopkins, Baltimore, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Washington University Medical Campus, Saint Louis, Missouri, United States|Columbia University Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03761095"
5,"NCT03206645","PTC-596 in Women With Ovarian Cancer Receiving Neoadjuvant Chemotherapy",,"Recruiting","No Results Available","Ovarian Cancer","Drug: PTC596","Maximum tolerated dose and dose limiting toxicities|Number of patients able to tolerate drug combination|Phase 2 Dose|Evaluate clinical response|Evaluate pharmacokinetic Area Under the Curve (AUC)|Evaluate pharmacokinetic Maximum Concentration observed (Cmax)|Evaluate pharmacokinetic Time of Maximum Concentration observed (Tmax)|Evaluate pharmacokinetic half life (t1/2)|Progression free survival","University of Oklahoma|PTC Therapeutics","Female","18 Years to 99 Years   (Adult, Older Adult)","Phase 1","27","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PTC-001","August 28, 2017","December 1, 2021","February 1, 2024","July 2, 2017",,"December 17, 2020","University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States",,"https://ClinicalTrials.gov/show/NCT03206645"
6,"NCT03091751","Efficacy and Safety of AlphaNine Versus BeneFIX in Patients With Severe Hereditary Haemophilia B",,"Completed","Has Results","Hemophilia B","Drug: BeneFIX","Mean Difference of Area Under the Curve (AUC): BeneFIX Compared to AlphaNine|Mean Difference of In Vivo Recovery: BeneFIX Compared to AlphaNine|Mean Difference of Terminal Half-Life: BeneFIX Compared to AlphaNine|Mean Difference of Clearance: BeneFIX Compared to AlphaNine|Mean Difference of Mean Residence Time (MRT): BeneFIX Compared to AlphaNine","Grifols Biologicals, LLC","All","12 Years and older   (Child, Adult, Older Adult)","Phase 2","13","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IG-404-1","August 2005","October 2009","October 2009","March 27, 2017","July 25, 2017","July 25, 2017","Medical University Pleven, Pleven, Bulgaria|National Center of Haematology, Sofia, Bulgaria|Medical University, University Hospital ""Sveta Marina"",, Varna, Bulgaria",,"https://ClinicalTrials.gov/show/NCT03091751"
7,"NCT04819984","Impact of Continuous Monitoring of PtC02 on Ventilatory Weaning in Neuro-injured Patients","CO2MBAWA","Not yet recruiting","No Results Available","Acute Brain Injury","Device: TCM5 device (Radiometer) for PtC02 continuous measurement","Predictive value (PPV and Se, Sp) of the PtCO2 variation for exhumation failure|Difference and variation between PtC02 and PaC02 (obtained on blood gases) measurements|Presence of a diaphragmatic dysfunction during ventilatory weaning test|presence of respiratory and non respiratory complications during a period from extubation to the hospital discharge","Centre Hospitalier St Anne","All","18 Years and older   (Adult, Older Adult)","Not Applicable","98","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","D20-P030","April 1, 2021","February 1, 2022","July 1, 2022","March 29, 2021",,"March 29, 2021",,,"https://ClinicalTrials.gov/show/NCT04819984"
8,"NCT00911248","PTC299 for Treatment of Neurofibromatosis Type 2",,"Terminated","No Results Available","Neurofibromatosis 2","Drug: PTC299","To assess the effects of PTC299 on tumor volume and/or word recognition in patients with NF2.|To assess the effects of PTC299 on pure tone thresholds, brainstem auditory evoked responses (BAERs), and otoacoustic emissions (OAEs) in patients with NF2|To determine if PTC299 alters the perception of tinnitus|To evaluate the effects of PTC299 on tumor blood flow|To assess the effects of PTC299 on concentrations of circulating angiogenic factors or cytokines|To describe the PTC299 safety profile|To evaluate compliance with PTC299 treatment|To assess PTC299 plasma exposure over time","PTC Therapeutics|United States Department of Defense","All","18 Years and older   (Adult, Older Adult)","Phase 2","11","Industry|U.S. Fed","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PTC299-ONC-007-NF2|NF080100","July 31, 2009","March 31, 2012","March 31, 2012","June 1, 2009",,"April 12, 2019","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00911248"
9,"NCT03605550","A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma",,"Recruiting","No Results Available","High Grade Glioma|Diffuse Intrinsic Pontine Glioma","Drug: PTC596|Radiation: Radiotherapy","Estimate maximum tolerated dose and/or recommended Phase 2 dose of PTC596 administered concurrently with radiation.|Estimate number of adverse events of PTC596 administered concurrently with radiation|Pharmacokinetics of PTC596|Time from diagnosis to death - Overall survival|Time from diagnosis to disease progression - Progression Free survival","Nationwide Children's Hospital|PTC Therapeutics","All","12 Months to 21 Years   (Child, Adult)","Phase 1","54","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CONNECT1702|#FD-R-6352","August 1, 2018","July 1, 2022","July 1, 2027","July 30, 2018",,"November 30, 2021","Children's Hospital Colorado, Aurora, Colorado, United States|Children's National Medical Center, Washington, District of Columbia, United States|Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Duke University Medical Center, Durham, North Carolina, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Texas Children's Hospital, Houston, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT03605550"
10,"NCT02404480","PTC596 in Patients With Advanced Solid Tumors",,"Completed","No Results Available","Cancer","Drug: PTC596","Dose-limiting toxicities|Adverse effects|Time to Maximum Plasma Concentration (T max)|Antitumor activity|Maximum Plasma Concentration (C max)|Plasma Concentration at 24 hours|Area under the plasma concentration-time curve (AUC)|Terminal half-life (t1/2).","PTC Therapeutics","All","18 Years and older   (Adult, Older Adult)","Phase 1","31","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PTC596-ONC-001-AST","January 2016","February 6, 2017","February 6, 2017","March 31, 2015",,"December 8, 2017","Dana Farber Cancer Institute, Boston, Massachusetts, United States|Duke University, Durham, North Carolina, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Princess Margaret Cancer Centre, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02404480"
11,"NCT03214978","Targeted-sequencing of PTC in Different Stages","PTC","Unknown status","No Results Available","Exploratory Study",,"types of mutation of targets genes in papillary thyroid carcinomas in different stages","Shanghai 6th People's Hospital","All","Child, Adult, Older Adult",,"80","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","LY-US-THY-001","July 30, 2017","December 1, 2017","December 31, 2017","July 12, 2017",,"July 12, 2017",,,"https://ClinicalTrials.gov/show/NCT03214978"
12,"NCT02336178","Safety and Efficacy of Benefix in Patients With Hemophilia B in Usual Care Settings in China",,"Completed","Has Results","HEMOPHILIA B","Drug: Benefix","Percentage of Participants Who Developed Factor IX Inhibitor|Number of Participants With Allergic Reactions|Number of Participants With Thrombotic Events|Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)|Annualized Bleeding Rates (ABRs) in Participants Receiving Prophylaxis Treatment With BeneFIX During Their Prophylaxis Period|Number of Spontaneous/Non-traumatic Breakthrough Bleeds Within 48 Hours of a Prophylaxis Dose of BeneFIX|Annualized Bleeding Rates (ABRs) in Participants Receiving On-demand Treatment With BeneFIX During Their On-demand Period|Number of Infusions Resulted in the Following Response to On-demand Treatment of Bleeds: Excellent, Good, Moderate, no Response|Number of BeneFIX Infusions to Treat Each New Bleed|Average Infusion Dose and Total Factor IX Consumption in On-demand Setting|Average Infusion Dose and Total Factor IX Consumption in Prophylaxis Setting|Average Infusion Dose and Total Factor IX Consumption in Recovery Setting|Percentage of Infusions With Less Than Expected Therapeutic Effects (LETEs) in On-demand Setting|Percentage of Infusions With Less Than Expected Therapeutic Effects (LETEs) in Prophylaxis Setting","Pfizer","All","Child, Adult, Older Adult","Phase 4","70","Industry","Interventional","Masking: None (Open Label)|Primary Purpose: Treatment","B1821052|2016-000765-22","January 2015","July 2016","August 2016","January 12, 2015","May 4, 2017","May 4, 2017","Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China|The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China|Henan Provincial People's Hospital, Zhengzhou, Henan, China|Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China|Xiangya Hospital of Centre-South University, Changsha, Hunan, China|Department of Hematology,The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China|Department of Hematology,The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China|Department of Hematology,Jiangxi Provincial People's Hospital, Nanchang, Jiangxi, China|Blood Center of Shandong Province, Jinan, Shandong, China|Ruijin Hospital Affiliated to Shanghai JiaoTong University School of Medicine/Hematology Department, Shanghai, Shanghai, China|Shanxi Medical University Second Hospital, Taiyuan, Shanxi, China|Chengdu Women's and Children's Central Hospital, Chengdu, Sichuan, China|Blood Diseases Hospital, Chinese Academy of Medical Science (Institute of Hematology), Tianjin, Tianjin, China|Department of Hematology,The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China|Hematology Department,Beijing Children's Hospital, Capital Medical University, Beijing, China|Children's Hospital of Chongqing Medical University, Chongqing, China",,"https://ClinicalTrials.gov/show/NCT02336178"
13,"NCT00947193","Study of Ataluren (PTC124) in Hemophilia A and B",,"Terminated","Has Results","Hemophilia A|Hemophilia B","Drug: Ataluren","Number of Participants With a Plasma FVIII/FIX Activity Response at Day 14|Number of Participants With a Change From Baseline in Plasma Anti-FVIII/FIX Inhibitor Titers at Day 14|Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (SAEs) by Severity and Relationship to Study Drug|Number of Participants With a Clinically Meaningful Abnormal Clinical Laboratory (Hematology, Adrenal Assays, Biochemistry, and Urinalysis) Parameters|Compliance With Ataluren Administration|Ataluren Plasma Exposure|Occurrence of Bleeding Episodes","PTC Therapeutics|Genzyme, a Sanofi Company","Male","18 Years and older   (Adult, Older Adult)","Phase 2","13","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PTC124-GD-011-HEM","October 14, 2009","August 30, 2011","August 30, 2011","July 27, 2009","June 16, 2020","June 16, 2020","The Bleeding and Clotting Disorders Institute, Peoria, Illinois, United States|St. Vincent Indianapolis Hospital, Indianapolis, Indiana, United States|New England Hemophilia Center, Worcester, Massachusetts, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Vanderbilt Hemostatis and Thrombosis Clinic, Nashville, Tennessee, United States|Puget Sound Blood Center, Seattle, Washington, United States|St. Paul's Hospital, Vancouver, British Columbia, Canada|Hôpital Cardiologique, Lille Cedex, France|Hôpital Edouard Herriot, Lyon Cedex, France|Hôpital Necker Enfants Malades, Paris, France|Azienda Ospedaliero-Universitaria Careggi Viale G.B. Morgagni, Firenze, Italy|A.Bianchi Bonomi Hemophilia and Thrombosis Center, Milano, Italy",,"https://ClinicalTrials.gov/show/NCT00947193"
14,"NCT00508586","PTC299 and Hormonal Agent for Treatment of Metastatic Breast Cancer",,"Completed","No Results Available","Metastatic Breast Cancer","Drug: PTC299","Maximum Tolerated Dose (MTD) within the tested dose range.|Overall safety profile|Study drug compliance|Pharmacokinetics|Circulating angiogenic markers|Tumor perfusion as assessed by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI)|Tumor metabolism as assessed by fluorodeoxyglucose positron emission tomography (FDG-PET)|Antitumor activity as assessed by computed tomography (CT) scans and tumor markers","PTC Therapeutics|United States Department of Defense","Female","18 Years and older   (Adult, Older Adult)","Phase 1","33","Industry|U.S. Fed","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PTC299-ONC-003-BRC|BC050203","November 2007","March 2012","March 2012","July 30, 2007",,"March 3, 2016","Indiana University Simon Cancer Center, Indianapolis, Indiana, United States|New York University Clinical Cancer Center, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00508586"
15,"NCT00704821","PTC299 for Treatment of Advanced Cancer",,"Terminated","No Results Available","Advanced Cancer","Drug: PTC299|Drug: Docetaxel","Maximum Tolerated Dose (MTD) of PTC299 within the tested dose range.|Number of Participants with Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (SAEs)|Number of Participants With a Clinically Relevant Abnormal Clinical Laboratory Parameter|Number of Participants With a Clinically Significant Abnormal Electrocardiogram (ECG)|Number of Participants With a Dose-limiting Toxicity (DLT)|Change From Baseline in the Circulating Concentrations of Vascular Endothelial Growth Factor (VEGF)|Proportion of Participants With a VEGF Response|Change From Baseline in Ktrans|Area Under the Concentration Blood Normalized, 90 Seconds (AUCBN90) in a Target Tumor Lesion|Tumor Metabolism as Assessed by Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)|Change From Baseline in Tumor Size|Proportion of Participants With an On-treatment Tumor Response|Change From Baseline in Tumor Marker Response","PTC Therapeutics","All","18 Years and older   (Adult, Older Adult)","Phase 1","76","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PTC299-ONC-004-AST","July 3, 2008","February 24, 2012","February 24, 2012","June 25, 2008",,"May 10, 2019","Memorial Sloan-Kettering Cancer Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00704821"
16,"NCT05103293","PTC Guiding Neoadjuvant Treatment in Breast Cancer",,"Not yet recruiting","No Results Available","Pathological Conditions, Signs and Symptoms","Diagnostic Test: patient-derived tumor-like cell clusters drug sensitivity test","pCR rate|objective response rate|2y-Disease free survival rate|5y-Disease free survival rate","Zhejiang Cancer Hospital","Female","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PTC-breastNAT","November 1, 2021","January 1, 2022","December 31, 2023","November 2, 2021",,"November 2, 2021",,,"https://ClinicalTrials.gov/show/NCT05103293"
17,"NCT03103672","Total Intravenous Anesthesia in Percutaneous Transhepatic Cholangiography",,"Unknown status","No Results Available","Percutaneous Transhepatic Cholangiography","Procedure: Percutaneous transhepatic cholangiography","Recovery time from anesthesia|Heart rate|Mean blood pressure","Inonu University","All","18 Years to 65 Years   (Adult, Older Adult)",,"60","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","2016/101","January 2, 2017","June 1, 2017","July 3, 2017","April 6, 2017",,"April 6, 2017",,,"https://ClinicalTrials.gov/show/NCT03103672"
18,"NCT04439071","A Study to Evaluate Efficacy and Safety of PTC299 (Emvododstat) in Hospitalized Participants With Coronavirus (COVID-19)","FITE19","Recruiting","No Results Available","Pneumonia|COVID-19|Coronavirus","Drug: PTC299|Other: SOC|Drug: Placebo","Time from Randomization to Respiratory Improvement|Percentage of Participants Requiring Invasive Ventilation|Percentage of Participants Requiring Supplemental Oxygen or Non-Invasive Ventilation in Participants who did not Require Supplemental Oxygen at Baseline|Time from Randomization to Defervescence in Participants Presenting With Fever at Enrollment (Temperature of ≥37.6℃ Axilla, ≥38.0℃ Oral, or ≥38.6°C Tympanic or Rectal)|Time from Randomization to Respiratory Rate ≤ 24 Breaths per Minute on Room Air|Time from Randomization to Cough Reported as Mild or Absent|Time from Randomization to Dyspnea Reported as Mild or Absent|Reduction of Immune Responses|Reduction in Viral Load|Duration of Hospitalization|Number of Mortalities|Number of Participants with Treatment-Emergent Adverse Events (TEAEs)","PTC Therapeutics","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","380","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PTC299-VIR-015-COV19|2020-001872-13","July 9, 2020","December 31, 2021","December 31, 2021","June 19, 2020",,"December 16, 2021","University of California, Irvine, Orange, California, United States|Augusta University, Augusta, Georgia, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|University of Massachusetts Memorial Health Care, Worcester, Massachusetts, United States|University Hospitals Cleveland, Cleveland, Ohio, United States|Ralph H. Johnson VA Medical Center, Charleston, South Carolina, United States|Westmead Hospital, Westmead, New South Wales, Australia|Monash Medical Centre, Clayton, Victoria, Australia|Sunshine Hospital, St. Albans, Victoria, Australia|St. Pierre University Hospital, Brussels, Belgium|Clinique Saint Pierre, Ottignies, Belgium|Hospital Vera Cruz, Belo Horizonte, MG, Brazil|Hospital Moinhos de Vento, Porto Alegre, RS, Brazil|Centro Hospitalar Unimed (CHU) - Joinville, Joinville, SC, Brazil|Hospital Guilherme Alvaro, Santos, SP, Brazil|Hospital Santa Casa de Misecórdia de Sorocoba, Sorocaba, SP, Brazil|Hospital Alemao Oswaldo Cruz, São Paulo, SP, Brazil|Escola Paulista de Medicina (UNIFESP), São Paulo, SP, Brazil|Fundação Faculdade Regional de Medicina de São José do Rio Preto, São Paulo, SP, Brazil|Fundación Santa Fe de Bogotá, Bogotá, Colombia|Centro Cardiovascular Somer Incare, Rionegro, Colombia|Hôpital Pitié-Salpêtrière, Paris, France|Centro Hospitalario MAC, Irapuato, Guanajuato, Mexico|Hospital Universitario Dr. José Eleuterio Gonzalez, Monterrey, Nuevo León, Mexico|Integra RGH Centro de Investigación/ Hospital MAC Puebla, Puebla, Mexico|SOMECO - Sociedad de Metabolismo y Corazón S.C., Veracruz, Mexico|Central Clinic Hospital of the MSWiA in Warsaw, Warsaw, Poland|Centro Hospitalar Universitário de Lisboa Norte (CHULN), E.P.E - Hospital de Santa Maria, Lisboa, Portugal|Centro Hospitalar de Entre o Douro e Vouga, EPE (CHEDV), Santa Maria da Feira, Portugal|Centro Hospitalar de Vila Nova de Gaia/Espinho, EPE (CHVNG/E), Vila Nova de Gaia, Portugal|Worthwhile Clinical Trials, Benoni, South Africa|TREAD Research, Cape Town, South Africa|Tiervlei Trial Centre, Cape Town, South Africa|Ahmed Al-Kadi Private Hospital, Durban, South Africa|Global Clinical Trials, Pretoria, South Africa|Hospital Del Mar, Barcelona, Spain|Hospital Universitario de Bellvitge, Barcelona, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Universitario Infanta Sofía, San Sebastián de los Reyes, Spain",,"https://ClinicalTrials.gov/show/NCT04439071"
19,"NCT02107859","Study of Ataluren (PTC124) in Cystic Fibrosis",,"Terminated","Has Results","Cystic Fibrosis","Drug: Ataluren","Number of Participants With Treatment-Emergent Adverse Events (TEAEs)|Number of Participants With Clinically Significant Laboratory Abnormalities|Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) at the End of Treatment (Week 192), as Assessed by Spirometry|Percentage of Participants With Pulmonary Exacerbation, As Assessed by Modified Fuchs Criteria|Percentage of Participants With Pulmonary Exacerbation, As Assessed by Expanded Fuchs' Criteria|Percentage of Participants With Pulmonary Exacerbation, As Assessed by Classic Fuchs' Criteria|Change From Baseline in 12-Lead Electrocardiogram (ECG) Parameters at Final Visit (Week 196)|Change From Baseline in Heart Rate at Final Visit (Week 196), as Assessed by 12-Lead ECG|Change From Baseline in Vital Signs at Final Visit (Week 196)","PTC Therapeutics","All","6 Years and older   (Child, Adult, Older Adult)","Phase 3","61","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PTC124-GD-023-CF|2013-005449-35","May 23, 2014","June 5, 2017","June 5, 2017","April 8, 2014","March 25, 2020","March 25, 2020","University of Alabama-Birmingham, Birmingham, Alabama, United States|Miller Children's Hospital Long Beach, Long Beach, California, United States|Denver Children's Hospital, Aurora, Colorado, United States|Children's Hospital Chicago, Chicago, Illinois, United States|Children's Hospital Boston, Boston, Massachusetts, United States|Beth Israel Medical Center, New York, New York, United States|Rainbow Babies & Children's Hospital, Cleveland, Ohio, United States|Hôpital Universitaire des Enfants Reine Fabiola, Brussels, Belgium|University Hospital Brussels, Brussels, Belgium|University Hospital Leuven, Leuven, Belgium|Hôpital Necker - Enfants Malades, Paris, France|Hôpital des Enfants, Toulouse, France|Hadassah University Hospital - Mount Scopus, Jerusalem, Israel|Università La Sapienza, Roma, Italy|Azienda Ospedaliera di Verona, Verona, Italy|Hospital Universitario La Paz, Madrid, Spain|Karolinska University Hospital, Huddinge, Stockholm, Sweden","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/59/NCT02107859/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/59/NCT02107859/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02107859"
20,"NCT02090959","An Extension Study of Ataluren (PTC124) in Participants With Nonsense Mutation Dystrophinopathy",,"Terminated","Has Results","Muscular Dystrophy, Duchenne|Muscular Dystrophies|Muscular Disorders, Atrophic|Muscular Diseases|Musculoskeletal Diseases|Neuromuscular Diseases|Nervous System Diseases|Genetic Diseases, X-Linked|Genetic Diseases, Inborn","Drug: Ataluren","Number of Participants With Treatment-Emergent Adverse Events (TEAEs)|Number of Participants With Abnormalities in Clinical Laboratory Parameters|Change From Baseline in 6MWD at Week 144|Change From Baseline in Time to Stand From Supine Position at Week 144|Change From Baseline in Time to Walk/Run 10 Meters at Week 144|Change From Baseline in Time to Climb 4 Stairs at Week 144|Change From Baseline in Time to Descend 4 Stairs at Week 144|Change From Baseline in Physical Function Total Score as Measured by NSAA at Week 144|Change From Baseline in PUL Total Score at Week 144|Change From Baseline in Percent Predicted FVC as Measured by Spirometry at Week 144|Change From Baseline in Percent Predicted FEV1 as Measured by Spirometry at Week 144|Change From Baseline in PEF as Measured by Spirometry at Week 144|Change From Baseline in PCF as Measured by Spirometry at Week 144|Change From Baseline in PODCI Transfers/Basic Mobility Score at Week 144|Number of Participants With Change From Baseline in Activities of Daily Living and Disease Status at Week 144, as Assessed by a Standardized Survey Administered by Site Personnel|Ataluren Plasma Concentration|Change From Baseline in Systolic and Diastolic Blood Pressure at Week 144|Change From Baseline in Pulse Rate at Week 144|Change From Baseline in Body Temperature at Week 144","PTC Therapeutics","Male","7 Years to 15 Years   (Child)","Phase 3","219","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PTC124-GD-020e-DMD","March 20, 2014","June 12, 2018","June 12, 2018","March 19, 2014","August 11, 2020","August 11, 2020","University of California, Los Angeles, Los Angeles, California, United States|UC Davis Medical Center, Sacramento, California, United States|Stanford University Medical Center, Stanford, California, United States|Children's Hospital Colorado - Center for Cancer and Blood Disorders, Aurora, Colorado, United States|Child Neurology Center of Northwest Florida, Gulf Breeze, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Iowa, Iowa City, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Children's Hospital Boston, Boston, Massachusetts, United States|University of Minnesota, Minneapolis, Minnesota, United States|Washington University School of Medicine, Division of Endocrinology, Metabolism and Lipid Research, Saint Louis, Missouri, United States|Columbia University College of Physicians & Surgeons, New York, New York, United States|Children's Hospital Cincinnati, Cincinnati, Ohio, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|Childrens Medical Center Dallas, Texas, Dallas, Texas, United States|Texas Children's Hospital, Houston, Texas, United States|University of Utah, Salt Lake City, Utah, United States|Seattle Children's Hospital - Childhood Cancer and Blood Disorders, Seattle, Washington, United States|The Children's Hospital at Westmead, Westmead, New South Wales, Australia|The Royal Children's Hospital, Parkville, Victoria, Australia|UZ Leuven, Leuven, Belgium|Universidade Federal do Rio de Janeiro - Instituto de Puericultura e Pediatria Martagao Gesteira, Rio de Janeiro, Brazil|Sao Paulo University -HC/FMUSP, São Paulo, Brazil|Aleksandrovska Hospital, Sofia, Bulgaria|Alberta Children's Hospital, Calgary, Alberta, Canada|British Columbia Children's Hospital, Vancouver, British Columbia, Canada|Children's Hospital of Western Ontario, London, Ontario, Canada|Hospital Luis Calvo Mackenna, Santiago, Región Metropolitana, Chile|Hospital Clinico Universidad Catolica, Santiago, Chile|University Hospital Brno, Brno, Czechia|Motol University Hospital, Praha, Czechia|Hospital de la Timone, Marseille, France|CHU de Nantes, Nantes Cedex 1, France|Groupe Hospitalier Pitie-Salpetriere, Paris Cedex 13, France|Hopital Necker - Enfants Malades, Paris, France|Universitaetsklinikum Essen, Essen, Germany|University Medical Center Freiburg, Freiburg, Germany|Universitat Munchen - von Haunersche Kinder Clinic, Munchen, Germany|Hadassah University Hospital, Jerusalem, Israel|Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy|Bambino Gesu Hospital, Rome, Italy|U.O. Complessa di Neuropsichiatria Infantile, Rome, Italy|Policlinico Universitario G. Martino, Sicily, Italy|Seoul National University Hospital, Seoul, Korea, Republic of|Medical University of Warsaw, Warsaw, Poland|Hospital Sant Joan de Deu, Barcelona, Spain|Hospital Universitari i Politecnic la Fe, Valencia, Spain|Queen Silvia Children's Hospital, Goteburg, Sweden|Astrid Lindgren Childrens Hospital, Stockholm, Sweden|CHUV Lausanne, Lausanne, Switzerland|Hacettepe Childrens Hospital, Ankara, Turkey|Erciyes University Faculty of Medicine, Talas/Kayseri, Turkey|University College London Institute of Child Health, London, United Kingdom|Royal Manchester Children's Hospital, Manchester, United Kingdom|The Newcastle upon Tyne Hospitals, NHS Foundation Trust, Newcastle upon Tyne, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/59/NCT02090959/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/59/NCT02090959/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02090959"
21,"NCT00351078","PTC124 for the Treatment of Cystic Fibrosis",,"Completed","No Results Available","Cystic Fibrosis","Drug: PTC124","CFTR activity as assessed by nasal transepithelial potential difference (TEPD)|Side effects|Presence of CFTR protein and mRNA|Compliance with treatment|Lung function|Sputum test|PTC124 pharmacokinetics|Changes in CF symptoms|Changes in weight|Changes in cough","PTC Therapeutics","All","18 Years and older   (Adult, Older Adult)","Phase 2","19","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PTC124-GD-005e-CF","December 2006","July 2007","July 2007","July 12, 2006",,"December 13, 2017","Hadassah University Hospital - Mount Scopus, Jerusalem, Israel",,"https://ClinicalTrials.gov/show/NCT00351078"
22,"NCT00847379","Phase 2B Extension Study of Ataluren (PTC124) in Duchenne/Becker Muscular Dystrophy (DMD/BMD)",,"Terminated","Has Results","Duchenne Muscular Dystrophy|Becker Muscular Dystrophy","Drug: Ataluren","Number of Participants With Treatment-Emergent Adverse Events (AEs)|Number of Participants With Clinically Significant Abnormal Laboratory Parameters|Change From Baseline in 6-Minute Walk Distance (6MWD) at Week 60|Change From Baseline in Mean Activity Period/Day/Visit at Week 60, as Assessed by Step Activity Monitoring (SAM)|Change From Baseline in Mean Total Step Count/Day/Visit During the Active Periods at Week 60, as Assessed by SAM|Change From Baseline in Mean Total Step Count/Hour During the Active Period at Week 60, as Assessed by SAM|Change From Baseline in Maximum Continuous 10-minute, 20-minute, 30-minute, and 60-minute Total Step Count at Week 60, as Assessed by SAM|Change From Baseline in Percentage of Time During Active Period Spent at No Activity (0 Steps/Minute[Min]), Low Activity (Less Than or Equal to [≤]15 Steps/Min), Medium Activity (16-30 Steps/Min), and High Activity (Greater Than[>]30 Steps/Min) at Week 60|Change From Baseline in Time to Stand From Supine Position at Week 60|Change From Baseline in Time to Walk/Run 10 Meters at Week 60|Change From Baseline in Time to Climb 4 Stairs at Week 60|Change From Baseline in Time to Descend 4 Stairs at Week 60|Change From Baseline in Heart Rate Before, During, and After Each 6MWD Test at Week 60, as Assessed by Heart Rate Monitoring With the Polar® RS400|Change From Baseline in Number of Digits Recalled Forwards and Backwards on Digit Span Task at Week 60|Change From Baseline in Participant- Reported Health-Related Quality of Life (HRQL) as Measured by the Pediatric Quality of Life Inventory (PedsQL) Physical, Emotional, Social, and School Functioning Domain Scores at Week 60|Change From Baseline in Parent/Caregiver- Reported HRQL as Measured by the PedsQL Physical, Emotional, Social, and School Functioning Domain Scores at Week 60|Change From Baseline in Participant-Reported HRQL as Measured by the Total Fatigue Scale Score at Week 60|Change From Baseline in Parent/Caregiver-Reported HRQL as Measured by the Total Fatigue Scale Score at Week 60|Change From Baseline in Participant and Parent/Caregiver Reported Activities of Daily Living of Participants Who Were Unable to Complete the 6MWT (Nonambulatory Participants), as Measured by the Egen Klassifikation (EK) Scale at Week 60|Change From Baseline in Parent/Caregiver-Reported Treatment Satisfaction Questionnaire for Medication (TSQM) Score at Week 60|Change From Baseline in Serum Concentration of Creatine Kinase (CK) at Week 60|Study Drug Compliance|Trough Ataluren Plasma Concentration","PTC Therapeutics|Genzyme, a Sanofi Company","Male","5 Years and older   (Child, Adult, Older Adult)","Phase 2","173","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PTC124-GD-007e-DMD","January 31, 2009","May 24, 2010","May 24, 2010","February 19, 2009","July 15, 2020","July 15, 2020","University of California - Davis, Sacramento, California, United States|Department of Rehabilitation, The Children's Hospital, Aurora, Colorado, United States|Child Neurology Center of NW Florida, Gulf Breeze, Florida, United States|University of Iowa Children's Hospital, Division of Child Neurology, Iowa City, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Children's Hospital of Boston, Boston, Massachusetts, United States|University of Minnesota, Minneapolis, Minnesota, United States|Washington University Medical School, Saint Louis, Missouri, United States|Columbia University, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Shriners Hospital for Children-Portland, Portland, Oregon, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Southwestern University, Dallas, Texas, United States|University of Utah, Salt Lake City, Utah, United States|The Royal Children's Hospital, Parkville, Victoria, Australia|The Children's Hospital at Westmead, Westmead, Australia|UZ Leuven, Leuven, Belgium|Alberta Children's Hospital, London, Ontario, Canada|Children's Hospital of Western Ontario, London, Ontario, Canada|British Colombia Children's Hopsital, Vancouver, Canada|Hopital d'Enfants CHU Timone, Marseille cedex 20, France|Laboratoire d'Exploration Fonctionnelles, Nantes cedex 1, France|Groupe Hospitalier Pitie-Salpetriere, Institut de Myologie, Paris, France|University of Essen - Clinic for Children, Essen, Germany|University Hospital, Freiburg, Germany|Hadassah University Hopspital, Jerusalem, Israel|Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Milano, Italy|Ospedale Pediatrico Bambino Gesu, Roma, Italy|U.O. Complessa di Neuropsichiatria Infantile-Policlinico A. Gemelli-Universita Cattolica, Roma, Italy|Hospital Sant Joan de Deu, Barcelona, Spain|Hospital Universitario La Fe, Valencia, Spain|Queen Silvia Children's Hospital, Goteborg, Sweden|Astrid Lindgren Pediatric Hospital, Stockholm, Sweden|UCL Instititute of Child Health, Dubowitz, London, United Kingdom|University of Newcastle, Newcastle Upon Tyne, United Kingdom|Robert Jones & Agnes Hunt Orthopaedic Hospital, Oswestry, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00847379"
23,"NCT04625205","NEO-PTC-01 in Patients With Advanced or Metastatic Melanoma",,"Recruiting","No Results Available","Unresectable Melanoma|Metastatic Melanoma","Biological: NEO-PTC-01","Rate of adverse events (AEs), including serious adverse events (SAEs) and AEs leading to treatment discontinuation|Progression-free survival (PFS), defined as the time from the date of first dosing of NEO-PTC-01 to the date of first documented progressive disease (PD) or death, whichever comes first|Overall response rate (ORR), defined as the proportion of patients who achieve complete response (CR) or partial response (PR) based on RECIST v1.1|Duration of response (DOR), defined as the date of the first documentation of a confirmed response to the date of the first documented PD|Clinical benefit rate (CBR), defined as the proportion of patients who achieve CR, PR, or stable disease (SD) based on RECIST v1.1|Time to first subsequent therapy, defined as the time from the date of first dosing to the start date of first subsequent therapy","BioNTech US Inc.|BioNTech SE","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","52","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NTC-001|2019-003908-13","December 1, 2020","November 2023","November 2023","November 12, 2020",,"December 3, 2021","Universitair Ziekenhuis Brussel, Brussel, Belgium|Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, Netherlands|Hospital Universitario Valle de Hebrón, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT04625205"
24,"NCT01174446","Pivotal Study (Pharmacokinetics, Efficacy, Safety) of BAX 326 (rFIX) in Hemophilia B Patients",,"Completed","Has Results","Hemophilia B","Biological: BAX 326|Biological: BeneFIX","Study Part 1- Area Under the Plasma Concentration Versus Time Curve From 0 to 72 Hours Per Dose|Study Parts 1 and 3: Area Under the Plasma Concentration/Time Curve From Time 0 to Infinity Per Dose (AUC0-∞/ Dose)|Study Parts 1 and 3: Mean Residence Time (MRT)|Study Parts 1 and 3: Clearance (CL)|Study Parts 1 and 3: Incremental Recovery at Cmax (IR at Cmax)|Incremental Recovery (IR) at 30 Minutes Over Time|Change in Incremental Recovery (IR) at 30 Minutes Over Time|Study Parts 1 and 3: Half Life (T 1/2)|Study Parts 1 and 3: Volume of Distribution at Steady State (Vss)|Study Part 2: Annualized Bleed Rate (ABR) During Treatment With BAX326|Bleeding Episodes Treated With 1, 2 or ≥3 Infusions of BAX326 by Bleeding Site and Cause|Hemostatic Efficacy at Resolution of All Bleeding Episodes (BEs) Treated With BAX326 by Bleeding Site and Cause|Total Weight-adjusted Dose Per Bleeding Episode (BEs) of All BEs Treated With BAX326 by Bleeding Site and Cause|Consumption of BAX326 Per Event Per Participant|Consumption of BAX326 Per Participant: Median Number of Infusions Per Month|Consumption of BAX326 Per Participant: Median Weight-adjusted Consumption Per Month|Number of Participants Who Developed Inhibitory Antibodies to Factor IX (FIX)|Occurrence of Total Binding Antibodies of Indeterminate Specificity (Within Assay Variability)|Occurrence of Treatment Related Total Binding Antibodies|Number of Participants Who Experienced Severe Allergic Reactions (e.g. Anaphylaxis)|Number of Participants Who Experienced Thrombotic Events|Number of Participants With Clinically Significant Changes in Laboratory Parameters: Clinical Chemistry|Number of Participants With Clinically Significant Changes in Laboratory Parameters: Hematology|Number of Participants With Clinically Significant Changes in Laboratory Parameters: Vital Signs|Number of Participants With Clinically Significant Changes in Laboratory Parameters: Thrombogenic Markers|Number of Adverse Events (AEs) After BAX326 Treatment|Number of Participants With Adverse Events (AEs) After BAX326 Treatment|EuroQoL (Quality of Life)-5 Dimensions (EQ-5D) Total Index Scores|EuroQoL (Quality of Life)-5 Dimensions Visual Analogue Scale (EQ-5D VAS) Scores|General Pain Assessment Through a Visual Analog Scale (VAS)|Short Form (36) Health Survey (SF-36): HRQoL 'Physical Component Score' (PCS)|SF-36: HRQoL 'Mental Health' (MH)|SF-36: HRQoL Physical Functioning' (PF)|SF-36: HRQoL Role-Physical (RP)|SF-36: HRQoL Role-Emotional|SF-36: HRQoL Bodily Pain|SF-36: HRQoL Mental Health|SF-36: HRQoL Vitality|SF-36: HRQoL Social Functioning|SF-36: HRQoL General Health|Pediatric Quality of Life Questionnaire (PedsQL) Physical Health Summary Score (Ages 12-16)|Pediatric Quality of Life Questionnaire (PedsQL) Psychosocial Health Summary Score (Ages 12-16)|Pediatric Quality of Life Questionnaire (PedsQL) Total Score (Ages 12-16)|Health-Related Quality of Life (HRQoL) Disease-specific: Haem-A-QoL|Health-Related Quality of Life (HRQoL) Disease-specific: Haemo-QoL - Participants On-Demand (Ages 12-16)|Health Resource Use - Number of Hospitalizations|Health Resource Use - Total Days of Hospital Stay|Health Resource Use - Emergency Room Visits|Health Resource Use - Unscheduled Doctor's Office Visits|Health Resource Use - Days Lost From Work or School","Baxalta now part of Shire|Takeda","All","12 Years to 65 Years   (Child, Adult, Older Adult)","Phase 3","86","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","250901|2009-016720-31","July 29, 2010","May 3, 2012","May 3, 2012","August 3, 2010","November 25, 2013","May 20, 2021","Rosario, Argentina|Brasilia, Brazil|Sao Paulo, Brazil|Sofia, Bulgaria|Santiago, Chile|Bogotá, Colombia|Cali, Colombia|Prague, Czechia|Hiroshima, Japan|Nara, Japan|Tochigi, Japan|Tokyo, Japan|Gdansk, Poland|Krakow, Poland|Lodz, Poland|Warsaw, Poland|Bucharest, Romania|Timisoara, Romania|Kirov, Russian Federation|Moscow, Russian Federation|St. Petersburg, Russian Federation|Barcelona, Spain|Malmö, Sweden|Lviv, Ukraine|London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01174446"
25,"NCT00866606","Study Evaluating On-Demand Treatment With BeneFIX In Chinese Subjects",,"Completed","Has Results","Hemophilia B","Biological: Benefix","Investigator Hemostatic Efficacy Assessment of Participants After 8 Hours Post Infusion|Investigator Hemostatic Efficacy Assessment of Participants After 24 Hours Post Infusion|Percentage of Participants With FIX Inhibitor Development|Number of Infusions Required to Treat Each Bleed|FIX Incremental Recovery|Percentage of Participants With Less Than Expected Therapeutic Effect (LETE)|Percentage of Participants With Allergic-Type Allergic Reactions|Percentage of Participants With Thrombosis|Percentage of Participants With Red Blood Cell (RBC) Agglutination","Wyeth is now a wholly owned subsidiary of Pfizer","All","6 Years and older   (Child, Adult, Older Adult)","Phase 3","35","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","3090A1-3305|B1821004","February 2009","December 2009","December 2009","March 20, 2009","January 4, 2011","April 5, 2011","Pfizer Investigational Site, Guangzhou, Guangzhou, China|Pfizer Investigational Site, Suzhou, Jiangsu, China|Pfizer Investigational Site, Tianjin, Tianjin, China|Pfizer Investigational Site, Hangzhou, Zhejiang, China|Pfizer Investigational Site, Beijing, China|Pfizer Investigational Site, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT00866606"
26,"NCT03186677","Dose-escalation Study to Investigate the Safety, PK, and PD of ISU304/CB2679d in Hemophilia B Patients",,"Completed","Has Results","Hemophilia B","Biological: ISU304/CB2679d/Dalcinonacog alfa 75~150 IU/kg|Biological: BeneFIX","Number of Adverse Events (AEs) After the Administration of Investigational Products (IP)|Maximum Plasma Concentration (Cmax)|Factor IX Inhibitor","ISU Abxis Co., Ltd.|Catalyst Biosciences","All","12 Years to 65 Years   (Child, Adult, Older Adult)","Phase 1","11","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ISU304-001/CB2679d","June 3, 2017","October 10, 2018","February 22, 2019","June 14, 2017","November 10, 2020","November 10, 2020","Eulji University Hospital, Daejeon, Korea, Republic of|Pusan National Univesity Hospital, Pusan, Korea, Republic of|Yonsei University Medical Center, Seoul, Korea, Republic of","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/77/NCT03186677/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03186677"
27,"NCT00581126","Study Evaluating BENEFIX in Previously Treated Patients With Hemophilia B",,"Completed","No Results Available","Hemophilia B","Drug: Recombinant Factor IX Coagulation","The primary variable will be the clinical response of BeneFix* in avoiding stopping or avoiding bleeding.|The secondary variables will be hemostasis and blood loss during and after surgery.","Wyeth is now a wholly owned subsidiary of Pfizer","All","6 Years and older   (Child, Adult, Older Adult)","Phase 4","14","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","3090A-100932","December 2001",,"July 2004","December 27, 2007",,"December 27, 2007",,,"https://ClinicalTrials.gov/show/NCT00581126"
28,"NCT01009294","Study of Ataluren (PTC124) in Nonambulatory Participants With Nonsense-Mutation-Mediated Duchenne/Becker Muscular Dystrophy (nmDMD/BMD)",,"Terminated","Has Results","Duchenne Muscular Dystrophy|Becker Muscular Dystrophy","Drug: Ataluren|Drug: Chronic Corticosteroid Therapy","Number of Participants With Treatment Emergent Adverse Events (TEAEs)|Time to Complete Upper Limb Function Tasks as Measured by the Jebsen Test|Upper Limb Function as Measured by the Brooke Upper Extremity Functional Rating Scale|Participant Activities of Daily Living as Assessed Using the Egen Klassifikation (EK) Scale|Shoulder, Elbow, and Wrist Passive and Active Range of Motion as Measured by Goniometry|Force Exerted During Elbow Flexion and Extension, Shoulder Abduction, Hand Grip, Key Grip, and Finger Pinch as Assessed by Upper Extremity Myometry|Time to Complete Hand Fine Motor Coordination and Dexterity Tasks as Measured by 9-Hole Peg Test (9HPT)|Forced Vital Capacity (FVC) as Measured by Spirometry|Systolic and Diastolic Function as Measured by Echocardiography With Tissue Doppler|Heart Rate as Assessed by Radial Pulse|Verbal Memory and Attention as Assessed by the Digit Span Task|HRQL as Measured by the PedsQL Inventory Generic Core Scale|HRQL as Measured by the PedsQL Multidimensional Fatigue Scale|HRQL as Measured by the INQoL|Muscle Fragility as Determined by Serum Creatine Kinase (CK) Levels|Gastrocnemius Muscle Dystrophin Expression as Determined by Immunofluoresence or by Western Blotting Techniques|Study Drug Compliance|Pharmacokinetics: Ataluren Plasma Exposure","PTC Therapeutics|Genzyme, a Sanofi Company","Male","7 Years and older   (Child, Adult, Older Adult)","Phase 2","6","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PTC124-GD-008-DMD|2009-013169-24","January 13, 2010","March 23, 2010","March 23, 2010","November 6, 2009","July 29, 2020","July 29, 2020","University of California-Davis, Davis, California, United States|Children's Hospital of Boston, Boston, Massachusetts, United States|University of Minnesota, Minneapolis, Minnesota, United States|Washington University Medical School, Saint Louis, Missouri, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|University of Newcastle, Newcastle upon Tyne, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01009294"
29,"NCT00264888","Safety and Efficacy Study of PTC124 in Duchenne Muscular Dystrophy",,"Completed","No Results Available","Duchenne Muscular Dystrophy","Drug: PTC124","Dystrophin expression as assessed by immunofluorescence evaluation of tissue obtained by biopsy of the extensor digitorum brevis (EDB) muscle of the foot or tibialis anterior (TA) muscle of the leg|Presence of dystrophin mRNA and dystrophin-related proteins on EDB or TA muscle biopsy, muscle function, compliance with treatment, safety and PTC124 pharmacokinetics","PTC Therapeutics|Muscular Dystrophy Association","Male","5 Years and older   (Child, Adult, Older Adult)","Phase 2","38","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PTC124-GD-004-DMD","December 2005","May 2007","May 2007","December 13, 2005",,"January 14, 2009","Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|University of Utah, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT00264888"
30,"NCT04286412","Nonacog Alfa Prophylaxis And Treatment Of Bleeding Episodes In Previously Treated Patients With Hemophilia B",,"Completed","Has Results","Hemophilia B","Biological: Nonacog alfa","Percentage of Participants Who Developed Factor IX (FIX) Inhibitors|Number of Participants With Serious Adverse Events (SAEs) and Medically Important Events (MIEs)|Number of Participants With Treatment Emergent Adverse Events (TEAEs)|Mean Annualized Bleeding Rate (ABR)|Mean Annualized Total Factor Consumption (TFC) Per Participant|Mean Annualized Total Factor Consumption (TFC) by Weight Per Participant|Mean Number of Nonacog Alfa Infusions Used to Treat Each Bleed","Pfizer","Male","12 Years to 65 Years   (Child, Adult, Older Adult)","Phase 4","25","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","B1821059|2020-004430-38","February 10, 2020","September 24, 2020","September 24, 2020","February 27, 2020","July 30, 2021","July 30, 2021","Nirmal Hospital, Surat, Gujarat, India|K.J. Somaiya Hospital and Research Centre, Mumbai, Maharashtra, India|Sahyadri Clinical Research & Development Centre, Pune, Maharashtra, India|Christian Medical College and Hospital, Ludhiana, Punjab, India|Sahyadri Super Specialty Hospital, Pune, India","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/12/NCT04286412/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/12/NCT04286412/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT04286412"
31,"NCT00234663","PTC124 for Cystic Fibrosis",,"Completed","No Results Available","Cystic Fibrosis","Drug: PTC124","CFTR activity as assessed by nasal transepithelial potential difference (TEPD)|Side effects|Presence of CFTR protein and mRNA|Compliance with treatment|Lung function|PTC124 pharmacokinetics","PTC Therapeutics|Cystic Fibrosis Foundation|FDA Office of Orphan Products Development","All","18 Years and older   (Adult, Older Adult)","Phase 2","24","Industry|Other|U.S. Fed","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PTC124-GD-003-CF|1R01FD003009-01","September 2005","August 2006","August 2006","October 7, 2005",,"January 13, 2009","University of Alabama at Birmingham, Birmingham, Alabama, United States|Stanford University Medical Center, Palo Alto, California, United States|The Children's Hospital, Denver, Colorado, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00234663"
32,"NCT00686842","PTC299 in Treating Patients With HIV-Related Kaposi Sarcoma",,"Terminated","Has Results","Kaposi's Sarcoma","Drug: VEGF inhibitor PTC299|Genetic: gene expression analysis|Genetic: polymerase chain reaction|Genetic: protein expression analysis|Other: immunohistochemistry staining method|Other: laboratory biomarker analysis|Other: pharmacological study|Procedure: biopsy","Safety and Toxicity of Anti-VEGF Small Molecule PTC299|Maximum Tolerated Dose|Response to Treatment|Pharmacokinetics|Effects of Study Drug on Serum and Plasma VEGF, VEGFR, and Cytokine Profiles|Effects of Study Drug on HIV and KSHV Viral Loads|Effects of Study Drug on T-lymphocyte Subsets (i.e., CD4 and CD8)|Effects of Study Drug on VEGF, VEGFR-2 and -3, Phospho-Akt, p53, and HIF-1α Expression and Tumor Cell Proliferation, as Measured by Ki-67 Staining, in Tumor Biopsy Samples|Effects of Study Drug on Viral Gene Expression and Cellular Gene Transcription, as Measured by Real-time Quantitative PCR-based Profiling, in Tumor Biopsy Samples","AIDS Malignancy Consortium|National Cancer Institute (NCI)|PTC Therapeutics|The Emmes Company, LLC","All","18 Years to 120 Years   (Adult, Older Adult)","Phase 1|Phase 2","17","Other|NIH|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AMC-059|U01CA121947|CDR0000596565|PTC299-ONC-005-KS","September 2008","November 2010","December 2010","May 30, 2008","March 5, 2012","June 6, 2018","Rebecca and John Moores UCSD Cancer Center, La Jolla, California, United States|USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States|UCLA Clinical AIDS Research and Education (CARE) Center, Los Angeles, California, United States|Cancer Research Center of Hawaii, Honolulu, Hawaii, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Floyd and Delores Jones Cancer Institute at Virginia Mason Medical Center, Seattle, Washington, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT00686842/Prot_SAP_001.pdf","https://ClinicalTrials.gov/show/NCT00686842"
33,"NCT01335061","Study To Compare On-Demand Treatment To A Prophylaxis Regimen Of BeneFIX In Subjects With Moderately Severe to Severe Hemophilia B",,"Completed","Has Results","Hemophilia B","Biological: Nonacog alfa","Annualized Number of Bleeding Episodes.|Response to On-Demand Treatment for All Bleeding Episodes.|Number of Nonacog Alfa, Recombinant Factor IX (BeneFIX) Infusions Used to Treat Each Bleeding Episode.|Number of Breakthrough (Spontaneous/Non-Traumatic) Bleeds Within 48 Hours of a Prophylaxis Dose of BeneFIX.|Average Infusion Dose.|Total Factor Consumption.|Incidence of Less Than Expected Therapeutic Effect (LETE)","Pfizer","Male","12 Years to 65 Years   (Child, Adult, Older Adult)","Phase 3","25","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","B1821010|3090A1-3306|2011-000520-15","September 2011","April 2014","April 2014","April 13, 2011","May 4, 2015","June 8, 2015","UMBAL Sveti Georgi, Klinika po hematologia, Plovdiv, Bulgaria|The Ottawa Hospital, Ottawa, Ontario, Canada|University Hospital Center Zagreb, Zagreb, Croatia|Eulji University Hospital, Daejeon, Korea, Republic of|Hospital Tengku Ampuan Afzan, Kuantan, Pahang, Malaysia|National Blood Centre, Kuala Lumpur, Malaysia|Hospital y Clinica OCA, Monterrey, Nuevo Leon, Mexico|Instituto Biomedico de Investigacion A.C., Aguascalientes, Mexico|Nzoz Triclinium, Warszawa, Poland|Klinika Hematologii, Nowotworow Krwi i Transplantacji Szpiku, Wroclaw, Poland|Singapore General Hospital, Singapore, Singapore|Istanbul Universitesi Cerrahpasa Tip Fakultesi Ic Hastaliklari Anabilim Dali Hematoloji Bilim Dali, Fatih, Istanbul, Turkey|Hacettepe Universitesi Tip Fakultesi Ic Hastaliklari Anabilim Dali Hematoloji Bolumu, Ankara, Turkey|Ege Universitesi Tip Fakultesi, Bornova/Izmir, Turkey|Gaziantep Universitesi Tip Fakultesi Sahinbey Arastirma ve Uygulama Hastanesi Hematoloji Poliklinigi, Gaziantep, Turkey|Erciyes Universitesi Tip Fakultesi Hastaneleri M. Kemal Dedeman Onkoloji Hastanesi, KAYSERİ, Erciyes, Turkey|Erciyes Universitesi Tip Fakultesi, Kayseri, Turkey",,"https://ClinicalTrials.gov/show/NCT01335061"
34,"NCT00803205","Study of Ataluren (PTC124™) in Cystic Fibrosis",,"Completed","Has Results","Cystic Fibrosis","Drug: Ataluren|Drug: Placebo","Percentage of Predicted Function (Percent-Predicted) of Forced Expiratory Volume in One Second (FEV1) at Baseline|Percentage Change From Baseline in Percent-Predicted of FEV1 at Week 48|Rate of Pulmonary Exacerbations as Defined by Modified Fuch's Criteria Over 48 Weeks|Change From Baseline in Awake Cough Hourly Rate at Week 48|Change From Baseline in the Respiratory Domain Score of the Revised Cystic Fibrosis Questionnaire (CFQ-R) at Week 48|Percent-Predicted of Forced Vital Capacity (FVC) at Baseline|Percentage Change From Baseline in Percent-Predicted of FVC at Week 48","PTC Therapeutics|Cystic Fibrosis Foundation","All","6 Years and older   (Child, Adult, Older Adult)","Phase 3","238","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PTC124-GD-009-CF|Orphan Product Grant #FD003715|2008-003924-52","September 8, 2009","November 12, 2011","November 12, 2011","December 5, 2008","May 14, 2020","May 14, 2020","University of Alabama-Birmingham, Birmingham, Alabama, United States|Miller Children's Hospital Long Beach, Long Beach, California, United States|Lucile Packard Children's Hospital, Palo Alto, California, United States|Stanford, Palo Alto, California, United States|Rady Children's Hospital - San Diego, San Diego, California, United States|The Children's Hospital, Aurora, Colorado, United States|University of Miami, Miami, Florida, United States|Miami Children's Hospital, Miami, Florida, United States|Emory University Cystic Fibrosis Center, Atlanta, Georgia, United States|Children's Memorial Hospital, Chicago, Illinois, United States|University of Iowa, Iowa City, Iowa, United States|Johns Hopkins Children's Center, Baltimore, Maryland, United States|Children's Hospital Boston, Boston, Massachusetts, United States|Washington University, Saint Louis, Missouri, United States|Beth Israel Medical Center, New York, New York, United States|New York Medical College, Valhalla, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Rainbow Babies & Children's Hospital, Cleveland, Ohio, United States|Childrens Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|University of Texas, Tyler, Texas, United States|University of Washington, Seattle, Washington, United States|Hôpital Erasme, Brussels, Belgium|Hôpital Universitaire des Enfants Reine Fabiola, Brussels, Belgium|University Hospital Brussels, Brussels, Belgium|University Hospital Leuven, Leuven, Belgium|University of Toronto, Toronto, Canada|Hôpital Cochin, Paris, France|Hôpital Necker - Enfants Malades, Paris, France|Hôpital des Enfants, Toulouse, France|Klinikum der Universität Köln, Köln, Germany|Hadassah University Hospital - Mount Scopus, Jerusalem, Israel|Università La Sapienza, Rome, Italy|Azienda Ospedaliera di Verona, Verona, Italy|Universitair Medisch Centrum Utrecht, Utrecht, Netherlands|Hospital Universitario La Paz, Madrid, Spain|Karolinska University Hospital, Huddinge, Stockholm, Sweden|Belfast City Hospital, Belfast, United Kingdom|Alder Hey Children's Hospital, Liverpool, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00803205"
35,"NCT00714415","Registry For Patients Treated With BeneFix In Usual Care Setting In Germany",,"Completed","Has Results","Hemophilia B","Drug: BeneFIX","Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Treatment-Related Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Factor IX (FIX) Inhibitor Development as Measured by the Nijmegen-Modified Bethesda Assay|Number of Participants With Adverse Events (AEs) of Special Interest|Investigator Assessment of Treatment Tolerability of Participants|Participant Assessment of Treatment Tolerability|Mean Total Number of Bleeding Episodes in Participants|Mean Total Number of Bleeding Episodes Per Year in Participants|Number of Participants With Change From Baseline Status in Number of Days Missed From School or Work|Investigator Assessment of Treatment Efficacy of Participants|Investigator Assessment of Treatment Handling of Participants|Assessment of Treatment Efficacy by the Participants|Assessment of Treatment Handling by the Participants|Investigator Assessment of Treatment Satisfaction of Participants","Pfizer","All","Child, Adult, Older Adult",,"80","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","3090A1-4406|B1821011","January 2008","October 2016","October 2016","July 14, 2008","September 24, 2018","October 25, 2018","Allgemeines Krankenhaus Linz, Kinderklinik, Linz, Austria|Sonnengesundheitszentrum, München, Bayern, Germany|Werlhof-Institut für Haemostaseologie GmbH, Hannover, Niedersachsen, Germany|Institut für Thrombophilie und Hämostaseologie, Muenster, Nordrhein-westfalen, Germany|Vivantes Klinikum im Friedrichshain, Berlin, Germany|Charite Campus Virchow-Klinikum, Padiatrie mit S. Hamatologie und Onkologie, Berlin, Germany|Kinder- und Jugendarzt-Praxis Blaubeuren, Blaubeuren, Germany|Institute of Experimental Haematology and Transfusion Medicine, Bonn, Germany|Praxis fur Kinder- und Jugendmedizin, Homoopathie, Brannenburg, Germany|Klinikum Bremen-Mitte gGmbH, Professor Hess Kinderklinik, Bremen, Germany|Klinikum Delmehorst gGmbH, Padiatrie, Delmenhorst, Germany|Universitaetsklinikum Duesseldorf, Klinik f. Kinder-Onkologie, Haematologie u. Klinische Immunologie, Duesseldorf, Germany|CRC Coagulation Research Centre GmbH, Duisburg, Germany|Klinikum der Martin-Luther-Universitaet Halle-Wittenberg, Halle, Germany|Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany|Universitaetsklinikum Eppendorf, Hamburg, Germany|SRH Kurpfalzkrankenhaus Heidelberg, Heidelberg, Germany|Gemeinschaftspraxis fuer Haematologie und Onkologie, Koeln, Germany|Klinikum Memmingen, Kinderklinik, Memmingen, Germany|Universitaetskinderklinik und Poliklinik im Dr. von Haunerschen, Muenchen, Germany|Universitaetsklinik fuer Kinder- und Jugendmedizin, Tuebingen, Germany",,"https://ClinicalTrials.gov/show/NCT00714415"
36,"NCT02263456","A Study to Compare the Pharmacokinetics and Safety of Replenine®-VF, Replenine® or Other Factor IX in Haemophilia B",,"Completed","No Results Available","Haemophilia B","Biological: Replenine®-VF (High Purity Factor IX)","Area under the concentration/time curve (AUC) for plasma Factor IX","Bio Products Laboratory","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3",,"Other","Interventional","Primary Purpose: Treatment","RP9VFPK","July 1997","September 2001",,"October 13, 2014",,"October 13, 2014","The Royal Free Hospital, Pond Street, Hampstead, London, United Kingdom|The North Hampshire Hospital, Aldermaston Road, Basingstoke, United Kingdom|Addenbrooke's Hospital, Hills Road, Cambridge, United Kingdom|University Hospital of Wales, Health Park, Cardiff, United Kingdom|Kingston General Hospital, Beverly Road, Hull, United Kingdom|Leicester Royal Infirmary, Infirmary Square, Leicester, United Kingdom|Lincoln County Hospital, Greetwell Road, Lincoln, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02263456"
37,"NCT02250573","An Open-study to Investigate the Safety and Efficacy of Replenine®-VF in Haemophilia B Subjects Undergoing Surgery",,"Completed","No Results Available","Haemophilia B","Biological: Replenine®-VF (High Purity Factor IX)","Incremental recovery for Factor IX","Bio Products Laboratory","All","Child, Adult, Older Adult","Phase 3",,"Other","Interventional","Primary Purpose: Treatment","R9VFSUR","December 2005","April 2006",,"September 26, 2014",,"February 22, 2018","Samodzielny Publiczny Zaklad Opieki Zdrowotnej nad Matka I Dzieckiem, ul. Krysiewicza 7/8., Poznan, Poland|Institutul National de Haemtologie, 2-8 Constantin Caracas Str., Bucharest, Romania|Spitalul de urgenta pentru copii ""Louis Turcana"", Str. losef Nemoianu 2., Timisoara, Romania|Kirov Research Institute of Haematology, 72 Krasnoarmeyskaya ul., Kirov, Russian Federation|Haematology Centre, Russian Academy if Medical Sciences, 4a Novozykovsky Proezed., Moscow, Russian Federation",,"https://ClinicalTrials.gov/show/NCT02250573"
38,"NCT00759876","Phase 2a Extension Study of Ataluren (PTC124) in Duchenne Muscular Dystrophy (DMD)",,"Terminated","Has Results","Duchenne Muscular Dystrophy","Drug: Ataluren","Number of Participants With Treatment Emergent Adverse Events (TEAEs)|Change From Baseline in 6-Minute Walk Distance (6MWD) as Measured by the 6-minute Walk Test (6MWT)|Change From Baseline in Proximal Muscle Function as Assessed by Speed During Timed Function Tests|Change From Baseline in Standing From Supine Position as Assessed by Method Scores During Timed Function Tests|Change From Baseline in Run/Walk 10-Meters as Assessed by Method Scores During Timed Function Tests|Change From Baseline in Ascending 4 Stairs as Assessed by Method Scores During Timed Function Tests|Change From Baseline in Descending 4 Stairs as Assessed by Method Scores During Timed Function Tests|Change From Baseline in Force Exerted During Knee Flexion and Extension, Elbow Flexion and Extension, Shoulder Abduction, and Hand Grip as Assessed by Myometry|Change in Resting, Active, and Recovery Heart Rate as Assessed by Heart Rate Monitoring With the Polar RS400|Change From Baseline in Verbal Memory and Attention as Assessed by the Digit Span Task|Change From Baseline in Participant-Reported Health-Related Quality of Life (HRQL) as Measured by the Pediatric Quality of Life Inventory (PedsQL) Inventory|Change From Baseline in Parent- or Caregiver-Reported HRQL as Measured by the PedsQL Inventory|Change From Baseline in Serum Creatine Kinase (CK) Levels|Change From Baseline in Dystrophin Expression on Biceps Muscle Biopsy as Measured by Immunofluorescence Staining of the Sarcolemmal Membrane With an Antibody to the C-Terminal Portion of the Dystrophin Protein|Study Drug Compliance|Pharmacokinetics: Ataluren Plasma Exposure in All Participants|Pharmacokinetics: Ataluren Plasma Exposure in Ambulatory Participants|Corticosteroid Plasma Concentrations as Assessed by a Validated Bioanalytical Method, in Participants Who Received a Daily Corticosteroid Regimen With Prednisone or Deflazacort|Change in Muscle Composition as Assessed by Limb Magnetic Resonance (MR) Testing","PTC Therapeutics|Genzyme, a Sanofi Company","Male","Child, Adult, Older Adult","Phase 2","36","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PTC124-GD-004e-DMD","August 13, 2008","May 17, 2010","May 17, 2010","September 25, 2008","October 29, 2020","October 29, 2020","Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|University of Utah, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT00759876"
39,"NCT01154231","BeneFIX Drug Use Results Survey [All-Case Surveillance]",,"Completed","Has Results","Hemophilia B","Drug: Nonacog Alfa (Genetical Recombination)","Number of Bleeding Episodes (Annual Bleeding Event Rate) During Periodic Replacement Therapy|Number of Administrations Required for Hemostasis for Bleeding Events|Subjective Evaluation of Each Therapeutic Administration for Bleeding Episodes","Pfizer",,"Child, Adult, Older Adult",,"314","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","3090X1-4415|B1821004|B1821009","February 2010","August 2014","February 27, 2017","June 30, 2010","April 11, 2017","October 17, 2018","Tokyo Medical University Hospital, Shinjuku-ku, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT01154231"
40,"NCT00592553","Phase 2B Study of PTC124 (Ataluren) in Duchenne/Becker Muscular Dystrophy (DMD/BMD)",,"Completed","Has Results","Duchenne Muscular Dystrophy|Becker Muscular Dystrophy","Drug: Ataluren|Drug: Placebo","Change From Baseline in 6MWD at Week 48|Change From Baseline in Time to Stand From Supine Position at Week 48|Change From Baseline in Time to Walk/Run 10 Meters at Week 48|Change From Baseline in Time to Climb 4 Stairs at Week 48|Change From Baseline in Time to Descend 4 Stairs at Week 48|Change From Baseline in Force Exerted During Knee Flexion and Extension, Elbow Flexion and Extension, and Shoulder Abduction at Week 48, as Assessed by Myometry|Change From Baseline in Mean Activity Period/Day/Visit at Week 48, as Assessed by Step Activity Monitoring (SAM)|Change From Baseline in Mean Total Step Count/Day/Visit During the Active Periods at Week 48, as Assessed by SAM|Change From Baseline in Mean Total Step Count/Hour During the Active Period at Week 48, as Assessed by SAM|Change From Baseline in Maximum Continuous 10-minute, 20-minute, 30-minute, and 60-minute Total Step Count at Week 48, as Assessed by SAM|Change From Baseline in Percentage of Time During the Active Period Spent at Low Activity (Less Than or Equal to [≤] 15 Steps/Minute), Medium Activity (16-30 Steps/Minute), and High Activity (Greater Than [>]30 Steps/Minute) at Week 48|Change From Baseline in Participant- Reported Health-Related Quality of Life (HRQL) as Measured by the Pediatric Quality of Life Inventory (PedsQL) Physical, Emotional, Social, and School Functioning Domain Scores at Week 48|Change From Baseline in Parent/Caregiver- Reported HRQL as Measured by the PedsQL Physical, Emotional, Social, and School Functioning Domain Scores at Week 48|Change From Baseline in Participant-Reported HRQL as Measured by the Total Fatigue Scale Score at Week 48|Change From Baseline in Parent/Caregiver-Reported HRQL as Measured by the Total Fatigue Scale Score at Week 48|Parent/Caregiver-Reported Treatment Satisfaction Questionnaire for Medication (TSQM) Score|Change From Baseline in Participant/Caregiver-Reported Number of Daily Accidental Falls at Week 48|Change From Baseline in Number of Digits Recalled Forwards and Backwards on Digit Span Task at Week 48|Change From Baseline in Heart Rate Before, During, and After Each 6MWT at Week 48, as Assessed by Heart Rate Monitoring With the Polar® RS400|Change From Baseline in Serum Concentration of Creatine Kinase (CK) at Week 48|Percent Change From Pre-Treatment Visit (1 Week Prior to Baseline Visit) in Biceps Muscle Dystrophin Expression at Post-Treatment Visit (Week 36), as Determined by Immunofluorescence","PTC Therapeutics","Male","5 Years and older   (Child, Adult, Older Adult)","Phase 2","174","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PTC124-GD-007-DMD|2007-005478-29","February 29, 2008","December 31, 2009","December 31, 2009","January 14, 2008","April 7, 2020","April 7, 2020","University of California-Davis, Sacramento, California, United States|The Children's Hospital, Aurora, Colorado, United States|Child Neurology Center of Pensacola, Pensacola, Florida, United States|University of Iowa Healthcare, Iowa City, Iowa, United States|University of Kansas Medical Centre, Kansas City, Kansas, United States|Children's Hospital of Boston/Harvard Medical School, Boston, Massachusetts, United States|University of Minnesota, Minneapolis, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Columbia University Medical School, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Shriners Hospital for Children, Portland, Oregon, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Southwestern University, Dallas, Texas, United States|University of Utah, Salt Lake City, Utah, United States|Royal Children's Hospital, Parkville, Victoria, Australia|Institute For Neuromuscular Research, The Children's Hospital at Westmead, Westmead, Australia|University Hospital KU Leuven, Leuven, Belgium|Alberta Children's Hospital, Calgary, Alberta, Canada|British Columbia Children's Hospital, Vancouver, British Columbia, Canada|London Health Sciences Center, London, Ontario, Canada|Service de Neuropediatrie, hôpital La Timone, Marseille, France|Neuromuscular center of Nantes, Nantes, France|Groupe Hospitalier La Pitie-Salpetriere, Paris, France|University Clinic for Children, University of Essen, Essen, Germany|University Hospital, Freiburg, Germany|Hadassah Medical Center, Hebrew University Hospital, Jerusalem, Israel|Ospedale Maggiore Policlinico in Milan, Milan, Italy|Ospedale Pediatrico Bambino Gesu, Rome, Italy|U.O. Complessa di Neuropsichiatria Infantile, Rome, Italy|Hospital Sant Joan de déu, Barcelona, Spain|Hospital Universitari La Fe, Valencia, Spain|Queen Silvia Children's Hospital, Göteborg, Sweden|Astrid Lindgren Pediatric Hospital, Stockholm, Sweden|Imperial College London, Hammersmith Hospital, London, United Kingdom|Univ of Newcastle, Institute of Human Genetics, Newcastle, United Kingdom|Robert Jones and Agnes Hunt Orthopaedic NHS Trust, Oswestry, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00592553"
41,"NCT01140451","Extension Study of Ataluren (PTC124) in Cystic Fibrosis",,"Completed","Has Results","Cystic Fibrosis","Drug: Ataluren","Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)|Number of Participants With Any Treatment-Emergent Laboratory Abnormality (TELA)|Percentage of Predicted Function (Percent-Predicted) of Forced Expiratory Volume in 1 Second (FEV1) at Baseline|Percentage Change From Baseline in Percent-Predicted of FEV1 at Weeks 48 and 96|Percent-Predicted of Forced Vital Capacity (FVC) at Baseline|Percentage Change From Baseline in Percent-Predicted of FVC at Weeks 48 and 96|Percent-Predicted of Forced Expiratory Flow Between 25% and 75% of Expiration (FEF25-75) at Baseline|Percentage Change From Baseline in Percent-Predicted of FEF25-75 at Weeks 48 and 96|Number of Participants With Pulmonary Exacerbations as Defined by Modified Fuch's Criteria|Rate of Pulmonary Exacerbations as Defined by Modified Fuch's Criteria Over 48 Weeks|Duration of Pulmonary Exacerbations as Defined by Modified Fuch's Criteria|Number of Participants With Severe Pulmonary Exacerbations as Defined by Modified Fuch's Criteria|Change From Baseline for the Respiratory Domain Score of the Cystic Fibrosis (CF) Questionnaire-Revised (CFQ-R) at Weeks 48 and 96|Rate of Study Drug Compliance|Predose Concentration of Ataluren|Number of Participants Who Required Interventions for Pulmonary Symptoms|Number of Participants With Disruptions in Activities of Daily Living Because of Pulmonary Symptoms|Duration of Disruptions in Activities of Daily Living Because of Pulmonary Symptoms|Change From Baseline in Body Weight at Weeks 48 and 96|Change From Baseline in Body Mass Index (BMI) at Weeks 48 and 96|Total Lung Computed Tomography (CT) Score at Weeks 48 and 96|Change From Baseline in the Nasal Transepithelial Potential Difference (TEPD) at Week 48|Change From Baseline in the Concentration of Sweat Chloride at Week 48","PTC Therapeutics|Cystic Fibrosis Foundation","All","6 Years and older   (Child, Adult, Older Adult)","Phase 3","191","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PTC124-GD-009e-CF|Orphan Product Grant #FD003715|2010-019692-30","August 12, 2010","December 2, 2013","December 2, 2013","June 9, 2010","October 19, 2020","October 19, 2020","University of Alabama-Birmingham, Birmingham, Alabama, United States|Miller Children's Hospital Long Beach, Long Beach, California, United States|Lucile Packard Children's Hospital, Palo Alto, California, United States|The Children's Hospital, Aurora, Colorado, United States|University of Miami, Miami, Florida, United States|Emory University Cystic Fibrosis Center, Atlanta, Georgia, United States|Children's Memorial Hospital, Chicago, Illinois, United States|Johns Hopkins Children's Center, Baltimore, Maryland, United States|Children's Hospital Boston, Boston, Massachusetts, United States|Washington University, Saint Louis, Missouri, United States|St. Vincent's Hospital, New York, New York, United States|New York Medical College, Valhalla, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Rainbow Babies & Children's Hospital, Cleveland, Ohio, United States|Childrens Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|Hôpital Erasme, Brussels, Belgium|Hôpital Universitaire des Enfants Reine Fabiola, Brussels, Belgium|University Hospital Brussels, Brussels, Belgium|University Hospital Leuven, Leuven, Belgium|University of Toronto, Toronto, Canada|Hôpital Cochin, Paris, France|Hôpital Necker - Enfants Malades, Paris, France|Hôpital des Enfants, Toulouse, France|Klinikum der Universität Köln, Köln, Germany|Hadassah University Hospital - Mount Scopus, Jerusalem, Israel|Università La Sapienza, Roma, Italy|Azienda Ospedaliera di Verona, Verona, Italy|Universitair Medisch Centrum Utrecht, Utrecht, Netherlands|Hospital Universitario La Paz, Madrid, Spain|Karolinska University Hospital, Huddinge, Stockholm, Sweden|Belfast City Hospital, Belfast, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01140451"
42,"NCT00835068","Post Marketing Observational Study of Reformulated BeneFIX",,"Completed","Has Results","Hemophilia B","Other: No intervention","Number of Participants With Treatment-Related Adverse Events (AEs) and Serious Adverse Events (SAEs) Prior to Safety Amendment|Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) by Relationship After Safety Amendment|Number of Participants With Events of Special Interest|Number of Bleeding Episodes|Number of Bleeding Episodes Requiring Treatment by Injection|Total Consumption of BeneFIX|Subjective Assessment of Efficacy by Participant|Dose Per Injection of BeneFIX|Subjective Assessment of Efficacy by Physician|Subjective Assessment of Ease of Use by Participant","Pfizer","All","Child, Adult, Older Adult",,"58","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","3090X1-4409|B1821007","January 2009","October 2013","October 2013","February 3, 2009","September 17, 2014","September 17, 2014","Pfizer Investigational Site, Chamberry, Cedex, France|Pfizer Investigational Site, Le Chesnay, Cedex, France|Pfizer Investigational Site, Caen Cedex 9, France|Pfizer Investigational Site, Clermont Ferrand, France|Pfizer Investigational Site, Dijon Cedex, France|Pfizer Investigational Site, leKremlin-Bicetre, France|Pfizer Investigational Site, Lyon, France|Pfizer Investigational Site, Marseille Cedex 05, France|Pfizer Investigational Site, Montmorency, France|Pfizer Investigational Site, Montpellier Cedex 5, France|Pfizer Investigational Site, Nantes cedex 1, France|Pfizer Investigational Site, Paris, France|Pfizer Investigational Site, Paris, France|Pfizer Investigational Site, Rouen, France|Pfizer Investigational Site, Saint Priest en Jarez, France|Pfizer Investigational Site, Tours, France|Pfizer Investigational Site, Vandoeuvre Les Nancy Cedex, France",,"https://ClinicalTrials.gov/show/NCT00835068"
43,"NCT01659385","Leptin Levels in Papillary Thyroid Cancer","LL-PTC","Completed","No Results Available","Thyroid Cancer, Papillary|Leptin Levels",,"evaluating Leptin level Evaluating Serum Leptin Levels Between 3 Groups. One Group with Papillary Thyroid Carcinoma. One Group With Benign Nodules. One Group with Normal Thyroid.","University of Nebraska","Female","19 Years to 75 Years   (Adult, Older Adult)",,"18","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","276-12-EP","August 2012","June 2013","June 2013","August 7, 2012",,"May 11, 2017","University of Nebraska Medical Center, Omaha, Nebraska, United States",,"https://ClinicalTrials.gov/show/NCT01659385"
44,"NCT05044845","Needs Assessment of Knowledge, Beliefs, and Attitudes of Patients With Hemophilia B About Gene Therapy",,"Recruiting","No Results Available","Gene Therapy|Hemophilia B","Behavioral: Interview","Use of semi-structured interviews to qualitatively describe their attitudes, beliefs, and knowledge of gene therapy in hemophilia B","St. Jude Children's Research Hospital","All","12 Years and older   (Child, Adult, Older Adult)",,"60","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","BINFORMED","February 2022","June 2022","July 2022","September 16, 2021",,"January 19, 2022","St. Jude Children's Research Hospital, Memphis, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT05044845"
45,"NCT02213250","An Open-Label, Single Dose Pharmacokinetic Study of Benefix (Recombinant Factor IX) in Male Chinese Subjects With Hemophilia B",,"Completed","Has Results","Hemophilia B","Drug: BENEFIX","Maximum Observed Plasma Concentration (Cmax)|Area Under the Concentration Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast)|Area Under the Concentration Time Curve From Time 0 to Infinity (AUCinf)|Time to Reach Cmax (Tmax)|Volume of Distribution at Steady State (Vss)|Terminal Phase Rate Constant (Kel)|Mean Residence Time (MRT)|Plasma Decay Half-Life (t½)|Systemic Clearance (CL)|Incremental Recovery|Number of Participants With Treatment-Emergent Adverse Events (TEAE), Serious Adverse Events (SAE), and Withdrawals Due to Adverse Events (AE)|Number of Participants With Abnormal Clinical Laboratory Measurements (Without Regard to Baseline Abnormality)|Number of Participants With Vital Signs Post-Dose Data Met Criteria of Potential Clinical Concern (Without Regard to Baseline Abnormality)|Number of Participants With Inhibitor Development|Number of Participants With Allergic Reactions|Number of Subjects With Thrombogenicity","Pfizer","Male","6 Years and older   (Child, Adult, Older Adult)","Phase 1","12","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","B1821048|2015-003027-61","March 2015","April 2015","April 2015","August 11, 2014","July 25, 2016","July 25, 2016","Peking Union Medical College Hospital, Beijing, China|Hematology Department,Beijing Children's Hospital, Capital Medical University, Beijing, China",,"https://ClinicalTrials.gov/show/NCT02213250"
46,"NCT01158300","PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors",,"Completed","No Results Available","Brain and Central Nervous System Tumors","Drug: VEGF inhibitor PTC299","Maximum-tolerated dose|Adverse events|Percentage of study participants with complete response or partial response to the study treatment|Pharmacokinetics|Change from baseline in blood angiogenic markers and cytokines at discontinuation or completion of treatment","Pediatric Brain Tumor Consortium|National Cancer Institute (NCI)|PTC Therapeutics","All","3 Years to 21 Years   (Child, Adult)","Phase 1","28","Other|NIH|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000680634|U01CA081457|PBTC-031|PTC299-ONC-010-PBT","November 2010","January 2015","January 2015","July 8, 2010",,"May 4, 2015","UCSF Cancer Center and Cancer Research Institute, San Francisco, California, United States|Children's National Medical Center, Washington, District of Columbia, United States|Children's Memorial Hospital - Chicago, Chicago, Illinois, United States|Duke Comprehensive Cancer Center, Durham, North Carolina, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|Texas Children's Cancer Center and Hematology Service at Texas Children's Hospital, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01158300"
47,"NCT03995784","Study of Next-Generation Recombinant Factor IX Variant in Adult Subjects With Hemophilia B",,"Completed","Has Results","Hemophilia B","Biological: Coagulation Factor IX variant","Number of Subjects Who Achieved FIX Level ≥12%|FIX Activity Levels (Actual and Change From Baseline) in All Subjects|Pharmacokinetic (PK) Analysis - AUC|PK Analysis - Clearance|PK Analysis - Maximum Concentration During SC Dosing|PK Analysis - Half-Life and Residence Time|PK Analysis - Volume of Distribution at Steady-State Observed|Occurrence of Clinical Thrombotic Event|Occurrence of an Antibody Response|Thrombogenicity Assessment - Fibrinogen|Thrombogenicity Assessment - D-Dimer|Thrombogenicity Assessment - Prothrombin Fragments 1 + 2|Thrombogenicity Assessment - Thrombin/Antithrombin","Catalyst Biosciences","Male","18 Years and older   (Adult, Older Adult)","Phase 2","6","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DLZ-201","June 18, 2019","February 28, 2020","April 30, 2020","June 24, 2019","August 9, 2021","August 9, 2021","Haemophilia Comprehensive Care Centre, Johannesburg, South Africa","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/84/NCT03995784/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/84/NCT03995784/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03995784"
48,"NCT01507896","BAX 326 Surgery Study in Hemophilia B Patients",,"Completed","Has Results","Hemophilia B","Biological: Recombinant factor IX","Intraoperative Hemostatic Efficacy|Actual Intraoperative Blood Loss|Actual Intraoperative Blood Loss Compared to Average and Maximum Blood Loss Predicted Preoperatively by the Operating Surgeon|Postoperative Hemostatic Efficacy at Drain Removal|Postoperative Hemostatic Efficacy at Postoperative Day 3|Postoperative Hemostatic Efficacy on Day of Discharge|Actual Postoperative Blood Loss|Actual Postoperative Blood Loss Compared to Average and Maximum Blood Loss Predicated Preoperatively by the Operating Surgeon|Daily Weight-Adjusted Dose of BAX326 Per Participant|Total Weight-Adjusted Dose of BAX326 Per Participant|Number of Units of Blood Product Transfused|Volume of Blood Product Transfused|Safety: Number of Participants Who Developed Inhibitory Antibodies to Factor IX (FIX)|Safety: Number of Participants Who Developed Total Binding Antibodies to Factor IX (FIX)|Safety: Number of Adverse Events Related to BAX326|Safety: Occurence of a Thrombotic Event|Pre-Surgical Pharmacokinetics (PK): Area Under the Plasma Concentration Versus Time Curve (AUC) From 0 to 72 Hours Post-infusion Per Dose|Pre-Surgical Pharmacokinetics (PK): Total Area Under the Plasma Concentration Versus Time Curve Per Dose (Total AUC/Dose)|Pre-Surgical Pharmacokinetics (PK): Mean Residence Time (MRT)|Pre-Surgical Pharmacokinetics (PK): Factor IX (FIX) Clearance (CL)|Pre-Surgical Pharmacokinetics (PK): Incremental Recovery (IR) at 30 Min|Pre-Surgical Pharmacokinetics (PK): Elimination Phase Half-life (T 1/2)|Pre-Surgical Pharmacokinetics (PK): Volume of Distribution at Steady State (Vss)|Incremental Recovery (IR) at 15±5 Minutes Following Loading Dose Prior to Surgery","Baxalta now part of Shire|Takeda","All","12 Years to 65 Years   (Child, Adult, Older Adult)","Phase 3","30","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","251002|2011-000413-39","December 19, 2011","May 15, 2014","May 15, 2014","January 11, 2012","February 15, 2017","May 19, 2021","Instituto de Hematología y Medicina Clínica Rubén Dávoli, Rosario, Argentina|Specialized Haematological Hospital ""Joan Pavel"", Sofia, Bulgaria|Hospital Dr. Sotero del Rio, Santiago, Chile|Centro Medico Imbanaco, Cali, Colombia|Klinika detska hematologie a onkologie, Fakultni Nemocnice Motol, Prague, Czechia|Medical University Lodz, Copernicus Hospital, Department of Hematology, Lodz, Poland|Independent Public Pediatric Teaching Hospital, Clinical Department of Hematology and Pediatrics, Warsaw, Poland|Institute of Haematology and Transfusion Medicine, Warsaw, Poland|Louis Turcanu Emergency Clinical Children´s Hospital, Timisoara, Romania|Federal State Institution Kirov, Hematology and Blood Transfusion Research Institute under the Federal Agency for High-Tech Medical Care, Kirov, Russian Federation|Children's Territorial Clinical Hospital, Krasnodar, Russian Federation|Hematology Research Center RAMS, Moscow, Russian Federation|State Institution ""Institute of Blood Pathology and Transfusion Medicine under the Academy of Medical Sciences of Ukraine"", Lviv, Ukraine|Royal Manchester Children's Hospital, Department of Hematology, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01507896"
49,"NCT01027364","Study of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Participants With Hemophilia B",,"Completed","Has Results","Severe Hemophilia B","Drug: Factor IX (rFIXFc)|Drug: rFIX","Number of Participants With Potentially Clinically Significant Laboratory Abnormalities|Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)|Number of Participants With Non-serious Treatment-emergent Adverse Events (TEAEs) During the Surgical / Rehabilitation Period|Number of Participants With Treatment-emergent Serious Adverse Events (TESAEs) During the Surgical / Rehabilitation Period|Incidence Rate of FIX Inhibitor Development|Annualized Bleeding Rate|Comparison of Annualized Bleeding Rates|Participant Assessment of Response to Injections to Treat a Bleeding Episode|Physicians' Global Assessments of Participants' Response to Treatment With rFIXFc|Annualized rFIXFc Consumption Per Participant|Average Weekly Dose For the Fixed Weekly Interval Prophylaxis Arm|Average Dosing Interval For the Individualized Interval Prophylaxis Arm|Annualized Bleeding Rate by Type of Bleed (Spontaneous and Traumatic)|Annualized Bleeding Rate by Location of Bleed (Joint, Muscle, Internal, Skin/Mucosa)|Number of Days From Last Injection to Treat a New Bleeding Episode|Number of Injections Required for Resolution of a Bleeding Episode|Number of Injections Required for Resolution of a Bleeding Episode by Location of Bleed|Total Dose Per Injection Required for Resolution of a Bleeding Episode by Location of Bleed|Hemophilia-Specific Quality of Life Index for Adults (Haem-A-QoL) Questionnaire: Change From Baseline to Week 26|Haem-A-QoL Questionnaire for Adults: Change From Baseline to Week 52|Hemophilia-Specific Quality of Life Index for Children (Haemo-QoL) Questionnaire: Change From Baseline to Week 26 and Week 52|Investigators'/Surgeons' Assessment of Participants' Response to rFIXFc for Major Surgery|Number of Injections Required to Maintain Hemostasis During Major Surgery|Dose Per Injection and Total Dose Required to Maintain Hemostasis During Major Surgery|Estimated Total Blood Loss During Major Surgery|Number of Transfusions Required Per Surgery|Maximum Concentration (Cmax)|Area Under the Curve (AUC) Per Dose|Half Life (t1/2) Alpha and t1/2 Beta|Clearance (CL)|Mean Residence Time (MRT)|Volume in Steady State (Vss)|Incremental Recovery|Time to 1% and 3% FIX Activity|Number of Participants With Clinically Relevant Abnormalities or Relevant Changes From Baseline in Vital Signs|Coagulation Parameter: Change From Pre-dose Values in Prothrombin Split Fragments 1+ 2 (F 1+2)|Coagulation Parameter: Change From Pre-dose Values in Thrombin-antithrombin (TAT) Complex|Coagulation Parameter: Change From Pre-dose Values in D-dimer","Bioverativ Therapeutics Inc.|Swedish Orphan Biovitrum|Sanofi","Male","12 Years and older   (Child, Adult, Older Adult)","Phase 3","123","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","998HB102|2009-014295-21","December 2009","July 2012","July 2012","December 7, 2009","September 4, 2014","December 19, 2020","Research Site, Phoenix, Arizona, United States|Research Site, Sacramento, California, United States|Research Site, Aurora, Colorado, United States|Research Site, Chicago, Illinois, United States|Research Site, Indianapolis, Indiana, United States|Research Site, East Lansing, Michigan, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Seattle, Washington, United States|Research Site, Camperdown, New South Wales, Australia|Research Site, Adelaide, South Australia, Australia|Research Site, Perth, Western Australia, Australia|Research Site, Bruxelles, Belgium|Research Site, Leuven, Belgium|Research Site, Campinas, Brazil|Research Site, Calgary, Alberta, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Vancouver, Canada|Research site, Beijing, China|Research Site, Guangzhou, China|Research Site, Shanghai, China|Research Site, Tianjin, China|Research Site, Lyon, France|Research Site, Marseille, France|Research Site, Berlin, Germany|Research Site, Bonn, Germany|Research Site, Pokfulam, Hong Kong|Research Site, Shatin, Hong Kong|Research Site, Ludhiana, Punjab, India|Research Site, Vellore, Tamil Nadu, India|Research Site, Bangalore, India|Research Site, Pune, India|Research Site, Firenze, Italy|Research Site, Milano, Italy|Research Site, Kasihara-City, Japan|Research Site, Kawasaki City, Japan|Research Site, Kitakyushu, Japan|Research Site, Nagoya, Japan|Ressearch Site, Suginami-ku, Japan|Research Site, Tokyo, Japan|Research Site, Lodz, Poland|Research Site, Warszawa, Poland|Research Site, Moscow, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, Johannesburg, Gauteng, South Africa|Research Site, Cape Town, Western Cape, South Africa|Research Site, Malmö, Sweden|Research Site, Stockholm, Sweden|Research Site, Cambridge, United Kingdom|Research Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01027364"
50,"NCT00037557","Study Evaluating rFIX; BeneFIX in Severe Hemophilia B",,"Completed","No Results Available","Hemophilia B","Drug: BeneFIX","To characterize the safety and efficacy of rFIX in children less than 6 years of age with severe hemophilia B in the setting of acute bleeding episodes, prophylaxis, and/or surgery.|To measure the incremental recovery of rFIX in children following a 75-IU/kg bolus infusion.","Wyeth is now a wholly owned subsidiary of Pfizer","All","up to 5 Years   (Child)","Phase 3","20","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","3090A1-301","September 2002",,"November 2007","May 20, 2002",,"December 27, 2007","Aurora, Colorado, United States|Detroit, Michigan, United States|New Brunswick, New Jersey, United States|Chapel Hill, North Carolina, United States|Dayton, Ohio, United States|Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00037557"
51,"NCT01557400","Study of Ataluren for Previously Treated Participants With Nonsense Mutation Duchenne/Becker Muscular Dystrophy (nmDBMD) in Europe, Israel, Australia, and Canada",,"Completed","Has Results","Duchenne Muscular Dystrophy|Becker Muscular Dystrophy|Dystrophinopathy","Drug: Ataluren","Number of Participants With Treatment Emergent Adverse Events (TEAEs)|Change From Baseline in 6MWD as Measured by the 6MWT|Change From Baseline in Physical Function as Measured by the NSAA|Change From Baseline in Time to Stand From Supine Position|Change From Baseline in Time to Walk/Run 10 Meters|Change From Baseline in Pulmonary Function as Measured by Spirometry|Change From Baseline in Participant and Parent/Caregiver-Reported ADL, as Measured by the EK Scale","PTC Therapeutics","Male","Child, Adult, Older Adult","Phase 3","94","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PTC124-GD-019-DMD","May 20, 2012","January 19, 2018","January 19, 2018","March 19, 2012","November 25, 2020","November 25, 2020","Royal Children's Hospital, Parkville, Melbourne, Australia|Institute For Neuromuscular Research, The Children's Hospital at Westmead, Westmead, Australia|University Hospital KU Leuven, Leuven, Belgium|Alberta Children's Hospital, Calgary, Alberta, Canada|British Columbia Children's Hospital, Vancouver, British Columbia, Canada|Children's Hospital of Western Ontario, London, Ontario, Canada|Hôpital d'Enfants CHU Timone, Marseille, France|Laboratoire d'Exploration Fonctionnelles, Nantes, France|Groupe Hospitalier La Pitie-Salpetriere, Paris, France|University of Essen - Clinic for Children, Essen, Germany|University Hospital, Freiburg, Germany|Hadassah Medical Center, Hebrew University Hospital, Jerusalem, Israel|Ospedale Maggiore Policlinico in Milan, Milan, Italy|Ospedale Pediatrico Bambino Gesu, Rome, Italy|U.O. Complessa di Neuropsichiatria Infantile, Rome, Italy|Hospital Sant Joan de déu, Barcelona, Spain|Hospital Universitari La Fe, Valencia, Spain|Queen Silvia Children's Hospital, Göteborg, Sweden|Astrid Lindgren Pediatric Hospital, Stockholm, Sweden|Great Ormond Street Hospital, London, United Kingdom|University of Newcastle Institute of Human Genetics, Newcastle Upon Tyne, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/00/NCT01557400/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/00/NCT01557400/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01557400"
52,"NCT02263469","A Study to Investigate the Safety and Efficacy of Replenine®-VF in Haemophilia B Patients Under the Age of 6 Years",,"Completed","No Results Available","Haemophilia B","Biological: Replenine®-VF (High Purity Factor IX)","Amount of Factor IX Administered per Month (IU/KG)","Bio Products Laboratory","All","up to 6 Years   (Child)","Phase 3",,"Other","Interventional",,"R9VF03","August 2005","July 2006",,"October 13, 2014",,"October 13, 2014","Samodzielny Publiczny Dzieciecy Szpital Kliniczny, Oddzial Pediatrii, Hematologii I Onkologii, ul. Marszalkowska 24, 00-576, Warsaw, Poland|Institute of Urgent and Recovery Surgery, Academy of Medical Science of Ukraine, Leninski Avenue, Donetsk, Ukraine|Institute of Haematology and Transfusiology, Academy of Medical Science of Ukrainem Berlynskogo Str., Kiev, Ukraine|Institute of Blood Pathology and Transfusion Medicine, Academy of Medical Science of Ukraine, Gen. Chuprynkea Str., Lviv, Ukraine",,"https://ClinicalTrials.gov/show/NCT02263469"
53,"NCT00484185","Post Marketing Surveillance To Observe Safety and Efficacy Of BeneFIX In Patients With Hemophilia B",,"Completed","Has Results","Hemophilia B","Drug: BeneFIX (coagulation factor IX (recombinant))","Number of Participants With Adverse Events (AEs) According to Baseline Characteristics|Number of Participants With Adverse Events (AEs) According to Severity|Number of Participants With Action Taken in Response to Adverse Events (AEs)|Number of Participants With Adverse Events (AEs) According to Seriousness|Number of Participants With Outcome in Response to Adverse Events (AEs)|Number of Participants With Adverse Events (AEs) by Relationship|Number of Participants With Unexpected Adverse Events (AEs)|Mean Annualized Bleeding Rate (ABR)|Number of Responses to On-demand Treatment With Study Medication|Mean Number of Infusion of Study Medication|Mean Number of Breakthrough Bleeds Within 48 Hours of Study Medication|Average Infusion Dose of Study Medication|Total Infusion of Study Medication|Percentage of Participants With Efficacy Evaluation","Pfizer","All","Child, Adult, Older Adult",,"183","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","3090X1-4403|B1821005","August 2007","June 2012","June 2012","June 8, 2007","August 12, 2013","August 12, 2013","Pfizer Investigational Site, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT00484185"
54,"NCT02396342","Trial of AAV5-hFIX in Severe or Moderately Severe Hemophilia B",,"Completed","No Results Available","Hemophilia B","Genetic: AAV5-hFIX","Adverse Events|FIX-replacement-therapy-free FIX activity|Bleeding rate|Total consumption of FIX replacement therapy|Short Form-36 Quality of Life scores|Vector DNA in semen, blood, saliva, nasal secretions, urine and faeces|Neutralizing antibodies to AAV5|Total (IgM and IgG) antibodies to AAV5|AAV5 capsid-specific T cells|Antibodies to FIX|FIX inhibitors|Inflammatory markers: Interleukin(IL)-1β, IL-2, IL-6, Interferon γ, Monocyte Chemotactic Protein-1","UniQure Biopharma B.V.","Male","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","10","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CT-AMT-060-01","June 10, 2015","April 15, 2021","April 15, 2021","March 24, 2015",,"April 23, 2021","uniQure Investigative Site, Copenhagen, Denmark|uniQure Investigative Site, Berlin, Germany|uniQure Investigative Site, Frankfurt, Germany|uniQure Investigative Site, Amsterdam, Netherlands|uniQure Investigative Site, Groningen, Netherlands|uniQure Investigative Site, Rotterdam, Netherlands|uniQure Investigative Site, Utrecht, Netherlands",,"https://ClinicalTrials.gov/show/NCT02396342"
55,"NCT05203679","Evaluation of the Safety and Efficacy of Hemophilia B Gene Therapy Drug",,"Recruiting","No Results Available","Hemophilia B","Genetic: Single dose intravenous injection of BBM-H901","Incidence of dose limiting toxicity (DLT) events.|The incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)|Changes in liver function|FIX activity|FIX antigen level|The viral load of AAV vector|Annualized bleeding rate (ABR)|Improvement in patient's quality of life","Shanghai Belief-Delivery BioMed Co., Ltd","Male","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","12","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BBM001-CLN1001","December 30, 2021","June 30, 2024","June 30, 2028","January 24, 2022",,"January 24, 2022","Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, Tianjin, China",,"https://ClinicalTrials.gov/show/NCT05203679"
56,"NCT01247207","Study of Ataluren in Previously Treated Participants With Nonsense Mutation Dystrophinopathy (nmDBMD)",,"Enrolling by invitation","No Results Available","Duchenne Muscular Dystrophy","Drug: Ataluren","Number of Participants With Adverse Events|Number of Participants With Laboratory Parameters Abnormalities|Number of Participants With Abnormal Physical Findings","PTC Therapeutics","Male","Child, Adult, Older Adult","Phase 3","160","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PTC124-GD-016 DMD","November 30, 2010","December 15, 2023","December 15, 2023","November 24, 2010",,"November 9, 2021","Phoenix Childrens Hospital, Phoenix, Arizona, United States|UCLA, Los Angeles, California, United States|Stanford University, Palo Alto, California, United States|University of California-Davis, Sacramento, California, United States|University of CA, San Francisco-Benioff Children's Hospital, San Francisco, California, United States|The Children's Hospital, Aurora, Colorado, United States|Child Neurology Center of NW Florida, Gulf Breeze, Florida, United States|Rush Univ Medical Center, Chicago, Illinois, United States|University of Iowa Children's Hospital, Iowa City, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Children's Hospital of Boston/Harvard Medical School, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|University of Minnesota, Minneapolis, Minnesota, United States|Washington University Medical School, Saint Louis, Missouri, United States|Columbia University Medical School, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Shriners Hospital for Children-Portland, Portland, Oregon, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Univ of Pitt Medical Center, Pittsburgh, Pennsylvania, United States|Southwestern University, Dallas, Texas, United States|Texas Children's Hospital, Houston, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|University of Utah, Salt Lake City, Utah, United States|Children's Hospital of the King's Daughters, Norfolk, Virginia, United States|Seattle Children's Hospital, Seattle, Washington, United States|Alberta Children's Hospital, Calgary, Alberta, Canada|British Columbia Children's Hospital, Vancouver, British Columbia, Canada|Children's Hospital, London, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01247207"
57,"NCT03271892","Deciding on Active Surveillance or Surgery for Primary Management of Low Risk Papillary Thyroid Cancer","AS-PTC","Recruiting","No Results Available","Thyroid Cancer Stage I",,"Disease management decision (first part of the study, focused on treatment management choice)|Decision regret (second part of the study - follow-up of respective active surveillance and surgical patient groups)|Disease management decision rationale/explanation|Disease management decision-maker identification|Disease management decision satisfaction|Baseline coping mechanisms in all patients and respective study groups|Baseline evaluation of fear of disease progression in all patients and respective study groups (i.e. those who ultimately choose active surveillance or surgery)|Fear of disease progression at 1 year follow-up - in respective study groups (active surveillance or surgery)|Baseline evaluation of surgical fear in all patients and respective study groups (i.e. those who ultimately choose active surveillance or surgery)|Baseline evaluation of decision self-efficacy in all patients and respective study groups (i.e. those who ultimately choose active surveillance or surgery)|Psychological distress at 1 year in respective study groups|Disease-specific quality of life at 1 year|Body image perception at 1 year|Thyroid cancer surgery in patients who initially choose active surveillance|Disease progression|Thyroid surgical complications|New chronic prescription thyroid hormone use|Healthcare resource utilization|Serum thyroglobulin measurement in the active surveillance group","University Health Network, Toronto|Ontario Ministry of Health and Long Term Care|Canadian Cancer Society (CCS)","All","18 Years to 100 Years   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","15-8942","May 11, 2016","May 11, 2026","December 31, 2026","September 5, 2017",,"September 24, 2020","University Health Network, Toronto, Ontario, Canada|University Health Network, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03271892"
58,"NCT00139828","Post Marketing Study in Haemophilia B Patients Using Nonafact® (Human Coagulation Factor IX)",,"Completed","No Results Available","Hemophilia B","Drug: human coagulation Factor IX","Number of bleeding episodes (efficacy after administration)|Haematological variables and clinical chemistry (safety)|Adverse events (safety)|Occurrence of antibodies to factor IX","Prothya Biosolutions","All","6 Years and older   (Child, Adult, Older Adult)","Phase 4","12","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KB2000.03","May 2003",,"February 2007","August 31, 2005",,"August 30, 2007","Academic Medical Centre, Amsterdam, Netherlands|Kennemer Gasthuis, Haarlem, Netherlands|LUMC, Leiden, Netherlands|UMC St. Radboud, Nijmegen, Netherlands|Erasmus Medical Centre, Rotterdam, Netherlands|Leyenburg Hospital, The Hague, Netherlands|Van Creveldkliniek, Utrecht, Netherlands",,"https://ClinicalTrials.gov/show/NCT00139828"
59,"NCT01271868","Study of Recombinant Factor IX Product, IB1001, in Previously Treated Pediatric Subjects With Hemophilia B",,"Terminated","Has Results","Hemophilia B","Biological: IB1001","Number of Infusions Required for Bleed Control|Area Under the Curve (0-inf)|Terminal Half-life|Concentration (Max)|Incremental Recovery|Clearance|Volume of Distribution (Steady State)|Annualized Bleed Rate","Medexus Pharma, Inc.","All","up to 12 Years   (Child)","Phase 3","9","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IB1001-02","November 2010","December 2016","December 2016","January 7, 2011","April 11, 2019","March 15, 2021","RUSH University Medical Center, Chicago, Illinois, United States|Indiana Hemophilia & Thrombosis Center, Indianapolis, Indiana, United States|Gulf States Hemophilia & Thrombophilia Center, Houston, Texas, United States|AMRI Hospital, Institute of Haematology & Transfusion Medicine, Kolkata, India|Christian Medical College and Hospital, Ludhiana, India|Jehangir Clinical Development Centre Pvt. Ltd. Jehangir Hospital Premises, Pune, India|Sahyadri Speciality Hospital, Pune, India|Bhailal Amin General Hospital, Vadodara, India|Christian Medical College, Vellore, India|Great Ormond Street Hospital for Children, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01271868"
60,"NCT00749476","Study Evaluating BeneFIX in Patients With Haemophilia B, Previously Treated With Plasma Derived Factor IX",,"Completed","Has Results","Hemophilia B","Biological: Factor IX recovery","Number of Participants Reporting Efficacy","Wyeth is now a wholly owned subsidiary of Pfizer","Male","12 Years and older   (Child, Adult, Older Adult)","Phase 4","1","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)","3090X1-4405","April 2008","January 2009","January 2009","September 9, 2008","June 29, 2010","June 8, 2011","Dr. Lambert, Le kremlin Bicetre, France|Pr Chambost, Marseille, France|Dr. Hassoun, Montmorency, France|Pr Schved, Montpellier, France|Dr. Rothschild, Paris, France|Dr. Duillet, Rennes, France|Dr. Borg, Rouen, France|Pr Gruel, Tours, France",,"https://ClinicalTrials.gov/show/NCT00749476"
61,"NCT01440946","Study of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB029, in Previously Treated Pediatric Participants With Hemophilia B","Kids B-LONG","Completed","Has Results","Hemophilia B","Drug: rFIXFc|Drug: FIX","Occurence of Factor IX (FIX) Inhibitor Development|Annualized Bleeding Rate|Annualized Joint Bleeding Rate (Spontaneous)|Participant Assessment of Response to Injections to Treat a Bleeding Episode|Physician's Global Assessment of the Participant's Response to His rFIXFc Regimen|Annualized rFIXFc Consumption by Type of Injection|Number of Days From the Last Prophylaxis Injection to a Spontaneous Bleeding Episode|Number of Injections Required for Resolution of a Bleeding Episode|Total Dose Required for Resolution of a Bleeding Episode|Maximum Plasma Activity (Cmax; One-stage Activated Partial Thromboplastin Time [aPTT] Clotting Assay)|Terminal Half Life (t1/2; One-stage aPTT Clotting Assay)|Clearance (CL; One-stage aPTT Clotting Assay)|Volume of Distribution at Steady State (Vss; One-stage aPTT Clotting Assay)|Dose Normalized Area Under the Curve (DNAUC; One-stage aPTT Clotting Assay)|Mean Residence Time (MRT; One-stage aPTT Clotting Assay)|Incremental Recovery (IR; One-stage aPTT Clotting Assay)","Bioverativ Therapeutics Inc.|Swedish Orphan Biovitrum|Sanofi","Male","up to 11 Years   (Child)","Phase 3","30","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","9HB02PED|2011-003076-36","June 2012","November 2014","November 2014","September 27, 2011","June 18, 2015","December 19, 2020","Research Site, Phoenix, Arizona, United States|Research Site, Sacramento, California, United States|Research Site, Atlanta, Georgia, United States|Research Site, Honolulu, Hawaii, United States|Research Site, Indianapolis, Indiana, United States|Research Site, East Lansing, Michigan, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Parkville, Victoria, Australia|Research Site, Subiaco, Western Australia, Australia|Research Site, Dublin, Ireland|Research Site, Utrecht, Netherlands|Research Site, Johannesburg, South Africa|Research Site, Basingstoke, United Kingdom|Research Site, Cambridge, United Kingdom|Research Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01440946"
62,"NCT00237380","Safety and Efficacy of Ataluren (PTC124) for Cystic Fibrosis",,"Completed","No Results Available","Cystic Fibrosis","Drug: Ataluren","Change From Baseline to End of Treatment in Total Chloride Transport|Number of Participants With a Chloride Transport Response|Number of Participants With a Chloride Transport Normalization Between Baseline and End of Treatment|Change From Baseline in Nasal Chloride Secretion as Assessed by Transepithelial Potential Difference (TEPD)|Change From Baseline in Sweat Chloride Concentration as Determined by Pilocarpine Iontophoresis|Change From Baseline in CFTR Protein in Nasal Mucosa as Determined by Immunofluorescence|Change From Baseline in Nonsense Mutation CFTR mRNA in Nasal Mucosa as Determined by Quantitative Polymerase Chain Reaction (PCR) Assay|Change From Baseline in Number of Neutrophils in Blood|Change From Baseline in Pulmonary Function as Measured by Spirometry|Change From Baseline in Body Weight|Compliance with Study Treatment|Pharmacokinetics (PK): Time to Maximum Concentration (Tmax) of Ataluren|PK: Maximum Plasma Concentration (Cmax) of Ataluren|PK: Area Under the Plasma Concentration Time Curve (AUC) of Ataluren|PK: Terminal Elimination Half Life (T1/2) of Ataluren","PTC Therapeutics","All","18 Years and older   (Adult, Older Adult)","Phase 2","24","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PTC124-GD-005-CF|20050188","November 30, 2005","May 31, 2006","May 31, 2006","October 12, 2005",,"June 11, 2020","Hadassah University Hospital - Mount Scopus, Jerusalem, Israel",,"https://ClinicalTrials.gov/show/NCT00237380"
63,"NCT00364182","Study Comparing On-Demand Treatment With Two Prophylaxis Regimens Of BeneFIX In Patients With Severe Hemophilia B",,"Completed","Has Results","Hemophilia B","Drug: Recombinant Coagulation Factor IX (BeneFIX)","Annualized Number of Bleeding Episodes|Amount of Sleep Measured by Sleep Diary After Hemarthrosis|Quality of Sleep Measured by Sleep Diary After Hemarthrosis|Acute Pain After Hemarthrosis|Health-Related Productivity Questionnaire (HRPQ) Score: Hours Lost From Work or School at 24 Hours Post-bleed|HRPQ Score: Hours Lost From Work or School at 48 Hours Post-bleed|36-Item Short-Form Health Survey (SF-36): Physical Functioning Domain","Pfizer","Male","6 Years to 65 Years   (Child, Adult, Older Adult)","Phase 3","50","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","3090A1-400|B1821002","May 2007","October 2010","October 2010","August 15, 2006","August 23, 2011","October 4, 2011","Pfizer Investigational Site, Phoenix, Arizona, United States|Pfizer Investigational Site, Chicago, Illinois, United States|Pfizer Investigational Site, Chicago, Illinois, United States|Pfizer Investigational Site, New Brunswick, New Jersey, United States|Pfizer Investigational Site, Houston, Texas, United States|Pfizer Investigational Site, Edmonton, Alberta, Canada|Pfizer Investigational Site, Edmonton, Alberta, Canada|Pfizer Investigational Site, Ottawa, Ontario, Canada|Pfizer Investigational Site, Zagreb, Croatia|Pfizer Investigational Site, Budapest, Hungary|Pfizer Investigational Site, Castelfranco Veneto (TV), Italy|Pfizer Investigational Site, Coppito (AQ), Italy|Pfizer Investigational Site, Bucuresti, Romania|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Saint Petersburg, Russian Federation|Pfizer Investigational Site, Belgrade, Serbia|Pfizer Investigational Site, Nis, Serbia|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Sevilla, Spain",,"https://ClinicalTrials.gov/show/NCT00364182"
64,"NCT02234310","Study to Determine the Safety and Efficacy of rFIXFc in Previously Untreated Males With Severe Hemophilia B","PUPs B-LONG","Completed","Has Results","Hemophilia B","Biological: rFIXFc","Percentage of Participants With Confirmed Inhibitor Development as Measured by the Nijmegen-Modified Bethesda Assay|Annualized Number of Bleeding Episodes (Spontaneous and Traumatic) Per Participant (Annualized Bleeding Rate [ABR])|Annualized Number of Spontaneous Joint Bleeding Episodes|Number of rFIXFc Injections With Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale|Total Number of Exposure Days (EDs)|Total Annualized rFIXFc Consumption Per Participant for the Prevention and Treatment of Bleeding Episodes|Number of Injections of rFIXFc Required to Resolve a Bleeding Episode|Average Dose Per Injection of rFIXFc Required to Resolve a Bleeding Episode|Change From Baseline in rFIXFc Incremental Recovery (IR)","Bioverativ, a Sanofi company|Swedish Orphan Biovitrum|Sanofi","Male","up to 17 Years   (Child)","Phase 3","33","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","998HB303|2013-003629-27","November 13, 2014","August 20, 2019","August 20, 2019","September 9, 2014","July 31, 2020","July 31, 2020","Research Site, Sacramento, California, United States|Research Site, Washington, District of Columbia, United States|Research Site, Atlanta, Georgia, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Louisville, Kentucky, United States|Research Site, New Orleans, Louisiana, United States|Research Site, East Lansing, Michigan, United States|Research Site, Traverse City, Michigan, United States|Research Site, Columbus, Ohio, United States|Research Site, Portland, Oregon, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Westmead, New South Wales, Australia|Research Site, Aarhus, Denmark|Hopital Cardiologique - CHU Lille, Lille, Nord, France|Research Site, Lyon Cedex 3, Rhone, France|Research Site, Dublin, Ireland|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Parma, Italy|Research Site, Roma, Italy|Research Site, Utrecht, Netherlands|Research Site, Auckland, New Zealand|Research Site, Warszawa, Poland|Research Site, Malmo, Sweden|Research Site, Cambridge, Cambridgeshire, United Kingdom|Research Site, Whitechapel, London, United Kingdom|Research Site, London, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/10/NCT02234310/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/10/NCT02234310/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02234310"
65,"NCT04117880","A Phase 2 Open Label Extension Study in Participants With Nonsense Mutation Aniridia",,"Withdrawn","No Results Available","Aniridia","Drug: Ataluren","Number of Participants With Treatment-Emergent Adverse Events (TEAEs)|Change From Baseline in Visual Acuity at Week 104|Change From Baseline in Severity of Corneal Keratopathy at Week 104","PTC Therapeutics","All","2 Years and older   (Child, Adult, Older Adult)","Phase 2","0","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PTC124-GD-028e- ANI","December 31, 2018","January 31, 2021","January 31, 2021","October 7, 2019",,"October 7, 2019",,,"https://ClinicalTrials.gov/show/NCT04117880"
66,"NCT04135300","Gene Therapy for Chinese Hemophilia B",,"Active, not recruiting","No Results Available","Hemophilia B","Genetic: Single dose intravenous injection of BBM-H901","Incidence of treatment- related adverse events|Change from baseline alanine aminotransferase ans aspartate amino transferase|Antibody against AAV capsid protein|Vector- derived FIX:C and FIX antigen levels.","Institute of Hematology & Blood Diseases Hospital|East China University of Science and Technology","Male","18 Years and older   (Adult, Older Adult)","Not Applicable","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IHBDH-GT2019001","October 16, 2019","February 2022","December 2022","October 22, 2019",,"January 3, 2022","Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China",,"https://ClinicalTrials.gov/show/NCT04135300"
67,"NCT04076514","The Role of Central Neck Dissection in Stage N0 Papillary Thyroid Carcinoma","pCND","Recruiting","No Results Available","Papillary Thyroid Cancer","Procedure: central neck dissection","the incidence metastatic lymph node in patients with clinically node-negative thyroid carcinoma who underwent total thyroidectomy with central neck dissection","Assiut University","All","16 Years and older   (Child, Adult, Older Adult)",,"20","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","Ahmed1712","September 1, 2020","September 30, 2020","November 1, 2020","September 3, 2019",,"July 14, 2020","Ahmed Kamel, Asyūţ, Asyut, Egypt",,"https://ClinicalTrials.gov/show/NCT04076514"
68,"NCT01620801","Hemophilia B Gene Therapy With AAV8 Vector",,"Terminated","No Results Available","Hemophilia B","Biological: AAV8-hFIX19","Number of subjects with adverse events related to investigational product|Circulating plasma factor IX levels","Spark Therapeutics|Children's Hospital of Philadelphia|University of Pittsburgh|Royal Prince Alfred Hospital, Sydney, Australia|St. James's Hospital, Ireland","Male","18 Years and older   (Adult, Older Adult)","Phase 1","4","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AAV8-hFIX19-101","October 2012","March 2016","March 2016","June 15, 2012",,"March 12, 2019","The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia",,"https://ClinicalTrials.gov/show/NCT01620801"
69,"NCT02484092","A Gene Therapy Study for Hemophilia B",,"Completed","Has Results","Hemophilia B","Biological: SPK-9001","Number of Participants With Clinically Significant Change From Baseline in Physical Examination Findings|Number of Participants With Clinically Significant Change From Baseline in Vital Signs|Number of Participants With Clinical Laboratory Abnormalities Reported as TEAE|Number of Participants With Drug -Related TEAEs and Serious Adverse Events (SAEs)|Number of Participants With Positive Immune Reponses Against Adeno-associated Virus Vector (AAV) Capsid|Number of Participants Who Reached > 150% Vector-derived FIX:C Activity Level After SPK-9001 Infusion|Number of Participants With FIX Inhibitor|Incremental Recovery of FIX Product|FIX:C Activity|Change From Baseline in FIX:C Antigen Level at Steady State","Pfizer","Male","18 Years and older   (Adult, Older Adult)","Phase 2","15","Industry","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","C0371005|SPK-9001-101","November 18, 2015","April 8, 2019","April 8, 2019","June 29, 2015","May 19, 2020","June 16, 2020","UC Davis Comprehensive Cancer Center, Sacramento, California, United States|UC Davis CTSC Clinical Research Center, Sacramento, California, United States|UC Davis Ellison Ambulatory Care Clinic, Sacramento, California, United States|UC Davis Investigational Pharmacy, Sacramento, California, United States|UC Davis Medical Center, Sacramento, California, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Mississippi Center for Advanced Medicine, Madison, Mississippi, United States|Weill Cornell Medicine - New York Presbyterian Hospital, New York, New York, United States|The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Royal Prince Alfred Hospital, Camperdown/Sydney, New South Wales, Australia","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/92/NCT02484092/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/92/NCT02484092/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02484092"
70,"NCT03946384","Mutation p.Ile112Thr : Discrepancy Between Factor IX Level and Bleeding Phenotype","Hémophilie B","Unknown status","No Results Available","Hemophilia B","Other: data collection","Bleeding phenotype","Centre Hospitalier Universitaire Dijon","All","Child, Adult, Older Adult",,"12","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","BOVET 2019","June 2019","October 2019","October 2019","May 10, 2019",,"May 10, 2019","CHU Dijon Bourgogne, Dijon, France",,"https://ClinicalTrials.gov/show/NCT03946384"
71,"NCT03745924","A Study Following Males With Haemophilia B on Prophylaxis With Refixia/REBINYN",,"Enrolling by invitation","No Results Available","Haemophilia B","Drug: Nonacog beta pegol","Number of Adverse Drug Reactions (ADRs) (FIX inhibitors, allergic reactions, and thromboembolic events)|Number of Serious Adverse Events (SAEs)|Number of bleeding episodes during long-term routine use of N9-GP (prophylaxis) as assessed by annualised bleeding rate (ABR)|Number of treatment requiring bleeding episodes during long-term routine use of N9-GP (prophylaxis) as assessed by annualised bleeding rate (ABR)|Haemostatic effect of N9-GP when used for treatment of bleeding episodes|Haemostatic response of N9-GP when used in perioperative management","Novo Nordisk A/S","Male","Child, Adult, Older Adult",,"60","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","NN7999-4031|U1111-1165-8657|EUPAS26592","April 1, 2019","December 15, 2027","December 15, 2027","November 19, 2018",,"December 20, 2021","Novo Nordisk Investigational Site, Wien, Austria|Novo Nordisk Investigational Site, Bruxelles, Belgium|Novo Nordisk Investigational Site, Edegem, Belgium|Novo Nordisk Investigational Site, Leuven, Belgium|Novo Nordisk Investigational Site, Calgary, Alberta, Canada|Novo Nordisk Investigational Site, Edmonton, Alberta, Canada|Novo Nordisk Investigational Site, Winnipeg, Manitoba, Canada|Novo Nordisk Investigational Site, St. John's, Newfoundland and Labrador, Canada|Novo Nordisk Investigational Site, Hamilton, Ontario, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, Canada|Novo Nordisk Investigational Site, Zagreb, Croatia|Novo Nordisk Investigational Site, Berlin, Germany|Novo Nordisk Investigational Site, Bonn, Germany|Novo Nordisk Investigational Site, Oslo, Norway|Novo Nordisk Investigational Site, Lisboa, Portugal|Novo Nordisk Investigational Site, Lisboa, Portugal|Novo Nordisk Investigational Site, Zürich, Switzerland|Novo Nordisk Investigational Site, Aberdeen, United Kingdom|Novo Nordisk Investigational Site, Cardiff, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03745924"
72,"NCT01496274","A Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B",,"Completed","Has Results","Hemophilia B","Biological: rIX-FP","Change in Frequency of Spontaneous Bleeding Events Between On-demand and Prophylaxis Treatments (Annualized)|Number of Subjects Developing Inhibitors Against Factor IX (FIX)|The Frequency of Related Adverse Events|Number of Subjects Developing Antibodies Against rIX-FP|Proportion of Bleeding Episodes Requiring One or ≤ Two Injections of rIX-FP to Achieve Hemostasis|Investigator's Overall Clinical Assessment of Hemostatic Efficacy for Treatment of Bleeding Episodes, Based on a Four Point Ordinal Scales (Excellent, Good, Moderate, Poor/No Response)|rIX-FP Consumed Per Month While Maintaining Assigned Prophylactic Treatment Interval During Routine Prophylaxis.|Incremental Recovery of rIX-FP|Half-life (t1/2) of a Single Dose of rIX-FP|Area Under the Curve (AUC)|Clearance of a Single Dose of rIX-FP|Investigator's (or Surgeon's) Overall Clinical Assessment of Hemostatic Efficacy for Surgical Prophylaxis, Based on a Four Point Ordinal Scale (Excellent, Good, Moderate, Poor/No Response)|Annualized Spontaneous Bleeding Events Compared Between 7 Day Prophylactic and Extended Regimens","CSL Behring","Male","12 Years to 65 Years   (Child, Adult, Older Adult)","Phase 2|Phase 3","63","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CSL654_3001|2011-002415-28","February 2012","July 2014",,"December 21, 2011","May 9, 2016","May 9, 2016","Rush University Medical Center, Chicago, Illinois, United States|Indiana Hemophilia and Thrombosis Center, Inc., Indianapolis, Indiana, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|BloodCenter of Wisconsin, Milwaukee, Wisconsin, United States|AKH Wien [Hämatologie, Hämostaseol, Wien, Austria|SHAT ""Joan Pavel"" OOD [Hemorrhagic Diathesis and Anemia], Sophia, Bulgaria|Centre Hospitalier Universitaire de Brest/CHU Morvan, Brest, France|C.R.T.H. Hôp. Bicêtre-Hémophilie, Le Kremlin-Bicêtre, France|CHU de Lyon - Hôpital Edouard Herriot [Hemophilie], Lyon, France|Hôpital Necker-CRTH, Paris, France|Instit. für Experimentelle - Hämato & Transfusionsmedizin, Bonn, Germany|Zentralkrankenhaus Prof. Hess-Kinderklinik, Bremen, Germany|Unikinderklinik Frankfurt/Main [Kinderheilkunde], Frankfurt, Germany|Universitätsklinikum Hamburg-Eppendorf, Abt für Pädiatr. Hämatologie, Hamburg, Germany|Werlhof-Inst. Hannover, Hannover, Germany|Chaim Sheba Medical Center, Tel Aviv, Israel|IRCCS Ospedale Maggiore[Centro emofilia e Trombosi], Milano, Italy|A.O.U. di Parma [Centro di Rif. Reg. per la cura dell'Emofil, Parma, Italy|Osp. S.Bortolo ULSS N.6 [Terapie Cell. ed Ematologia], Vicenza, Italy|Nara Medical University Hospital [PEDIATRICS], Kashihara, Japan|University of Occupational and Environmental Health, Kitakyushu, Japan|Nagoya University Hospital, Nagoya, Japan|The Hospital of Hyogo College of Medicine, Nishinomiya, Japan|Ogikubo Hospital, Tokyo, Japan|Tokyo Medical University Hospital, Tokyo, Japan|St. Marianna University, School of Medicine, Yokohama Seibu, Yokohama, Japan|FGU ""Kirov Research Institute of Haemotology and Blood Trans, Kirov, Russian Federation|C.H.U. A Coruña [Hematología], A Coruna, Spain|H.U.Vall d'Hebrón [Hemofillia], Barcelona, Spain|H.U. La Paz [Coagulopatias Congénitas], Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT01496274"
73,"NCT01361126","A Safety and Efficacy Study of a Recombinant Factor IX in Patients With Severe Hemophilia B",,"Completed","Has Results","Hemophilia B","Biological: Recombinant Coagulation Factor IX Albumin Fusion Protein","Number of Subjects With Treatment-related Adverse Events|Number of Subjects With Inhibitors Against Factor IX (FIX)|Number of Subjects Who Developed Antibodies to rIX-FP|Area Under the Curve to the Last Sample With Quantifiable Drug Concentration (AUC0-t) After a Single Dose of rIX-FP|Half-life (t1/2) of a Single Dose of rIX-FP|Incremental Recovery of rIX-FP at 30 Minutes Following Infusion of rIX-FP|Clearance of a Single Dose of rIX-FP|Breakthrough Bleeding Events","CSL Behring","Male","12 Years to 65 Years   (Child, Adult, Older Adult)","Phase 1|Phase 2","17","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CSL654_2004|2010-023793-39","July 2011","June 2012","July 2012","May 26, 2011","May 9, 2016","May 9, 2016","Study Site, Sofia, Bulgaria|Study Site, Tel Aviv, Israel",,"https://ClinicalTrials.gov/show/NCT01361126"
74,"NCT02502409","Natural History Study of Factor IX Treatment and Complications","B-Natural","Active, not recruiting","No Results Available","Factor IX Deficiency","Other: Standard care with blood and urine sample collection","Inhibitory antibodies|Annualized bleeding rate|Joint assessment|Renal disorders|Hemophilia treatment adherence|Health related quality of life|Non-inhibitory antibodies|Factor IX usage|Number of hospitalizations|Number of surgical procedures|number of days missed from school or work","Skane University Hospital|Indiana Hemophilia &Thrombosis Center, Inc.|Bioverativ Therapeutics Inc.|Swedish Orphan Biovitrum","All","Child, Adult, Older Adult",,"550","Other|Industry","Observational","Observational Model: Other|Time Perspective: Prospective","B-Natural","July 2015","June 2019","December 2021","July 20, 2015",,"May 25, 2021","Indiana Hemophilia & Thrombosis Center, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT02502409"
75,"NCT03901755","An International Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B","B-MORE","Recruiting","No Results Available","Hemophilia B","Drug: Alprolix","Annualised bleeding rate (ABR)|Annualised injection frequency|Annualised factor consumption","Swedish Orphan Biovitrum","All","Child, Adult, Older Adult",,"150","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","Sobi.Alprolix-002","September 12, 2019","December 2023","June 2024","April 3, 2019",,"December 1, 2021","Swedish Orphan Biovitrum Research Site, Brno, Czechia|Swedish Orphan Biovitrum Research Site, Prague, Czechia|Swedish Orphan Biovitrum Research Site (Haemophilia Center Aghia Sophia Children's Hospital), Athens, Greece|Swedish Orphan Biovitrum Research Site (Laikο General Hospital of Athens), Athens, Greece|Swedish Orphan Biovitrum Research Site, Dublin, Ireland|Swedish Orphan Biovitrum Research Site, Bari, Italy|Swedish Orphan Biovitrum Research Site, Florence, Italy|Swedish Orphan Biovitrum Research Site, Genova, Italy|Swedish Orphan Biovitrum Research Site, Milan, Italy|Swedish Orphan Biovitrum Research Site, Roma, Italy|Swedish Orphan Biovitrum Research Site, Turin, Italy|Swedish Orphan Biovitrum Research Site, Oslo, Norway|Swedish Orphan Biovitrum Research Site, Buraydah, Saudi Arabia|Swedish Orphan Biovitrum Research Site (King Faisal Hospital adult), Riyadh, Saudi Arabia|Swedish Orphan Biovitrum Research Site (King Faisal Hospital pediatric), Riyadh, Saudi Arabia|Swedish Orphan Biovitrum Research Site (Hospital de Vall d'Hebrón), Barcelona, Spain|Swedish Orphan Biovitrum Research Site (Hospital Sant Joan de Deu), Barcelona, Spain|Swedish Orphan Biovitrum Research Site, Murcia, Spain|Swedish Orphan Biovitrum Research Site, Vigo, Spain|Swedish Orphan Biovitrum Research Site, Gothenburg, Sweden|Swedish Orphan Biovitrum Research Site, Malmö, Sweden|Swedish Orphan Biovitrum Research Site (Karolinska University Hospital adult), Stockholm, Sweden|Swedish Orphan Biovitrum Research Site (Karolinska University Hospital pediatric), Stockholm, Sweden|Swedish Orphan Biovitrum Research Site, Al Ain, United Arab Emirates|Swedish Orphan Biovitrum Research Site, Hull, United Kingdom|Swedish Orphan Biovitrum Research Site, London, United Kingdom|Swedish Orphan Biovitrum Research Site, London, United Kingdom|Swedish Orphan Biovitrum Research Site, London, United Kingdom|Swedish Orphan Biovitrum Research Site, London, United Kingdom|Swedish Orphan Biovitrum Research Site, Manchester, United Kingdom|Swedish Orphan Biovitrum Research Site, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03901755"
76,"NCT03473132","Assessment of Coagulation Factor Levels in Left Ventricular Device (LVAD )Patients Following Temporary Warfarin Reversal With Four Factor Prothrombin Complex Concentrate (4F-PCC)","KVAD","Recruiting","No Results Available","Anticoagulation|Anticoagulation Reversal","Drug: four factor prothrombin complex concentrate","plasma concentration of factors II,VII, IX, X, proteins S and C every 6 hours for 48 hours after treatment with 4F-PCC and correlation with international normalized ratio|Adverse events|adverse events","Brigham and Women's Hospital|CSL Behring","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","50","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2017P001254","March 15, 2018","December 31, 2021","March 31, 2022","March 22, 2018",,"May 5, 2021","Brigham and Women's Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03473132"
77,"NCT03655340","A Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B in France","B-SURE","Active, not recruiting","No Results Available","Haemophilia B","Drug: Alprolix","Annualised bleeding rate (ABR) (prophylactic treatment)|Annualised injection frequency (prophylactic treatment)|Annualised factor consumption (International Unit [IU]) (prophylactic treatment)|Amount of factor Product used to treat a bleed (on-demand treatment)|Number of injections to treat a bleed (on-demand treatment)","Swedish Orphan Biovitrum|Kantar Health","All","Child, Adult, Older Adult",,"91","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","Sobi.Alprolix-001","September 12, 2018","December 2021","December 2021","August 31, 2018",,"June 25, 2021","Swedish Orphan Biovitrum Research Site, Bordeau, France|Swedish Orphan Biovitrum Research Site, Brest, France|Swedish Orphan Biovitrum Research Site, Caen, France|Swedish Orphan Biovitrum Research Site, Chambéry, France|Swedish Orphan Biovitrum Research Site, Clermont-Ferrand, France|Swedish Orphan Biovitrum Research Site, Dijon, France|Swedish Orphan Biovitrum Research Site, La Réunion, France|Swedish Orphan Biovitrum Research Site, Lille, France|Swedish Orphan Biovitrum Research Site, Marseille, France|Swedish Orphan Biovitrum Research Site, Montpellier, France|Swedish Orphan Biovitrum Research Site, Nantes, France|Swedish Orphan Biovitrum Research Site, Nîmes, France|Swedish Orphan Biovitrum research site, Paris, France|Swedish Orphan Biovitrum research site, Poitiers, France|Swedish Orphan Biovitrum research site, Rennes, France|Swedish Orphan Biovitrum Research Site, Rouen, France|Swedish Orphan Biovitrum research site, Strasbourg, France|Swedish Orphan Biovitrum Research Site, Toulouse, France",,"https://ClinicalTrials.gov/show/NCT03655340"
78,"NCT01534897","Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436",,"Completed","Has Results","Papillary Thyroid Carcinoma","Drug: GSK2118436","Increased Radioiodine Uptake|Safety Analysis as Number of Participants With Adverse Events|Clinical Benefit as Measured by Change in Tumor Size|Number of Participants Who Complete the Study With Minimal Delays and no Dose Reductions|Clinical Benefit as Measured by Change in Thyroglobulin Level","Massachusetts General Hospital|GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)","Not Applicable","10","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11-337","July 2012","March 2014","March 2014","February 17, 2012","March 15, 2017","March 15, 2017","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01534897"
79,"NCT02139306","Study of Ataluren in Nonsense Mutation Cystic Fibrosis (ACT CF)",,"Completed","Has Results","Cystic Fibrosis","Drug: Ataluren (PTC124®)|Drug: Placebo","Absolute Change From Baseline in Percent-predicted Forced Expiratory Volume in One Second (ppFEV1) at Week 48|48-week Rate of Pulmonary Exacerbations|Change From Baseline in the Cystic Fibrosis Questionnaire - Revised (CFQ-R) Respiratory Domain at Week 48|Change From Baseline in Body Mass Index (BMI) at Week 48|Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (SAEs)|Number of Participants With TEAEs by Severity and Relationship to Study Drugs|Number of Participants With SAEs by Severity and Relationship to Study Drugs|Number of Participants With Abnormal Vital Signs Reported as TEAEs|Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs|Number of Participants With Abnormal Electrocardiogram Reported as TEAEs","PTC Therapeutics|Cystic Fibrosis Foundation|ECFS-Clinical Trial Network (ECFS-CTN)","All","6 Years and older   (Child, Adult, Older Adult)","Phase 3","279","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PTC124-GD-021-CF|2013-004581-34","August 2014","November 2016","November 2016","May 15, 2014","May 14, 2020","May 14, 2020","University of Alabama at Birmingham, Birmingham, Alabama, United States|Pulmonary Associates of Mobile PC, Mobile, Alabama, United States|Miller Children's Hospital Long Beach, Long Beach, California, United States|Children's Hospital Los Angeles, Los Angeles, California, United States|Children's Hospital and Research Center at Oakland, Oakland, California, United States|Stanford University-Children's Hospital, Palo Alto, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Nemours Children's Clinic, Jacksonville, Florida, United States|University of Miami, Miami, Florida, United States|Miami Children's Hospital, Miami, Florida, United States|All Children's Hospital, Saint Petersburg, Florida, United States|Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|Children's Hospital Boston, Boston, Massachusetts, United States|Washington University, Saint Louis, Missouri, United States|Monmouth Medical Center, Long Branch, New Jersey, United States|Morristown Medical Center, Morristown, New Jersey, United States|Beth Israel Medical Center, New York, New York, United States|New York University Langone Medical Center, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|University of Cincinnati, Cincinnati, Ohio, United States|Rainbow Babies & Children's Hospital, Cleveland, Ohio, United States|Santiago Reyes, MD, Oklahoma City, Oklahoma, United States|Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Drexel University College of Medicine, Philadelphia, Pennsylvania, United States|Texas Children's Hospital, Houston, Texas, United States|University of Texas Health Science Center, Tyler, Texas, United States|Childrens Hospital of Wisconsin, Milwaukee, Wisconsin, United States|Hospital Universitario Austral, Buenos Aires, Argentina|Hospital de Niños Dr. Ricardo Gutiérrez, Buenos Aires, Argentina|Hospital de Niños Superiora Sor Maria Ludovica, La Plata, Argentina|Royal Adelaide Hospital, Adelaide, Australia|Prince Charles Hospital, Chermside, Australia|Princess Margaret Hospital, Perth, Australia|University Hospital Brussels, Brussels, Belgium|Hôpital Universitaire des Enfants Reine Fabiola, Bruxelles, Belgium|University Hospital Leuven, Leuven, Belgium|Hospital Sao Lucas Da Pontificia Universidade Catolica Do Rio Grande Do Sul, Porto Alegre, Brazil|Instituto da Criança - Hospital das Clínicas, São Paulo, Brazil|University Mulitiprofile Hospital for Active Treatment Sveti Georgi EAD, Plovdiv, Bulgaria|University Multiprofile Hospital for Active Treatment Aleksandrovska EAD, Sofia, Bulgaria|Clinical Research Institute of Montreal, Montreal, Canada|CHU de Quebec - Hopital CHUL, Québec City, Canada|University of Toronto Hospital for Sick Children, Toronto, Canada|British Columbia Children's Hospital, Vancouver, Canada|Hôpital Femme-Mère-Enfant, Bron, France|Hôpital Arnaud de Villeneuve, Montpellier, France|Hôpital Necker-Enfants Malades, Paris, France|Centre de Perharidy, Roscoff, France|Centre Hospitalier Regional Sud Reunion, Saint-Pierre, France|Charité Universitätsmedizin Berlin, Berlin, Germany|St. Josef Hospital GmbH, Bochum, Germany|Universitätsklinikum Köln, Cologne, Germany|Christiane Herzog CF-Zentrum, Frankfurt am Main, Germany|Universitätsklinikum Jena, Jena, Germany|LMU Klinikum der Universität München, München, Germany|Dr. Von Haunersches Kinderspital, München, Germany|General Hospital of Thessaloniki Ippokration, Thessaloniki, Greece|Meyer Children's Hospital, Haifa, Israel|Hadassah University Hospital, Jerusalem, Israel|Ospedali Riuniti di Ancona, Ancona, Italy|Azienda Ospedaliera A Meyer, Firenze, Italy|Lombardia Cystic Fibrosis Center, Milan, Italy|Ospedale Pediatrico Bambino Gesù IRCCS, Roma, Italy|Azienda Policlinico Umberto I, Rome, Italy|University of Verona, Verona, Italy|Hagaziekenhuis, Den Haag, Netherlands|Radboud University, Nijmegen, Netherlands|Erasmus MC, Rotterdam, Netherlands|Szpital Dzieciecy Polanki im Macieja Plazynskiego w Gdansku, Gdansk, Poland|NZOZ Sanatorium Cassia-Villa Medica, Rabka-Zdrój, Poland|NZOZ Podkarpacki Osrodek Pulmonologii i Alergologii, Rzeszow, Poland|Instytut Matki I Dziecka, Warsaw, Poland|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Hospital University, Barcelona, Spain|Hospital Sant Joan de Deu, Esplugues De Llobregat, Spain|Hospital Regional Universitario de Malaga, Málaga, Spain|Hospital de Sabadell, Consorci Sanitari Parc Tauli, Sabadell, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Birmingham Children's Hospital NHS Foundation Trust, Birmingham, United Kingdom|Heart of England NHS Foundation Trust, Birmingham, United Kingdom|Southern General Hospital, Glasgow, United Kingdom|St James's University Hospital, Leeds, United Kingdom|Royal Brompton Hospital, London, United Kingdom|Llandough Hospital, Penarth, United Kingdom|Southampton University Hospitals NHS Trust, Southampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02139306"
80,"NCT01662531","A Safety, Efficacy and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Children With Hemophilia B",,"Completed","Has Results","Hemophilia B","Biological: rIX-FP","Incremental Recovery Following a Single Intravenous Dose of 50 IU/kg rIX-FP or Previous FIX Product|Half-life (t1/2) Following a Single Intravenous Dose of 50 IU/kg rIX-FP or Previous FIX Product|Area Under the Concentration Versus Time Curve From Time Point Zero to the Last Sample With Quantifiable Drug Concentration (AUClast)|Clearance for FIX Activity Following a Single Intravenous Dose of 50 IU/kg rIX-FP or Previous FIX Product|Number of Subjects Developing Inhibitors to Factor IX (FIX)|Number of Subjects With Treatment-related Adverse Events|Number of Subjects Developing Antibodies Against rIX-FP|Number of Bleeding Episodes Requiring One, Two or More Than Two Infusions of rIX-FP to Achieve Hemostasis|Consumption of rIX-FP During Routine Prophylaxis","CSL Behring","Male","up to 11 Years   (Child)","Phase 3","27","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CSL654_3002|2011-006032-23","January 2013","October 2014",,"August 10, 2012","May 9, 2016","May 9, 2016","The Royal Children's Hospital, Melbourne, Parkville, Victoria, Australia|The Children's Hospital at Westmead, Westmead, Australia|AKH Wien (Paediatrics), Wien, Austria|McMaster Children's Hospital, Hamilton, Ontario, Canada|Fakultni nemocnice Brno, Brno, Czech Republic|Fakultni nemocnice Ostrava, Ostrava, Czech Republic|Fakultni nemocnice Motole, Praha 5, Czech Republic|C.R.T.H. Hopital de Bicentre (Hemophilie), Le Kremlin-Bicentre, France|Hospital Edouard Herriot, Lyon, France|Hôpital d'enfants La Timone, Marseille, France|CRC Coagulation Research Center GmbH, Duisburg/Altstadt, Germany|Universitätsklinikum Düsseldorf, Düsseldorf, Germany|Sheba Medical Center, Tel Hashomer, Israel|AOU Careggi, Firenze, Italy|IRCCS Ospendale Maggiore (Centro emofilia e Trombosi), Milano, Italy|FGU ""Kirov Research Institute of Haemotology and Blood Trans), Kirov, Russian Federation|H.U. La Paz, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT01662531"
81,"NCT02740413","Treatment Patterns And Outcomes In Patients Treated With Benefix Or Refacto/Refacto AF - A Swedish Cohort Study",,"Completed","Has Results","Hemophilia A|Hemophilia B",,"Age of Participants at Disease Diagnosis|Age of Participants at Start of Treatment With Benefix or Refacto|Age of Participants at Start of Replacement Treatment|Average Prescribed Dose Per Infusion for Factor VIII and Factor IX Concentrates|Average Prescribed Dose Per Kilogram Bodyweight for Factor VIII and Factor IX Concentrates|Percentage of Participants on Prophylactic Treatment|Average Prescribed Frequency of Infusions Per Week Dispensed for Haemophilia A or B Participants With Prophylaxis|Average Prescribed Annual Dose of Factor VIII and IX Concentrates for Participants on Prophylaxis|Average Prescribed Annual Dose of Factor VIII and IX Concentrates Per Kilogram Bodyweight for Participants on Prophylaxis|Average Annual Registered Consumption of Factor VIII and IX Concentrates|Number of Participants With Consumption of Factor VIII, Factor IX, Factor rVIIa and/or aPCC Concentrate|Percentage of Time on Refacto or Benefix|Average Use of Factor Concentrate Per Surgery Event at Hospital for Invasive Procedures|Average Factor Concentrate Use at Hospital for Invasive Procedures|Average Annual Number of Filled Prescriptions of Factor Concentrate|Average Annual Number of Dispensed Units of Factor Concentrate|Average Number of Units of Benefix or Refacto|Total Number of Bleeds|Number of Joint Bleed, Muscle Bleeds and Other Bleed Events in Participants|Gilbert Joint Score|Haemophilia Joint Health Score|Percentage of Participants With Surgeries|Average Relative Dose Intensity of Factor Concentrate Dispensed for Haemophilia A or B Participants on Prophylaxis Based on Dispensed Volume of Units|Average Cost of Replacement Treatment (Benefix or Refacto/Refacto AF) Related to Bleed Event|Average Annual Cost of Prescribed Factor Concentrate and Dispensed Replacement Treatment|Average Cost of Replacement Treatment Related to Invasive Procedures","Pfizer",,"Child, Adult, Older Adult",,"86","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","B1821054","January 11, 2016","December 31, 2017","December 31, 2017","April 15, 2016","May 3, 2019","May 3, 2019",,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/13/NCT02740413/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/13/NCT02740413/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02740413"
82,"NCT02053792","A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B",,"Completed","No Results Available","Hemophilia B","Biological: rIX-FP","Total number of subjects who develop inhibitors against factor IX (FIX)|Incremental recovery in previously untreated patients (PUPs)|Comparison of annualized bleeding rate between different prophylaxis treatment intervals.|Comparison of annualized bleeding rate between 2 different prophylaxis treatment intervals and on-demand treatment.|rIX-FP consumed per month per subject during routine prophylaxis treatment.|Overall adverse events (AEs) and rIX-FP-related AEs|Hemostatic response to rIX-FP treatment in PUPs","CSL Behring","Male","up to 70 Years   (Child, Adult, Older Adult)","Phase 3","97","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CSL654_3003|2012-005489-37","February 6, 2014","June 2, 2021","June 2, 2021","February 4, 2014",,"November 12, 2021","University of Colorado, Aurora, Colorado, United States|Indiana Hemophilia & Thrombosis Center Inc., Indianapolis, Indiana, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Utah, Salt Lake City, Utah, United States|Royal Children's Hospital, Parkville, Victoria, Australia|The Children's Hospital Westmead, Westmead, Victoria, Australia|Department of Pediatrics, Medical University of Vienna, Vienna, Austria|Medical University of Vienna, Vienna General Hospital, Vienna, Austria|SHAT ""Joan Pavel"" ODD [Hemorrhagic Diathesis & Anemia], Sofia, Bulgaria|McMaster University, Hamilton, Ontario, Canada|Fakultni nemocnice Brno, Brno, Czechia|Fakultni Nemocrice Ostrava, Ostrava-Poruba, Czechia|Fakultni nemocnice v Motole, Praha, Czechia|CHRU Hopital Morvan, Brest, France|Hopital Louis Pradel, Bron Cedex, France|Hopital Bicetre - Centre de Traitement del'Hemophilia, Le Kremlin-Bicetre, France|Hopital d'Enfants La Timonepital, Marseille Cedex, France|Hopital Necker-Enfants Malades, Paris, France|Institut fur experimentelle Hamatologie, Bonn, Germany|Prof. Hess Kinderklinik, Bremen, Germany|CRC Coagulation Research Centre GmbH, Duisburg, Germany|Heinrich Heine University Dusseldorf, Dusseldorf, Germany|Universtatsklinikum Hamburg-Eppendorf, Hamburg, Germany|Werlhof-Institute for Haemostasis and Thrombosis, Hannover, Germany|Kurpfalzkrankenhaus Heidlerberg GmbH, Heidelberg, Germany|Chaim Sheba Medical Center, Tel Aviv, Israel|IRCCS Ospedale Maggiore[Centro emofilia e Trobosi], Milano, Italy|UOS Gestione e Organizzazione Funzlone Hub Emofilia, Parma, Italy|Centro Malattie Emorragiche e Trombotiche Ospedale, Vicenza, Italy|Nara Medical University Hospital, Kashihara, Japan|University of Occupational and Environmental Health, Kitakyushu, Japan|Nagoya University Hospital, Nagoya, Japan|The Hospital of Hyogo College of Medicine, Nishinomiya, Japan|Tokyo Medical University Hospital, Tokyo, Japan|Ogikubo Hospital, Tokyo, Japan|St. Marianna University, School of Medicine, Seibu Hospital, Yokohama, Japan|National Blood Center, Kuala Lumpur, Malaysia|Perpetual Succour Hospital, Cebu, Philippines|Haemophilia Comprehensive Care Centre, Parktown, South Africa|C.H.U. A Coruna, A Coruna, Spain|Hospital Vall Hebron, Barcelona, Spain|H.U. La Paz, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT02053792"
83,"NCT00076557","Safety of a New Type of Treatment Called Gene Transfer for the Treatment of Severe Hemophilia B",,"Terminated","No Results Available","Hemophilia B","Genetic: Adeno-Associated Viral with Human Factor IX",,"Avigen|Stanford University|Children's Hospital of Philadelphia|The Hemophilia Center of Western Pennsylvania|University of Washington|The University of Texas Health Science Center, Houston|University of Campinas, Brazil|Christian Medical College, Vellore, India|Royal Prince Alfred Hospital, Sydney, Australia","Male","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","15","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BB IND 9398","January 2004",,,"January 28, 2004",,"April 4, 2007","Stanford University, Palo Alto, California, United States|The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|The Hemophilia Center of Western Pennsylvania, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00076557"
84,"NCT00979238","Dose-Escalation Study Of A Self Complementary Adeno-Associated Viral Vector For Gene Transfer in Hemophilia B",,"Active, not recruiting","No Results Available","Hemophilia B","Genetic: Gene Transfer|Drug: scAAV2/8-LP1-hFIXco","To assess the safety of systemic administration of a novel self-complementary AAV vector in adults with severe hemophilia B at up to four different dosage levels.","St. Jude Children's Research Hospital|National Heart, Lung, and Blood Institute (NHLBI)|Hemophilia of Georgia, Inc.|Children's Hospital of Philadelphia|University College, London","Male","18 Years and older   (Adult, Older Adult)","Phase 1","14","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","AGT4HB|5R01HL094396","February 22, 2010","June 12, 2032","December 31, 2032","September 17, 2009",,"June 18, 2021","Stanford Medical School, Stanford, California, United States|University of Kentucky, Lexington, Kentucky, United States|Oregon Health and Science University, Portland, Oregon, United States|Hemophilia Center of Western Pennsylvania, Pittsburgh, Pennsylvania, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|University of Texas Southwestern, Dallas, Texas, United States|Scott and White Memorial Hospital, Temple, Texas, United States|Katharine Dormandy Haemophilia Centre and Haemostasis Unit, University College of London, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00979238"
85,"NCT01686425","Percutaneous Transhepatic Cholangiography Versus Endoscopic Ultrasound Guided Biliary Drainage","PETRUS","Unknown status","No Results Available","Malignant Biliary Obstruction","Procedure: Percutaneous transhepatic cholangiography vs. endoscopic biliary drainage","Pain: Post-procedural pain as measured by visual analogue score (VAS) at 2, 24, and 72 hours following the procedures|Major complications including bile leak, bleeding, sepsis or death","Universitaire Ziekenhuizen Leuven","All","18 Years and older   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ML8383","July 2012","July 2014","December 2014","September 18, 2012",,"June 13, 2013","UZ Leuven, Leuven, Belgium",,"https://ClinicalTrials.gov/show/NCT01686425"
86,"NCT05024929","Targeted Therapy to Increase RAI Uptake in Metastatic PTC",,"Not yet recruiting","No Results Available","Papillary Thyroid Cancer|Pediatric Cancer","Procedure: Whole body scan","Proportion of patients with increased tumor RAI-avidity after receiving oncogene-specific, targeted therapy","Children's Hospital of Philadelphia","All","up to 21 Years   (Child, Adult)",,"32","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","21-018612","February 1, 2022","February 1, 2031","February 1, 2033","August 27, 2021",,"January 11, 2022","Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT05024929"
87,"NCT01687608","Open-Label Single Ascending Dose of Adeno-associated Virus Serotype 8 Factor IX Gene Therapy in Adults With Hemophilia B",,"Active, not recruiting","No Results Available","Hemophilia B","Biological: AskBio009","Number of patients experiencing treatment-related adverse events by dose group|Change from baseline in clinical laboratory evaluations|Changes from Baseline in FIX activity levels, FIX protein levels, and Bleeding Episode Severity & Frequency|Immune Response to AskBio009|Detection of AskBio009 genomes in blood, saliva, urine, stool, and semen","Baxalta now part of Shire|Takeda","Male","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","30","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AskBio009-101|231401","February 11, 2013","November 30, 2021","November 30, 2021","September 19, 2012",,"October 26, 2021","Orthopaedic Hemophilia Treatment Center, Los Angeles, California, United States|Children's Hospital Los Angeles, Los Angeles, California, United States|University of California Davis Medical Center, Sacramento, California, United States|University of California at San Diego Medical Center, San Diego, California, United States|U of Colorado School of Medicine, Hemophilia & Thrombosis Treatment Center, Aurora, Colorado, United States|Emory University, Atlanta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|Children's Hospital of Boston, Boston, Massachusetts, United States|University of Minnesota, Masonic Clinical Research Unit, Clinical and Translational Science Institute, Minneapolis, Minnesota, United States|Mount Sinai Medical Center, New York, New York, United States|The Hemophilia Center, Oregon Health and Science University, Portland, Oregon, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Gulf States Hemophilia and Thrombosis Center, Houston, Texas, United States|Bloodworks Northwest, Seattle, Washington, United States|BloodCenter of Wisconsin, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01687608"
88,"NCT02250560","A Study to Investigate the Safety and Efficacy of Replenine®-VF in Haemophilia B Patients Undergoing Major Surgery.",,"Completed","No Results Available","Haemophilia B","Biological: Replenine®-VF (High Purity Factor IX)","Assessment of control of prevention of bleeding","Bio Products Laboratory","All","16 Years and older   (Child, Adult, Older Adult)","Phase 3",,"Other","Interventional",,"R9VFCIMS","April 2000","November 2003",,"September 26, 2014",,"February 22, 2018","North Hampshire Haemophilia Centre, Uplands House, North Hampshire Hospital, Aldermaston Road, Basingstoke, United Kingdom|Haemophilia Centre, The Royal London Hospital, White Chapel, London, United Kingdom|Haemophilia Centre and Haemostasis Unit, Royal Free Hospital, Pond Street, London, United Kingdom|Manchester Thrombosis and Haemostasis Centre, University of Manchester, Department of Haematology, Manchester Royal Infirmary, Oxford Road, Manchester, United Kingdom|Haemophilia Centre, Southampton General Hospital, Tremona Road, Southampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02250560"
89,"NCT03855280","Evaluation of a Recombinant Factor IX Product, APVO101, in Previously-Treated Pediatric Patients With Hemophilia B",,"Active, not recruiting","No Results Available","Hemophilia B","Drug: APVO101","Annualized Bleed Rate|Area under the plasma concentration curve from time 0 to t (AUC0-t)|Terminal Half-life (t 1/2)|Maximum post-infusion plasma concentration (Cmax)|Incremental Recovery|Clearance (CL)|Volume of Distribution at steady-state (V dss)|Degree of Hemorrhage Control","Medexus Pharma, Inc.","All","up to 12 Years   (Child)","Phase 3","21","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","APVO101-903","January 16, 2020","July 30, 2022","July 30, 2022","February 26, 2019",,"September 23, 2021","Centro Estadual de Hemopterapia e Hematologia do Espirito Santo, Vitória, Espirito Santo, Brazil|Universidade Estadual de Campinas - Centro de Hematologia e Hemoterapia, Campinas, Brazil|Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo, Ribeirão Preto, Brazil|JSC K Eristavi National Center for Experimental and Clinical Surgery, Tbilisi, Georgia|PMSI Institute of Mother and Child, Chisinau, Moldova, Republic of|Worthwhile Clinical Trials, Lakeview Hospital, Benoni, Gauteng, South Africa|Haemophilia Comprehensive Care Centre, Johannesburg, South Africa|Cukurova University School of Medicine, Adana, Turkey|Ege University School ofMedicine, İzmir, Turkey|National Specialized Children's Hospital OKHMATDYT, Kyiv, Ukraine|State Institute: Institute of Blood Pathology and Transfusion Medicine of the National Academy of Medical Sciences of Ukraine, Lviv, Ukraine",,"https://ClinicalTrials.gov/show/NCT03855280"
90,"NCT00768287","Study of Recombinant Factor IX Product, IB1001, in Subjects With Hemophilia B",,"Completed","Has Results","Hemophilia B","Biological: IB1001|Biological: nonacog alfa","Degree of Hemorrhage Control by Treatment Regimen|Area Under the Curve (0-inf)|Area Under the Curve (0-72 hr)|Terminal Half-life|Concentration (Max)|Incremental Recovery|Mean Residence Time|Clearance|Volume of Distribution (Steady State)|Annualized Bleed Rate","Medexus Pharma, Inc.","All","5 Years and older   (Child, Adult, Older Adult)","Phase 2|Phase 3","77","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","IB1001-01","January 2009","March 2013","December 2016","October 8, 2008","September 10, 2018","April 6, 2021","City of Hope, Duarte, California, United States|The Hemophilia Treatment Center of Orthopaedic Hospital, Los Angeles, California, United States|Emory University School of Medicine Pediatric Hematology, Atlanta, Georgia, United States|Rush University Medical Center-Pediatric Hematology Oncology, Chicago, Illinois, United States|Indiana Hemophilia & Thrombosis Center, Indianapolis, Indiana, United States|University of Minnesota Center for Bleeding and Clotting Disorder, Minneapolis, Minnesota, United States|Hemophilia Treatment Center of Las Vegas, Las Vegas, Nevada, United States|Hemophilia and Thrombosis Center, Cincinnati, Ohio, United States|The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|University of Texas Health Science Center-Houston, Gulf States Hemophilia & Thrombophilia Center, Houston, Texas, United States|Centre Regional de Traitement de l 'Hemophilie, Nantes, Loire-Atlantique, France|Hopital Edouard Herriot, Lyon, France|Sahyadri Specialty Hospital, Deccan Gymkhana, Pune, Maharashtra, India|Jehangir Clinical Development Centre, Pune, Maharashtra, India|The National Hemophilia Center-Sheba MC, Tel Hashomer, Ramat Gan, Israel|Ospedale di Careggi, Florence, Italy|University of Milan, Milano, Italy|MTZ Clinical Research, Warsaw, Poland|Royal Free Hospital, London, England, United Kingdom|Manchester Haemophilia Comprehensive Care Manchester Royal Infirmary, Manchester, England, United Kingdom|Royal Hallamshire Hospital, Sheffield, England, United Kingdom|Centre for Haemostasis and Thrombosis, Basingstoke and North Hampshire Foundation Trust, Basingstoke, Hampshire, United Kingdom|University Hospital of Wales Health Park, Cardiff, Wales, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00768287"
91,"NCT02922231","Post-Marketing Surveillance (Usage Results Study) of RIXUBIS in Adult and Pediatric Patients With Haemophilia B in South Korea",,"Completed","No Results Available","Hemophilia B","Biological: RIXUBIS","Number of adverse events (AEs)|Physician rated effectiveness of RIXUBIS for prophylactic treatment in participants <12 years old|Participant rated effectiveness of RIXUBIS for prophylactic treatment in participants ≥12 years old|Physician rated effectiveness of RIXUBIS for on-demand treatment in participants <12 years old|Participant rated effectiveness of RIXUBIS for on-demand treatment in participants ≥12 years old","Baxalta now part of Shire|Takeda","All","Child, Adult, Older Adult",,"57","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","251501","January 6, 2017","April 4, 2019","April 4, 2019","October 4, 2016",,"May 5, 2021","Daegu Catholic University Medical Center, Daegu, Korea, Republic of|DaeJeon Eulji University Hospital, Daejeon, Korea, Republic of|Chung Hospital, Gyeonggi-do, Korea, Republic of|Kim Hugh Chul Internal Medicine, Seoul, Korea, Republic of|Korea Hemophilia Foundation, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02922231"
92,"NCT01425723","Long-Term Safety and Efficacy of rFIXFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia B","B-YOND","Completed","Has Results","Severe Hemophilia B","Biological: rFIXFc","Number of Participants With Any Positive Inhibitor Development|Annualized Bleeding Rate (ABR)|Annualized Spontaneous Joint Bleeding Episodes|Total Number of Exposure Days (EDs)|Annualized rFIXFc Consumption (International Units Per Kilogram [IU/kg])|Physicians' Global Assessment of Participant's Response to rFIXFc Regimen Using a 4-Point Scale|Participant's Assessment of Response (Excellent or Good Response) to rFIXFc Injections for the Treatment of Bleeding Episodes Using a 4-Point Scale","Bioverativ Therapeutics Inc.|Sanofi","Male","Child, Adult, Older Adult","Phase 3","120","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","9HB01EXT|2011-003075-11","December 8, 2011","October 2017","October 2017","August 30, 2011","November 23, 2018","December 19, 2020","Research Site, Phoenix, Arizona, United States|Research Site, Sacramento, California, United States|Research Site, Aurora, Colorado, United States|Research Site, Atlanta, Georgia, United States|Research Site, Honolulu, Hawaii, United States|Research Site, Indianapolis, Indiana, United States|Research Site, New Orleans, Louisiana, United States|Research Site, East Lansing, Michigan, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Seattle, Washington, United States|Research Site, Adelaide, South Australia, Australia|Research site, Parkville, Victoria, Australia|Research site, Murdoch, Western Australia, Australia|Research Site, Perth, Western Australia, Australia|Research Site, Bruxelles, Belgium|Research Site, Leuven, Belgium|Research Site, Campinas, Sao Paulo, Brazil|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Beijing, Beijingshì, China|Research Site, Guangzhou, Guangdongsheng, China|Research Site, Shanghai, Shànghaishì, China|Research Site, Tianjing, Tianjinshì, China|Research Site, Marseille, Bouches-Du-Rhône, France|Research Site, Bonn, North Rhine-westphalia, Germany|Research Site, Hong Kong, New Territories, Hong Kong|Research site, Hong Kong, Hong Kong|Research Site, Bangalore, Karnataka, India|Research Site, Pune, Maharashtra, India|Research Site, Vellore, Tamil Nadu, India|Research Site, Dublin, Ireland|Research Site, Florence, Italy|Research Site, Milano, Italy|Research Site, Nagoya-Shi, Aichi-Ken, Japan|Research Site, Kitakyushu, Fukuoka-Ken, Japan|Research Site, Kawasaki, Kanagawa-Ken, Japan|Research Site, Kashihara-shi, Nara-Ken, Japan|Research Site, Shinjuku-ku, Tokyo-To, Japan|Research Site, Tokyo, Tokyo-To, Japan|Research Site, Utrecht, Netherlands|Research Site, Lodz, Poland|Research Site, Johannesburg, Gauteng, South Africa|Research Site, Cape Town, Western Cape, South Africa|Research Site, Malmö, Sweden|Research Site, Stockholm, Sweden|Research Site, Cambridge, Cambridgeshire, United Kingdom|Research Site, London, Greater London, United Kingdom|Research site, London, Greater London, United Kingdom|Research Site, Basingstoke, Hampshire, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/23/NCT01425723/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/23/NCT01425723/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01425723"
93,"NCT01417442","BRAF V600E Mutations In Papillary Thyroid Carcinoma",,"Unknown status","No Results Available","Papillary Thyroid Carcinoma","Genetic: BRAF V600E POSITIVITY","BRAF V600E MUTATION","Bezmialem Vakif University","All","Child, Adult, Older Adult","Early Phase 1","150","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2011/5","July 2011","July 2012","July 2012","August 16, 2011",,"August 16, 2011","Yeliz Emine Ersoy, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT01417442"
94,"NCT05152732","Safety and Tolerability of VGB-R04 in Patients With Haemophilia B",,"Not yet recruiting","No Results Available","Hemophilia B","Genetic: VGB-R04","Incidence of adverse events|Incidence of serious adverse events|Number of Participants with Clinically Significant Change from Baseline in Vital Signs|Number of Participants with Clinically Significant Change From Baseline in Physical Examination Findings|Number of Participants with Clinical Laboratory Abnormalities|Vector- derived FIX:C Activity|Vector- derived FIX antigen levels|Annualized bleeding rate changes from baseline|Annualized FIX consumption changes from baseline|Number of target joints|Vector shedding of VGB-R04","Institute of Hematology & Blood Diseases Hospital","Male","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","3","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VGB-R04-001","December 2021","March 2023","March 2023","December 10, 2021",,"December 10, 2021",,,"https://ClinicalTrials.gov/show/NCT05152732"
95,"NCT02814032","Proteomics of Papillary Thyroid Carcinoma",,"Unknown status","No Results Available","Papillary Thyroid Carcinoma",,"differences in protein expression","The Affiliated Hospital of Inner Mongolia Medical University","All","18 Years to 65 Years   (Adult, Older Adult)",,"32","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","AHInnerMongolia-Thyroid-02","June 2016","December 2016","June 2017","June 27, 2016",,"June 27, 2016","Shan Jin, Hohhot, Inner Mongolia, China",,"https://ClinicalTrials.gov/show/NCT02814032"
96,"NCT03961243","Lentiviral FIX Gene Therapy",,"Not yet recruiting","No Results Available","Hemophilia B","Biological: YUVA-GT-F901","Number of participants experiencing drug-related adverse events|Changes from baseline in circulating FIX activity (IU/dL or % normal)","Shenzhen Geno-Immune Medical Institute","All","2 Years to 65 Years   (Child, Adult, Older Adult)","Phase 1","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GIMI-IRB-19002","June 1, 2020","May 31, 2022","June 1, 2022","May 23, 2019",,"May 23, 2019",,,"https://ClinicalTrials.gov/show/NCT03961243"
97,"NCT01333111","Safety and Efficacy of NNC-0156-0000-0009 in Haemophilia B Patients","paradigm™ 2","Completed","Has Results","Congenital Bleeding Disorder|Haemophilia B","Drug: nonacog beta pegol","Incidence of Inhibitory Antibodies Against Factor IX Defined as Titre Equal to or Above 0.6 BU (Bethesda Units)|Haemostatic Effect of NNC-0156-0000-0009 When Used for Prophylaxis of Bleeding Episodes, Assessed as Success/Failure Based on a Four-point Scale for Haemostatic Response|Haemostatic Effect of NNC-0156-0000-0009 When Used for Treatment of Bleeding Episodes, Assessed as Success/Failure Based on a Four-point Scale for Haemostatic Response|Number of Bleeding Episodes Per Patient During Routine Prophylaxis|Factor IX Trough Levels|Incidence of Adverse Events (AEs)|Incidence of Serious Adverse Events (SAEs)|Host Cell Proteins (HCP) Antibodies","Novo Nordisk A/S","Male","13 Years to 70 Years   (Child, Adult, Older Adult)","Phase 3","74","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","NN7999-3747|2010-023069-24|U1111-1119-6415|JapicCTI-111644","April 27, 2011","March 31, 2013","March 31, 2013","April 11, 2011","July 28, 2017","July 28, 2017","Novo Nordisk Investigational Site, Los Angeles, California, United States|Novo Nordisk Investigational Site, Jacksonville, Florida, United States|Novo Nordisk Investigational Site, Augusta, Georgia, United States|Novo Nordisk Investigational Site, Iowa City, Iowa, United States|Novo Nordisk Investigational Site, Baltimore, Maryland, United States|Novo Nordisk Investigational Site, Minneapolis, Minnesota, United States|Novo Nordisk Investigational Site, Omaha, Nebraska, United States|Novo Nordisk Investigational Site, Newark, New Jersey, United States|Novo Nordisk Investigational Site, New York, New York, United States|Novo Nordisk Investigational Site, Syracuse, New York, United States|Novo Nordisk Investigational Site, Hershey, Pennsylvania, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Edmonton, Alberta, Canada|Novo Nordisk Investigational Site, Kremlin-Bicêtre, France|Novo Nordisk Investigational Site, Lyon, France|Novo Nordisk Investigational Site, Bonn, Germany|Novo Nordisk Investigational Site, Duisburg, Germany|Novo Nordisk Investigational Site, Giessen, Germany|Novo Nordisk Investigational Site, Hannover, Germany|Novo Nordisk Investigational Site, Budapest, Hungary|Novo Nordisk Investigational Site, Firenze, Italy|Novo Nordisk Investigational Site, Milano, Italy|Novo Nordisk Investigational Site, Kawasaki-shi, Kanagawa, Japan|Novo Nordisk Investigational Site, Nagoya-shi, Aichi, Japan|Novo Nordisk Investigational Site, Nishinomiya-shi, Japan|Novo Nordisk Investigational Site, Shinjuku-ku, Tokyo, Japan|Novo Nordisk Investigational Site, Suginami-ku, Tokyo, Japan|Novo Nordisk Investigational Site, Skopje, Macedonia, The Former Yugoslav Republic of|Novo Nordisk Investigational Site, Kuala Lumpur, Malaysia|Novo Nordisk Investigational Site, Utrecht, Netherlands|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Parktown Johannesburg, Gauteng, South Africa|Novo Nordisk Investigational Site, Bangkok, Thailand|Novo Nordisk Investigational Site, Ankara, Turkey|Novo Nordisk Investigational Site, Kayseri, Turkey|Novo Nordisk Investigational Site, Konya, Turkey|Novo Nordisk Investigational Site, Basingstoke, United Kingdom|Novo Nordisk Investigational Site, Cardiff, United Kingdom|Novo Nordisk Investigational Site, London, United Kingdom|Novo Nordisk Investigational Site, London, United Kingdom|Novo Nordisk Investigational Site, Manchester, United Kingdom|Novo Nordisk Investigational Site, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01333111"
98,"NCT01467427","Safety, Efficacy and Pharmacokinetics of NNC-0156-0000-0009 in Previously Treated Children With Haemophilia B.","paradigm™5","Active, not recruiting","Has Results","Congenital Bleeding Disorder|Haemophilia B","Drug: nonacog beta pegol","Incidence of Inhibitory Antibodies Against Coagulation Factor IX (FIX) Defined as Titre Above or Equal to 0.6 Bethesda Units (BU)|Number of Bleeding Episodes During Prophylaxis|Haemostatic Effect of N9-GP in Treatment of Bleeding Episodes by 4-point Categorical Scale for Haemostatic Response (Excellent, Good, Moderate and Poor)|Incremental Recovery at 30 Minutes (IR30min)|Trough Level (Single-dose )|Trough Level (Steady State)|Terminal Half-life (t1/2)|Number of Adverse Events|Number of Serious Adverse Events (SAEs)|Medical Events of Special Interest (MESI)|Development of Host Cell Protein (HCP) Antibodies|FIX Consumption Described as Frequency of Dose/kg for Prophylaxis Use for the Treatment of Bleeding Episodes|FIX Consumption Described as Amount Consumed for the Treatment of Bleeding Episodes|Number of Doses of FIX Consumed for the Treatment of Bleeding Episodes|Area Under the Curve Activity Versus Time Profile From Time Zero to 168 Hours Post Dose (AUC(0-168))|Clearance (CL)|Mean Residence Time (MRT)|Volume of Distribution at Steady State (Vss)|FIX Activity at 30 Minutes (C30min) (Single Dose)|FIX Activity at 30 Minutes (C30min) (Steady State)|TNO-AZL Preschool Quality of Life (TAPQOL)|Health Economic Impact of N9-GP Treatment Through Characterisation of General Hospitalisation|Health Economic Impact of N9-GP Treatment Through Characterisation of Intensive Care Hospitalisation|Health Economic Impact of N9-GP Treatment Through Characterisation of Bleedings Caused Missing School or Studies|Health Economic Impact of N9-GP Treatment Through Characterisation of Number of Days Bleedings Caused Using of Mobility Aids|Health Economic Impact of N9-GP Treatment Through Characterisation of Number of Days Bleedings Caused Parents to Miss Work","Novo Nordisk A/S","Male","up to 12 Years   (Child)","Phase 3","25","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NN7999-3774|2011-000826-31|U1111-1119-5013|JapicCTI- 121877","May 16, 2012","November 30, 2023","November 30, 2023","November 8, 2011","November 17, 2017","November 23, 2021","Novo Nordisk Investigational Site, Washington, District of Columbia, United States|Novo Nordisk Investigational Site, Miami, Florida, United States|Novo Nordisk Investigational Site, Augusta, Georgia, United States|Novo Nordisk Investigational Site, Iowa City, Iowa, United States|Novo Nordisk Investigational Site, Minneapolis, Minnesota, United States|Novo Nordisk Investigational Site, Kansas City, Missouri, United States|Novo Nordisk Investigational Site, Omaha, Nebraska, United States|Novo Nordisk Investigational Site, New Brunswick, New Jersey, United States|Novo Nordisk Investigational Site, Brooklyn, New York, United States|Novo Nordisk Investigational Site, New York, New York, United States|Novo Nordisk Investigational Site, Cleveland, Ohio, United States|Novo Nordisk Investigational Site, Oklahoma City, Oklahoma, United States|Novo Nordisk Investigational Site, Philadelphia, Pennsylvania, United States|Novo Nordisk Investigational Site, Nashville, Tennessee, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Curitiba, Parana, Brazil|Novo Nordisk Investigational Site, Campinas, Sao Paulo, Brazil|Novo Nordisk Investigational Site, Rio de Janeiro, Brazil|Novo Nordisk Investigational Site, Toronto, Ontario, Canada|Novo Nordisk Investigational Site, Split, Croatia|Novo Nordisk Investigational Site, Kremlin-Bicêtre, France|Novo Nordisk Investigational Site, Marseille, France|Novo Nordisk Investigational Site, Paris, France|Novo Nordisk Investigational Site, Duisburg, Germany|Novo Nordisk Investigational Site, Hannover, Germany|Novo Nordisk Investigational Site, Milano, Italy|Novo Nordisk Investigational Site, Kanagawa, Japan|Novo Nordisk Investigational Site, Shizuoka, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Kuala Lumpur, Malaysia|Novo Nordisk Investigational Site, Taipei, Taiwan|Novo Nordisk Investigational Site, Basingstoke, United Kingdom|Novo Nordisk Investigational Site, Birmingham, United Kingdom|Novo Nordisk Investigational Site, Leicester, United Kingdom|Novo Nordisk Investigational Site, London, United Kingdom|Novo Nordisk Investigational Site, Oxford, United Kingdom","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/27/NCT01467427/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01467427"
99,"NCT02231944","An Open Study to Investigate the Safety and Efficacy of Replenine®-VF in Severe Haemophilia B Patients",,"Completed","No Results Available","Haemophilia B","Biological: Replenine®-VF (High Purity Factor IX)","Recovery calculated from the first infusion of Replenine®-VF compared with that calculated 12 weeks later.","Bio Products Laboratory","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3",,"Other","Interventional","Primary Purpose: Treatment","R9VFSE","July 1997","October 2003",,"September 4, 2014",,"February 22, 2018","Klinika Hematologii Instytutu Medycyny Wewnetrznej, Lodz, Poland|Klinika Hematologii AM Lublin, ul.Jaczewskiego 8, Lublin, Poland|Addenbrooke's Hospital, Hills Road, Cambridge, United Kingdom|University Hospital of Wales, Heath Park, Cardiff, United Kingdom|The Royal London Hospital, London, United Kingdom|Manchester Royal Infirmary, Oxford Road, Manchester, United Kingdom|Norwich and Norfolk Hospital, Norwich, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02231944"
100,"NCT01141075","Ataluren for Nonsense Mutation Methylmalonic Acidemia",,"Terminated","Has Results","Amino Acid Metabolism, Inborn Errors","Drug: Ataluren","Plasma Methylmalonic Acid (MMacid) Levels|Urinary MMacid Levels|Plasma Propionylcarnitine Levels|Urine Methylcitric Acid Levels|Number of Participants With Adverse Events (AEs)|Number of Participants With Potentially Clinically Significant Laboratory (Hematology and Biochemistry) Abnormal Results|Number of Participants With a Metabolic Decompensation Episode|Number of Participants Compliant With Study Treatment|Ataluren Plasma Exposure","PTC Therapeutics|Genzyme, a Sanofi Company","All","2 Years and older   (Child, Adult, Older Adult)","Phase 2","11","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PTC124-GD-012-MMA","July 19, 2010","November 3, 2011","November 3, 2011","June 10, 2010","July 7, 2020","July 7, 2020","ZNA Queen Paola Child Hospital and Provincial Centre for Metabolic Disorders, Antwerp, Belgium|Hôpital Edouard Herriot, Lyon, France|Necker-Enfants Malades Hospital, Paris, France|University Children's Hospital, Duesseldorf, Germany|Istituti Clinici di Perfezionamento, Milano, Milan, Italy|Federico II University, Naples, Italy|University Hospital, Department of Pediatrics, Padova, Italy|University Children's Hospital, Zürich, Switzerland|Great Ormand Street Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01141075"
101,"NCT03307980","Long-term Safety and Efficacy Study and Dose-Escalation Substudy of PF 06838435 in Individuals With Hemophilia B",,"Recruiting","No Results Available","Hemophilia B","Biological: PF-06838435 (formerly SPK-9001)","Dose-Escalation Substudy: Number of participants with clinically significant changes from baseline in physical examination|Dose-Escalation Substudy: Number of participants with clinically significant changes from baseline in vital signs|Dose-Escalation Substudy: Number of participants with clinically significant changes from baseline in laboratory values|Dose-Escalation Substudy: Number of participants with PF-06838435-related adverse events|Dose-Escalation Substudy: Immune response against AAV capsid protein and hFIX transgene|Dose-Escalation Substudy: Number of participants PF-06838435-related elevated hepatic transaminases that fail to improve or resolve|Dose-Escalation Substudy: Number of participants with clinical thrombotic events|Dose-Escalation Substudy: Number of participants with FIX inhibitor development|Dose-Escalation Substudy: Number of participants with hypersensitivity reaction|Dose-Escalation Substudy: Number of participants with hepatic malignancy|Dose-Escalation Substudy: Number of participants with PF-06838435-related mailgnancy|LTFU: Number of participants with PF-06838435-related adverse advents|Dose-Escalation Substudy: Mean and standard deviation of vector-derived FIX Activity levels|Dose-Escalation Substudy: Mean and standard deviation of FIX Antigen levels|LTFU: Coagulation Clotting Assay for FIX activity levels|LTFU: Annualized (factor FIX) infusion rate|LTFU: Total factor consumption (IU)|LTFU: Total factor consumption (volume)|LTFU: Annualized bleeding rate|LTFU: Total number of bleeding events|LTFU: Haem-A-QoL|LTFU: EQ-5D-5L|LTFU: Brief Pain Inventory","Pfizer","Male","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","55","Industry","Interventional","Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","C0371003|SPK-9001-LTFU-101","June 22, 2017","May 12, 2028","May 12, 2028","October 12, 2017",,"August 24, 2021","UC Davis Comprehensive Cancer Center, Sacramento, California, United States|UC Davis Ellison Ambulatory Care Clinic, Sacramento, California, United States|UC Davis Medical Center department of Radiology, Sacramento, California, United States|UC Davis Medical Center, Sacramento, California, United States|UC Davis Midtown Cancer Center, Sacramento, California, United States|UC DavisHealth Main Hospital, Sacramento, California, United States|PPD Global Central Labs, LLC, Highland Heights, Kentucky, United States|Louisiana Center for Advanced Medicine, Slidell, Louisiana, United States|Mississippi Center for Advanced Medicine, Madison, Mississippi, United States|Weill Cornell Medicine - New York Presbyterian Hospital, New York, New York, United States|The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia",,"https://ClinicalTrials.gov/show/NCT03307980"
102,"NCT03369444","A Factor IX Gene Therapy Study (FIX-GT)","FIX-GT","Terminated","No Results Available","Hemophilia B","Biological: FLT180a","Frequency and severity of treatment-emergent Adverse Events (Safety)|hFIX activity level|FIX concentrate usage|Bleeding Frequency|Immune response - development of inhibitors|Immune response to AAV capsid|T-cell response to AAV capsid|Viral Shedding|Endogenous FIX production","University College, London","Male","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","10","Other","Interventional","Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UCL/15/0552","December 5, 2017","October 20, 2020","October 20, 2020","December 12, 2017",,"October 26, 2021","St Jude Children's Research Hospital, Memphis, Tennessee, United States|St James's Hospital, Dublin, Ireland|University of Milan, Milan, Italy|Basingstoke Haemostasis and Thrombosis Centre, Basingstoke, United Kingdom|East Kent Hospitals University, Canterbury, United Kingdom|Guy's and St Thomas's NHS Foundation Trust, London, United Kingdom|Royal Free Hospital, London, United Kingdom|Newcastle Hospitals NHS Trust, Newcastle Upon Tyne, United Kingdom|Oxford University Hospital, Oxford, United Kingdom|University of Sheffield, Sheffield, United Kingdom|University Hospital Southampton, Southampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03369444"
103,"NCT05164471","Phase 1/2 Dose Confirmation Study of FLT180a in Hemophilia B",,"Recruiting","No Results Available","Hemophilia B","Genetic: verbrinacogene setparvovec","Safety and tolerability of FLT180a as assessed by incidence and severity of AEs and SAEs|Assessment of FIX activity levels to allow dose confirmation for future Phase 3 study|Assessment of change in annualized bleeding rate (ABR)|Assessment of change in annualized FIX concentrate consumption|Proportion of subjects achieving FIX activity level above 40%|The proportion of subjects remaining free from continuous routine FIX prophylaxis|The proportion of subjects achieving a FIX activity level between 50-150%|Assessment of health-related Quality of Life Questionnaire (measuring physical health, feelings, sport and leisure, dealing with haemophilia treatment) (Haem-A-QoL questionnaire)|Joint bleeding rates|Spontaneous bleeding rates|Number of target joints|Assessment of Quality of Life Questionnaire (measuring mobility, self-care, usual activities, pain/discomfort & anxiety/depression)(EQ-5D-5L questionnaire).|Measurement of Anti-AAVS3 antibodies and neutralizing antibodies|Evaluation of AAVS3 capsid-specific T-cell reactions|Abnormal or change from baseline findings for liver ultrasound|Abnormal or change from baseline findings for serum alpha-fetoprotein (AFP) levels.|FIX inhibitor level|Use of immunosuppressants (dose and duration per participant) for the prevention and treatment of increased Liver Enzymes|Clearance of vector genomes in plasma and semen as assessed by PCR test|Assessment of Clinically significant changes in 12-lead ECG","Freeline Therapeutics","Male","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","9","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","FLT180a-06","December 6, 2021","November 2023","November 2023","December 20, 2021",,"January 11, 2022","Children's Hospital of Los Angeles, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT05164471"
104,"NCT02971969","Long-Term Safety, Tolerability, and Efficacy of DTX101 (AAVrh10FIX) in Adults With Moderate/Severe to Severe Hemophilia B",,"Completed","No Results Available","Hemophilia B",,"Incidence of adverse events and serious adverse events by dosing group|Change from baseline in FIX activity level|Number of bleeding episodes requiring recombinant FIX infusion","Ultragenyx Pharmaceutical Inc","Male","18 Years and older   (Adult, Older Adult)",,"6","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","101HEMB02|2016-003430-25","January 2017","November 6, 2021","November 6, 2021","November 23, 2016",,"January 6, 2022","Arkansas Children's Hospital, Little Rock, Arkansas, United States|UF CRC - Clinical Research Center, Gainesville, Florida, United States|University of Michigan Hospital and Health Systems, Ann Arbor, Michigan, United States|Haemophilia, Haemostasis & Thrombosis Centre, Basingstoke, Hampshire, United Kingdom|Manchester Haemophilia Comprehensive Care Center, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02971969"
105,"NCT02618915","Safety and Dose Finding Study of DTX101 (AAVrh10FIX) in Adults With Moderate/Severe to Severe Hemophilia B",,"Terminated","Has Results","Hemophilia B","Genetic: DTX101","Number of Participants With Adverse Events (AEs), Treatment-Related Adverse Events (TEAEs), and Serious AEs (SAEs)|Change From Baseline in FIX Activity at Week 6|Annualized Bleeding Rate|Change From Baseline in FIX Activity Over Time|Annualized FIX Replacement Therapy|Number of Participants With Neutralizing Antibodies to FIX (FIX Inhibitors)|Number of Participants With Cell-Mediated Immune Response to FIX|Number of Participants Responding to the EuroQoL-5D-5 Level (EQ-5D-5L) Questionnaire|Number of Participants Responding to the Haemophilia-Specific Quality of Life Questionnaire|Average Weekly Use of FIX Replacement Therapy","Ultragenyx Pharmaceutical Inc","Male","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","6","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","101HEMB01","December 16, 2015","October 18, 2017","October 18, 2017","December 2, 2015","November 14, 2018","November 14, 2018","Arkansas Children's Hospital, Little Rock, Arkansas, United States|Orthopaedic Institute for Children, Los Angeles, California, United States|University of Florida, Gainesville, Florida, United States|Boston Children's Hospital, Boston, Massachusetts, United States|University of Michigan Hospital and Health Systems, Michigan Clinical Research Unit, Ann Arbor, Michigan, United States|Vanderbilt Hemostasis-Thrombosis Clinic, Nashville, Tennessee, United States|Specialized Hospital for Active Treatment for Hematological Disease, Sofia, Bulgaria|Basingstoke and North Hampshire Hospital, Haemophilia, Haemostasis and Thrombosis Centre, Basingstoke, Hampshire, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/15/NCT02618915/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/15/NCT02618915/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02618915"
106,"NCT00244114","Study Evaluating Allergic Reactions To Benefix In Hemophilia B Patients",,"Completed","No Results Available","Hemophilia B","Drug: blood draw|Procedure: Blood draw","Descriptive presentation of the results of the Basophil histamine release assay for both study and control groups|Collect and evaluate adverse events that occur from the time the subject signs the informed consent form to 15 days following the study visit will be collected|Any serious adverse events and/or adverse events of special interest occurring outside of the predefined study reporting period noted to be possibly, probably or definitely related to treatment with BeneFIX will be reported.","Wyeth is now a wholly owned subsidiary of Pfizer","All","Child, Adult, Older Adult",,"20","Industry","Observational","Time Perspective: Prospective","3090A1-900|B1821003; 3090A-101795","February 2006","December 2009","December 2009","October 25, 2005",,"February 18, 2013",,,"https://ClinicalTrials.gov/show/NCT00244114"
107,"NCT00167973","Prospective Registry of European Hemophilia B Patients Receiving BeneFIX® for Usual Use",,"Completed","No Results Available","Hemophilia B",,"Observation for safety","Wyeth is now a wholly owned subsidiary of Pfizer","All","Child, Adult, Older Adult",,"218","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","3090A-101039","January 2002","June 2009","June 2009","September 14, 2005",,"May 26, 2010","Vienna, Austria|Brussels, Belgium|Brussel, Belgium|Bruxelles, Belgium|Edegem, Belgium|Leuven, Belgium|Montegnée, Belgium|Amiens Cedex, France|Angers Cedex 01, France|Caen Cedex, France|Chambery Cedex, France|Grenoble Cedex 09, France|Le Chesnay Cedex, France|Le Kremlin Bicetre Cedex, France|Liffre, France|Limoges, France|Lyon Cedex, France|Lyon, France|Marseille Cedex 5, France|Montmorency, France|Montpellier Cedex 5, France|Montpellier Cedex, France|Nantes Cedex, France|Nevers, France|Nice Cedex, France|Osseja Cedex, France|Paris Cedex 14, France|Paris Cedex 15, France|Rouen, France|Saint Priest en Jarez, France|St Priest en Jarez, France|Tours Cedex, France|Erlangen, BY, Germany|Hamburg, HH, Germany|Muenster, NW, Germany|Ancona, AN, Italy|Bari, BA, Italy|Catania, CT, Italy|Catanzaro, CZ, Italy|Milano, MI, Italy|Palermo, PA, Italy|Pescara, PE, Italy|Parma, PR, Italy|Reggio Calabria, RC, Italy|Sassari, SS, Italy|Napoli, Italy|Padova, Italy|Palermo, Italy|Perugia, Italy|Roma, Italy|Vicenza, Italy|Amsterdam, Netherlands|Breda, Netherlands|Eindhoven, Netherlands|Maastricht, Netherlands|Nijmegen, Netherlands|Utrecht, Netherlands|Coimbra, Portugal|Almeria, Spain|Barcelona, Spain|Burgos, Spain|Cadiz, Spain|Esplugues de Llobregat, Spain|Madrid, Spain|Mérida-Badajoz, Spain|Santander, Spain|Sevilla, Spain|Valencia, Spain|Valladolid, Spain|Vitoria, Spain|Zaragoza, Spain|Malmö, Sweden|Stockholm, Sweden|Truro, Cnwll, United Kingdom|London, Gt Lon, United Kingdom|London, Gt Lon, United Kingdom|London, Gt Lon, United Kingdom|Manchester, Gt Man, United Kingdom|Edinburgh, Loth, United Kingdom|Liverpool, Mersyd, United Kingdom|Sheffield, Mersyd, United Kingdom|Oxford, Oxon, United Kingdom|Sheffield, Syorks, United Kingdom|Cardiff, W Glam, United Kingdom|Birmingham, Wstmid, United Kingdom|Wolverhampton, Wstmid, United Kingdom|Leeds, Wyorks, United Kingdom|London, United Kingdom|Plymouth, United Kingdom|Poole, United Kingdom|Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00167973"
108,"NCT03641703","A Long-Term Follow-Up Study of Haemophilia B Patients Who Have Undergone Gene Therapy",,"Active, not recruiting","No Results Available","Hemophilia B","Biological: FLT180a","Primary Safety Measurement|Durability of Response|Secondary Safety Measurement|FIX Activity Levels at or below 150%|FIX Activity Levels including 150% or above|FIX Activity Levels - Change from baseline|Haemostatic Effectiveness - Bleeding Rates|Haemostatic Effectiveness - FIX Concentrate Consumption|FLT180a effectiveness related to surgical/dental procedures by assessment of consumption of exogenous clotting factors at Time of surgery, Time of drain removal (if applicable)|FLT180a effectiveness related to surgical/dental procedures by assessment of measurement of absolute blood loss at Time of surgery, Time of drain removal (if applicable)|FLT180a effectiveness related to surgical/dental procedures by assessment of blood transfusion requirement, volume and number of transfusions at Time of surgery, Time of drain removal (if applicable)|FLT180a effectiveness related to surgical/dental procedures by assessment of efficacy of haemostasis as judged by surgeon on a 4-point scale at Time of surgery, Time of drain removal (if applicable)|Immune response to the hFIX transgene product (i.e., development of inhibitors) will be assessed by measurement of the level of inhibitors.|Clearance of vector genomes (vgs) in plasma, urine, saliva, stool and semen.","Freeline Therapeutics","Male","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","10","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FLT180a-04","July 10, 2018","December 31, 2035","December 31, 2035","August 22, 2018",,"December 1, 2020","The Haemophilia and Thrombosis Centre, Canterbury, Kent, United Kingdom|Sheffield Teaching Hospital, Sheffield, South Yorkshire, United Kingdom|Royal Free London NHS Foundation Tust, London, United Kingdom|Newcastle Hemophilia Comprehensive Care Centre, Newcastle, United Kingdom|Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom|Southampton Haemophilia Comprehensive Care Centre, Southampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03641703"
109,"NCT02048111","Study of Recombinant Factor IX Product, IB1001, in Previously Treated Subjects With Hemophilia B",,"Withdrawn","No Results Available","Hemophilia B","Biological: IB1001","Number of study subjects with adverse events|Number of bleeding episodes divided by number of months of observation","Cangene Corporation","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","0","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","IB1001-04","March 2014","October 2015","November 2015","January 29, 2014",,"August 23, 2016","Chicago, Illinois, United States|Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02048111"
110,"NCT03861273","A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemophilia B","BENEGENE-2","Recruiting","No Results Available","Hemophilia B","Biological: PF-06838435/ fidanacogene elaparvovec","Annualized bleeding rate (ABR)|Vector derived FIX:C level|Annualized infusion rate (AIR) of exogenous Factor IX Activity|Annualized bleeding rate (ABR) for treated and untreated bleeds|Annualized Factor IX Activity consumption|Annualized number of bleeding events of specific type: spontaneous and traumatic, and untreated|Frequency of target joint bleeds|Percentage of the participants without bleeds|Change in joint health as measured by the Hemophilia Joint Health Score (HJHS) instrument|Patient Reported Outcome (PRO) instrument - Hemophilia Quality of Life (Haem A QoL) Physical Health domain|Patient Reported Outcome (PRO) instrument - Hemophilia Activities List (HAL) Complex Lower Extremity Activities Component Score|Annualized Bleeding Rate for treated bleeds|Vector derived Factor IX activity (FIX:C) level at steady state|Annualized infusion rate (AIR) of exogenous Factor IX|ABR for total bleeds (treated and untreated)|Annualized Factor IX consumption|Hemophilia Joint Health Score (HJHS)|Incidence and severity of all adverse events collected during the study","Pfizer","Male","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","55","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","C0371002|2018-003086-33","July 29, 2019","November 21, 2022","September 30, 2029","March 4, 2019",,"January 6, 2022","University of California, San Francisco - Investigational Drug Service (IDS) Pharmacy, San Francisco, California, United States|University of California, San Francisco - Clinical Research Center, San Francisco, California, United States|University of California, San Francisco - Outpatient Hematology Clinic, San Francisco, California, United States|Hemophilia and Thrombosis Center at the University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States|Indiana Hemophilia and Thrombosis Center, Inc, Indianapolis, Indiana, United States|St. Vincent Hospital & Health Care Center, Inc., Indianapolis, Indiana, United States|Mississippi Baptist Medical Center, Jackson, Mississippi, United States|Madison Radiological Group, Madison, Mississippi, United States|Mississippi Center for Advanced Medicine, Madison, Mississippi, United States|Center for Human Phenomic Science CHPS, Philadelphia, Pennsylvania, United States|Center for Human Phenomic Science, Philadelphia, Pennsylvania, United States|Penn Blood Disorder Center, Philadelphia, Pennsylvania, United States|Penn Comprehensive Hemophilia & Thrombosis Program, Hospital of University of Pennsylvania, Philadelphia, Pennsylvania, United States|Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Centro de Hematologia e Hemoterapia - Hemocentro de Campinas - UNICAMP, Campinas, SÃO Paulo, Brazil|Instituto Estadual de Hematologia Arthur de Siqueira Cavalcanti - HEMORIO, Rio de Janeiro, Brazil|Instituto Estadual de Hematologia Arthur de Siqueira Cavalcanti- HEMORIO, Rio de Janeiro, Brazil|McMaster University Medical Centre - Hamilton Health Sciences, Hamilton, Ontario, Canada|Juravinski Hospital - Hamilton Health Sciences, Hamilton, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Hopital Cardiologique Louis Pradel - CRTH, Bron, France|Hopital Necker, Paris, France|Vivantes Klinikum Friedrichshain, Berlin, Germany|Vivantes Klinikum im Friedrichshain, Berlin, Germany|Universitätsklinikum Bonn, Anstalt des öffentlichen Rechts, Bonn, Germany|Universitätsklinikum Bonn, Bonn, Germany|General Hospital of Athens ""LAIKO"", 2nd Regional Blood Transfusion Center, Athens, Greece|Nara Medical University Hospital, Kashihara, Nara, Japan|National Center for Child Health and Development, Setagaya-ku, Tokyo, Japan|King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia|Skåne University Hospital, Department of Hematology, Oncology and Radiation Physics, Malmö, Sweden|ApoEx AB, Malmö, Sweden|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Acibadem Adana Hospital, Adana, Turkey|Gaziantep University Sahinbey Training and Research Hospital, Gaziantep, Turkey|Ege University Medical Faculty Hospital, Izmir, Turkey|Newcastle upon Tyne Hospitals NHS FT, Newcastle Upon Tyne, Tyne & Wear, United Kingdom|Newcastle upon Tyne Hospitals NHS FT, Newcastle Upon Tyne, Tyne & Wear, United Kingdom|Newcastle upon Tyne Hospitals NHS FT, Newcastle upon Tyne, Tyne & Wear, United Kingdom|Newcastle upon Tyne Hospitals NHS FT, Newcastle upon Tyne, Tyne & Wear, United Kingdom|Glasgow Royal Infirmary, Glasgow, United Kingdom|Glasgow Royal Infirmary, Glasgow, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03861273"
111,"NCT05191927","A Nomogram Model to Predict Central Lymphnode Metastasis in Thyroid Papillary Carcinoma",,"Completed","No Results Available","Thyroid Papillary Carcinoma","Other: male","Multivariate logistic regression analysis","Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|The First Affiliated Hospital of Zhengzhou University","All","Child, Adult, Older Adult",,"1200","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","NO.SYSEC-KY-KS-2021-180","January 1, 2020","January 1, 2021","August 1, 2021","January 14, 2022",,"January 14, 2022","Sun Yat-sen Memorial Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/27/NCT05191927/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT05191927"
112,"NCT02456103","Extension Study of Ataluren in Participants With Nonsense Mutation Cystic Fibrosis",,"Terminated","Has Results","Cystic Fibrosis","Drug: Ataluren","Number of Participants With Treatment Emergent Adverse Events (TEAEs)|Number of Participants With a Clinically Meaningful Abnormal Clinical Laboratory (Serum Biochemistry, Hematology, and Urinalysis) Parameter|Change From Baseline in Percent-Predicted Forced Expiratory Volume in 1 Second (FEV1) as Measured by Spirometry at Week 24|Change From Baseline in Percent-Predicted of Forced Vital Capacity (FVC) as Measured by Spirometry at Week 24|Change From Baseline in Forced Expiratory Flow Between 25% and 75% of Expiration (FEF25-75) as Measured by Spirometry at Week 24|Rate of Pulmonary Exacerbations as Defined by Modified Fuch's Criteria Over 48 Weeks","PTC Therapeutics","All","6 Years and older   (Child, Adult, Older Adult)","Phase 3","246","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PTC124-GD-021e-CF","August 31, 2015","June 2, 2017","June 2, 2017","May 28, 2015","April 15, 2020","April 27, 2020","University of Alabama at Birmingham, Birmingham, Alabama, United States|Miller Children's Hospital Long Beach, Long Beach, California, United States|Children's Hospital Los Angeles, Los Angeles, California, United States|Children's Hospital and Research Center at Oakland, Oakland, California, United States|Stanford University-Children's Hospital, Palo Alto, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Nemours Children's Clinic, Jacksonville, Florida, United States|University of Miami, Miami, Florida, United States|Miami Children's Hospital, Miami, Florida, United States|All Children's Hospital, Saint Petersburg, Florida, United States|Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|Children's Hospital Boston, Boston, Massachusetts, United States|Washington University, Saint Louis, Missouri, United States|Morristown Medical Center, Morristown, New Jersey, United States|Beth Israel Medical Center, New York, New York, United States|New York University Langone Medical Center, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|University of Cincinnati, Cincinnati, Ohio, United States|Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Drexel University College of Medicine, Philadelphia, Pennsylvania, United States|Texas Children's Hospital, Houston, Texas, United States|University of Texas Health Science Center, Tyler, Texas, United States|Childrens Hospital of Wisconsin, Milwaukee, Wisconsin, United States|Hospital de Ninos Ricardo Gutierrez, Buenos Aires, Argentina|Hospital Universitario Austral, Buenos Aires, Argentina|Royal Adelaide Hospital, Adelaide, Australia|Prince Charles Hospital, Chermside, Australia|Princess Margaret Hospital, Perth, Australia|University Hospital Brussels, Brussels, Belgium|Hopital Universitaire des Enfants Reine Fabiola, Brussels, Belgium|University Hospital Leuven, Leuven, Belgium|Hospital Sao Lucas Da Pontificia Universidade Catolica Do Rio Grande Do Sul, Porto Alegre, Brazil|University Mulitiprofile Hospital for Active Treatment Sveti Georgi EAD, Plovdiv, Bulgaria|University Multiprofile Hospital for Active Treatment Aleksandrovska EAD, Sofia, Bulgaria|Clinical Research Institute of Montreal, Montreal, Canada|University of Toronto Hospital for Sick Children, Toronto, Canada|British Columbia Children's Hospital, Vancouver, Canada|Hoptial Arnaud de Villeneuve, Montpellier, France|Hopital Necker - Enfants Malades, Paris, France|Centre de Perharidy, Roscoff, France|Centre Hospitalier Regional Sud Reunion, Saint-Pierre, France|Charite-Universitatsmedizin Berlin, Berlin, Germany|St. Josef Hospital GmbH, Bochum, Germany|University of Cologne Children's Hospital, Cologne, Germany|Christiane Herzog CF-Zentrum, Frankfurt am Main, Germany|Universitatsklinikum Jena, Jena, Germany|Dr. Von Haunersches Kinderspital, Munchen, Germany|LMU Klinikum der Universitat Muchen, Munich, Germany|Ippokratio General Hospital Of Thessaloniki, Thessaloniki, Greece|Meyer Children's Hospital, Haifa, Israel|Hadassah University Hospital, Jerusalem, Israel|Azienda Ospedaliero Universitaria Ospedall Riuniti di Acona-Umberto I G.M. Lancisi G. Salesi, Ancona, Italy|Azienda Ospedaliera A Meyer, Firenze, Italy|Lombardia Cystic Fibrosis Center, Milan, Italy|Azienda Policlinico Umberto I, Rome, Italy|Ospedale Pediatrico Bambino Gesu, Rome, Italy|Azienda Ospedaliera di Verona, Verona, Italy|Hagaziekenhuis, s-Gravenweg, Zuid-Holland, Netherlands|Radboud University, Nijmegen, Netherlands|Szpital Dzieciecy Polanki im Macieja Plazynskiego w Gdansku, Gdansk, Poland|Institute of Mother and Child, Warsaw, Poland|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Hospital University, Barcelona, Spain|Hospital San Juan, Esplugues De Llobregat, Spain|Hospital Regional Universitario de Malaga, Malaga, Spain|Hospital de Sabadell, Consorci Sanitari Parc Tauli, Sabadell, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|St James University Hospital, Leeds, United Kingdom|Royal Brompton Hospital, London, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/03/NCT02456103/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/03/NCT02456103/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02456103"
113,"NCT02565836","Fixed-dose Activated Versus Variable-dose Inactivated Prothrombin Complex Concentrate for Warfarin-associated Major Bleed",,"Completed","No Results Available","Hemorrhage","Drug: fixed-dose activated prothrombin complex concentrate|Drug: variable-dose inactivated prothrombin complex concentrate","Achievement of INR less than or equal to 1.5|Incidence of mortality or thrombotic events","Rush University Medical Center|Advocate Health Care","All","18 Years and older   (Adult, Older Adult)",,"342","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","15092404","October 2015","September 30, 2016","September 30, 2016","October 1, 2015",,"October 25, 2017",,,"https://ClinicalTrials.gov/show/NCT02565836"
114,"NCT02819557","Study of Ataluren in ≥2 to <5 Year-Old Male Participants With Duchenne Muscular Dystrophy",,"Completed","Has Results","Duchenne Muscular Dystrophy","Drug: Ataluren","Number of Participants With Treatment Emergent Adverse Events (TEAEs), TEAEs Leading to Discontinuation, and Serious Adverse Events (SAEs)|Number of Participants With a Clinically Meaningful Abnormal Clinical Laboratory (Biochemistry, Hematology, and Urinalysis) Parameter|Number of Participants With a Clinically Meaningful Abnormal Electrocardiogram (ECG) Test Results|Number of Participants With a Dose-Limiting Toxicity as Measured by Hepatic and Renal Toxicity|Pharmacokinetics: Maximum Observed Plasma Concentration From Time Zero up to 6 Hours After the Morning Dose (Cmax0-6hr)|Pharmacokinetics: Time to Reach Maximum Observed Plasma Concentration From Time Zero up to 6 Hours After the Morning Dose (Tmax0-6hr)|Area Under the Plasma Concentration Time Curve From Time Zero up to 10 Hours After the Morning Dose (AUC0-10hr)|Pharmacokinetics: Concentration at the End of the First (Morning) Dose Interval (Ctrough6hr)|Change From Baseline in Proximal Muscle Function as Assessed by Speed During TFTs|Change From Baseline in Physical Function as Measured by the NSAA|Change From Baseline in Height of Participants at Weeks 4, 16, 28, 40, 52, and 56|Change From Baseline in Weight of Participants at Weeks 4, 16, 28, 40, 52, and 56|Change From Baseline in Body Mass Index of Participants at Weeks 4, 16, 28, 40, 52, and 56|Ataluren Palatability Characteristics as Determined by a Parent/Caregiver Questionnaire","PTC Therapeutics","Male","2 Years to 5 Years   (Child)","Phase 2","14","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PTC124-GD-030-DMD","June 9, 2016","February 9, 2018","February 9, 2018","June 30, 2016","August 28, 2020","August 28, 2020","Child Neuro NWF, Gulf Breeze, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|Children's Hospital Boston, Boston, Massachusetts, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Children's Medical Center Dallas, Dallas, Texas, United States|University of Utah, Salt Lake City, Utah, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/57/NCT02819557/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/57/NCT02819557/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02819557"
115,"NCT00716716","Phase I/IIa Study of FIXFc in Hemophilia B Patients",,"Completed","No Results Available","Hemophilia B","Drug: rFIXFc","Number of Participants experiencing Adverse Events|Time to reach maximum concentration (Tmax)|Maximum concentration (Cmax)|Half-life (t½)|Clearance (CL)|Volume of distribution (Vd)|Area under the curve (AUC)|Mean residence time (MRT)|Incremental recovery (K)|Factor IX protein (FIX) activity|Recombinant (FIXFc) concentration over time curves","Bioverativ Therapeutics Inc.|Syntonix Pharmaceuticals, Inc.|Swedish Orphan Biovitrum|Sanofi","Male","18 Years and older   (Adult, Older Adult)","Phase 1","10","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SYN-FIXFc-07-001","April 2008","October 2009","October 2009","July 16, 2008",,"December 19, 2020","RUSH University Medical Center, Chicago, Illinois, United States|Indiana Hemophilia & Thrombosis Center, Indianapolis, Indiana, United States|Brigham & Women's Hospital, Boston, Massachusetts, United States|University of North Carolina Medical School, Chapel Hill, North Carolina, United States|Hemophilia Center of Western PA, Pittsburgh, Pennsylvania, United States|Puget Sound Blood Center, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00716716"
116,"NCT03690336","Adverse Event Data Collection From External Registries on Nonacog Beta Pegol",,"Enrolling by invitation","No Results Available","Haemophilia B","Drug: Nonacog beta pegol","Adverse Drug Reactions (ADRs) reported to the registries with suspected relation to nonacog beta pegol in patients with haemophilia B|Other ADRs reported to the registries during the study period with suspected relation to nonacog beta pegol in patients with haemophilia B","Novo Nordisk A/S","All","Child, Adult, Older Adult",,"10","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","NN7999-4413|U1111-1212-4050|EUPAS25696","October 1, 2018","October 1, 2027","October 1, 2027","October 1, 2018",,"January 11, 2022","Novo Nordisk Investigational Site, Baarn, Netherlands|Novo Nordisk Investigational Site, Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03690336"
117,"NCT03363347","BRAF V600E and Redifferentiation Therapy in Radioiodine-refractory Papillary Thyroid Cancer",,"Completed","No Results Available","Thyroid Cancer","Drug: Redifferentiation with retinoid acid","Response to radioiodine therapy after redifferentiation|Parameter tumor size|Parameter thyroglobulin levels (serum Tg)|Parameter radioiodine-uptake (RI-Uptake)","Heidelberg University","All","24 Years to 69 Years   (Adult, Older Adult)",,"25","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","S-206/2005","January 1, 2008","December 31, 2014","December 31, 2014","December 6, 2017",,"December 6, 2017",,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/47/NCT03363347/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT03363347"
118,"NCT05086575","Observatory of Patients With Haemophilia B Treated by IdElvion®","OrPHEe","Recruiting","No Results Available","Haemophilia B",,"Annual bleeding rates (overall, spontaneous and traumatic) under the scope of long-term prophylaxis or on-demand treatment of non-surgical bleeding events|Number of spontaneous bleeding events per patient|Number of Idelvion® infusions and doses injected by infusion required to prevent and resolve non-surgical bleeding episodes|Incidence of non-surgical bleeding episodes|The number of infusions and total dose of Idelvion® (in IU/kg) required to prevent or treat surgical bleeding episodes|Incidence of surgical bleeding episodes|The number of infusions and total dose of Idelvion® (in IU/kg) required to cover a high risk of bleeding|The number of infusions and total dose of Factor IX consumed in the year prior to taking Idelvion®|The number of infusions and total dose of Idelvion®|The type and incidence of adverse events (AE) in particular severe AE,and AE related to Idelvion®|Completion of the following questionnaire: EQ-5D-3L for adults|Completion of the following questionnaire: EQ-5D-Y for children from 8 to 12 years","CSL Behring","All","Child, Adult, Older Adult",,"100","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","OrPHEe study|2021-A00468-33","December 3, 2021","September 2026","September 2026","October 21, 2021",,"January 11, 2022","CH Annecy Genevois, Annecy, France|CHRU Besançon, Besançon, France|CHU Bordeaux - Hôpital Pellegrin, Bordeaux, France|CHRU Brest, Brest, France|CHU Caen, Caen, France|CHU Clermont-Ferrand, Clermont-Ferrand, France|CHU Dijon, Dijon, France|Hôpital Simone Veil, Eaubonne, France|CRC-MHC Hôpital Kremlin Bicêtre, Le Kremlin-Bicêtre, France|CH du Mans, Le Mans, France|CHRU Lille, Lille, France|Hôpital Edouard Herriot, Lyon, France|CHU Montpellier, Montpellier, France|CHRU Nancy, Nancy, France|CHU Nantes, Nantes, France|Hôpital Necker Enfants Malades, Paris, France|CHU Rennes, Rennes, France|CHU Rouen, Rouen, France|CHU Saint-Etienne, Saint-Étienne, France|Hôpital André Mignot - CH Versailles, Versailles, France",,"https://ClinicalTrials.gov/show/NCT05086575"
119,"NCT02647359","Study of Ataluren in Participants With Nonsense Mutation Aniridia","STAR","Completed","No Results Available","Aniridia","Drug: Ataluren|Drug: Placebo","Change From Baseline in Maximum Reading Speed of Oculus Unitas (OU) (Both Eyes) at Week 48, as Measured Using the MNREAD Acuity Charts|Change From Baseline in Reading Accessibility Index of OU at Week 48|Change From Baseline in Best Corrected Visual Acuity (BCVA) at Week 48|Change From Baseline in Maximum Reading Speed of Oculus Dexter (OD) (Right Eye) and Oculus Sinister (OS) (Left Eye) at Week 48|Change From Baseline in Reading Accessibility Index of OD and OS at Week 48|Change From Baseline in Critical Print Size of OU, OD and OS at Week 48|Change From Baseline in Reading Acuity of OU, OD and OS at Week 48|Change From Baseline in Severity of Corneal Keratopathy at Week 48 as Graded by Duke Reading Center|Change From Baseline in Iris Area at Week 48|Change From Baseline in BCVA at Week 240 (Sub-Study End of Study Visit)|Number of Participants With Treatment-Emergent Adverse Events (TEAEs)","PTC Therapeutics","All","2 Years and older   (Child, Adult, Older Adult)","Phase 2","39","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PTC124-GD-028 ANI","January 31, 2016","January 22, 2021","January 22, 2021","January 6, 2016",,"November 10, 2021","Casey Eye Institute, Oregon Health & Science University, Portland, Oregon, United States|University of Virginia, Charlottesville, Virginia, United States|University of British Columbia, Vancouver, British Columbia, Canada",,"https://ClinicalTrials.gov/show/NCT02647359"
120,"NCT03075670","A Trial Comparing Nonacog Beta Pegol (N9-GP) and ALPROLIX® in Patients With Haemophilia B","paradigm™7","Completed","No Results Available","Congenital Bleeding Disorder|Haemophilia B","Drug: N9-GP|Drug: ALPROLIX®","Area under the factor IX activity-time curve from 0 to infinity dose-normalised to 50 IU/kg|Maximum activity dose-normalised to 50 IU/kg (Cmax,norm)|Incremental recovery at 30 minutes (IR30min)|Terminal half-life (t½)|Clearance (CL)|Area under the activity-time curve|Maximum activity (Cmax)|Activity at 30 minutes (C30min)|Activity at 168 hours (C168h)|Incremental recovery at maximum activity (IRCmax)|Time of maximum activity (tmax)|Apparent volume of distribution during terminal phase (Vz)|Apparent volume of distribution at steady-state (Vss)|Mean residence time (MRT)|Terminal elimination rate constant|Area under the activity-time curve from 0 to infinity|Area under the activity-time curve from 0 to t last|Number of adverse events","Novo Nordisk A/S","Male","18 Years and older   (Adult, Older Adult)","Phase 1","15","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NN7999-4260|2016-001149-25|U1111-1180-7154","March 7, 2017","December 8, 2017","December 8, 2017","March 9, 2017",,"November 22, 2019","Novo Nordisk Investigational Site, Phoenix, Arizona, United States|Novo Nordisk Investigational Site, Chicago, Illinois, United States|Novo Nordisk Investigational Site, Peoria, Illinois, United States|Novo Nordisk Investigational Site, East Lansing, Michigan, United States|Novo Nordisk Investigational Site, Rochester, Minnesota, United States|Novo Nordisk Investigational Site, Oklahoma City, Oklahoma, United States|Novo Nordisk Investigational Site, Philadelphia, Pennsylvania, United States|Novo Nordisk Investigational Site, Berlin, Germany|Novo Nordisk Investigational Site, Duisburg, Germany|Novo Nordisk Investigational Site, Hannover, Germany|Novo Nordisk Investigational Site, Mörfelden-Walldorf, Germany|Novo Nordisk Investigational Site, Zürich, Switzerland",,"https://ClinicalTrials.gov/show/NCT03075670"
121,"NCT03569891","HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients",,"Active, not recruiting","No Results Available","Hemophilia B","Genetic: AAV5-hFIXco-Padua","Annualized bleeding rate (ABR)|Factor IX activity levels|Use of factor IX replacement therapy|Adverse events","UniQure Biopharma B.V.","Male","18 Years and older   (Adult, Older Adult)","Phase 3","56","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CT-AMT-061-02","June 27, 2018","September 22, 2021","March 2025","June 26, 2018",,"November 9, 2021","Phoenix Children's Hospital, Phoenix, Arizona, United States|Arkansas Children's Hospital, Little Rock, Arkansas, United States|Los Angeles Orthopedic Hospital, Los Angeles, California, United States|Children's Hospital of Los Angeles, Los Angeles, California, United States|University of California, Davis, Sacramento, California, United States|University of California, San Diego, San Diego, California, United States|University of Colorado Denver, Aurora, Colorado, United States|Children's National Medical Center Hematology and Oncology, Washington, District of Columbia, United States|University of South Florida, Tampa, Florida, United States|University of Michigan, Ann Arbor, Michigan, United States|Hemophilia Center of Western New York, Buffalo, New York, United States|University of North Carolina, Chapel Hill, Chapel Hill, North Carolina, United States|Oregon Health & Science University, Portland, Oregon, United States|University of Tennessee Health Science Center, Memphis, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University of Texas Health Science Center & Medical School, Houston, Texas, United States|University of Utah, Salt Lake City, Utah, United States|Washington Institute for Coagulation, Seattle, Washington, United States|University of Washington, Seattle, Washington, United States|Cliniques universitaires Saint-Luc, Bruxelles, Belgium|University Hospital Leuven, Leuven, Belgium|Righospitalet, Copenhagen, Denmark|Vivantes Klinikum im Friedrichshain, Berlin, Germany|Klinikum der Johann Wolfgang Goethe Universitat, Frankfurt am main, Germany|National Coagulation Centre, St James's Hospital, Dublin, Ireland|Center for Bleeding Disorders, Careggi University Hospital, Florence, Italy|Azienda Ospedaliero Universitaria Federico II di Napolis, Napoli, Italy|Amsterdam UMC - Locatie AMC, Amsterdam, Netherlands|Universitair Medisch Centrum Groningen, Groningen, Netherlands|Erasmus MC, Rotterdam, Netherlands|UMC Utrecht, Van Creveldkliniek, Utrecht, Netherlands|Center for Thrombosis and Hemostasis Skåne University Hospital Malmö, Malmö, Sweden|The Cambridge Haemophilia and Thrombophilia Centre Camridge University Hospitals NHS Foundation Trust - Box 217 Addenbrooke's Hospital, Cambridge, United Kingdom|The Royal London Hospital (Barts Health NHS Trust), London, United Kingdom|University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03569891"
122,"NCT04394286","A Phase 1/2 Study of SHP648, an Adeno-Associated Viral Vector for Gene Transfer in Hemophilia B Subjects",,"Terminated","No Results Available","Hemophilia B","Genetic: SHP648","Number of Participants With SHP648 Related Serious or Non-Serious Adverse Events (AEs)|Plasma FIX levels before and after SHP648 infusion|Annualized Bleed Rate (ABR)|Number of Participants With Positive Binding Antibody Titers to Adeno-Associated Virus (AAV8)|Number of Participants With Positive Neutralizing Antibody Titers to Adeno-Associated Virus (AAV8)|Number of Participants with T-cell Response to Adeno-Associated Virus (AAV8)|Number of Participants with T-cell Response to Factor IX (FIX) Transgene Products|Duration of SHP648 Genomes Present in Bodily Fluids|Percent Change in Consumption of Exogenous Factor IX (FIX) Before and After Gene Transfer","Baxalta now part of Shire|Takeda","Male","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","2","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SHP648-101|2018-004024-11","May 13, 2020","May 3, 2021","May 3, 2021","May 19, 2020",,"July 1, 2021","Hospital Universitario Virgen de la Arrixaca, El Palmar, Spain|Ege University Medical Faculty, Izmir, Turkey",,"https://ClinicalTrials.gov/show/NCT04394286"
123,"NCT05166694","Evaluating Personalized Therapeutics Clinic (PTC) on Drug-Drug Interactions and Drug-Gene Interactions",,"Not yet recruiting","No Results Available","Cancer|Advanced Cancer|Advanced Solid Tumor","Other: Drug-Drug Interaction Profile|Other: Drug-Gene Interaction Profile|Other: Standard of Care","Change in Rate of Drug-Drug Interactions and Drug-Gene Interactions Among Participants|Participants At High-Risk for Drug-Drug and Drug-Gene Interactions|Strategy to Implement at Personalize Therapeutic Clinic (PTC) at Specific Sites Based on Available Mediators (PTC Partners)|Rate of Hospitalizations|Rate of Emergency Department Visits|Rate of Reported Adverse Events as Assessed by Clinical Records|Changes in Participant Knowledge and Perceptions of the Personalized Therapeutic Clinic (PTC) as Assessed by Survey Results|Changes in provider knowledge and perceptions of the Personalized Therapeutic Clinics (PTC) Assessed by Survey Results","University of Chicago","All","18 Years and older   (Adult, Older Adult)","Not Applicable","1300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB21-1527","February 1, 2022","November 1, 2022","November 1, 2024","December 22, 2021",,"December 22, 2021",,,"https://ClinicalTrials.gov/show/NCT05166694"
124,"NCT02561533","Detection of BRAF Mutation on FNAB From Papillary Thyroid Carcinoma",,"Completed","No Results Available","Papillary Thyroid Carcinoma","Other: BRAF detection on fine needle aspiration biopsy (FNAB)","Immunohistochemical detection of BRAF mutation on fine needle aspiration biopsy (FNAB)","University of Aarhus","All","18 Years and older   (Adult, Older Adult)","Not Applicable","53","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","TIHCDBMTC1","December 2014","July 2017","July 2017","September 28, 2015",,"July 14, 2017","Aarhus University Hospital, Aarhus C, Denmark",,"https://ClinicalTrials.gov/show/NCT02561533"
125,"NCT03796637","A Study to Assess Dystrophin Levels in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) Who Have Been Treated With Ataluren",,"Completed","No Results Available","Duchenne Muscular Dystrophy","Other: Dystrophin levels|Drug: Ataluren","Mean Dystrophin Levels as Measured by Electrochemiluminescence (ECL)|Dystrophin Protein Levels as Determined by Immunohistochemistry","PTC Therapeutics","Male","Child, Adult, Older Adult","Phase 2","6","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","PTC124-GD-046-DMD|2019-001691-11","April 11, 2019","May 24, 2019","May 24, 2019","January 8, 2019",,"April 10, 2020","University of California, Los Angeles (UCLA), Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT03796637"
126,"NCT03359668","CT Detection of Metastatic Lymphadenopathy in Papillary Thyroid Cancer",,"Completed","No Results Available","Papillary Thyroid Cancer","Diagnostic Test: Use of IV contrast during head and neck CT","Increased detection of suspicious lymph nodes in PTC with IV-contrast enhanced CT","University Health Network, Toronto","All","Child, Adult, Older Adult","Not Applicable","47","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Diagnostic","11-0192-C","April 28, 2011","April 20, 2017","April 20, 2017","December 2, 2017",,"December 2, 2017",,,"https://ClinicalTrials.gov/show/NCT03359668"
127,"NCT00458341","A Study of Ataluren in Pediatric Participants With Cystic Fibrosis",,"Completed","Has Results","Cystic Fibrosis","Drug: Ataluren","Change From Baseline in Total Chloride Transport at Day 14 of Cycles 1 and 2|Number of Participants With a Chloride Transport Response at Day 14 of Cycles 1 and 2|Number of Participants With Normalization of Chloride Transport Between Baseline and Day 14 of Cycles 1 and 2|Change From Baseline in Parameters of Transepithelial Difference at Day 14 of Cycles 1 and 2|Change From Baseline in CFTR Protein in Nasal Mucosa as Determined by Immunofluorescence at Overall Day 56|Change From Baseline in Nonsense Mutation CFTR mRNA in Nasal Mucosa as Determined by Quantitative Real-Time Polymerase Chain Reaction (RT-PCR) Assay at Overall Day 42|Change From Baseline in Pulmonary Function as Measured by Spirometry at Day 14 or 15 of Cycles 1 and 2 and Overall Day 56|Change From Baseline in Sputum Markers of Inflammation (Free Elastase) at Day 14 or 15 of Cycles 1 and 2 and Overall Day 56|Change From Baseline in Sputum Markers of Inflammation (Matrix Metalloproteinase 9 [MMP-9] Active) at Day 14 or 15 of Cycles 1 and 2 and Overall Day 56|Change From Baseline in Sputum Markers of Inflammation (Tumor Necrosis Factor-Alpha [TNF-α], Interleukin-8 [IL-8], Transforming Growth Factor Beta 1 [TGF-β1]) at Day 14 or 15 of Cycles 1 and 2 and Overall Day 56|Change From Baseline in Sputum Markers of Inflammation (Uridine-5'-Triphosphate [UTP]) at Day 14 or 15 of Cycles 1 and 2 and Overall Day 56|Change From Baseline in Clinically Significant Neutrophil Levels in Blood at Day 14 or 15 of Cycles 1 and 2 and Overall Day 56|Change From Baseline in Clinically Significant Serum Levels of C-Reactive Protein at Day 14 or 15 of Cycles 1 and 2 and Overall Day 56|Change From Baseline in Body Weight at Day 14 or 15 of Cycles 1 and 2 and Overall Day 56|Change From Baseline in the CF-Related Symptom Scores, as Assessed Using a Participant-Reported Questionnaire at Day 14 of Cycles 1 and 2 and Overall Day 56|PK: Area Under the Concentration Time Curve From Time 0 (Dosing) to 24 Hours (AUC0-24) of Ataluren|Compliance With Study Treatment","PTC Therapeutics","All","6 Years to 18 Years   (Child, Adult)","Phase 2","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PTC124-GD-006-CF","March 23, 2007","February 29, 2008","February 29, 2008","April 10, 2007","March 6, 2020","March 6, 2020","Reine Fabiola Hospital, Brussels, Belgium|UZ Gasthuisberg Leuven, Leuven, Belgium|Hopital Necker Enfants Malades, Paris, France",,"https://ClinicalTrials.gov/show/NCT00458341"
128,"NCT00195221","Study to Describe the Allergic Reactions to Factor IX in Patients With Hemophilia B",,"Completed","No Results Available","Hemophilia B|Allergic Reactions",,,"Wyeth is now a wholly owned subsidiary of Pfizer","All","Child, Adult, Older Adult",,"166","Industry","Observational","Time Perspective: Retrospective","3090A-101657","February 2005",,"November 2007","September 19, 2005",,"December 5, 2007","Phoenix, Arizona, United States|Orange, California, United States|Atlanta, Georgia, United States|Boise, Idaho, United States|Peoria, Illinois, United States|Iowa City, Iowa, United States|East Lansing, Michigan, United States|Rochester, Minnesota, United States|New Brunswick, New Jersey, United States|Dayton, Ohio, United States|Philadelphia, Pennsylvania, United States|Memphis, Tennessee, United States|Fort Worth, Texas, United States|San Antonio, Texas, United States|Seattle, Washington, United States|Vienna, Austria|Brussels, Belgium|Montegnee, Belgium|Calgary, Alberta, Canada|Liffre, France|Montmorency, France|Paris, France|Strasbourg, France|Hamburg, Germany|Muenster, Germany|Catania, Italy|Catanzaro, Italy|Milano, Italy|Naples, Italy|Padova, Italy|Palermo, Italy|Parma, Italy|Perugia, Italy|Vicenza, Italy|Valencia, Spain|Valladolid, Spain|Wolverhampton, Wstmid, United Kingdom|Cardiff, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00195221"
129,"NCT01656330","A Study to Assess the Effects of 2 Different Prothrombin Complex Concentrates on the Pharmacodynamics of Rivaroxaban in Healthy Adult Volunteers",,"Completed","No Results Available","Healthy","Drug: Rivaroxaban 20 mg twice daily|Drug: Rivaroxaban 20 mg once daily|Drug: Profilnine SD|Drug: Beriplex P/N|Other: Saline","Measurement of pharmacodynamic (PD) variables: prothrombin time (PT), International Normalized Ratio (INR), activated partial thromboplastin time (aPTT), thrombin generation assay (TGA) and anti-Factor Xa (anti-FXa)|Rivaroxaban plasma concentrations|The number of healthy volunteers reporting adverse events|Changes from baseline in clinical laboratory tests performed|Change from baseline in electrocardiogram (ECG) findings|Change from baseline physical examination findings|Change from baseline in vital signs measurements","Janssen Research & Development, LLC|Bayer","All","18 Years to 55 Years   (Adult)","Phase 1","35","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","CR100867|RIVAROXNAP1003|2012-002313-20","July 2012","August 2012","August 2012","August 3, 2012",,"January 24, 2017","Merksem, Belgium",,"https://ClinicalTrials.gov/show/NCT01656330"
130,"NCT04129411","Treatment of Papillary Thyroid Carcinoma With Radiofrequency Ablation",,"Recruiting","No Results Available","Papillary Thyroid Cancer|Papillary Thyroid Microcarcinoma","Device: RFA","Changes in thyroid nodule size (overall volume measured in percentage)|Pain related to RFA procedure|Development of lymph node involvement|Development of distant metastasis|Safety of the RFA procedure","Mayo Clinic","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","5","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19-005486","June 15, 2020","March 31, 2022","March 31, 2022","October 16, 2019",,"November 5, 2021","Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT04129411"
131,"NCT01286779","BAX 326 (rFIX) Continuation Study",,"Completed","Has Results","Hemophilia B","Biological: BAX 326 (Recombinant factor IX)","Adverse Events Possibly or Probably Related to the Investigational Product|Treatment of Bleeding Episodes: Number of Infusions Per Bleeding Episode Required Until Bleed Resolution|Treatment of Bleeding Episodes: Overall Hemostatic Efficacy Rating at Resolution of Bleed|Annualized Bleed Rate During Prophylaxis Treatment|Consumption of BAX 326: Number of Infusions Per Month and Per Year|Consumption of BAX 326: Weight Adjusted Consumption Per Month and Per Year|Consumption of BAX326: Weight Adjusted Consumption Per Bleeding Episode|Development of Inhibitory and Total Binding Antibodies to Factor IX|Development of Antibodies to Chinese Hamster Ovary Proteins (CHO Proteins) and rFurin|Occurrence of Severe Allergic Reactions and Thrombotic Events|Clinical Significant Changes in Routine Laboratory Parameters and Vital Signs|Pharmacokinetics: Incremental Recovery (IR) Over Time|Pharmacokinetics: Area Under the Plasma Concentration Versus Time Curve From Time 0 to Infinity (AUC 0-∞)|Pharmacokinetics: Elimination Phase Half-life (T1/2)|Pharmacokinetics: Mean Residence Time (MRT)|Pharmacokinetics: Systemic Clearance (CL)|Pharmacokinetics: Volume of Distribution at Steady State (Vss)|Pharmacokinetics: Incremental Recovery (IR)|Changes in Health Related Quality of Life (HR QoL) Based on Questionnaire SF-36|Changes in Health Related Quality of Life Using the Peds QL|Changes in Health Related Quality of Life (HR QoL) Based on Questionnaire Haemo-QoL and Haem-A-QoL|Changes in Health Related Quality of Life (HR QoL) Based on Questionnaire EQ-5D and Pain Score.","Baxalta now part of Shire|Takeda","All","up to 65 Years   (Child, Adult, Older Adult)","Phase 3","117","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","251001|2010-022726-33","April 12, 2011","June 29, 2017","June 29, 2017","January 31, 2011","September 10, 2018","May 20, 2021","Instituto de Hematología y Medicina Clíncia Rubén Dávoli, Rosario, Argentina|UNIFESP - Universidade Estadual de Sao Paulo, Sao Paulo, Brazil|Specialized Haematological Hospital ""Joan Pavel"", Sofia, Bulgaria|Hospital Dr. Sotero del Rio, Santiago, Chile|Hospital de San Jose, Bogotá, Colombia|Centro Medico Imbanaco, Cali, Colombia|Hospital Pablo Tobon Uribe, Medellin, Colombia|Klinika detské hematologie a onkologie, Prague, Czechia|Maulana Azad Medical College and Associated Hospital, New Delhi, India|St. James's Hospital, National Center for Hereditary Coagulation Disorders, Dublin, Ireland|University Hospital Policlinico Vittorio Emanuele, Hospital Ferrarotto Alessi, Catania, Italy|University Hospital Careggi, Agency of Hemophilia - Regional Reference Center for Inherited Bleeding, Florence, Italy|University of Foggia Riuniti Hospital, Department of Clinical and Experimental Medicine, Foggia, Italy|Hospital San Giovanni Bosco, Center for Hemophilia and Thrombosis, Department of Hematology, Naples, Italy|Padova University Hospital, Medical Clinic II, Center for Hemophilia, Padova, Italy|Nara Medical University, Department of Pediatrics, Nara, Japan|Tokyo Medical University, Tokyo, Japan|Ogikubo Hospital, Tokyo, Japan|Hematology and Transplantology Clinic, University Clinic Centre - Medical University Hospital, Gdansk, Poland|University Pediatric Hospital in Cracow, Krakow, Poland|Medical College of the Jagiellonian University, Department of Hematology, Krakow, Poland|Copernicus Hospital, Medical University in Lodz, Department of Hematology, Lodz, Poland|Professor Tadeusz Sokolowski Independent Public Teaching Hospital No. 1 of the Pomeranian Medical University in Szczecin, Szczecin, Poland|Klinika Hematologii, Warsaw, Poland|Institute of Haematology and Transfusion Medicine, Warsaw, Poland|Prof. Dr. C.T. Nicolau National Institute for Transfusional Hematology, Bucharest, Romania|Louis Turcanu Emergency Clinical Children´s Hospital, Timisoara, Romania|Regional clinical hospital, Ekaterinburg, Russian Federation|Federal State Institution Kirov Hematology and Blood Transfusion Research Institute under the Federal Agency for High-Tech Medical Care, Kirov, Russian Federation|Pediatric Regional Clinical Hospital, Hematology Department, Krasnodar, Russian Federation|Hematology Research Center RAMS, Department of Reconstructive Orthopedics for Haemophilia Patients, Moscow, Russian Federation|Republican Center for Hemophilia Treatment Outpatient Clinic No. 37, St. Petersburg, Russian Federation|Malmö University Hospital, Department of Coagulation Disorders, Malmö, Sweden|Taipei Medical University Hospital, Taipei City, Taipei, Taiwan|Chung-Ho Memorial Hospital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Tri-Service General Hospital, Taipei, Taiwan|State Institution ""Institute of Blood Pathology and Transfusion Medicine of the Academy of Medical Sciences of Ukraine"", Lviv, Ukraine|Katharine Dormandy Haemophilia Centre and Haemostasis Unit, Royal Free Hospital, London, United Kingdom|Manchester Children's Hospital, Manchester, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/79/NCT01286779/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/79/NCT01286779/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01286779"
132,"NCT01233440","Safety and Pharmacokinetic Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein in Subjects With Hemophilia B",,"Completed","No Results Available","Hemophilia B","Biological: Recombinant Coagulation Factor IX Albumin Fusion Protein|Biological: Plasma derived FIX [pdFIX]","Frequency of adverse events (AEs)|Frequency of serious adverse events (SAEs)|Occurrence of inhibitor against FIX|Occurrence of antibodies against rIX-FP|AUC to the last sample with quantifiable drug concentration (AUC0-t)|AUC extrapolated to infinity (AUCt-∞)|Half-life (t1/2)|Incremental recovery (IU/mL/IU/kg)|Clearance","CSL Behring","Male","12 Years to 65 Years   (Child, Adult, Older Adult)","Phase 1","25","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CSL654_2001|1508|2010-018477-38","October 2010","July 2011","July 2011","November 3, 2010",,"January 31, 2012","Study site, Vienna, Austria|Study site, Le Kremlin-Bicetre, France|Study Site, Lyon, France|Study site, Nantes, France|Study site, Paris, France|Study Site, Berlin, Germany|Study Site, Hamburg, Germany|Study Site, Hannover, Germany|Study site, Munster, Germany|Study Site, Tel Hashomer, Israel|Study Site, Catania, Italy|Study Site, Firenze, Italy|Study Site, Genova, Italy|Study site, Milan, Italy|Study Site, Napoli, Italy|Study Site, Parma, Italy|Study Site, Vicenza, Italy|Study Site, A Coruna, Spain|Study Site, Barcelona, Spain|Study Site, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT01233440"
133,"NCT02141074","Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia B","paradigm™6","Active, not recruiting","No Results Available","Congenital Bleeding Disorder|Haemophilia B","Drug: nonacog beta pegol","Incidence of inhibitory antibodies against coagulation factor IX (FIX)|Number and frequency of adverse events|Number and frequency of serious adverse events|Number and frequency of Medical Events of Special Interest|Number of breakthrough bleeding episodes during prophylaxis (annualised bleeding rate)|Haemostatic effect by 4-point haemostatic response scale (""excellent"", ""good"", ""moderate"" and ""poor"")","Novo Nordisk A/S","Male","up to 6 Years   (Child)","Phase 3","60","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NN7999-3895|2012-004867-38|U1111-1135-9557|JapicCTI-142611|NL53683.091.15","July 2, 2014","October 30, 2022","October 30, 2022","May 19, 2014",,"December 1, 2021","Novo Nordisk Investigational Site, Los Angeles, California, United States|Novo Nordisk Investigational Site, Augusta, Georgia, United States|Novo Nordisk Investigational Site, Macon, Georgia, United States|Novo Nordisk Investigational Site, Boise, Idaho, United States|Novo Nordisk Investigational Site, New Orleans, Louisiana, United States|Novo Nordisk Investigational Site, Baltimore, Maryland, United States|Novo Nordisk Investigational Site, Omaha, Nebraska, United States|Novo Nordisk Investigational Site, Charlotte, North Carolina, United States|Novo Nordisk Investigational Site, Cleveland, Ohio, United States|Novo Nordisk Investigational Site, Dayton, Ohio, United States|Novo Nordisk Investigational Site, Philadelphia, Pennsylvania, United States|Novo Nordisk Investigational Site, Nashville, Tennessee, United States|Novo Nordisk Investigational Site, Salt Lake City, Utah, United States|Novo Nordisk Investigational Site, Algiers, Algeria|Novo Nordisk Investigational Site, Setif, Algeria|Novo Nordisk Investigational Site, Caba, Argentina|Novo Nordisk Investigational Site, Cordoba, Argentina|Novo Nordisk Investigational Site, South Brisbane, Queensland, Australia|Novo Nordisk Investigational Site, Parkville, Victoria, Australia|Novo Nordisk Investigational Site, Graz, Austria|Novo Nordisk Investigational Site, Innsbruck, Austria|Novo Nordisk Investigational Site, Klagenfurt, Austria|Novo Nordisk Investigational Site, Linz, Austria|Novo Nordisk Investigational Site, Salzburg, Austria|Novo Nordisk Investigational Site, St. Poelten, Austria|Novo Nordisk Investigational Site, Wien, Austria|Novo Nordisk Investigational Site, Hamilton, Ontario, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, Canada|Novo Nordisk Investigational Site, Clermont Ferrand, France|Novo Nordisk Investigational Site, Kremlin-Bicêtre, France|Novo Nordisk Investigational Site, Nantes Cedex 1, France|Novo Nordisk Investigational Site, Bonn, Germany|Novo Nordisk Investigational Site, Duisburg, Germany|Novo Nordisk Investigational Site, Hannover, Germany|Novo Nordisk Investigational Site, Mörfelden-Walldorf, Germany|Novo Nordisk Investigational Site, Tel-Hashomer, Israel|Novo Nordisk Investigational Site, Firenze, Italy|Novo Nordisk Investigational Site, Aichi, Japan|Novo Nordisk Investigational Site, Kanagawa, Japan|Novo Nordisk Investigational Site, Saitama, Japan|Novo Nordisk Investigational Site, Shizuoka, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Georgetown, Penang, Malaysia|Novo Nordisk Investigational Site, Klang, Selangor, Malaysia|Novo Nordisk Investigational Site, Kuala Lumpur, Malaysia|Novo Nordisk Investigational Site, Kuantan, Malaysia|Novo Nordisk Investigational Site, Nijmegen, Netherlands|Novo Nordisk Investigational Site, Esplugues Llobregat, Spain|Novo Nordisk Investigational Site, Madrid, Spain|Novo Nordisk Investigational Site, Valencia, Spain|Novo Nordisk Investigational Site, Changhua, Taiwan|Novo Nordisk Investigational Site, Kaohsiung, Taiwan|Novo Nordisk Investigational Site, Taichung, Taiwan|Novo Nordisk Investigational Site, Taipei, Taiwan|Novo Nordisk Investigational Site, Bangkok, Thailand|Novo Nordisk Investigational Site, Bangkok, Thailand|Novo Nordisk Investigational Site, Chiang Mai, Thailand|Novo Nordisk Investigational Site, Birmingham, United Kingdom|Novo Nordisk Investigational Site, Glasgow, United Kingdom|Novo Nordisk Investigational Site, Leicester, United Kingdom|Novo Nordisk Investigational Site, London, United Kingdom|Novo Nordisk Investigational Site, Manchester, United Kingdom|Novo Nordisk Investigational Site, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02141074"
134,"NCT00515710","LTFU for Gene Transfer Subjects With Hemophilia B",,"Completed","No Results Available","Hemophilia B",,"Safety and tolerability of intra-hepatic administration of AAV2-hFIX. Toxicity related to the administration of AAV2-hFIX will be evaluated locally and systemically.","Spark Therapeutics|Children's Hospital of Philadelphia|The Hemophilia Center of Western Pennsylvania|Royal Prince Alfred Hospital, Sydney, Australia","Male","18 Years and older   (Adult, Older Adult)",,"4","Industry|Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","AAV2-hFIX16-LTFU-01","August 2007","December 2017","December 2017","August 14, 2007",,"May 15, 2020","Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Hemophilia Center of Western Pennsylvania, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00515710"
135,"NCT02568202","Bridging Hemophilia B Experiences, Results and Opportunities Into Solutions (B-HERO-S)",,"Completed","No Results Available","Haemostasis|Congenital Bleeding Disorder|Haemophilia B","Other: No treatment given","An online survey of Prevalence and characteristics of adults with hemophilia B|An online survey of Prevalence and characteristics of children with hemophilia B (and their parents)|An online survey of Prevalence of psychosocial and other comorbidities in patients with hemophilia B|Percentage of participants reporting difficulty with access to treatment (e.g. factor)|An online survey of Percentage of participants reporting difficulty with access to treatment centers|Percentage of participants reporting hemophilia interference with employment/education|Percentage of participants reporting hemophilia interference with physical activities|Percentage of participants reporting hemophilia interference with relationships|Health related quality of life: EuroQol|Health related quality of life:EQ-5D-5L|Health related quality of life: VAS (Visual Analog Scale)|Health related quality of life: BPI (Brief Pain Inventory) short form - Pain severity and interference|Health related quality of life: HAL (Hemophilia Activities List)|Health related quality of life: HemoCAB (Caregiver Hemophilia Burden Scale|Drivers of psychosocial impact (e.g. hemophilia severity, age, weight, prior treatment history, education)","Novo Nordisk A/S","All","18 Years and older   (Adult, Older Adult)",,"449","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","HAEM-4268|U1111-1171-8168","September 2015","November 2015","November 2015","October 5, 2015",,"January 12, 2016","Novo Nordisk Clinical Trial Call Center, Plainsboro, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02568202"
136,"NCT03587116","Six Month lead-in Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adult Hemophilia B Subjects (FIX:C≤2%) or Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Subjects (FVIII:C≤1%)",,"Recruiting","No Results Available","Hemophilia B|Hemophilia A","Drug: Standard of Care FIX Replacement therapy|Drug: Standard of Care FVIII Replacement therapy","Annualized bleeding rate (ABR)|Incidence of serious adverse events|Events of special interest (ESI):inhibitor against FIX or FVIII, thrombotic events, and FIX or FVIII hypersensitivity reactions|Annualized infusion rate (AIR)|Dose and total factor consumption|Number of bleeding events (spontaneous and/or traumatic)","Pfizer","Male","18 Years to 64 Years   (Adult)","Phase 3","250","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","C0371004|2017-001271-23|NAB PROTOCOL","July 26, 2018","October 24, 2022","October 24, 2022","July 16, 2018",,"December 14, 2021","Clinical and Translational Research Unit (CTRU), Palo Alto, California, United States|Lucile Packard Childrens Hospital, Palo Alto, California, United States|University of California, San Francisco - Outpatient Hematology Clinic, San Francisco, California, United States|Stanford Health Care, Stanford, California, United States|Hemophilia and Thrombosis Center at the University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States|Emory University Hospital Midtown, Atlanta, Georgia, United States|Emory University Hospital, Atlanta, Georgia, United States|Investigational Drug Service, Atlanta, Georgia, United States|Indiana Hemophilia & Thrombosis Center, Inc., Indianapolis, Indiana, United States|Mississippi Center for Advanced Medicine, Madison, Mississippi, United States|Alliance for Childhood Diseases, Las Vegas, Nevada, United States|Penn Blood Disorder Center, Philadelphia, Pennsylvania, United States|Penn Comprehensive Hemophilia & Thrombosis Program, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Bloodworks NW, Seattle, Washington, United States|Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Fiona Stanley Hospital, Murdoch, Western Australia, Australia|Cliniques universitaires Saint-Luc/Unité d'Hématology et Hémostase, Brussels, Belgium|Centro de Hemoterapia e Hematologia do Para - Fundação HEMOPA, Belem, Para, Brazil|Centro de Hematologia e Hemoterapia - Hemocentro de Campinas - UNICAMP, Campinas, SAO Paulo, Brazil|lnstituto Estadual de Hematologia Arthur de Siqueira Cavalcanti - HEMORIO, Rio de Janeiro, Brazil|McMaster University Medical Centre - Hamilton Health Sciences, Hamilton, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|CHRU de Brest - Hôpital Morvan, Brest, France|Hôpital Cardiologique Louis Pradel, Bron, France|Hôpital Timone - Enfants, Marseille, France|CHU Hôtel-Dieu, Nantes Cedex 1, France|Hopital Necker, Hematologie Adultes, Paris, France|Vivantes Klinikum Friedrichshain, Berlin, Germany|Universitatsklinikum Bonn. Anstalt des oeffentlichen Rechts, Bonn, Germany|Universitaetsklinikum Frankfurt, Goethe-Universitaet, Frankfurt/Main, Germany|General Hospital of Athens ""Hippokration"", Athens, Attica, Greece|General Hospital of Athens ""LAIKO"", 2nd Regional Blood Transfusion Center, Athens, Attica, Greece|The Chaim Sheba Medical Center, The National Hemophilia Center, Tel-Hashomer, Israel|SODc. Malattie Emorragiche e della Coagulazione Centro di Riferimento Regionale per le, Firenze, Italy|Azienda Ospedaliera Universitaria Federico II, Napoli, Italy|Università degli studi di Roma ""La Sapienza""- Policlinico Umberto I, Roma, Italy|Nagoya University Hospital - Transfusion Medicine, Nagoya, Aichi, Japan|Sapporo Tokushukai Hospital, Sapporo, Hokkaido, Japan|Nara Medical University Hospital, Kashihara, Nara, Japan|Saitama Medical University Hospital, Iruma-gun, Saitama, Japan|National Center for Child Health and Development, Setagaya-ku, Tokyo, Japan|Ogikubo Hospital, Suginami-ku, Tokyo, Japan|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Kyung Hee University Hospital at Gangdong, Seoul, Korea, Republic of|King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia|Hospital Universitari Vall d´Hebrón, Barcelona, Spain|H.U. La Paz., Madrid, Spain|H.U. Rio Hortega, Valladolid, Spain|Skåne University Hospital, Malmö, Sweden|Changhua Christian Hospital, Changhua, Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|Taipei Medical University Hospital, Taipei City, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Ege Universitesi Tip Fakultesi Cocuk Sagligi Ve Hastaliklari Anabilim Dali Pediatric Hematoloji, Bornova, İ̇zmir, Turkey|Ege Universitesi Tip Fakultesi Hematoloji BD, Bornova, İ̇zmir, Turkey|Acibadem Adana Hospital, Department of Pediatric Hematology, Adana, Turkey|Akdeniz University Medical Faculty Hospital, Antalya, Turkey|Gaziantep University Sahinbey Training and Research Hospital, Gaziantep, Turkey|Istanbul University Oncology Institute, Istanbul, Turkey|Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, Tyne & Wear, United Kingdom|Non Malignant Haematology Research Unit, Newcastle upon Tyne, Tyne & Wear, United Kingdom|Clinical Research Facility, Glasgow, United Kingdom|Department of Haematology, Glasgow, United Kingdom|Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03587116"
137,"NCT04336696","Is Routine Dissection of Central Lymph Node Necessary for Papillary Thyroid Carcinoma, T1-2 N0?",,"Recruiting","No Results Available","Papillary Thyroid Carcinoma","Procedure: Total thyroidectomy and central neck dissection","recurrence free survival","Bassem Mohamed Sieda|Zagazig University","All","42 Years to 55 Years   (Adult)","Not Applicable","199","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","0000-0002-9836-9580","November 2, 2016","April 3, 2020","May 3, 2020","April 7, 2020",,"April 7, 2020","Zagazig University Hospitals, Zagazig, Egypt",,"https://ClinicalTrials.gov/show/NCT04336696"
138,"NCT04743089","Cost-Effectiveness of Spyglass Direct Visualization System Facilitated Management for the Patients With Intrahepatic Bile Duct Stone and/or Large Extrahepatic Bile Duct Stone",,"Recruiting","No Results Available","Patients With Large or Impacted Intra- or Extra-hepatic Bile Duct Stone","Device: ERCP using SpyGlass™ DS Direct Visualization System|Other: PTCS","Total hospital stay (# of days)|Total procedure-related cost|Efficacy; Technical success rate|Safety; Procedure-related complication rate","Yonsei University","All","19 Years to 100 Years   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1-2018-0031","December 11, 2020","January 2022","January 2023","February 8, 2021",,"February 8, 2021","Yonsei University College of Medicine, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04743089"
139,"NCT01510002","Prophylactic Central Neck Dissection for Papillary Thyroid Cancer",,"Completed","No Results Available","Papillary Thyroid Cancer","Procedure: Total thyroidectomy|Procedure: Total thyroidectomy + prophylactic central neck dissection","overall survival|disease-specific survival|locoregional control|number of patients with negative serum thyroglobulin levels|postoperative morbidity rate (hypoparathyroidism and recurrent laryngeal nerve injury).","Jagiellonian University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","640","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BBN/501/ZKL/1447","January 1993","September 2011","December 2011","January 13, 2012",,"January 13, 2012","Jagiellonian Univerity, Medical College, 3rd Department of General Surgery, Krakow, Malopolska, Poland",,"https://ClinicalTrials.gov/show/NCT01510002"
140,"NCT02695160","Ascending Dose Study of Genome Editing by Zinc Finger Nuclease Therapeutic SB-FIX in Subjects With Severe Hemophilia B",,"Terminated","No Results Available","Hemophilia B","Biological: SB-FIX","Treatment related Adverse Events in subjects who received SB-FIX as assessed by Common Terminology Criteria for Adverse Events (CTCAE)|Change from baseline in FIX antigen and activity levels|Presence and shedding of AAV2/6 vector DNA by PCR in plasma, saliva, urine, stool and semen","Sangamo Therapeutics","Male","18 Years and older   (Adult, Older Adult)","Phase 1","1","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SB-FIX-1501","November 15, 2016","April 19, 2021","April 19, 2021","March 1, 2016",,"May 3, 2021","Georgetown University Medical Center, Washington, District of Columbia, United States",,"https://ClinicalTrials.gov/show/NCT02695160"
141,"NCT01103557","Prophylactic Selective Lateral Neck Dissection in Patients With Papillary Thyroid Carcinoma",,"Completed","No Results Available","Thyroid Neoplasm|Lymphatic Metastasis","Procedure: prophylactic selective lateral neck dissection",,"Pusan National University Hospital","All","20 Years to 76 Years   (Adult, Older Adult)","Not Applicable","62","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","PTC_CND_LND",,,,"April 14, 2010",,"April 14, 2010",,,"https://ClinicalTrials.gov/show/NCT01103557"
142,"NCT03064035","Fixed Versus Variable Dosing of 4-factor Prothrombin Complex Concentrate for Emergent Warfarin Reversal","kcentra","Completed","No Results Available","Acute Bleeding on Long-Term Anticoagulation Therapy|Hemorrhage|Significant Bleeding in Patients With a Coagulopathy (Prolonged Thrombin Time)|Urgent Reversal of Vitamin K Antagonist (VKA) Anticoagulation","Drug: 4-factor prothrombin complex concentrate (4FPCC)","Whole blood clotting time|Occurrence of thromboembolic event|Total cost","HealthPartners Institute","All","18 Years to 125 Years   (Adult, Older Adult)","Phase 4","79","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","A16-732","April 5, 2017","April 17, 2019","April 24, 2019","February 24, 2017",,"June 10, 2019","Regions Hospital, Saint Paul, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03064035"
143,"NCT03830242","Diagnostic Significance of FDG PET/CT Dynamic Imaging in Detecting Metastatic Lymph Nodes With Papillary Thyroid Cancer.",,"Recruiting","No Results Available","Positron-Emission Tomography|Lymph Node Metastases|Thyroid Cancer","Diagnostic Test: <Sup>18<Sup>F-FDG PET/CT dynamic scan|Diagnostic Test: B-ultrasonography","Number of lymph nodes dissected|Number of Participants diagnosed with lymph node metastasis by <Sup>18<Sup>F-FDG PET/CT dynamic scans.|Number of Participants diagnosed with lymph node metastasis by Postoperative pathology|The number of lymph node metastases in patients with different Genetic types|Calculating the overall diagnostic sensitivity of <Sup>18<Sup>F-FDG PET/CT dynamic scans|Calculating the overall diagnostic specificity of <Sup>18<Sup>F-FDG PET/CT dynamic scans|Calculating the receiver operating characteristic curve（ROC）|Calculating the radionics indicators of <Sup>18<Sup>F-FDG PET/CT","Fifth Affiliated Hospital, Sun Yat-Sen University","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Diagnostic","ZDWY.JRWK.001","November 1, 2018","December 31, 2022","December 31, 2022","February 5, 2019",,"August 14, 2020","Fifth Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT03830242"
144,"NCT00702715","Comparison of 4.0 mg/kg Sugammadex at 1-2 Post Tetanic Counts (PTC) in Renal or Control Patients (19.4.328)(P05769)",,"Completed","Has Results","Anesthesia","Drug: sugammadex","Time to Recovery of the T4/T1 Ratio to 0.9.|Time to Recovery of the T4/T1 Ratio to 0.8|Time to Recovery of T4/T1 Ratio to 0.7","Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 3","69","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P05769|19.4.328","September 24, 2008","March 15, 2010","March 15, 2010","June 20, 2008","April 11, 2011","May 16, 2017",,,"https://ClinicalTrials.gov/show/NCT00702715"
145,"NCT01395810","Safety and Efficacy of NNC-0156-0000-0009 After Long-Term Exposure in Patients With Haemophilia B: An Extension to Trials NN7999-3747 and NN7999-3773","paradigm™ 4","Completed","Has Results","Congenital Bleeding Disorder|Haemophilia B","Drug: nonacog beta pegol","Incidence of Inhibitory Antibodies Against FIX Defined as Titre Above or Equal to 0.6 BU (Bethesda Units)|Haemostatic Effect of Nonacog Beta Pegol When Used for Treatment of Bleeding Episodes, Assessed as Success/Failure Based on a Four-point Scale for Haemostatic Response (Excellent, Good, Moderate, Poor)|Number of Bleeding Episodes During Routine Prophylaxis|FIX Trough Levels|Incidence of Adverse Events (AEs)|Incidence of Serious Adverse Events (SAEs)","Novo Nordisk A/S","Male","13 Years to 70 Years   (Child, Adult, Older Adult)","Phase 3","71","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NN7999-3775|2010-023072-17|U1111-1121-5408|JapicCTI-121812","April 15, 2012","March 30, 2014","March 30, 2014","July 18, 2011","May 9, 2018","May 9, 2018","Novo Nordisk Investigational Site, Los Angeles, California, United States|Novo Nordisk Investigational Site, San Francisco, California, United States|Novo Nordisk Investigational Site, Washington, District of Columbia, United States|Novo Nordisk Investigational Site, Jacksonville, Florida, United States|Novo Nordisk Investigational Site, Augusta, Georgia, United States|Novo Nordisk Investigational Site, Iowa City, Iowa, United States|Novo Nordisk Investigational Site, Baltimore, Maryland, United States|Novo Nordisk Investigational Site, Minneapolis, Minnesota, United States|Novo Nordisk Investigational Site, Omaha, Nebraska, United States|Novo Nordisk Investigational Site, Newark, New Jersey, United States|Novo Nordisk Investigational Site, New York, New York, United States|Novo Nordisk Investigational Site, Syracuse, New York, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Wien, Austria|Novo Nordisk Investigational Site, Bron Cedex, France|Novo Nordisk Investigational Site, Kremlin-Bicêtre, France|Novo Nordisk Investigational Site, Bonn, Germany|Novo Nordisk Investigational Site, Duisburg, Germany|Novo Nordisk Investigational Site, Giessen, Germany|Novo Nordisk Investigational Site, Hannover, Germany|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Firenze, Italy|Novo Nordisk Investigational Site, Milano, Italy|Novo Nordisk Investigational Site, Kashihara-shi, Nara, Japan|Novo Nordisk Investigational Site, Kawasaki-shi, Kanagawa, Japan|Novo Nordisk Investigational Site, Nagoya-shi, Aichi, Japan|Novo Nordisk Investigational Site, Nishinomiya-shi, Japan|Novo Nordisk Investigational Site, Shinjuku-ku, Tokyo, Japan|Novo Nordisk Investigational Site, Suginami-ku, Tokyo, Japan|Novo Nordisk Investigational Site, Skopje, Macedonia, The Former Yugoslav Republic of|Novo Nordisk Investigational Site, Kuala Lumpur, Malaysia|Novo Nordisk Investigational Site, Utrecht, Netherlands|Novo Nordisk Investigational Site, Timisoara, Timis, Romania|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Parktown Johannesburg, Gauteng, South Africa|Novo Nordisk Investigational Site, Madrid, Spain|Novo Nordisk Investigational Site, Valencia, Spain|Novo Nordisk Investigational Site, Taipei, Taiwan|Novo Nordisk Investigational Site, Bangkok, Thailand|Novo Nordisk Investigational Site, Ankara, Turkey|Novo Nordisk Investigational Site, Kayseri, Turkey|Novo Nordisk Investigational Site, Konya, Turkey|Novo Nordisk Investigational Site, Basingstoke, United Kingdom|Novo Nordisk Investigational Site, Cardiff, United Kingdom|Novo Nordisk Investigational Site, London, United Kingdom|Novo Nordisk Investigational Site, London, United Kingdom|Novo Nordisk Investigational Site, Manchester, United Kingdom|Novo Nordisk Investigational Site, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01395810"
146,"NCT00004801","Phase I/II Study of Monoclonal Factor IX Concentrate for Factor IX Deficiency",,"Completed","No Results Available","Hemophilia B|Factor IX Deficiency","Drug: monoclonal factor IX replacement therapy",,"National Center for Research Resources (NCRR)|University of North Carolina|Office of Rare Diseases (ORD)","All","12 Years and older   (Child, Adult, Older Adult)","Phase 1|Phase 2","3","NIH|Other","Interventional","Primary Purpose: Treatment","199/11956|UNCCH-621","March 1992",,,"February 25, 2000",,"June 24, 2005",,,"https://ClinicalTrials.gov/show/NCT00004801"
147,"NCT03660891","OS NMB Depth Measured by Central and Peripheral Monitor.",,"Not yet recruiting","No Results Available","Neuromuscular Blockade","Diagnostic Test: measuring neuromuscular block","TOF-PTC value","AZ Sint-Jan AV","All","18 Years and older   (Adult, Older Adult)",,"20","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","OS NMBcentralperipheral","August 1, 2020","December 30, 2020","December 31, 2021","September 7, 2018",,"March 23, 2020","Azsintjan, Brugge, Belgium",,"https://ClinicalTrials.gov/show/NCT03660891"
148,"NCT00093171","Study Evaluating rFIX; BeneFIX® in Hemophilia B",,"Completed","No Results Available","Hemophilia B","Drug: rFIX",,"Wyeth is now a wholly owned subsidiary of Pfizer","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","23","Industry","Interventional","Allocation: Non-Randomized|Masking: None (Open Label)|Primary Purpose: Treatment","3090A1-302",,"May 2005","May 2005","October 7, 2004",,"August 21, 2009","Los Angeles, California, United States|Aurora, Colorado, United States|Detroit, Michigan, United States|New Brunswick, New Jersey, United States|Chapel Hill, North Carolina, United States|Dayton, Ohio, United States|Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00093171"
149,"NCT01128881","IMMUNINE Pre-Treatment Study",,"Completed","No Results Available","Hemophilia B","Biological: Factor IX Concentrate (purified, virus-inactivated)","Hemostatic Efficacy","Baxalta now part of Shire|Takeda","All","up to 64 Years   (Child, Adult)","Phase 4","57","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","050901|2009-016719-39","May 31, 2010","August 28, 2012","August 28, 2012","May 24, 2010",,"April 23, 2021","Hospital JR Vidal (Servicio de Hemotologie - Area de Investiagacion, Corrientes, Argentina|Instituto de Hemofilia y Medicina Clinica Rubén Dávoli, Rosario, Argentina|Hospital do apoio de Brasilia, Distrito Federal, Brazil|UNIFESP - Universidade Estadual de Sáo Paulo, Sáo Paulo, Brazil|Specialized Haematological Hospital ""Joan Pavel"", Sofia, Bulgaria|Hospital Dr. Sotero del Rio, Santiago, Chile|Hospital san José, Centro de Hemofilia, Santiago, Chile|Centro Medico Imbanaco, Cali, Colombia|Klinika detske hematologie a onkologie UK, Prague, Czechia|Hematology and Transplantology Clinic, University Clinic Centre - Medical University Hospital, Gdansk, Poland|Medical College of the Jagiellonian University, Krakow, Poland|Medical University Lodz, Department of Hematology, Lodz, Poland|Institute of Haematology and Transfusion, Warsaw, Poland|Prof. Dr. C. T. Nicolau National Institute for Transfusional Hematology, Bucharest, Romania|Louis Turcanu Emergency Clinical Children´s Hospital, Timisoara, Romania|Hematology Research Center RAMS, Department of Hemophilia and Other Coagulopathies, Moscow, Russian Federation|Republican Center for Hemophilia Treatment, Outpatient Clinic No. 37, St. Petersburg, Russian Federation|State Institution ""Institute of Blood Pathology and Transfusion Medicine of Academy of Medical Sciences of Ukraine"", Lviv, Ukraine",,"https://ClinicalTrials.gov/show/NCT01128881"
150,"NCT00826176","Efficacy and Safety of 4.0 mg/kg Sugammadex at 1-2 PTC in Chinese and European Subjects (Study 19.4.335)(P05775AM1)(COMPLETED)",,"Completed","Has Results","Anesthesia, General|Neuromuscular Blockade","Drug: Sugammadex","Time From Start of Administration of Sugammadex to Recovery of the T4/T1 Ratio to 0.9|Time From Start of Administration of Sugammadex to Recovery of the T4/T1 Ratio to 0.7|Time From Start of Administration of Sugammadex to Recovery of the T4/T1 Ratio to 0.8","Merck Sharp & Dohme Corp.","All","18 Years to 64 Years   (Adult)","Phase 3","164","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P05775|19.4.335","January 2010","August 2010","August 2010","January 21, 2009","September 16, 2011","October 7, 2015",,,"https://ClinicalTrials.gov/show/NCT00826176"
151,"NCT02442661","Clinical Validation of a Predictive Model for the Presence of Cervical Lymph Node Metastasis in Papillary Thyroid Cancer",,"Completed","No Results Available","Papillary Thyroid Cancer",,"Detection of lymph node metastasis in a patient with Papillary Thyroid Cancer by neck ultrasound by radiologist's standard assessment method (Ir test).|Detection of lymph node metastasis in a patient with Papillary Thyroid Cancer by neck ultrasound by predictive model method (Im test).|Confirmation of the lymph node metastasis by fine needle aspiration biopsy prior to the surgery.|Measure true positive and false positive results of Ir test and Im test for comparison.","University of Colorado, Denver","All","18 Years and older   (Adult, Older Adult)",,"103","Other","Observational","Observational Model: Other|Time Perspective: Prospective","14-2053","April 2015","December 2016","May 2017","May 13, 2015",,"June 12, 2017","Rebecca J Guigli, Aurora, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT02442661"
152,"NCT03889769","Evaluation of Accuracy of One-Step Nucleic Acid Amplification (OSNA) in Diagnosis of Lymph Node Metastases of Papillary Thyroid Carcinoma",,"Unknown status","No Results Available","Papillary Thyroid Cancer|Lymph Node Metastases","Diagnostic Test: OSNA test","Accuracy of OSNA","University of Cagliari","All","Child, Adult, Older Adult",,"50","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","NP20164594","December 20, 2016","April 1, 2019","September 30, 2019","March 26, 2019",,"March 26, 2019","Policlinico di Monserrato, Monserrato, Cagliari, Italy",,"https://ClinicalTrials.gov/show/NCT03889769"
153,"NCT02777424","CPP Versus PFC to Correct Coagulation Disorders in Adult Neurosurgical Patients","CLOT-CRANE","Recruiting","No Results Available","Intracranial Hemorrhages","Drug: Prothrombin Complex Concentrate|Biological: Fresh Frozen Plasma","Proportion of patients with correction of prothrombin time (PT more than 60%)","Fondation Ophtalmologique Adolphe de Rothschild","All","18 Years and older   (Adult, Older Adult)","Phase 4","46","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AGR_2014-22","January 2016","July 21, 2020","July 27, 2022","May 19, 2016",,"December 1, 2020","CHU de Lille, Lille, France|CHU de NANCY, Nancy, France|Fondation Ophtalmologique Adolphe de Rothschild (FOR), Paris, France|Hôpital Foch, Suresnes, France",,"https://ClinicalTrials.gov/show/NCT02777424"
154,"NCT02270918","Reversibility of Apixaban Anticoagulation With the Four Factor Prothrombin Complex Concentrate Kcentra","4PAR","Completed","No Results Available","Thrombosis","Drug: Kcentra|Drug: Apixaban|Drug: Placebo","thrombin generation assay (TGA)|Anti-factor Xa activity","Thomas Jefferson University|Bristol-Myers Squibb|CSL Behring","All","18 Years to 55 Years   (Adult)","Phase 1","12","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","14P.366","November 2014","December 2014","December 2014","October 21, 2014",,"June 7, 2016","Thomas Jefferson University Hosptial, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02270918"
155,"NCT04624477","Active Surveillance and Surgery Outcomes in Low Risk Papillary Thyroid Cancer",,"Recruiting","No Results Available","Papillary Thyroid Cancer|Papillary Thyroid Carcinoma|Papillary Microcarcinoma of the Thyroid",,"Number of Participants in the Active Surveillance Group who Experience 'Failure' of Active Surveillance Disease Management|Number of Participants in the Surgical Group who Experience 'Failure' of Surgical Disease Management|Number of Participants in Respective Thyroid Cancer Disease Status Categories at Last Follow-up|Number of Participants in the Active Surveillance Group who Undergo Thyroidectomy During Follow-up|Number of Participants who Experience Long-term Complications of Thyroid Surgery|Description of Quality of Life (Thyroid Cancer-specific)|Description of Quality of Life (Cancer-specific)|Measure of Anxiety|Measure of Survivor Concerns|Measure of Decision Regret (relating to the original decision to undergo active surveillance or thyroid surgery).","University Health Network, Toronto|University of British Columbia|University of Calgary|Lawson Health Research Institute|Ottawa Hospital Research Institute|McMaster University|CHU de Quebec-Universite Laval|Centre hospitalier de l'Université de Montréal (CHUM)|Dalhousie University|Canadian Institutes of Health Research (CIHR)|Canadian Cancer Society (CCS)","All","18 Years and older   (Adult, Older Adult)",,"450","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20-5102","February 3, 2021","March 31, 2025","March 31, 2030","November 10, 2020",,"February 8, 2021","Nova Scotia Health, Halifax, Nova Scotia, Canada|Lawson Health Research Institute, London, Ontario, Canada|Ottawa Hospital Research Institute, Ottawa, Ontario, Canada|University Health Network, Toronto, Ontario, Canada|CHU de Québec - Université Laval, Québec, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT04624477"
156,"NCT02178345","Predictive MRI Metrics for Tumor Aggressiveness in Papillary Thyroid Cancer",,"Completed","No Results Available","Papillary Thyroid Cancer","Procedure: diffusion weighted (DW) MRI|Procedure: dynamic contrast agent (DCE) MRI","feasibility of MRI biomarkers","Memorial Sloan Kettering Cancer Center","All","18 Years and older   (Adult, Older Adult)",,"123","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","14-126","June 24, 2014","December 3, 2021","December 3, 2021","June 30, 2014",,"December 8, 2021","Memorial Sloan Kettering Cancer Center, New York, New York, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT02178345/ICF_000.pdf","https://ClinicalTrials.gov/show/NCT02178345"
157,"NCT01826487","Phase 3 Study of Ataluren in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)","ACT DMD","Completed","Has Results","Muscular Dystrophy, Duchenne|Muscular Dystrophies|Muscular Disorders, Atrophic|Muscular Diseases|Musculoskeletal Diseases|Neuromuscular Diseases|Nervous System Diseases|Genetic Diseases, X-Linked|Genetic Diseases, Inborn","Drug: Ataluren|Drug: Placebo","Change From Baseline in 6MWD at Week 48|Time to 10 Percent (%) Persistent Worsening in 6MWD|Change From Baseline in Time to Walk/Run 10 Meters at Week 48|Change From Baseline in Time to Climb 4 Stairs at Week 48|Change From Baseline in Time to Descend 4 Stairs at Week 48|Percentage of Participants With Treatment-Emergent Adverse Events (AEs)","PTC Therapeutics","Male","7 Years to 16 Years   (Child)","Phase 3","230","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PTC124-GD-020-DMD|2012-004527-20","March 26, 2013","August 20, 2015","August 20, 2015","April 8, 2013","August 4, 2020","August 4, 2020","University of California, Los Angeles, Los Angeles, California, United States|UC Davis Medical Center, Sacramento, California, United States|Children's Hospital Colorado - Center for Cancer and Blood Disorders, Aurora, Colorado, United States|Child Neurology Center of Northwest Florida, Gulf Breeze, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Iowa, Iowa City, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Boston Children's Hospital, Boston, Massachusetts, United States|Children's Hospital Boston, Boston, Massachusetts, United States|University of Minnesota, Minneapolis, Minnesota, United States|Washington University School of Medicine, Division of Endocrinology, Metabolism and Lipid Research, Saint Louis, Missouri, United States|Columbia University College of Physicians & Surgeons, New York, New York, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|Childrens Medical Center Dallas, Texas, Dallas, Texas, United States|Texas Children's Hospital, Houston, Texas, United States|University of Utah, Salt Lake City, Utah, United States|Seattle Children's Hospital - Childhood Cancer and Blood Disorders, Seattle, Washington, United States|The Children's Hospital at Westmead, Westmead, New South Wales, Australia|The Royal Children's Hospital, Parkville, Victoria, Australia|UZ Leuven, Leuven, Belgium|Universidade Federal do Rio de Janeiro - Instituto de Puericultura e Pediatria Martagao Gesteira, Rio de Janeiro, Brazil|Sao Paulo University -HC/FMUSP, São Paulo, Brazil|Alberta Children's Hospital, Calgary, Alberta, Canada|British Columbia Children's Hospital, Vancouver, British Columbia, Canada|Children's Hospital of Western Ontario, London, Ontario, Canada|Hospital Luis Calvo Mackenna, Santiago, Región Metropolitana, Chile|Hospital Clinico Universidad Catolica, Santiago, Chile|University Hospital Brno, Brno, Czechia|Motol University Hospital, Praha, Czechia|Hospital de la Timone, Marseille, France|CHU de Nantes, Nantes Cedex, France|Hopital Necker - Enfants Malades, Paris, France|Groupe Hospitalier La Pitie-Salpetriere, Paris, France|University of Essen-Duisburg, Essen, Germany|University Hospital Medical Center Freiburg, Freiburg, Germany|Hadassah University Hospital, Jerusalem, Israel|Policlinico Universitario G. Martino, Messina, Sicily, Italy|Fondazione IRCS Ca Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy|Bambino Gesu Hospital, Rome, Italy|U.O. Complessa di Neuropsichiatria Infantile, Rome, Italy|Seoul National University Hospital, Seoul, Korea, Republic of|Medical University of Warsaw, Warsaw, Poland|Hospital Sant Joan de Deu, Barcelona, Spain|Hospital Universitari i Politecnic la Fe, Valencia, Spain|Queen Silvia Children's Hospital, Goteburg, Sweden|Astrid Lindgren Childrens Hospital, Stockholm, Sweden|CHUV Lausanne, Lausanne, Switzerland|Hacettepe Childrens Hospital, Ankara, Turkey|University College London Institute of Child Health, London, United Kingdom|Royal Manchester Children's Hospital, Manchester, United Kingdom|The Newcastle upon Tyne Hospitals, NHS Foundation Trust, Newcastle upon Tyne, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01826487"
158,"NCT02429453","FFP Versus PCC in Intracranial Hemorrhage",,"Withdrawn","No Results Available","Intracranial Hemorrhage, Traumatic|Intracranial Hemorrhage, Spontaneous","Drug: Four Factor Prothrombin Complex Concentrate|Biological: Fresh Frozen Plasma","Rapid reversal of warfarin as measured by international normalized ratio (INR) drawn at 30 minutes after transfusion|Radiographic expansion of traumatic intracerebral hemorrhage as measured by CT scan within 24 hours of presentation|Timing of reversal of warfarin as measured by INR drawn at 3 hours, 8 hours and 24 hours after transfusion|Thromboelastography response as measured by results of ROTEM analysis at 30 minutes and 24 hours after transfusion|Absolute INR reversal as measured by INR drawn 24 hours after transfusion|Need for operative intervention as measured by need for neurosurgical procedure during the hospitalization|Estimated blood loss during any neurosurgical procedure|Further transfusion needs as measured by number of units of blood/platelet/plasma products transfused during the hospitalization|In hospital mortality|Total hospital cost|30 day outcome as measured by the Glasgow outcome score|Complications as measured by development of deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke, unanticipated intubation, heart failure, or need for aggressive diuresis during the hospitalization","University of Utah","All","18 Years and older   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB_00078143","April 2015","March 2016","March 2016","April 29, 2015",,"November 16, 2016","University of Utah Medical Center, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT02429453"
159,"NCT03820063","Image-guided De-escalation of Neo-adjuvant Chemotherapy in HER2-positive Breast Cancer: the TRAIN-3 Study","TRAIN-3","Active, not recruiting","No Results Available","Breast Cancer","Drug: PTC-Pz","Event free survival at three years|Overall survival at three years|Pathologic complete response in breast and axilla|Radiologic complete response|Number of neoadjuvant chemotherapy cycles administered|Number of radical and non-radical resections|Incidence and severity of adverse events|Incidence and severity of cardiotoxicity and neuropathy|Incidence of symptomatic LVSD (heart failure),|Grade ≥3 laboratory test abnormalities|Incidence of number of tumor positive Vacuum Assisted Core Biopsy","Borstkanker Onderzoek Groep|Roche Pharma AG|BOOG Study Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","462","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BOOG 2018-01","February 27, 2019","May 1, 2022","May 1, 2032","January 29, 2019",,"July 23, 2021","Noordwest Ziekenhuisgroep, Alkmaar, Netherlands|Ziekenhuisgroep Twente, Almelo, Netherlands|Meander Medisch Centrum, Amersfoort, Netherlands|Ziekenhuis Amstelland, Amstelveen, Netherlands|Amsterdam UMC, Amsterdam, Netherlands|NKI-AVL, Amsterdam, Netherlands|OLVG, Amsterdam, Netherlands|Gelre ziekenhuizen, Apeldoorn, Netherlands|Rijnstate, Arnhem, Netherlands|Rode Kruis Ziekenhuis, Beverwijk, Netherlands|Alexander Monro ziekenhuis, Bilthoven, Netherlands|Amphia Ziekenhuis, Breda, Netherlands|Reinier de Graaf Groep, Delft, Netherlands|Jeroen Bosch Ziekenhuis, Den Bosch, Netherlands|Haaglanden MC, Den Haag, Netherlands|Haga Ziekenhuis, Den Haag, Netherlands|Deventer ziekenhuis, Deventer, Netherlands|van Weel Bethesda, Dirksland, Netherlands|Nij Smellinghe, Drachten, Netherlands|Ziekenhuisvoorziening Gelderse Vallei, Ede, Netherlands|Catharina ziekenhuis, Eindhoven, Netherlands|Maxima Medisch Centrum, Eindhoven, Netherlands|Sint Annaziekenhuis, Geldrop, Netherlands|RIVAS Beatrixziekenhuis, Gorinchem, Netherlands|Groene Hart Ziekenhuis, Gouda, Netherlands|Martini ziekenhuis, Groningen, Netherlands|Ziekenhuis St. Jansdal, Harderwijk, Netherlands|Tjongerschans, Heerenveen, Netherlands|Zuyderland Medisch Centrum, Heerlen, Netherlands|Elkerliek ziekenhuis, Helmond, Netherlands|Tergooi, Hilversum, Netherlands|Spaarne Gasthuis, Hoofddorp, Netherlands|Medisch Centrum Leeuwarden, Leeuwarden, Netherlands|MUMC, Maastricht, Netherlands|Sint Antonius ziekenhuis, Nieuwegein, Netherlands|Canisius Wilhelmina Ziekenhuis, Nijmegen, Netherlands|Bernhoven, Oss, Netherlands|Stichting ziekenhuizen West-Friesland en Waterland, Purmerend, Netherlands|Laurentius ziekenhuis, Roermond, Netherlands|Erasmus MC, Universitair Medisch Centrum Rotterdam, Rotterdam, Netherlands|Franciscus Gasthuis en Vlietland, Rotterdam, Netherlands|Ikazia Ziekenhuis, Rotterdam, Netherlands|Maasstadziekenhuis, Rotterdam, Netherlands|ZorgSaam, Terneuzen, Netherlands|Rivierenland Ziekenhuis, Tiel, Netherlands|Elisabeth TweeSteden ziekenhuis, Tilburg, Netherlands|Diakonessenhuis Utrecht, Utrecht, Netherlands|Universitair Medisch Centrum Utrecht, Utrecht, Netherlands|VieCurie Medisch Centrum voor Noord-Limburg, Venlo, Netherlands|SKB Ziekenhuis Winterswijk, Winterswijk, Netherlands|Zaans Medisch Centrum, Zaandam, Netherlands|Isala Klinieken, Zwolle, Netherlands",,"https://ClinicalTrials.gov/show/NCT03820063"
160,"NCT01386528","Efficacy and Safety of NNC-0156-0000-0009 During Surgical Procedures in Subjects With Haemophilia B","paradigm™ 3","Completed","Has Results","Congenital Bleeding Disorder|Haemophilia B","Drug: nonacog beta pegol","Haemostatic Effect During Surgery Evaluated by the Four-point Response Scale (Excellent, Good, Moderate, Poor)|Consumption of NNC-0156-0000-0009 (U/kg Body Weight)|Transfusion Requirements (Fulfilling Transfusion Criteria)|Haemoglobin Pre- and Post-surgery Start|Incidence of Adverse Events (AEs)|Incidence of Serious Adverse Events (SAE)|Incidence of Inhibitors Against FIX (Coagulation Factor Nine)","Novo Nordisk A/S","Male","13 Years to 70 Years   (Child, Adult, Older Adult)","Phase 3","13","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NN7999-3773|2010-023070-40|U1111-1121-4554","June 7, 2012","December 1, 2013","December 1, 2013","July 1, 2011","July 24, 2017","August 23, 2017","Novo Nordisk Investigational Site, Los Angeles, California, United States|Novo Nordisk Investigational Site, San Francisco, California, United States|Novo Nordisk Investigational Site, Washington, D.C., District of Columbia, United States|Novo Nordisk Investigational Site, Augusta, Georgia, United States|Novo Nordisk Investigational Site, Iowa City, Iowa, United States|Novo Nordisk Investigational Site, Syracuse, New York, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Wien, Austria|Novo Nordisk Investigational Site, Kremlin-Bicêtre, France|Novo Nordisk Investigational Site, Lyon, France|Novo Nordisk Investigational Site, Bonn, Germany|Novo Nordisk Investigational Site, Duisburg, Germany|Novo Nordisk Investigational Site, Giessen, Germany|Novo Nordisk Investigational Site, Hannover, Germany|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Firenze, Italy|Novo Nordisk Investigational Site, Milano, Italy|Novo Nordisk Investigational Site, Kashihara-shi, Nara, Japan|Novo Nordisk Investigational Site, Kawasaki-shi, Kanagawa, Japan|Novo Nordisk Investigational Site, Nagoya-shi, Aichi, Japan|Novo Nordisk Investigational Site, Nishinomiya-shi, Japan|Novo Nordisk Investigational Site, Suginami-ku, Tokyo, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Skopje, Macedonia, The Former Yugoslav Republic of|Novo Nordisk Investigational Site, Kuala Lumpur, Malaysia|Novo Nordisk Investigational Site, Utrecht, Netherlands|Novo Nordisk Investigational Site, Timisoara, Timis, Romania|Novo Nordisk Investigational Site, Parktown Johannesburg, Gauteng, South Africa|Novo Nordisk Investigational Site, Madrid, Spain|Novo Nordisk Investigational Site, Valencia, Spain|Novo Nordisk Investigational Site, Taipei, Taiwan|Novo Nordisk Investigational Site, Bangkok, Thailand|Novo Nordisk Investigational Site, Ankara, Turkey|Novo Nordisk Investigational Site, Kayseri, Turkey|Novo Nordisk Investigational Site, Konya, Turkey|Novo Nordisk Investigational Site, Basingstoke, United Kingdom|Novo Nordisk Investigational Site, Cardiff, United Kingdom|Novo Nordisk Investigational Site, London, United Kingdom|Novo Nordisk Investigational Site, London, United Kingdom|Novo Nordisk Investigational Site, Manchester, United Kingdom|Novo Nordisk Investigational Site, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01386528"
161,"NCT02776969","A Gene Hunting Study for Familial Papillary Thyroid Cancer",,"Recruiting","No Results Available","Thyroid",,"Genetic variants associated with familial papillary thyroid cancer as assessed by multiple genetic testing methodologies","Ohio State University Comprehensive Cancer Center","All","18 Years and older   (Adult, Older Adult)",,"1200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","OSU-9812","July 1998","December 2021","December 2021","May 19, 2016",,"March 5, 2020","Ohio State University, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT02776969"
162,"NCT04336826","A Study to Evaluate the Safety and Pharmacokinetics of Ataluren in Participants From ≥6 Months to <2 Years of Age With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)",,"Recruiting","No Results Available","Nonsene Mutation Duchenne Muscular Dystrophy","Drug: Ataluren","Number of Participants With Treatment-Emergent Adverse Events|Pharmacokinetics: Area Under the Concentration Curve From Time 0 to 24 Hours (AUC0-24) of Ataluren|Pharmacokinetics: Area Under the Concentration Curve From Time 0 to 6 Hours (AUC0-6) of Ataluren|Pharmacokinetics: Maximum Concentration (Cmax) of Ataluren|Pharmacokinetics: Time to Maximal Plasma Concentration (Tmax) of Ataluren|Pharmacokinetics: Trough Concentration (Ctrough) of Ataluren","PTC Therapeutics","Male","6 Months to 2 Years   (Child)","Phase 2","10","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PTC124-GD-048-DMD|2020-000980-21","December 29, 2021","December 20, 2022","December 20, 2022","April 7, 2020",,"January 24, 2022","Rare Disease Research, LLC, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT04336826"
163,"NCT04750122","Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for HER2 Positive Early Breast Cancer Patients",,"Recruiting","No Results Available","HER2-positive Early Breast Cancer","Drug: neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screenning","pathological complete response(pCR)|event-free survival (EFS)|invasive disease-free survival(IDFS)|objective response rate","Peking University People's Hospital","Female","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","46","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PekingUPH10B003","March 28, 2021","June 30, 2022","December 31, 2026","February 11, 2021",,"April 1, 2021","Peking University People'S Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04750122"
164,"NCT01182324","The PTC124 (Ataluren) Clinical Trial for Duchenne Muscular Dystrophy: Exploration of the Experiences of Parents, Clinician Researchers, and the Industry Sponsor",,"Completed","No Results Available","Duchenne Muscular Dystrophy",,"To describe, inclusive of the perspectives and voices of all of the major participants, the shared experiences of parents, clinician researchers, and industry professionals who were involved in phase II clinical trials for Duchenne Muscular Dyst...","National Human Genome Research Institute (NHGRI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 99 Years   (Adult, Older Adult)",,"21","NIH","Observational","Time Perspective: Retrospective","999910171|10-HG-N171","July 30, 2010",,"June 24, 2013","August 16, 2010",,"April 5, 2018","National Human Genome Research Institute (NHGRI), 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01182324"
165,"NCT03648827","A Study to Assess Dystrophin Levels in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)",,"Completed","No Results Available","Duchenne Muscular Dystrophy","Drug: Ataluren","Percent Change From Baseline in Dystrophin Levels at Week 40, as Measured by ECL|Percent Change From Baseline in Dystrophin Levels/Intensity at Week 40, as Determined by a Validated Immunohistochemistry Assay","PTC Therapeutics","Male","2 Years to 7 Years   (Child)","Phase 2","20","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PTC124-GD-045-DMD|2019-001767-67","December 21, 2018","October 30, 2020","October 30, 2020","August 27, 2018",,"January 29, 2021","Phoenix Childrens Hospital, Phoenix, Arizona, United States|University of California, Los Angeles (UCLA), Los Angeles, California, United States|University of California (UC) Davis Medical Center, Sacramento, California, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|University of Minnesota, Minneapolis, Minnesota, United States|Columbia University College of Physicians & Surgeons, New York, New York, United States|Texas Children's Hospital, Houston, Texas, United States|University of Texas Heath Science Center at San Antonio, San Antonio, Texas, United States|Children's Hospital of the King's Daughters, Norfolk, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT03648827"
166,"NCT01083550","Decision Making on Radioactive Iodine Treatment for Papillary Thyroid Cancer",,"Completed","No Results Available","Thyroid Cancer","Other: Decision aid exposure","Knowledge about papillary thyroid cancer and radioactive iodine treatment|Decisional conflict (and subscale measures)|Decisional regret|Reasons for accepting or declining radioactive iodine treatment|The final decision to accept or decline adjuvant radioactive iodine treatment|Feeling informed about RAI treatment decision|Feeling satisfied with RAI treatment decision|Cancer-related worry|Trust in the treating physician|Mood|Qualitative data|Cancer Impact|Information Needs|General Concerns|Cancer-related Worry","University Health Network, Toronto|Ontario Ministry of Health and Long Term Care|Canadian Institutes of Health Research (CIHR)","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","74","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","REB 09-0986-BE|UHNREB 09-0986-BE","February 2010","November 2016","November 2016","March 9, 2010",,"November 29, 2016","University Health Network, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01083550"
167,"NCT04590950","Dosage and PD Study of Eftrenonacog-alfa","BIOPAL","Not yet recruiting","No Results Available","Severe Haemophilia B","Other: Non interventional study","FIX activity levels|Thrombin generation assay","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)",,"15","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","APHP191124","October 2020","December 2020","December 2021","October 19, 2020",,"October 19, 2020","Service d'hématologie biologique - Hôpital Cochin, Paris, France",,"https://ClinicalTrials.gov/show/NCT04590950"
168,"NCT03875547","Post-marketing Surveillance (Use Result Surveillance) With Refixia®",,"Enrolling by invitation","No Results Available","Haemophilia B","Drug: Refixia®","Number of Adverse Reactions (ARs)|Number of Serious Adverse Events (SAEs)|Number of Serious Adverse Reactions (SARs)|Number of bleeding episodes as assessed by annualised bleeding rate (ABR)|Number of treatment requiring bleeding episodes as assessed by ABR|Haemostatic response of Refixia® in treatment of bleeds|Haemostatic response of Refixia® in treatment of bleeds in perioperative management during surgical procedures","Novo Nordisk A/S","All","Child, Adult, Older Adult",,"20","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","NN7999-4404|U1111-1198-6270","August 23, 2019","September 30, 2025","September 30, 2025","March 14, 2019",,"December 10, 2021","Novo Nordisk Investigational Site, Søborg, Denmark|Novo Nordisk Investigational Site, Aichi, Japan|Novo Nordisk Investigational Site, Aomori, Japan|Novo Nordisk Investigational Site, Chiba-shi, Chiba, Japan|Novo Nordisk Investigational Site, Chiba, Japan|Novo Nordisk Investigational Site, Chiba, Japan|Novo Nordisk Investigational Site, Hyogo, Japan|Novo Nordisk Investigational Site, Ibaraki, Japan|Novo Nordisk Investigational Site, Ishikawa, Japan|Novo Nordisk Investigational Site, Kanagawa, Japan|Novo Nordisk Investigational Site, Kitakyusyu-shi, Fukuoka, Japan|Novo Nordisk Investigational Site, Maebashi-shi, Gunma, Japan|Novo Nordisk Investigational Site, Naha-shi, Okinawa, Japan|Novo Nordisk Investigational Site, Nishinomiya-shi, Hyogo, Japan|Novo Nordisk Investigational Site, Saitama, Japan|Novo Nordisk Investigational Site, Tokushima, Japan|Novo Nordisk Investigational Site, Tokushima, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Yokohama-shi, Kanagawa, Japan",,"https://ClinicalTrials.gov/show/NCT03875547"
169,"NCT03813173","Central Cervical Dissection for Clinical Node Negative Papillary Thyroid Carcinoma",,"Not yet recruiting","No Results Available","Lymph Node Metastases","Procedure: lymph node dissection","Recurrence of thyroid cancer","Zhejiang University","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","6000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ZhejiangU20190116","January 2020","December 2040","December 2040","January 23, 2019",,"July 5, 2019",,,"https://ClinicalTrials.gov/show/NCT03813173"
170,"NCT04108260","The Effectiveness of Recombinant Coagulation Factor IX With Recombinant Albumin (rIX-FP) in Severe Hemophilia B Patients",,"Recruiting","No Results Available","Hemophilia","Drug: Albutrepenonacog Alfa 1 UNT [IDELVION]","AsBR","National Taiwan University Hospital","Male","20 Years and older   (Adult, Older Adult)","Phase 4","5","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","201907004MIPB","April 21, 2020","November 2021","April 2022","September 30, 2019",,"October 30, 2020","National Taiwan University Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT04108260"
171,"NCT03320603","Use of Prothrombin Complex Concentrate in Patients Admitted in Emergency Care Units for Severe Bleeding While Receiving Oral Anticoagulants",,"Completed","No Results Available","Emergency Care for Severe Bleeding While on Anticoagulants","Other: Expert eCRF|Other: Prothrombin Complex Concentrate","Proper Use of PCC Proportion|Time to Death|Survival Rate|Proportion of Patients with Poor Outcome|Predictors of Poor Outcome|Proportion of Patients with Seroconversion","Octapharma","All","18 Years and older   (Adult, Older Adult)","Not Applicable","397","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Other","OPTIPLEX 2","October 13, 2017","December 20, 2020","December 20, 2020","October 25, 2017",,"July 27, 2021","Centre Hospitalier d'Avignon, Avignon, France|Centre Hospitalier Régional Universitaire de Besançon Hôpital Jean Minjoz, Besançon, France|Clinique Médipole Saint-Roch, Cabestany, France|Centre Hospitalier Universitaire de Caen Hôpital Côte de Nacre Service de Réanimation, Caen, France|Centre Hospitalier Universitaire de Caen Hôpital Côte de Nacre Service des Urgences, Caen, France|Centre Hospitalier Chalon-sur-Saône William Morey, Chalon-sur-Saône, France|Hôpitaux Civils de Colmar, Colmar, France|Hospices Civils de Lyon Hopital Edouard Herriot Service des Urgences, Lyon, France|Clinique du Tonkin, Lyon, France|Hospices Civils de Lyon Centre Hospitalier Lyon-Sud Service de Réanimation, Lyon, France|Hospices Civils de Lyon Centre Hospitalier Lyon-Sud Service des Urgences, Lyon, France|Centre Hospitalier Régional Metz-Thionville Hôpital Mercy, Metz, France|Centre Hospitalier Universitaire de Nantes Hôtel-Dieu, Nantes, France|Centre Hospitalier de Pau, Pau, France|Centre Hospitalier de Perpignan, Perpignan, France|Centre Hospitalier Universitaire de Reims Hôpital Maison Blanche, Reims, France|Centre Hospitalier Universitaire de Rennes Hôpital Pontchaillou, Rennes, France|Centre Hospitalier Universitaire de Rouen Hôpital Charles-Nicolle, Rouen, France|Centre Hospitalier Universitaire de Strasbourg Nouvel Hôpital Civil Service des Urgences, Strasbourg, France|Centre Hospitalier Universitaire de Strasbourg Hôpital de Hautepierre Service de Réanimation, Strasbourg, France|Centre Hospitalier Universitaire de Strasbourg Hôpital de Hautepierre Service des Urgences, Strasbourg, France|Hôpital d'Instruction des Armées Sainte-Anne, Toulon, France|Centre Hospitalier Universitaire de Toulouse Hôpitaux Purpan et Rangueil, Toulouse, France|Centre Hospitalier Régional Universitaire de Tours Hôpital Trousseau, Tours, France|Centre Hospitalier de Valence, Valence, France|Groupe Hospitalier de la Haute-Saône Site de Vesoul, Vesoul, France",,"https://ClinicalTrials.gov/show/NCT03320603"
172,"NCT03780517","Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors",,"Active, not recruiting","No Results Available","Advanced Nonhaematologic Malignancies","Drug: BOS172738","Number of participants with any treatment-emergent (TE) serious adverse event (SAE)|Number of participants with any non-serious TEAE|Number of participants with grade 3, grade 4, or grade 5 TEAEs|Number of participants with any related TEAE|Number of participants with any TEAE leading to study drug discontinuation|Maximum tolerated dose (MTD) of BOS172738|Recommended phase 2 dose (RP2D) of BOS172738|Objective Response Rate (ORR)|Objective Disease Control Rate (ODCR)|Progression-Free Survival (PFS)|Duration of Response (DoR)|Time to Response (TTR)|Duration of Complete Response (DoCR)|Part A: Plasma concentration of BOS172738|Part B: Plasma concentration of BOS172738","Boston Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 1","117","Industry","Interventional","Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BOS172738-01|2018-002612-27","December 12, 2018","June 30, 2022","June 30, 2022","December 19, 2018",,"December 27, 2021","Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|MD Anderson Cancer Center, Houston, Texas, United States|Institut Jules Bordet, Bruxelles, Belgium|UZ Leuven, Leuven, Belgium|Institut Bergonié, Bordeaux, France|Centre Léon Bérard, Lyon, France|Hôpital Pitié-Salpêtrière, Paris, France|Institut Gustave Roussy, Villejuif, France|Prince of Wales Hospital, Hong Kong, Hong Kong|Chungbuk National University Hospital, Cheongju-si, Korea, Republic of|Seoul National University Bundang Hospital, Gyeonggi-do, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of|Hospital Universitario Virgen de la Victoria, Málaga, Andalucia, Spain|Hospital Germans Trias i Pujol, Badalona, Spain|Instituto Oncológico Dr. Rosell, S.L., Barcelona, Spain|Start Madrid - Ciocc, Madrid, Spain|START MADRID-FJD, Hospital Fundación Jiménez Díaz, Madrid, Spain|Taichung Veterans General Hospital, Taichung, Taiwan|National Taiwan University Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT03780517"
173,"NCT02557672","PCC vs. FFP for Post Cardiopulmonary Bypass Coagulopathy and Bleeding",,"Completed","No Results Available","Bleeding|Blood Loss, Surgical|Cardiovascular Surgical Procedures|Prothrombin Complex Concentrates|Fresh Frozen Plasma","Drug: Prothrombin complex concentrate (Human)|Biological: Fresh frozen plasma (FFP)","Blood loss|Blood product transfusion","Mayo Clinic|CSL Behring","All","18 Years and older   (Adult, Older Adult)","Phase 4","100","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14-009579","August 2016","June 2021","January 2022","September 23, 2015",,"January 21, 2022","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT02557672"
174,"NCT04836156","Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for Human Epidermal Growth Factor Receptor 2 (HER2) Negative Early Breast Cancer Patients",,"Not yet recruiting","No Results Available","HER2-negative Early Breast Cancer","Drug: neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for triple negative breast cancer|Drug: neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for luminal like breast cancer","pathological complete response(pCR)|event-free survival (EFS)|invasive disease-free survival (IDFS)|objective response rate","Peking University People's Hospital","Female","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","46","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PekingUPH10B004","March 31, 2021","June 30, 2022","December 31, 2026","April 8, 2021",,"April 8, 2021",,,"https://ClinicalTrials.gov/show/NCT04836156"
175,"NCT00956345","Safety of 40K Pegylated Recombinant Factor IX in Non-Bleeding Patients With Haemophilia B",,"Completed","No Results Available","Congenital Bleeding Disorder|Haemophilia B","Drug: nonacog beta pegol","Frequency of Adverse Events (AEs), Serious Adverse Events (SAEs) and Medical Events of Special Interests (MESIs) reported during the trial period|Antibody formation against 40K PEG-rFIX and test for inhibitors (Bethesda)|AUC, CL, T½, Incremental recovery (first sample) from 0 to 48 hours after trial product administration|AUC, CL, T½, Incremental recovery (first sample) from 0 to 168 hours after trial product administration","Novo Nordisk A/S","Male","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","18","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NN7999-3639|2009-011085-28|090857","August 2009","July 2010","July 2010","August 11, 2009",,"January 20, 2017","Novo Nordisk Investigational Site, Cincinnati, Ohio, United States|Novo Nordisk Investigational Site, Portland, Oregon, United States|Novo Nordisk Investigational Site, Richmond, Virginia, United States|Novo Nordisk Investigational Site, København, Denmark|Novo Nordisk Investigational Site, Kremlin-Bicêtre, France|Novo Nordisk Investigational Site, Lyon, France|Novo Nordisk Investigational Site, Berlin, Germany|Novo Nordisk Investigational Site, Bonn, Germany|Novo Nordisk Investigational Site, Frankfurt/M., Germany|Novo Nordisk Investigational Site, Hannover, Germany|Novo Nordisk Investigational Site, Kashihara-shi, Nara, Japan|Novo Nordisk Investigational Site, Nagoya-shi, Aichi, Japan|Novo Nordisk Investigational Site, Nishinomiya-shi, Japan|Novo Nordisk Investigational Site, Madrid, Spain|Novo Nordisk Investigational Site, Stockholm, Sweden|Novo Nordisk Investigational Site, London, United Kingdom|Novo Nordisk Investigational Site, London, United Kingdom|Novo Nordisk Investigational Site, Manchester, United Kingdom|Novo Nordisk Investigational Site, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00956345"
176,"NCT04244981","Efficacy of Prothrombin Complex Concentrate Reducing Perioperative Blood Loss in Cardiac Surgery",,"Not yet recruiting","No Results Available","Cardiac Surgical Procedures","Drug: Prothrombin Complex Concentrate, Human|Drug: Fresh Frozen Plasma","volume of blood loss during and within 24 hours after surgery|total units of allogeneic RBCs transfused during and within 7 days after surgery|re-exploration due to postoperative bleeding","Chinese Academy of Medical Sciences, Fuwai Hospital|Peking Union Medical College Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","560","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","PCC vs FFP Study","January 1, 2021","December 31, 2022","March 1, 2023","January 28, 2020",,"August 4, 2020",,,"https://ClinicalTrials.gov/show/NCT04244981"
177,"NCT03981484","REPlaCE- Randomized Trial Evaluating the Use of Prothrombin Complex concEntrate to Improve Survival in Patients With Traumatic Coagulopathy","REPLaCE","Not yet recruiting","No Results Available","Coagulopathy|Hemorrhage","Biological: Prothrombin Complex Concentrate|Biological: Whole Blood, Plasma, Packed Red Blood Cells","24 Hour Mortality","Bellal A. Joseph, MD, FACS|University of Arizona","All","15 Years and older   (Child, Adult, Older Adult)","Phase 2","280","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","00001","January 2020","October 2022","January 2023","June 10, 2019",,"June 10, 2019",,,"https://ClinicalTrials.gov/show/NCT03981484"
178,"NCT01089335","Sentinel Lymphnode in Patients With Papillary Thyroid Carcinoma and in Patients With Suspected Thyroid Neoplasia","SNTC","Completed","No Results Available","Thyroid Neoplasms|Thyroid Cancer","Procedure: Histological investigation of the SN","Sensitivity and specificity of SN histology compared with the final histology of the non SN central lymph nodes (metastasis or no metastasis)|Sensitivity of 99mTc-nanocolloid albumin in the diagnosis of a sentinel lymphnode","Region Skane","All","18 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2009/71","March 2010","December 2018","December 2018","March 18, 2010",,"March 28, 2019","Department of Surgery and Department of Imaging, Skåne University Hospital, Lund, Sweden",,"https://ClinicalTrials.gov/show/NCT01089335"
179,"NCT00770718","Factor VII, Prothrombin Complex Concentrate, and Fresh Frozen Plasma in Warfarin-Related Intracranial Hemorrhage",,"Terminated","No Results Available","Intracranial Hemorrhage","Drug: Recombinant Activated Factor VII (rFVIIa)|Drug: Prothrombin Complex Concentrate|Biological: Fresh Frozen Plasma","Normalization of INR (<1.4)|Hematoma progression|Neurological status|Timing of intervention completion|Dosing of intervention required|Medical complications during hospitalization","University of Utah|Sheila B. Terry Memorial Research Fund","All","18 Years and older   (Adult, Older Adult)","Phase 1","2","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","21152","April 2008","April 2010","April 2010","October 10, 2008",,"November 24, 2011",,,"https://ClinicalTrials.gov/show/NCT00770718"
180,"NCT04543383","A Study to Assess the Reversal of the Anticoagulant Effects of JNJ-70033093 by 4-Factor Prothrombin Complex Concentrate (4F-PCC) (Part 1) and Recombinant Human Factor VIIa (rFVIIa) (Part 2) in Healthy Participants",,"Suspended","No Results Available","Healthy","Drug: JNJ-70033093|Biological: 4-Factor Prothrombin Complex Concentrate (4F-PCC)|Biological: Recombinant Human Factor VIIa (rFVIIa)|Biological: Placebo matching to 4F-PCC|Biological: Placebo matching to rFVIIa","Part 1: Ratio of Postbaseline to Baseline in Activated Partial Thromboplastin Time (aPTT)|Part 2: Ratio of Postbaseline to Baseline in Activated Partial Thromboplastin Time|Part 1: Ratio of Postbaseline to Baseline in Endogenous Thrombin Potential (ETP) (Thrombin Generation Assay [TGA]) Parameter|Part 2: Ratio of Postbaseline to Baseline in ETP (TGA Parameter)|Part 1: Ratio of Postbaseline to Baseline in Lag time (TGA Parameter)|Part 2: Ratio of Postbaseline to Baseline in Lag time (TGA Parameter)|Part 1: Ratio of Postbaseline to Baseline in Time to Peak Thrombin (TGA Parameter)|Part 2: Ratio of Postbaseline to Baseline in Time to peak Thrombin (TGA Parameter)|Part 1: Ratio of Postbaseline to Baseline in Peak Thrombin (TGA parameter)|Part 2: Ratio of Postbaseline to Baseline in Peak Thrombin (TGA parameter)|Parts 1 and 2: Number of Participants with Treatment-Emergent Adverse Events (TEAE) as a Measure of Safety and Tolerability|Parts 1 and 2: Number of Participants with TEAEs of interest|Parts 1 and 2: Change From Baseline in Pulse rate|Parts 1 and 2: Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)|Parts 1 and 2: Change From Baseline in QTc Interval|Parts 1 and 2: Change from Baseline in Heart Rate (HR)|Parts 1 and 2: Change from Baseline in QRS Interval|Parts 1 and 2: Change from Baseline in PR Interval|Parts 1 and 2: Change From Baseline in QT Interval|Parts 1 and 2: Change From Baseline in Hematology Parameter: Platelet count|Parts 1 and 2: Change From Baseline in Hematology Parameter: Red Blood Cell (RBC) count|Parts 1 and 2: Change From Baseline in Hematology Parameter: Hemoglobin (Hb)|Parts 1 and 2: Change From Baseline in Hematology Parameter: Hematocrit|Parts 1 and 2: Change From Baseline in Hematology Parameter: Mean Corpuscular Volume (MCV)|Parts 1 and 2: Change From Baseline in Hematology Parameter: Mean Corpuscular Hemoglobin (MCH)|Parts 1 and 2: Change From Baseline in Hematology Parameter: Percentage of Reticulocytes|Parts 1 and 2: Change From Baseline in Hematology Parameters: Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils|Parts 1 and 2: Change From Baseline Coagulation Parameter: Activated Partial Thromboplastin Time (aPTT) and Prothrombin Time (PT)|Parts 1 and 2: Change from Baseline in Serum Chemistry Parameters: Bicarbonate, Calcium, Glucose, Chloride, Magnesium, Phosphate, Sodium, BUN, Cholesterol, HDL, LDL, Triglycerides|Parts 1 and 2: Change from Baseline in Serum Chemistry Parameters: ALT, AST, GGT, LDH, Alkaline phosphatase, CPK|Parts 1 and 2: Change from Baseline in Serum Chemistry Parameters: Amylase|Parts 1 and 2: Change from Baseline in Serum Chemistry Parameters: Lipase|Parts 1 and 2: Change from Baseline in Serum Chemistry Parameters: Total bilirubin, Creatinine and Uric acid|Parts 1 and 2: Change from Baseline in Serum Chemistry Parameters: Total protein and Albumin|Parts 1 and 2: Change From Baseline in Urinalysis Parameter: Specific gravity|Parts 1 and 2: Change From Baseline in Urinalysis Parameters: Bilirubin|Parts 1 and 2: Change From Baseline in Urinalysis Parameters: Nitrite|Parts 1 and 2: Change From Baseline in Urinalysis Parameter: Ketones|Parts 1 and 2: Change From Baseline in Urinalysis Parameter: Blood|Parts 1 and 2: Change From Baseline in Urinalysis Parameter: Protein|Parts 1 and 2: Change From Baseline in Urinalysis Parameter: Glucose|Parts 1 and 2: Change From Baseline in Urinalysis Parameter: pH|Parts 1 and 2: Change From Baseline in Urinalysis Parameter: Urobilinogen|Parts 1 and 2: Change From Baseline in Urinalysis Parameter: Leukocyte esterase|Parts 1 and 2: Maximum Observed Analyte Concentration (Cmax) of JNJ-70033093|Part 2: Maximum Observed Analyte Concentration (Cmax) of rFVIIa|Parts 1 and 2: Time to Reach Maximum Plasma Concentration (Tmax) of JNJ-70033093|Part 2: Time to Reach Maximum Plasma Concentration (Tmax) of rFVIIa|Parts 1 and 2: Elimination Half-Life (t1/2) of JNJ-70033093|Part 2: Elimination Half-Life (t1/2) of rFVIIa|Parts 1 and 2: Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC [0-infinity]) of JNJ-70033093|Part 2: Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC [0-infinity]) of rFVIIa|Parts 1 and 2: Area Under Plasma Concentration From Time Zero to the Last Quantifiable Concentration (AUC [0-last]) of JNJ-70033093|Part 2: Area Under Plasma Concentration From Time Zero to the Last Quantifiable Concentration (AUC [0-last]) of rFVIIa|Part 2: Systemic Clearance (CL) of rFVIIa|Part 2: Volume of distribution (Vz) of rFVIIa","Janssen Research & Development, LLC","All","18 Years to 54 Years   (Adult)","Phase 1","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR108769|2020-000180-24|70033093EDI1001","July 27, 2020","June 11, 2022","June 11, 2022","September 10, 2020",,"January 5, 2022","PRA Health Sciences, Groningen, Netherlands",,"https://ClinicalTrials.gov/show/NCT04543383"
181,"NCT00591786","A Bridging Trial Comparing Sugammadex (Org 25969) at 1-2 Post-Tetanic Count (PTC) in Japanese Participants. Part A (P05957)",,"Completed","Has Results","Anesthesia, General","Drug: Sugammadex","Time From Start of Sugammadex Administration to Recovery of the Neuromuscular Response to a Ratio of 0.9 for Train-Of-Four (TOF) Stimulation|Time From Start of Sugammadex Administration to Recovery of the Neuromuscular Response to a Ratio of 0.7 for TOF Stimulation|Time From Start of Sugammadex Administration to Recovery of the Neuromuscular Response to a Ratio of 0.8 for TOF Stimulation","Merck Sharp & Dohme Corp.","All","20 Years to 65 Years   (Adult, Older Adult)","Phase 2","100","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P05957|2005-001133-15|MK-8616-031|19.4.209A","December 5, 2005","August 31, 2006","October 19, 2006","January 11, 2008","February 18, 2019","March 15, 2019",,,"https://ClinicalTrials.gov/show/NCT00591786"
182,"NCT02463591","Reversal of Dabigatran With Prothrombin Complex Concentrate",,"Unknown status","No Results Available","Drug Action Reversal","Drug: Beriplex","Inhibition of the anticoagulant effect of Dabigatran, assessed by the ""shed and washed blood"" methods|Change in Standard Coagulation Assays before / after Dabigatran and before / after PCC.","University Medical Center Groningen|Boehringer Ingelheim|CSL Behring","Male","18 Years to 50 Years   (Adult)","Phase 2","12","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BI 1160.203|2014-002204-24","January 2015","July 2016","December 2016","June 4, 2015",,"May 12, 2016","University Medical Centre, Groningen, Netherlands",,"https://ClinicalTrials.gov/show/NCT02463591"
183,"NCT00552929","A Bridging Trial Comparing Sugammadex (Org 25969) at 1-2 Post-Tetanic Count (PTC) in Caucasian Participants. Part B (P05974)",,"Completed","Has Results","Anesthesia, General","Drug: Sugammadex","Time From Start of Sugammadex Administration to Recovery of the Neuromuscular Response to a Ratio of 0.9 for Train-Of-Four (TOF) Stimulation|Time From Start of Sugammadex Administration to a T4/T1 Recovery Ratio of 0.7|Time From Start of Sugammadex Administration to a T4/T1 Recovery Ratio of 0.8|Number of Participants With An Adverse Event (AE)","Merck Sharp & Dohme Corp.","All","20 Years to 64 Years   (Adult)","Phase 2","102","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P05974|2005-001133-15|MK-8616-036|19.4.209B","October 4, 2005","September 15, 2006","September 15, 2006","November 2, 2007","February 22, 2019","March 5, 2019",,,"https://ClinicalTrials.gov/show/NCT00552929"
184,"NCT02408887","Total Thyroidectomy With and Without Prophylactic Central Neck Lymph Node Dissection in People With Low-risk Papillary Thyroid Cancer",,"Terminated","No Results Available","Low-risk Papillary Thyroid Cancer|Endocrine Malignancy|Thyroid Cancer","Procedure: Total Thyroidectomy (TT)|Procedure: Prophylactic central neck lymph nodedissection (pCND)","Biochemical cure rates undergoing total thyroidectomy (TT) with and without pCND as measured by postoperative TSH-stimulated serum thyroglobulin (stim-Tg) at 3 months (prior to RAI treatment)|Biochemical cure rates in patients undergoing total thyroidectomy with and without pCND by postoperative TSH-stimulated serum thyroglobulin (stim-Tg) at 1 year postoperatively in patients who will not receive RAI or 1 year post remnant ablation|The QOL of patients|Subjective voice quality, swallowing impairment|Rate and duration of both symptomatic and asymptomatic hypoparathyroidism|Rate of cervical wound complications|The impact of BRAF V600E mutation status on lymph node metastasis|Neck pain","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)","Phase 2","14","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","150105|15-C-0105","April 15, 2015","March 26, 2019","May 7, 2019","April 6, 2015",,"October 27, 2021","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02408887"
185,"NCT01963442","Short Duration Treatment of Non-severe Community Acquired Pneumonia","PTC","Unknown status","No Results Available","Community Acquired Pneumonia","Radiation: Chest X-ray|Biological: blood sampling /Cell Counts/ C reactive protein (CRP)/Biochemistry|Drug: Augmentin|Drug: Placebo (for Augmentin)|Drug: Beta-Lactams","clinical evaluation at Day 15|clinical evaluation at Day 30","Versailles Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 2","310","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","PHRC-12-202.0496 - PTC|2013-000265-36","November 2013","June 2018","June 2018","October 16, 2013",,"August 14, 2017","CH Argenteuil, Argenteuil, France|CHU Ambroise Paré, Boulogne-Billancourt, France|CH Beaujon, Clichy, France|CHI Creteil, Creteil, France|Central Hospital Raymon Poincaré, Garches, France|CHU de Grenoble, La Tronche, France|CH Versailles, Le Chesnay, France|CH Bicêtre, Le Kremlin Bicètre, France|Melun Hospital, Melun, France|CH d'Annecy Genevois, Metz-Tessy, France|CH Lariboisière, Paris, France|CHU Saint Antoine, Paris, France|CHU Cochin, Paris, France|CHU Bichat, Paris, France|CH Tenon, Paris, France|CH Pontoise, Pontoise, France|CHU Rennes Pontchaillou, Rennes, France|CHU Rouen, Rouen, France|CH Saint Denis, Saint Denis, France|Foch Hospital, Suresnes, France",,"https://ClinicalTrials.gov/show/NCT01963442"
186,"NCT00168077","Prothrombin Complex Concentrate for Anticoagulant Reversal",,"Completed","No Results Available","Acquired Coagulation Factor Deficiency","Drug: Prothrombin Complex Concentrate","Rapid reversal of anticoagulatory effect|Clinical efficacy assessment (hemostatic effect)|Increase of coagulation factors","CSL Behring","All","18 Years and older   (Adult, Older Adult)","Phase 3","40","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BE1116_3001","September 2005",,"November 2006","September 14, 2005",,"February 11, 2011","Clinical Trials Registration Coordinator, Feldkirch, Austria|Clinical Trials Registration Coordinator, Wien, Austria|Clinical Trials Registration Coordinator, Halle/Saale, Germany|Clinical Trials Registration Coordinator, Hannover, Germany|Clinical Trials Registration Coordinator, Leipzig, Germany|For information on sites in Europe, please contact our clinical research team in, Marburg, Germany|Clinical Trials Registration Coordinator, München, Germany|Clinical Trials Registration Coordinator, Györ, Hungary|Clinical Trials Registration Coordinator, Veszprém, Hungary|Clinical Trials Registration Coordinator, Haifa, Israel|Clinical Trials Registration Coordinator, Kaunas, Lithuania|Clinical Trials Registration Coordinator, Vilnius, Lithuania|Clinical Trials Registration Coordinator, Amsterdam, Netherlands|Clinical Trials Registration Coordinator, Warsaw, Poland|Clinical Trials Registration Coordinator, Zuerich, Switzerland",,"https://ClinicalTrials.gov/show/NCT00168077"
187,"NCT03938792","Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B",,"Recruiting","No Results Available","Hemophilia A|Hemophilia B","Drug: PF-06741086","Annualized bleeding rate (ABR) of treated bleeding events|Incidence and severity of thrombotic events|Incidence of anti drug antibody [ADA] against PF-06741086|Incidence of clinically significant persistent neutralizing antibody [NAb] against PF-06741086|Incidence and severity of injection site reaction|Number of participants with clinically significant changes from baseline in physical exam|Incidence of clinically significant laboratory value abnormalities|Incidence of severe hypersensitivity and anaphylactic reactions|Incidence of adverse events and serious adverse events|Number of participants with clinically significant changes from baseline in vital signs|Incidence and severity of thromboticangiopathy|Incidence of intravascular coagulation/consumption coagulopathy|Total coagulation factor and/or bypass product consumption|Incidence of joint bleeds|Incidence of spontaneous bleeds|Incidence of target joint bleeds|Incidence of total bleeds (treated and untreated)|Percentage of participants with no bleeding episodes|Change from baseline in the Hemophilia Joint Health Score (HJHS)|Change from baseline in (Haemophilia Adult Quality of Life Questionnaire (Haem-A-QoL)|Change from baseline in Haemophilia Quality of Life Questionnaire for Children (Haemo-QoL)|Change from baseline in Hemophilia Adult Activities List (HAL)|Change from baseline in Hemophilia Pediatric Activities List (PedHAL)|Patient Global Impression of Change - Hemophilia (PGIC-H)|Change from baseline in EuroQol 5 Dimensions 5 Level (EQ-5D-5L)","Pfizer","Male","12 Years to 74 Years   (Child, Adult, Older Adult)","Phase 3","145","Industry","Interventional","Allocation: N/A|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","B7841005|2018-003660-31","March 9, 2020","September 27, 2024","September 27, 2024","May 6, 2019",,"January 20, 2022","USF Health Morsani Center For Advanced Healthcare, Tampa, Florida, United States|University of Iowa, Iowa City, Iowa, United States|Northwell Health HTC, New Hyde Park, New York, United States|National Specialized Hospital for the Active Treatment of Hematological Diseases - EAD, Sofia, Sofia, Bulgaria|UMHAT ""Prof.Dr. Stoyan Kirkovich"", Stara Zagora, Bulgaria|McMaster Children's Hospital, Hamilton, Ontario, Canada|McMaster University Medical Centre - Hamilton Health Sciences, Hamilton, Ontario, Canada|McMaster University, Hamilton, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|The Hospital For Sick Children, Toronto, Ontario, Canada|Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China|The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China|Jiangxi Provincial People's Hospital, Nanchang, Jiangxi, China|Jiangxi Provincial People's Hospital, Nanchang, Jiangxi, China|Institute of Hematology, Chinese Academy of Medical Sciences, Tianjin, Tianjin, China|Klinicki bolnicki centar Zagreb, Zagreb, Croatia|Hôpital Necker Enfants Malades, Paris, France|Prince of Wales Hospital, Hong Kong, Hong Kong|Queen Mary Hospital, Hong Kong, Hong Kong|Nirmal Hospital Pvt, Ltd, Surat, Gujarat, India|Sahyadri Clinical Research and Development Center, Pune, Maharashtra, India|Sahyadri Super Speciality Hospital, Pune, Maharashtra, India|Christian Medical College, Vellore, Tamil NADU, India|Azienda Ospedaliero Universitaria Careggi, Firenze, FI, Italy|Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milano, Milan, Italy|Università degli Studi di Roma ""Sapienza""-Policlinico Umberto I, Roma, RM, Italy|Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone, Palermo, Italy|Università degli Studi di Perugia, Azienda Ospedaliera di Perugia, Ospedale Santa Maria della, Perugia, Italy|Nagoya University Hospital - Transfusion Medicine, Nagoya, Aichi, Japan|Tokyo Metropolitan Children's Medical Center, Fuchu, Tokyo, Japan|National Center for Child Health and Development, Setagaya-ku, Tokyo, Japan|Ogikubo Hospital, Suginami-ku, Tokyo, Japan|Hiroshima University Hospital, Hiroshima, Japan|Kyungpook National University Hospital, Daegu, Korea, Republic of|Daejeon Eulji Medical Center Eulji University, Daejeon, Korea, Republic of|Chonnam National University Hwasun Hospital, Jeollanam-do, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Kyung Hee University Hospital at Gangdong, Seoul, Korea, Republic of|Hospital Universitario ""Dr Jose Eleuterio Gonzalez"", Monterrey, Nuevo LEON, Mexico|Centro Multidisciplinario para el Desarrollo Especializado de la Inv. Clínica en Yucatán, S.C.P., Mérida, Yucatán, Mexico|Sultan Qaboos University Hospital, Muscat, Oman|FGBOU VO ""Samara State Medical University"" of MoH of Russia, Samara, Russian Federation|King Abdulaziz University Hospital, Jeddah, Saudi Arabia|King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia|Clinical Center of Serbia, Belgrade, Serbia|Institute for Mother and Child healthcare ""Dr Vukan Cupic"", Belgrade, Serbia|Clinical Center Kragujevac, Kragujevac, Serbia|Clinical Center Nis, Nis, Serbia|Hospital Universitario A Coruna, A Coruna, Spain|Hospital Universitario Vall d´Hebron, Barcelona, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario de Salamanca - Complejo Asistencial Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain|ChangHua Christian Hospital, Changhua City, Changhua County, Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Acibadem Adana Hospital, Adana, Turkey|Hacettepe University Medical Faculty, Ankara, Turkey|Gazi University Health Research and Practice Center Gazi Hospital, Ankara, Turkey|Akdeniz University Medical Faculty, Antalya, Turkey|Gaziantep University Sahinbey Research and Training Hospital, Gaziantep, Turkey|Istanbul University Oncology Institute, Istanbul, Turkey|Ege University Medical Faculty, Izmir, Turkey|Dr. Behcet Uz Child Diseases Surgery Education and Research Hospital, Izmir, Turkey|Erciyes University Medical Faculty, Kayseri, Turkey|Ondokuz Mayıs University Medical Faculty, Samsun, Turkey|Karadeniz Technical University Medical Faculty, Trabzon, Turkey",,"https://ClinicalTrials.gov/show/NCT03938792"
188,"NCT03179631","Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy",,"Active, not recruiting","No Results Available","Muscular Dystrophy, Duchenne|Muscular Dystrophies|Muscular Disorders, Atrophic|Muscular Diseases|Musculoskeletal Disease|Neuromuscular Diseases|Nervous System Diseases|Genetic Diseases, X-Linked|Genetic Diseases, Inborn","Drug: Ataluren|Drug: PLACEBO","Slope of Change in 6-Minute Walk Distance (6MWD) Over 72 Weeks|Change from Baseline to Week 72 in 6MWD|Change from Baseline to Week 72 in Time to Run/Walk 10 Meters|Change from Baseline to Week 72 in Time to Climb 4 Stairs|Change from Baseline to Week 72 in Time to Descend 4 Stairs|Change from Baseline to Week 72 in North Start Ambulatory Assessment (NSAA) Total Score|Time to Loss of Ambulation Over 72 Weeks|Time to Loss of Stair-Climbing Over 72 Weeks|Time to Loss of Stair-Descending Over 72 Weeks|Risk of Loss of NSAA Items Over 72 weeks|Number of Treatment-Emergent Adverse Events Considered Related to Study Drug","PTC Therapeutics","Male","5 Years and older   (Child, Adult, Older Adult)","Phase 3","250","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PTC124-GD-041-DMD","July 6, 2017","March 3, 2022","July 20, 2023","June 7, 2017",,"January 24, 2022","Phoenix Childrens Hospital, Phoenix, Arizona, United States|Children's Hospital of Los Angeles, Los Angeles, California, United States|University of California, San Francisco (UCSF) - Benioff Children's Hospital - Oakland, Oakland, California, United States|Stanford University Medical Center, Palo Alto, California, United States|University of California (UC) Davis Medical Center, Sacramento, California, United States|Loma Linda University Children's Hospital, San Bernardino, California, United States|Child Neurology Center of Northwest Florida, Gulf Breeze, Florida, United States|Indiana University Health - Riley Child Neurology, Indianapolis, Indiana, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|University of Michigan - CS Mott Children's Hospital, Ann Arbor, Michigan, United States|Children's Hospital of Michigan, Detroit, Michigan, United States|University of Minnesota, Minneapolis, Minnesota, United States|Columbia University College of Physicians & Surgeons, New York, New York, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Shriners Hospital for Children, Portland, Oregon, United States|University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States|Cook Childrens Medical Center, Fort Worth, Texas, United States|Texas Children's Hospital, Houston, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|University Of Utah, Salt Lake City, Utah, United States|Children's Hospital of the King's Daughters, Norfolk, Virginia, United States|Seattle Children's Hospital, Seattle, Washington, United States|The Childrens Hospital at Westmead, Westmead, New South Wales, Australia|The Royal Childrens Hospital, Parkville, Victoria, Australia|Perth Children's Hospital, Nedlands, Western Australia, Australia|Queensland Children's Hospital, South Brisbane, Australia|Hospital de Clínicas da Universidade Federal de Minas Gerais, Belo Horizonte, Brazil|Universidade Federal do Rio de Janeiro, Rio De Janeiro, Brazil|Sao Paulo University, São Paulo, Brazil|UMHAT Sofiamed, Sofia, Bulgaria|Childrens Hospital London Health Sciences Centre, London, Ontario, Canada|Childrens Hospital of Eastern Ontario, Ottawa, Ontario, Canada|General Hospital of Chinese Armed Police Forces, Beijing, China|The First Affiliated Hospital of Fujian Medical University, Fuzhou, China|Xiangya Hospital Central South University, Hunan, China|Children's Hospital of Fudan University, Shanghai, China|Shenzhen Children's Hospital, Shenzhen, China|Queen Mary Hospital, Hong Kong, Hong Kong|Panchshil Hospital, Ahmedabad, Gujarat, India|National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India|P.D. Hinduja Hospital, Mahim, Maharashtra, India|Apollo Children's Hospital Chennai, Chennai, Tamil Nadu, India|Christian Medical College Hospital Vellore, Vellore, Tamil Nadu, India|Nizam's Institute of Medical Sciences (NIMS), Hyderabad, Telangana, India|Apollo Gleneagles Hospital, Kolkata, West Bengal, India|Postgraduate Institute of Medical Education and Research, Chandigarh, India|All India Institute of Medical Sciences, New Delhi, India|National Hospital Organization Higashisaitama National Hospital, Hasuda-city, Japan|National Center of Neurology and Psychiatry, Kodaira, Japan|Kumamoto University Hospital, Kumamoto-shi, Japan|Kyoto University Hospital, Kyoto, Japan|Nagoya City University Hospital, Nagoya-shi, Japan|Hyogo College of Medicine Hospital, Nishinomiya, Japan|Miyagi Children's Hospital, Sendai, Japan|National Hospital Organization Toneyama National Hospital, Toyonaka-shi, Japan|Tottori University Hospital, Yonago, Japan|Pusan National University Yangsan Hospital, Yangsan, Gyeongsangnamdo, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Kuala Lumpur Hospital - Pediatrics Neurology, Kuala Lumpur, Malaysia|University Malaya Medical Centre (UMMC), Pantai, Malaysia|Hospital Angeles Chihuahua, Chihuahua, Mexico|Instituto Nacional de Pediatría, Ciudad de mexico, Mexico|Instituto Nacional de Rehabilitacion, Tlalpan, Mexico|Samodzielny Publiczny Centralny Szpital Kliniczny w Warszawie, Warszawa, Poland|University of Puerto Rico - School of Medicine, San Juan, Puerto Rico|Russian National Research Medical University n.a. N.I.Pirogov, structural branch - Research Clinical Institute of Pediatrics n.a. Academician Yu. E. Veltishchev, Moscow, Russian Federation|""Saint Petersburg State Paediatric Medical University"" based at Consultative and Diagnostic Centre, Saint Petersburg, Russian Federation|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Siriraj Hospital, Bangkok, Thailand|Istanbul University- Instanbul Medical Faculty, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT03179631"
189,"NCT03715348","Trial of PCC Versus FFP in Patients Undergoing Heart Surgery","PROPHESY","Completed","No Results Available","Bleeding|Surgery|Transfusion","Drug: Prothrombin Complex Concentrate (PCC)|Biological: Fresh Frozen Plasma","Recruitment rate|Delivery of different components of the trial to see if a larger trial is feasible|To compare the impact of FFP and PCC on the haemostatic capacity of bleeding patients after cardiac surgery|Qualitative research involving completion of a Delphi survey to apprise the management and conduct of a larger trial|Qualitative research involving interviews of patients and healthcare professionals involved in PROPHESY to apprise the management and conduct of a larger trial","Queen Mary University of London|British Heart Foundation","All","18 Years and older   (Adult, Older Adult)","Phase 2","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","012507|2018-003041-41","March 1, 2019","January 29, 2020","January 29, 2020","October 23, 2018",,"November 17, 2020","St Bartholomew's Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03715348"
190,"NCT05041517","Brief Online Training (BOLT) for Routine Outcome Monitoring",,"Completed","No Results Available","Mental Health Issue|Adoption of Measurement-Based Care (MBC)","Behavioral: BOLT + PTC","Current Assessment Practice Evaluation - Revised (CAPER) - Change of use of MBC|Monitoring & Feedback Attitudes Scale (MFAS) - Change of attitudes about MBC use|MBC Knowledge Questionnaire (MBCKQ) - Change of knowledge about MBC|Routine-Outcome Monitoring Skill - Change of skill of MBC use","University of Washington|National Institute of Mental Health (NIMH)","All","22 Years to 80 Years   (Adult, Older Adult)","Not Applicable","75","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","52550|R34MH109605","February 16, 2017","July 16, 2019","December 31, 2020","September 13, 2021",,"September 13, 2021","University of Washington, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT05041517"
191,"NCT00086242","Telephone Counseling or Standard Care in Patients Who Have Completed Treatment for Stages I, II, or III Cervical Cancer",,"Completed","No Results Available","Cervical Cancer|Psychosocial Effects of Cancer and Its Treatment","Behavioral: Psychosocial Telephone Counseling (PTC)","Change in quality of life measured by FACT-Cx|Change in neuroendocrine parameters|Change in immune parameters|Correlation of psychosocial measures and immunologic stance","University of California, Irvine|National Cancer Institute (NCI)","Female","18 Years to 120 Years   (Adult, Older Adult)","Not Applicable","36","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other","UCIRVINE-2003-3030|CDR0000510143|R21CA098794","August 1, 2004","December 31, 2005","June 30, 2007","June 29, 2004",,"March 8, 2019","UCI, Health Policy and Research Center, Irvine, California, United States",,"https://ClinicalTrials.gov/show/NCT00086242"
192,"NCT00093210","Study Evaluating of Recombinant Human Factor IX (BeneFIX) and a New Formulation of BeneFIX (rFIX-R) in Moderate to Severe Hemophilia B",,"Completed","No Results Available","Hemophilia B","Drug: rFIX|Drug: rFIX-R",,"Wyeth is now a wholly owned subsidiary of Pfizer","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3",,"Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Primary Purpose: Treatment","3090A1-304",,,"September 2005","October 7, 2004",,"December 5, 2007",,,"https://ClinicalTrials.gov/show/NCT00093210"
193,"NCT04378075","A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy","MIT-E","Recruiting","No Results Available","Mitochondrial Diseases|Drug Resistant Epilepsy|Leigh Disease|Leigh Syndrome|Mitochondrial Encephalopathy (MELAS)|Pontocerebellar Hypoplasia Type 6 (PCH6)|Alpers Disease|Alpers Syndrome","Drug: Vatiquinone|Other: Placebo","Change from Baseline to Week 24 in the Number of Observable Motor Seizures per 28 Days|Number of Disease-Related Hospital Days|Number of Participants with Occurrences or Recurrence of Status Epilepticus|Number of Participants with Disease-Related In-Patient Hospitalizations or Emergency Room Visits|Number of Disease-Related In-Patient Hospital Admissions or Emergency Room Visits|Change from Baseline to Week 72 in Total Seizure Frequency (All Types) per 28 Days|Percentage of Participants with ≥25%, ≥50%, ≥75%, and 100% Reduction in Motor Seizures|Percentage of Participants with ≥25%, ≥50%, ≥75%, and 100% Reduction in Total Seizures (All Types)|Number of Participants Who Require Rescue Seizure Medication|Health-Related Quality of Life as Measured by the Care-Related Quality of Life of Informal Caregivers (CarerQoL-7D) Questionnaire|Number of Participants with Seizure Clusters","PTC Therapeutics","All","up to 18 Years   (Child, Adult)","Phase 2|Phase 3","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PTC743-MIT-001-EP|2020-002100-39","September 28, 2020","July 18, 2022","July 19, 2023","May 7, 2020",,"November 5, 2021","University of California, San Diego, California, United States|Stanford University, Stanford, California, United States|Children's National Medical Center - Department Of Neurology, Washington, District of Columbia, United States|John Hopkins Medicine, Baltimore, Maryland, United States|Pediatric Genetics Clinic (Main MGH Hospital), Boston, Massachusetts, United States|Boston Children Hospital, Boston, Massachusetts, United States|Children's of Minnesota, Minneapolis, Minnesota, United States|Akron Children's Hospital, Akron, Ohio, United States|Baylor College of Medicine, Houston, Texas, United States|University of Texas Health Science, Houston, Texas, United States|Seattle Children's hospital, Seattle, Washington, United States|U.O.C. Malattie Muscolari e Neurodegenerative, Dipartimento di Scienze Neurologiche e Psichiatriche, Ospedale Pediatrico Bambino Gesù, Roma, Italy|Hospital Universitario 12 de Octubre, Madrid, Spain|Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom|The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04378075"
194,"NCT04580940","SpyGlass™ Discover Percutaneous",,"Recruiting","No Results Available","Pancreatic Diseases|Bile Duct Obstruction|Bile Duct Diseases","Device: SpyGlass™ Discover Digital System","Achieving clinical intent of procedure as indicated|Number of Adverse Events|Technical success|Procedural Time|Number of PTCS procedures|Endoscopist rating","Boston Scientific Corporation","All","18 Years and older   (Adult, Older Adult)",,"50","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","E7160","July 27, 2021","March 2022","April 2022","October 9, 2020",,"December 20, 2021","Stanford University Medical Center, Stanford, California, United States|Virginia Mason Medical Center, Seattle, Washington, United States|DAICIM Foundation, Caba, Argentina|Erasme University Hospital, Brussels, Belgium|Hospital das Clinicas, São Paulo, Brazil|Toronto General Hospital, University Health Network, Toronto, Ontario, Canada|Evangelisches Krakenhaus Düsseldorf, Düsseldorf, Germany|Prince of Wales Hospital, Shatin, NewTerritories, Hong Kong|Asian Institute of Gastroenterology, Hyderabad, Somajiguda, India|Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy",,"https://ClinicalTrials.gov/show/NCT04580940"
195,"NCT00390507","Modification of Posttetanic Count (PTC) for Monitoring Deep Neuromuscular Block II",,"Completed","No Results Available","Neuromuscular Blockade","Procedure: Post-tetanic count frequency","Time to first response to TOF stimulation (T1)|Time to second response to TOF stimulation (T2)|Time to first post-tetanic count (PTC)|Number of post-tetanic count at first response to TOF|Time to T1=25%|Interval 25-75%|Time to TOF 0.9|Time to TOF 1.0","Rigshospitalet, Denmark","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","45","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Treatment","PTC-II","October 2006","April 2010",,"October 20, 2006",,"September 6, 2010","Dep. of Anesthesia, Rigshospitalet, Copenhagen, Denmark|Dep. of Anesthesia, Herlev hospital, Herlev, Denmark",,"https://ClinicalTrials.gov/show/NCT00390507"
196,"NCT04145453","Vegetables Intake and Polymorphism TAS2R38 Gene by Healthy Adults",,"Active, not recruiting","No Results Available","Healthy Lifestyle|Taste Disorders|Diet Habit","Behavioral: Intervention genotype personalized nutritional recommendations|Behavioral: Control Group 1 personalized nutritional recommendations|Behavioral: Control Group 2 general nutritional recommendations","Vegetables intake|TAS2R38 polymorphism|Body Mass (BM)|Fat free mass (FFM)|Fat Mass (FM) %|Waist circumference (WC)|Total Cholesterol (TChol)|LDL Cholesterol(LDL-Chol)|HDL Cholesterol (HDL-Chol)|Triglycerides (TG)|Glucose (GLU)|Insulin (INS)|Alanine transaminase (ALAT)|aspartate aminotransferase (ASPAT)","Poznan University of Life Sciences","All","18 Years to 60 Years   (Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Basic Science","UKB 872/19","October 1, 2019","November 30, 2021","November 30, 2021","October 30, 2019",,"October 29, 2021","Poznan University of Life Sciences, Poznań, Poland",,"https://ClinicalTrials.gov/show/NCT04145453"
197,"NCT02418390","The Efficacy and Safety of Prophylactic Central Lymph Node Dissection in Papillary Thyroid Carcinoma",,"Recruiting","No Results Available","Thyroid Cancer, Papillary","Procedure: prophylactic central lymph node dissection","Recurrence of thyroid cancer|operation time|postoperative complications including hypoparathyroidism and recurrent nerve palsy|Quality of life","Seoul National University Hospital","All","20 Years to 70 Years   (Adult, Older Adult)","Not Applicable","5750","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","H-1404-050-571","April 1, 2015","February 2022","February 2022","April 16, 2015",,"September 23, 2019","Seoul National University Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02418390"
198,"NCT04339517","Postoperative Identification of Tumor Cells at the Lumpectomy Site of Patients With Early Breast Cancer",,"Recruiting","No Results Available","Breast Cancer","Procedure: Aspiration of seroma fluid","Identification of Persistent Tumor Cells (PTCs)","Lawson Health Research Institute","Female","up to 50 Years   (Child, Adult)","Not Applicable","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","Breast PTC","August 17, 2021","August 30, 2025","August 30, 2026","April 9, 2020",,"August 24, 2021","London Regional Cancer Program; Lawson Research Institute, London, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04339517"
199,"NCT04664413","Percentage of BRAFV600E Alleles and Outcome in Thyroid Carcinoma","ABOUT","Not yet recruiting","No Results Available","Papillary Thyroid Cancer",,"Intratumor BRAFV600E heterogeneity and outcome|Intratumor BRAFV600E heterogeneity quantification|Intratumor BRAFV600E heterogeneity and clinicopathological features","University of Salerno","All","18 Years and older   (Adult, Older Adult)",,"300","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","ABOUT","February 1, 2021","April 30, 2021","May 30, 2021","December 11, 2020",,"December 14, 2020","Department of Medicine and Surgery, Univeristy of Salerno, Baronissi, Salerno, Italy",,"https://ClinicalTrials.gov/show/NCT04664413"
200,"NCT01286753","A Study of Vemurafenib (RO5185426) in Participants With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation",,"Completed","Has Results","Neoplasms","Drug: Vemurafenib","Best Overall Response Rate in TKI-Naive Participants|Best Overall Response Rate in TKI-Experienced Participants|Clinical Benefit Rate|Duration of Response|Progression-Free Survival|Overall Survival|Percentage of Participants With Adverse Events|Pharmacokinetics of Vemurafenib: Area Under the Concentration-Time Curve (AUC)","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 2","51","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NO25530|2010-024133-23","June 2011","November 2014","May 2015","January 31, 2011","September 7, 2016","September 7, 2016","Torrance, California, United States|New Haven, Connecticut, United States|Chicago, Illinois, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|New York, New York, United States|Philadelphia, Pennsylvania, United States|Houston, Texas, United States|Lyon, France|Paris, France|Villejuif, France|Milano, Lombardia, Italy|Pisa, Toscana, Italy|Groningen, Netherlands|Leiden, Netherlands",,"https://ClinicalTrials.gov/show/NCT01286753"
201,"NCT05156983","A Trial of PROTHROMPLEX TOTAL for Reversal of Direct Oral Factor Xa Inhibitor-induced Anticoagulation",,"Not yet recruiting","No Results Available","Coagulation Disorder","Drug: PROTHROMPLEX TOTAL|Drug: 4F-PCC","Percentage of Participants With Intraoperative Effective Hemostasis|Percentage of Participants With Postoperative Effective Hemostasis|Percentage of Participants With Intraoperative Effective Hemostasis Based on Hemostatic Efficacy Rating Algorithm|Number of Participants With Usage of Blood Products or Non-Study Hemostatic Agents for Bleeding Control|Number of Units of Packed red Blood Cells (PRBCs) Administered to Achieve Bleeding Control|Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interests (AESIs)|Number of Participants With Thrombotic Events|Number of Participants With Deaths Within 30 Days Post-Surgery/Invasive Procedure","Takeda|Takeda Development Center Americas, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","328","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TAK-330-3001|2021-004138-12","March 21, 2022","June 30, 2023","June 30, 2023","December 14, 2021",,"January 11, 2022",,,"https://ClinicalTrials.gov/show/NCT05156983"
202,"NCT03256968","PTC Study to Evaluate Ataluren in Combination With Ivacaftor",,"Completed","Has Results","Cystic Fibrosis","Drug: Ataluren","FEV1 as a Measure of Lung Function","University of Alabama at Birmingham","All","6 Years and older   (Child, Adult, Older Adult)","Phase 4","1","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","F160106006","January 27, 2017","December 1, 2018","December 31, 2018","August 22, 2017","March 26, 2020","March 26, 2020","University of Alabama at Birmingham, Birmingham, Alabama, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/68/NCT03256968/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03256968"
203,"NCT01149161","Extent of Central Lymph Node Dissection in Papillary Thyroid Microcarcinoma",,"Unknown status","No Results Available","Carcinoma","Procedure: Routine central neck dissection","Is routine neck node dissection necessary in micro PTC?|The efficacy of sentinel lymph node biopsy in micro PTC","Samsung Medical Center","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2|Phase 3","2000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment","2009-02-017","May 2009","December 2017","December 2020","June 23, 2010",,"April 21, 2016","Samsung Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01149161"
204,"NCT01137097","Lateral Neck Sentinel Lymph Node Biopsy(LSLNB)in PTC","LSLNB","Completed","No Results Available","Thyroid Neoplasm","Procedure: Lateral sentinel lymph node biopsy","The usefulness of lateral sentinel lymph node biopsy in PTC","Samsung Medical Center","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2|Phase 3","278","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2009-07-101","June 2009","January 2011","January 2011","June 4, 2010",,"April 21, 2016","Samsung Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01137097"
205,"NCT02409004","Effects of Rifampin on the Pharmacokinetics of Ataluren",,"Completed","No Results Available","Healthy","Drug: Ataluren|Drug: Rifampin","Area under the plasma concentration versus time curve (AUC)|Maximum plasma concentration (Cmax)|Safety as measured by adverse events, laboratory abnormalities, vital signs, and electrocardiogram parameters","PTC Therapeutics","Male","18 Years to 55 Years   (Adult)","Phase 1","15","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PTC124-GD-026-HV","February 2015","March 2015","March 2015","April 6, 2015",,"December 22, 2017","Inventiv, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT02409004"
206,"NCT01488994","BAX 326 Pediatric Study",,"Completed","Has Results","Hemophilia B","Biological: BAX326","Adverse Events (AEs) Possibly or Probably Related to BAX326|Pharmacokinetics (PK): Total Area Under the Plasma Concentration Versus Time Curve From 0 to 72 Hours Post-infusion Per Dose (AUC 0-72h/Dose)|Pharmacokinetics (PK): Total Area Under the Plasma Concentration Versus Time Curve From 0 to Infinity Post-infusion Per Dose (Total AUC/Dose)|Pharmacokinetics (PK): Mean Residence Time (MRT)|Pharmacokinetics (PK): Factor IX (FIX) Clearance (CL)|Pharmacokinetics (PK): Incremental Recovery (IR)|Pharmacokinetics (PK): Elimination Phase Half-life (T 1/2)|Pharmacokinetics (PK): Volume of Distribution at Steady State (Vss)|Pharmacokinetics (PK): Incremental Recovery (IR) Over Time|Hemostatic Efficacy: Treatment of Bleeding Episodes: Number of Infusions Per Bleeding Episode|Hemostatic Efficacy: Treatment of Bleeding Episodes: Overall Hemostatic Efficacy Rating at Resolution of Bleed|Hemostatic Efficacy: Prophylaxis: Annualized Bleeding Rate (ABR)|Consumption of BAX326: Number of Infusions Per Month|Consumption of BAX326: Number of Infusions Per Year|Consumption of BAX326: Weight-adjusted Consumption Per Month|Consumption of BAX326: Weight-adjusted Consumption Per Year (Annualized)|Consumption of BAX326: Weight-adjusted Consumption Per Event|Safety and Immunogenicity: Number of Participants Who Developed Inhibitory Antibodies to Factor IX (FIX)|Safety and Immunogenicity: Number of Participants Who Developed Total Binding Antibodies to Factor IX (FIX)|Safety: Number of Participants With Severe Allergic Reactions, e.g. Anaphylaxis|Safety: Number of Participants With Thrombotic Events|Safety: Number of Participants With Clinically Significant Changes in Routine Laboratory Parameters (Haematology and Clinical Chemistry), and Vital Signs|Safety: Number of Participants Who Developed Antibodies to Chinese Hamster Ovary (CHO) Proteins and Recombinant Furin (rFurin)|Health-related Quality of Life (HRQoL): PedsQL™ Change From Baseline in Total Score|Health-related Quality of Life (HRQoL): Haemo-QoL, Change From Baseline in Total Score|Health Resource Use: Number of Hospitalizations|Health Resource Use: Length of Hospitalization|Health Resource Use: Unscheduled Doctor's Office Visits|Health Resource Use: Emergency Room Visits|Health Resource Use: Days Lost From School","Baxalta now part of Shire|Takeda","All","up to 12 Years   (Child)","Phase 2|Phase 3","23","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","251101|2011-002437-19","December 20, 2011","May 14, 2013","May 14, 2013","December 9, 2011","September 1, 2016","May 20, 2021","LNJP Maulana Azad Medical College & Associated Hospitals, New Delhi, India|University Pediatric Hospital, Krakow, Poland|Stanislaw Popowski Provincial Specialist Pediatric Hospital, Olsztyn, Poland|Professor Tadeusz Sokolowski Independent Public Teaching Hospital of the Pomeranian Medical University in Szczecin, Szczecin, Poland|S.C. Sanador SRL, Bucharest, Romania|Louis Turcanu Emergency Children's Hospital, Timisoara, Romania|Regional Clinical Hospital, Ekaterinburg, Russian Federation|Pediatric Regional Clinical Hospital, Hematology Department, Krasnodar, Russian Federation|Republican Center for Hemophilia Treatment, St. Petersburg, Russian Federation|State Institution ""Institute of Blood Pathology and Transfusion Medicine of the Academy of Medical Sciences of Ukraine"", Lviv, Ukraine|Manchester Children´s Hospital, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01488994"
207,"NCT00675792","Comparison of Sugammadex Administered at 1-2 Post Tetanic Counts (PTCs) or Better With Neostigmine Administered as Per Standard of Care to Reverse Rocuronium-Induced Neuromuscular Blockade in Adults Undergoing Elective Open Abdominal Procedure (19.4.334) (P05774)",,"Completed","Has Results","Anesthesia","Drug: Sugammadex|Drug: Neostigmine|Drug: Rocuronium","Residual Neuromuscular Blockade Evidenced by T4/T1 Ratio at the Time of Tracheal Extubation|Number of Participants With Post-operative Complications|Number of Participants With Evidence of Possible Interaction of Sugammadex With Endogenous Compounds or Exogenous Compounds Other Than Rocuronium Bromide|Time From Start of Administration of Investigational Medicinal Product (IMP) to Recovery of the T4/T1 Ratio to 0.9|Time From Start of Administration of IMP to Recovery of the T4/T1 Ratio to 0.8|Time From Start of Administration of IMP to Recovery of the T4/T1 Ratio to 0.7","Merck Sharp & Dohme Corp.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","100","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","P05774|19.4.334","May 2008","September 2008","September 2008","May 12, 2008","July 11, 2013","March 13, 2015",,,"https://ClinicalTrials.gov/show/NCT00675792"
208,"NCT02392156","Fc factOrs and Real-World hemophiliA Patient-ReporteD Outcomes","FORWARD","Terminated","No Results Available","Hemophilia A|Hemophilia B","Biological: rFVIIIFc|Biological: rFIXFc|Drug: non-Fc FVIII replacement products|Drug: non-Fc FIX replacement products","Annualized number of injections for prophylactic treatment with a Factor VIII or Factor IX replacement product|The total annualized factor consumption (in International Units [IU] per kilogram [IU/kg]) calculated for each participant|Change in Treatment Satisfaction Questionnaire for Medication (TSQM)|Change in Hemophilia Activities List (HAL)|Change in Validated Hemophilia Regimen Treatment Adherence Scale-Prophylaxis (VERITAS-Pro)|Change in Wong-Baker Faces Pain Rating Scale|Change in Work Productivity and Impairment Questionnaire plus Classroom Impairment Questions: Hemophilia Specific (WPAI+CIQ:HS)|Change in Missed planned activity and productivity|Change in Caregiver burden|Number of inpatient and outpatient healthcare visits","Bioverativ Therapeutics Inc.|Swedish Orphan Biovitrum|Sanofi","Male","Child, Adult, Older Adult",,"3","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","997HA401","July 2015","December 2015","December 2015","March 18, 2015",,"December 19, 2020","Research Site, Los Angeles, California, United States|Research Site, East Lansing, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT02392156"
209,"NCT00618098","Study of Octaplex (Human Prothrombin Complex Concentrate) and Fresh Frozen Plasma in Patients Under Vitamin K Therapy Antagonist Needing Urgent Surgery or Invasive Procedures",,"Completed","No Results Available","Reversal of Anticoagulant Treatment","Biological: Octaplex (human prothrombin complex concentrate)|Biological: Fresh frozen plasma","There will be two primary end points in this study. The first primary efficacy endpoint is the correction of INR to < 1.5.|number of intra-operative red blood cell units (RBC) transfused","Octapharma","All","18 Years and older   (Adult, Older Adult)","Phase 3","200","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LEX-205","May 2008","March 2012","August 2012","February 18, 2008",,"October 18, 2016","Contact Octapharma for Facility details, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00618098"
210,"NCT00724932","Comparison of Sugammadex With Neostigmine During Laparoscopic Cholecystectomy or Appendectomy (P05699)",,"Completed","Has Results","Anesthesia, General","Drug: Rocuronium|Drug: Sugammadex|Drug: Neostigmine|Drug: Atropine","Time From Start of Administration of Investigational Medicinal Product (IMP, Sugammadex or Neostigmine) to Recovery of the Fourth Twitch/First Twitch (T4/T1) Ratio to 0.9|Time From Start of Administration of IMP to Recovery of the T4/T1 Ratio to 0.7|Time From Start of Administration of IMP to Recovery of the T4/T1 Ratio to 0.8|Number of Participants Who Experienced Pre-treatment Serious Adverse Events (SAEs) and Post-treatment SAEs|Number of Participants Who Experienced Pre-treatment Non-serious Adverse Events (AEs) and Post-treatment Non-serious AEs","Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 3","140","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","P05699|19.4.318|MK-8616-002|2007-007951-14","July 16, 2008","April 1, 2009","May 3, 2009","July 30, 2008","April 29, 2013","May 16, 2017",,,"https://ClinicalTrials.gov/show/NCT00724932"
211,"NCT02724176","Potential Role for Carbon Nanoparticles to Guide Central Neck Dissection in Patients With Papillary Thyroid Cancer",,"Completed","No Results Available","Thyroid Cancer","Drug: carbon nanoparticles","lymph node metastatic rates between the carbon nanoparticles and control group|total dissected lymph nodes less than 5mm between the carbon nanoparticles and control group|the number of metastatic lymph nodes with diameter < 5mm between the carbon nanoparticles and control group","Beijing Cancer Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","140","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BJ20161206","January 2012","January 2016","January 2016","March 31, 2016",,"March 31, 2016",,,"https://ClinicalTrials.gov/show/NCT02724176"
212,"NCT00473694","Comparison of Sugammadex (MK-8616/Org 25969) With Neostigmine Administered at 1-2 Post-tetanic Counts (PTCs) After Administration of Rocuronium or Vecuronium (19.4.302/P05945/MK-8616-025)",,"Completed","Has Results","Anesthesia, General","Drug: sugammadex|Drug: neostigmine|Drug: vecuronium|Drug: rocuronium|Drug: glycopyrrolate","Time From Start of Administration of Sugammadex or Neostigmine to Recovery of the T4/T1 Ratio to 0.9 After Neuromuscular Block (NMB) Induced by Rocuronium|Time From Start of Administration of Sugammadex or Neostigmine to Recovery of the T4/T1 Ratio to 0.9 After Neuromuscular Block (NMB) Induced by Vecuronium|Time From Start of Administration of Sugammadex or Neostigmine to Recovery of the T4/T1 Ratio to 0.7 After Neuromuscular Block (NMB) Induced by Rocuronium|Time From Start of Administration of Sugammadex or Neostigmine to Recovery of the T4/T1 Ratio to 0.7 After Neuromuscular Block (NMB) Induced by Vecuronium|Time From Start of Administration of Sugammadex or Neostigmine to Recovery of the T4/T1 Ratio to 0.8 After Neuromuscular Block (NMB) Induced by Rocuronium|Time From Start of Administration of Sugammadex or Neostigmine to Recovery of the T4/T1 Ratio to 0.8 After Neuromuscular Block (NMB) Induced by Vecuronium|Number of Participants Awake and Oriented After Anesthesia (Clinical Assessment of Level of Consciousness)|Number of Participants Aroused With Minimal Stimulation After Anesthesia (Clinical Assessment of Level of Consciousness)|Number of Participants Responsive Only to Tactile Stimulation After Anesthesia (Clinical Assessment of Level of Consciousness)|Number of Participants Able to Perform a 5-second Head Lift|Number of Participants Experiencing General Muscle Weakness","Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 3","182","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","P05945|19.4.302|MK-8616-025","November 28, 2005","November 6, 2006","January 29, 2007","May 15, 2007","March 7, 2019","March 19, 2019",,,"https://ClinicalTrials.gov/show/NCT00473694"
213,"NCT00559949","Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine",,"Completed","Has Results","Recurrent Thyroid Gland Carcinoma|Stage I Thyroid Gland Papillary Carcinoma|Stage II Thyroid Gland Papillary Carcinoma|Stage III Thyroid Gland Papillary Carcinoma|Stage IV Thyroid Gland Papillary Carcinoma","Other: Laboratory Biomarker Analysis|Drug: Selumetinib","Objective Response Rate (ORR)|Median Progression-Free Survival (PFS)|Occurrence of Treatment Related Adverse Events|Overall Survival (OS)","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","39","NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2009-01056|LOI 7918|CDR0000574262|7918|N01CM62201|N01CM62203|N01CM62208|P30CA076292","December 2007","August 2016","August 2016","November 19, 2007","January 30, 2017","January 30, 2017","Moffitt Cancer Center, Tampa, Florida, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States|University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00559949"
214,"NCT03341156","Administration of Prothrombin Complex Concentrate vs. Standard Transfusion During/After Heart Transplantation","OPSTAHT","Recruiting","No Results Available","Heart Disease End Stage|Heart Failure，Congestive","Drug: Kcentra|Drug: Frozen Plasma Product, Human","Amount of Chest Tube Drainage|Postoperative INR|Blood Product Use|Red Blood Cell Use|Need for circulatory support|Mechanical Ventilation|Tracheostomy|Renal Failure|Sepsis|Death|Stroke or postoperative neurological dysfunction|Gastrointestinal complication requiring bowel resection|Peripheral vascular complication|Deep Vein Thrombosis and Pulmonary Thromboembolism|Plasma Coagulation Factor levels|Thrombin Generation Assay|Surgical Re-exploration","Kathirvel Subramaniam|University of Maryland, Baltimore|CSL Behring|University of Pittsburgh","All","18 Years and older   (Adult, Older Adult)","Phase 3","60","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PRO17080509","July 11, 2018","October 1, 2022","December 1, 2022","November 14, 2017",,"January 11, 2022","University of Maryland, Baltimore, Maryland, United States|Upmc Presbyterian Montefiore Hospital, Pittsburgh, Pennsylvania, United States|UPMC Presbyterian Shadyside, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03341156"
215,"NCT02937831","RIXUBIS Drug Use-Result Survey (Japan)",,"Recruiting","No Results Available","Hemophilia B","Biological: RIXUBIS","Number of participants who discontinued the use of Rixubis|Number of participants who developed a Factor IX (FIX) inhibitor|Annual bleed rate (ABR) of participants on a prophylaxis regimen|Number of doses to treat a bleed of participants on an on-demand regimen|Hemostatic effectiveness of Rixubis for participants on an on-demand regimen|Hemostatic effectiveness of Rixubis in surgery- perioperative and postoperative|Number of participants who experience shock or anaphylaxis|Number of participants who experience a thromboembolism","Baxalta now part of Shire|Takeda","All","Child, Adult, Older Adult",,"30","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","251601","November 16, 2016","May 31, 2022","May 31, 2022","October 19, 2016",,"January 22, 2021","Seki-shi, Japan, Seki-shi, Gifu Prefecture, Japan|Maebashi-shi, Japan, Maebashi-shi, Gunma Prefecture, Japan|Nobeoka-shi, Japan, Nobeoka-shi, Miyazaki Prefecture, Japan|Niigata-shi, Japan, Niigata-shi, Niigata Prefecture, Japan|Osaka-shi, Japan, Osaka-shi, Osaka Prefecture, Japan",,"https://ClinicalTrials.gov/show/NCT02937831"
216,"NCT01499537","Prospective Randomized Study of PTC and EUS-guided Drainage of the Bile Duct",,"Completed","No Results Available","Jaundice","Device: biliary drainage|Device: EUS guided biliary drainage","Morbidity rate|efficacy|feasibility|biliary drainage duration|quality of life","Institut Paoli-Calmettes","All","18 Years and older   (Adult, Older Adult)","Not Applicable","65","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","APHAGE/IPC 2010-002","January 2011","February 2016","March 2016","December 26, 2011",,"May 19, 2016","Institut Paoli-Calmettes, Marseille, France|Hopital Nord, Marseille, France|Centre Hospitalier Princesse Grace, Monaco, Monaco",,"https://ClinicalTrials.gov/show/NCT01499537"
217,"NCT00984191","Pilot 99mTechnetium-MIBI Single Photon Emission Computed Tomography - Computed Tomography (SPECT-CT) in Papillary Carcinoma (CA) Thyroid",,"Unknown status","No Results Available","Papillary Thyroid Cancer","Radiation: 99mTc-MIBI SPECT-CT","Diagnostic Tool Statistic (PPV , NPV , Sensitivity , Specificity , Accuracy )","Chulalongkorn University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","15","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","NapadonChula_01","March 2010","October 2011","November 2011","September 25, 2009",,"June 27, 2011","King Chulalongkorn Hospital, Pathumwan, Bangkok, Thailand",,"https://ClinicalTrials.gov/show/NCT00984191"
218,"NCT04601298","The Risk Stratification of Papillary Thyroid Cancer With AUS/FLUS by FNA",,"Completed","No Results Available","Thyroid Cancer|Atypia of Undetermined Significance|FLUS",,"Extra-thyroid extension|Multifocality","Shanghai 10th People's Hospital","All","18 Years to 77 Years   (Adult, Older Adult)",,"290","Other","Observational","Observational Model: Case-Crossover|Time Perspective: Cross-Sectional","Bethesda Category III","August 1, 2015","September 30, 2020","September 30, 2020","October 23, 2020",,"March 17, 2021","Shanghai 10Th People'S Hospital, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04601298"
219,"NCT02766959","Allele-specific Expression of a Bitter Taste Receptor",,"Completed","No Results Available","Rhinosinusitis","Other: Observational study","TAS2R38 genotype|TAS2R38 mRNA expression levels measured by RT-qPCR|Ciliary beat frequency|Production of nitric oxide by a participant's nasal epithelium culture measured in fold change of 4,5-diaminofluorescence diacetate|Bitter taste perception as measured by a visual analog scale|Caffeine intake measured by number caffeinated beverages consumed per week (normalized to 1 cup = 180 mg caffeine)|Taste papillae density","Monell Chemical Senses Center|University of Pennsylvania|Corporal Michael J. Crescenz VA Medical Center","All","21 Years to 50 Years   (Adult)",,"57","Other|U.S. Fed","Observational","Observational Model: Cohort|Time Perspective: Prospective","823078","January 2016","August 2017","August 2018","May 10, 2016",,"September 18, 2018","Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Monell Chemical Senses Center, Philadelphia, Pennsylvania, United States|Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02766959"
220,"NCT03519867","Efficacy and Safety of Org 25969 Administered After Zemuron® (MK-8616-042)",,"Completed","Has Results","Neuromuscular Blockade","Drug: MK-8616|Drug: Zemuron®","Time From Start of Administration of MK-8616 to Recovery T4/T1 Ratio to 0.9|Percentage of Participants Experiencing ≥1 Adverse Events (AEs)","Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 2","50","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","P06387|MK-8616-042|19.4.204","August 1, 2004","May 26, 2005","May 26, 2005","May 9, 2018","January 31, 2019","January 31, 2019",,,"https://ClinicalTrials.gov/show/NCT03519867"
221,"NCT04272554","AAV Gene Therapy Screening/Observational Protocol (ECLIPSE)","ECLIPSE","Recruiting","No Results Available","Hemophilia B|Blood Coagulation Disorders, Inherited|Blood Coagulation Disorder|Haematologic Disease",,"Bleeding episodes|Factor IX replacement therapy consumption|To screen Haemophilia B patients for neutralising antibodies to a novel AAV vector (AAVS3).|To characterise baseline clinical parameters related to Haemophilia B.","Freeline Therapeutics","Male","16 Years and older   (Child, Adult, Older Adult)",,"200","Industry","Observational","Observational Model: Case-Only|Time Perspective: Other","FLT-01","February 14, 2020","August 1, 2026","August 1, 2026","February 17, 2020",,"December 7, 2021","Phoenix Childrens Hospital, Phoenix, Arizona, United States|Children's Hospital of Los Angeles, Los Angeles, California, United States|University of California - Davis, Sacramento, California, United States|University of South Florida, Tampa, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|Indiana Hemophilia and Thrombosis Center, Indianapolis, Indiana, United States|University of Michigan, Ann Arbor, Michigan, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Hemophilia Center of Western New York, Buffalo, New York, United States|University of North Carolina (UNC), Chapel Hill, North Carolina, United States|East Carolina University, Greenville, North Carolina, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Nationwide Childrens Hospital, Columbus, Ohio, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Lombardi Comprehensive Cancer Center at Georgetown University, Georgetown, Washington, United States|Blood Center of Wisconsin, Milwaukee, Wisconsin, United States|Royal Children's Hospital, Parkville, Melbourne, Australia|The Alfred Hospital, Melbourne, Australia|Calvary Mater Hospital, Newcastle, Australia|Royal Prince Alfred Hospital, Sydney, Australia|Westmead Hospital, Sydney, Australia|Medical University of Vienna, Vienna, Austria|McMaster University Medical Centre, Hamilton, Canada|Lawson Health Research Institute, London, Canada|The Moncton Hospital, Moncton, Canada|Saskatoon City Hospital, Saskatoon, Canada|University of Alberta Hospital, Winnipeg, Canada|Hôpital Louis Pradel - HCL, Bron, France|CHU Bicetre, Paris, France|Hopital Necker-Enfants Malades - AP-HP, Paris, France|Universitaetsklinikum Frankfurt - Klinikum der Johann Wolfgang Goethe Universitaet, Frankfurt, Germany|Universitaetsklinikum des Saarlandes und Medizinische Fakultaet der Universitaet des Saarlandes, Homburg, Germany|St James Hospital, Dublin, Ireland|Azienda Ospedaliero-Universitaria Careggi, Firenze, Italy|Istituto Giannina Gaslini, Genova, Italy|Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy|Citta della Salute e della Scienza di Torino - Ospedale le Molinette, Torino, Italy|Groningen UMC, Groningen, Netherlands|Erasmus MC, Rotterdam, Netherlands|Universitair Medisch Centrum Utrecht, Utrecht, Netherlands|University of Cape Town Clinical Research Center, Cape Town, South Africa|Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South Africa|Istanbul University Faculty of Medicine, Istanbul, Turkey|Ege University Medical Faculty, İzmir, Turkey|Samsun Ondokuz Mayis University Medical Faculty, Samsun, Turkey|Özel Acibadem Adana Hastanesi, Seyhan, Turkey|The Haemophilia and Thrombosis Centre, Canterbury, Kent, United Kingdom|Queen Elizabeth Hospital, Birmingham, United Kingdom|Cardiff University Hospital, Cardiff, United Kingdom|Glasgow Royal Infirmary, Glasgow, United Kingdom|Hammersmith Hospital, London, United Kingdom|Royal Free London NHS Foundation Tust, London, United Kingdom|St Thomas' Hospital, London, United Kingdom|Manchester Royal Infirmary, Manchester, United Kingdom|Newcastle Hemophilia Comprehensive Care Centre, Newcastle, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04272554"
222,"NCT03154086","A Phase 1, First Time in Human (FTIH) Study to Evaluate GSK3352589, a REarranged During Transfection (RET) Growth Factor Receptor Tyrosine Kinase Inhibitor, in Healthy Volunteers",,"Completed","Has Results","Irritable Bowel Syndrome","Drug: GSK3352589|Drug: Matching Placebo","Part A: Number of Participants With Serious Adverse Events (SAEs) and Non-SAEs in Cohort 1|Part A: Number of Participants With SAEs and Non-SAEs in Cohort 2|Part A: Number of Participants With SAEs and Non-SAEs in Cohort 3|Part B: Number of Participants With SAEs and Non-SAEs|Part A: Number of Participants With Abnormal Findings After Physical Examination in Cohort 1|Part A: Number of Participants With Abnormal Findings After Physical Examination in Cohort 2|Part A: Number of Participants With Abnormal Findings After Physical Examination in Cohort 3|Part B: Number of Participants With Abnormal Findings After Physical Examination|Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings in Cohort 1 and Cohort 3|Part A: Number of Participants With Abnormal ECG Findings in Cohort 2|Part B: Number of Participants With Abnormal ECG Findings|Part A: Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) in Cohort 1 and Cohort 3|Part A: Change From Baseline in SBP and DBP in Cohort 2|Part B: Change From Baseline in SBP and DBP|Part A: Change From Baseline in Pulse Rate in Cohort 1 and Cohort 3|Part A: Change From Baseline in Pulse Rate in Cohort 2|Part B: Change From Baseline in Pulse Rate|Part A: Change From Baseline in Body Temperature in Cohort 1 and Cohort 3|Part A: Change From Baseline in Body Temperature in Cohort 2|Part B: Change From Baseline in Body Temperature|Part A: Number of Participants With Different Stool Types Assessed Using Bristol Stool Form Scale (BSFS) in Cohort 1|Part A: Number of Participants With Different Stool Types Assessed Using BSFS in Cohort 2|Part A: Number of Participants With Different Stool Types Assessed Using BSFS in Cohort 3|Part B: Average BSFS at Indicated Time Points|Part A: Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, Leukocytes in Cohort 1 and Cohort 3|Part A: Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, Leukocytes in Cohort 2|Part B: Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, Leukocytes|Part A: Change From Baseline in Erythrocytes in Cohort 1 and 3|Part A: Change From Baseline in Erythrocytes in Cohort 2|Part B: Change From Baseline in Erythrocytes|Part A: Change From Baseline in Hemoglobin in Cohort 1 and 3|Part A: Change From Baseline in Hemoglobin in Cohort 2|Part B: Change From Baseline in Hemoglobin|Part A: Change From Baseline in Erythrocyte Mean Corpuscular Volume (MCV) in Cohort 1 and Cohort 3|Part A: Change From Baseline in Erythrocyte MCV in Cohort 2|Part B: Change From Baseline in Erythrocyte MCV|Part A: Change From Baseline in Erythorocyte Mean Corpuscular Hemoglobin (MCH) in Cohort 1 and 3|Part A: Change From Baseline in Erythrocyte MCH in Cohort 2|Part B: Change From Baseline in Erythrocyte MCH|Part A: Change From Baseline in Hematocrit in Cohort 1 and 3|Part A: Change From Baseline in Hematocrit in Cohort 2|Part B: Change From Baseline in Hematocrit|Part A: Change From Baseline in Alanine Aminotransferase (ALT),Aspartate Aminotransferase (AST), Alkaline Phosphatase (Alk Phos) in Cohort 1 and 3|Part A: Change From Baseline in ALT, AST and Alk Phos in Cohort 2|Part B: Change From Baseline in ALT, AST and Alk Phos|Part A: Change From Baseline in Bilirubin, Creatinine, Direct Bilirubin in Cohort 1 and 3|Part A: Change From Baseline in Bilirubin, Creatinine, Direct Bilirubin in Cohort 2|Part B: Change From Baseline in Bilirubin, Creatinine, Direct Bilirubin|Part A: Change From Baseline in Calcium, Glucose, Potassium, Sodium, Urea in Cohort 1 and 3|Part A: Change From Baseline in Calcium, Glucose, Potassium, Sodium, Urea in Cohort 2|Part B: Change From Baseline in Calcium, Glucose, Potassium, Sodium, Urea|Part A: Change From Baseline in Albumin and Total Protein in Cohort 1 and 3|Part A: Change From Baseline in Albumin and Total Protein in Cohort 2|Part B: Change From Baseline in Albumin, Total Protein|Part A: Number of Participants With Abnormal Findings for Urine Parameters in Cohort 1 and Cohort 3|Part A: Number of Participants With Abnormal Findings for Urine Parameters in Cohort 2|Part B: Number of Participants With Abnormal Findings for Urine Parameters|Part A: Area Under the Concentration-time Curve From Time Zero (Pre-dose) to Last Non-zero Concentration (AUC [0-t]) Following Single Dose Administration of GSK3352589|Part A: Area Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC [0-infinity]) Following Single Dose Administration of GSK3352589|Part A: Maximum Observed Plasma Concentration (Cmax) Following Single Dose Administration of GSK3352589|Part A: Time to Reach Cmax (Tmax) Following Single Dose Administration of GSK3352589|Part A: Terminal Elimination Half-life (t1/2) Following Single Dose Administration of GSK3352589|Part A: Cmax Following Single Dose Administration of GSK3352589-Food Effect|Part A: AUC (0-t) Following Single Dose Administration of GSK3352589- Food Effect|Part A: AUC (0-infinity) Following Single Dose Administration of GSK3352589- Food Effect|Part B: AUC (0-t) Following Repeat Dose Administration of GSK3352589|Part B: Area Under the Concentration-time Curve From Time Zero (Pre-dose) to 24 Hours Post-dose (AUC [0-24]) Following Repeat Dose Administration of GSK3352589|Part B: Area Under the Concentration-time Curve Over the Dosing Interval (AUC [0-tau]) Following Repeat Dose Administration of GSK3352589|Part B: Cmax Following Repeat Dose Administration of GSK3352589|Part B: Tmax Following Repeat Dose Administration of GSK3352589","GlaxoSmithKline","All","18 Years to 55 Years   (Adult)","Phase 1","68","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","207440","May 17, 2017","March 5, 2018","March 5, 2018","May 15, 2017","August 9, 2019","August 9, 2019","GSK Investigational Site, Adelaide, South Australia, Australia","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/86/NCT03154086/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/86/NCT03154086/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03154086"
223,"NCT01352143","Thrombin Generation in Neonatal Plasma After Cardiopulmonary Bypass",,"Completed","No Results Available","Cardiopulmonary Bypass","Drug: Recombinant activated factor VII|Drug: Prothrombin Complex Concentrate","Peak thrombin Generation","Emory University|Children's Research Oversight Committee Funds","All","up to 30 Days   (Child)",,"24","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","IRB00048151","March 2011","June 2012","June 2012","May 11, 2011",,"November 20, 2013","Children's Healthcare of Atlanta, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT01352143"
224,"NCT02693249","Dysfunctional Posttraumatic Cognitions in Children and Adolescents","PTC","Completed","No Results Available","Motor Vehicle Accident|Burns",,"Child Posttraumatic Cognitions Inventory (CPTCI)|University of California at Los Angeles Post-Traumatic Stress Disorder Reaction Index DSM-5 version (UCLA PTSD RI DSM-5)|Children's Depression Inventory (CDI)|Screen for Child Anxiety Related Disorders (SCARED)","University Children's Hospital, Zurich","All","7 Years to 18 Years   (Child, Adult)",,"130","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","PB_2016-00275","February 2016","September 2018","September 2018","February 26, 2016",,"September 26, 2018","University Children's Hospital, Zurich, Switzerland",,"https://ClinicalTrials.gov/show/NCT02693249"
225,"NCT03185897","Global Epidemiologic Study of Preexisting Immunity to AAV in Adults With Severe Hemophilia",,"Completed","No Results Available","Hemophilia A|Hemophilia B","Other: Non-treatment, seroprevalence","Prevalence of neutralizing antibodies (NAb) - Baseline visit|Prevalence of neutralizing antibodies (NAb) - Year 1 Visit|Prevalence of neutralizing antibodies (NAb) - Year 2 Visit|Prevalence of neutralizing antibodies (NAb) - Year 3 Visit|Prevalence of NAb to AAV including AAV2 and AAV8|Prevalence of binding antibodies to AAV, including AAV8 and AAV2|T-cell mediated immune response to AAV8","Baxalta now part of Shire|Takeda","Male","18 Years to 75 Years   (Adult, Older Adult)",,"242","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","201601","June 14, 2017","March 17, 2021","March 17, 2021","June 14, 2017",,"October 25, 2021","Orthopaedic Hemophilia Treatment Center, Los Angeles, California, United States|University of Colorado Hemophilia & Thrombosis Center, Aurora, Colorado, United States|Michigan State University, East Lansing, Michigan, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Medical University of South Carolina (MUSC), Charleston, South Carolina, United States|Gulf States Hemophilia and Thrombophilia Center, Houston, Texas, United States|University of Washington, Seattle, Washington, United States|AKH - Medizinische Universität Wien, Vienna, Austria|Hôpital Morvan, Brest Cedex, France|Groupement Hospitalier Est- Hôpital Louis Pradel, Bron cedex, France|Groupement Hospitalier Sud - Hôpital Bicêtre, Le Kremlin Bicêtre cedex, France|Hopital Jeanne de Flandre - CHU Lille, Lille Cedex, France|Hôpital de la Timone, Marseille Cedex 05, France|CHU de Nantes Site Hotel Dieu, Nantes Cedex 1, France|Vivantes Klinikum im Friedrichshain, Berlin, Germany|Klinikum der Johann Wolfgang Goethe-Universitaet, Frankfurt, Germany|Presidio Ospedaliero di Castelfranco Veneto, Castelfranco Veneto, Italy|Azienda Ospedaliera Universitaria Careggi, Firenze, Italy|Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico, Milano, Italy|Ospedale San Bortolo di Vicenza, Vicenza, Italy|Hospital Universitario La Paz, Madrid, Spain|Hospital Regional Universitario de Malaga, Malaga, Spain|Hospital Universitario de Salamanca, Salamanca, Spain",,"https://ClinicalTrials.gov/show/NCT03185897"
226,"NCT02648399","Prospective Study on the Clinical Prognosis of Bilateral Central Lymph Node Dissection in the Patients With Unilateral Thyroid Papillary Carcinoma",,"Unknown status","No Results Available","Thyroid Papillary Carcinoma","Procedure: surgery：BCND（bilateral central lymph node dissection）|Procedure: surgery：UCND（unilateral central lymph node dissection）","tumor recurrence|numbers of metastatic lymph node|adverse events related to treatment|relations between the lymph metastasis and TNM staging|relations between the lymph metastasis and tumor location","Fujian Medical University","All","15 Years to 60 Years   (Child, Adult)","Not Applicable","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","wzhao","December 2015","December 2016","December 2016","January 7, 2016",,"January 7, 2016","Fujian Medical University Union Hospital, Fuzhou, Fujian, China",,"https://ClinicalTrials.gov/show/NCT02648399"
227,"NCT03248141","Understanding Hemophilia A and B Drug Dosage Administration Patterns",,"Terminated","Has Results","Hemophilia A|Hemophilia B","Drug: Hemophilia B standard half-life|Drug: Hemophilia B extended half-life|Drug: Hemophilia A standard half-life|Drug: Hemophilia A extended half-life","Resource Utilization Pattern|Dosing Pattern","Pfizer","All","Child, Adult, Older Adult",,"11","Industry","Observational","Observational Model: Cohort|Time Perspective: Other","B1821056|HEMOBAFS","September 1, 2017","March 14, 2018","March 14, 2018","August 14, 2017","May 20, 2019","May 20, 2019","University of Florida College of Medicine, Gainesville, Florida, United States|Alliance for Childhood Diseases, dba Hemophilia Treatment Center of Nevada, Las Vegas, Nevada, United States|Cook Children's Medical Center, Fort Worth, Texas, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/41/NCT03248141/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/41/NCT03248141/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03248141"
228,"NCT03300284","Decision Making and Psychological Outcomes in Low-Risk Papillary Thyroid Cancer",,"Active, not recruiting","No Results Available","Thyroid Cancer","Behavioral: Questionnaires","influencing decision making pre-visit|influencing decision making post-visit","Memorial Sloan Kettering Cancer Center","All","18 Years and older   (Adult, Older Adult)",,"186","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","17-382","August 7, 2017","August 2022","August 2022","October 3, 2017",,"August 6, 2021","Hartford Healthcare (Data Collection), Hartford, Connecticut, United States|Memoral Sloan Kettering Monmouth (Consent and Follow up), Middletown, New Jersey, United States|MAIMONIDES MEDICAL CENTER (Data collection only), Brooklyn, New York, United States|NYU Langone Health, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03300284"
229,"NCT02740335","Study of Octaplex, a Four-factor Prothrombin Complex Concentrate (4F-PCC) and Beriplex® P/N (Kcentra) for the Reversal of Vitamin K Antagonist (VKA) Induced Anticoagulation in Patients Needing Urgent Surgery With Significant Bleeding Risk.",,"Recruiting","No Results Available","Significant Bleeding Risk","Drug: Octaplex|Drug: Beriplex P/N (Kcentra)","Hemostatic efficacy rating|Correction of international normalized ratio (INR) to < 1.5|Coagulation Factor Levels|Number of patients requiring Red Blood Cells (RBC)","Octapharma","All","18 Years and older   (Adult, Older Adult)","Phase 3","370","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","LEX-209","June 8, 2017","December 2021","December 2021","April 15, 2016",,"July 28, 2021","Octapharma Research Site, Aurora, Colorado, United States|Octapharma Research Site, New Haven, Connecticut, United States|Octapharma Research Site, Miami, Florida, United States|Octapharma Research Site, Tampa, Florida, United States|Octapharma Research Site, Iowa City, Iowa, United States|Octapharma Research Site, Boston, Massachusetts, United States|Octapharma Research Site, Rochester, New York, United States|Octapharma Research Site, Durham, North Carolina, United States|Octapharma Research Site, Cleveland, Ohio, United States|Octapharma Research Site, Columbus, Ohio, United States|Octapharma Research Site, Dayton, Ohio, United States|Octapharma Research Site, Fairborn, Ohio, United States|Octapharma Research Site, Pittsburgh, Pennsylvania, United States|Octapharma Study Site, Pittsburgh, Pennsylvania, United States|Octapharma Research Site, Pittsburgh, Pennsylvania, United States|Octapharma Research Site, Pittsburgh, Pennsylvania, United States|Octapharma Research Site, Pittsburgh, Pennsylvania, United States|Octapharma Research Site (0115), Austin, Texas, United States|Octapharma Research Site (0127), Austin, Texas, United States|Octapharma Research Site, Dallas, Texas, United States|Octapharma Research Site, Round Rock, Texas, United States|Octapharma Research Site, Puyallup, Washington, United States|Octapharma Research Site, Lesnoy, Belarus|Octapharma Research Site, Minsk, Belarus|Octapharma Research Site, Minsk, Belarus|Octapharma Research Site, Minsk, Belarus|Octapharma Research Site, Plovdiv, Bulgaria|Octapharma Research Site, Ruse, Bulgaria|Octapharma Research Site, Sofia, Bulgaria|Octapharma Study Site, Sofia, Bulgaria|Octapharma Research Site, Varna, Bulgaria|Octapharma Research Site, Batumi, Georgia|Octapharma Research Site, Kutaisi, Georgia|Octapharma Research Site - Tbilisi, Tbilisi, Georgia|Octapharma Research Location - Tbilisi, Tbilisi, Georgia|Octapharma Research Site, Tbilisi, Georgia|Octapharma Research Location, Tbilisi, Georgia|Octapharma Research Site, Tbilisi, Georgia|Octapharma Research Site, Zugdidi, Georgia|Octapharma Research Site, Berlin, Germany|Octapharma Research Site, Dresden, Germany|Octapharma Research Site, Frankfurt am Main, Germany|Octapharma Research Site, Heidelberg, Germany|Octapharma Research Site, Chisinau, Moldova, Republic of|Octapharma Research Site, Chisinau, Moldova, Republic of|Octapharma Research Site, Chisinau, Moldova, Republic of|Octapharma Research Site, Bochnia, Poland|Octapharma Research Site, Łódź, Poland|Octapharma Research Site, Bucharest, Romania|Octapharma Research Site, Bucharest, Romania|Octapharma Research Site, Cluj-Napoca, Romania|Octapharma Research Site, Craiova, Romania|Octapharma Research Site, Oradea, Romania|Octapharma Research Site, Timişoara, Romania|Octapharma Research Site, Moscow, Russian Federation|Octapharma Research Site, Moscow, Russian Federation|Octapharma Research Site, Moscow, Russian Federation|Octapharma Research Site, Moscow, Russian Federation|Octapharma Research Site, Novosibirsk, Russian Federation|Octapharma Research Site, Omsk, Russian Federation|Octapharma Research Site, Saint Petersburg, Russian Federation|Octapharma Research Site, Saint Petersburg, Russian Federation|Octapharma Research Site, Saint Petersburg, Russian Federation|Regional Clinical Hospital, Saratov, Russian Federation|Octapharma Research Site, Smolensk, Russian Federation|Octapharma Research Site, Tver, Russian Federation|Octapharma Research Site, Yekaterinburg, Russian Federation|Octapharma Research Site, Barcelona, Spain|Octapharma Research Site, Palma De Mallorca, Spain|Octapharma Research Site, Valencia, Spain|Octapharma Research Site, Cherkasy, Ukraine|Octapharma Research Site, Chernivtsi, Ukraine|Octapharma Research Location, Dnipro, Ukraine|Octapharma Research Site, Dnipro, Ukraine|Octapharma Research Site, Dnipro, Ukraine|Octapharma Research Site, Ivano-Frankivs'k, Ukraine|Octapharma Research Site, Kharkiv, Ukraine|Octapharma Research Site, Kharkiv, Ukraine|Octapharma Research Site, Kropyvnytskyi, Ukraine|Octapharma Research Site, Kyiv, Ukraine|Octapharma Research Site, L'viv, Ukraine|Octapharma Research Site, Luts'k, Ukraine|Octapharma Research Site, Lviv, Ukraine|Octapharma Research Site, Odesa, Ukraine|Octapharma Research Site, Vinnytsia, Ukraine|Octapharma Research Site, Vinnytsya, Ukraine|Octapharma Research Site, Zaporizhzhya, Ukraine|Octapharma Research Site, Zhytomyr, Ukraine",,"https://ClinicalTrials.gov/show/NCT02740335"
230,"NCT02267499","Combined Cognitive and Physical Exercises Through Computer Games in Elderly: The LLM Project","LLM","Completed","No Results Available","Mild Cognitive Impairment|Mild Dementia|Healthy","Other: LLM training","overall cognition|physical fitness|Episodic memory|working memory|executive function|Quality of Life|Instrumental Activities of daily living|Depressive symptoms|Brain function","Aristotle University Of Thessaloniki|National and Kapodistrian University of Athens|University of Ulm|Greek Alzheimer's Association and Related Disorders","All","55 Years and older   (Adult, Older Adult)","Not Applicable","322","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","84171|238904","November 2010","April 2012","April 2013","October 17, 2014",,"October 20, 2014",,,"https://ClinicalTrials.gov/show/NCT02267499"
231,"NCT03813706","the Dissection of Lymph Node Posterior to Right Recurrent Laryngeal Nerve for Papillary Thyroid Carcinoma",,"Not yet recruiting","No Results Available","Lymph Node Metastases","Procedure: lymph node dissection","Recurrence of thyroid cancer","Zhejiang University","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","4000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ZhejiangU20190115","January 2020","December 2040","December 2040","January 23, 2019",,"July 5, 2019",,,"https://ClinicalTrials.gov/show/NCT03813706"
232,"NCT00085293","Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131",,"Completed","Has Results","Recurrent Thyroid Cancer|Stage IVA Follicular Thyroid Cancer|Stage IVA Papillary Thyroid Cancer|Stage IVB Follicular Thyroid Cancer|Stage IVB Papillary Thyroid Cancer|Stage IVC Follicular Thyroid Cancer|Stage IVC Papillary Thyroid Cancer","Drug: Decitabine|Radiation: Iodine I 131|Biological: Recombinant thyrotropin alfa|Radiation: Fludeoxyglucose F 18|Procedure: Positron emission tomography","Restoration of Radioiodine Uptake in Metastatic Lesions as Demonstrated by Diagnostic Whole-body Scanning After Decitabine Administration|Frequency of Adverse Events According to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0|Efficacy of Subsequent Radioiodine Therapy in Terms of CR/PR/SD of Any Radiographic Disease.|Change in Fludeoxyglucose (FDG) Uptake Measured by Positron Emission Tomography in Metastatic Tumor Sites Before and After DNA-methyltransferase Inhibitor Therapy (Optional). No Secondary Endpoints Were Measured as no Patient Met the Primary Endpoint.|Efficacy of Subsequent Radioiodine Therapy in Terms of Complete Response (CR)/Partial Response (PR)/Stable Disease (SD) of Any Radiographic Disease|Efficacy of Subsequent Radioiodine Therapy in Terms of Change in Serum Thyroglobulin Level|Efficacy of Subsequent Radioiodine Therapy in Terms of Change in Serum Thyroglobulin Level.These Secondary Endpoints Would Only Have Been Assessed if a Patient Had Met the Primary Endpoint, Restoration of Radioiodine Uptake to Justify Radioiodine Therapy.","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","12","NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2009-00033|CDR0000368467|5954|2003-0308|P30CA016672|N01CM62207","May 2004","January 2014","May 2014","June 11, 2004","September 1, 2014","November 29, 2018","University of Colorado at Denver, Aurora, Colorado, United States|Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States|M D Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00085293"
233,"NCT04683250","Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities","(MARGARET)","Recruiting","No Results Available","RET-altered Non Small Cell Lung Cancer|RET-altered Solid Tumors","Drug: TAS0953/HM06","Phase 1 (dose-escalation): Maximum Tolerated Dose (MTD)|Phase 1 (dose-expansion): Recommended Phase 2 dose (RP2D)|Phase 2: Objective Response Rate (ORR) by independent data monitoring committee (IDMC)|Phase 1 (dose expansion): Objective Response Rate (ORR) by IDMC|Phase 2: ORR by Investigator|Phase 2: Disease Control Rate (DCR)|Phase 2: Time to Tumor Response (TTR)|Phase 2: Progression Free Survival (PFS)|Phase 2: Time to Progression (TTP)|Phase 2: Duration of Response (DOR)|Phase 2: Overall Survival (OS)|Phase 2: Central Nervous System (CNS) ORR (C-ORR)|Phase 2: Central Nervous System DOR (C-DOR)|Phase 2: Time to CNS progression|Phase 1 (dose-escalation): Area under the plasma concentration versus time curve from time 0 to 12 hours (AUC0-12)|Phase 1 (dose-escalation): AUC0-24|Phase 1 (dose-escalation): AUC0-infinity|Phase 1 (dose-escalation): AUC0-12 at steady state|Phase 1 (dose-escalation): Maximum drug concentration (Cmax)|Phase 1 (dose-escalation): Trough drug concentration at 12 hours (Ctrough)|Phase 1 (dose-escalation): Time to maximum plasma concentration (tmax)|Phase 1 (dose-escalation): Terminal half-life (t1/2)|Phase 1 (dose-escalation): Accumulation factor based on Cmax (Rmax)|Phase 1 (dose-escalation): Accumulation factor based on Ctrough (Rmin)|Phase 1 (dose-escalation): Terminal rate constant (lambda_z)|Phase 1 (dose-escalation): Volume of Distribution (Vz/F)|Phase 1 (dose-escalation): Systemic clearance (CL/F)|Phase 1 (dose-escalation): Amount excreted in 0-24 hour urine (Ae0-24)|Phase 1 (dose-escalation): Renal Clearance (CL_R)|Phase 1 (dose-expansion): AUC0-12 at steady state|Phase 1 (dose-expansion): Maximum drug concentration (Cmax)|Phase 1 (dose-expansion): Trough drug concentration at 12 hours (Ctrough)|Phase 1 (dose-expansion): Time to maximum plasma concentration (tmax)|Phase 1 (dose-expansion): Terminal rate constant (lambda_z)|Phase 1 (dose-expansion): Terminal half-life (t1/2)|Phase 2 Population PK: Typical value of absorption rate constant (Ka)|Phase 2 Population PK: Typical value of CL/F|Phase 2 Population PK: Typical value of volume of distribution (V/F)|Phase 1: Incidence of abnormal electrocardiograms (ECG QT interval). QT will be corrected for heart rate (QTc) using Fridericia's formula (QTcF).|Phase 1: Incidence of treatment-emergent adverse events (TEAEs)|Phase 1: Incidence of serious adverse events (SAEs)|Phase 2: Incidence of abnormal electrocardiograms (ECG QT interval). QT will be corrected for heart rate (QTc) using Fridericia's formula (QTcF).|Phase 2: Incidence of treatment-emergent adverse events (TEAEs)|Phase 2: Incidence of serious adverse events (SAEs)","Helsinn Healthcare SA|ICON Clinical Research","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","202","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HM06-19-26","December 16, 2020","December 2023","August 2024","December 24, 2020",,"December 14, 2021","Chao Family Comprehensive Cancer Center, Orange, California, United States|Stanford Cancer Center, Stanford, California, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|START Midwest - Cancer & Hematology Centers of Western Michigan, Grand Rapids, Michigan, United States|Laura and Isaac Perlmutter Cancer Center at NYU Langone Health, New York, New York, United States|The Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee, United States|The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States|National Cancer Center Hospital East, Kashiwa-shi, Chiba, Japan",,"https://ClinicalTrials.gov/show/NCT04683250"
234,"NCT02281201","Study of a Prothrombin Complex Concentrate for Rapid Reversal of Coagulopathy Induced by Vitamin K Antagonists in Japanese Subjects",,"Completed","No Results Available","Acute Major Bleeding|Reversal of Coagulopathy","Biological: BE1116 (Prothrombin Complex Concentrate)","Percentage of Subjects With a Rapid Reversal of VKA Effect|Percentage of Subjects Achieving Hemostatic Efficacy During Surgery|Percentage of Subjects Achieving Hemostatic Efficacy of Stopping an Ongoing Major Bleed|Increase in Plasma Levels of Factor (F)II, FVII, FIX, and FX, and Protein C and Protein S|Percentage of Subjects With INR Correction|Percentage of Subjects With INR Correction at Various Times After the End of Infusion|Percentage of Subjects Who Receive Red Blood Cells|Percentage of Subjects Who Receive Other Blood Products and Hemostatic Agents|45-Day All-cause Mortality|Overall Treatment-emergent Adverse Events (TEAEs)|Mean modified Rankin Scale for all subjects with intracranial haemorrhage|Mean Predicted and Actual Blood Loss (mls) for all Surgical/Invasive Procedures|Mean Volume (mls) of Wound Drainage for all Surgical/Invasive Procedures|Mean Time (mins) Between Last Suture and Cessation of Wound Drainage for all Surgical/Invasive Procedure|Vital signs|Viral serology","CSL Behring","All","20 Years and older   (Adult, Older Adult)","Phase 3","11","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BE1116_3004","October 2014","January 2016","March 2016","November 2, 2014",,"May 4, 2016","Nippon Medical School Hospital, Sendagi, Bunkyo, Japan|Kyushu Medical Center, Chuo-ku, Fukuoka, Japan|Nippon Medical School Chiba Hokusoh Hospital, Kamagari, Inzai, Japan|Kurashiki Central Hospital, Miwa, Kurashiki, Japan|Osaka National Hospital, Chuo-ku, Osaka, Japan|Kinki University, Higashiosaka, Osaka, Japan|National Cerebral and Cardiovascular Center, Suita, Osaka, Japan|Tohoku University Hospital, Aoba-ku, Sendai, Japan|National Center for Global Health and Medicine, Toyama, Shinjuku, Japan|Osaka University Hospital, Yamadaoka, Suita, Japan|St. Luke's International Hospital, Chuo, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT02281201"
235,"NCT04320888","Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial",,"Recruiting","No Results Available","Hematopoietic and Lymphoid Cell Neoplasm|Recurrent Ependymoma|Recurrent Ewing Sarcoma|Recurrent Hepatoblastoma|Recurrent Histiocytic and Dendritic Cell Neoplasm|Recurrent Langerhans Cell Histiocytosis|Recurrent Lymphoma|Recurrent Malignant Germ Cell Tumor|Recurrent Malignant Glioma|Recurrent Malignant Solid Neoplasm|Recurrent Medulloblastoma|Recurrent Neuroblastoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Osteosarcoma|Recurrent Peripheral Primitive Neuroectodermal Tumor|Recurrent Rhabdoid Tumor|Recurrent Rhabdomyosarcoma|Recurrent Soft Tissue Sarcoma|Recurrent WHO Grade II Glioma|Refractory Ependymoma|Refractory Ewing Sarcoma|Refractory Hepatoblastoma|Refractory Histiocytic and Dendritic Cell Neoplasm|Refractory Langerhans Cell Histiocytosis|Refractory Lymphoma|Refractory Malignant Germ Cell Tumor|Refractory Malignant Glioma|Refractory Malignant Solid Neoplasm|Refractory Medulloblastoma|Refractory Neuroblastoma|Refractory Non-Hodgkin Lymphoma|Refractory Osteosarcoma|Refractory Peripheral Primitive Neuroectodermal Tumor|Refractory Rhabdoid Tumor|Refractory Rhabdomyosarcoma|Refractory Soft Tissue Sarcoma|Refractory WHO Grade II Glioma|Wilms Tumor","Drug: Selpercatinib","Objective response rate (complete response + partial response) in pediatric patients treated with selpercatinib (LOXO-292)|Progression-free survival (PFS)|Percentage of patients experiencing grade 3 or 4 adverse events","National Cancer Institute (NCI)|Children's Oncology Group","All","12 Months to 21 Years   (Child, Adult)","Phase 2","49","NIH|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2020-01756|APEC1621N|U10CA180886","September 14, 2020","September 30, 2027","September 30, 2027","March 25, 2020",,"January 12, 2022","Children's Hospital of Alabama, Birmingham, Alabama, United States|Providence Alaska Medical Center, Anchorage, Alaska, United States|Banner Children's at Desert, Mesa, Arizona, United States|Phoenix Childrens Hospital, Phoenix, Arizona, United States|Banner University Medical Center - Tucson, Tucson, Arizona, United States|Arkansas Children's Hospital, Little Rock, Arkansas, United States|Kaiser Permanente Downey Medical Center, Downey, California, United States|City of Hope Comprehensive Cancer Center, Duarte, California, United States|Loma Linda University Medical Center, Loma Linda, California, United States|Miller Children's and Women's Hospital Long Beach, Long Beach, California, United States|Children's Hospital Los Angeles, Los Angeles, California, United States|Cedars Sinai Medical Center, Los Angeles, California, United States|Mattel Children's Hospital UCLA, Los Angeles, California, United States|Valley Children's Hospital, Madera, California, United States|UCSF Benioff Children's Hospital Oakland, Oakland, California, United States|Kaiser Permanente-Oakland, Oakland, California, United States|Children's Hospital of Orange County, Orange, California, United States|Lucile Packard Children's Hospital Stanford University, Palo Alto, California, United States|University of California Davis Comprehensive Cancer Center, Sacramento, California, United States|Rady Children's Hospital - San Diego, San Diego, California, United States|Naval Medical Center -San Diego, San Diego, California, United States|UCSF Medical Center-Mission Bay, San Francisco, California, United States|Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center, Denver, Colorado, United States|Connecticut Children's Medical Center, Hartford, Connecticut, United States|Yale University, New Haven, Connecticut, United States|Alfred I duPont Hospital for Children, Wilmington, Delaware, United States|MedStar Georgetown University Hospital, Washington, District of Columbia, United States|Children's National Medical Center, Washington, District of Columbia, United States|Broward Health Medical Center, Fort Lauderdale, Florida, United States|Golisano Children's Hospital of Southwest Florida, Fort Myers, Florida, United States|University of Florida Health Science Center - Gainesville, Gainesville, Florida, United States|Memorial Regional Hospital/Joe DiMaggio Children's Hospital, Hollywood, Florida, United States|Nemours Children's Clinic-Jacksonville, Jacksonville, Florida, United States|University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States|Nicklaus Children's Hospital, Miami, Florida, United States|Miami Cancer Institute, Miami, Florida, United States|AdventHealth Orlando, Orlando, Florida, United States|Arnold Palmer Hospital for Children, Orlando, Florida, United States|Nemours Children's Hospital, Orlando, Florida, United States|Sacred Heart Hospital, Pensacola, Florida, United States|Johns Hopkins All Children's Hospital, Saint Petersburg, Florida, United States|Tampa General Hospital, Tampa, Florida, United States|Saint Joseph's Hospital/Children's Hospital-Tampa, Tampa, Florida, United States|Saint Mary's Hospital, West Palm Beach, Florida, United States|Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States|Memorial Health University Medical Center, Savannah, Georgia, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States|Saint Luke's Cancer Institute - Boise, Boise, Idaho, United States|Lurie Children's Hospital-Chicago, Chicago, Illinois, United States|University of Illinois, Chicago, Illinois, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Saint Jude Midwest Affiliate, Peoria, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|Saint Vincent Hospital and Health Care Center, Indianapolis, Indiana, United States|Blank Children's Hospital, Des Moines, Iowa, United States|University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States|University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States|Norton Children's Hospital, Louisville, Kentucky, United States|Children's Hospital New Orleans, New Orleans, Louisiana, United States|Ochsner Medical Center Jefferson, New Orleans, Louisiana, United States|Eastern Maine Medical Center, Bangor, Maine, United States|Maine Children's Cancer Program, Scarborough, Maine, United States|University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States|Sinai Hospital of Baltimore, Baltimore, Maryland, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|National Institutes of Health Clinical Center, Bethesda, Maryland, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|UMass Memorial Medical Center - University Campus, Worcester, Massachusetts, United States|C S Mott Children's Hospital, Ann Arbor, Michigan, United States|Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States|Helen DeVos Children's Hospital at Spectrum Health, Grand Rapids, Michigan, United States|Bronson Methodist Hospital, Kalamazoo, Michigan, United States|Beaumont Children's Hospital-Royal Oak, Royal Oak, Michigan, United States|Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis, Minnesota, United States|University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Children's Mercy Hospitals and Clinics, Kansas City, Missouri, United States|Cardinal Glennon Children's Medical Center, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Mercy Hospital Saint Louis, Saint Louis, Missouri, United States|Children's Hospital and Medical Center of Omaha, Omaha, Nebraska, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|University Medical Center of Southern Nevada, Las Vegas, Nevada, United States|Sunrise Hospital and Medical Center, Las Vegas, Nevada, United States|Alliance for Childhood Diseases/Cure 4 the Kids Foundation, Las Vegas, Nevada, United States|Summerlin Hospital Medical Center, Las Vegas, Nevada, United States|Renown Regional Medical Center, Reno, Nevada, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Morristown Medical Center, Morristown, New Jersey, United States|Saint Peter's University Hospital, New Brunswick, New Jersey, United States|Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States|Albany Medical Center, Albany, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|NYU Winthrop Hospital, Mineola, New York, United States|The Steven and Alexandra Cohen Children's Medical Center of New York, New Hyde Park, New York, United States|Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States|NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|NYP/Weill Cornell Medical Center, New York, New York, United States|University of Rochester, Rochester, New York, United States|Stony Brook University Medical Center, Stony Brook, New York, United States|State University of New York Upstate Medical University, Syracuse, New York, United States|New York Medical College, Valhalla, New York, United States|Mission Hospital, Asheville, North Carolina, United States|UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Carolinas Medical Center/Levine Cancer Institute, Charlotte, North Carolina, United States|Novant Health Presbyterian Medical Center, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|East Carolina University, Greenville, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Sanford Broadway Medical Center, Fargo, North Dakota, United States|Children's Hospital Medical Center of Akron, Akron, Ohio, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Rainbow Babies and Childrens Hospital, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Dayton Children's Hospital, Dayton, Ohio, United States|ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital, Toledo, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Legacy Emanuel Children's Hospital, Portland, Oregon, United States|Oregon Health and Science University, Portland, Oregon, United States|Lehigh Valley Hospital-Cedar Crest, Allentown, Pennsylvania, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Saint Christopher's Hospital for Children, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Prisma Health Richland Hospital, Columbia, South Carolina, United States|BI-LO Charities Children's Cancer Center, Greenville, South Carolina, United States|Sanford USD Medical Center - Sioux Falls, Sioux Falls, South Dakota, United States|T C Thompson Children's Hospital, Chattanooga, Tennessee, United States|East Tennessee Childrens Hospital, Knoxville, Tennessee, United States|Saint Jude Children's Research Hospital, Memphis, Tennessee, United States|The Children's Hospital at TriStar Centennial, Nashville, Tennessee, United States|Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States|Dell Children's Medical Center of Central Texas, Austin, Texas, United States|Driscoll Children's Hospital, Corpus Christi, Texas, United States|Medical City Dallas Hospital, Dallas, Texas, United States|UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States|El Paso Children's Hospital, El Paso, Texas, United States|Cook Children's Medical Center, Fort Worth, Texas, United States|Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, United States|M D Anderson Cancer Center, Houston, Texas, United States|Covenant Children's Hospital, Lubbock, Texas, United States|UMC Cancer Center / UMC Health System, Lubbock, Texas, United States|Children's Hospital of San Antonio, San Antonio, Texas, United States|Methodist Children's Hospital of South Texas, San Antonio, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Scott and White Memorial Hospital, Temple, Texas, United States|Primary Children's Hospital, Salt Lake City, Utah, United States|University of Vermont and State Agricultural College, Burlington, Vermont, United States|Children's Hospital of The King's Daughters, Norfolk, Virginia, United States|Naval Medical Center - Portsmouth, Portsmouth, Virginia, United States|Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States|Seattle Children's Hospital, Seattle, Washington, United States|Providence Sacred Heart Medical Center and Children's Hospital, Spokane, Washington, United States|Mary Bridge Children's Hospital and Health Center, Tacoma, Washington, United States|Madigan Army Medical Center, Tacoma, Washington, United States|West Virginia University Healthcare, Morgantown, West Virginia, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Marshfield Medical Center-Marshfield, Marshfield, Wisconsin, United States|Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States|University Pediatric Hospital, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT04320888"
236,"NCT03470259","Precision Thyroid Cancer Surgery With Molecular Fluorescent Guided Imaging","TARGET","Completed","No Results Available","Papillary Thyroid Cancer|Lymph Node Metastases","Drug: IV adminstration of EMI-137|Device: Multispectral Fluorescence Reflectance Imaging|Device: Spectroscopy","The feasibility of Molecular Fluorescence Guided Surgery using EMI-137|Safety of using EMI-137 through monitoring vital signs|Safety of using EMI-137 through monitoring injection site|Feasibility of MFGS for detecting nodal metastasis|Feasibility of spectroscopy for detecting fluorescence of PTC and lymph nodes|Validation of flourescence|Distribution of EMI-137|Sensitivity and specificity of EMI-137","University Medical Center Groningen|Erasmus Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 1","19","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","NL62817.042.17","June 20, 2018","December 31, 2019","December 31, 2019","March 19, 2018",,"January 18, 2020","University Medical Center Groningen, Groningen, Netherlands|Erasmus Medical Center, Rotterdam, Netherlands",,"https://ClinicalTrials.gov/show/NCT03470259"
237,"NCT04114643","Factor Replacement in Surgery","FARES","Active, not recruiting","No Results Available","Bleeding in Cardiac Surgery","Biological: Prothrombin Complex Concentrate|Biological: Frozen Plasma","Treatment response|Amount of allogeneic blood products|Number of patients who do not receive any RBC transfusions or any allogeneic blood transfusions","University Health Network, Toronto","All","18 Years and older   (Adult, Older Adult)","Phase 2","103","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Other","19-5393","September 24, 2019","July 21, 2020","December 31, 2020","October 3, 2019",,"November 3, 2020","Sunnybrook Health Science Centre, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04114643"
238,"NCT03886818","Efficacy of Negative Pressure Wound Therapy After Total Ankle Arthroplasty","PICO-PTC","Recruiting","No Results Available","Ankle Disease","Device: Standard dressings|Device: PICO strategy","Number of days from suture removal (i.e. day 21 after surgery) to achieve complete wound healing defined as: no visible exudate on protection dressing; and no blister; and no necrosis; and no wound dehiscence.|Rate of technical failures of the PICO™ device, and type of failure: device failure, non-hermetic dressing, other.|Number and type of adverse effects related to the PICO™ device.|Rate of wound healing complications: presence of exudate; blister; necrosis; wound dehiscence.|Rate of surgical site infection (superficial, deep or of a surgical site other than the incision site).|Rate of surgical revision for wound healing complications defined by: mechanical debridement; surgical debridement; flap surgery and skin graft.|Incremental Cost-Effectiveness Ratio (ICER) between the two dressing strategies.","Hospices Civils de Lyon","All","18 Years and older   (Adult, Older Adult)","Not Applicable","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","69HCL18_0753","March 25, 2019","March 25, 2022","March 25, 2022","March 22, 2019",,"June 29, 2021","Service de Chirurgie orthopédique - Groupement Hospitalier Lyon Sud, Lyon, France",,"https://ClinicalTrials.gov/show/NCT03886818"
239,"NCT03304314","Multifocal Chromatic Pupilloperimetry in Patients With Pseudotumor Cerebri and Healthy Subjects.",,"Recruiting","No Results Available","Pseudotumor Cerebri","Diagnostic Test: objective chromatic multifocal pupillometer","Measurement of maximal precentage of pupil contraction and dilation in response to chromatic light stimulus|Measurement of maximal velocity of pupil contraction and dilation in response to chromatic light stimulus|Measurement of latency of pupil contraction and dilation in response to chromatic light stimulus|Subjective visual field|Optic nerve structure by OCT|Change from baseline pupil contraction and dilation precentage in PCT patients at 48 hours|Change from baseline pupil contraction and dilation maximal velocity in PCT patients at 48 hours|Change from baseline pupil contraction and dilation latency in PCT patients at 48 hours|Change from baseline pupil contraction and dilation precentage in PCT patients at 1 week.|Change from baseline pupil contraction and dilation maximal velocity in PCT patients at 1 week.|Change from baseline pupil contraction and dilation latency in PCT patients at 1 week.|Change from baseline pupil contraction and dilation precentage in PCT patients at 2 months.|Change from baseline pupil contraction and dilation maximal velocity in PCT patients at 2 months.|Change from baseline pupil contraction and dilation latency in PCT patients at 2 months.","Sheba Medical Center","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","SHEBA-17-3754-YR-CTIL","November 3, 2017","December 31, 2021","December 31, 2021","October 9, 2017",,"March 20, 2020","Sheba Medical Center, Tel HaShomer, Israel",,"https://ClinicalTrials.gov/show/NCT03304314"
240,"NCT03489291","Dose Confirmation Trial of AAV5-hFIXco-Padua",,"Active, not recruiting","No Results Available","Hemophilia B","Genetic: AAV5-hFIXco-Padua (AMT-061)","FIX activity levels|Usage of FIX replacement therapy|Annualized Bleeding Rate|Adverse Events","UniQure Biopharma B.V.","Male","18 Years and older   (Adult, Older Adult)","Phase 2","3","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CT-AMT-061-01","July 24, 2018","October 30, 2018","September 20, 2023","April 5, 2018",,"May 26, 2020","Los Angeles Orthopedic Hospital, Los Angeles, California, United States|University of California, Davis, Sacramento, California, United States|University of California, San Diego, San Diego, California, United States|University of Michigan, Ann Arbor, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT03489291"
241,"NCT02796222","Factor Product Utilization and Health Outcomes in Patients With Hemophilia",,"Completed","No Results Available","Hemophilia A, Congenital|Hemophilia B, Congenital",,"Change in the total annualized factor consumption (in units/kilogram/year)|Change in health-related quality of life (HRQoL) SF-36|Change in health-related quality of life (HRQoL) Haem-A-Qol|Change in health-related quality of life (HRQoL) CHO-KLAT|Change in the Work Productivity and Impairment Questionnaire (WPAI+CIQ: HS) score|Change in chronic pain Numeric Rating Scale (0-10)|Change in chronic pain ""Bodily Pain"" subscale of SF-36|Change in physical activity (IPAQ)|Change in physical activity ""Physical Functioning"" subscale of SF-36.|Change in treatment satisfaction ""Treatment"" domain of Haem-A-QoL|Change in treatment satisfaction abbreviated 9-item Treatment Satisfaction Questionnaire for Medication (TSQM-9) questionnaire.|Change in mood ""Mental Health"" subscale of SF-36|Change in mood partner/caregiver subjective assessment numeric rating scale (0-10)|Clinicians' and patients' reason for switching to rFVIIIFc|Clinicians' and patients' reason for switching to rFIXFc|Product used for treatment of breakthrough bleeding and surgical procedures|Total annualized number of factor infusions|Annualized bleeding rate|Ratio of annual factor consumption-to-annual factor prescription|Number of infusions required to treat a breakthrough bleed|Incremental factor utilization per joint bleed avoided|Adverse events leading to permanent discontinuation of rFVIIIFc or rFIXFc|Serious adverse events","University of British Columbia|Biogen","Male","12 Years and older   (Child, Adult, Older Adult)",,"61","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","CAN-FAB-15-10911","April 2016","April 26, 2021","April 26, 2021","June 10, 2016",,"April 28, 2021","BC Hemophilia Adult Program, Vancouver, British Columbia, Canada",,"https://ClinicalTrials.gov/show/NCT02796222"
242,"NCT02561923","A Study to Assess the Independent Effects of 4-Factor Prothrombin Complex Concentrate and Tranexamic Acid on Bleeding/Pharmacodynamics in Healthy Participants",,"Completed","No Results Available","Healthy","Drug: Rivaroxaban|Drug: Tranexamic acid|Drug: Kcentra, a 4-factor PCC|Drug: Saline","Change From Baseline in Blood Volume in Part 1|Change From Baseline in Bleeding Duration in Part 1|Mean Change in Thrombin Generation Assay (TGA) - Endogenous Thrombin Potential (ETP) Lag-time in Part 2|Mean Change in Thrombin Generation Assay (TGA) - Endogenous Thrombin Potential (ETP) Peak in Part 2|Mean Change in Thrombin Generation Assay (TGA) - Endogenous Thrombin Potential (ETP) Time to Peak in Part 2|Mean Change in Thrombin Generation Assay (TGA) - Endogenous Thrombin Potential (ETP) Area Under Curve (AUC) in Part 2|Mean Change in Prothrombin Time (PT) in Part 2|Change From Baseline in Blood Volume in Part 2|Change From Baseline in Bleeding Duration in Part 2|Maximum Observed Plasma Concentration (Cmax) in Part 1|Time to Maximum Observed Plasma Concentration in Part 1 (Tmax)|Area under Plasma Concentration Time Curve From Time 0 to 24 in Part 1 (AUC [0 TO 24]|Maximum Observed Plasma Concentration (Cmax) in Part 2|Minimum Observed Plasma Concentration (Cmin) in Part 2|Time to Maximum Observed Plasma Concentration (Tmax) in Part 2|Area under plasma concentration time curve during the dosing interval (AUCtau) in Part 2|Mean Change in Thrombin Generation Assay (TGA) Endogenous Thrombin Potential (ETP) Lag-time in Part 1|Mean Change in Thrombin Generation Assay (TGA) Endogenous Thrombin Potential (ETP) Peak in Part 1|Mean Change in Thrombin Generation Assay (TGA) Endogenous Thrombin Potential (ETP) Time to Peak in Part 1|Mean Change in Thrombin Generation Assay (TGA) Endogenous Thrombin Potential (ETP) Area Under Curve (AUC) in Part 1|Mean Change in Prothrombin Time (PT) in Part 1|Trough Plasma Concentration (Ctrough) in Part 2|Number of Participants With Adverse Events as a Measure of Safety and Tolerability","Janssen Scientific Affairs, LLC|Bayer","All","18 Years to 55 Years   (Adult)","Phase 1","158","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CR107832|39039039NAP1004","August 27, 2015","June 17, 2016","June 17, 2016","September 28, 2015",,"June 14, 2017","Overland Park, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT02561923"
243,"NCT02697721","Powerful Tools for Caregivers of Dementia Patients","PTC-dementia","Completed","No Results Available","Caregivers|Dementia|Alzheimer Disease","Behavioral: Powerful Tools for Caregivers|Other: Control with delayed intervention","Caregiver Burden|Frequency and reaction to care recipient behavioral and psychological symptoms of dementia|Frequency of care recipient agitated behaviors|Activity parameters as assessed by FitBit|Depressive symptoms|Caregiving Self-Efficacy|Self-rated health|Life satisfaction|Perceived change|Neuropsychiatric symptoms in care recipients","Florida State University|Florida Department of Health","All","18 Years and older   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","6AZ09","February 2016","May 30, 2018","February 2019","March 3, 2016",,"January 29, 2021","Florida State University College of Medicine, Tallahassee, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02697721"
244,"NCT00496106","Stress, Immunity and Cervical Cancer: Biobehavioral Outcomes","CXR01","Completed","No Results Available","Ovarian Cancer","Behavioral: Telephone counseling|Behavioral: Telephone interview","To evaluate the efficacy of a multicomponent biobehavioral psychosocial telephone counseling (PTC) intervention for cervical cancer survivors, compared to usual care|To evaluate the longitudinal immune and neuroendocrine parameters in cervical cancer patients who have received the PTC intervention, compared to usual care","University of California, Irvine|National Institutes of Health (NIH)|National Cancer Institute (NCI)","Female","21 Years and older   (Adult, Older Adult)","Not Applicable","204","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","2005-4526|R01CA118136-01A1","August 2007","August 2010","February 2011","July 4, 2007",,"March 7, 2019","University of California, Irvine Medical Center, Orange, California, United States",,"https://ClinicalTrials.gov/show/NCT00496106"
245,"NCT03358836","Joint Health Study",,"Active, not recruiting","No Results Available","Hemophilia B",,"Joint health status|Joint and overall health status|Joint health at year 1|Joint health at year 2|Acute events/bleeding|Biomarkers","Bloodworks|CSL Behring","Male","16 Years and older   (Child, Adult, Older Adult)",,"50","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","Joint Health Study","November 15, 2017","December 31, 2027","December 31, 2027","December 2, 2017",,"January 22, 2019","Orthopaedic Institute for Children at University of California Los Angeles, Los Angeles, California, United States|University of California San Diego, San Diego, California, United States|Tulane University, New Orleans, Louisiana, United States|Oregon Health & Science University, Portland, Oregon, United States|Washington Center for Bleeding Disorders at Bloodworks Northwest, Seattle, Washington, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/36/NCT03358836/Prot_SAP_000.pdf|""Informed Consent Form: Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/36/NCT03358836/ICF_001.pdf|""Informed Consent Form: Assent Ages 16 to 17"", https://ClinicalTrials.gov/ProvidedDocs/36/NCT03358836/ICF_002.pdf","https://ClinicalTrials.gov/show/NCT03358836"
246,"NCT01996267","Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2","TRAIN-2","Active, not recruiting","No Results Available","Breast Cancer|HER2 Positive","Drug: PTC+Pertuzumab|Drug: FEC-T+Pertuzumab","Number of patients with pathological complete response|Number of patients with grade >2 adverse events as a measure of safety and tolerability|identify prognostic and predictive biomarkers for pCR","The Netherlands Cancer Institute|Roche Pharma AG|Borstkanker Onderzoek Groep","All","18 Years and older   (Adult, Older Adult)","Phase 3","437","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M13TRT","December 2013","December 2018","December 2022","November 27, 2013",,"October 19, 2021","MCA, Alkmaar, Netherlands|ZGT, Almelo, Netherlands|Antoni van Leeuwenhoek, Amsterdam, Netherlands|AZVU, Amsterdam, Netherlands|OLVG, Amsterdam, Netherlands|Rode Kruis Ziekenhuis, Beverwijk, Netherlands|Amphia ziekenhuis, Breda, Netherlands|Reinier de Graaf Groep, Delft, Netherlands|Jeroen Bosch Hospital, Den Bosch, Netherlands|Haga, Den Haag, Netherlands|Bronovo Ziekenhuis, den Haag, Netherlands|Deventer ziekenhuis, Deventer, Netherlands|Ziekenhuis Gelderse Vallei, Ede, Netherlands|Catharina Ziekenhuis, Eindhoven, Netherlands|Maxima Medisch Centrum, Eindhoven, Netherlands|St Anna Geldrop, Geldrop, Netherlands|Orbis Medisch Centrum, Geleen, Netherlands|Groene Hart, Gouda, Netherlands|Kennemer Gasthuis, Haarlem, Netherlands|Atrium Medisch Centrum Parkstad, Heerlen, Netherlands|Spaarne ziekenhuis, Hoofddorp, Netherlands|Westfries Gasthuis, Hoorn, Netherlands|MCL, Leeuwarden, Netherlands|LUMC, Leiden, Netherlands|Diaconessenhuis Meppel, Meppel, Netherlands|Canisius-Wilhelmina Hospital, Nijmegen, Netherlands|Waterlandziekenhuis, Purmerend, Netherlands|Vlietland Ziekenhuis, Schiedam, Netherlands|St. Elisabeth, Tilburg, Netherlands|Diaconessenhuis Utrecht, Utrecht, Netherlands|VieCuri Medisch Centrum voor Noord-Limburg, Venlo, Netherlands|Zaans Medisch Centrum, Zaandam, Netherlands|Isala Klinieken, Zwolle, Netherlands",,"https://ClinicalTrials.gov/show/NCT01996267"
247,"NCT00221195","Efficacy Study of Activated Prothrombin Complex for Prevention of Bleeds in Hemophilia A With Inhibitors","ProFEIBA","Completed","Has Results","Hemophilia A With Inhibitors","Drug: activated prothrombin complex concentrate (FEIBA)","Number of Bleeds During 6 Month Treatment Period","Tulane University School of Medicine|Tulane University","All","24 Months and older   (Child, Adult, Older Adult)","Phase 2|Phase 3","34","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","PRO-FEIBA Study","June 2003","December 2009","July 2010","September 22, 2005","February 6, 2017","March 2, 2020","Tulane University School of Medicine, New Orleans, Louisiana, United States",,"https://ClinicalTrials.gov/show/NCT00221195"
248,"NCT02190149","Study of Prophylaxis, ACtivity and Effectiveness (SPACE) in Hemophilia Patients Currently Treated With ADVATE or RIXUBIS","SPACE","Completed","No Results Available","Hemophilia A|Hemophilia B","Biological: ADVATE (Antihemophilic Factor [Recombinant])|Biological: RIXUBIS (Coagulation Factor IX [Recombinant])","Advancing the understanding of the relationship between patient physical activity levels, infusion and occurrence of bleeding episodes (BEs)|Types of current physical activities of participants|Activity measurement|Infusion schedule for participants on prophylaxis|Infusion amount (either ADVATE (Hemophilia A), or RIXUBIS (Hemophilia B)|Occurrence of bleeding episodes (BEs)|Patient-reported outcome: Hemophilia Activities List (HAL) questionnaire - for adult patients|Patient-reported outcome: pediatric Hemophilia Activities List (pedHAL) questionnaire - for pediatric patients","Baxalta now part of Shire|Takeda","All","13 Years to 65 Years   (Child, Adult, Older Adult)",,"64","Industry","Observational","Observational Model: Other|Time Perspective: Prospective","061302","July 22, 2014","March 29, 2016","March 29, 2016","July 15, 2014",,"March 17, 2021","Orthopaedic Hospital DBA Orthopaedic Hemophilia Treatment Center, Los Angeles, California, United States|Rady Childrens Hospital, San Diego, California, United States|University of Colorado, Aurora, Colorado, United States|Bleeding and Clotting Disorders Institute, Peoria, Illinois, United States|University of Kentucky Medical Center, Lexington, Kentucky, United States|Johns Hopkins University School Of Medicine, Baltimore, Maryland, United States|Childrens Hospital of Michigan, Detroit, Michigan, United States|Michigan State University, East Lansing, Michigan, United States|Munson Medical Center, Traverse City, Michigan, United States|Children's Mercy Hospitals & Clinics, Kansas City, Missouri, United States|North Shore/Long Island Jewish PRIME, Great Neck, New York, United States|The Presbyterian Hospital, Charlotte, North Carolina, United States|Oregon Health & Science University, Portland, Oregon, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|The Vanderbilt Clinic, Nashville, Tennessee, United States|The University of Texas MD Anderson, Harlingen, Texas, United States|Puget Sound Blood Center, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02190149"
249,"NCT03565237","RIXUBIS PMS India (RIXUBIS PMS)",,"Completed","No Results Available","Hemophilia B","Biological: RIXUBIS: On-Demand|Biological: RIXUBIS: Prophylaxis","Incidence of serious adverse events (SAEs)|Incidence of adverse events (AEs)|Clinically significant changes in clinical laboratory parameters|Incidence of binding IgG antibodies|Incidence of binding IgM antibodies|Incidence of antibodies to CHO proteins|Incidence of antibodies to rFurin|Annualized bleeding rate|Rate of success of RIXUBIS","Baxalta now part of Shire|Baxalta Innovations GmbH, now part of Shire|Takeda","All","Child, Adult, Older Adult","Phase 4","25","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","251602","December 7, 2018","August 5, 2021","August 5, 2021","June 21, 2018",,"January 18, 2022","Sahyadri Super Speciality Hospital, Pune, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT03565237"
250,"NCT02313935","Cognitive/Physical Computer-Game Blended Training of Elderly: Neuroscientific LLM Studies","LLM-AUTH","Completed","No Results Available","Mild Cognitive Impairment, So Stated|Mild Dementia|Healthy","Other: LLM|Other: FFA|Other: Brain Fitness|Other: VideoGrade","overall cognition|physical fitness|Episodic memory|working memory|executive function|Quality of Life|Instrumental Activities of daily living|Depressive symptoms|Brain function","Aristotle University Of Thessaloniki|Greek Alzheimer's Association and Related Disorders","All","55 Years and older   (Adult, Older Adult)","Not Applicable","581","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","84171-A","November 2010","May 2012","April 2013","December 10, 2014",,"December 11, 2014",,,"https://ClinicalTrials.gov/show/NCT02313935"
251,"NCT02047565","A Two-part Study in Edoxaban-treated Healthy Subjects to Establish a Punch Biopsy Bleeding Model and to Evaluate the Effect of a 4-factor Prothrombin Complex Concentrate on Anticoagulation",,"Completed","No Results Available","Bleeding","Drug: 60mg edoxaban|Drug: 180mg edoxaban|Drug: 50 IU/kg Beriplex P/N|Drug: 25 IU/kg Beriplex P/N|Drug: 10 IU/kg Beriplex P/N","Bleeding duration 60mg edoxaban|Bleeding volume 60mg edoxaban|Bleeding duration 180mg edoxaban|Bleeding volume 180mg edoxaban|Prothrombin Time|International Normalized Ratio|Activated Partial Thromboplastin Time|Thrombin Generation Assay|procoagulant markers D dimer|prothrombin fragment F1 + 2|coagulation factor concentrations|cmax of edoxaban and its active metabolite, D21-2393|tmax of edoxaban and its active metabolite, D21-2393|AUC 0-24 of edoxaban and its active metabolite, D21-2393","Daiichi Sankyo, Inc.","All","18 Years to 45 Years   (Adult)","Phase 1","110","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Supportive Care","DU176b-A-U158","October 2013","May 2014","May 2014","January 28, 2014",,"February 12, 2019","Quintiles, Overland Park, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT02047565"
252,"NCT03055611","A Study to Evaluate the Real-world Usage and Effectiveness of Elocta and Alprolix in Patients With Haemophilia A or B","PREVENT","Active, not recruiting","No Results Available","Haemophilia A|Haemophilia B","Drug: ELOCTA|Drug: ALPROLIX","Annualised bleeding rate (ABR)|Annualised injection frequency|Annualised factor consumption (IU)","Swedish Orphan Biovitrum","All","Child, Adult, Older Adult",,"201","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","Sobi.HAEM89-002","May 9, 2017","April 2022","April 2022","February 16, 2017",,"December 8, 2021","Swedish Orphan Biovitrum Reserach site, Berlin, Germany|Swedish Orphan Biovitrum Reserach Site, Blaubeuren, Germany|Swedish Orphan Biovitrum Research Site, Bonn, Germany|Swedish Orphan Biovitrum Research Site, Delmenhorst, Germany|Swedish Orphan Biovitrum Research Site, Duisburg, Germany|Swedish Orphan Biovitrum Reserach site, Erlangen, Germany|Swedish Orphan Biovitrum Research Site, Frankfurt, Germany|Swedish Orphan Biovitrum Reserach site, Frankfurt, Germany|Swedish Orphan Biovitrum Research Site, Fürth, Germany|Swedish Orphan Biovitrum Research Site, Hamburg, Germany|Swedish Orphan Biovitrum Research Site, Hannover, Germany|Swedish Orphan Biovitrum Reserach site, Hannover, Germany|Swedish Orphan Biovitrum Reserach site, Heidelberg, Germany|Swedish Orphan Biovitrum Reserach site, Homburg, Germany|Swedish Orphan Biovitrum Research Site, Jena, Germany|Swedish Orphan Biovitrum Reserach Site, Jena, Germany|Swedish Orphan Biovitrum Reserach site, Leipzig, Germany|Swedish Orphan Biovitrum Reserach Site, Mörfelden-Walldorf, Germany|Swedish Orphan Biovitrum Research Site, München, Germany|Swedish Orphan Biovitrum Reserach site, München, Germany|Swedish Orphan Biovitrum Reserach site, Münster, Germany|Swedish Orphan Biovitrum Research Site, Würzburg, Germany",,"https://ClinicalTrials.gov/show/NCT03055611"
253,"NCT02032446","Umbilical Cord Derived Mesenchymal Stromal Cells For The Treatment of Severe Steroid-resistant Graft Versus Host Disease","PTC-UC-MSC","Unknown status","No Results Available","Hematologic Malignancies","Biological: UMBILICAL CORD DERIVED MESENCHYMAL STROMAL CELLS (UC-MSC)","vital parameters|assessed of acute graft versus host disease (GvHD)","A.O. Ospedale Papa Giovanni XXIII|Associazione Italiana per la Ricerca sul Cancro","All","up to 70 Years   (Child, Adult, Older Adult)","Phase 1|Phase 2","47","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EudraCT 2012-000582-21","September 2013","September 2016","September 2019","January 10, 2014",,"January 18, 2019","A O Papa Giovanni XXIII, Bergamo, Italy|Ao S Croce E Carle, Cuneo, Italy|AO Careggi, Firenze, Italy|IRCCS G Gaslini, Genova, Italy|Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico, Milano, Italy|Clinica Pediatrica San Gerardo, Monza, Italy|Azienda Ospedaliero-Universitaria Di Udine, Udine, Italy|Ospedale San Bortolo, Vicenza, Italy",,"https://ClinicalTrials.gov/show/NCT02032446"
254,"NCT03087747","Percutaneous Transhepatic Cholangiography (PTHC) in Acute Cholecystitis and Clinical Outcomes",,"Withdrawn","No Results Available","Cholecystitis, Acute|Elderly Infection|Drain Abscess","Procedure: Percutaneous cholecystostomy","C-reactive protein (CRP)|Drainage duration (expressed in days)|White blood cells (WBCs) count","University of Split, School of Medicine","All","Child, Adult, Older Adult",,"0","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","AChol","January 1, 2015","October 1, 2019","May 1, 2020","March 22, 2017",,"June 3, 2021","University of Split, School of Medicine, Split, Croatia",,"https://ClinicalTrials.gov/show/NCT03087747"
255,"NCT02140476","Comparative Analysis Between Bipolar Device and Conventional Tie & Suture Technique in Thyroidectomy",,"Unknown status","No Results Available","Thyroid Goiter|Papillary Thyroid Cancer","Device: Bipolar vessel sealing and cutting device|Procedure: Conventional thyroidectomy","Operative time and surgical safety|Surgical complications","Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|University of Sao Paulo|Ethicon Endo-Surgery","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","160","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Outcomes Assessor)","SCI-1151-13/13-1","May 2014","May 2015","July 2015","May 16, 2014",,"May 28, 2014","Hospital Das Clinicas, Universidad de Sao Paulo, Sao Paulo, Brazil|Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico",,"https://ClinicalTrials.gov/show/NCT02140476"
256,"NCT05020483","FEIBA to Optimize Postcardiopulmonary Bypass Hemostasis in Pediatric Cardiac Patients",,"Recruiting","No Results Available","Cardiac Disease","Drug: FEIBA|Drug: Placebo","Number of units of allogeneic blood products required early perioperatively in pediatric cardiac patients.|Hospital length of stay|Mortality|Intravascular and intracardiac thromboses","Mayo Clinic","All","up to 5 Years   (Child)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","21-005539","October 28, 2021","December 31, 2022","December 31, 2023","August 25, 2021",,"December 1, 2021","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT05020483"
257,"NCT02049099","A Non-interventional Retrospective Study of the Current Treatment Practice in European Haemophilia Care",,"Completed","No Results Available","Haemophilia A|Haemophilia B",,"Total dose (IU) issued of Factor VIII during a 12 month period|Total dose (IU) issued of Factor IX during a 12 month period","Swedish Orphan Biovitrum","Male","2 Years and older   (Child, Adult, Older Adult)",,"1658","Industry","Observational","Time Perspective: Retrospective","Sobi.HAEM89-001","March 2014","September 2015","September 2015","January 29, 2014",,"March 14, 2016","Swedish Orphan Biovitrum Investigational Site, Brussel, Belgium|Swedish Orphan Biovitrum Investigational Site, Montpellier, France|Swedish Orphan Biovitrum Investigational Site, Nantes, France|Swedish Orphan Biovitrum Investigational Site, Bonn, Germany|Swedish Orphan Biovitrum Investigational Site, Leipzig, Germany|Swedish Orphan Biovitrum Investigational Site, Firenze, Italy|Swedish Orphan Biovitrum Investigational Site, Milano, Italy|Swedish Orphan Biovitrum Investigational Site, Vicenza, Italy|Swedish Orphan Biovitrum Investigational Site, Barcelona, Spain|Swedish Orphan Biovitrum Investigational Site, Madrid, Spain|Swedish Orphan Biovitrum Investigational Site, Stockholm, Sweden|UKHCDO, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02049099"
258,"NCT03782233","Study on the Level of Neuromuscular Blockade",,"Completed","Has Results","Neuromuscular Blockade","Drug: A continuous intravenous infusion of 0.5-0.6 mg/kg/h Rocuronium Bromide Intravenous Solution (50 Mg/5 mL) to keep the target neuromuscular blockade (PTC = 1-2).|Drug: A continuous intravenous infusion of 0.2-0.3 mg/kg/h Rocuronium Bromide Intravenous Solution (50 Mg/5 mL) to keep the target neuromuscular blockade (TOF = 1-2).","Plasma Concentration of D-lactic Acid Before the Surgery|Plasma Concentration of Diamine Oxidase (DAO) Before the Surgery|Total Number of Operational Taxonomic Units (OUTs) of Intestinal Microbiota|Postoperative Exhaust Time|Plasma Concentration of D-lactic Acid 24 h After the Surgery|Plasma Concentration of Diamine Oxidase (DAO) 24 h After the Surgery|Relative Abundance of Intestinal Microbiota|16s rRNA Sequencing of Postoperative Feces|Duration of Surgery|Surgical Condition Scores Rated by Surgeons|Duration of CO2 Pneumoperitoneum|Duration of Postoperative Hospital Stay|Postoperative VAS (12 h After Surgery, Rest State)|Postoperative VAS (12 h After Surgery, Active State)|Postoperative VAS (24 h After Surgery, Rest State)|Postoperative VAS (24 h After Surgery, Active State)|Postoperative VAS (48 h After Surgery, Rest State)|Postoperative VAS (48 h After Surgery, Active State)|Surgical Condition Scores Rated by Surgeons (Average Scores)","The First Affiliated Hospital with Nanjing Medical University|Wu Jieping Medical Foundation","All","40 Years to 80 Years   (Adult, Older Adult)","Not Applicable","83","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","He Huang","January 1, 2019","July 31, 2019","December 31, 2019","December 20, 2018","September 24, 2020","September 24, 2020","The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT03782233/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT03782233/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT03782233"
259,"NCT04354324","Treatment Efficacy and Safety of Low-dose Radioiodine Ablation for Intermediate-risk Differentiated Thyroid Carcinoma",,"Not yet recruiting","No Results Available","Papillary Thyroid Cancer","Drug: Radioiodine","disease-free survival","Zhujiang Hospital","All","16 Years and older   (Child, Adult, Older Adult)","Not Applicable","254","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","2019-KY-050-02","May 15, 2020","June 30, 2024","June 30, 2024","April 21, 2020",,"May 8, 2020",,,"https://ClinicalTrials.gov/show/NCT04354324"
260,"NCT03533504","Web Accessible Population Pharmacokinetics Service - Hemophilia: Sources of Variability","WAPPS-Hemo","Enrolling by invitation","No Results Available","Hemophilia A|Hemophilia B","Other: Variability in individual PK","Sources of variability in individual pharmacokinetics for factor VII and IX concentrates","McMaster University","All","Child, Adult, Older Adult",,"1000","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","14-601-D","May 9, 2018","June 30, 2024","June 30, 2024","May 23, 2018",,"September 21, 2021","McMaster University, Hamilton, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03533504"
261,"NCT03906331","Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation",,"Available","No Results Available","Non Small Cell Lung Cancer|Medullary Thyroid Cancer|Colon Cancer|Breast Cancer|Pancreatic Cancer|Papillary Thyroid Cancer|Other Solid Tumors With Evidence of Activating RET Alteration","Drug: Selpercatinib",,"Loxo Oncology, Inc.|Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)",,,"Industry","Expanded Access:Individual Patients",,"17494|Selpercatinib EAP|J2G-OX-Y001",,,,"April 8, 2019",,"January 19, 2022","Cancer Treatment Centers of America, Goodyear, Arizona, United States|Mayo Clinic of Scottsdale, Scottsdale, Arizona, United States|City of Hope National Medical Center, Duarte, California, United States|UCLA Medical Center, Los Angeles, California, United States|Kaiser Permanente, Oakland, California, United States|Irvine Medical Center, Orange, California, United States|Kaiser Permanente Medical Center, Sacramento, California, United States|University of California - San Diego, San Diego, California, United States|Kaiser Permanente Medical Center, San Francisco, California, United States|Univ of California San Francisco, San Francisco, California, United States|Kaiser Permanente, Santa Clara, California, United States|Kaiser Permanente Medical Center, Vallejo, California, United States|Memorial Cancer Institute, Hollywood, Florida, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Florida Hospital, Orlando, Florida, United States|Tallahassee Memorial Cancer Center, Tallahassee, Florida, United States|University Cancer and Blood Center, Athens, Georgia, United States|Emory University, Atlanta, Georgia, United States|University of Chicago Medicine-Comprehensive Cancer Center, Chicago, Illinois, United States|Cancer Treatment Centers of America, Zion, Illinois, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|START Midwest, Grand Rapids, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University Medical Center, Columbus, Ohio, United States|Cancer Treatment Centers of America, Tulsa, Oklahoma, United States|University of Pennsylvania Hospital, Philadelphia, Pennsylvania, United States|Eastern Regional Medical Center, Philadelphia, Pennsylvania, United States|Oncology Consultants, Houston, Texas, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Virginia Cancer Specialists, Fairfax, Virginia, United States|University of Wisconsin-Madison Hospital and Health Clinic, Madison, Wisconsin, United States|NSW Health - Sydney Local Health District, Camperdown, New South Wales, Australia|Royal North Shore Hospital, St. Leonards, New South Wales, Australia|Queensland Health - Metro North Hospital and Health Service, Chermside, Queensland, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|Linear Clinical Research Ltd, Nedlands, Western Australia, Australia|Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest, Bordeaux, Aquitaine, France|Centre Leon Berard, Lyon Cedex 08, France|AP-HM, Marseille, France|CHU - l'Assistance Publique - Hôpitaux de Marseille, Marseille, France|Gustave Roussy, Villejuif Cedex, France|Universitätsklinikum Würzburg A. ö. R., Würzburg, Bayern, Germany|Universitätsklinikum Köln, Köln, Nordrhein-Westfalen, Germany|Charité Campus Virchow-Klinikum, Berlin, Germany|Prince of Wales Hospital, Hong Kong, Shatin, New Territories, Hong Kong|Sheba Medical Center, Ramat Gan, HaMerkaz, Israel|Shaare Zedek Medical Center, Jerusalem, Yerushalayim, Israel|Soroka Medical Center - Pediatric Outpatient Clinic, Beer-Sheva, Israel|Istituto Nazionale dei Tumori, Milano, Lombardie, Italy|Azienda Ospedaliero Universitaria Pisana, Pisa, PI, Italy|ASST Grande Ospedale Metropolitano Niguarda Comitato Etico Milano Area C, Milano, Italy|National Cancer Center Hospital East, Kashiwa, Chiba, Japan|Hokkaido University Hospital, Sapporo, Hokkaido, Japan|Kanazawa University Hospital, Kanazawa, Ishikawa, Japan|National Cancer Center Hospital, Chuo-ku, Tokyo, Japan|Tottori University Hospital, Yonago, Tottori, Japan|Osaka City General Hospital, Osaka, Japan|University of Auckland, Auckland, New Zealand|Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Centrum Onkologii Instytut im Marii Curie w Warszawie, Warszawa, Poland|National Cancer Centre Singapore, Singapore, Central Singapore, Singapore|Hospital Universitari Vall d'Hebron, Barcelona, Barcelona [Barcelona], Spain|Hospital Madrid Norte Sanchinarro, Madrid, Spain|Kantonsspital Luzern, Luzern 16, Luzern, Switzerland",,"https://ClinicalTrials.gov/show/NCT03906331"
262,"NCT03194893","A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer",,"Active, not recruiting","No Results Available","Neoplasms","Drug: Alectinib|Drug: Crizotinib","Number of Patients with Serious Adverse Events (SAEs), Non-serious Adverse Events (non-SAEs) and Adverse Events of Special Interest|Number of Patients With Clinically Significant Laboratory Values as per Protocol for Selected Safety Laboratory Parameters|Number and Causes of Death Occurring on Study","Hoffmann-La Roche","All","Child, Adult, Older Adult","Phase 3","200","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BO39694|2017-000207-24","July 5, 2017","June 12, 2024","June 12, 2024","June 21, 2017",,"December 22, 2021","Chao Family Comprehensive Cancer Center; UC Irvine Medical Center, Orange, California, United States|Miami Cancer Institute of Baptist Health, Inc., Miami, Florida, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Centre Francois Baclesse, Caen, France|Centre Georges François Leclerc; Service Pharmacie, Bp 77980, Dijon, France|Centre Oscar Lambret, Lille, France|Centre Leon Berard, Lyon, France|Groupe Hospitalier Sud - Hôpital Haut Lévêque, Pessac, France|Hopital Pontchaillou - CHU de Rennes, Rennes, France|CHU de Toulouse - Hôpital Larrey; Service de pneumologie et oncologie pneumologique, Toulouse cedex 9, France|Hopital Robert Schuman; Pneumologie, Vantoux, France|Queen Mary Hospital; Dept. of Clinical Oncology, Hong Kong, Hong Kong|Queen Elizabeth Hospital Department of Clinical Oncology, Kowloon, Hong Kong|Irccs Centro Di Riferimento Oncologico (CRO); Dipartimento Di Oncologia Medica, Aviano, Friuli-Venezia Giulia, Italy|Azienda Ospedaliera San Camillo Forlanini - Unità Operativa Complessa di Pneumologia Oncologica 1, Roma, Lazio, Italy|Azienda Ospedaliero-Universitaria Careggi;S.C. Oncologia Medica 1, Firenze, Toscana, Italy|Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia; Oncologia Medica, Perugia, Umbria, Italy|Seoul National University Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Uniwersyteckie Centrum Kliniczne; Klinika Onkologii i Radioterapii, Gdańsk, Poland|University сlinic of headaches, Moscow, Moskovskaja Oblast, Russian Federation|FSBSI ""Russian Oncological Scientific Center n.a. N.N. Blokhin"", Moscow, Russian Federation|City Clinical Oncology Hospital, Moscow, Russian Federation|Hospital del Mar; Servicio de Oncologia, Barcelona, Spain|Hospital Universitari Dexeus - Grupo Quironsalud; Servicio de Oncologia Medica, Barcelona, Spain|Hospital Universitario La Paz; Servicio de Oncologia, Madrid, Spain|Adana Acıbadem Hospital Oncology Department, Adana, Turkey|Istanbul Uni Capa Medical Faculty; Inst. of Oncology, Istanbul, Turkey|Ege University Medical Faculty; Chest Diseases, Izmir, Turkey|Hacettepe Uni Medical Faculty Hospital; Oncology Dept, Sihhiye/Ankara, Turkey",,"https://ClinicalTrials.gov/show/NCT03194893"
263,"NCT03623516","Overdiagnosis of Thyroid Cancer in the Marne and Ardennes Departments of France From 1975 to 2014","OTCancer","Completed","No Results Available","Papillary Thyroid Cancer",,"Overdiagnosis of thyroid cancer","CHU de Reims","All","18 Years and older   (Adult, Older Adult)",,"2008","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","2017Ao001","January 1, 1975","December 1, 2014","December 1, 2014","August 9, 2018",,"August 9, 2018","Damien JOLLY, Reims, France",,"https://ClinicalTrials.gov/show/NCT03623516"
264,"NCT02540187","Tissue Factor Pathway Inhibitor (TFPI) and Haemorrhagic Manifestations in Haemophilia A and B Patients",,"Completed","No Results Available","Hemophilia","Other: blood specimen","Comparison for TFPI level between Haemophilia A and Haemophilia B|Comparison for TFPI level between severe Haemophilia A and severe Haemophilia B|Comparison for TFPI level between moderate or mild Haemophilia A and moderate or mild Haemophilia B|Correlation between free TFPI and hemorrhagic score|Correlation between TFPI activity and hemorrhagic score|Correlation between Endogenous Thrombin Potential (ETP) and free TFPI|Correlation between Lag Time and free TFPI|Correlation between Peak value and free TFPI|Correlation between Time to Peak and free TFPI|Correlation between ETP and hemorrhagic score|Correlation between Lag Time and hemorrhagic score|Correlation between Peak Value and hemorrhagic score|Correlation between Time to Peak and hemorrhagic score|Comparison for ETP between haemophilia A et Haemophilia B|Comparison for lag time between haemophilia A et Haemophilia B|Comparison for Peak Value between haemophilia A et Haemophilia B|Comparison for Time to Peak between haemophilia A et Haemophilia B","Centre Hospitalier Universitaire de Saint Etienne|Pfizer","Male","18 Years to 65 Years   (Adult, Older Adult)",,"164","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","1108164","February 2012","February 2016","February 2016","September 3, 2015",,"March 10, 2016","CHRU Lille, Lille, France|HCL, Lyon, France|AP-HM, Marseille, France|Chu Nancy, Nancy, France|Chu Reims, Reims, France|CHU Saint-Etienne, Saint-Etienne, France|Chu Tours, Tours, France",,"https://ClinicalTrials.gov/show/NCT02540187"
265,"NCT04489537","Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Hemophilia A or B",,"Terminated","No Results Available","Hemophilia A With Inhibitor|Hemophilia B With Inhibitor","Biological: MarzAA","Bleeding episode treatment success","Catalyst Biosciences","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","18","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MAA-304","May 4, 2021","November 15, 2021","December 1, 2021","July 28, 2020",,"December 17, 2021","Phoenix Children's Hospital, Phoenix, Arizona, United States|Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States|Hematology Center after Prof. R. Yeolyan, Yerevan, Armenia|JSC ""K.Eristavi National Center of Experimental and Clinical Surgery"", Tbilisi, Georgia|Magyar Honvédség Egészségügyi Központ, Országos Haemophilia Központ, Budapest, Hungary|Nirmal Hospital, Gujrat, India|K.L.E.S Dr. Prabhakar Kore Hospital and Medical Research Centre, Karnad, India|Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India|K.J Somaiya Hospital and Research Centre, Mumbai, India|MCGM - Comprehensive Thalassemia Care, Pediatric Hematology-Oncology & BMT Centre, Mumbai, India|Sahyadri Specialty Hospital, Mumbai, India|Grant Medical Foundation, Ruby Hall Clinic, Pune, India|All India Institute of Medical Sciences, Rishikesh, Rishīkesh, India|Azienda Ospedaliero-Universitaria Careggi, Firenze, Italy|Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy|Azienda Ospedaliera Universitaria Federico II, Napoli, Italy|Citta della Salute e della Scienza di Torino - Ospedale le Molinette, Torino, Italy|Hospital Ampang, Ampang, Malaysia|Raja Perempuan Zainab II Hospital, Kota Bharu, Malaysia|Queen Elizabeth Hospital Malaysia, Kota Kinabalu, Malaysia|Hospital Tunku Azizah Kuala Lumpur, Kuala Lumpur, Malaysia|Tuanku Ja'afar Hospital, Seremban, Sungai Petani, Malaysia|Instituto Nacional de Pediatria, Ciudad de mexico, Mexico|Instituto de Investigaciones Aplicada a la Neurociencia A.C., Durango, Mexico|Investigación e Innovación en Medicina Traslacional S.A.P.I. de C.V., Mexico City, Mexico|Korczowski Bartosz, Gabinet Lekarski, Rzeszów, Poland|Kirov Research Institute of Hematology and Blood Transfusion, Kirov, Russian Federation|Medis, Llc, Nizhny Novgorod, Russian Federation|Haemophilia Comprehensive Care Centre, Johannesburg, South Africa|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Hospital de Malaga, Málaga, Spain|Changhua Christian Hospital (CCH), Changhua City, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|Akdeniz University Medical Faculty Hospital, Antalya, Turkey|Istanbul University Faculty of Medicine, Istanbul, Turkey|Ege University Medical Faculty, İzmir, Turkey|Özel Acibadem Adana Hastanesi, Seyhan, Turkey|""Cherkasy Regional Oncological Dispensary of Cherkasy Regional Council"", Regional Treatment and Diagnostic Center of Hematology, Cherkasy, Ukraine|""Kyiv City Clinical Hospital #9"" of Executive Body of Kyiv City Council (Kyiv City State Administration), City Scientific-Practical Centre of Diagnostics and Treatment, Kyiv, Ukraine|""Institute of Blood Pathology and Transfusion Medicine of National Academy of Medical Sciences of Ukraine"", Haematology Department, Lviv, Ukraine|Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom|Royal Liverpool University Hospital, Liverpool, United Kingdom|University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04489537"
266,"NCT04867837","Study of OCTAPLEX in Patients With Acute Major Bleeding on DOAC Therapy With Factor Xa Inhibitor",,"Recruiting","No Results Available","Acute Major Bleeding","Drug: Octaplex","Hemostatic efficacy|Change in endogenous thrombin potential (ETP)|30-Day thromboembolic events (TEEs)|30-Day all-cause mortality|Occurrence of adverse events (AEs)|Body Temperature|Pulse|Respiration rate|Blood pressure","Octapharma","All","18 Years and older   (Adult, Older Adult)","Phase 3","200","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","LEX-210","September 1, 2021","January 2024","February 2024","April 30, 2021",,"January 3, 2022","Harbor-UCLA Medical Center, Torrance, California, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|OU Health - University of Oklahoma Medical Center, Oklahoma City, Oklahoma, United States",,"https://ClinicalTrials.gov/show/NCT04867837"
267,"NCT02758626","Ataluren for Nonsense Mutation in CDKL5 and Dravet Syndrome",,"Completed","No Results Available","Epilepsy","Drug: ataluren|Drug: Placebo","Number of adverse events and serious adverse events related to ataluren|Seizure frequency from baseline after ataluren treatment in patients w/ CDKL5 or Dravet from daily seizure diary.","NYU Langone Health|PTC Therapeutics","All","2 Years to 12 Years   (Child)","Phase 2","16","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","15-00426","November 2016","February 27, 2021","February 27, 2021","May 2, 2016",,"September 8, 2021","New York University School of Medicine, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02758626"
268,"NCT00758485","Comparing 4.0 mg.Kg-1 Sugammadex With Placebo in the Reversal of Profound Neuromuscular Blockade (P05767)",,"Completed","Has Results","Anesthesia|Neuromuscular Blockade","Drug: Sugammadex|Drug: 0.9% sodium chloride (NaCl)","Time From Start of Administration of Investigational Medicinal Product (IMP, Sugammadex or Placebo) to Recovery of the Fourth Twitch/First Twitch (T4/T1) Ratio to 0.9|Time From Start of Administration of IMP to Recovery of the T4/T1 Ratio to 0.7|Time From Start of Administration of IMP to Recovery of the T4/T1 Ratio to 0.8","Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 3","140","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","P05767|2008-002518-23|19.4.316|MK-8616-004","October 2008","May 2009","June 2009","September 25, 2008","April 22, 2013","August 21, 2015",,,"https://ClinicalTrials.gov/show/NCT00758485"
269,"NCT03910998","Impact of Intraoperative Deep Neuromuscular Blockade on NOL-guided Opioid Requirement in LSC Colorectal Surgeries",,"Recruiting","No Results Available","Laparoscopic Colorectal Surgeries","Drug: Rocuronium IV bolus 0.1 mg/kg guided by TOF that must remain between 1-3 during surgery|Drug: Rocuronium IV bolus 0.1 mg/kg guided by TOF 0/4 and PTC≤ 2","Total intra-operative remifentanil consumption during surgery in mcg/kg/h|Number of IV boluses and increases of remifentanil infusion, number, no unit|Number of times NOL index passes over the threshold of 25, number, no unit|Area Under the Curve (AUCs) whenever the NOL is above 25, no unit|Total intraoperative time from T0 until Tend with NOL above 25 in minutes|Intraoperative level of intra-abdominal pressure (IAP) in mmHg|Abdominal insufflation duration in minutes|Time for awakening and extubation in seconds|Pain score at rest on a scale from 0 to 10|Pain score at coughing/mobilization on a scale from 0 to 10|Pain score at the shoulder on a scale from 0 to 10|Postoperative Hydromorphone consumption in mg in Postoperative Care Unit (PACU)|Pain score at rest at 8hs on a scale from 0 to 10|Pain score at coughing/mobilization at 8hs on a scale from 0 to 10|Pain score at rest at 16hs on a scale from 0 to 10|Pain score at coughing/mobilization at 16hs on a scale from 0 to 10|Pain score at rest at 24hs on a scale from 0 to 10|Pain score at coughing/mobilization at 24hs on a scale from 0 to 10|Amount of opioids received in 24h as Patient Controlled Analgesia in mg|Recovery score QOR15 questionnaire (150 points maximum for this questionnaire)|POSS postoperative Sedation score in PACU on a scale from 1 to 4|postoperative nausea and vomiting score in PACU on a scale from 0 to 3|postoperative Aldrete score in PACU on a scale from 5 to 15","Ciusss de L'Est de l'Île de Montréal|Merck Canada Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 4","100","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2019-1610","May 30, 2019","March 1, 2022","July 1, 2022","April 10, 2019",,"October 4, 2021","Hopital Maisonneuve Rosemont, CIUSSS de l'Est de l'Ile de Montréal, Montréal-Est, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT03910998"
270,"NCT01159210","Efficacy and Safety of Prothromplex Total (Prothrombin Complex Concentrate) in Oral Anticoagulant Reversal",,"Completed","No Results Available","Prothrombin Complex Factor Deficiency","Biological: Prothrombin complex concentrate (coagulation factors IX, II, VII and X in combination)","Proportion of subjects who achieve normalisation of International normalised ratio (INR) to <= 1.3 within 30 (±5) minutes post administration of Prothromplex Total","Baxalta now part of Shire|Takeda","All","16 Years and older   (Child, Adult, Older Adult)","Phase 4","61","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","220901|2010-019250-41","July 9, 2010","April 7, 2012","April 7, 2012","July 9, 2010",,"May 5, 2021","Landeskrankenhaus Feldkirch, Feldkirch, Austria|Universitätsklinik für Innere Medizin I (University Hospital for Internal Medicine I), Allgemeines Krankenhaus der Stadt Wien (General Hospital Vienna), Vienna, Austria|Krankenhaus Hietzing mit Neurologischem Zentrum Rosenhügel, Vienna, Austria|DEOEC, University of Debrecen, Medical and Health Science Centre, Debrecen, Hungary|Fejer Megyei Szent György Korhaz, Szekesfehervar, Hungary|Veszprem Megyei Csolnoky Korhaz Nonprofit Zrt., Belgyógyászati Centrum, Haematológiai Részleg, Veszprem, Hungary",,"https://ClinicalTrials.gov/show/NCT01159210"
271,"NCT04082429","Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors","explorer8","Active, not recruiting","No Results Available","Haemophilia A Without Inhibitors|Haemophilia B Without Inhibitors","Drug: Concizumab","For haemophilia A patients without inhibitors: The number of treated spontaneous and traumatic bleeding episodes|For haemophilia B patients without inhibitors: The number of treated spontaneous and traumatic bleeding episodes|For haemophilia A patients without inhibitors: Number of treated spontaneous bleeding episodes|For haemophilia B patients without inhibitors: Number of treated spontaneous bleeding episodes|For haemophilia A patients without inhibitors: Number of treated spontaneous and traumatic joint bleeds|For haemophilia B patients without inhibitors: Number of treated spontaneous and traumatic joint bleeds|For haemophilia A patients without inhibitors: Number of treated spontaneous and traumatic target joint bleeds|For haemophilia B patients without inhibitors: Number of treated spontaneous and traumatic target joint bleeds|Number of thromboembolic events|Number of hypersensitivity type reactions|Number of injection site reactions|Number of patients with antibodies to concizumab|Pre-dose (trough) concizumab plasma concentration (Ctrough)|Pre-dose thrombin peak|Pre-dose free tissue factor pathway inhibitor (TFPI) concentration|Maximum concizumab plasma concentration (Cmax)|Area under the concizumab plasma concentration-time curve (AUC)","Novo Nordisk A/S","Male","12 Years and older   (Child, Adult, Older Adult)","Phase 3","158","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NN7415-4307|U1111-1225-9722|2018-004891-36","November 13, 2019","May 19, 2022","December 19, 2024","September 9, 2019",,"January 24, 2022","Novo Nordisk Investigational Site, Orange, California, United States|Novo Nordisk Investigational Site, Augusta, Georgia, United States|Novo Nordisk Investigational Site, Indianapolis, Indiana, United States|Novo Nordisk Investigational Site, Iowa City, Iowa, United States|Novo Nordisk Investigational Site, Detroit, Michigan, United States|Novo Nordisk Investigational Site, Lansing, Michigan, United States|Novo Nordisk Investigational Site, Charlotte, North Carolina, United States|Novo Nordisk Investigational Site, Hershey, Pennsylvania, United States|Novo Nordisk Investigational Site, Nashville, Tennessee, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, Milwaukee, Wisconsin, United States|Novo Nordisk Investigational Site, Algiers, Algeria|Novo Nordisk Investigational Site, Constantine, Algeria|Novo Nordisk Investigational Site, Melbourne, Victoria, Australia|Novo Nordisk Investigational Site, Parkville, Victoria, Australia|Novo Nordisk Investigational Site, Murdoch, Western Australia, Australia|Novo Nordisk Investigational Site, Banja Luka, Bosnia and Herzegovina|Novo Nordisk Investigational Site, Sofia, Bulgaria|Novo Nordisk Investigational Site, Varna, Bulgaria|Novo Nordisk Investigational Site, St. Johns, Newfoundland and Labrador, Canada|Novo Nordisk Investigational Site, Hamilton, Ontario, Canada|Novo Nordisk Investigational Site, Zagreb, Croatia|Novo Nordisk Investigational Site, København, Denmark|Novo Nordisk Investigational Site, Brest, France|Novo Nordisk Investigational Site, Caen, France|Novo Nordisk Investigational Site, Le Kremlin Bicetre, France|Novo Nordisk Investigational Site, Nantes Cedex 1, France|Novo Nordisk Investigational Site, Rennes, France|Novo Nordisk Investigational Site, Saint Etienne, France|Novo Nordisk Investigational Site, Bonn, Germany|Novo Nordisk Investigational Site, Homburg, Germany|Novo Nordisk Investigational Site, Budapest, Hungary|Novo Nordisk Investigational Site, Bangalore, Karnataka, India|Novo Nordisk Investigational Site, Pune, Maharashtra, India|Novo Nordisk Investigational Site, Jaipur, Rajasthan, India|Novo Nordisk Investigational Site, Vellore, Tamil Nadu, India|Novo Nordisk Investigational Site, Tel-Hashomer, Israel|Novo Nordisk Investigational Site, Firenze, Italy|Novo Nordisk Investigational Site, Milano, Italy|Novo Nordisk Investigational Site, Roma, Italy|Novo Nordisk Investigational Site, Torino, Italy|Novo Nordisk Investigational Site, Aichi, Japan|Novo Nordisk Investigational Site, Hiroshima, Japan|Novo Nordisk Investigational Site, Hyogo, Japan|Novo Nordisk Investigational Site, Niigata, Japan|Novo Nordisk Investigational Site, Osaka, Japan|Novo Nordisk Investigational Site, Saitama, Japan|Novo Nordisk Investigational Site, Saitama, Japan|Novo Nordisk Investigational Site, Shizuoka, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Daejeon, Korea, Republic of|Novo Nordisk Investigational Site, Jeju-do, Korea, Republic of|Novo Nordisk Investigational Site, Seoul, Korea, Republic of|Novo Nordisk Investigational Site, Vilnius, Lithuania|Novo Nordisk Investigational Site, Vilnius, Lithuania|Novo Nordisk Investigational Site, Ampang, Selangor, Malaysia|Novo Nordisk Investigational Site, Monterrey, Nuevo León, Mexico|Novo Nordisk Investigational Site, Krakow, Poland|Novo Nordisk Investigational Site, Lublin, Poland|Novo Nordisk Investigational Site, Lublin, Poland|Novo Nordisk Investigational Site, Poznań, Poland|Novo Nordisk Investigational Site, Warszawa, Poland|Novo Nordisk Investigational Site, Wroclaw, Poland|Novo Nordisk Investigational Site, Porto, Portugal|Novo Nordisk Investigational Site, Krasnodar, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Petrozavodsk, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Belgrade, Serbia|Novo Nordisk Investigational Site, Belgrade, Serbia|Novo Nordisk Investigational Site, Kragujevac, Serbia|Novo Nordisk Investigational Site, Novi Sad, Serbia|Novo Nordisk Investigational Site, Bratislava, Slovakia|Novo Nordisk Investigational Site, Parktown, Johannesburg, Gauteng, South Africa|Novo Nordisk Investigational Site, Polokwane, Limpopo, South Africa|Novo Nordisk Investigational Site, Madrid, Spain|Novo Nordisk Investigational Site, Málaga, Spain|Novo Nordisk Investigational Site, Oviedo, Spain|Novo Nordisk Investigational Site, Sevilla, Spain|Novo Nordisk Investigational Site, Valencia, Spain|Novo Nordisk Investigational Site, Malmö, Sweden|Novo Nordisk Investigational Site, Solna, Sweden|Novo Nordisk Investigational Site, Zürich, Switzerland|Novo Nordisk Investigational Site, Bangkok, Thailand|Novo Nordisk Investigational Site, Adana, Turkey|Novo Nordisk Investigational Site, Ankara, Turkey|Novo Nordisk Investigational Site, Ankara, Turkey|Novo Nordisk Investigational Site, Capa-ISTANBUL, Turkey|Novo Nordisk Investigational Site, Edirne, Turkey|Novo Nordisk Investigational Site, Izmir, Turkey|Novo Nordisk Investigational Site, Samsun, Turkey|Novo Nordisk Investigational Site, Kyiv, Ukraine|Novo Nordisk Investigational Site, Lviv, Ukraine|Novo Nordisk Investigational Site, Belfast, United Kingdom|Novo Nordisk Investigational Site, London, United Kingdom|Novo Nordisk Investigational Site, Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04082429"
272,"NCT02074358","A Study to Assess the Effects of 2 Prothrombin Complex Concentrates on the Pharmacodynamics of Apixaban in Healthy Adult Subjects",,"Completed","Has Results","Anticoagulation","Drug: Apixaban|Drug: Cofact (4-Factor PCC)|Drug: Beriplex P/N (4-Factor PCC)|Drug: Placebo (Saline solution)","Pharmacodynamic (PD) Parameter: Adjusted Mean Change in Endogenous Thrombin Potential (ETP) From Day 4 Pre-Infusion (PCC or Placebo) Baseline at Day 4, 30 Minutes Post Infusion of PCC or Placebo|PD Parameter: Adjusted Mean Change in Endogenous Thrombin Potential (ETP) From Day 1 Pre-Dose Apixaban Baseline at Day 4, 30 Minutes Post Infusion of PCC or Placebo|PD Parameters: Adjusted Mean Change in TGA Lag Time and Adjusted Mean Change in TGA Time to Peak From Day 4 Pre-Infusion (PCC or Placebo) Baseline at Day 4, 30 Minutes Post Infusion of PCC or Placebo|PD Parameter: Adjusted Mean Change in TGA Peak Height From Day 4 Pre-Infusion (PCC or Placebo) Baseline at Day 4, 30 Minutes Post Infusion of PCC or Placebo|PD Parameter: Adjusted Mean Change in TGA Velocity Index From Day 4 Pre-Infusion (PCC or Placebo) Baseline at Day 4, 30 Minutes Post Infusion of PCC or Placebo|PD Parameter: Adjusted Mean Change in Coagulation Parameters Prothrombin Time (PT) and Activated Partial Thromboplastin Time (aPTT) From Day 4 Pre-Infusion (PCC or Placebo) Baseline at Day 4, 30 Minutes Post Infusion of PCC or Placebo|PD Parameter: Adjusted Mean Change in Coagulation Parameter International Normalized Ratio (INR) From Day 4 Pre-Infusion (PCC or Placebo) Baseline at Day 4, 30 Minutes Post Infusion of PCC or Placebo|PD Parameter: Adjusted Mean Change in Plasma Anti-Xa Activity From Day 4 Pre-Infusion (PCC or Placebo) Baseline at Day 4, 30 Minutes Post Infusion of PCC or Placebo|PD Parameter: Adjusted Mean Change in TGA Lag Time and TGA Time to Peak From Day 1 Pre-Dose Apixaban Baseline at Day 4, 30 Minutes Post Infusion of PCC or Placebo|PD Parameter: Adjusted Mean Change in TGA Peak Height From Day 1 Pre-Dose Apixaban Baseline at Day 4, 30 Minutes Post Infusion of PCC or Placebo|PD Parameter: Adjusted Mean Change in TGA Velocity Index From Day 1 Pre-Dose Apixaban Baseline at Day 4, 30 Minutes Post Infusion of PCC or Placebo|PD Parameter: Adjusted Mean Change in Coagulation Parameters PT and aPTT From Day 1 Pre-Dose Apixaban Baseline at Day 4, 30 Minutes Post Infusion of PCC or Placebo|PD Parameter: Adjusted Mean Change in Coagulation Parameter INR From Day 1 Pre-Dose Apixaban Baseline at Day 4, 30 Minutes Post Infusion of PCC or Placebo|Geometric Mean Maximum Observed Plasma Concentration (Cmax) of Apixaban on Day 4|Geometric Mean Time of Maximum Observed Plasma Concentration (Tmax) of Apixaban on Day 4|Geometric Mean Area Under the Plasma Concentration-Time Curve in One Dosing Interval [AUC(0-12)] of Apixaban on Day 4|Adjusted Geometric Mean AUC (0-12) of Apixaban on Day 4|Geometric Mean Area Under the Plasma Concentration-Time Curve From Time Zero to 24 Hours After Dose Administration [AUC(0-24)] of Apixaban on Day 4|Adjusted Geometric Mean AUC (0-24) for Apixaban on Day 4|Geometric Mean Trough Observed Plasma Concentration at the End of One Dosing Interval (12h) [Cmin] of Apixaban on Day 4|Mean Terminal Elimination Half-Life (T-HALF) of Apixaban on Day 4|Number of Participants With Death, Serious Adverse Events (SAEs), Adverse Events (AEs), and Discontinuation Due to AEs - Treatment Population|Number of Participants With Marked Abnormalities (MA) in Laboratory Tests - Treated Population|Number of Participants With Out of Range Electrocardiogram (ECG) Intervals and Number of Participants With a Change From Baseline of Greater Than 30 Milliseconds in QT and QTcF|Mean Change From Baseline in Diastolic and Systolic Blood Pressure on Day 4 and Day 7|Mean Change From Baseline in Heart Rate on Day 4 and Day 7|Mean Change From Baseline in Respiration Rate on Day 4 and Day 7|Mean Change From Baseline Temperature on Day 4 and Day 7","Bristol-Myers Squibb","All","18 Years to 45 Years   (Adult)","Phase 1","43","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","CV185-156|2013-000646-18","February 2014","April 2014","April 2014","February 28, 2014","August 13, 2015","August 13, 2015",,,"https://ClinicalTrials.gov/show/NCT02074358"
273,"NCT01809886","Reversal With Sugammadex From Deep Neuromuscular Blockade Induced by Rocuronium in Children: Randomised Clinical Trial","SUGAPED-01","Completed","No Results Available","Neuromuscular Blockade","Drug: Sugammadex|Drug: Neostigmine","The time in seconds which has elapsed until a T4/T1 ratio >0,9.|Heart Rate (beats / min)|Systolic and Diastolic blood pressure (mm HG)|Arterial oxygen saturation (%)|Total dose of rocuronium (mg/kg)|Number of participants with at least One Adverse event (AE)|Time in seconds from the initial dose administered of rocuronium until the maximum block is achieved(Onset time)|The time in seconds which has elapsed until a T4/T1 >0,8 is achieved.|The time in seconds which has elapsed until a T4/T1 ratio >0,7","Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia|Hospital Universitario Virgen de la Arrixaca|Hospital Universitario Santa Maria del Rosell","All","2 Years to 11 Years   (Child)","Phase 3","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CT-PED-2010-01CT|2011-000401-50","October 2011","October 2013","December 2013","March 13, 2013",,"March 6, 2014","Mª Dolores Cárceles Barón, El Palmar, Murcia, Spain",,"https://ClinicalTrials.gov/show/NCT01809886"
274,"NCT02554773","An Open-label Extension Study of an Investigational Drug, Fitusiran, in Patients With Moderate or Severe Hemophilia A or B",,"Active, not recruiting","No Results Available","Hemophilia A|Hemophilia B","Drug: Fitusiran (SAR439774)","Number of participants with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and AEs leading to study drug discontinuation|Annualized bleed rate (ABR)|Time intervals between bleeding episodes|Weight-adjusted consumption of FVIII, FIX, or BPA|Changes in health-related quality of life (QOL) with long-term dosing of fitusiran|Pharmacokinetics (PK) of fitusiran: Cmax|Pharmacokinetics (PK) of fitusiran: AUC|Pharmacokinetics (PK) of fitusiran: t1/2|Pharmacokinetics (PK) of fitusiran: CL/F|Pharmacokinetics (PK) of fitusiran: V/F|The effect of fitusiran on plasma levels of antithrombin (AT) and thrombin generation (TG)","Genzyme, a Sanofi Company|Sanofi","Male","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","37","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LTE14762|ALN-AT3SC-002|2015-001395-21|U1111-1251-5204","September 18, 2015","October 20, 2023","October 20, 2023","September 18, 2015",,"October 26, 2021","Clinical Trial Site, Ann Arbor, Michigan, United States|Clinical Trial Site, Pittsburgh, Pennsylvania, United States|Clinical Trial Site, Plovdiv, Bulgaria|Clinical Trial Site, Sofia, Bulgaria|Clinical Trial Site, Kirov, Russian Federation|Clinical Trial Site, Moscow, Russian Federation|Clinical Trial Site, Zurich, Switzerland|Clinical Trial Site, Basingstoke, United Kingdom|Clinical Trial Site, Glasgow, United Kingdom|Clinical Trial Site, London, United Kingdom|Clinical Trial Site, London, United Kingdom|Clinical Trial Site, Truro, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02554773"
275,"NCT03415178","Usability Study of the Commercial Auto-injector Device and the New Auto-injector Device (SYDNEY) in Patients With High or Very High CV Risk With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy",,"Completed","Has Results","Hypercholesterolaemia","Drug: Alirocumab SAR236553|Device: Current auto-injector device (AI)|Device: New auto-injector device (SYDNEY)|Drug: Atorvastatin|Drug: Rosuvastatin","Percentage of SYDNEY-Associated Product Technical Complaints (PTCs) (Overall) at the Unsupervised Injections: Single-Arm Period|Percentage of SYDNEY-Associated Product Technical Complaints (PTCs) (by Type) at the Unsupervised Injections: Single-Arm Period|Percentage of Participants With a SYDNEY or Current Auto-Injector (AI)-Associated Product Technical Complaint (PTCs) (Overall and by Type) at the Supervised Injections on Week 0 (Day 1): Parallel-Arm Period|Percentage of Participants With SYDNEY-Associated Product Technical Complaint (PTCs) (Overall and by Type) at the Unsupervised Injections : Single-Arm Period|Injection Experience Questionnaire at Initial Supervised Injection: Overall Ease of Use Scores: Parallel-Arm Period|Patient Perspective Questionnaire After the Last Injection (at Week 12): Single-Arm Period|Injection-Treatment Acceptance Questionnaire (I-TAQ©) After Last Injection (at Week 12) - Overall Acceptance Scores: Single-Arm Period|Maximum Serum Alirocumab Concentration Observed - Cmax : Parallel-Arm Period|Time to Reach Maximum Observed Plasma Concentration (Tmax) of Alirocumab : Parallel-Arm Period|Area Under the Curve-During the Dosing Interval Tau (AUC [0-tau]) : Parallel-Arm Period|Maximum Serum Alirocumab Concentration Observed - Cmax : Single-Arm Period|Time to Reach Maximum Observed Plasma Concentration (Tmax) of Alirocumab: Single-Arm Period|Area Under the Curve-During the Dosing Interval Tau (AUC [0-tau]) : Single-Arm Period|Free Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Concentrations : Parallel-Arm Period|Free Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Concentrations : Single-Arm Period|Total Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Concentrations : Parallel-Arm Period|Total Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Concentrations : Single-Arm Period|Number of Participants With Treatment-Emergent Anti-Alirocumab Antibodies (ADA) Positive Response: Parallel-Arm Period|Number of Participants With Treatment-Emergent Anti-Alirocumab Antibodies (ADA) Positive Response According to ADA Status During Parallel-Arm Period: Single Arm Period|Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 4: Parallel-Arm Period|Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 8, 12, 16: Single-Arm Period","Sanofi|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","69","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSC14864|U1111-1186-3466","March 29, 2018","August 9, 2018","August 9, 2018","January 30, 2018","September 9, 2019","September 9, 2019","Investigational Site Number 8400024, Los Angeles, California, United States|Investigational Site Number 8400007, Jacksonville, Florida, United States|Investigational Site Number 8400017, Jacksonville, Florida, United States|Investigational Site Number 8400013, Ponte Vedra, Florida, United States|Investigational Site Number 8400014, Wellington, Florida, United States|Investigational Site Number 8400001, West Des Moines, Iowa, United States|Investigational Site Number 8400019, Topeka, Kansas, United States|Investigational Site Number 8400006, Cincinnati, Ohio, United States|Investigational Site Number 8400010, Cincinnati, Ohio, United States|Investigational Site Number 8400022, Summerville, South Carolina, United States|Investigational Site Number 8400026, Amarillo, Texas, United States|Investigational Site Number 8400005, Richmond, Virginia, United States|Investigational Site Number 8400027, Manitowoc, Wisconsin, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT03415178/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT03415178/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03415178"
276,"NCT01502410","Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer",,"Completed","Has Results","Childhood Hepatocellular Carcinoma|Papillary Thyroid Cancer|Previously Treated Childhood Rhabdomyosarcoma|Recurrent Childhood Liver Cancer|Recurrent Childhood Rhabdomyosarcoma|Recurrent Thyroid Cancer|Recurrent Wilms Tumor and Other Childhood Kidney Tumors","Drug: sorafenib tosylate|Other: pharmacological study|Other: laboratory biomarker analysis","Objective Response by RECIST Criteria v 1.1|Progression-free Survival According to RECIST Version 1.1|The Number of Patients Who Experience at Least One Grade 3 or Higher CTC Version 4 Toxicity,|Pharmacokinetic (PK) Parameters of Sorafenib Tosylate|Change in VEGF and VEGFR-2|Presence of BRAF Mutation or RET/PTC Rearrangement","National Cancer Institute (NCI)","All","2 Years to 30 Years   (Child, Adult)","Phase 2","20","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2012-00106|COG-ADVL1121|CDR0000721611|ADVL1121|U10CA098543","January 2012","June 2014","June 2014","December 30, 2011","May 15, 2015","June 26, 2018","Children's Hospital of Alabama, Birmingham, Alabama, United States|University of Alabama at Birmingham, Birmingham, Alabama, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Southern California Permanente Medical Group, Downey, California, United States|Miller Children's Hospital, Long Beach, California, United States|Children's Hospital Los Angeles, Los Angeles, California, United States|Children's Hospital Central California, Madera, California, United States|Childrens Hospital of Orange County, Orange, California, United States|Rady Children's Hospital - San Diego, San Diego, California, United States|University of California San Francisco Medical Center-Parnassus, San Francisco, California, United States|Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center, Denver, Colorado, United States|Connecticut Children's Medical Center, Hartford, Connecticut, United States|Alfred I duPont Hospital for Children, Wilmington, Delaware, United States|Children's National Medical Center, Washington, District of Columbia, United States|Lee Memorial Health System, Fort Myers, Florida, United States|Nemours Children's Clinic - Jacksonville, Jacksonville, Florida, United States|Florida Hospital, Orlando, Florida, United States|Nemours Children's Clinic - Orlando, Orlando, Florida, United States|Nemours Children's Clinic - Pensacola, Pensacola, Florida, United States|All Children's Hospital, Saint Petersburg, Florida, United States|Saint Joseph Children's Hospital of Tampa, Tampa, Florida, United States|Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States|University of Hawaii, Honolulu, Hawaii, United States|Saint Luke's Mountain States Tumor Institute, Boise, Idaho, United States|Lurie Children's Hospital-Chicago, Chicago, Illinois, United States|University of Illinois, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Saint Jude Midwest Affiliate, Peoria, Illinois, United States|Southern Illinois University, Springfield, Illinois, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|University of Kentucky, Lexington, Kentucky, United States|Kosair Children's Hospital, Louisville, Kentucky, United States|Tulane University Health Sciences Center, New Orleans, Louisiana, United States|Sinai Hospital of Baltimore, Baltimore, Maryland, United States|Mark O Hatfield-Warren Grant Magnuson Clinical Center, Bethesda, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Dana-Farber Harvard Cancer Center, Boston, Massachusetts, United States|Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States|Bronson Methodist Hospital, Kalamazoo, Michigan, United States|University of Minnesota Medical Center-Fairview, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|The Childrens Mercy Hospital, Kansas City, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Children's Hospital and Medical Center of Omaha, Omaha, Nebraska, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Morristown Memorial Hospital, Morristown, New Jersey, United States|UMDNJ - Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States|Overlook Hospital, Summit, New Jersey, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|Montefiore Medical Center - Moses Campus, Bronx, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Columbia University Medical Center, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|University of Rochester, Rochester, New York, United States|State University of New York Upstate Medical University, Syracuse, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Carolinas Medical Center, Charlotte, North Carolina, United States|Novant Health Presbyterian Medical Center, Charlotte, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Children's Hospital Medical Center of Akron, Akron, Ohio, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Rainbow Babies and Childrens Hospital, Cleveland, Ohio, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Dayton Children's Hospital, Dayton, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Oregon Health and Science University, Portland, Oregon, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Oncology Group, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|BI-LO Charities Children's Cancer Center, Greenville, South Carolina, United States|Greenville Cancer Treatment Center, Greenville, South Carolina, United States|East Tennessee Childrens Hospital, Knoxville, Tennessee, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|Driscoll Children's Hospital, Corpus Christi, Texas, United States|Medical City Dallas Hospital, Dallas, Texas, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Cook Children's Medical Center, Fort Worth, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Childrens Hospital-King's Daughters, Norfolk, Virginia, United States|Seattle Children's Hospital, Seattle, Washington, United States|Providence Sacred Heart Medical Center and Children's Hospital, Spokane, Washington, United States|Midwest Children's Cancer Center, Milwaukee, Wisconsin, United States|Sydney Children's Hospital, Randwick, New South Wales, Australia|Princess Margaret Hospital for Children, Perth, Western Australia, Australia|British Columbia Children's Hospital, Vancouver, British Columbia, Canada|IWK Health Centre, Halifax, Nova Scotia, Canada|McMaster Children's Hospital at Hamilton Health Sciences, Hamilton, Ontario, Canada|Hospital for Sick Children, Toronto, Ontario, Canada|The Montreal Children's Hospital of the MUHC, Montreal, Quebec, Canada|Centre Hospitalier Universitaire Sainte-Justine, Montreal, Quebec, Canada|Centre Hospitalier Universitaire de Quebec, Ste-Foy, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT01502410"
277,"NCT05145127","Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors",,"Recruiting","No Results Available","Hemophilia A|Hemophilia B","Drug: PF-06741086","Number of subject reporting Adverse Events|Number of subjects reporting Serious Adverse Events|Incidence and severity of thrombotic events|Incidence and severity of thrombotic microangiopathy|Number of subjects reporting Disseminated intravascular coagulalopathy/consumption coagulopathy|Incidence of clinically significant persistent NAb against marstacimab|Incidence and severity of injection site reaction|Clinically significant changes in vital signs from baseline|Incidence of clinically significant laboratory value abnormalities|Incidence of severe hypersensitivity and anaphylactic reactions|Annualized rate of bleeding episodes|Total coagulation factor product consumption|Incidence of joint bleeds|Incidence of spontaneous bleeds|Incidence of target joint bleeds|Incidence of total bleeds (treated and untreated)|Percentage of participants with no bleeding episodes|Change in joints measured by the HJHS|Change in number of target joints per subject from baseline|Changes in Health Utilities Measure questionnaire data|Changes in Haem-A-QoL questionnaire data for participants ≥17 years of age|Changes in Haemo-QoL questionnaire data for participants 12 to <17 years of age|Total bypass product consumption","Pfizer","Male","12 Years to 74 Years   (Child, Adult, Older Adult)","Phase 3","145","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","B7841007|PHASE 3 ANTI-TFPI OLE","November 17, 2021","July 31, 2030","July 31, 2030","December 6, 2021",,"January 20, 2022","Nirmal Hospital Pvt Ltd., Surat, Gjuarat, India|Kyung Hee University Hospital at Gangdong, Seoul, Seoul-teukbyeolsi [seoul], Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Seoul-teukbyeolsi[seoul], Korea, Republic of|Kyungpook National University Hospital, Daegu, Taegu-kwangyǒkshi, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT05145127"
278,"NCT02369731","Registry of Translarna (Ataluren) in Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)",,"Recruiting","No Results Available","Muscular Dystrophy, Duchenne",,"Percentage of Participants With Adverse Events|Prescriber and Participant Compliance With Prescribing Information According to the Approved Labelling","PTC Therapeutics|The John Walton Muscular Dystrophy Research Centre (TREAT-NMD)|Cooperative International Neuromuscular Research Group","All","2 Years and older   (Child, Adult, Older Adult)",,"360","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","PTC124-GD-025o-DMD","April 30, 2015","May 30, 2025","May 30, 2025","February 24, 2015",,"January 11, 2022","Krankenhaus der Barmherzigen Schwestern Linz, Linz, Austria|Sozialmedizinisches Zentrum Süd Kaiser-Franz-Josef Spital mit Gottfried von Preyer´schen Kinderspital, Wien, Austria|Hospital das Clínicas da Universidade de São Paulo, São Paulo, Brazil|The University Hospital Brno, Brno, Czechia|Motol University Hospital, Praha 5 - Motol, Czechia|CHU de Bordeaux Hôpital Pellegrin Enfant, Bordeaux Cedex, France|CHRU de Brest Hôpital Morvan, Brest, France|Hospices Civils de Lyon Groupement Hospitalier Est - Bâtiment ""Les Tilleuls"", Bron Cedex, France|CHU de Clermont-Ferrand, hôpital Estaing, Clermont-Ferrand, France|CHU de Martinique - Hôpital P. Zobda-Quitman, Fort De France Cedex, France|CHRU de Lille, Lille Cedex, France|CHU de Marseille Hôpital de la Timone, Marseille Cedex 5, France|CHU de Nantes, Nantes, France|Hôpital Armand Trousseau, Paris, France|Hôpital Necker - Enfants malades, Paris, France|CHU de Reims American Memorial Hospital, Reims Cedex, France|CHU de Saint-Etienne Hôpital Bellevue, Saint Etienne Cedex 2, France|CHU de la Réunion - GHSR - GH Sud-Réunion, Saint Pierre, France|CHU de Strasbourg, Strasbourg Cedex, France|CHU de Toulouse Hôpital Pierre Paul Riquet, Toulouse Cedex, France|CHRU de Tours Hôpital Bretonneau, Tours, France|CHU de Nancy Hôpital de Brabois-Enfants Rue du Morvan, Vandoeuvre-les-Nancy, France|Klinikum Bayreuth GmbH, Bayreuth, Germany|Sozialpädiatrisches Zentrum (SPZ) Charité Berlin, Berlin, Germany|Universitätsklinikum Erlangen, Erlangen, Germany|Universitaetsklinikum Essen (AoR), Essen, Germany|SPZ Frankfurt Mitte, Frankfurt am Main, Germany|Universitaetsklinikum Freiburg, Freiburg, Germany|MVZ Kinder- und Jugendärzte Fürth GmbH, Fürth, Germany|Universitätskinderklinik Gießen, Gießen, Germany|Klinik und Poliklinik f. Kinder- und Jugendmedizin, Hamburg, Germany|Muskelzentrum, Schwerpunkt Neuropädiatrie, Kassel, Germany|Children's Hospital ""Aghia Sophia"", Athens, Greece|Ahepa University Hospital, Thessaloniki, Greece|Semmelweis Egyetem II (Semmelweis University II), Budapest, Hungary|Szent László Kórház Gyermekneurológiai szakrendelés, Budapest, Hungary|Hadassah Mount Scopus Medical Center, Jerusalem, Israel|Schneider Medical Center Tel Aviv University, Petah Tikva, Israel|Sheba Medical Center The Joseph Sagol EMG, Neuroscience Center, Ramat Gan, Israel|IRCSS Istituto delle Scienze Neurologiche, Bologna, Italy|Istituto Giannina Gaslini, Genova, Italy|AOU Policlinico ""G. Martino"", Messina, Italy|Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy|IRCCS Istituto Neurologico Carlo Besta, Milano, Italy|ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy|II Policlinico Neurofisiopatologia (Edificio 11 G), Napoli, Italy|Cardiomiologia e Genetica Medica Primo Policlinico, Napoli, Italy|AO Padova Clinica Neurologica, Padova, Italy|Fondazione Policlinico Universitario Agostino Gemelli, Roma, Italy|Bambino Gesù Children's Hospital, Rome, Italy|Ospedale Molinette SCDU Neuropsichiatria Infantile AO Città della Salute e della Scienza di Torino, Torino, Italy|Bērnu klīniskā universitātes slimnīca, Riga, Latvia|St. Olavs hospital University children's clinical hospital, Trondheim, Norway|Centro Hospitalar e Universitário de coimbra EPE - Hospital Pediátrico de Coimbra, Coimbra, Portugal|Centro Hospitalar Lisboa Norte EPE - Hospital de Santa Maria, Lisboa, Portugal|Centro Hospitalar do Porto EPE - Hospital Geral de Santo António, Porto, Portugal|Spitalul Clinic de Copii ""Dr. Victor Gomoiu"" Sectia Clinica Neurologie Pediatrica, Bucharest, Romania|Regina Maria Policlinica Opera Center, Bucharest, Romania|University Children's Hospital University Medical Centre Ljubljana, Ljubljana, Slovenia|Göteborgs Universitet Avdelningen för pediatrik vid institutionen för kliniska vetenskaper, Goteborg, Sweden|Karolinska Institutet, Stockholm, Sweden|Birmingham Heartlands Hospital, Birmingham, United Kingdom|Bristol Children's Hospital, Bristol, United Kingdom|Addenbrooke's Hospital, Cambridge, United Kingdom|Children Hospital - Children's Neurosciences Leeds TEACHING HOSPITALS NHS Trust, Leeds, United Kingdom|Children's Hospital Alder Hey Children's Hospital NHS Trust, Liverpool, United Kingdom|St Thomas' Hospital Children Services, London, United Kingdom|UCL Great Ormond Street Institute of Child Health, London, United Kingdom|Royal Manchester Children's Hospital, Manchester, United Kingdom|The John Walton Muscular Dystrophy Research Centre, Newcastle, United Kingdom|NIHR Lancashire Clinical Research Facility Royal Preston Hospital, Preston, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02369731"
279,"NCT05132205","Radiofrequency Ablation of Papillary Thyroid Microcarcinoma",,"Recruiting","No Results Available","Papillary Thyroid Cancer","Procedure: Radiofrequency Ablation","Percentage change in nodule volume|Change in voice related quality of life as assessed by the VHI-10|Scar cosmesis score|Change in eating assessment score as assessed by the EAT-10|Change in overall quality of life assessed by the PROMIS score|Number of complications","Johns Hopkins University","All","18 Years to 100 Years   (Adult, Older Adult)","Not Applicable","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00236242","December 17, 2021","September 28, 2024","September 28, 2024","November 24, 2021",,"December 21, 2021","Johns Hopkins Hospital, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT05132205"
280,"NCT03441828","Effects of Depth of Neuromuscular Block on Surgical Operating Conditions in Gynecologic Laparoscopic Surgery",,"Completed","No Results Available","Neuromuscular Blockade","Procedure: Quality of surgical field conditions|Drug: Deep Neuromuscular Block|Drug: Moderate Neuromuscular Block","impact of a deep neuromuscular blockade on surgical conditions|the time to discharge from post-anesthesia care unit","Federico II University","Female","18 Years to 60 Years   (Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Supportive Care","Registro MISP n.54876","February 1, 2020","July 1, 2020","July 31, 2020","February 22, 2018",,"December 4, 2020","University Federico II - AOU, Napoli, Italy",,"https://ClinicalTrials.gov/show/NCT03441828"
281,"NCT01539044","Optimal Relaxation Technique for Laparotomies With Rocuronium Infusion Followed by Sugammadex Reversal","ProjectO5Rs","Completed","No Results Available","Underdosing of Skeletal Muscle Relaxants for Laparotomy|Reversal of Skeletal Muscle Relaxant","Drug: Neostigmine, atropine|Drug: Sugammadex","speed of reversal|Vital signs, i.e. heart rate and blood pressure|intraoperative events|incidence of residual neuromuscular blockade","Hospital Sultanah Aminah Johor Bahru","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","49","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","NMRR-10-1323-7843","February 2012","June 2013","June 2013","February 27, 2012",,"August 7, 2015","Hospital Sulatanah Aminah, Johor Bahru, Johor, Malaysia",,"https://ClinicalTrials.gov/show/NCT01539044"
282,"NCT01565486","Safety and Efficacy Study of Ultrasonic Coagulation Device and Bipolar Energy Sealing System","UCBEST","Unknown status","No Results Available","Thyroid Cancer","Device: Ultrasonic coagulation device (Harmonic ACE® scalpel)|Device: bipolar energy sealing system (LigaSure Precise)","operation time|postoperative complications|postoperative drainage volume|admission time|Cost|Relapse-free survival (RFS)|Overall Survival (OS)","Seoul St. Mary's Hospital","All","20 Years to 80 Years   (Adult, Older Adult)","Not Applicable","304","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","KC11DISI0534","August 2011","January 2013","August 2017","March 28, 2012",,"December 5, 2012","Seoul St. Mary's Hospital, Seocho-gu, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01565486"
283,"NCT01757405","Recombinant Factor VIIa BI (rFVIIa BI) Treatment of Acute Bleeding Episodes Per an On-demand Regimen",,"Completed","Has Results","Hemophilia A|Hemophilia B","Biological: Recombinant Factor VIIa BI (rFVIIa BI)","Percentage of Bleeding Episode With ""Treatment Success""|Treatment Response for Each Bleeding Episode|Percentage of Clinical Responders (Sustained Bleeding Control) for All Acute Bleeding Episodes|Safety and Tolerability of Treatment Regimens by Clinical Assessment of Percentage of Participants With Adverse Events (AEs)|Safety and Tolerability of Treatment Regimens by Clinical Assessment of Adverse Events (AEs)|Percentage of Participants With Inhibitor Development to FVII","Baxalta now part of Shire|Takeda","Male","12 Years to 65 Years   (Child, Adult, Older Adult)","Phase 3","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","021101|2011-006294-26","February 20, 2013","November 11, 2014","November 11, 2014","December 28, 2012","October 25, 2016","May 11, 2021","Health Point Medical Group ""St Joseph's Children's Hospital"", Tampa, Florida, United States|Nara Medical University Hospital, Nara, Japan|Tokyo Medical University Hospital, Tokyo, Japan|Kracow Medical Center, LLC, Krakow, Poland|Institute of Haematology and Transfusion Medicine, Clinic of Haemostatic Disorders and Internal Diseases, Warszawa, Poland|Louis Turcanu Emergency Clinical Children´s Hospital, Timisoara, Romania|Kirov Hematology and Blood Transfusion Research Institute under the Federal Medical and Biological Agency of Russia, Kirov, Russian Federation|Hematology Research Center under RAMS (State Institution), Department of Reconstructive Orthopedic Surgery for Hemophilia Patients, Moscow, Russian Federation|St. Petersburg City Healthcare Institution Municipal Policlinic # 37, St. Petersburg, Russian Federation|Clinic for Hematology of the Clinical Center of Serbia, Belgrade, Serbia|Hospital Teresa Herrera Materno Infantil del C.H.U.Carretera del Pasajes/nlaboratorio de hematología, A Coruña, Spain|University Hospital Virgen del Rocio, Sevilla, Spain|Tri-Service General Hospital (TSGH), Taipei City, Taiwan|V.K. Gusak Institute of Urgent and Reconstructive Surgery within the Ukrainian National Academy of Medical Sciences, Hematology Department, Donetsk, Ukraine|Kyiv City Clinical Hospital #9, City Scientific-Practical Center for Diagnostics and Treatment of Patients with Hemostatic Pathlogies, Kiev, Ukraine|State Institution ""Institute of Blood Pathology and Transfusion Medicine within the Ukrainian National Academy of Medical Sciences"", Hematology Department, Lviv, Ukraine",,"https://ClinicalTrials.gov/show/NCT01757405"
284,"NCT02405416","Infrahepatic Inferior Vena Cava Clamping Versus Selective Hepatic Vascular Exclusion Involving the Portal Triad Clamping",,"Unknown status","No Results Available","Liver Neoplasms|Liver Cirrhosis","Procedure: Infrahepatic inferior vena cava clamping|Procedure: Selective hepatic vascular exclusion|Procedure: Portal triad clamping","Intraoperative blood loss|Normalized transection-related blood loss|Time of infrahepatic inferior vena cava or selected hepatic vein dissection|Variations of intraoperative infrahepatic inferior vena cava pressure or hepatic vein pressure|Drop of hemoglobin level|Postrecovery of liver function|Postrecovery of renal function|Morbidity of postoperative complications|Postoperative mortality","Huazhong University of Science and Technology","All","18 Years and older   (Adult, Older Adult)","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","chenxp006|2012ZX10002016-004","March 2015","March 2017","June 2017","April 1, 2015",,"April 1, 2015","Tongji Hospital, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT02405416"
285,"NCT00000582","Cooperative Study of Factor VIII Inhibitors",,"Completed","No Results Available","Blood Coagulation Disorders|Hematologic Diseases|Hemophilia A|Hemorrhagic Disorders","Drug: factor ix",,"National Heart, Lung, and Blood Institute (NHLBI)","Male","18 Years to 75 Years   (Adult, Older Adult)","Phase 3",,"NIH","Interventional","Masking: Double|Primary Purpose: Treatment","302","July 1978",,"July 1979","October 28, 1999",,"April 27, 2012",,,"https://ClinicalTrials.gov/show/NCT00000582"
286,"NCT03800238","Telehealth Powerful Tools for Caregivers Effectiveness Study","TPTC","Completed","No Results Available","Caregivers","Behavioral: Telehealth Delivery Format|Behavioral: Standard Delivery Format","Center for Epidemiologic Studies Depression Scale - Revised (CESD-R)|Bakas Caregiving Outcomes Scale (BCOS)|Custom created questionnaire: PTC Taking Care of You Survey","Concordia University Wisconsin","All","18 Years and older   (Adult, Older Adult)","Not Applicable","115","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","ConcordiaUW","February 1, 2019","October 8, 2020","October 8, 2020","January 11, 2019",,"October 29, 2020","OPICA Adult Day Program, Los Angeles, California, United States|Health Projects Center, Santa Cruz, California, United States|Tampa General Hospital, Tampa, Florida, United States|Southeast Idaho Council of Governments Inc, Pocatello, Idaho, United States|Iowa State University (ISU) Extension and Outreach, Webster City, Iowa, United States|Michigan State University, Grand Rapids, Michigan, United States|Lutheran Social Service, Moorhead, Minnesota, United States|Executive Services Corps - NE, Plattsmouth, Nebraska, United States|Concord Regional Visiting Nurse Association (VNA), Concord, New Hampshire, United States|Kettering Health Network, Beavercreek, Ohio, United States|Hope Grows and UPMC Health Plan, Allegheny, Pennsylvania, United States|Jane Joyce, Morristown, Tennessee, United States|Central East Local Health Integration Network, Whitby, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03800238"
287,"NCT04594720","Circulating Biomarkers to Identify Thyroid Cancer",,"Completed","No Results Available","Thyroid Cancer|Thyroid Cancer, Papillary|Benign Thyroid Tumor","Other: Identification group|Other: Validation group","Stage of thyroid cancers","Chang Gung Memorial Hospital","All","20 Years to 100 Years   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","201801437B0","October 1, 2018","October 31, 2019","September 30, 2020","October 20, 2020",,"October 20, 2020","Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan",,"https://ClinicalTrials.gov/show/NCT04594720"
288,"NCT04434001","ZEPLAST- PED: ZEro_PLASma Trial in Small Infants Undergoing Cardiac Surgery","ZEPLAST-PED","Terminated","No Results Available","Bleeding|Cardiac Defect|Surgery--Complications|Fibrinogenopenia; Acquired|Transfusion-Related Acute Lung Injury|Transfusion-Associated Circulatory Overload|Congenital Heart Disease","Drug: Fibrinogen Concentrate Human|Drug: Prothrombin Complex Concentrate|Biological: Fresh Frozen Plasma","Transfusion of Fresh Frozen Plasma (FFP)|Postoperative bleeding|Severe bleeding|Surgical re-exploration for bleeding","IRCCS Policlinico S. Donato","All","up to 2 Years   (Child)","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","ZEPLAST-PED","February 27, 2020","May 31, 2021","June 30, 2021","June 16, 2020",,"November 3, 2021","IRCCS Policlinico San Donato, San Donato Milanese, MI, Italy",,"https://ClinicalTrials.gov/show/NCT04434001"
289,"NCT00103155","Radiofrequency Ablation in Treating Patients Who Are Undergoing Surgery for Thyroid Cancer",,"Unknown status","No Results Available","Head and Neck Cancer","Procedure: conventional surgery|Procedure: radiofrequency ablation","Frequency of radiofrequency ablation-associated complications at 2 weeks|Amount of tumor destruction at 2 weeks","University of California, San Francisco|National Cancer Institute (NCI)","All","21 Years and older   (Adult, Older Adult)","Phase 1",,"Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000410790|UCSF-H28355-23383-01|UCSF-03202","September 2004",,,"February 8, 2005",,"September 20, 2013","UCSF Comprehensive Cancer Center, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT00103155"
290,"NCT00890617","Cryotherapy in Treating Patients With Primary Stage I Non-Small Cell Lung Cancer or Lung Metastasis",,"Active, not recruiting","Has Results","Lung Cancer|Metastatic Cancer","Procedure: Cryotherapy (PTC)|Drug: Prednisone","The Number of Patients With a Response (Complete Response and Partial Response)|The Number of Patients With a Pathologic Response","Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI)","All","18 Years to 120 Years   (Adult, Older Adult)","Phase 1","9","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000640304|P30CA022453|WSU-2008-048","March 2009","July 27, 2019","December 2022","April 30, 2009","July 29, 2020","November 3, 2021","Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/17/NCT00890617/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT00890617"
291,"NCT04073498","The Safety and Tolerability of SerpinPC in Healthy Men and in Men With Severe Blood Disorders (Haemophilia A and B)",,"Active, not recruiting","No Results Available","Hemophilia A|Hemophilia B","Drug: SerpinPC|Drug: Placebo","Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|PK of SerpinPC in plasma after single dose administration - Cmax|PK of SerpinPC in plasma after single dose administration - Tmax|PK of SerpinPC in plasma after single dose administration - kel|PK of SerpinPC in plasma after single dose administration - t1/2|PK of SerpinPC in plasma after single dose administration - AUC|PK of SerpinPC in plasma after single dose administration - AUC0-t|PK of SerpinPC in plasma after single dose administration - AUC0-inf|PK of SerpinPC in plasma after single dose administration - AUC%|PK following multiple dose administration - Cmax|PK following multiple dose administration - Tmax|PK following multiple dose administration - Kel|PK following multiple dose administration - t1/2|PK following multiple dose administration - AUC|PK following multiple dose administration - AUC(0-τ)|PK following multiple dose administration - R0|PK following multiple dose administration - Ctrough","ApcinteX Ltd","Male","18 Years to 55 Years   (Adult)","Phase 1|Phase 2","50","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","AP-0101","August 14, 2019","October 2022","October 2022","August 29, 2019",,"December 28, 2021","Arensia Clinical Research Unit, Tbilisi, Georgia|Arensia Clinical Research Unit, Chisinau, Moldova, Republic of|Simbec Research Ltd, Merthyr Tydfil, Cardiff, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04073498"
292,"NCT00638001","Impact of Conservative Treatment by Custom-made Orthoses in Patients With Haemophilic Ankle Arthropathy",,"Completed","No Results Available","Haemophilia A|Haemophilia B","Device: custom-molded insoles and custom-molded shoes","Gait analysis, foot pressure measurement, specific joint score","Cliniques universitaires Saint-Luc- Université Catholique de Louvain","Male","13 Years to 80 Years   (Child, Adult, Older Adult)","Phase 4","70","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","READ-LOBET-01","March 2008","March 2012","March 2012","March 18, 2008",,"July 11, 2014","cliniques Universitaires Saint Luc, Brussels, Belgium",,"https://ClinicalTrials.gov/show/NCT00638001"
293,"NCT02300519","Thrombin Generation Numerical Models Validation in Haemophilic Case",,"Completed","No Results Available","Haemophilia B|Haemophilia A","Other: blood sampling","Endogenous Thrombin Potential (ETP) predicted by numerical models|Lag Time of the thrombin generation curve predicted by numerical models|Peak value of the thrombin generation curve predicted by numerical models|Time to peak (TTP) of the thrombin generation curve predicted by numerical models|Velocity Index (V) of the thrombin generation curve predicted by numerical models|Endogenous Thrombin Potential (ETP) for volunteers|Lag Time of the thrombin generation curve for volunteers|Peak value of the thrombin generation curve for volunteers|Time to peak (TTP) of the thrombin generation curve for volunteers|Velocity Index (V) of the thrombin generation curve for volunteers","Centre Hospitalier Universitaire de Saint Etienne|Pfizer|Ecole Normale Supérieure des Mines de Saint-Etienne","Male","18 Years to 45 Years   (Adult)",,"40","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","1408185|2014-A01734-43","March 2015","July 2015","July 2015","November 25, 2014",,"August 13, 2015","Chu Saint-Etienne, Saint-Etienne, France",,"https://ClinicalTrials.gov/show/NCT02300519"
294,"NCT01933425","Optimizing Surgical Conditions During Gynecologic Laparoscopic Surgery With Deep Neuromuscular Blockade",,"Completed","Has Results","Neuromuscular Blockade","Drug: rocuronium|Drug: sugammadex|Drug: placebo","Intraabdominal Distance (Centimeters)|Surgical Conditions During Suturing of the Abdominal Fascia","Herlev Hospital","Female","18 Years and older   (Adult, Older Adult)","Phase 4","14","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","NMBDK2013|2013-001164-29","August 2013","April 2014","April 2014","September 2, 2013","March 30, 2015","March 30, 2015","Department of minimal invasive gynecology Aleris-Hamlet Private Hospital, Copenhagen, Søborg, Denmark",,"https://ClinicalTrials.gov/show/NCT01933425"
295,"NCT04567719","Measuring Taste Perception During Chemotherapy for Muscle Invasive Bladder Cancer",,"Recruiting","No Results Available","Bladder Cancer",,"Perceived strength of taste for the bitter and sweet tastes|Changes in nutrition status|Change in body composition|TAS2R38 expression in tongue and tumor/ tumor- adjacent tissues|Differences between nutrition status at protocol scheduled visits|Difference between body composition at protocol scheduled visits|Difference between TAS2R38 expression at protocol scheduled visits.","University of Kansas Medical Center|American Cancer Society, Inc.","All","18 Years and older   (Adult, Older Adult)",,"20","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","IIT-2019-BitterTaste","March 3, 2020","December 2022","December 2023","September 28, 2020",,"January 24, 2022","The University of Kansas Medical Center, Kansas City, Kansas, United States|The University of Kansas Cancer Center, Westwood Campus, Kansas City, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT04567719"
296,"NCT00459459","Prognostic Significance of Fine-Needle Aspiration Cytology Features in Papillary Thyroid Carcinoma",,"Completed","No Results Available","Thyroid Neoplasms","Procedure: Fine needle aspiration of the thyroid",,"National Taiwan University Hospital","All","10 Years to 90 Years   (Child, Adult, Older Adult)",,"100","Other","Observational","Observational Model: Defined Population|Time Perspective: Retrospective","200704016R","January 2006",,"December 2006","April 12, 2007",,"April 12, 2007","Shyang-Rong, Shih, Dou-Liou city, Yun-Lin County, Taiwan",,"https://ClinicalTrials.gov/show/NCT00459459"
297,"NCT04312087","Lateral Neck Lymph Node Mapping in Thyroid Cancer",,"Recruiting","No Results Available","Thyroid Cancer","Procedure: Lateral neck sentinel lymph node biopsy|Procedure: Modified lateral neck lymph node dissection|Procedure: Super selective lateral neck lymph node dissection","Lymph node counts|Lymph node metastasis rate","Fudan University","All","14 Years to 80 Years   (Child, Adult, Older Adult)","Not Applicable","250","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","TC-MAP","August 1, 2016","August 1, 2021","December 31, 2022","March 18, 2020",,"March 18, 2020","Fudan University Shanghai Cancer Center, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04312087"
298,"NCT02798991","A Phase I, Randomized, Placebo-controlled, Double Blind, Repeat Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Gastrointestinal Transit Time and Pharmacodynamic Biomarkers of GSK3179106 in Normal Subjects",,"Completed","No Results Available","Irritable Bowel Syndrome","Drug: GSK3179106|Drug: Matched Placebo","Number of subjects with adverse event (AE)","GlaxoSmithKline","All","18 Years to 55 Years   (Adult)","Phase 1","46","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","205181","June 2016","November 2016","November 2016","June 14, 2016",,"January 18, 2017","GSK Investigational Site, Adelaide, South Australia, Australia",,"https://ClinicalTrials.gov/show/NCT02798991"
299,"NCT04197960","Microwave Ablation and Surgical Resection for Micropapillary Thyroid Carcinoma",,"Not yet recruiting","No Results Available","Papillary Thyroid Carcinoma","Procedure: Microwave ablation|Procedure: Surgical resection","local tumor progression|lymph node metastasis|distant metastasis|complication rate|blood loss|free thyroxine|free triiodothyronine|thyroid-stimulating hormone","Chinese PLA General Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","820","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","301jrcsk-lp","December 15, 2019","September 30, 2020","December 31, 2022","December 13, 2019",,"December 13, 2019","Chinese PLA General Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04197960"
300,"NCT04931576","No Drainage During Transoral Endoscopic Thyroidectomy Vestibular Approach(TOETVA)",,"Not yet recruiting","No Results Available","Drainage|Thyroid Cancer","Procedure: no drainage tube applied","The incidence rate of hemorrhage on week 1 after surgery|The incidence rate of infections on week 2 after surgery|The incidence rate of postoperative hematoma or seroma on week 2 after surgery|Pain score on day 1 after surgery|Body temperature on day 1 after surgery|WBC on day 1 after surgery|CRP on day 1 after surgery|Length of post-operative hospital stay","Second Affiliated Hospital, School of Medicine, Zhejiang University","Female","18 Years to 55 Years   (Adult)","Not Applicable","600","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Supportive Care","2021-0316","July 1, 2021","June 1, 2023","October 1, 2023","June 18, 2021",,"June 18, 2021",,,"https://ClinicalTrials.gov/show/NCT04931576"
301,"NCT03802344","This Trial is a Randomised, Multicentre, Investigator-blind, Vehicle and Comparator-controlled, Parallel-group Trial With the Purpose of Evaluation Efficacy, Safety and Convenience of the MC2-01 Cream",,"Completed","Has Results","Psoriasis Vulgaris","Drug: MC2-01 cream|Drug: Cal/BDP combination|Drug: Vehicle","Percentage Change in mPASI (Modified Psoriasis Area and Severity Index) Score|The Psoriasis Treatment Convenience Scale (PTCS)","MC2 Therapeutics","All","18 Years and older   (Adult, Older Adult)","Phase 3","498","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MC2-01-C7","December 12, 2018","October 2, 2019","October 2, 2019","January 14, 2019","November 27, 2020","December 16, 2020","Dermatovenerologie a korektivní dermatologie, Praha 1, Czechia|University Medical Center Hamburg, Hamburg, Germany","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT03802344/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT03802344/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03802344"
302,"NCT01354639","Comparative Study of Surgical Completeness After Robotic Thyroidectomy Versus Conventional Open Thyroidectomy",,"Completed","No Results Available","Papillary Thyroid Carcinoma",,"surgical completeness of conventional open thyroidectomy and robotic thyroidectomy","Yonsei University","All","20 Years and older   (Adult, Older Adult)",,"150","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","4-2011-0082","April 2011","October 2011","October 2011","May 17, 2011",,"February 5, 2014","Severance Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01354639"
303,"NCT04768699","Study of Recombinant Human Coagulation Factor VIIa for Injection (FⅦa) in Patients With Hemophilia.",,"Recruiting","No Results Available","Hemophilia A With Inhibitor|Hemophilia B With Inhibitor","Drug: TQG203|Drug: TQG203/NovoSeven®","Pharmacokinetic assessment, based on plasma concentration of Recombinant Human Coagulation Factor VIIa.|Pharmacodynamic assessment, based on changes of activated partial thromboplastin time (APTT).|Pharmacodynamic assessment, based on changes of prothrombin time (PT).|Immunogenicity assessment, based on inhibitors to Factor VIIa (FVIIa) or Factor VIII (FVIII) or Factor IX (FIX).|Adverse events","Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TQG203-I-01","December 1, 2020","December 1, 2021","December 1, 2021","February 24, 2021",,"February 24, 2021","Hematology Hospital of Chinese Academy of Medical Sciences, Tianjin, Tianjin, China",,"https://ClinicalTrials.gov/show/NCT04768699"
304,"NCT02448680","A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa","PERSEPT2","Completed","Has Results","Hemophilia A With Inhibitors|Hemophilia B With Inhibitors","Biological: Coagulation FVIIa (Recombinant)","Proportion of Successfully Treated Mild/Moderate Bleeding Episodes Per FDA Requirement.|Proportion of Successfully Treated Bleeding Episodes (Mild/Moderate/Severe) Per EMA Definition|Patient-Reported ""Good"" or ""Excellent"" Response for Mild/Moderate Bleeding Episodes|Time to Patient Assessment of a ""Good"" or ""Excellent"" Response for Mild/Moderate Bleeding Episodes|Number of Administrations of Study Drug Per Mild/Moderate Bleeding Episode|Total Amount of Study Drug Administered Per Mild/Moderate Bleeding Episode","LFB USA, Inc.|Laboratoire français de Fractionnement et de Biotechnologies","Male","up to 11 Years   (Child)","Phase 3","25","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LFB-FVIIa-007-14","December 7, 2015","June 30, 2017","August 30, 2017","May 19, 2015","August 28, 2020","September 29, 2020","University of Colorado Denver Hemophilia & Thrombosis Center, Aurora, Colorado, United States|Jimmy Everest Center for Cancer and Bleeding Disorders, Oklahoma City, Oklahoma, United States|UT Southwestern Medical Center at Dallas / Children's Medical Center, Dallas, Texas, United States|University Multiprofile Hospital for Active Treatment ""Sveti Georgi"", Plovdiv, Bulgaria|University Hospital Motol, Prague, Czechia|Hematology of Department Hemophilia and Thromboses center, Tbilisi, Georgia|Worthwhile Clinical Trials, Benoni, South Africa|National Specialized Children's Hospital OKHMATDYT, Centre for Hemostatic Pathology (Ukraine), Kyiv, Ukraine|Institute of Blood Pathology and Transfusion Medicine, Lviv, Ukraine","""Statistical Analysis Plan: Final Version 2.0"", https://ClinicalTrials.gov/ProvidedDocs/80/NCT02448680/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/80/NCT02448680/Prot_001.pdf|""Statistical Analysis Plan: Statistical Analysis Plan (v2.0) Addendum"", https://ClinicalTrials.gov/ProvidedDocs/80/NCT02448680/SAP_002.pdf","https://ClinicalTrials.gov/show/NCT02448680"
305,"NCT01153048","Trial on an Educative Structured Intervention by Peer Educators to Improve HbA1c of Patients With Type 2 Diabetes in the Sikasso Region in Mali",,"Completed","No Results Available","Type 2 Diabetes","Other: Intensification of education","compare the improvement of HbA1c 1 year after an intervention led by peer educators, versus a conventional care in health centre|Study the evolution of bio clinical parameters: fasting glucose, weight, BMI, blood pressure, waist size","Sante Diabete Mali|Société Francophone du Diabète|French Development Agency|Centre hospitalo-universiaire du Point G de Bamako (CHU Pt G)","All","30 Years to 80 Years   (Adult, Older Adult)","Phase 1","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Supportive Care","SDMSFD01","June 2010","July 2011","September 2011","June 29, 2010",,"January 6, 2021","ONG Santé Diabète Mali, Bamako, Mali",,"https://ClinicalTrials.gov/show/NCT01153048"
306,"NCT01545635","RETIC Trial: Reversal of Trauma Induced Coagulopathy Using Coagulation Factor Concentrates or Fresh Frozen Plasma",,"Terminated","No Results Available","Major Trauma","Drug: Fibrinogen concentrate, Prothrombin complex concentrate and FXIII concentrate|Drug: Fresh Frozen Plasma blood type 0, A, B and AB","Multiple Organ Failure (MOF)","Medical University Innsbruck","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RETIC","March 2012","February 2016","February 2016","March 7, 2012",,"March 23, 2016","Medical University Innsbruck / Department for Anesthesia and Intensive Care Medicine, Innsbruck, Tyrol, Austria",,"https://ClinicalTrials.gov/show/NCT01545635"
307,"NCT01910675","PCC and Fibrinogen Compared With FFP in PPH",,"Withdrawn","No Results Available","Postpartum Haemorrhage","Drug: PCC|Drug: FFP","Blood loss|Maximum clot firmness (MCF)|Endogenous thrombin potential|Fibrinogen level|Platelet function|Clotting time (CT)|Clot formation time (CFT)","Helsinki University Central Hospital","Female","18 Years to 45 Years   (Adult)","Phase 4","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EudraCT-2012-003128|U1030N7560","July 2013","October 2018","October 2018","July 30, 2013",,"October 10, 2018","Maternity Hospital, Helsinki University Central Hospital, Helsinki, Uusimaa, Finland",,"https://ClinicalTrials.gov/show/NCT01910675"
308,"NCT00928915","International Normalized Ratio (INR) Normalization in Coumadin Associated Intracerebral Haemorrhage","INCH","Completed","No Results Available","Intracranial Hemorrhages","Drug: Prothrombin complex concentrate (PCC); fresh frozen plasma (FFP)","INR ≤ 1.2 within 3 hours after start of drug infusion|Safety: Number of thromboembolic events|Efficacy: Percentage of volume increase|Clinical outcome","Heidelberg University","All","18 Years and older   (Adult, Older Adult)","Phase 4","54","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AFmu-344/2008|EUDRAT 2008-005653-37","July 2009","January 2015","January 2015","June 26, 2009",,"October 26, 2016","Heidelberg University Clinic, Heidelberg, Germany",,"https://ClinicalTrials.gov/show/NCT00928915"
309,"NCT03054389","Non-Interventional Study to Capture the Patient Experience on Gene Therapy for Hemophilia Within the AskBio009-101 Study Through Patient and Investigator Interviews",,"Completed","No Results Available","Hemophilia B","Other: Qualitative Interview - Participants/ Patients|Other: Qualitative Interview - Investigators and Study Coordinators","Interview - AskBio009-101 Study - Participants/ Patients|Interview - AskBio009-101 Study - Investigators and Study Coordinators","Baxalta now part of Shire|Takeda","All","18 Years to 75 Years   (Adult, Older Adult)",,"27","Industry","Observational","Observational Model: Other|Time Perspective: Retrospective","001601","March 31, 2017","June 6, 2017","June 6, 2017","February 15, 2017",,"April 23, 2021","QuintilesIMS, Cambridge, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03054389"
310,"NCT02140593","The Laparotomy Study",,"Completed","Has Results","Gastrointestinal Cancer","Drug: Group STANDARD: Rocuronium 0.6 mg/kg followed by bolus rocuronium according to standard treatment combined with saline infusion (placebo).|Drug: Group DEEP: Rocuronium 0.6 mg/kg followed by rocuronium infusion with target level PTC 0-1 combined with bolus saline (placebo) mimicking standard treatment.","Surgical Rating Score|The Surgical Rating Score During Fascial Closure","Herlev Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 4","128","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","Lap2014NMB|2014-001155-22","September 2014","May 2016","June 2016","May 16, 2014","April 20, 2017","April 20, 2017","Aarhus University Hospital Nørrebrogade, Aarhus, Denmark",,"https://ClinicalTrials.gov/show/NCT02140593"
311,"NCT04903288","A Study of SmartFlow® Magnetic Resonance (MR) Compatible Ventricular Cannula for Administering Eladocagene Exuparvovec to Pediatric Participants",,"Recruiting","No Results Available","AADC Deficiency","Genetic: Eladocagene Exuparvovec","Number of Participants With Adverse Events (AEs) Associated With the Surgical Administration of Eladocagene Exuparvovec Using the SmartFlow® MR Compatible Ventricular Cannula|Change From Baseline in Positron Emission Tomography (PET) Imaging of Putaminal-Specific L-6-[18F] Fluoro-3,4-Dihydroxyphenylalnine (18F-DOPA) PET Uptake at the End of the Trial Phase (Week 8)","PTC Therapeutics","All","1 Year to 17 Years   (Child)","Phase 2","3","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PTC-AADC-GT-002","May 12, 2021","July 15, 2023","July 15, 2023","May 26, 2021",,"January 11, 2022","Lucile Packard Children's Hospital Stanford, Palo Alto, California, United States|Boston Children's Hospital, Boston, Massachusetts, United States|Duke University Hospital, Durham, North Carolina, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Texas Children's Hospital, Houston, Texas, United States|Chaim Sheba Medical Center, Ramat Gan, Israel|National Taiwan University Hospital, Department of Pediatrics and Medical Genetics, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT04903288"
312,"NCT00851721","Efficacy and Safety Study of Prophylactic Versus On-Demand Treatment With Feiba NF in Subjects With Hemophilia A or B and a High Titer Inhibitor",,"Completed","Has Results","Hemophilia A or B With Inhibitors|Hemophilia A|Hemophilia B","Biological: Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated)","Reduction in Annualized Bleeding Episode Rate (ABR) Among Participants Receiving Prophylactic Treatment as Compared to Those Treated On-demand|Annualized Bleeding Rate by Treatment Regimen, Bleeding Etiology, and Bleed Type|Differences in Mean Transformed Annualized Bleeding Rate Between On-Demand and Prophylaxis Treatment Regimens by Bleeding Etiology, and Bleeding Type|Annualized Bleeding Rate for New Target Joints|Differences in Mean Transformed Annualized Bleeding Rate Between On-Demand and Prophylaxis Treatment Regimens: New Target Joints|Number of New Target Joints|Assessment of Objective Clinical Symptoms- Visual Analog Scale (VAS): Pain in Adolescents and Adults (≥12 Years Old)|Assessment of Clinical Symptoms - Visual Analog Scale (VAS): Pain in Pediatrics (<12 Years Old)|Assessment of Clinical Symptoms - Range of Motion (ROM)|Assessment of Hemostasis for Treatment of Bleeding Episodes- Overall Efficacy Rating at 6 Hours|Assessment of Hemostasis for Treatment of Bleeding Episodes- Overall Efficacy Rating at 24 Hours|Total Weight Adjusted Dose to Control a Bleeding Episode|The Number of Bleeding Episode (BE) Which Required 1, 2, 3, or ≥4 Infusions to Control Bleeding|Abnormal Activated Partial Thromboplastin Time (aPTT) Assay Results|Abnormal D-Dimer Assay Results|Abnormal Fibrinogen Assay Results|Abnormal Fibrin Degradation Products (FDP) Assay Results|Abnormal Prothrombin Fragment F 1.2 Assay Results|Abnormal Prothrombin Time Assay Results|Abnormal Thrombin-Antithrombin III (TAT) Assay Results|Viral Serology From Screening Visit and Study Termination Visit: Hepatitis A, Hepatitis B, and Hepatitis C|Viral Serology From Screening Visit and Study Termination Visit: HIV-1/2 Antibody (Ab)|Viral Serology From Screening Visit and Study Termination Visit: Parvovirus B19 IgG Antibody [IV]|Viral Serology From Screening Visit and Study Termination Visit: Parvovirus B19 IgM Antibody [IV]|Rate of Related Adverse Events (AEs) Per Year|Rate of Related Adverse Events (AEs) During or Within 1 Hour of Infusion Per Year|Number of Related Thromboembolic Adverse Events (AEs)|Absolute Changes in Inhibitor Titer of Hemophilia A Participants With Shifts in Factor VIII (FVIII) Inhibitor Titer Levels|Absolute Changes in Inhibitor Titer of Hemophilia B Participants With Shifts in Factor IX (FIX) Inhibitor Titer Levels|Pharmacoeconomics: Annual Days Lost Due to Bleeding (Work or School)|Pharmacoeconomics: Annual Number of Hospitalizations for Bleeding|Pharmacoeconomics: Annual Number of Hospitalizations for Indwelling Line|Pharmacoeconomics: Annual Number of Emergency Room Visits|Pharmacoeconomics: Annual Number of Physician's Office Visits|Pharmacoeconomics: Annual Total Length of Hospitalization for Bleeding|Pharmacoeconomics: Annual Total Length of Hospitalization for Indwelling Line|Pharmacoeconomics: Annual Total Number of Days Lost (Work or School)|Health-Related Quality of Life (HRQoL): EuroQoL (Quality of Life)-5 Dimensions (EQ-5D) Index Scores|Hemophilia-specific Quality of Life Questionnaire for Adults (Haem-A-QoL) ≥ 16 Years Old|Hemophilia-specific Quality of Life Questionnaire for Children and Adolescents < 16 Years Old (Haemo-QoL) - Parent's Evaluation|Hemophilia-specific Quality of Life Questionnaire for Children and Adolescents < 16 Years Old (Haemo-QoL) - Child's Evaluation|Health-Related Quality of Life (HRQoL) - General Pain Assessment Using a Visual Analogue Scale (VAS) in Adults and Adolescents ≥12 Years Old|Health-Related Quality of Life (HRQoL) - General Pain Assessment Using a Visual Analogue Scale (VAS) in Pediatrics <12 Years Old","Baxalta now part of Shire|Takeda","All","4 Years to 65 Years   (Child, Adult, Older Adult)","Phase 3","52","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","090701|2008-003855-65","March 31, 2009","October 17, 2012","October 17, 2012","February 26, 2009","March 14, 2014","May 19, 2021","Chicago, Illinois, United States|Cleveland, Ohio, United States|Rio de Janeiro, RJ, Brazil|Sao Paulo, SP, Brazil|Sofia, Bulgaria|Zagreb, Croatia|Kanagawa, Japan|Nara, Japan|Wellington, New Zealand|Krakow, Poland|Warsaw, Poland|Bucharest, Romania|Timisoara, Romania|Ekaterinburg, Russian Federation|Kirov, Russian Federation|Moscow, Russian Federation|Lviv, Ukraine",,"https://ClinicalTrials.gov/show/NCT00851721"
313,"NCT01813734","Ponatinib in Advanced NSCLC w/ RET Translocations",,"Completed","Has Results","Non Small Cell Lung Cancer","Drug: Ponatinib","Overall Response Rate|Disease Control Rate|Median Progression-Free Survival|1 Year Overall Survival Rate|Number of Participants With Adverse Events","Massachusetts General Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 2","9","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","13-103","September 2013","June 2018","August 2018","March 19, 2013","December 24, 2019","December 24, 2019","University of California, Irvine, Orange, California, United States|University of Maryland, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Ohio State University, Columbus, Ohio, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/34/NCT01813734/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01813734"
314,"NCT04577352","A Study to Assess the Efficacy and Safety of Vatiquinone for the Treatment of Participants With Friedreich Ataxia","MOVE-FA","Active, not recruiting","No Results Available","Friedreich Ataxia","Drug: Vatiquinone|Drug: Placebo","Change From Baseline in the Modified Friedreich Ataxia Rating Scale (mFARS) Score at Week 72|Change From Baseline in Friedreich Ataxia Rating Scale Activities of Daily Living (FARS-ADL) Score at Week 72|Change From Baseline in 1-Minute Walk Test (1MWT) at Week 72|Number of Falls Through Week 72","PTC Therapeutics","All","7 Years and older   (Child, Adult, Older Adult)","Phase 2|Phase 3","146","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PTC743-NEU-003-FA","December 17, 2020","April 3, 2023","September 18, 2023","October 6, 2020",,"January 20, 2022","UCLA, Los Angeles, California, United States|University of Florida, Gainesville, Florida, United States|University of South Florida, Tampa, Florida, United States|University of Iowa, Iowa City, Iowa, United States|The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Murdoch Children's Research Institute, Parkville, Victoria, Australia|University of Campinas (UNICAMP) - School of Medical Sciences, Dept of Neurology, São Paulo, Brazil|Centre de Recherche du Centre Hospitalier de l'Université de Montreal (CRCHUM), Montreal, Quebec, Canada|CHU Sainte-Justine, Montréal, Quebec, Canada|Hôpital Pitié-Salpêtrière, Institut du Cerveau (Paris Brain Institute), PARIS cedex, France|Department of Neurology and Hertie-Institute for Clinical Brain Research German Center of Neurodegenerative Diseases (DZNE), Tuebingen, Germany|Ospedale Pediatrico Bambino Gesu' IRCCS, Roma, Italy|CBR Neurogenetic Research Clinic, University of Auckland, Auckland, New Zealand|Hospital Sant Joan de Déu Barcelona Unidad de Enfermedades Neuromusculares, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT04577352"
315,"NCT03417245","A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors",,"Completed","No Results Available","Hemophilia A|Hemophilia B","Drug: fitusiran|Drug: factor concentrates","Annualized bleeding rate (ABR)|Annualized spontaneous bleeding rate|Annualized joint bleeding rate|Quality of Life (QOL) as measured by Haem-A-QOL Questionnaire score on a scale of 0-100 with higher scores representing greater impairment|Number of participants reported with treatment-emergent adverse events","Genzyme, a Sanofi Company|Sanofi","Male","12 Years and older   (Child, Adult, Older Adult)","Phase 3","122","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EFC14769|ALN-AT3SC-004|2016-001464-11","March 1, 2018","January 26, 2021","July 14, 2021","January 31, 2018",,"July 19, 2021","Investigational Site Number 0140, Little Rock, Arkansas, United States|Investigational Site Number 128, Gainesville, Florida, United States|Investigational Site Number 103, Tampa, Florida, United States|Investigational Site Number 102, Chicago, Illinois, United States|Investigational Site Number 119, New Orleans, Louisiana, United States|Investigational Site Number 125, Ann Arbor, Michigan, United States|Investigational Site Number 111, Las Vegas, Nevada, United States|Investigational Site Number 110, Akron, Ohio, United States|Investigational Site Number 6101, Camperdown, Australia|Investigational Site Number 6103, Murdoch, Australia|Investigational Site Number 6104, Prahran, Australia|Investigational Site Number 8604, Beijing, China|Investigational Site Number 8602, Guangzhou, China|Investigational Site Number 8605, Hangzhou, China|Investigational Site Number 8603, Shanghai, China|Investigational Site Number 8601, Tianjin, China|Investigational Site Number 4501, Copenhagen, Denmark|Investigational Site Number 3303, Lyon, France|Investigational Site Number 3305, Paris, France|Investigational Site Number 3301, Rouen, France|Investigational Site Number 4904, Berlin, Germany|Investigational Site Number 4905, Frankfurt Am Main, Germany|Investigational Site Number 4906, Leipzig, Germany|Investigational Site Number 3602, Budapest, Hungary|Investigational Site Number 9102, Bangalore, India|Investigational Site Number 9104, Jaipur, India|Investigational Site Number 9106, Lucknow, India|Investigational Site Number 9109, Mumbai, India|Investigational Site Number 9108, Mumbai, India|Investigational Site Number 9111, Mumbai, India|Investigational Site Number 9103, Pune, India|Investigational Site Number 9105, Vellore, India|Investigational Site Number 9701, Ramat-Gan, Israel|Investigational Site Number 3904, Padova, Italy|Investigational Site Number 8105, Isehara, Japan|Investigational Site Number 8104, Saitama, Japan|Investigational Site Number 8201, Busan, Korea, Republic of|Investigational Site Number 8202, Daejeon, Korea, Republic of|Investigational Site Number 8204, Seoul, Korea, Republic of|Investigational Site Number 6004, Ampang, Malaysia|Investigational Site Number 6002, Johor Bahru, Malaysia|Investigational Site Number 6003, Kota Kinabalu, Malaysia|Investigational Site Number 2701, Parktown, South Africa|Investigational Site Number 2702, Port Elizabeth, South Africa|Investigational Site Number 3402, Madrid, Spain|Investigational Site Number 8807, Taichung, Taiwan|Investigational Site Number 8805, Taichung, Taiwan|Investigational Site Number 8804, Taipei, Taiwan|Investigational Site Number 8801, Taipei, Taiwan|Investigational Site Number 8808, Taoyuan, Taiwan|Investigational Site Number 9002, Adana, Turkey|Investigational Site Number 9004, Antalya, Turkey|Investigational Site Number 9008, Gaziantep, Turkey|Investigational Site Number 9005, Istanbul, Turkey|Investigational Site Number 9003, Izmir, Turkey|Investigational Site Number 9009, Kayseri, Turkey|Investigational Site Number 9006, Samsun, Turkey|Investigational Site Number 8001, Kyiv, Ukraine|Investigational Site Number 8003, Kyiv, Ukraine|Investigational Site Number 8002, Lviv, Ukraine|Investigational Site Number 8005, Mykolaiv, Ukraine|Investigational Site Number 4402, Glasgow, United Kingdom|Investigational Site Number 4407, London, United Kingdom|Investigational Site Number 4401, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03417245"
316,"NCT03417102","A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors","ATLAS-INH","Completed","Has Results","Hemophilia A|Hemophilia B","Drug: fitusiran|Drug: Bypassing agents","Estimated Annualized Bleeding Rate (ABR) for Treated Bleeds During the Efficacy Period|Observed Annualized Bleeding Rate (ABR) for Treated Bleeds During the Efficacy Period|Estimated Annualized Bleeding Rate (ABR) for Treated Bleeds During the Treatment Period|Observed Annualized Bleeding Rate (ABR) for Treated Bleeds During the Treatment Period|Estimated Annualized Spontaneous Bleeding Rate for Treated Bleeds During Efficacy Period|Observed Annualized Spontaneous Bleeding Rate for Treated Bleeds During the Efficacy Period|Estimated Annualized Joint Bleeding Rate for Treated Bleeds During the Efficacy Period|Observed Annualized Joint Bleeding Rate for Treated Bleeds During the Efficacy Period|Health-related Quality of Life (HRQOL): Change From Baseline in Haemophilia Quality of Life Questionnaire for Adults (Haem-A-QOL) Physical Health Domain Score at Month 9|Health-related Quality of Life (HRQOL): Change From Baseline in Haem-A-QOL Total Score at Month 9|Estimated Annualized Bleeding Rate (ABR) for Treated Bleeds During the Onset Period|Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)","Genzyme, a Sanofi Company|Sanofi","Male","12 Years and older   (Child, Adult, Older Adult)","Phase 3","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EFC14768|2016-001463-36|ALN-AT3SC-003","February 14, 2018","November 25, 2020","June 23, 2021","January 31, 2018","December 21, 2021","December 21, 2021","Investigational Site Number 0117, Phoenix, Arizona, United States|Investigational Site Number 0139, Los Angeles, California, United States|Investigational Site Number 0135, Orange, California, United States|Investigational Site Number 0137, San Diego, California, United States|Investigational Site Number 0128, Gainesville, Florida, United States|Investigational Site Number 0115, Jacksonville, Florida, United States|Investigational Site Number 0105, Miami, Florida, United States|Investigational Site Number 0103, Tampa, Florida, United States|Investigational Site Number 0119, New Orleans, Louisiana, United States|Investigational Site Number 0136, Baltimore, Maryland, United States|Investigational Site Number 0111, Las Vegas, Nevada, United States|Investigational Site Number 0104, Philadelphia, Pennsylvania, United States|Investigational Site Number 6101, Camperdown, Australia|Investigational Site Number 6104, Clayton, Australia|Investigational Site Number 1102, Montreal, Canada|Investigational Site Number 8604, Beijing, China|Investigational Site Number 8602, Guangzhou, China|Investigational Site Number 8605, Hangzhou, China|Investigational Site Number 8603, Shanghai, China|Investigational Site Number 8601, Tianjin, China|Investigational Site Number 3303, Lyon, France|Investigational Site Number 3301, Rouen, France|Investigational Site Number 4905, Frankfurt Am Main, Germany|Investigational Site Number 4906, Leipzig, Germany|Investigational Site Number 9102, Bangalore, India|Investigational Site Number 9108, India, India|Investigational Site Number 9104, Jaipur, India|Investigational Site Number 9106, Lucknow, India|Investigational Site Number 9103, Pune, India|Investigational Site Number 9111, Pune, India|Investigational Site Number 9105, Vellore, India|Investigational Site Number 3901, Florence, Italy|Investigational Site Number 3904, Padua, Italy|Investigational Site Number 8110, Japan, Japan|Investigational Site Number 8103, Kita Kyushu-Shi, Japan|Investigational Site Number 8202, Daejeon, Korea, Republic of|Investigational Site Number 8203, Seoul, Korea, Republic of|Investigational Site Number 8204, Seoul, Korea, Republic of|Investigational Site Number 6003, Kota Kinabalu, Malaysia|Investigational Site Number 6004, Malaysia, Malaysia|Investigational Site Number 2701, Parktown, South Africa|Investigational Site Number 2703, Polokwane, South Africa|Investigational Site Number 2702, Port Elizabeth, South Africa|Investigational Site Number 3402, Madrid, Spain|Investigational Site Number 8803, Changhua, Taiwan|Investigational Site Number 8801, Taipei, Taiwan|Investigational Site Number 8804, Taiwan, Taiwan|Investigational Site Number 8805, Taiwan, Taiwan|Investigational Site Number 9002, Adana, Turkey|Investigational Site Number 9004, Akdeniz, Turkey|Investigational Site Number 9001, Ankara, Turkey|Investigational Site Number 9005, Istanbul, Turkey|Investigational Site Number 9003, Izmir, Turkey|Investigational Site Number 9006, Turkey, Turkey|Investigational Site Number 8003, Kyiv, Ukraine|Investigational Site Number 8001, Kyiv, Ukraine|Investigational Site Number 8002, Lviv, Ukraine|Investigational Site Number 4407, London, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/02/NCT03417102/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/02/NCT03417102/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03417102"
317,"NCT03784378","Continued Access to RXDX-105",,"Completed","No Results Available","Non Small Cell Lung Cancer|Ovarian Cancer|RET Gene Mutation|BRAF Gene Mutation","Drug: RXDX-105","Evaluation during treatment/intervention","Memorial Sloan Kettering Cancer Center","All","18 Years and older   (Adult, Older Adult)","Phase 1","3","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18-487","December 14, 2018","September 30, 2020","September 30, 2020","December 21, 2018",,"October 5, 2020","Memorial Sloan Kettering Cancer Center 1275 York Avenue, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03784378"
318,"NCT02061072","Web-based Application for the Population Pharmacokinetic Service - Phase 1","WAPPS","Completed","No Results Available","Hemophilia A|Hemophilia B","Other: Population pharmacokinetic estimation","Population pharmacokinetic model(s) performance measure|Usability testing of the web-interface|Tally of number of patients with successful individual PK estimation|Tally of the number of patients with concordant population based and classic PK estimation|Tally of the minimum number of data point allowing a reliable PK estimate for an individual subject","McMaster University|Canadian Hemophilia Society","All","Child, Adult, Older Adult",,"400","Other","Observational","Observational Model: Other|Time Perspective: Other","13-351-D","January 2015","June 2019","June 2019","February 12, 2014",,"March 16, 2021","Hemophilia Clinic, McMaster University, Hamilton, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02061072"
319,"NCT00303901","Cryotherapy in Treating Patients With Primary Lung Cancer or Lung Metastases That Cannot Be Removed By Surgery",,"Completed","Has Results","Lung Cancer|Metastatic Cancer","Procedure: cryosurgery|Procedure: positron emission tomography","Local Failure Rates by CT Scan|Distant Failure Rate|Rate of Complications and Adverse Reactions by Occurrences of Toxicities|Correlate Procedural Parameters and Follow-up Imaging Parameters|Point and Exact Confidence Interval Estimates of Patients Who Undergo Multiple Cryotherapy Procedures","Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI)","All","18 Years to 120 Years   (Adult, Older Adult)","Not Applicable","40","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000462091|P30CA022453|WSU-C-2975|WSU-0509002942","November 2005","July 2011","July 2011","March 17, 2006","February 23, 2015","July 22, 2020","Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT00303901"
320,"NCT04647227","SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors",,"Recruiting","No Results Available","Hemophilia A With Inhibitor|Hemophilia B With Inhibitor","Drug: coagulation factor VIIa [recombinant]-jncw","Number of participants and percentage of Safety Events (AEs)","American Thrombosis and Hemostasis Network|LFB USA, Inc.","All","12 Years to 65 Years   (Child, Adult, Older Adult)","Phase 4","55","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ATHN 16","June 28, 2021","October 31, 2023","June 1, 2025","November 30, 2020",,"December 9, 2021","Arizona Hemophilia and Thrombosis Center at Phoenix Children's Hospital, Phoenix, Arizona, United States|Orthopaedic Institute for Children, Los Angeles, California, United States|University of California at Davis UC Davis Hemostasis and Thrombosis Center, Sacramento, California, United States|Children's National Hemophilia Center, Washington, District of Columbia, United States|Hemophilia of Georgia Center for Bleeding and Clotting Disorders of Emory, Adult Division, Atlanta, Georgia, United States|Willett Children's Hospital at Memorial University Medical Center, Savannah, Georgia, United States|Louisiana Center for Bleeding and Clotting Disorders, Tulane, New Orleans, Louisiana, United States|Louisiana Center for Advanced Medicine, Slidell, Louisiana, United States|Maine Hemophilia and Thrombosis Center, Scarborough, Maine, United States|Children's Hospital of Michigan, Detroit, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|MSU Center for Bleeding and Clotting Disorders, Lansing, Michigan, United States|Center for Bleeding and Clotting Disorders, University of Minnesota, Minneapolis, Minnesota, United States|Mayo Comprehensive Hemophilia Center, Rochester, Minnesota, United States|Mississippi Center for Advanced Medicine, Madison, Mississippi, United States|Kansas City Regional Hemophilia Center, Kansas City, Missouri, United States|Kansas City Reional Hemophilia Center, Kansas City, Missouri, United States|Northwell Health, Long Island Jewish, New Hyde Park, New York, United States|Brody School of Medicine at East Carolina University, Greenville, North Carolina, United States|University Hospitals Health System Cleveland, Cleveland, Ohio, United States|Oklahoma Center for Bleeding and Clotting Disorders, Oklahoma City, Oklahoma, United States|Gulf States Hemophilia and Thrombophilia Center-University of Texas Health Science Center @Houston, Houston, Texas, United States|University of Puerto Rico School of Medicine, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT04647227"
321,"NCT03256799","Evaluation of Ivacaftor in Patients Using Ataluren for Nonsense Mutations",,"Completed","Has Results","Cystic Fibrosis","Drug: Ivacaftor/Ataluren","Lung Function","University of Alabama at Birmingham","All","19 Years and older   (Adult, Older Adult)","Phase 4","1","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","F161208009","March 17, 2017","July 10, 2017","February 16, 2018","August 22, 2017","July 19, 2019","July 19, 2019","University of Alabama at Birmingham, Birmingham, Alabama, United States","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT03256799/Prot_SAP_ICF_000.pdf","https://ClinicalTrials.gov/show/NCT03256799"
322,"NCT02938702","Active Surveillance on Papillary Thyroid Microcarcinoma",,"Active, not recruiting","No Results Available","Thyroid Cancer|Papillary Thyroid Microcarcinoma",,"Rate of Progression of Thyroid Papillary Microcarcinoma|Comparison of Progression Rate between Active Surveillance and Surgery Group","Seoul National University Hospital","All","18 Years and older   (Adult, Older Adult)",,"1211","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2520160010","May 2016","March 2025","March 2030","October 19, 2016",,"March 18, 2020","Seoul National University Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02938702"
323,"NCT03272568","Extended Half Life Factor (EHF) Products For Heavy Menstrual Bleeding in Hemophilia Carriers",,"Completed","No Results Available","Hemophilia|Menstrual Flow Excessive","Drug: Recombinant FVIII Fc fusion product Eloctate|Drug: Recombinant FIX Fc fusion product Alprolix|Device: Patient-operated diagnostic device for anemia AnemoCheck.","Reduction in menstrual bleeding measured by the Pictorial Bleeding Assessment Chart (PBAC).|Change in Patient-Reported Outcomes Measurement Information Systems (PROMIS-43) score.|Change in Short Form 36 (SF-36) score.|Change in Menorrhagia Impact Questionnaire (MIQ) score.|Number of hypersensitivity reactions.|Accuracy of hemoglobin levels detection by Anemocheck.|Change in FVIII level after the first dose of Eloctate.|Change in FIX level after the first dose of Alpolix.","Emory University|Bioverativ Therapeutics Inc.","Female","14 Years to 55 Years   (Child, Adult)","Early Phase 1","3","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00095067","February 14, 2018","December 31, 2019","December 31, 2019","September 5, 2017",,"May 18, 2020","Emory University Hospital Clinical Research Network, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT03272568"
324,"NCT03481946","A Study to Assess Pharmacokinetics and Pharmacodynamics Following Administration of BAY1093884 in Patients With Severe Hemophilia",,"Completed","No Results Available","Hemophilia A; Hemophilia B","Drug: BAY1093884","AUC (0-tlast) of BAY1093884 in plasma|AUC(0-tlast)/D of BAY1093884 in plasma|Cmax of BAY1093884 in plasma|Cmax/D of BAY1093884 in plasma|Tissue factor plasma inhibitor activity: effect of BAY1093884 to inhibit the anticoagulatory activity of plasma TFPI as assessed by a chromogenic assay","Bayer","Male","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","6","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","19592","May 10, 2018","October 17, 2018","February 20, 2019","March 29, 2018",,"September 16, 2020","Chaim Sheba Medical Center, Ramat Gan, Israel",,"https://ClinicalTrials.gov/show/NCT03481946"
325,"NCT04259112","Effect of Pneumoperitoneum and Neuromuscular Block on Renal Function in Diabetes Patients",,"Not yet recruiting","No Results Available","Diabetes Mellitus|Acute Kidney Injury|Laparoscopic Surgical Procedure|Neuromuscular Blockade","Procedure: high pressure|Drug: deep neuromuscular block|Procedure: low pressure|Drug: moderate neuromuscular block","Serum cystatin C (CysC) level|Serum creatine level|The volume of intraoperative urine output|The presence of isomorphic or dysmorphic erythrocyte in urinary sediment|Duration of surgery|Leiden-surgical rating scale|The number of bucking and body movement during the surgery|Renal tissue oxygen saturation","Peking Union Medical College Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","648","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","PUMCH-ml","October 1, 2020","October 1, 2023","December 1, 2023","February 6, 2020",,"October 6, 2020",,,"https://ClinicalTrials.gov/show/NCT04259112"
326,"NCT01625390","A Phase 2/ 3 Trial to Evaluate the Efficacy and Safety of BAY86-6150",,"Completed","No Results Available","Hemophilia A, Hemophilia B","Drug: BAY86-6150|Drug: eptacog alfa [activated]","Successful treatments of bleeding episodes.|Proportion of successful treatments of bleeding episodes on subject level.|Time to stop the bleed|Number of injections needed to stop the bleeding episode.|Effectiveness of treatment as rated by the subject's assessment (very effective, effective, partially effective, not effective).|Participant's reported outcome as assessed by Euro QoL (EQ-5D).|Participant's reported outcome as assessed by Brief Pain Inventory.|Participant's reported outcome as assessed by Work Productivity and Activity Impairment Questionaire.","Bayer","Male","12 Years to 62 Years   (Child, Adult)","Phase 2|Phase 3","10","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15534|2011-000323-33|U1111-1133-2156","June 2012","March 2014","March 2014","June 21, 2012",,"July 1, 2015","Sacramento, California, United States|Chattanooga, Tennessee, United States|Melbourne, Victoria, Australia|São Paulo, Sao Paulo, Brazil|Rio de Janeiro, Brazil|Sao Paulo, Brazil|Sofia, Bulgaria|Santiago, Chile|Guangzhou, Guangdong, China|Beijing, China|Tianjin, China|Barranquilla, Atlántico, Colombia|Bogotá, Colombia|Aarhus N, Denmark|Lyon Cedex, France|Tours, France|Villingen-Schwenningen, Baden-Württemberg, Germany|Mainz, Rheinland-Pfalz, Germany|Budapest, Hungary|Debrecen, Hungary|Hyderabad, Andhra Pradesh, India|Ludhiana, Punjab, India|Bangalore, India|Pune, India|Tel Hashomer, Israel|Firenze, Italy|Milano, Italy|Kashihara, Nara, Japan|Shinjuku-ku, Tokyo, Japan|Suginami, Tokyo, Japan|Seoul, Korea, Republic of|Guadalajara, Jalisco, Mexico|México D. F., Mexico|Oaxaca, Mexico|San Luis Potosí, Mexico|Utrecht, Netherlands|Christchurch, New Zealand|Warszawa, Poland|Timisoara, Timis, Romania|Bucharest, Romania|Bucharest, Romania|Ekaterinburg, Russian Federation|Khabarovsk, Russian Federation|Samara, Russian Federation|St. Petersburg, Russian Federation|Singapore, Singapore|Singapore, Singapore|Bloemfontein, Freestate, South Africa|Johannesburg, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Göteborg, Sweden|Changhua, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Istanbul, Turkey|Izmir, Turkey|Donetsk, Ukraine|Lviv, Ukraine|Odessa, Ukraine|London, United Kingdom|Truro, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01625390"
327,"NCT04083781","Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia With Inhibitors","explorer7","Active, not recruiting","No Results Available","Haemophilia A With Inhibitors|Haemophilia B With Inhibitors","Drug: Concizumab","The number of treated spontaneous and traumatic bleeding episodes|Change in 36 Item short form health survey version 2 (SF36v2) bodily pain|Change in SF36v2 physical functioning|Number of treated spontaneous bleeding episodes|Number of treated spontaneous and traumatic joint bleeds|Number of treated spontaneous and traumatic target joint bleeds|Number of thromboembolic events|Number of hypersensitivity type reactions|Number of injection site reactions|Number of patients with antibodies to concizumab|Pre-dose (trough) concizumab plasma concentration (Ctrough)|Pre-dose thrombin peak|Pre-dose free tissue factor pathway inhibitor (TFPI) concentration|Maximum concizumab plasma concentration (Cmax)|Area under the concizumab plasma concentration-time curve (AUC)","Novo Nordisk A/S","Male","12 Years and older   (Child, Adult, Older Adult)","Phase 3","136","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NN7415-4311|U1111-1225-9670|2018-004889-34","October 21, 2019","November 17, 2021","June 20, 2024","September 10, 2019",,"September 5, 2021","Novo Nordisk Investigational Site, Orange, California, United States|Novo Nordisk Investigational Site, Atlanta, Georgia, United States|Novo Nordisk Investigational Site, Indianapolis, Indiana, United States|Novo Nordisk Investigational Site, Saint Louis, Missouri, United States|Novo Nordisk Investigational Site, Charlotte, North Carolina, United States|Novo Nordisk Investigational Site, Nashville, Tennessee, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, Algiers, Algeria|Novo Nordisk Investigational Site, Constantine, Algeria|Novo Nordisk Investigational Site, Melbourne, Victoria, Australia|Novo Nordisk Investigational Site, Parkville, Victoria, Australia|Novo Nordisk Investigational Site, Murdoch, Western Australia, Australia|Novo Nordisk Investigational Site, Wien, Austria|Novo Nordisk Investigational Site, Sofia, Bulgaria|Novo Nordisk Investigational Site, Hamilton, Ontario, Canada|Novo Nordisk Investigational Site, Zagreb, Croatia|Novo Nordisk Investigational Site, Zagreb, Croatia|Novo Nordisk Investigational Site, Praha 2, Czechia|Novo Nordisk Investigational Site, Praha, Czechia|Novo Nordisk Investigational Site, Aarhus N, Denmark|Novo Nordisk Investigational Site, Bron Cedex, France|Novo Nordisk Investigational Site, Clermont-Ferrand, France|Novo Nordisk Investigational Site, Kremlin-Bicêtre, France|Novo Nordisk Investigational Site, Rennes, France|Novo Nordisk Investigational Site, Bangalore, Karnataka, India|Novo Nordisk Investigational Site, Pune, Maharashtra, India|Novo Nordisk Investigational Site, New Dehli, New Delhi, India|Novo Nordisk Investigational Site, Vellore, Tamil Nadu, India|Novo Nordisk Investigational Site, Castelfranco Veneto, Italy|Novo Nordisk Investigational Site, Firenze, Italy|Novo Nordisk Investigational Site, Milano, Italy|Novo Nordisk Investigational Site, Udine, Italy|Novo Nordisk Investigational Site, Verona, Italy|Novo Nordisk Investigational Site, Aichi, Japan|Novo Nordisk Investigational Site, Kagoshima, Japan|Novo Nordisk Investigational Site, Kanagawa, Japan|Novo Nordisk Investigational Site, Mie, Japan|Novo Nordisk Investigational Site, Nara, Japan|Novo Nordisk Investigational Site, Saitama, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Daejeon, Korea, Republic of|Novo Nordisk Investigational Site, Seoul, Korea, Republic of|Novo Nordisk Investigational Site, Ampang, Selangor, Malaysia|Novo Nordisk Investigational Site, Georgetown, Penang, Malaysia|Novo Nordisk Investigational Site, Kota Kinabalu, Malaysia|Novo Nordisk Investigational Site, Monterrey, Nuevo León, Mexico|Novo Nordisk Investigational Site, Oslo, Norway|Novo Nordisk Investigational Site, Krakow, Poland|Novo Nordisk Investigational Site, Lublin, Poland|Novo Nordisk Investigational Site, Poznań, Poland|Novo Nordisk Investigational Site, Warszawa, Poland|Novo Nordisk Investigational Site, Wroclaw, Poland|Novo Nordisk Investigational Site, Porto, Portugal|Novo Nordisk Investigational Site, Krasnodar, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Petrozavodsk, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Belgrade, Serbia|Novo Nordisk Investigational Site, Belgrade, Serbia|Novo Nordisk Investigational Site, Kragujevac, Serbia|Novo Nordisk Investigational Site, Novi Sad, Serbia|Novo Nordisk Investigational Site, Bratislava, Slovakia|Novo Nordisk Investigational Site, Parktown, Johannesburg, Gauteng, South Africa|Novo Nordisk Investigational Site, Durban, KwaZulu-Natal, South Africa|Novo Nordisk Investigational Site, Polokwane, Limpopo, South Africa|Novo Nordisk Investigational Site, Barcelona, Spain|Novo Nordisk Investigational Site, Madrid, Spain|Novo Nordisk Investigational Site, Málaga, Spain|Novo Nordisk Investigational Site, Oviedo, Spain|Novo Nordisk Investigational Site, Sevilla, Spain|Novo Nordisk Investigational Site, Malmö, Sweden|Novo Nordisk Investigational Site, Solna, Sweden|Novo Nordisk Investigational Site, Bangkok, Thailand|Novo Nordisk Investigational Site, Chiang Mai, Thailand|Novo Nordisk Investigational Site, Ubon Ratchathani, Thailand|Novo Nordisk Investigational Site, Adana, Turkey|Novo Nordisk Investigational Site, Antalya, Turkey|Novo Nordisk Investigational Site, Capa-ISTANBUL, Turkey|Novo Nordisk Investigational Site, Kyiv, Ukraine|Novo Nordisk Investigational Site, Lviv, Ukraine|Novo Nordisk Investigational Site, Birmingham, United Kingdom|Novo Nordisk Investigational Site, London, United Kingdom|Novo Nordisk Investigational Site, Manchester, United Kingdom|Novo Nordisk Investigational Site, Nottingham, United Kingdom|Novo Nordisk Investigational Site, Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04083781"
328,"NCT03045068","Platelet Transfusion During Neonatal Open Heart Surgery","CPB","Active, not recruiting","No Results Available","Cardiac Disease|Cardiac Surgery|Cardiopulmonary Bypass|Platelet Transfusion|Arrythmia, Cardiac|Mortality","Biological: Platelet Transfusion|Biological: FFP and Cryoprecipitate|Biological: PRBC and cell saver Transfusion|Biological: Factor Concentrate (Bebulin)","Number of Donor Exposures|4-PCC and Factor 7|CPB to Chest Approximation|Chest tube output|Inotropic support|mechanical ventilation|Mortality|Perioperative cardiac arrest|Arrhythmia","The University of Texas Health Science Center, Houston","All","up to 3 Months   (Child)","Not Applicable","44","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","HSC-MS-16-1034","April 11, 2017","December 31, 2021","December 31, 2021","February 7, 2017",,"April 13, 2021","Memorial Hermann Hospital, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03045068"
329,"NCT03783923","A Study of Deflazacort (Emflaza®) in Participants With Limb-Girdle Muscular Dystrophy 2I (LGMD2I)",,"Completed","No Results Available","Limb-Girdle Muscular Dystrophy","Drug: Deflazacort","Change From Baseline in Time to Climb 4 Stairs After 26 Weeks of Treatment|Change From Baseline in Forced Vital Capacity (FVC) After 26 Weeks of Treatment|Change From Baseline in 2-Minute Walk Test After 26 Weeks of Treatment|Change From Baseline in Time to up and go After 26 Weeks of Treatment|Change From Baseline in Time to Descent 4 Stairs After 26 Weeks of Treatment|Change From Baseline in Time to Run/Walk 10 Meters After 26 Weeks of Treatment|Change From Baseline in Maximal Inspiratory Pressure (MIP) and Maximal Expiratory Pressure (MEP) After 26 Weeks of Treatment|Change From Baseline in Hand-Held Myometry After 26 Weeks of Treatment|Change From Baseline in Global T2 Relaxation Time of Selected Upper and Lower Limb Muscles After 26 Weeks of Treatment|Number of Participants With Adverse Events (AEs)|Number of Participants With Laboratory Abnormalities|Number of Participants With Electrocardiogram (ECG) Abnormalities|Number of Participants With Ophthalmologic Abnormalities|Area Under the Concentration curve From Time Zero to t (AUC0-t) of 21-desacetyl deflazacort and 6β-hydroxy-21-desacetyl deflazacort|Area Under the Concentration curve From Time Zero to Infinity (AUC0-inf) of 21-desacetyl deflazacort and 6β-hydroxy-21-desacetyl deflazacort|Maximum Observed Plasma Concentration (Cmax) of 21-desacetyl deflazacort and 6β-hydroxy-21-desacetyl deflazacort|Time to Reach Cmax (Tmax) of 21-desacetyl deflazacort and 6β-hydroxy-21-desacetyl deflazacort|Clearance (CL/F) of 21-desacetyl deflazacort and 6β-hydroxy-21-desacetyl deflazacort|Volume of Distribution (Vz/F) of 21-desacetyl deflazacort and 6β-hydroxy-21-desacetyl deflazacort|Terminal Elimination Rate Constant (Lambda z [λz]) of 21-desacetyl deflazacort and 6β-hydroxy-21-desacetyl deflazacort|Half-Life (t1/2) of 21-desacetyl deflazacort and 6β-hydroxy-21-desacetyl deflazacort","PTC Therapeutics","All","18 Years and older   (Adult, Older Adult)","Phase 3","30","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PTCEMF-GD-004","May 15, 2019","January 31, 2021","January 31, 2021","December 21, 2018",,"November 10, 2021","Rare Disease Research, LLC, Atlanta, Georgia, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|The University of Kansas Medical Center, Kansas City, Kansas, United States|Hugo W Moser Research Institute at Kennedy Krieger Institute, Baltimore, Maryland, United States|University of Minnesota, Minneapolis, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Washington, Seattle, Washington, United States|University of Alberta, Edmonton, Alberta, Canada|Ottawa Hospital, Ottawa, Canada|Rigshospitalet, University of Copenhagen, Copenhagen, Denmark|CHRU de NANCY Service de Neurologie, France, France|University Hospital La Timone, Marseille, France|Ludwig-Maximilians University Munich, Friedrich-Baur-Institute, Munich, Germany|Oslo University Hospital, Oslo, Norway|Pirogov Russian National Research Medical University, Moscow, Russian Federation|Saint-Petersburg State Pediatric Medical University, Saint Petersburg, Russian Federation|Sahlgrenska University Hospital, Gothenburg, Sweden",,"https://ClinicalTrials.gov/show/NCT03783923"
330,"NCT03642145","A Study of Deflazacort (Emflaza®) in Participants With Duchenne Muscular Dystrophy (DMD)","PTCEMF","Withdrawn","No Results Available","Duchenne Muscular Dystrophy","Drug: Deflazacort","Period 1 and 2: Number of Participants With Treatment Emergent Adverse Events (TEAEs)|Period 1 and 2: Change From Baseline in Vital Signs and Electrocardiogram (ECG) at Week 52|Period 1 and 2: Change From Baseline in the Child Behavior Checklist Score at Week 52|Period 1 and 2: Change From Baseline in the Normalized Measure of Bone Density Change (Z-score) for the Dual Energy X-ray Absorptiometry (DEXA) at Week 52|Period 1 and 2: Mean Change From Baseline in Height at Week 52|Period 1 and 2: Mean Change From Baseline in Body Weight at Week 52|Period 1 and 2: Mean Change From Baseline in Height Percentile for Age at Week 52|Period 1 and 2: Number of Participants With Clinically Significant Laboratory Tests|Period 1: Peak Plasma Concentration (Cmax) of Deflazacort|Period 1: Area Under the Curve (AUC) of Deflazacort|Period 1: Volume of Distribution (Vd) of Deflazacort|Period 1: Clearance (CL) of Deflazacort","PTC Therapeutics","Male","2 Years to 4 Years   (Child)","Phase 3","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PTCEMF-GD-003","October 31, 2018","July 31, 2021","July 31, 2021","August 22, 2018",,"June 21, 2019",,,"https://ClinicalTrials.gov/show/NCT03642145"
331,"NCT02460679","Safety and Biomarker Study of EPI-589 in Participants With Amyotrophic Lateral Sclerosis (ALS)","EPI-589","Completed","Has Results","Amyotrophic Lateral Sclerosis","Drug: EPI-589","Number of Participants With Drug-Related Serious Adverse Events (SAEs)|Area Under the Plasma Concentration Versus Time Curve From Time 0 to 12 Hours (AUC0-12)|Maximum Observed Plasma Concentration (Cmax)|Change From Baseline in ALSFRS-R Total Score at Month 6|Change From Baseline in Vital Capacity at Month 6|Change From Baseline in MIP at Month 6|Change From Baseline in Respiratory Rate at Month 6|Change From Baseline in Heart Rate at Month 6|Change From Baseline in SpO2 at Month 6|Change From Baseline in ETCO2 at Month 6|Failure to Thrive: Number of Participants With Weight Loss of More Than 5 Percent (%) From Baseline at Month 6|Change From Baseline in Average Solid Swallowing Time and Water Swallowing Time at Month 6|Change From Baseline in Muscle Function at Month 6, as Assessed by Handheld Dynamometry Parameters (Grip Strength, Shoulder Flexion, Knee Extension, Hip Flexion, Elbow Flexion, Elbow Extension, and Ankle Dorsi Flexion)|Change From Baseline in Number of Words Participant Read at Month 6|Change From Baseline in Time Spent in Reading at Month 6|Change From Baseline in Number of Words Per Minute Read at Month 6|Number of Participants With Normal Loudness, Normal Nasality, and Normal Intelligibility|Level of Disease-Related Biomarker (Glutathione) in Plasma|Level of Disease-Related Biomarker (Glutathione) in Cerebrospinal Fluid (CSF)|Level of Disease-Related Biomarker (Glutathione) in Urine","PTC Therapeutics","All","21 Years to 70 Years   (Adult, Older Adult)","Phase 2","19","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EPI589-15-001","January 14, 2016","February 23, 2018","February 23, 2018","June 2, 2015","September 23, 2020","October 14, 2020","Cedar's Sinai, Los Angeles, California, United States|California Pacific Medical Center, San Francisco, California, United States|Providence Brain and Spine Institute ALS Center, Portland, Oregon, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/79/NCT02460679/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/79/NCT02460679/SAP_002.pdf","https://ClinicalTrials.gov/show/NCT02460679"
332,"NCT04019015","Prehospital Kcentra for Hemorrhagic Shock",,"Active, not recruiting","No Results Available","Trauma Injury","Drug: Prothrombin Complex Concentrate, Human|Drug: Placebo","Feasibility of study drug administration|Mortality|Hospital Free Days|ICU Free Days|Ventilator Free Days|Blood Transfusions","Oregon Health and Science University","All","18 Years and older   (Adult, Older Adult)","Phase 2","166","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","OHSU IRB 17077","March 15, 2021","March 2022","September 2022","July 15, 2019",,"September 14, 2021","Oregon Health & Science University, Portland, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT04019015"
333,"NCT03881423","Deep vs Moderate Neuromuscular Blockade in Day Case Laparoscopic Cholecystectomy.",,"Completed","No Results Available","Muscle Relaxation","Drug: Rocuronium Bromide","Surgical conditions|Quality of recovery|Postoperative pain","Wahba bakhet|Elite medical center|Ain Shams University","All","21 Years to 60 Years   (Adult)","Phase 4","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care","wbakhet","April 1, 2017","April 1, 2019","July 1, 2019","March 19, 2019",,"October 29, 2019","Ainshams University Hospitals, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT03881423"
334,"NCT02319460","An Observational Cohort Study to Investigate the Risk of Thromboembolic Events in Patients Receiving Kcentra® or Plasma to Reverse Vitamin K Antagonist (VKA) Therapy in the Setting of Acute Major Bleeding",,"Completed","No Results Available","Hemorrhage","Biological: Kcentra®|Biological: Plasma","Risk of thromboembolic events (TEE) for patients without a recent history of TEE|Risk of thromboembolic events|Risk of death from any cause|Rates of use of VKA therapy after the index date","CSL Behring|Kaiser Permanente","All","18 Years and older   (Adult, Older Adult)",,"2238","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Other","BE1116_4001","April 24, 2014","June 30, 2020","June 30, 2020","December 18, 2014",,"May 26, 2021","Study Site, Oakland, California, United States",,"https://ClinicalTrials.gov/show/NCT02319460"
335,"NCT00104871","Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy",,"Completed","Has Results","Insular Thyroid Cancer|Recurrent Thyroid Cancer|Stage II Follicular Thyroid Cancer|Stage II Papillary Thyroid Cancer|Stage IV Follicular Thyroid Cancer|Stage IV Papillary Thyroid Cancer","Drug: Bortezomib","Objective Tumor Response Rate Assessed by RECIST|Participant Tumor Response Assessed by RECIST|Progression-free Survival Assessed by RECIST","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","24","NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2009-00045|2004-0059|N01CM62202|N01CM62203|N01CM17003|CDR0000415376","December 2004","May 2010","April 2014","March 4, 2005","June 25, 2014","December 19, 2018","University of Colorado at Denver Health Sciences Center, Aurora, Colorado, United States|Lombardi Comprehensive Cancer Center at Georgetown University, Washington, District of Columbia, United States|Emory University, Atlanta, Georgia, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Dana-Farber Harvard Cancer Center, Boston, Massachusetts, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States|Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States|M D Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00104871"
336,"NCT03899792","A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors","LIBRETTO-121","Recruiting","No Results Available","Medullary Thyroid Cancer|Infantile Myofibromatosis|Infantile Fibrosarcoma|Papillary Thyroid Cancer|Soft Tissue Sarcoma","Drug: LOXO-292","To Determine the Safety of Oral LOXO-292 in Pediatric Participants with Advanced Solid Tumors: Dose Limiting Toxicities (DLTs)|To Determine the Safety of Oral LOXO-292 in Pediatric Participants with Primary CNS Tumors: DLTs|Overall Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 per Independent Review Committee (IRC)|ORR Based on Response Assessment in Neuro-Oncology (RANO) per IRC|Plasma Concentrations of LOXO-292|Area Under the Concentration-Time Curve from 0 to 24 hours (AUC0-24) of LOXO-292|Maximum Concentration (Cmax) of LOXO-292|Time to Maximum Concentration (Tmax) of LOXO-292|Recommended LOXO-292 Dose for Phase 2 (MTD)|To Assess the Preliminary Anti-Tumor Activity of LOXO-292 in Pediatric Participants with Tumors Harboring an Activating RET Alteration as Determined by ORR Based on RECIST v1.1|Changes from Baseline in Pain Measures as Measured by Wong Baker Faces scales. Wong-Baker Faces Pain Scale includes pictures of facial expressions with correlating scores of 0 being 'no hurt' and 10 being 'hurts worst'.|Changes from Baseline in Health Related Quality of Life Measures as Measured by Pediatric Quality of Life (PedsQoL) Inventory Core. PedsQoL includes a list of problems with scores of 0 being 'never a problem' and 4 being 'almost always a problem'.|Objective Response Rate as Assessed by RECIST v1.1, as Assessed by Investigator|Objective Response Rate as Assessed by RANO, as Assessed by Investigator|Duration of Response (DOR) as Assessed by Investigator|Duration of Response (DOR) as Assessed by the IRC|Progression Free Survival (PFS) as Assessed by Investigator|PFS as Assessed by IRC|Overall survival (OS)|Clinical Benefit Rate (by Investigator)|Clinical Benefit Rate (by IRC)|Frequency of Adverse Events (AEs)|To Evaluate the Concordance of Prior Molecular that Detected a RET Alteration within the Participant's Tumor with Diagnostic Tests Being Evaluated by Sponsor|Phase 2: Post-Operative Stage on Participants Treated with LOXO-292|Phase 2: Surgical Margin Status in Participants Treated with LOXO-292|Descriptive Analysis of Pretreatment Surgical Plan|Descriptive Analysis of Post-Treatment Plans","Loxo Oncology, Inc.|Eli Lilly and Company","All","6 Months to 21 Years   (Child, Adult)","Phase 1|Phase 2","100","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17493|J2G-OX-JZJJ|LOXO-RET-18036|2019-000212-28","June 13, 2019","March 26, 2023","March 26, 2024","April 2, 2019",,"December 17, 2021","Childrens Hospital of Los Angeles, Los Angeles, California, United States|Lucile Packard Children's Hospital, Palo Alto, California, United States|The Children's Hospital for Cancer and Blood Disorders, Aurora, Colorado, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University of Minnesota Hospital, Minneapolis, Minnesota, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|St Jude Childrens Research Hospital, Memphis, Tennessee, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States|Texas Childrens Hospital, Houston, Texas, United States|Seattle Children's Hospital Research Foundation, Seattle, Washington, United States|The Children's Hospital at Westmead, Sydney, New South Wales, Australia|Royal Children's Hospital, Parkville, Victoria, Australia|The Hospital for Sick Children, Toronto, Ontario, Canada|Rigshospitalet, Copenhagen, Denmark|Gustave Roussy, Villejuif Cedex, France|Universitätsklinikum Heidelberg, Heidelberg, Baden-Württemberg, Germany|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, MI, Italy|Hokkaido University Hospital, Sapporo, Hokkaido, Japan|National Cancer Center Hospital, Chuo-ku, Tokyo, Japan|Hiroshima University Hospital, Hiroshima, Japan|Kyoto University Hospital, Kyoto, Japan|Seoul National University Hospital, Seoul, Korea, Korea, Republic of|Hospital Universitari Vall d'Hebron, Barcelona, Barcelona [Barcelona], Spain",,"https://ClinicalTrials.gov/show/NCT03899792"
337,"NCT01355887","A Trial to Compare Pringle Maneuver With Either Infrahepatic Inferior Vena Cava Clamping or Low Central Venous Pressure",,"Unknown status","No Results Available","Liver Resection",,,"Huazhong University of Science and Technology|Chinese University of Hong Kong","All","Child, Adult, Older Adult",,"192","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","CHENXP003","January 2008","December 2011","December 2011","May 18, 2011",,"May 18, 2011","Hepatic surgery center, Tong ji Hospital, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT01355887"
338,"NCT03430154","Awareness, Care, and Treatment In Obesity Management of Patients With Hemophilia (ACTION) to Inform Hemophilia Obesity Patient Empowerment (HOPE)","ACTION to HOPE","Completed","No Results Available","Haemophilia A, Haemophilia B, Obesity","Other: No treatment given","Prevalence of obesity awareness and perceptions|Prevalence of attitudes on obesity|Prevalence of weight loss support structure|Prevalence of interactions between patients and HCPs around obesity/overweight|Prevalence of awareness about weight loss solutions|Characteristics of obesity awareness and perceptions|Characteristics of attitudes on obesity|Characteristics of weight loss support structure|Characteristics of interactions between patients and HCPs around obesity/overweight|Characteristics of awareness about weight loss solutions","Novo Nordisk A/S","All","18 Years and older   (Adult, Older Adult)",,"317","Industry","Observational","Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional","HAEM-4414|U1111-1199-8271","December 1, 2017","April 29, 2018","April 29, 2018","February 12, 2018",,"September 5, 2018","Novo Nordisk Investigational Site, Plainsboro, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT03430154"
339,"NCT00929318","Influence of Thyroid Hormones on the Woundhealing Process",,"Unknown status","No Results Available","Thyroid Neoplasms|Thyroid Carcinoma","Procedure: blood sampling","Evidence for different cytokine levels in euthyroid vs hypothyroid condition confirmed by bood serum samples|Differences in duration and clinical characteristics of the wound healing process verified by a modified ASEPSIS score.","Hannover Medical School|Genzyme, a Sanofi Company","All","18 Years and older   (Adult, Older Adult)","Not Applicable","26","Other|Industry","Interventional","Allocation: Randomized|Masking: None (Open Label)|Primary Purpose: Basic Science","MHH-THY-WH-09","June 2009","December 2009","April 2010","June 29, 2009",,"June 29, 2009","Medizinische Hoochschule Hannover, Allgemein-, Viszeral-und Transplantationscirurgie OE 6220, Hannover, Germany",,"https://ClinicalTrials.gov/show/NCT00929318"
340,"NCT02546622","ATHN 2: Factor Switching Study",,"Completed","No Results Available","Hemophilia","Biological: Factor VIII Replacement Products for Hemophilia which were FDA approved after January 1, 2013|Biological: Factor IX Replacement Products for Hemophilia which were FDA approved after January 1, 2013","Inhibitor Development|Prevalence of risk factors for inhibitor development|Targeted post-marketing approval safety and efficacy data|Platform for additional substudies","American Thrombosis and Hemostasis Network|Shire|CSL Behring|Bioverativ Therapeutics Inc.|Bayer","All","Child, Adult, Older Adult",,"310","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Other","ATHN 2","September 2015","June 30, 2020","June 30, 2020","September 11, 2015",,"December 9, 2021","University of California San Diego (UCSD), San Diego, California, United States|University of Colorado Denver Hemophilia and Thrombosis Center, Aurora, Colorado, United States|Yale Hemophilia Treatment Center, New Haven, Connecticut, United States|Children's National Medical Center, Washington, District of Columbia, United States|Johns Hopkins All Children's Hospital, Saint Petersburg, Florida, United States|St. Joseph's Children's Hospital, Tampa, Florida, United States|Children's Healthcare of Atlanta/Emory, Atlanta, Georgia, United States|Bleeding and Clotting Disorders Institute, Peoria, Illinois, United States|Indiana Hemophilia and Thrombosis Center (IHTC), Indianapolis, Indiana, United States|Louisiana Center for Bleeding and Clotting Disorders, New Orleans, Louisiana, United States|Maine Hemophilia and Thrombosis Center, Scarborough, Maine, United States|Johns Hopkins University Medical Center, Baltimore, Maryland, United States|Boston Hemophilia Center at Children's Hospital of Boston, Boston, Massachusetts, United States|University of Michigan Hemophilia and Coagulation Disorders Program, Ann Arbor, Michigan, United States|Michigan State University Center for Bleeding and Clotting Disorders, East Lansing, Michigan, United States|Children's Mercy Hospital, Kansas City, Missouri, United States|Dartmouth-Hitchcock Comprehensive Hemophilia and Thrombosis Center, Lebanon, New Hampshire, United States|Weill Cornell Medicine, New York, New York, United States|Mary M. Gooley Hemophilia Center, Rochester, New York, United States|Oregon Health and Science University, Portland, Oregon, United States|Children's Hospital of Philadelphia (CHOP), Philadelphia, Pennsylvania, United States|Pennsylvania Comprehensive Hemophilia and Thrombophilia Program / Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|The Hemophilia Center of Western Pennsylvania, Pittsburgh, Pennsylvania, United States|St Jude Children's Research Hospital, Memphis, Tennessee, United States|UTSW Medical Center at Dallas/Children's Medical Center, Dallas, Texas, United States|Washington Center for Bleeding Disorders Bloodworks Northwest d/b/a Puget Sound Blood Center, Seattle, Washington, United States|Blood Center of Wisconsin, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT02546622"
341,"NCT04731701","Psychometric Validation of the Hemophilia Functional Ability Scoring Tool (Hemo-FAST)","Hemo-FAST","Recruiting","No Results Available","Hemophilia A|Hemophilia B","Diagnostic Test: Hemophilia Joint Health Score (HJHS)","Psychometric validation of the Hemophilia Functional Ability Scoring Tool (Hemo-FAST).","Swedish Orphan Biovitrum|Kantar Health","All","18 Years and older   (Adult, Older Adult)",,"180","Industry","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","Sobi.HAEM89-005","May 5, 2021","June 2022","June 2022","February 1, 2021",,"September 9, 2021","Swedish Orphan Biovitrum Clinical site, Bordeaux, France|Swedish Orphan Biovitrum Clinical site, Caen, France|Swedish Orphan Biovitrum Clinical site, Dijon, France|Swedish Orphan Biovitrum Clinical site, Lyon, France|Swedish Orphan Biovitrum Clinical site, Rouen, France|Swedish Orphan Biovitrum Clinical site, Strasbourg, France|Swedish Orphan Biovitrum Clinical site, Toulouse, France",,"https://ClinicalTrials.gov/show/NCT04731701"
342,"NCT02432014","Parent Preferences and Family Engagement in a Conduct Problems Prevention Program",,"Completed","No Results Available","Conduct Problems","Behavioral: PMTO-PTC Group clinic-based|Behavioral: PMTO Individual home-based|Behavioral: PMTO Individual clinic-based|Behavioral: Services as Usual","Family Interaction Task (FIT)|Strengths and Difficulties Questionnaire|Brief Symptom Inventory 18 (BSI-18) Questionnaire|Perceptions of Intervention Benefits and Barriers Questionnaire|Parent Locus of Control Questionnaire|Perceived Susceptibility & Severity Questionnaire|Perceived Need to Improve Parenting Questionnaire|Child Service Utilization Summary Questionnaire","University of Minnesota|National Institute of Mental Health (NIMH)|Michigan Department of Community Health","All","5 Years to 12 Years   (Child)","Not Applicable","134","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","1006S83774|P20MH085987","January 2012","July 2015","September 2015","May 1, 2015",,"November 1, 2019","Center for Personalized Prevention Research in Children's Mental Health, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT02432014"
343,"NCT03615053","Personalized Medicine for Canadians With Hemophilia","PMCH","Recruiting","No Results Available","Hemophilia A|Hemophilia B","Other: Implementation of WAPPS-Hemo personalized dosing regimen","Change in patient quality of life|Annualized Bleeding Rate (ABR) pre and post-tailoring implementation|Change in physical activity|Adherence to prescribed regimen|Consumption of factor concentrates|Feasibility and acceptability of the WAPPS-Hemo based prophylaxis tailoring|Characteristics of reported bleeds|Assessment of the predictive performance of the WAPPS-Hemo clinical calculator|Change in joint function","McMaster University","All","6 Years and older   (Child, Adult, Older Adult)","Not Applicable","600","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","PMCH Study","July 24, 2019","September 30, 2022","September 30, 2023","August 3, 2018",,"September 21, 2021","University of Calgary, Calgary, Alberta, Canada|University of Alberta, Edmonton, Alberta, Canada|University of British Columbia, Vancouver, British Columbia, Canada|University of Manitoba, Winnipeg, Manitoba, Canada|McMaster University, Hamilton, Ontario, Canada|McMaster University, Hamilton, Ontario, Canada|Queen's University, Kingston, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03615053"
344,"NCT03507582","Virtual Reality for Hemophilia",,"Completed","No Results Available","Hemophilia A|Hemophilia B","Other: Virtual Reality Distraction|Other: Standard of Care Distraction","Nurse Orchestrated Virtual Reality Distraction|Standard of Care Distraction|Effectiveness of the distraction technique|Usability and Likeability","Nationwide Children's Hospital","All","6 Years to 19 Years   (Child, Adult)","Not Applicable","25","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other","IRB16-00403","April 2016","December 28, 2016","December 28, 2016","April 25, 2018",,"April 25, 2018","Nationwide Children's Hospital, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT03507582"
345,"NCT03660774","A Study of the Impact of Hemophilia and Its Treatment on Brain Development, Thinking and Behaviour in Children With Hemophilia","eTHINK","Completed","No Results Available","Haemophilia A|Haemophilia B","Other: No treatment given","Cognition composite score according to the BAYLEY-III instrument|Behavioural Symptoms Index according to Behavior Assessment System for Children - Third Edition (BASC-3) parent rating scale|Adaptive behaviour domain score according to Adaptive Behavior Assessment System, Third Edition (ABAS-3) rating scale|Global executive composite index according to Behavior Rating Inventory of Executive Function (BRIEF)|Attention and processing speed (full scale IQ) according to Wechsler Preschool and Primary Scale of Intelligence-4th Edition (WPPSI-IV) for age group 4-6 years or Wechsler Abbreviated Scale of Intelligence, 2nd Edition (WASI-II) for age group 7-22 years","Novo Nordisk A/S","Male","1 Year to 21 Years   (Child, Adult)",,"563","Industry","Observational","Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional","HAEM-4436|U1111-1202-3415","September 27, 2018","October 11, 2019","October 11, 2019","September 7, 2018",,"November 22, 2019","Novo Nordisk Investigational Site, Los Angeles, California, United States|Novo Nordisk Investigational Site, Orange, California, United States|Novo Nordisk Investigational Site, San Diego, California, United States|Novo Nordisk Investigational Site, Aurora, Colorado, United States|Novo Nordisk Investigational Site, Washington, District of Columbia, United States|Novo Nordisk Investigational Site, Tampa, Florida, United States|Novo Nordisk Investigational Site, Atlanta, Georgia, United States|Novo Nordisk Investigational Site, Chicago, Illinois, United States|Novo Nordisk Investigational Site, Indianapolis, Indiana, United States|Novo Nordisk Investigational Site, New Orleans, Louisiana, United States|Novo Nordisk Investigational Site, Boston, Massachusetts, United States|Novo Nordisk Investigational Site, Ann Arbor, Michigan, United States|Novo Nordisk Investigational Site, Detroit, Michigan, United States|Novo Nordisk Investigational Site, Minneapolis, Minnesota, United States|Novo Nordisk Investigational Site, Omaha, Nebraska, United States|Novo Nordisk Investigational Site, Charlotte, North Carolina, United States|Novo Nordisk Investigational Site, Cleveland, Ohio, United States|Novo Nordisk Investigational Site, Oklahoma City, Oklahoma, United States|Novo Nordisk Investigational Site, Philadelphia, Pennsylvania, United States|Novo Nordisk Investigational Site, Nashville, Tennessee, United States|Novo Nordisk Investigational Site, Salt Lake City, Utah, United States|Novo Nordisk Investigational Site, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT03660774"
346,"NCT03276130","Management of Health-Related QoL Impairment, Including Pain, Depression and Anxiety, in People With Haemophilia A and B","MIND","Completed","No Results Available","Haemophilia A|Haemophilia B",,"Use of medication for pain, depression and anxiety (yes/no?)|Annualised consumption of pain medications as assessed by filled prescription|Annualised consumption of anti-anxiety medications as assessed by filled prescription|Annualised consumption of anti-depressive medications as assessed by filled prescription|Duration of pain medications as measured by expected doses of medicines.|Duration of anti-depressive medications as measured by expected doses of medicines.|Duration of anti-anxiety medications as measured by expected doses of medicines.|Pharmacological and non-pharmacological treatments for management of Health-Related Quality of Life (HRQoL) impairment, including treatment of pain|Pharmacological and non-pharmacological treatments for management of HRQoL impairment, including treatment of anxiety|Pharmacological and non-pharmacological treatments for management of HRQoL impairment, including treatment of depression|The perspective and experience of HCPs with direct and frequent patient Contacts on the strategies for the management of HRQoL impairment, including treatment of pain at each Haemophlia Treatment Centre|The perspective and experience of HCPs with direct and frequent patient Contacts on the strategies for the management of HRQoL impairment, including treatment of anxiety at each Haemophlia Treatment Centre|The perspective and experience of HCPs with direct and frequent patient Contacts on the strategies for the management of HRQoL impairment, including treatment of depression at each Haemophlia Treatment Centre|Self-reported current and previous use of medications for pain|Self-reported current and previous use of medications for anxiety|Self-reported current and previous use of medications for depression|Social and physical activity level|Euro-QoL 5 Dimensions 5 Levels (EQ-5D-5L)|Patient satisfaction with current management of pain|Patient satisfaction with current management anxiety|Patient satisfaction with current management of depression|Patient satisfaction of received treatment for pain|Patient satisfaction of received treatment for anxiety|Patient satisfaction of received treatment for depression","Swedish Orphan Biovitrum","All","5 Years and older   (Child, Adult, Older Adult)",,"2300","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","Sobi.HAEM89-003","October 30, 2018","January 30, 2020","January 30, 2020","September 8, 2017",,"July 17, 2020","Swedish Orphan Biovitrum Research Site, Copenhagen, Denmark|Swedish Orphan Biovitrum Research Site, Helsinki, Finland|Swedish Orphan Biovitrum Research Site, Göteborg, Sweden|Swedish Orphan Biovitrum Research Site, Malmö, Sweden|Swedish Orphan Biovitrum Research Site, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT03276130"
347,"NCT02938156","UK - EHL Outcomes Registry",,"Unknown status","No Results Available","Hemophilia A|Hemophilia B",,"Bleed Control|Joint Health|EQ-5D-5L|HAEM-A-QoL|Haemo-QoL|Physical Activity QoL|Haemoprefer|Identify the value of individualised prophylaxis","Royal Free Hospital NHS Foundation Trust","Male","Child, Adult, Older Adult",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RFH/9782","December 17, 2016","October 2019","October 2019","October 19, 2016",,"September 4, 2018","Basingstoke and North Hampshire Hospital, Basingstoke, United Kingdom|Birmingham Women and Childrens, Birmingham, United Kingdom|Queen Elizabeth Hospital, Birmingham, United Kingdom|University Hospital Bristol, Bristol, United Kingdom|Kent & Canterbury Hospital, Canterbury, United Kingdom|University Hospital of Wales, Cardiff, United Kingdom|University of Coventry & Warwickshire, Coventry, United Kingdom|Glasgow Royal Hospital for Children, Glasgow, United Kingdom|Royal Infirmary, Glasgow, United Kingdom|Lincoln County Hospital, Lincoln, United Kingdom|Liverpool University Hospital, Liverpool, United Kingdom|Royal Free Hospital NHS Foundation Trust, London, United Kingdom|Great Ormond Street Hospital, London, United Kingdom|Hammersmith Hospital, London, United Kingdom|St George's Hospital, London, United Kingdom|Royal Victoria Hospital, Newcastle upon Tyne, United Kingdom|Nottingham University Hospital, Nottingham, United Kingdom|Churchill Hospital Oxford, Oxford, United Kingdom|Royal Hallamshire Hospital, Sheffield, United Kingdom|Sheffield Children's Hospital, Sheffield, United Kingdom|Royal Cornwall Hospital, Truro, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02938156"
348,"NCT02807753","The Hemophilia Ultrasound Project","HUP","Terminated","No Results Available","Hemophilia A|Hemophilia B","Other: Ankle and Knee Ultrasound Joint Assessment|Other: Ankle and Knee Magnetic Resonance Imaging","Prevalence and natural progression of subclinical arthropathy (joint changes) in children with severe hemophilia undergoing prophylaxis using a validated ultrasound (HEAD-US) protocol.|Prevalence and natural progression of subclinical arthropathy (joint changes) in children with mild and/or moderate hemophilia using a validated ultrasound (HEAD-US) protocol.|Characteristics of subclinical joint changes (time of presentation, natural evolution, etc.) between patients with severe hemophilia and those with mild/moderate hemophilia.","University of Miami|Shire","All","up to 30 Months   (Child)",,"18","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","20151156","September 16, 2016","December 7, 2020","December 7, 2020","June 21, 2016",,"January 22, 2021","University of Florida, Gainesville, Florida, United States|The University of Miami - Department of Pediatrics, Miami, Florida, United States|University of Kentucky, Lexington, Kentucky, United States|Tulane, New Orleans, Louisiana, United States",,"https://ClinicalTrials.gov/show/NCT02807753"
349,"NCT03454893","FAB- GT Open-Label, Study Of Efficacy and Safety Of AVR-RD-01 for Treatment -Naive Subjects With Classic Fabry Disease",,"Recruiting","No Results Available","Fabry Disease","Drug: AVR-RD-01","Incidence of Treatment-Emergent Adverse Events of AVR-RD-01 drug product|Change in the average number of Gb3 inclusions (ie, myelinosomes) per kidney peritubular capillary (PTC) per subject","AVROBIO","Male","16 Years to 50 Years   (Child, Adult)","Phase 1|Phase 2","12","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AVRO-RD-01-201","February 21, 2018","July 2021","November 2021","March 6, 2018",,"November 18, 2020","Hackensack University Medical Center, Hackensack, New Jersey, United States|Royal Melbourne Hospital, Melbourne, Parkville VIC, Australia|Royal Perth Hospital, Perth, Australia|Alberta Children's Hospital, Calgary, Alberta, Canada",,"https://ClinicalTrials.gov/show/NCT03454893"
350,"NCT02571569","A Single Escalating Dose and Multiple Dose Study of BAY 1093884 in Subjects With Severe Hemophilia Types A or B, With or Without Inhibitors",,"Completed","No Results Available","Hemophilia A|Hemophilia B","Drug: BAY1093884","Number of participants (single dose cohors) with adverse events as measure of safety and tolerability|Plasma levels of anti-BAY1093884 antibodies|Plasma concentration of BAY1093884 characterized by AUC(0-tlast)|Plasma concentration of BAY1093884 characterized by AUC(0-tlast)/D|Plasma concentration of BAY1093884 characterized by Cmax|Plasma concentration of BAY1093884 characterized by Cmax/D|Tissue factor pathway inhibitor (TFPI) activity|Number of participants (multiple dose cohort) with adverse events as a measure of safety and tolerability|Plasma levels of anti-BAY1093884 antibodies (multiple dose cohort)|Plasma concentration of BAY1093884 characterized by AUC(0-7d and AUC(0-tau) (multiple dose cohort)|Plasma concentration of BAY1093884 characterized by AUC(0-7d/D and AUC(0-tau)/D after multiple dose|Plasma concentration of BAY1093884 characterized by Cmax after first dose and last dose (Cmax,md)|Plasma concentration of BAY1093884 characterized by Cmax/D after first dose and last dose (Cmax,md/D)|Accumulation of BAY 1093884 in plasma as defined by ratio for Cmax and AUC (after first and last dose)","Bayer","Male","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","32","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","16144|2014-003283-20","October 28, 2015","July 9, 2018","October 11, 2018","October 8, 2015",,"October 18, 2018","Plovdiv, Bulgaria|Sofia, Bulgaria|Varna, Bulgaria|Gießen, Hessen, Germany|Berlin, Germany|Suginami, Tokyo, Japan|Kiev, Ukraine|Lviv, Ukraine|London, United Kingdom|Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02571569"
351,"NCT01561391","Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery",,"Completed","No Results Available","Congenital Bleeding Disorder|Haemophilia A With Inhibitors|Haemophilia B With Inhibitors","Drug: activated recombinant human factor VII|Other: factor IX|Drug: factor VIII","Presence and maintenance of haemostasis|Changes in FVII:C (Factor VII clotting activity) levels following administration of activated recombinant human factor VII|Adverse Events|Changes in coagulation-related parameters","Novo Nordisk A/S",,"5 Years and older   (Child, Adult, Older Adult)","Phase 4","36","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","F7HAEM/USA/4/USA","April 1998","May 2004","May 2004","March 23, 2012",,"January 12, 2017","Novo Nordisk Investigational Site, Los Angeles, California, United States|Novo Nordisk Investigational Site, Chicago, Illinois, United States|Novo Nordisk Investigational Site, Chicago, Illinois, United States|Novo Nordisk Investigational Site, New Orleans, Louisiana, United States|Novo Nordisk Investigational Site, Boston, Massachusetts, United States|Novo Nordisk Investigational Site, Rochester, Minnesota, United States|Novo Nordisk Investigational Site, New Brunswick, New Jersey, United States|Novo Nordisk Investigational Site, Albuquerque, New Mexico, United States|Novo Nordisk Investigational Site, New York, New York, United States|Novo Nordisk Investigational Site, Chapel Hill, North Carolina, United States|Novo Nordisk Investigational Site, Hershey, Pennsylvania, United States|Novo Nordisk Investigational Site, Philadelphia, Pennsylvania, United States|Novo Nordisk Investigational Site, Philadelphia, Pennsylvania, United States|Novo Nordisk Investigational Site, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01561391"
352,"NCT02418793","A Study of a Long-Acting r-Factor 7a (Factor VIIa) in Adult Men With Hemophilia A or B",,"Completed","No Results Available","Hemophilia A|Hemophilia B","Drug: MOD-5014","Composite safety and tolerability parameters as measured by adverse events, electrocardiograms (ECG), laboratory results, vital signs and injection site reactions|Pharmacokinetic Profile","OPKO Health, Inc.","Male","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","27","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CP-5-001","May 2015","September 2018","September 2018","April 16, 2015",,"May 20, 2021","City of Hope, Duarte, California, United States|Children's Hospital Los Angeles, Los Angeles, California, United States|Orthopaedic Hemophilia Treatment Center, Los Angeles, California, United States|University of California Davis Medical Center, Sacramento, California, United States|Rush University Medical Center, Chicago, Illinois, United States|Bleeding & Clotting Disorders Institute, Peoria, Illinois, United States|Indiana Hemophilia & Thrombosis Center, Indianapolis, Indiana, United States|Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|UPMC Presbyterian Shadyside, Pittsburgh, Pennsylvania, United States|UT Southwestern Medical Center, Dallas, Texas, United States|The Gulf States Hemophilia and Thrombophilia Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02418793"
353,"NCT02035605","A Phase 1 Study of an Investigational Drug, ALN-AT3SC, in Healthy Volunteers and Hemophilia A or B Patients",,"Completed","No Results Available","Hemophilia A|Hemophilia B","Drug: ALN-AT3SC|Drug: Sterile Normal Saline (0.9% NaCl)","The safety of ALN-AT3SC evaluated by the proportion of subjects experiencing adverse events (AEs), serious adverse events (SAEs), dose-limiting toxicities (DLTs), and AEs leading to study drug discontinuation.|The pharmacokinetics (PK) of ALN-AT3SC as characterized by plasma PK profiles and urine samples.|The pharmacodynamic (PD) effect of ALN-AT3SC, evaluated by Plasma AT levels.|The pharmacodynamic (PD) effect of ALN-AT3SC, evaluated by Plasma TG.","Sanofi","Male","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","51","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","ALN-AT3SC-001","January 20, 2014","July 20, 2017","July 20, 2017","January 14, 2014",,"December 19, 2020","Clinical Trial Site, Pittsburgh, Pennsylvania, United States|Clinical Trial Site, Plovdiv, Bulgaria|Clinical Trial Site, Sofia, Bulgaria|Clinical Trial Site, Varna, Bulgaria|Clinical Trial Site, Kirov, Russian Federation|Clinical Trial Site, Moscow, Russian Federation|Clinical Trial Site, St. Petersburg, Russian Federation|Clinical Trial Site, St. Gallen, Switzerland|Clinical Trial Site, Zurich, Switzerland|Clinical Trial Site, Glasgow, United Kingdom|Clinical Trial Site, London, United Kingdom|Clinical Trial Site, London, United Kingdom|Clinical Trial Site, Manchester, United Kingdom|Clinical Trial Site, Truro, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02035605"
354,"NCT01921855","Study of FVIIa Variant BAY86-6150 (B0189) in Subjects With Moderate or Severe Hemophilia Types A or B With or Without Inhibitors","MATCHBOX","Completed","No Results Available","Hemophilia A|Hemophilia B","Drug: BAY Factor VII (BAY86-6150)|Drug: Placebo","Number of participants with adverse events as a measure of safety and tolerability|Pharmacokinetic assessment, based on plasma concentration of BAY86-6150|Pharmacodynamic assessment, based on plasma hemostasis marker level|Immunogenicity assessment, based on anti-BAY86-6150 binding antibody levels","Bayer","Male","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","16","Industry","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","13787|2008-000117-29","January 2009","December 2009","December 2009","August 13, 2013",,"August 21, 2014","Warszawa, Poland|Bloemfontein, Freestate, South Africa|Johannesburg, Gauteng, South Africa|London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01921855"
355,"NCT03428971","P-wave Terminal Force in Patients With Atrial Fibrillation.","Ptf-AF","Unknown status","No Results Available","Atrial Fibrillation","Procedure: cardioversion","Changes of P-wave time (PT), P-wave amplitude (PAM) and Ptf (P wave terminal force terminal V1-lead ) in 5-year follow-up (5FU).|Correlation between index PT0, PAM0, Ptf0 and number of hospitalizations (HOSP) in 5-year follow-up|Correlation between number of hospitalizations (HOSP) in 5- year follow-up and final PT5, PAM5, Ptf5 at the end of 5-year follow-up period.|Correlation between changes of PT, PAM, Ptf (PTC, PAMC, PtfC) and number of hospitalizations (HOSP) in 5-year follow-up.","Medical University of Lublin","All","18 Years to 90 Years   (Adult, Older Adult)",,"600","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","MW-MULublin-1","March 1, 2018","March 7, 2020","December 7, 2020","February 12, 2018",,"January 22, 2020","Medical University of Lublin, Lublin, Poland",,"https://ClinicalTrials.gov/show/NCT03428971"
356,"NCT01510418","Socialization of Adult Men With Congenital Hemophilia A or B","PWBCD","Completed","No Results Available","Hemophilia A|Hemophilia B",,"Health related quality of life, description of support and networks.|Quality of life and description of role of SSO in health care of their PWCBD partner","Dana-Farber Cancer Institute|Brigham and Women's Hospital","All","21 Years and older   (Adult, Older Adult)",,"27","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","10-343","May 2011","May 2013","December 2013","January 16, 2012",,"August 3, 2016","Dana-Farber Cancer Institute, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01510418"
357,"NCT01217255","Comparing the Burden of Illness of Hemophilia in the Developing and the Developed World",,"Completed","No Results Available","Hemophilia A|Hemophilia B",,"Burden of Illness|The Activity Scale for Kids (ASK)|Functional Independence Scale for Hemophilia (FISH)|Hemophilia Joint Health Score (HJHS)|Radiographs|Canadian Haemophilia Outcomes - Kids Life Assessment Tool (CHO-KLAT)|Bleeding Frequency|Biometrics|Personal Factors|Environmental domain","The Hospital for Sick Children","Male","7 Years to 18 Years   (Child, Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","1000020214","September 2010","October 2013","October 2013","October 8, 2010",,"June 6, 2018","Universidade Estadual de Campinas, UNICAMP, Campinas, Sao Paulo, Brazil|Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil|Universidade Federal de São Paulo (UNIFESP), Sao Paulo, Brazil|The Hospital for Sick Children, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01217255"
358,"NCT03469011","A Study to Try to Bring Back Radioiodine Sensitivity in Patients With Advanced Thyroid Cancer.",,"Recruiting","No Results Available","Papillary Thyroid Cancer","Drug: Imatinib Oral Tablet","Restore iodine uptake|Decrease overall tumor burden","AHS Cancer Control Alberta|Alberta Cancer Foundation","All","18 Years and older   (Adult, Older Adult)","Phase 1","18","Other","Interventional","Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Imatinib-CCI-PH1-01","September 18, 2018","December 31, 2021","December 31, 2021","March 19, 2018",,"June 29, 2021","Cross Cancer Institute, Edmonton, Alberta, Canada",,"https://ClinicalTrials.gov/show/NCT03469011"
359,"NCT04170101","RCT Deep vs Moderat NMB on Surgical Conditions During THP",,"Not yet recruiting","No Results Available","Muscle Injury","Procedure: deep NMB|Procedure: moderate NMB","surgical exposure|muscle injury|creatinine kinase (CK)|C-reactive protein (CRP)|leaving bed|Length of stay|postoperative complications|quality of recovery","AZ Sint-Jan AV","All","18 Years and older   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","2019RCTdeepNMBTHP","April 1, 2021","December 31, 2021","June 30, 2022","November 20, 2019",,"January 20, 2021","Azsintjan, Brugge, Belgium",,"https://ClinicalTrials.gov/show/NCT04170101"
360,"NCT00936845","Females With Severe or Moderate Hemophilia A or B: A Multi-Center Study",,"Completed","No Results Available","Hemophilia A|Hemophilia B",,"The prevalence of females with severe or moderate hemophilia A or B in the United States.|Collect existing data on the genetic and/or chromosomal causes for severe and moderate hemophilia A and B in females in the United States.|To determine the natural history of hemophilia in females by collecting and analyzing data on the symptoms, treatment patterns, and complications of hemophilia in this cohort.|Collect and analyze data on the health-related quality of life and psychosocial adaptation to disease of females in the United States.","Weill Medical College of Cornell University|CSL Behring|University of Pennsylvania","Female","1 Month and older   (Child, Adult, Older Adult)",,"22","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","Females with Hemophilia","April 2005","January 2010","January 2010","July 10, 2009",,"December 10, 2012","City of Hope National Medical Center, Duarte, California, United States|Mountain States Regional Hemophilia and Thrombosis Center, Aurora, Colorado, United States|Georgetown University Hospital, Washington, District of Columbia, United States|Emory University Hemophilia Program Office, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|University of Kentucky Hemophilia Treatment Center, Lexington, Kentucky, United States|Boston Hemophilia Center- Children's Hospital, Boston, Massachusetts, United States|Henry Ford Hospital Adult Hemophilia and Thrombosis Treatment Center, Detroit, Michigan, United States|Newark Beth Israel Medical Center, Newark, New Jersey, United States|Hemophilia Center of Western New York - Pediatric, Buffalo, New York, United States|Long Island Jewish Medical Center, New Hyde Park, New York, United States|Weill Cornell Medical College, New York, New York, United States|Mary M. Gooley Hemophilia Center, Inc., Rochester, New York, United States|Children's Hospital Medical Center of Akron, Akron, Ohio, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Oklahoma Center for Bleeding Disorders, Oklahoma City, Oklahoma, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Gulf States Hemophilia and Thrombophilia Center, Houston, Texas, United States|Puerto Rico Hemophilia Treatment Center, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT00936845"
361,"NCT00936312","Females With Severe or Moderate Hemophilia A or B: an International Multi-center Study",,"Completed","No Results Available","Hemophilia A|Hemophilia B",,"The molecular and cytogenetic etiology of the condition will be compiled. Clinical manifestation demonstrated by the female hemophiliacs will be compared to published data available. Genotype and phenotype will be correlated.","Weill Medical College of Cornell University|Bayer|University Hospital, Bonn","Female","Child, Adult, Older Adult",,"200","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","Intl Female Hemophilia Study","March 2008","August 2011","August 2011","July 10, 2009",,"December 10, 2012","Weill Cornell Medical College, New York, New York, United States|Princess Margaret Hospital for Children, Perth, Australia|University Clinic Bonn, Bonn, Germany|University Clinic Munich, Munich, Germany|Sheba Medical Center, Tel Hashomer, Israel|Instituto G. Gaslini, Genova, Italy|A. Bianchi Bonomi Hemophilia Center, Milan, Italy|Nara Medical University, Nara, Japan|University Hospital Utrecht, Utrecht, Netherlands|Malmo University Hospital, Malmo, Sweden|Changhua Christian Hospital, Chunghua City, Changhua, Taiwan",,"https://ClinicalTrials.gov/show/NCT00936312"
362,"NCT00927992","Study Evaluating Liver Transplantation in Haemophilia Patients in Spain",,"Completed","Has Results","Hemophilia|Hemophilia B","Other: Epidemiological Non interventional","Number of Participants Requiring Immunosuppressive Therapy After Liver Transplantation|Number of Participants With Acute Rejection of Liver Transplant|Number of Participants With Hepatitis C Viral Infection Recurrence After Liver Transplantation|Number of Participants Who Survived After Liver Transplantation|Number of Participants Requiring Exogenous Clotting Factor Infusion During Liver Transplantation|Dose of Exogenous Clotting Factors Used During Liver Transplantation|Number of Participants With and Without Hemophilia Requiring Immunosuppressive Therapy, Had Acute Rejection, Hepatitis C Viral Infection Recurrence and Who Survived After Liver Transplantation","Wyeth is now a wholly owned subsidiary of Pfizer","All","Child, Adult, Older Adult",,"11","Industry","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","B1831011|3082B1-4436","July 2009","June 2010","June 2010","June 25, 2009","January 30, 2013","January 30, 2013",,,"https://ClinicalTrials.gov/show/NCT00927992"
363,"NCT00824798","Gait Evaluation in Haemophiliac Patients","GAIT_GENERAL","Completed","No Results Available","Hemophilia A|Hemophilia B",,"evaluate specific changes in gait in patients suffering from haemophilic arthropathy","Cliniques universitaires Saint-Luc- Université Catholique de Louvain","Male","5 Years to 80 Years   (Child, Adult, Older Adult)",,"31","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","READ-LOBET-02","January 2009","January 2011","January 2011","January 19, 2009",,"July 11, 2019","Cliniques universitaires Saint-Luc, Brussels, Belgium",,"https://ClinicalTrials.gov/show/NCT00824798"
364,"NCT04817462","Liver Biopsy In Haemophilia Gene Therapy",,"Not yet recruiting","No Results Available","Hemophilia B, Severe|Hemophilia A, Severe",,"Comprehensive analysis of AAV integration frequency in hepatocytes|The degree of hepatocyte damage at a morphological level","University College, London","Male","18 Years to 80 Years   (Adult, Older Adult)",,"10","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","18/0130","April 1, 2021","October 1, 2021","October 1, 2021","March 26, 2021",,"March 26, 2021",,,"https://ClinicalTrials.gov/show/NCT04817462"
365,"NCT00581438","Study Evaluating Approach to Treatment of Haemophilia A and B in Spain",,"Completed","No Results Available","Hemophilia A|Hemophilia B",,"Analyze the clinical and therapeutic approach to treament of haemophilia A and B in habitual clinical practice conditions in Spain during the first 3 years since diagnosis.|Assess haemophilia A or B patient profile, study different kinds of habitual clinical treatment of haemophilia A and B patients, and estimate the dosage units used per year in patients under habitual clinical practice conditions.","Wyeth is now a wholly owned subsidiary of Pfizer","All","Child, Adult, Older Adult",,"52","Industry","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","3082A-102378","June 2007","December 2007","December 2007","December 27, 2007",,"December 27, 2007",,,"https://ClinicalTrials.gov/show/NCT00581438"
366,"NCT02979119","The European Paediatric Network for Haemophilia Management ( PedNet Registry)","PedNet","Recruiting","No Results Available","Factor VIII Deficiency|Factor IX Deficiency",,"Number of patients with antibody development to exogenous clotting factors|Long term outcome of haemophilia on joint status using the Hemophilia Joint Health Score (HJHS) and MRI techniques.|Long term outcome different Immune Tolerance Induction (ITI) therapies in patients with inhibitor.","PedNet Haemophilia Research Foundation|Lund University Hospital","All","Child, Adult, Older Adult",,"4000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Version 6.0 May 2020","June 2014","December 2029","December 2029","December 1, 2016",,"September 29, 2020","Universitäts-Klinik für Kinder- und Jugendheilkunde, Graz, Austria|Medical University of Vienna - Department of Paediatrics, Vienna, Austria|Service of Pediatric Haematology University Hospital Leuven, Leuven, Belgium|Division of Hematology/Oncology Hôpital St Justine, Montréal, Canada|Division of Haematology/Oncology Hospital for Sick Children, Toronto, Canada|Haemophilia Comprehensive Care Centre, Centre for Thrombosis and Haemostasis Children's University Hospital Brno, Brno, Czechia|Department of Paediatric Haematology/oncology - University Hospital Motol, Praha, Czechia|Department of Pediatrics Århus Kommunehospital Skejby Sygehus, Aarhus, Denmark|Children's Hospital Helsinki University Hospital, Helsinki, Finland|Service Hématologique Centre Regional Traitement d'Hemophilie Bicetre, Le Kremlin Bicêtre, France|Service d'Hématologie Pédiatrique Hôpital Universitaire La Timone, Marseille Cedex-05, France|Centre de traitement des hémophiles Hôpital Universitaire Purpan, Toulouse, France|Institut für Experimentelle Hämatologie und Transfusionsmedizin Universitätsklinikum Bonn, Bonn, Germany|Klinik Bremen-Mitte Prof.-Hess-Kinderklinik, Bremen, Germany|University Hospital Frankfurt & Goethe University - Clinical and Molecular Hemostasis, Department of Pediatrics, Frankfurt am Main, Germany|Dr. v. Haunersches Kinderspital University of Munich, Munich, Germany|Hämophilie Zentrum Rhein Main, Mörfelden-Walldorf, Germany|Haemophilia-Haemostasis Unit St. Sophia Children's Hospital, Athens, Greece|Dept of Paediatric Haematology Our Lady's Children's Hospital for Sick Children Crumlin, Dublin, Ireland|The National Hemophilia Center Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel|Gaslini Hospital, Genova, Italy|A. Bianchi Bonomi Hemophilia and Thrombosis Centre IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy|Van Creveld Kliniek University Medical Center Utrecht, Utrecht, Netherlands|Oslo University Hospital, Oslo, Norway|Centro Hospitalar São João, S. Imuno-hemoterapia, Porto, Portugal|Unitat Hemofilia Hospital Vall d'Hebron, Barcelona, Spain|Unidad de Coagulopatías Hospital Universitario La Paz, Madrid, Spain|Hospital General Unidad de Hemofilia 1 Sur Hospitales Universitarios Virgen del Rocio, Seville, Spain|Unidad de Coagulopatias Congenitas Hospital Universitario la Fe, Valencia, Spain|Lund University Hospital, Malmo, Sweden|Department of Pediatrics, Clinic of Coag. Disorders Karolinska Hospital, Stockholm, Sweden|Inselspital Bern, University Children's Hospital, Bern, Switzerland|Birmingham Children's Hospital NHS Trust - Department of Haematology, Birmingham, United Kingdom|Royal Hospital for Sick Children, Edinburgh, United Kingdom|Department of Haematology Royal Hospital for Sick Children, Glasgow, United Kingdom|Haemophila Center Great Ormond Street Hospital for Children, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02979119"
367,"NCT01974284","Percutaneous Ethanol Injection for Primary Papillary Thyroid Microcarcinoma",,"Terminated","Has Results","Papillary Thyroid Cancer","Drug: percutaneous ethanol ablation","Disease-free|Overall Survival|Quality of Life|Patient Satisfaction","Yale University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","7","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HIC1312013168","March 2014","March 2, 2017","June 29, 2017","November 1, 2013","November 25, 2019","November 25, 2019","Endocrine Surgery Smilow Cancer Hospital at Yale-New Haven, New Haven, Connecticut, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/84/NCT01974284/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01974284"
368,"NCT02323724","APPLICATION OF MOLECULAR TECHNIQUES FOR IMPROVING THE DIAGNOSIS AND TREATMENT OF NODULAR THYROID LESIONS.",,"Completed","No Results Available","Papillary Thyroid Carcinoma","Genetic: BRAF V600E mutation by pyrosequencing technique","Improvement in diagnosis","Corporacion Parc Tauli","All","Child, Adult, Older Adult",,"25","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","2014/617","February 2015","July 2015","July 2015","December 23, 2014",,"September 22, 2016","Corporació Sanitària Parc Taulí, Sabadell, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT02323724"
369,"NCT04948437","Urinary Exosomal Biomarkers of Thyroglobulin and Galectin-3 for Prognosis and Follow-up in Patients of Thyroid Cancer",,"Recruiting","No Results Available","Thyroid Cancer|Papillary Thyroid Cancer|Follicular Thyroid Cancer",,"Change of serum thyroglobulin level|Change of serum free T4 level|Change of serum TSH level|Change of anti-thyroglobulin level|Urinary exosomal thyroglobulin detection|Urinary exosomal galectin-3 detection|Urinary exosomal calprotectin A9 detection|Urinary exosomal transketolase detection|Urinary exosomal keratin 19 detection|Urinary exosomal angiopoietin-1 detection|Urinary exosomal tissue inhibitor of metalloproteinase detection|Urinary exosomal keratin 8 detection|Urinary exosomal calprotectin A8 detection|Urinary exosomal annexin II detection|Urinary exosomal afamin detection","National Taiwan University Hospital","All","20 Years to 80 Years   (Adult, Older Adult)",,"103","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","202012036RIND","August 19, 2021","October 31, 2024","October 31, 2026","July 2, 2021",,"September 2, 2021","Chih-Yuan Wang, M.D, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT04948437"
370,"NCT04789954","Study on the Dose-response Relationship of Pharmacodynamic Parameters in Patients With Hemophilia With Inhibitors",,"Recruiting","No Results Available","Hemophilia A With Inhibitor|Hemophilia B With Inhibitor","Biological: Eptacog alfa, activated","Lag time of the thrombin generation curve|Endogenous Thrombin Potential (PD parameter)|Time to Peak (PD parameter)|Peak height (PD parameter)|F1.2 prothrombin fragments (PD parameter)|D-dimer (PD parameter)|AUCinf (PK parameter)|Cmax (PK parameter)|Time of Cmax (PK parameter)","AryoGen Pharmed Co.","Male","12 Years and older   (Child, Adult, Older Adult)","Early Phase 1","12","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","UGA 2020-01","December 29, 2020","April 2021","July 2021","March 10, 2021",,"March 10, 2021","Comprehensive Hemophilia Care Center, Teheran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT04789954"
371,"NCT01311089","A Comparative Study of Robotic Thyroidectomy Using Transaxillary Approach Versus Conventional Open Thyroidectomy",,"Completed","No Results Available","Papillary Thyroid Carcinoma",,,"Yonsei University","All","20 Years and older   (Adult, Older Adult)",,"169","Other","Observational","Time Perspective: Prospective","1-2010-0055","January 2011","September 2011","September 2011","March 9, 2011",,"January 27, 2015","Severance Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01311089"
372,"NCT01668095","Biomarkers in Patients With Advanced Rhabdomyosarcoma",,"Completed","No Results Available","Adult Rhabdomyosarcoma|Childhood Alveolar Rhabdomyosarcoma|Childhood Embryonal Rhabdomyosarcoma|Previously Treated Childhood Rhabdomyosarcoma|Recurrent Adult Soft Tissue Sarcoma|Recurrent Childhood Rhabdomyosarcoma|Stage III Adult Soft Tissue Sarcoma|Stage IV Adult Soft Tissue Sarcoma","Other: Laboratory Biomarker Analysis","Prevalence of the candidate target (Pax3, Pax7, or Patched-1), and whether the candidate target is expressed in the tumor vs stroma","Children's Oncology Group|National Cancer Institute (NCI)","All","Child, Adult, Older Adult",,"10","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","ARST12B8|NCI-2012-01997|COG-ARST12B8|CDR0000738499","August 2012","October 2012",,"August 17, 2012",,"May 18, 2016","Children's Oncology Group, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01668095"
373,"NCT03890406","The Effect of Deep Neuromuscular Blockade on Requirement of Intravenous Anesthetic Agent",,"Completed","No Results Available","Laparoscopy|General Anesthesia|Neuromuscular Blockade","Drug: Rocuronium: PTC(Post-tetanic count) 1~2|Drug: Rocuronium: TOF(Train-of-four) 1~2","Dosage of propofol|Dosage of remifentanil|Patient movement|Patient self respiration|Surgical condition score","Seoul National University Bundang Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","88","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","DEEPTIVA","April 1, 2019","December 31, 2019","March 31, 2020","March 26, 2019",,"June 30, 2020","Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03890406"
374,"NCT03407651","Study of Coagulation Factor VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia A and B",,"Completed","Has Results","Hemophilia A With Inhibitor|Hemophilia B With Inhibitor","Biological: Coagulation Factor VIIa variant","Bleeding Episode Prevention Success|Occurrence of Breakthrough Bleeding|Occurrence of Clinical Thrombotic Event|Coagulation Assessment - Prothrombin Time|Coagulation Assessment - Activated Partial Thromboplastin Time|Coagulation Assessment - Fibrinogen|Number of Events of Antibody Formation|Number of Events of an Antibody Response|Thrombogenicity Assessment","Catalyst Biosciences","Male","18 Years and older   (Adult, Older Adult)","Phase 2","11","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MAA-201","December 18, 2017","March 15, 2019","April 13, 2019","January 23, 2018","September 23, 2021","September 23, 2021","Hematology Center after Prof. R. Yeolyan, Yerevan, Armenia|JSC ""K.Eristavi National Center of Experimental and Clinical Surgery"", Tbilisi, Georgia|LTD M.Zodelava Hematology Centre, Tbilisi, Georgia|LTD Medinvest - Institute of Hematology and Transfusiology, Tbilisi, Georgia|Gabinet Lekarski, Bartosz Korczowski, Rzeszów, Poland|Regional Clinical Hospital, Kemerovo, Russian Federation|FGU Kirov Scientific Research, Kirov, Russian Federation|Center for Hemophilia Treatment, Saint Petersburg, Russian Federation|Haemophilia Comprehensive Care Centre, Johannesburg, South Africa","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/51/NCT03407651/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/51/NCT03407651/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03407651"
375,"NCT02484638","Study of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) for On-demand Treatment of Bleeding Episodes in Patients With Hemophilia A or B With Inhibitors",,"Terminated","No Results Available","Hemophilia A With Inhibitors|Hemophilia B With Inhibitors","Drug: CSL689|Drug: Eptacog alfa (activated)","Area under the curve (AUC0-t)|Incremental recovery|Elimination half-life|Total clearance|Treatment success with first CSL689 injection|Treatment success with first CSL689 injection at the population best dose|Treatment success with first or second CSL689 injection at the population best dose|Treatment success with first or second CSL689 injection|Number of bleeding events requiring > 1 CSL689 injection|Number of CSL689 injections per bleeding event|Total dose of CSL689 per bleeding event|Percentage of first bleeding events successfully treated with first CSL689 injection at population best dose in Part 3|Treatment success at population best dose|Treatment success with CSL689 at the dose level that is not the population best dose|Percentage of bleeding events with only ""definite"" or ""abrupt"" subject-reported pain relief at the population best dose|Percentage of bleeding events with ""good"" or ""excellent"" investigator-reported assessment of treatment response at the population best dose of CSL689|Proportion of recurrences|Proportion of bleeding events with ultrarapid progression.|Proportion of bleeding events requiring post-hemostatic maintenance dosing|Number of subjects with treatment-emergent adverse events (TEAEs)|Percentage of subjects with TEAEs|Number of subjects with an antibody response|Percentage of subjects with an antibody response|AUC(0-inf)|Maximum observed plasma FVIIa activity (Cmax)|Time of occurrence of maximum observed plasma FVIIa activity (Tmax)|Volume of distribution at steady state (Vss)|Mean residence time (MRT)","CSL Behring","Male","12 Years to 65 Years   (Child, Adult, Older Adult)","Phase 2|Phase 3","25","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CSL689_2001|2012-001309-26","July 23, 2015","March 28, 2018","March 28, 2018","June 29, 2015",,"August 28, 2019","Site Reference # 2680001, Tbilisi, Georgia|Site Reference # 3800023, Milano, Italy|Site Reference # 4580001, Kuala Lumpur, Malaysia|Site Reference # 6430026, Kemerovo, Russian Federation|Site Reference # 7100001, Johannesburg, South Africa|Site Reference # 7240007, Madrid, Spain|Site Reference # 7640006, Bangkok, Thailand|Site Reference # 7640004, Khon Kaen, Thailand|Site Reference # 8040005, Lviv, Ukraine|Site Reference # 8260008, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02484638"
376,"NCT02020369","Phase III Study of Coagulation FVIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors",,"Completed","Has Results","Hemophilia A With Inhibitors|Hemophilia B With Inhibitors","Biological: Coagulation Factor VIIa (Recombinant)","Proportion of Successfully Treated Mild/Moderate Bleeding Episodes|Proportion of Mild/Moderate Bleeding Episodes With Patient (Pt)-Reported ""Good"" or ""Excellent"" Responses at 12 Hours|Time to Assessment of a ""Good"" or ""Excellent"" Response of Mild/Moderate Bleeding Episodes by the Patient|Number of Administrations of Study Drug Per Mild/Moderate Bleeding Episode|Total Amount of Study Drug Administered Per Mild/Moderate Bleeding Episode","rEVO Biologics|Laboratoire français de Fractionnement et de Biotechnologies","Male","12 Years to 75 Years   (Child, Adult, Older Adult)","Phase 3","27","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RB-FVIIa-006-13","April 2014","July 2015","August 2015","December 24, 2013","June 14, 2017","June 14, 2017","Orthopaedic Hemophilia Treatment Center, Los Angeles, California, United States|University of California Davis Comprehensive Cancer Center, Sacramento, California, United States|University of Colorado Hemophilia and Thrombosis Center, Aurora, Colorado, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Minnesota Medical Center Fairview, Minneapolis, Minnesota, United States|Republican Research Center for Radiation Medicine and Human Ecology, Gomel, Belarus|Specialized Hospital for Active Treatment of Hematological Diseases, Sofia, Bulgaria|LTD HEMA, Tbilisi, Georgia|Chaim Sheba Medical Center, Tel-hashomer hospital, Ramat Gan, Israel|Institute of Hematology and Transfusion Medicine, Warsaw, Poland|Sandor SRL, Bucharest, Romania|Kirov Research Institute of Hematology and Blood Transfusion, Kirov, Russian Federation|Hematology Research Center, Moscow, Russian Federation|City Outpatient Clinic #37, Saint-Petersburg, Russian Federation|Kyiv City Clinical Hospital #9, Kyiv, Ukraine|Institute of Blood Pathology and Transfusion Medicine of Academy of Medical Sciences of Ukraine, Lviv, Ukraine|Basingstoke and North Hampshire Hospital, Hemophilia, Hemostasis and Thrombosis Center, Basingstoke, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02020369"
377,"NCT00119457","Factor IX Inhibition in Thrombosis Prevention (The FIXIT Trial)",,"Completed","No Results Available","Venous Thromboembolism|Embolism and Thrombosis|Hip Fractures","Drug: TTP889","To evaluate the antithrombotic efficacy of TTP889, administered once daily for three weeks, in patients who have completed standard prophylactic treatment for deep vein thrombosis after hip fracture surgery.|Evaluation of safety of once daily oral administration of TTP889 for three weeks|To assess the correlation between peak and trough plasma concentrations of TTP889 and clinical safety and efficacy outcomes.","vTv Therapeutics","All","18 Years and older   (Adult, Older Adult)","Phase 2","300","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Prevention","TTP889-201|Eudract CT#2004-002511-83","January 2005",,"April 2006","July 13, 2005",,"June 3, 2009","Nemocnice Ceske Budejovice, Urazove oddeleni, Ceske Budejovice, Czech Republic|FN s Poliklinikou Ostrava, Traumatologicke Centrum, Ostrava-Poruba, Czech Republic|FN Motol, Ortopedicka Klinicka UK 2.LF a FN Notol, Praha 5, Czech Republic|FN Na Bulovce, Ortopedicka Klinika IPVZ a 1.LF UK ORT, Budinova 2, Praha 8, Czech Republic|VFN, I. Chirurgicka klinika, Praha-2, Czech Republic|AAlborg Hospital, Aalborg, Denmark|Ortopaedkirurgisk Klinik, Farso, Farso, Denmark|Amtsygehuset i Gentofte, Hellerup, Denmark|KAS Herlev, Herlev, Denmark|Horsholm Hospital, Horsholm, Denmark|H:S Bispebjerg Hospital, Kobenhavn, Denmark|Silkeborg Hospital, Silkeborg, Denmark|Orthopedics, Alesund Sykehus, Alesund, Norway|Skyehuset Innlandet HF, Gjovik, Norway|Skyehuset Innlandet HF, Lillehammer, Norway|Halfdan Wilhelmsens Alle 17, Tonsberg, Norway|Ortoped Kliniken, Sahlgrenska Universitetssjukhus, Ostra, Goteborg, Sweden|Ortopedsektionen, Kirurgkliniken, Kungalvs Sjukhus, Kungalv, Sweden|Ortoped kliniken, Sahlgrenska Universitetssjukhus, Molndal, Sweden|Ortoped kliniken, NU-sjukvarden, Udevalla Sjukhus, Udevalla, Sweden|Ortoped kliniken, Sjukhuset i Varberg, Varberg, Sweden",,"https://ClinicalTrials.gov/show/NCT00119457"
378,"NCT02451202","Deep vs Moderate Neuromuscular Blockade With Rocuronium in Patients Undergoing Endolaryngeal Procedures",,"Completed","Has Results","Laryngoscopic Surgical Procedures","Procedure: Deep Neuromuscular Blockade|Procedure: Moderate Neuromuscular Blockade|Drug: Sugammadex|Drug: Rocuronium","Proportion of Patients Who Have a Clinically Acceptable Surgical Conditions|Time to Modified Aldrete's Score ≥ 9","Chulalongkorn University|Merck Sharp & Dohme Corp.","All","18 Years to 60 Years   (Adult)","Phase 4","102","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","51815","June 2016","March 2018","March 2018","May 21, 2015","January 7, 2020","January 7, 2020",,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/02/NCT02451202/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02451202"
379,"NCT03871387","The Effects of Deep Neuromuscular Blockade During Robot-assisted Transaxillary Thyroidectomy on Postoperative Pain and Sensory Change",,"Completed","No Results Available","Thyroid Neoplasms","Drug: Deep Group|Drug: Control Group","Postoperative pain: NRS|Postoperative sensory change|Nausea/Vomiting|The time from sugammadex injection to TOF ratio 0.9.|Number of patients with complications due to deep neuromuscular blockade (e.g. Respiratory failure, Desaturation)","Yonsei University","All","20 Years to 70 Years   (Adult, Older Adult)","Not Applicable","88","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Prevention","4-2018-0963","March 4, 2019","February 24, 2020","February 24, 2020","March 12, 2019",,"June 16, 2020","Department of Anesthesiology and Pain Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03871387"
380,"NCT01299051","Steps to Health: Targeting Obesity in the Health Care Workplace",,"Completed","No Results Available","Overweight|Obese","Behavioral: Steps to Health|Behavioral: Steps to Health Plus!","Weight loss|Improvement in level of physical activity|Relative impact of the different programs|Relative cost of different programs|Improvement in nutrition","Duke University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","550","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","Pro00010727|R01HD06578","January 2011","October 2014","March 2016","February 18, 2011",,"March 8, 2016","Duke University Dept. of Community and Family Medicine, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01299051"
381,"NCT04105764","Deep NMB in Ambulatory Gynecological Laparoscopy",,"Completed","No Results Available","Muscle Relaxation","Drug: Rocuronium|Drug: Rocuronium bromide","Quality of recovery|Postoperative pain","Wahba bakhet|Elite medical center|Ain Shams University","Female","21 Years to 60 Years   (Adult)","Phase 4","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Supportive Care","elite NMB","December 1, 2016","November 1, 2018","June 15, 2019","September 26, 2019",,"December 10, 2019","Elite Medical Center, Kuwait, Kuwait",,"https://ClinicalTrials.gov/show/NCT04105764"
382,"NCT00729508","Effectiveness of Cat-PAD to Treat Cat Allergy in Cat Allergic Subjects",,"Completed","No Results Available","Cat Allergy","Biological: Cat-PAD","Change from baseline in Total Rhinoconjunctivitis Symptom Score (TRSS) using all timepoints during PTC in Cat-PAD treatment groups compared to placebo.|Change from baseline in TRSS in Cat-PAD treatment groups at last two timepoints on third and fourth challenge days compared to placebo.|Change from baseline in individual symptom scores for ocular and nasal symptoms at all timepoints during Exposure Chamber visit in Cat-PAD treatment groups compared to placebo.|Change from baseline in TRSS at all timepoints during Exposure Chamber visit in pooled data from Cat-PAD treatment groups compared to placebo.|Proportion of subjects prematurely leaving the EEC due to intolerable symptoms during Post-Treatment Challenge (PTC) in Cat-PAD treatment groups compared to placebo.|Change from baseline in EEC-Rhinoconjunctivitis Quality of Life Questionnaire (EEC-RQOL) at all timepoints during Exposure Chamber visit in Cat-PAD treatment groups compared to placebo.|Exploratory analyses of change from baseline in asthma symptoms, FEV1 and use of rescue medication in Cat-PAD treatment groups compared to placebo in asthmatic subjects.","Circassia Limited","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","120","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CP002","August 2008","April 2009","May 2009","August 7, 2008",,"July 8, 2009","Cetero Research, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00729508"
383,"NCT01053169","Observational Study of Prophylaxis and Treatment of Acute Perioperative Bleeding With Beriplex® P/N (Probe Study)",,"Completed","No Results Available","Coagulation Protein Disorders|Blood Loss, Surgical|Perioperative Care","Biological: Beriplex® P/N|Biological: Fresh Frozen Plasma (FFP) and Beriplex® P/N|Other: Fresh Frozen Plasma","Adequacy of stopping or preventing bleeding|Transfusions required|Clinical trigger for administration of the intervention|Mortality|International normalized ratio (INR)|Prothrombin time (PT)|Receipt of other blood products and /or hemostatic agents|Vital signs","CSL Behring","All","16 Years and older   (Child, Adult, Older Adult)",,"445","Industry","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","BE1116_5001|1492","May 2010","January 2012","January 2012","January 21, 2010",,"October 3, 2017","Royal Blackburn Hospital, Blackburn, United Kingdom|Blackpool, Blackpool, United Kingdom|Addenbrokes, Cambridge, United Kingdom|Royal Free Hospital, London, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|Southhampton General Hospital, Southhampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01053169"
384,"NCT00212459","The Effect of Patient Counseling on Adolescent Hemophilia Patient Compliance With Bleeding Logs",,"Completed","No Results Available","Hemophilia A|Hemophilia B","Behavioral: Counseling|Behavioral: Control","Study and control groups will be compared with respect to the % of bleeds reported to the HTC and % of recommended therapy recorded in bleeding logs after a 6 month period|Study and control groups will be compared with respect to time between initiation of target joint bleeding and the identification and treatment of such by HTC personnel|Clotting factor consumption and the cost of therapy in each group will be compared","New York Presbyterian Hospital","Male","12 Years to 20 Years   (Child, Adult)","Not Applicable","14","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","Bleeding Logs","May 2005","February 2006","April 2008","September 21, 2005",,"March 27, 2013","NY Presbyterian Hospital, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00212459"
385,"NCT02727283","A Phase 1, Randomized, Placebo-Controlled, Ascending Cohort, Dose Escalation Study in Normal Healthy Volunteers",,"Completed","No Results Available","Irritable Bowel Syndrome","Drug: GSK3179106|Drug: Placebo","Number of subjects with adverse events (AE) and clinical observations as a measure of safety|Assessment of physical examination findings as a measure of safety|Safety as assessed by 12-lead electrocardiogram (ECG)|Safety as assessed by systolic and diastolic blood pressure measurements|Safety as assessed by temperature measurements|Safety as assessed by pulse rate measurements|Composite of clinical laboratory assessments as a measure of safety includes hematology, clinical chemistry and urinalysis|Bristol Stool Form Scale|Area under the plasma concentration-time curve (AUC) from zero to time t (AUC [0-t]) of GSK3179106 administered under fasting condition|AUC from zero to infinity (AUC [0-infinity]) of GSK3179106 administered under fasting condition|AUC from zero to 24 h (AUC [0-24 h]) of GSK3179106 administered under fasting condition|Maximum observed plasma concentration (Cmax) of escalating single oral doses of GSK3179106 administered under fasting conditions|Time to maximum observed plasma concentration (tmax) of GSK3179106 administered under fasting condition|Apparent terminal phase half-life (t1/2) of GSK3179106 administered under fasting condition|Clearance (CL/F) of GSK3179106 administered under fasting condition|Volume of distribution (V/F) of GSK3179106 administered under fasting condition|Absorption rate constant (Ka) of GSK3179106 administered under fasting condition|Area under the plasma concentration-time curve (AUC) from zero to time t (AUC [0-t]) of GSK3179106 administered under fasting and fed condition|AUC from zero to infinity (AUC [0-infinity]) of GSK3179106 administered under fasting condition fasting and fed condition|AUC from zero to 24 h (AUC [0-24 h]) of GSK3179106 administered under fasting condition fasting and fed condition|Maximum observed plasma concentration (Cmax) of escalating single oral doses of GSK3179106 administered under fasting and fed condition|Time to maximum observed plasma concentration (tmax) of GSK3179106 administered under fasting and fed condition|Apparent terminal phase half-life (t1/2) of GSK3179106 administered under fasting and fed condition|Clearance (CL/F) of GSK3179106 administered under fasting and fed condition|Volume of distribution (V/F) of GSK3179106 administered under fasting and fed condition|Absorption rate constant (Ka) of GSK3179106 administered under fasting and fed condition","GlaxoSmithKline","All","18 Years to 55 Years   (Adult)","Phase 1","16","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","204729","November 26, 2015","March 18, 2016","March 18, 2016","April 4, 2016",,"May 8, 2017","GSK Investigational Site, Adelaide, South Australia, Australia",,"https://ClinicalTrials.gov/show/NCT02727283"
386,"NCT01303159","Endoscopic Bipolar Radiofrequency Probe (ENDOHPB) in the Management of Unresectable Bile Duct and Pancreatic Cancer",,"Terminated","Has Results","Cholangiocarcinoma|Pancreatic Cancer","Device: Endoscopic bipolar radiofrequency probe (ENDOHPB)","Change From Baseline in Bile Duct Stricture Diameter|Number of Participants With Adverse Events","Weill Medical College of Cornell University|EMcision Limited","All","18 Years and older   (Adult, Older Adult)","Not Applicable","29","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1107011793","March 2010","January 13, 2014","January 13, 2014","February 24, 2011","May 23, 2017","May 23, 2017","Weill Medical College of Cornell University, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01303159"
387,"NCT01838642","Ponatinib for Advanced Medullary Thyroid Cancer",,"Terminated","Has Results","Thyroid Neoplasms","Drug: Ponatinib","Overall Response Rate.|Progression Free Survival|Number of Participants With Adverse Events|Molecular Differences in Advanced Medullary Thyroid Cancer (MTC)|Changes in Serum Levels of MTC Tumor Markers Calcitonin (CTN) and Its Relation With Clinical Response|Objective Response to Ponatinib|Changes in Serum Levels of MTC Tumor Markers Carcinoemybryonic Antigen (CEA) and Its Relation With Clinical Response|Overall Survival","National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI)","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","3","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","130108|13-C-0108","March 2013","December 2015","January 2016","April 24, 2013","March 17, 2016","February 15, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01838642"
388,"NCT00882882","To Demonstrate the Relative Bioavailability of Metformin HCL 500 mg Extended Release (XR) Tablets Under Fasting Conditions",,"Completed","No Results Available","Type II Diabetes","Drug: Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC|Drug: GLUCOPHAGE XR 500 mg ER Tablets Bristol-Myers Squibb","Bioequivalence based on AUC and Cmax","Sandoz","All","19 Years to 49 Years   (Adult)","Phase 1","16","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","B013701","June 2001","June 2001","June 2001","April 17, 2009",,"March 29, 2017",,,"https://ClinicalTrials.gov/show/NCT00882882"
389,"NCT03623295","The Dynamic Interplay Between Bleeding Phenotype and Baseline Factor Level in Moderate and Mild Hemophilia A and B","DYNAMO","Recruiting","No Results Available","Hemophilia","Other: Blood sample|Other: Questionnaire|Other: MRI-imaging|Other: Physical examination","Bleeding phenotype","Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","Male","12 Years to 55 Years   (Child, Adult)",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Other","NL61564.018.17","January 1, 2018","April 1, 2020","April 1, 2022","August 9, 2018",,"August 9, 2018","Royal Adelaide Hospital, Adelaide, Australia|Medical University of Vienna, Vienna, Austria|Multicentre: Leuven, Brussels, Multiple Locations, Belgium|Multicentre: Vancouver, Toronto, Hamilton, Multiple Locations, Canada|Helsinki University Central Hospital, Helsinki, Finland|Multicentre: Bonn, Berlin, Frankfurt, München, Hamburg, Multiple Locations, Germany|Multicentre: Florence, Rome, Parma, Milan, Turin, Multiple Locations, Italy|Academic Medical Center, Amsterdam, Netherlands|University Medical Center Groningen, Groningen, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Maastricht University Medical Center, Maastricht, Netherlands|Radboud University Medical Center, Nijmegen, Netherlands|Erasmus Medical Center, Rotterdam, Netherlands|Utrecht University Medical Center, Utrecht, Netherlands|Máxima Medical Center, Veldhoven, Netherlands|Multicentre: Valencia, Madrid, Barcelona, Multiple Locations, Spain|Multicentre: Manchester, London, Liverpool, Glasgow, Cardiff, Sheffield, Multiple Locations, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03623295"
390,"NCT01927887","Pre-Operative Nodal Staging of Thyroid Cancer Using USPIO MRI: Preliminary Study",,"Completed","Has Results","Papillary Carcinoma of Thyroid Gland|Metastatic Medullary Thyroid Cancer|Follicular Thyroid Cancer Lymph Node Metastasis","Drug: Ferumoxytol|Device: Nanoparticle MRI","Primary Efficacy Parameters of Sensitivity of High Resolution Magnetic Resonance Imaging With Lymphotrophic Superparamagnetic Nanoparticles (LSN MRI)|Primary Efficacy Parameters of Specificity of High Resolution Magnetic Resonance Imaging With Lymphotrophic Superparamagnetic Nanoparticles (LSN MRI)","Massachusetts General Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","12","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","12-132","July 2012","April 2015","April 2016","August 23, 2013","June 6, 2017","June 6, 2017","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01927887"
391,"NCT03327779","World Bleeding Disorders Registry","WBDR","Recruiting","No Results Available","Hemophilia A|Hemophilia B",,"Number of participants recruited|Number of participating Hemophilia Treatment Centres|Number of participating countries","World Federation of Hemophilia","All","Child, Adult, Older Adult",,"10000","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Prospective","WBDR","January 26, 2018","January 2023","January 2028","October 31, 2017",,"July 27, 2020","World Federation of Hemophilia, Montréal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT03327779"
392,"NCT00071903","The Role of Susceptibility to Thrombosis in the Pseudotumor Cerebri of Nephropathic Cystinosis: A Case-Control Study",,"Completed","No Results Available","Pseudotumor Cerebri|Cystinosis",,,"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","2 Years to 50 Years   (Child, Adult)",,"18","NIH","Observational",,"040010|04-CH-0010","October 30, 2003",,"July 18, 2008","November 4, 2003",,"July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00071903"
393,"NCT01804933","Influence of Profound Muscle Relaxation on Muscle Trauma and Postoperative Pulmonary Function",,"Unknown status","No Results Available","Profound Muscle Relaxation|Muscle Trauma|Postoperative Analgesic Demand|Postoperative Pulmonary Function","Drug: profound neuromuscular blockade","degree of muscle trauma|postoperative analgesic requirement","Ying Xiao|First Affiliated Hospital, Sun Yat-Sen University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","72","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","伦审[2012]326号","July 2012","July 2013","August 2013","March 5, 2013",,"March 5, 2013","The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT01804933"
394,"NCT02271009","Compare Dose Regimens of AllerT, in Adults With Allergic Rhino-Conjunctivitis to Birch Pollen Studied in EEC",,"Completed","No Results Available","Allergic Rhino-Conjunctivitis","Drug: AllerT|Drug: Placebo","The change in average Total Rhinoconjunctivitis Symptom Scores (TRSS) from the Baseline EEC Challenge (Visit 1 & Visit 2) to the Post-Treatment EEC Challenge (PTC) (Visit 8 & Visit 9).|Individual Nasal Symptom Scores (NSS)|Individual NSS|The Global Evaluation of Treatment Efficacy Questionnaire|The Asthma Symptom Score (ASS)|The mean TRSS|The mean TNSS|The mean TOSS|The mean Total Nasal Symptom Scores (TNSS)|Total Ocular Symptom Score (TOSS)","Anergis|Inflamax Research Incorporated","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","213","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","AN008T","October 2014","May 2015","May 2015","October 22, 2014",,"December 3, 2015","Inflamax Research Inc., Mississauga, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02271009"
395,"NCT03420937","Deep Neuromuscular Block During General Anaesthesia in Robotic Surgery",,"Completed","No Results Available","Observation of Neuromuscular Block|Complication of Ventilation Therapy|Postoperative Recovery","Drug: Sugammadex|Drug: Neostigmine, Atropin Biotika","Surgical conditions SRS|Intraabdominal pressure IAP (mmHg)|Operating theatre time (min)|Post-operative recovery","University Hospital Olomouc|Palacky University","Male","18 Years and older   (Adult, Older Adult)","Phase 4","138","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","IGA_LF_2016_021","June 2016","June 2017","August 2017","February 5, 2018",,"February 5, 2018","Dept. of Anesthesiology and Intensive Care Medicine, University Hospital Olomouc, Olomouc, Czechia",,"https://ClinicalTrials.gov/show/NCT03420937"
396,"NCT03808077","The Effect of Deep Versus Moderate Muscle Relaxants in Men During and After Robotic Surgery for Prostate Cancer",,"Recruiting","No Results Available","Prostate Cancer","Drug: Rocuronium 0.3mg/kg/hr|Drug: Rocuronium 1.5mg/kg/hr","Difference in levels of Intra-Abdominal Pressure (IAP) when performing robotic prostatectomy in participants under a moderate vs deep Neuromuscular Blockade technique|Difference in levels of postoperative pain in participants under a moderate vs deep Neuromuscular Blockade technique during robotic prostatectomy using the Visual Analog Scale (VAS)","Memorial Sloan Kettering Cancer Center","Male","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","130","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","18-408","January 14, 2019","January 2023","January 2023","January 17, 2019",,"December 27, 2021","Memorial Sloan Kettering Cancer Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03808077"
397,"NCT01961804","PREVACT : Preventive REversal of Vitamine K Antagonist in Minor Craniocerebral Trauma","PREVACT","Terminated","No Results Available","Coagulation; Intravascular|Craniocerebral Trauma|Haemorrhage","Drug: Reversion","Percentage of intracranial bleeding diagnosed in CT scan|Volumetric measure of intracranial haemorrhage|Percentage of patient having a decrease in their autonomy|Percentage of patient having a systemic or neurologic ischemic attacks","University Hospital, Angers","All","18 Years and older   (Adult, Older Adult)","Phase 3","202","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PHRC 2012-02","March 2014","February 28, 2020","September 3, 2020","October 11, 2013",,"April 27, 2021","CH Agen, Agen, France|CHU Angers, Angers, France|Ch Annecy, Annecy, France|CHU Chateauroux, Chateauroux, France|CHU Clermont Ferrand, Clermont Ferrand, France|CHG du Mans, Le Mans, France|Ch Les Sables D'Olonne, Les Sables d'Olonne, France|Ch Longjumeau, Longjumeau, France|HCL Edouard Herriot, Lyon, France|CHU METZ, Metz, France|Chg Montauban, Montauban, France|Chu Nantes, Nantes, France|CHU Nice, Nice, France|CHU Pitié Salpétrière, Paris, France|Chu Tenon, Paris, France|Chu Poitiers, Poitiers, France|Chu Saint Brieuc, Saint Brieuc, France|Ch Saint Malo, Saint Malo, France|Chu Toulouse, Toulouse, France|Chu Tours, Tours, France|Ch Versailles, Versailles, France",,"https://ClinicalTrials.gov/show/NCT01961804"
398,"NCT02778945","Neuromuscular Blockade for Optimising Surgical Conditions During Spinal Surgery",,"Unknown status","No Results Available","Neuromuscular Block|Orthopedic Disorder of Spine|Muscle Weakness","Drug: Rocuronium 0.9 mg/kg|Drug: Rocuronium 0.6 mg/kg","the operation time|back muscle stiffness ( 1. Shear Wave Ultrasound Elastography(SWE) )|back muscle stiffness (2.Mechanical Tension Weighing Scale (MTWS) of mechanical dynamometer)","The Catholic University of Korea","All","19 Years and older   (Adult, Older Adult)","Phase 4","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Diagnostic","ANESTHA-NMB1","September 1, 2016","March 28, 2019","May 1, 2019","May 20, 2016",,"April 1, 2019","Yeouido St. Mary's Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02778945"
399,"NCT03479489","Use of Human Dehydrated Amnion Chorion Allograft in Closed Hemorroidectomy",,"Completed","No Results Available","External Hemorrhoid|External Hemorrhoid Thrombosed","Other: Human dehydrated amnion chorion allograft","Reported Patient Pain","MiMedx Group, Inc.","All","18 Years and older   (Adult, Older Adult)","Not Applicable","11","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EFSUR001","February 5, 2018","December 30, 2018","December 30, 2018","March 27, 2018",,"December 18, 2019","Boulder Valley Surgical Associates, Boulder, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT03479489"
400,"NCT02061033","Global Hemostatic Methods in Hemophilia and Von Willebrand's Disease","GHMHW","Unknown status","No Results Available","Hemophilia A|Hemophilia B|Von Willebrand's Disease",,"Number of microparticles","Karolinska University Hospital|The Swedish Society of Medicine|Karolinska Institutet","All","10 Years and older   (Child, Adult, Older Adult)",,"180","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","GHMJA2014","March 2013","December 2017","December 2018","February 12, 2014",,"August 31, 2016","Karolinska University Hospital, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT02061033"
401,"NCT02794714","Deep vs Moderate Block: Impact on Operating Conditions & Patient Satisfaction",,"Withdrawn","No Results Available","Neuromuscular Blockade","Drug: Deep neuromuscular blockade|Drug: Moderate neuromuscular blockade","Deep block versus Moderate block: Impact on surgical satisfaction|Deep block versus Moderate block: Patient satisfaction score|Deep block versus Moderate block: Pain score|Deep block versus Moderate block: PONV Score","Kuala Lumpur General Hospital|Merck Sharp & Dohme Corp.","Female","18 Years to 64 Years   (Adult)","Phase 4","0","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","CVL#123","June 2016","December 2017","December 2017","June 9, 2016",,"October 4, 2018",,,"https://ClinicalTrials.gov/show/NCT02794714"
402,"NCT00762138","The AutoloGel™ Post-Market Surveillance (TAPS) Program","TAPS","Terminated","No Results Available","Wounds|Leg Ulcers|Pressure Ulcers|Diabetic Foot Ulcers","Device: AutoloGel System","Assess the incidence of hematological immunologic other ae's association with the application of AutoloGel on exuding wounds such as leg ulcers pressure ulcers and diabetics ulcers and during the management of mechanically or surgically debrided wounds|Absence of coagulopathies caused by inhibitors to coagulation Factor V as determined by a significant prolongation of the (PT) time. Depletion of Factor V activity with a positive Bethesda Assay","Cytomedix|CTI Clinical Trial and Consulting Services","All","18 Years to 95 Years   (Adult, Older Adult)","Not Applicable","131","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)","CM 306","September 2008","May 2012","June 2012","September 30, 2008",,"February 26, 2014","Aiyan Diabetes Center, Augusta, Georgia, United States|Providence Wound Institute, El Paso, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00762138"
403,"NCT01709292","Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer",,"Active, not recruiting","No Results Available","Thyroid Cancer","Drug: Vemurafenib (All Groups)|Drug: Vemurafenib (Post Surgery) - Group A + C|Other: Post Surgery - Group B","Percent Change in ERK (Extracellular-Signal-Regulated Kinase) Phosphorylation and Tumor Size|Objective Response Rate","M.D. Anderson Cancer Center|Genentech, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","24","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2012-0471|NCI-2012-02171","November 7, 2012","September 30, 2022","September 30, 2023","October 18, 2012",,"November 5, 2021","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01709292"
404,"NCT02812186","Deep Versus Moderate Neuromuscular Blockade During Laparoscopic Surgery",,"Completed","Has Results","Cholecystitis|Endometriosis|Bowel Obstruction|Fibroids|Prostate Cancer|Chronic Kidney Disease|Uterine Prolapse","Procedure: Deep to Moderate NMB|Procedure: Moderate to Deep NMB|Drug: Rocuronium","Peak Airway Pressures|Abdominal Insufflation Pressure|Surgical Rating Scale","Stony Brook University|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 4","79","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","823925","December 27, 2016","January 17, 2019","February 6, 2019","June 24, 2016","April 8, 2020","April 8, 2020","Stony Brook University Hospital, Stony Brook, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/86/NCT02812186/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02812186"
405,"NCT01860534","""Eye Protection After Mydriatic Use for ROP Screening: Impact on Vitals Signs and Pain Scores""",,"Completed","Has Results","Light Sensitivity","Behavioral: eye covers","Heart Rate|Respiratory Rate|Oxygen Percent Saturation|Pain","The University of Texas Medical Branch, Galveston","All","Child, Adult, Older Adult","Not Applicable","28","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","11-039","July 2011","September 2012","September 2012","May 22, 2013","January 14, 2016","January 14, 2016","University of Texas Medical Branch, Galveston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01860534"
406,"NCT03818529","ATHN 8: Previously Untreated Patients (PUPs) Matter Study",,"Recruiting","No Results Available","Hemophilia|Hemophilia A|Hemophilia B|Hemophilia A With Inhibitor|Hemophilia B With Inhibitor|Haemophilia B Without Inhibitor|Haemophilia A Without Inhibitor|Haemophilia",,"Determine percentage of patients with confirmed inhibitors|Determine risk factors including genetic variants associated with inhibitor development in PUPs|Determine percentage of eligible participants enrolled at each site|Determine mean age of diagnosis and first exposure to factor treatment product|Determine the number of exposure days prior to inhibitor development|Report bleeding complications that occur within the first 50 ED|Summarize factor replacement dosing regimen prescribed to this study population within the first 50 ED|Report on the number of transient inhibitor, e.g., those which resolve without change in therapy|Report on targeted post-approval safety data for events related to clotting factor replacement products used by prospectively enroll participants|Sub-study modules will be developed to evaluate and report on cohorts of study participants who initiated treatment with a specific product","American Thrombosis and Hemostasis Network|CSL Behring|Octapharma|Takeda","All","up to 13 Years   (Child)",,"250","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Other","ATHN 8","October 3, 2018","March 2023","December 2023","January 28, 2019",,"September 5, 2021","Arizona Hemophilia and Thrombosis Center at Phoenix Children's Hospital, Phoenix, Arizona, United States|Valley Children's Hospital, Madera, California, United States|Rady Children's Hospital San Diego, San Diego, California, United States|UCSF Pediatric Hemophilia Treatment Center at Mission Bay, San Francisco, California, United States|University of Colorado Denver Hemophilia and Thrombosis Center, Aurora, Colorado, United States|Connecticut Bleeding and Clotting Disorders Center, Farmington, Connecticut, United States|Children's National Medical Center, Washington, District of Columbia, United States|Johns Hopkins All Children's Hospital, Saint Petersburg, Florida, United States|Children's Healthcare of Atlanta/Emory, Atlanta, Georgia, United States|Augusta University Hemophilia Treatment Center, Augusta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|Indiana Hemophilia and Thrombosis Center (IHTC), Indianapolis, Indiana, United States|Kansas City Regional Hemophilia Center, Kansas City, Kansas, United States|Maine Hemophilia and Thrombosis Center, Scarborough, Maine, United States|Boston Hemophilia Center at Children's Hospital of Boston, Boston, Massachusetts, United States|University of Michigan Hemophilia and Coagulation Disorders, Ann Arbor, Michigan, United States|Mayo Comprehensive Hemophilia Center, Rochester, Minnesota, United States|Cincinnati Children's Hospital Medical Center, Hemophilia & Thrombosis Center, Cincinnati, Ohio, United States|UHHS Cleveland, Cleveland, Ohio, United States|Northwest Ohio Hemophilia Treatment Center at the Toledo Hospital, Toledo, Ohio, United States|Oklahoma Center for Bleeding and Clotting Disorders, Oklahoma City, Oklahoma, United States|Oregon Health and Science University, Portland, Oregon, United States|St Jude Children's Research Hospital, Memphis, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Utah Center for Bleeding & Clotting Disorders at Primary Children's Hospital, Salt Lake City, Utah, United States|Hemophilia Outreach Center, Green Bay, Wisconsin, United States|Blood Center of Wisconsin, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT03818529"
407,"NCT03219294","Does Deep Neuromuscular Blockade Improve Operating Conditions During Total Hip Replacements?",,"Completed","Has Results","Arthropathy of Hip","Drug: Vecuronium 0.1 mg/kg|Drug: Vecuronium 0.2mg/kg","Surgical Conditions|Duration of Surgery","Craig Curry|MaineHealth|Spectrum Medical Group Anesthesiology","All","50 Years to 75 Years   (Adult, Older Adult)","Phase 4","116","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Other","988210-2","May 1, 2017","April 30, 2018","May 1, 2018","July 17, 2017","September 10, 2019","September 18, 2019","Maine Medical Center, Portland, Maine, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT03219294/Prot_SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03219294"
408,"NCT04534751","Factor In the Initial Resuscitation of Severe Trauma 2 Patients","FiiRST-2","Recruiting","No Results Available","Traumatic Hemorrhage|Coagulopathy|Massive Hemorrhage","Biological: Fibrinogen + PCC|Biological: Frozen Plasma","Composite of total number of Allogeneic Blood Products (ABPs)|Total number of RBC units|Incidence of thromboembolic events|Ventilator-free days","University Health Network, Toronto|Sunnybrook Health Sciences Centre|Octapharma|Canadian Institutes of Health Research (CIHR)|Canadian Institute for Military and Veteran Health Research Defense Research & Development Canada","All","16 Years and older   (Child, Adult, Older Adult)","Phase 4","350","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2031 (CTO ID)","April 1, 2021","December 31, 2023","January 30, 2024","September 1, 2020",,"October 11, 2021","Hamilton Health Sciences and McMaster University, Hamitlon, Ontario, Canada|London Health Sciences Centre & St. Joseph's Health Care London, London, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04534751"
409,"NCT00630214","Prevention of Hypocalcemia in Patients Undergoing Total Thyroidectomy Plus Central Neck Dissection",,"Completed","No Results Available","Hypocalcemia","Dietary Supplement: Oral calcium plus vitamin D|Dietary Supplement: Oral calcium alone","The clinical utility of calcium and vitamin D supplements for prevention of hypocalcemia following total thyroidectomy plus central neck dissection","Asan Medical Center|Chungnam National University","All","15 Years to 85 Years   (Child, Adult, Older Adult)","Phase 2","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","2004-03-01","May 2004","February 2006","February 2006","March 6, 2008",,"March 6, 2008","Chungnam National University Hospital, Daejeon, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT00630214"
410,"NCT02328846","Transcutaneous-Arterial Carbon Dioxide and Microcirculatory Dysfunction",,"Withdrawn","No Results Available","Bypass Complications",,"Postoperative SOFA score|Postoperative Kidney Disease Improving Global Outcome (KDIGO) class","University of Virginia","All","18 Years and older   (Adult, Older Adult)",,"0","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","17872","January 2018","January 2019","February 2020","December 31, 2014",,"October 22, 2018",,,"https://ClinicalTrials.gov/show/NCT02328846"
411,"NCT02751541","Human Phototoxicity Test",,"Completed","No Results Available","Sunscreening Agents","Drug: Sunscreen Sport Spray (BAY987519)|Other: Untreated Skin","Intensity of skin reactions will be evaluated using 5 point grading scale.","Bayer","All","18 Years to 60 Years   (Adult)","Not Applicable","35","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18849","May 2, 2016","May 6, 2016","May 6, 2016","April 26, 2016",,"December 13, 2018","Piscataway, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02751541"
412,"NCT01460147","Osteoporosis and MRI Study in Hemophilia",,"Terminated","No Results Available","Bone Mineral Density|Hemophilia A|Hemophilia B","Other: DXA scan + MRI","Baseline Endpoint: Z-Score by dual-energy X-ray absorptiometry (DXA) at baseline|Longitudinal Endpoint: Change in bone mineral density by DXA over 2 years|Longitudinal Endpoint: Rate of loss of knee cartilage parameters over 2 years by MRI","Baxalta now part of Shire|Takeda","Male","25 Years and older   (Adult, Older Adult)","Not Applicable","3","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","001001","October 30, 2011","April 13, 2012","April 13, 2012","October 26, 2011",,"April 22, 2021","Los Angeles Orthopedic Hospital, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT01460147"
413,"NCT02750449","Human Photoallergy Test",,"Completed","No Results Available","Sunscreening Agents","Drug: Sun screening Sport Lotion, (BAY987516)|Other: Untreated skin","Intensity of skin reactions is evaluated by 5 point grading scale","Bayer","All","18 Years to 60 Years   (Adult)","Not Applicable","54","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Other","18852","May 9, 2016","July 1, 2016","July 1, 2016","April 25, 2016",,"December 13, 2018","Piscataway, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02750449"
414,"NCT02751463","18850 - Human Photoallergy Test",,"Completed","No Results Available","Sunscreening Agents","Drug: Sunscreening Sport Spray Rest (BAY987519)|Other: Untreated skin","Intensity of skin reactions is evaluated by 5 point grading scale","Bayer","All","18 Years to 60 Years   (Adult)","Not Applicable","54","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","18850","May 9, 2016","July 1, 2016","July 1, 2016","April 26, 2016",,"December 13, 2018","Piscataway, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02751463"
415,"NCT02823483","18348-Human Phototoxicity Test",,"Completed","No Results Available","Sunscreening Agents","Other: Sunscreen Lotion (BAY987521)|Other: Untreated Skin","Intensity of skin reactions will be evaluated using the 5 point","Bayer","All","18 Years to 60 Years   (Adult)","Not Applicable","35","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)","18348","November 2015","November 2015","November 2015","July 6, 2016",,"July 6, 2016","Piscataway, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02823483"
416,"NCT04628871","Long Term Follow-up (LTFU) of Subjects Who Received SB-318, SB-913, or SB-FIX","LTFU","Enrolling by invitation","No Results Available","Hemophilia B|Mucopolysaccharidosis I|Mucopolysaccharidosis II","Biological: SB-318|Biological: SB-913|Biological: SB-FIX","Long-term safety","Sangamo Therapeutics","All","18 Years and older   (Adult, Older Adult)",,"13","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","ST-IVPRP-LT01","November 3, 2020","January 1, 2030","January 1, 2030","November 16, 2020",,"October 25, 2021","UCSF Benioff Children's Hospital Oakland, Oakland, California, United States|Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|New York University Grossman School of Medicine, New York, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT04628871"
417,"NCT02750475","Human Phototoxicity Test",,"Completed","No Results Available","Sunscreening Agents","Drug: Sunscreen Sport Lotion (BAY987516)|Other: Untreated Skin","Intensity of skin reactions will be evaluated using the 5 point grading scale","Bayer","All","18 Years to 60 Years   (Adult)","Not Applicable","35","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","18851","May 2, 2016","May 6, 2016","May 6, 2016","April 25, 2016",,"December 13, 2018","Piscataway, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02750475"
418,"NCT02751372","18794 - Human Photo Toxicity Test",,"Completed","No Results Available","Sunscreening Agents","Drug: BAY 987517|Other: Untreated Skin","Intensity of skin reactions will be evaluated using 5 point grading scale","Bayer","All","18 Years to 60 Years   (Adult)","Not Applicable","35","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","18794","May 2, 2016","May 6, 2016","May 6, 2016","April 26, 2016",,"December 13, 2018","Piscataway, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02751372"
419,"NCT04385875","Study to Assess the Safety and Durability of Viral Control Beyond 24 Weeks of Analytical Treatment Interruption After the Administration of Candidate HIV-1 Vaccines DNA.HTI, MVA.HTI and ChAdOx1.HTI or Placebo in Early Treated HIV-1 Positive Individuals (ATI Extension of AELIX-002 Study)",,"Active, not recruiting","No Results Available","HIV-1 Infection","Biological: Vaccine + extension of the ATI period|Other: Placebo + extension of the ATI period","Percentage of participants with viral remission|Percentage of participants with viral control|Time to viral detection|Time to viral rebound|Percentage of participants who remain off cART|Time off cART|Phenotypes characterization|Change in a score for ATI psychological impact|The proportion of participants who develop symptoms compatible with acute retroviral syndrome.|The proportion of participants who suppress pVL to <50 copies/ml|The proportion of participants who develop new mutations not present in the pre-cART genotype|Description of participants who develop AEs related to the prime- boost regimen during this extension of ATI period.","Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia|Aelix Therapeutics","All","18 Years to 40 Years   (Adult)","Phase 1","6","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","ATI_extension","June 1, 2020","August 30, 2021","February 2022","May 13, 2020",,"October 19, 2021","Germans Trias i Pujol Hospital, Badalona, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT04385875"
420,"NCT03157128","A Study of LOXO-292 in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer","LIBRETTO-001","Recruiting","No Results Available","Non-Small Cell Lung Cancer|Medullary Thyroid Cancer|Colon Cancer|Any Solid Tumor","Drug: LOXO-292","Phase 1: MTD|Phase 1: RP2D|Phase 2: Objective Response Rate|Phase 1: Number of Participants with a Treatment-Related Adverse Event(s) (TRAE[s])|Phase 1: Number of Participants with an Abnormal Laboratory or Physical Exam Result(s)|Phase 1: Overall Response Rate (ORR) based on RECIST 1.1 or RANO, as Appropriate to Tumor Type|Phase 2: ORR (by Investigator)|Phase 2: Best Change in Tumor Size from Baseline (by IRC and Investigator)|Phase 2: Duration of Response (DOR; by IRC and Investigator)|Phase 2: Central Nervous System (CNS) ORR (by IRC)|Phase 2: CNS DOR (by IRC)|Phase 2: Time to Any and Best Response (by IRC and Investigator)|Phase 2: CBR (by IRC and Investigator)|Phase 2: PFS (by IRC and Investigator)|Phase 2: Overall Survival (OS)|Phase 2: Percentage of Participants with any Serious Adverse Event (SAE[s])|Phase 1 and 2: Pharmacokinetics (PK): Area Under the Plasma Concentration-Time Curve of LOXO-292 (Selpercatinib)|Phase 1 and 2: PK: Maximum Concentration (Cmax) of LOXO-292 (Selpercatinib)","Loxo Oncology, Inc.|Eli Lilly and Company","All","12 Years and older   (Child, Adult, Older Adult)","Phase 1|Phase 2","989","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17477|J2G-OX-JZJA|LOXO-RET-17001|2017-000800-59","May 2, 2017","November 21, 2022","November 21, 2023","May 17, 2017",,"January 19, 2022","Mayo Clinic of Scottsdale, Scottsdale, Arizona, United States|City of Hope National Medical Center, Duarte, California, United States|University of California - San Diego, La Jolla, California, United States|UCLA Medical Center, Los Angeles, California, United States|Hoag Memoriall Hospital Presbyterian, Newport Beach, California, United States|Irvine Medical Center, Orange, California, United States|UCSF Medical Center at Mission Bay, San Francisco, California, United States|Kaiser Permanente, Santa Clara, California, United States|Kaiser Permanente Medical Center, Vallejo, California, United States|Sarah Cannon Research Institute at HealthOne, Denver, Colorado, United States|Yale Cancer Center, New Haven, Connecticut, United States|Johns Hopkins University, Washington, District of Columbia, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Memorial Hospital Pembroke, Pembroke, Florida, United States|Emory University, Atlanta, Georgia, United States|University of Chicago Medicine-Comprehensive Cancer Center, Chicago, Illinois, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|START Midwest, Grand Rapids, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University Medical School, Saint Louis, Missouri, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|NYU Langone, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University Hospital, Columbus, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|University of Pennsylvania Hospital, Philadelphia, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Sarah Cannon Research Institute SCRI, Nashville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, United States|University of Wisconsin-Madison Hospital and Health Clinic, Madison, Wisconsin, United States|Royal North Shore Hospital, St. Leonards, New South Wales, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|British Columbia Cancer Agency, Vancouver, British Columbia, Canada|Rigshospitalet, Copenhagen, København Ø, Denmark|Hôpital Européen Georges Pompidou, Paris, Cedex 15, France|Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest, Bordeaux, France|Centre Leon Berard, Lyon Cedex 08, France|APHM Hôpital de la Timone, Marseille, France|Institut du Cancer de Montpellier - Val d'aurelle, Montpellier Cedex 5, France|Gustave Roussy, Villejuif Cedex, France|Universitätsklinikum Würzburg A. ö. R., Würzburg, Bayern, Germany|Universitätsklinikum Köln, Köln, Nordrhein-Westfalen, Germany|Prince of Wales Hospital, Hong Kong, Shatin, New Territories, Hong Kong|Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel|Shaare Zedek Medical Center, Jerusalem, Yerushalayim, Israel|Soroka Medical Center - Pediatric Outpatient Clinic, Beer-Sheva, Israel|Hadassah Medical Center, Jerusalem, Israel|Istituto Nazionale dei Tumori, Milano, Lombardie, Italy|Nagoya University Hospital, Nagoya, Aichi, Japan|National Cancer Center Hospital East, Kashiwa, Chiba, Japan|Hokkaido University Hospital, Sapporo, Hokkaido, Japan|Hyogo Cancer Center, Akashi, Hyogo, Japan|Kanazawa University Hospital, Kanazawa, Ishikawa, Japan|Kindai University Hospital, Osaka Sayama-shi, Osaka, Japan|Shizuoka Cancer Center, Nagaizumi-cho,Sunto-gun, Shizuoka, Japan|National Cancer Center Hospital, Chuo-ku, Tokyo, Japan|Japanese Foundation for Cancer Research, Koto, Tokyo, Japan|Tottori University Hospital, Yonago, Tottori, Japan|National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan|Okayama University Hospital, Okayama, Japan|Osaka City General Hospital, Osaka, Japan|National Cancer Center, Goyang-si, Gyeonggi-do, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam, Kyǒnggi-do, Korea, Republic of|Asan Medical Center, Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of|Samsung Medical Center, Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|National Cancer Centre Singapore, Singapore, Singapore|Hospital Universitari Vall d'Hebron, Barcelona, Barcelona [Barcelona], Spain|Fundacion Jimenez Diaz, Madrid, Spain|Hospital Madrid Norte Sanchinarro, Madrid, Spain|Kantonsspital Luzern, Luzern 16, Luzern, Switzerland|Taichung Veterans General Hospital, Taichung, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Royal Marsden Hospital, Sutton, Surrey, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03157128"
421,"NCT02513693","Deep Neuromuscular Blockade During Robotic Radical Prostatectomy",,"Unknown status","No Results Available","Neuromuscular Blockade","Drug: Standard neuromuscular blockade|Drug: Deep neuromuscular blockade","Surgical condition|Quality of recovery|""Ready to leave operating room (OR)"" time","Palacky University|University Hospital Olomouc|Masaryk Hospital Usti nad Labem","Male","19 Years and older   (Adult, Older Adult)","Phase 4","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","IGA_LF_2015_012","July 2015","March 2016","March 2016","August 3, 2015",,"August 3, 2015","Dept. of Anesthesiology and Intensive Care Medicine, University Hospital Olomouc, Olomouc, Czech Republic|Dept. of Anesthesiology, Perioperative Medicine and Intensive Care, J. E. Purkinje University, Masaryk Hospital, Usti nad Labem, Czech Republic",,"https://ClinicalTrials.gov/show/NCT02513693"
422,"NCT02199717","An Institutional Pilot Study to Investigate Physical Activity Patterns in Boys With Hemophilia","HEPS","Completed","Has Results","Hemophilia A|Hemophilia B|Factor VIII Deficiency|Factor IX Deficiency","Device: Accelerometer","MVPA|Sedentary Time","The Hospital for Sick Children|Canadian Hemophilia Society","Male","5 Years to 17 Years   (Child)",,"66","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","1000039947","September 2013","July 2014","September 2016","July 24, 2014","December 14, 2016","December 14, 2016","SickKids, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02199717"
423,"NCT03741881","A Study Following People With Haemophilia A and B, With or Without Inhibitors, When on Usual Treatment (Explorer™6)","explorer™6","Completed","No Results Available","Haemophilia A|Haemophilia A With Inhibitors|Haemophilia B|Haemophilia B With Inhibitors","Other: No treatment given","The number of treated bleeding episodes|The number of all bleeding episodes","Novo Nordisk A/S","Male","12 Years and older   (Child, Adult, Older Adult)",,"231","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","NN7415-4322|U1111-1182-3359","December 18, 2018","October 25, 2021","October 25, 2021","November 15, 2018",,"November 23, 2021","Novo Nordisk Investigational Site, Los Angeles, California, United States|Novo Nordisk Investigational Site, Sacramento, California, United States|Novo Nordisk Investigational Site, Aurora, Colorado, United States|Novo Nordisk Investigational Site, Washington, District of Columbia, United States|Novo Nordisk Investigational Site, Atlanta, Georgia, United States|Novo Nordisk Investigational Site, Augusta, Georgia, United States|Novo Nordisk Investigational Site, Macon, Georgia, United States|Novo Nordisk Investigational Site, Chicago, Illinois, United States|Novo Nordisk Investigational Site, Indianapolis, Indiana, United States|Novo Nordisk Investigational Site, Detroit, Michigan, United States|Novo Nordisk Investigational Site, East Lansing, Michigan, United States|Novo Nordisk Investigational Site, Saint Louis, Missouri, United States|Novo Nordisk Investigational Site, Las Vegas, Nevada, United States|Novo Nordisk Investigational Site, Newark, New Jersey, United States|Novo Nordisk Investigational Site, Albuquerque, New Mexico, United States|Novo Nordisk Investigational Site, Charlotte, North Carolina, United States|Novo Nordisk Investigational Site, Charlotte, North Carolina, United States|Novo Nordisk Investigational Site, Cleveland, Ohio, United States|Novo Nordisk Investigational Site, Dayton, Ohio, United States|Novo Nordisk Investigational Site, Hershey, Pennsylvania, United States|Novo Nordisk Investigational Site, Philadelphia, Pennsylvania, United States|Novo Nordisk Investigational Site, Philadelphia, Pennsylvania, United States|Novo Nordisk Investigational Site, Charleston, South Carolina, United States|Novo Nordisk Investigational Site, Nashville, Tennessee, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, Salt Lake City, Utah, United States|Novo Nordisk Investigational Site, Charlottesville, Virginia, United States|Novo Nordisk Investigational Site, Milwaukee, Wisconsin, United States|Novo Nordisk Investigational Site, Algiers, Algeria|Novo Nordisk Investigational Site, Constantine, Algeria|Novo Nordisk Investigational Site, Melbourne, Victoria, Australia|Novo Nordisk Investigational Site, Parkville, Victoria, Australia|Novo Nordisk Investigational Site, Murdoch, Western Australia, Australia|Novo Nordisk Investigational Site, Amstetten, Austria|Novo Nordisk Investigational Site, Banja Luka, Bosnia and Herzegovina|Novo Nordisk Investigational Site, Plovdiv, Bulgaria|Novo Nordisk Investigational Site, Sofia, Bulgaria|Novo Nordisk Investigational Site, Varna, Bulgaria|Novo Nordisk Investigational Site, Calgary, Alberta, Canada|Novo Nordisk Investigational Site, Saint John, New Brunswick, Canada|Novo Nordisk Investigational Site, St. John's, Newfoundland and Labrador, Canada|Novo Nordisk Investigational Site, Hamilton, Ontario, Canada|Novo Nordisk Investigational Site, Hamilton, Ontario, Canada|Novo Nordisk Investigational Site, Zagreb, Croatia|Novo Nordisk Investigational Site, Zagreb, Croatia|Novo Nordisk Investigational Site, Tallinn, Estonia|Novo Nordisk Investigational Site, Helsinki, Finland|Novo Nordisk Investigational Site, Brest, France|Novo Nordisk Investigational Site, Bron Cedex, France|Novo Nordisk Investigational Site, Caen, France|Novo Nordisk Investigational Site, Kremlin-Bicêtre, France|Novo Nordisk Investigational Site, Lille, France|Novo Nordisk Investigational Site, Nantes Cedex 1, France|Novo Nordisk Investigational Site, Paris, France|Novo Nordisk Investigational Site, Rennes, France|Novo Nordisk Investigational Site, Saint Etienne, France|Novo Nordisk Investigational Site, Bonn, Germany|Novo Nordisk Investigational Site, Homburg, Germany|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Thessaloniki, Greece|Novo Nordisk Investigational Site, Budapest, Hungary|Novo Nordisk Investigational Site, Bangalore, Karnataka, India|Novo Nordisk Investigational Site, Pune, Maharashtra, India|Novo Nordisk Investigational Site, New Dehli, New Delhi, India|Novo Nordisk Investigational Site, Vellore, Tamil Nadu, India|Novo Nordisk Investigational Site, Kolkatta, West Bengal, India|Novo Nordisk Investigational Site, Tel-Hashomer, Israel|Novo Nordisk Investigational Site, Castelfranco Veneto, Italy|Novo Nordisk Investigational Site, Firenze, Italy|Novo Nordisk Investigational Site, Roma, Italy|Novo Nordisk Investigational Site, Udine, Italy|Novo Nordisk Investigational Site, Verona, Italy|Novo Nordisk Investigational Site, Aichi, Japan|Novo Nordisk Investigational Site, Hiroshima, Japan|Novo Nordisk Investigational Site, Hyogo, Japan|Novo Nordisk Investigational Site, Kagoshima, Japan|Novo Nordisk Investigational Site, Kanagawa, Japan|Novo Nordisk Investigational Site, Kyoto, Japan|Novo Nordisk Investigational Site, Mie, Japan|Novo Nordisk Investigational Site, Nara, Japan|Novo Nordisk Investigational Site, Niigata, Japan|Novo Nordisk Investigational Site, Osaka, Japan|Novo Nordisk Investigational Site, Saitama, Japan|Novo Nordisk Investigational Site, Saitama, Japan|Novo Nordisk Investigational Site, Shizuoka, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Busan, Korea, Republic of|Novo Nordisk Investigational Site, Daejeon, Korea, Republic of|Novo Nordisk Investigational Site, Daejeon, Korea, Republic of|Novo Nordisk Investigational Site, Jeju-do, Korea, Republic of|Novo Nordisk Investigational Site, Seoul, Korea, Republic of|Novo Nordisk Investigational Site, Seoul, Korea, Republic of|Novo Nordisk Investigational Site, Vilnius, Lithuania|Novo Nordisk Investigational Site, Vilnius, Lithuania|Novo Nordisk Investigational Site, Selangor Darul Ehsan, Malaysia|Novo Nordisk Investigational Site, Monterrey, Nuevo León, Mexico|Novo Nordisk Investigational Site, Groningen, Netherlands|Novo Nordisk Investigational Site, Oslo, Norway|Novo Nordisk Investigational Site, Krakow, Poland|Novo Nordisk Investigational Site, Lublin, Poland|Novo Nordisk Investigational Site, Lublin, Poland|Novo Nordisk Investigational Site, Warszawa, Poland|Novo Nordisk Investigational Site, Porto, Portugal|Novo Nordisk Investigational Site, Krasnodar, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Belgrade, Serbia|Novo Nordisk Investigational Site, Belgrade, Serbia|Novo Nordisk Investigational Site, Kragujevac, Serbia|Novo Nordisk Investigational Site, Novi Sad, Serbia|Novo Nordisk Investigational Site, Bratislava, Slovakia|Novo Nordisk Investigational Site, Parktown, Johannesburg, Gauteng, South Africa|Novo Nordisk Investigational Site, Durban, KwaZulu-Natal, South Africa|Novo Nordisk Investigational Site, Polokwane, Limpopo, South Africa|Novo Nordisk Investigational Site, Madrid, Spain|Novo Nordisk Investigational Site, Málaga, Spain|Novo Nordisk Investigational Site, Oviedo, Spain|Novo Nordisk Investigational Site, Sevilla, Spain|Novo Nordisk Investigational Site, Valencia, Spain|Novo Nordisk Investigational Site, Malmö, Sweden|Novo Nordisk Investigational Site, Solna, Sweden|Novo Nordisk Investigational Site, Zürich, Switzerland|Novo Nordisk Investigational Site, Adana, Turkey|Novo Nordisk Investigational Site, Ankara, Turkey|Novo Nordisk Investigational Site, Ankara, Turkey|Novo Nordisk Investigational Site, Antalya, Turkey|Novo Nordisk Investigational Site, Bornova-IZMIR, Turkey|Novo Nordisk Investigational Site, Capa-ISTANBUL, Turkey|Novo Nordisk Investigational Site, Edirne, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Samsun, Turkey|Novo Nordisk Investigational Site, Kyiv, Ukraine|Novo Nordisk Investigational Site, Lviv, Ukraine|Novo Nordisk Investigational Site, Belfast, United Kingdom|Novo Nordisk Investigational Site, Birmingham, United Kingdom|Novo Nordisk Investigational Site, London, United Kingdom|Novo Nordisk Investigational Site, London, United Kingdom|Novo Nordisk Investigational Site, Manchester, United Kingdom|Novo Nordisk Investigational Site, Nottingham, United Kingdom|Novo Nordisk Investigational Site, Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03741881"
424,"NCT02962869","Human Photoallergy Test (824/2016)",,"Completed","No Results Available","Sunscreening Agents","Drug: BAY987517|Other: Untreated skin","Intensity of skin reactions is evaluated by 5 point scale","Bayer","All","18 Years to 60 Years   (Adult)","Not Applicable","53","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: Single|Primary Purpose: Other","18824","November 3, 2016","December 31, 2016","December 31, 2016","November 11, 2016",,"December 13, 2018","Piscataway, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02962869"
425,"NCT02823496","18349-Human Photoallergy Test",,"Completed","No Results Available","Sunscreening Agents","Other: Sunscreen Lotion , BAY 987521|Other: Untreated skin","Intensity of skin reactions is evaluated by 5 point scale","Bayer","All","18 Years to 60 Years   (Adult)","Not Applicable","60","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)","18349","November 2015","November 2015","November 2015","July 6, 2016",,"July 6, 2016","Piscataway, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02823496"
426,"NCT02751567","18776 - Human Photoallergy Test",,"Withdrawn","No Results Available","Sunscreening Agents","Other: BAY987516|Other: Untreated skin","Intensity of skin reactions is evaluated by 5 point scale","Bayer","All","18 Years to 60 Years   (Adult)","Not Applicable","0","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: Single (Participant)","18776","May 2016","June 2016","June 2016","April 26, 2016",,"May 23, 2016",,,"https://ClinicalTrials.gov/show/NCT02751567"
427,"NCT02751515","Human Photoallergy Test",,"Completed","No Results Available","Sunscreening Agents","Other: Bain De Soliel - Solid|Other: Untreated skin","Intensity of skin reactions is evaluated by 5 point scale","Bayer","All","18 Years to 60 Years   (Adult)","Not Applicable","54","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)","18601","May 2016","July 2016","July 2016","April 26, 2016",,"July 26, 2016","Piscataway, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02751515"
428,"NCT02750488","18793 - Human Photoallergy Test",,"Completed","No Results Available","Sunscreening Agents","Drug: BAY987517|Other: Untreated skin","Intensity of skin reactions is evaluated by 5 point scale","Bayer","All","18 Years to 60 Years   (Adult)","Not Applicable","54","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Other","18793","May 9, 2016","July 1, 2016","July 1, 2016","April 25, 2016",,"December 13, 2018","Piscataway, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02750488"
429,"NCT02962856","Human Phototoxicity Test (823/2016)",,"Completed","No Results Available","Sunscreening Agents","Drug: BAY987517|Other: Untreated Skin","Intensity of skin reactions will be evaluated using the 5 point grading scale","Bayer","All","18 Years to 60 Years   (Adult)","Not Applicable","38","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","18823","November 2, 2016","November 5, 2016","November 5, 2016","November 11, 2016",,"December 13, 2018","Piscataway, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02962856"
430,"NCT00592150","Effect of Gene Variants on Dopamine Receptor Natriuretic Responses",,"Unknown status","No Results Available","Hypertension","Drug: fenoldopam|Drug: Placebo","Urine sodium excretion|gene dose effect of GPK-4 on fenoldopam induced natriuresis","University of Virginia|National Institutes of Health (NIH)","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","44","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","13072","June 2007","March 2008","June 2013","January 11, 2008",,"January 23, 2013","University of Virginia, Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00592150"
431,"NCT04500925","The Incidence of Postoperative Re-stratification for Recurrence in Well-differentiated Thyroid Cancer - A Single Tertiary Israeli Center Experience",,"Completed","No Results Available","Well Differentiated Thyroid Carcinoma|Papillary Thyroid Cancer","Procedure: UNILATERAL THYROIDECTOMY","disease-specific recurrence","Tel-Aviv Sourasky Medical Center","All","38 Years to 61 Years   (Adult)",,"301","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","TASMC-20-NC-TLV-704-16-CTIL","January 1, 2006","January 1, 2018","January 1, 2020","August 5, 2020",,"August 5, 2020",,,"https://ClinicalTrials.gov/show/NCT04500925"
432,"NCT02768753","Comparison Between the Axillary Bilateral-breast Approach (ABBA) and Bilateral Axillo-breast Approach (BABA) for Robotic Thyroidectomy",,"Completed","Has Results","Thyroid Papillary Carcinoma|Thyroidectomy","Procedure: The Axillary Bilateral-breast Approach|Procedure: The bilateral Axillo-breast Approach","Change of VAS Pain Scores for the First 24 Hours|Cosmetic Outcomes|Subjective Voice|Swallowing Evaluation","Jinan Military General Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ShandongJJZY-01","May 2016","April 2017","April 2017","May 11, 2016","September 27, 2019","September 27, 2019","Department of thyroid and breast surgery, General Hospital of Jinan Military Area, Jinan, Shandong, China","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/53/NCT02768753/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/53/NCT02768753/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02768753"
433,"NCT05187936","Pre-clinical Models for Mesenchymal Stem Cell Therapy in Hemophilic Arthropathy",,"Recruiting","No Results Available","Hemophilia A|Hemophilia B|Arthropathy",,"Evaluation of surviva|Evaluation of proliferation|Evaluation of apoptosis, phenotype, function of cells|Evaluation of phenotype","University Hospital, Montpellier","All","18 Years and older   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Other|Time Perspective: Prospective","RECHMPL21_0640","October 1, 2021","July 1, 2022","December 31, 2022","January 12, 2022",,"January 12, 2022","Uhmontpellier, Montpellier, France",,"https://ClinicalTrials.gov/show/NCT05187936"
434,"NCT03619863","ATHN 7: Hemophilia Natural History Study","ATHN 7","Active, not recruiting","No Results Available","Hemophilia A With Inhibitor|Haemophilia A Without Inhibitor|Hemophilia B With Inhibitor|Haemophilia B Without Inhibitor",,"Safety of treatment products used for hemophilia care will be assessed based on the number of reportable European Haemophilia Safety Surveillance (EUHASS) events documented on the ATHN Adverse Event Module Form.|Effectiveness of non-factor products, bypassing agents and clotting factor replacement products will be evaluated based on the participant's number of bleeding events reported as the annualized bleeding rate (ABR).|Dosing regimens for hemophilia treatment products and total amount utilized by the study participant for prophylaxis and treatment of bleeds will be assessed.|Target joint monitoring|Efficacy of treatment is rated by health-related outcomes tools: EQ-5D-5L, Patient-Reported Outcomes Measurement Information System (PROMIS), Global Adherence Rating (GAR), and Treatment Satisfaction with Medicines Questionnaire (SATMED-Q).|Real world effectiveness of treatment products assessed by the healthcare providers as measure by the number and types of medical visits and/or hospitalizations per year.","American Thrombosis and Hemostasis Network|Genentech, Inc.","All","Child, Adult, Older Adult",,"395","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ATHN 7","October 24, 2018","September 2023","December 2023","August 8, 2018",,"December 9, 2021","Arizona Hemophilia and Thrombosis Center at Phoenix Children's Hospital, Phoenix, Arizona, United States|Orthopedic Institute for Children Hemophilia Program, Los Angeles, California, United States|UCD Hemostasis and Thrombosis Center, Sacramento, California, United States|Rady Children's Hospital San Diego, San Diego, California, United States|UCSF Pediatric Hemophilia Treatment Center at Mission Bay, San Francisco, California, United States|Hemophilia and Thrombosis Center/ University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States|Children's National Medical Center, Washington, District of Columbia, United States|University of Florida Hemophilia Treatment Center, Gainesville, Florida, United States|Children's Healthcare of Atlanta/Emory, Atlanta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|Indiana Hemophilia and Thrombosis Center (IHTC), Indianapolis, Indiana, United States|Kansas City Regional Hemophilia Center, Kansas City, Kansas, United States|Louisiana Center for Bleeding and Clotting Disorders, New Orleans, Louisiana, United States|Maine Hemophilia and Thrombosis Center, Scarborough, Maine, United States|Boston Hemophilia Center at Children's Hospital of Boston, Boston, Massachusetts, United States|University of Michigan Hemophilia and Coagulation Disorders Program, Ann Arbor, Michigan, United States|Children's Hospital of Michigan Hemostasis and Thrombosis Center, Detroit, Michigan, United States|Michigan State University Center for Bleeding and Clotting Disorders, East Lansing, Michigan, United States|The John Bouhasin Center for Children with Bleeding Disorders, Saint Louis, Missouri, United States|Hemostasis and Thrombosis Center of Nevada, Las Vegas, Nevada, United States|Newark Beth Israel Medical Center, Newark, New Jersey, United States|Ted R Montoya Hemophilia Program, Albuquerque, New Mexico, United States|Long Island Jewish Medical Center Comprehensive Hemophilia Center, Hyde Park, New York, United States|Weill Cornell Medicine, New York, New York, United States|St. Jude Affiliate Clinic at Novant Hemby Children's Hospital, Charlotte, North Carolina, United States|Wake Forest University Health Science, Winston-Salem, North Carolina, United States|University of Cincinnati Medical Center Hemophilia Treatment Center, Cincinnati, Ohio, United States|Northwest Ohio Hemophilia Treatment Center at the Toledo Hospital, Toledo, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Children's Hospital of Philadelphia (CHOP), Philadelphia, Pennsylvania, United States|Pennsylvania Comprehensive Hemophilia and Thrombophilia Program / Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|The Hemophilia Center of Western Pennsylvania, Pittsburgh, Pennsylvania, United States|St Jude Children's Research Hospital, Memphis, Tennessee, United States|University of Tennessee - Hemophilia Clinic of Memphis, Memphis, Tennessee, United States|Fort Worth Bleeding Disorders Program, Fort Worth, Texas, United States|Gulf States Hemophilia and Thrombosis Center, Houston, Texas, United States|Washington Center for Bleeding Disorders Bloodworks Northwest d/b/a Puget Sound Blood Center, Seattle, Washington, United States|Blood Center of Wisconsin, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT03619863"
435,"NCT01565304","Evaluation of the Effectiveness of the POWER Through Choices Program",,"Completed","No Results Available","Pregnancy|Sexually Transmitted Infections","Behavioral: POWER Through Choices","Consistent contraceptive use|Sexual initiation|Knowledge of contraceptive use and reproductive health|Intentions to delay sexual initiation and unprotected sex|Attitudes toward sexual activity and contraceptive use|Scores on scale of self-efficacy to avoid sexual risk behaviors","Mathematica Policy Research, Inc.|University of Oklahoma","All","13 Years to 18 Years   (Child, Adult)","Not Applicable","1039","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","MPR-06549-03","January 2012","July 2015","July 2015","March 28, 2012",,"September 23, 2015","Kern County Superintendent of Schools, Bakersfield, California, United States|Planned Parenthood of Maryland, Baltimore, Maryland, United States|Oklahoma Institute for Child Advocacy, Oklahoma City, Oklahoma, United States",,"https://ClinicalTrials.gov/show/NCT01565304"
436,"NCT04784390","Proof of Concept Study of Binocular Videogames Versus Patching for Amblyopia",,"Recruiting","No Results Available","Amblyopia","Device: Binocular video games|Device: Patching of the sound eye","Change in best corrected visual acuity (BCVA) in the amblyopic eye.|Attain BCVA of 0.1 logMAR or better in the amblyopic eye|Change in stereoacuity or binocular video game relative to patching.|Attain a 2-line or better improvement in BCVA in the amblyopic eye|Change in BCVA in the amblyopic eye|Frequency of treatment-emergent Adverse Events|Time played as recorded in the diary|Time patched as recorded in the diary|Time played as recorded in the video game system|Percentage of participants who complete at least 75% of prescribed game play","Novartis Pharmaceuticals|Novartis","All","4 Years to 12 Years   (Child)","Phase 1","95","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","CDDO001F12201","June 30, 2021","November 2, 2022","June 29, 2023","March 5, 2021",,"January 18, 2022","Novartis Investigative Site, Los Angeles, California, United States|Novartis Investigative Site, Gainesville, Florida, United States|Novartis Investigative Site, Maitland, Florida, United States|Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Frederick, Maryland, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Las Vegas, Nevada, United States|Novartis Investigative Site, Columbus, Ohio, United States|Novartis Investigative Site, North Ryde, New South Wales, Australia|Novartis Investigative Site, Sydney, New South Wales, Australia|Novartis Investigative Site, Westmead, Australia|Novartis Investigative Site, Kitchener, Ontario, Canada|Novartis Investigative Site, Waterloo, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04784390"
437,"NCT01906151","IOP Pattern in Primary Angle Closure and Primary Angle Closure Glaucoma Patients, Before and After LPI",,"Withdrawn","No Results Available","Glaucoma","Device: SENSIMED Triggerfish®","To evaluate the differences between the nycthemeral intraocular pressure patterns recorded with Triggerfish during two 24-hour periods, in patients with Primary angle closure and Primary angle closure glaucoma, before and after laser peripheral iridotomy|To assess the nycthemeral intraocular pressure patterns specific to primary angle closure and primary angle closure glaucoma|To assess the effect of laser peripheral iridotomy on diurnal and nocturnal intraocular pressure pattern in primary angle closure and primary angle closure glaucoma","Sensimed AG","All","18 Years and older   (Adult, Older Adult)","Not Applicable","0","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","TF-1306","January 2014","March 2014","March 2014","July 23, 2013",,"May 13, 2014","CHNO des Quinze-Vingts, 28 rue Charenton, Paris, France",,"https://ClinicalTrials.gov/show/NCT01906151"
438,"NCT01003782","Routine Bile Collection for Microbiological Analysis During Cholangiography","ERCP","Completed","No Results Available","Cholangitis",,,"Hannover Medical School","All","18 Years and older   (Adult, Older Adult)",,,"Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","MAERCP","January 2008","February 2009","February 2009","October 29, 2009",,"October 29, 2009","Hannover Medical school, Hannover, Germany",,"https://ClinicalTrials.gov/show/NCT01003782"
439,"NCT00022997","Study of Taste Deficits",,"Completed","No Results Available","Taste Disorder|Healthy",,,"National Institute on Deafness and Other Communication Disorders (NIDCD)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)",,"450","NIH","Observational",,"010230|01-DC-0230","August 16, 2001",,"June 4, 2019","August 20, 2001",,"June 6, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00022997"
440,"NCT02138214","Central Neck Dissection in Patients With Clinical Node Negative Thyroid Cancer",,"Completed","Has Results","Stage I Papillary Thyroid Cancer|Stage II Papillary Thyroid Cancer|Stage III Papillary Thyroid Cancer","Procedure: Thyroidectomy|Procedure: entral lymph node dissection (CLND)|Other: Quality-of-life assessment","Percentage of Participants With Transient Hypoparathyroidism, as Defined by a Day 1 Serum Parathyroid Hormone (PTH) Level of < 10 pg/ml|Post-operative Serum Calcium (mg/dL) at Day 12|Total Calcium Consumption in First 2 Weeks|Number of Participants With Hypocalcemia Symptoms in First 2 Weeks|Hypocalcemia Symptom Severity Scale (Range of 1-5)|Percentage of Participants That Required Calcium and Calcitriol at Month 6|Post-operative Serum PTH (pg/ml) at Month 6|Post-operative Serum Calcium Level at Month 6|Rate of Transient and Permanent Hypocalcemia|Rate of Voice and Swallowing Problems|Degree to Which Quality of Life (QOL) is Compromised|Clinical Recurrence Rates|Degree to Which Accurate Quality of Life (QOL) Measures Can be Extracted From Patient Interview Narratives Using Natural Language Processing Techniques","University of Wisconsin, Madison|National Cancer Institute (NCI)","All","21 Years to 73 Years   (Adult, Older Adult)","Phase 2","117","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","UW13115|NCI-2014-00833|R01CA176911|2014-0391|A539700|SMPH\SURGERY\SURGERY","June 6, 2014","October 30, 2019","October 26, 2020","May 14, 2014","December 21, 2020","December 21, 2020","University of Wisconsin, Madison, Wisconsin, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT02138214/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02138214"
441,"NCT04106323","A Study of Factor Inhibitors in Adult Patients With Hemophilia and Von Willebrand's Disease in Upper Egypt",,"Unknown status","No Results Available","Hemophilia|Von Willebrand Diseases|Christmas Disease",,"Number of patients with inhibitors|Number of patients on demand replacement therapy|Number of participants with low or high responding inhibitors","Safaa AA Khaled|Assiut University","All","18 Years to 55 Years   (Adult)",,"100","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","SKhaled20","May 10, 2020","November 10, 2020","August 20, 2021","September 27, 2019",,"March 12, 2020",,,"https://ClinicalTrials.gov/show/NCT04106323"
442,"NCT01090206","Correlation Between Vitamin D Status and Bone Mineral Density in Patients With Hemophilia",,"Completed","No Results Available","Hemophilia A|Hemophilia B|Vitamin D Deficiency","Dietary Supplement: Vitamin D and calcium","Correlate between Vitamin D deficiency, low bone mass and lack of weight bearing physical activity|Determine bone mass (density) in hemophilia patients|establish dose and duration of treatment with vitamin D","Virginia Commonwealth University|CSL Behring","Male","2 Years to 21 Years   (Child, Adult)","Not Applicable","20","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","PT 104212","March 2010","March 2013","March 2015","March 19, 2010",,"April 29, 2016","Virginia Commonwealth University Health System, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01090206"
443,"NCT03700632","Part-time Patch Therapy for Treatment of Intermittent Exotropia",,"Unknown status","No Results Available","Intermittent Exotropia","Other: patch therapy","3-point scale Deviation Control|6-point scale Deviation Control|Near stereopsis|Fusion","Tehran University of Medical Sciences","All","3 Years to 8 Years   (Child)","Not Applicable","64","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","9611257005","November 1, 2018","May 10, 2020","November 10, 2021","October 9, 2018",,"October 9, 2018",,,"https://ClinicalTrials.gov/show/NCT03700632"
444,"NCT01589848","Study on Von Willebrand Disease and Hemophilia in Cuenca, Ecuador","VWD","Completed","No Results Available","Von Willebrand Disease|Hemophilia A|Hemophilia B",,"Bleeding Score (BS)|Associations among BS and female subgroup characteristics and initial laboratory tests.","Universidad del Azuay","Female","18 Years to 50 Years   (Adult)",,"81","Other","Observational",,"001|UAzuay","March 2013","June 2013","June 2013","May 2, 2012",,"July 3, 2013","UAzuay, Cuenca, Azuay, Ecuador|Universidad del Azuay (UDA), Cuenca, Azuay, Ecuador",,"https://ClinicalTrials.gov/show/NCT01589848"
445,"NCT05172921","Environmental Factors and Thyroid Cancer",,"Not yet recruiting","No Results Available","Thyroid Cancer",,"Phospholipids|Ceramides|per-and polyfluoroalkyl substances (PFAS)","Icahn School of Medicine at Mount Sinai","All","18 Years and older   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","STUDY-21-01547","January 10, 2022","January 10, 2030","January 10, 2030","December 29, 2021",,"December 29, 2021","Icahn School of Medicine at Mount Sinai, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT05172921"
446,"NCT01379300","A Study to Investigate Biomarkers After Single Doses of Anticoagulants in Healthy Young Male and Healthy Elderly Participants (MK-0000-216 AM1)",,"Completed","No Results Available","Thrombosis","Drug: dabigatran etexilate|Drug: rivaroxaban","Endogenous thrombin potential by Thrombin Generation Assay (TGA)-2a assay|Level of fibrin degradation product (D-dimer)|Level of fibrinopeptide A (FPA)|Level of prothrombin split products (F1+2)|Level of thrombin-antithrombin complex (TAT)","Merck Sharp & Dohme Corp.","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1","42","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0000-216","May 2011","December 2011","December 2011","June 23, 2011",,"October 2, 2015",,,"https://ClinicalTrials.gov/show/NCT01379300"
447,"NCT05189821","RFA Treatment for Papillary Thyroid Microcarcinoma",,"Recruiting","No Results Available","Papillary Thyroid Microcarcinoma","Procedure: Radiofrequency Ablation","Complete sonographic disappearance (CD)|Complications","Columbia University","All","18 Years and older   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","AAAT6770","November 1, 2021","November 30, 2025","November 30, 2026","January 13, 2022",,"January 13, 2022","Columbia University, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT05189821"
448,"NCT01718236","Modern Myorelaxation Procedure and Reversal of Neuromuscular Blockade With General Anesthesia for Caesarean Section","RocSugIO","Completed","No Results Available","Caesarean Section|Pregnancy","Drug: Rocuronium + sugammadex|Drug: Succinylcholine + Neostigmine","time needed to tracheal intubation|total procedure time","Brno University Hospital|St. Anne's University Hospital Brno, Czech Republic|University Hospital Olomouc|IGA - internal grant agency, Ministry of Health","Female","14 Years to 60 Years   (Child, Adult)","Phase 4","500","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","IGA NT 13906-4","September 2012","January 2015","January 2015","October 31, 2012",,"July 26, 2016","Faculty hospital Brno, Brno, Jihomoravský Kraj, Czech Republic|Faculty Hospital Olomouc, Olomouc, Olomoucký kraj, Czech Republic",,"https://ClinicalTrials.gov/show/NCT01718236"
449,"NCT04250883","Low Pressure Pneumoperitoneum and Deep Neuromuscular Block Versus Standard Laparoscopy During Robot Assisted Radical Prostatectomy to Improve the Quality of Recovery and Immune Homeostasis; Study Protocol for a Randomized Controlled Study.","RECOVER-2","Recruiting","No Results Available","Quality of Life|Postoperative Complications|Acute Pain|Immune System Tolerance","Other: Low intra-abdominal pressure|Other: Deep neuromuscular blockade (NMB)|Other: Standard intra-abdominal pressure|Other: Moderate neuromuscular blockade (NMB)","Quality of recovery - 40 items questionnaire score (QoR-40)|Immune response represented by IL-6|Immune response represented by IL-10|Perfusion index of the parietal peritoneum|Health status with short form survey (SF-36)|Chronic pain with McGill pain questionnaire (MPQ)|Pain score with VAS|Analgesia use|PONV|Hospital stay|Postoperative recovery time|Operating conditions|Complications","Radboud University|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Not Applicable","96","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Prevention","NL72780.091.20|2020-000411-79","December 24, 2020","December 2021","March 2022","January 31, 2020",,"November 11, 2021","Canisius Wilhelmina ziekenhuis, Nijmegen, Netherlands",,"https://ClinicalTrials.gov/show/NCT04250883"
450,"NCT04613882","Quantification of the Visual Benefits of Soft Toric Contact Lenses Compared to Soft Spherical Contact Lenses",,"Active, not recruiting","No Results Available","Astigmatism","Device: Soft Toric Custom Made Contact lens|Device: Soft Spherical Contact Lenses|Device: Spectacle Correction","Visual Acuity|Slit Lamp Biomicroscopy Findings - Conjunctival Redness|Slit Lamp Biomicroscopy Findings - Limbal Redness|Slit Lamp Biomicroscopy Findings - Corneal staining|Slit Lamp Biomicroscopy Findings - Conjunctival staining|Slit Lamp Biomicroscopy Findings - Papillary conjunctivitis|Slit Lamp Biomicroscopy Findings - Location of Corneal staining|Slit Lamp Biomicroscopy Findings - Corneal Oedema","Coopervision, Inc.","All","18 Years to 40 Years   (Adult)","Not Applicable","55","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","C19-683 (EX-MKTG-116)","September 28, 2021","January 30, 2022","February 28, 2022","November 3, 2020",,"December 15, 2021","Eurolens Research, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04613882"
451,"NCT05199584","A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations",,"Not yet recruiting","No Results Available","Solid Tumors With PTCH1 Loss-of-function Mutations","Drug: ENV-101 (taladegib)","Objective Response Rate (ORR)|Frequency of Adverse Events (AEs)|Frequency of unacceptable toxicities|ORR by Investigator|Clinical Benefit Rate (CBR)|Overall Survival (OS)|Duration of Response (DOR)|Progression Free Survival (PFS)|Change in Gli1 inhibition|Change in steady-state exposure to study medication","Endeavor Biomedicines, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","44","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ENV-ONC-101","January 2022","May 2024","May 2024","January 20, 2022",,"January 20, 2022","Research Site, San Diego, California, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT05199584"
452,"NCT03643913","The Effect of Deep Neuromuscular Block and Reversal With Sugammadex on Surgical Conditions and Perioperative Morbidity in Shoulder Surgery Using a Deltopectoral Approach",,"Recruiting","No Results Available","Shoulder Pain|Anesthesia","Procedure: Deep neuromuscular block|Procedure: Moderate neuromuscular block|Drug: Neuromuscular Blocking Agents and reversing agents","Modified Leiden score|Visual analogue scale (VAS)|Muscular damage|VAS|Analgesic needs|Length of stay at post-anesthesia care unit (PACU)|Length of surgery|Length of stay|Evaluation of dry catheter technique","Universitaire Ziekenhuizen Leuven|MSD Belgium BVBA","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 4","52","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","NS918","December 18, 2018","August 2022","September 2022","August 23, 2018",,"September 16, 2021","University Hospitals Leuven, Leuven, Vlaams-Brabant, Belgium",,"https://ClinicalTrials.gov/show/NCT03643913"
453,"NCT01760980","Pivotal Bioequivalence Study of Exemestane 25 mg Tablets Under Fasting Conditions in Healthy Subjects",,"Withdrawn","No Results Available","Healthy","Drug: Reference product (A) Aromasin (Exemestane)|Drug: Test product (B) Exemestane","AUCt, AUCinf and Cmax of Exemestane 25 mg tablets","Actavis Inc.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","PXL209003","November 2012","December 2014","December 2014","January 4, 2013",,"July 5, 2019","Bloemfontein Early Phase Clinical Unit, PAREXEL International (South Africa), Bloemfontein, South Africa",,"https://ClinicalTrials.gov/show/NCT01760980"
454,"NCT01106443","Central Compartment Neck Dissection With Thyroidectomy",,"Terminated","No Results Available","Indeterminate Thyroid Nodules","Procedure: Total Thyroidectomy + CLND|Procedure: Total thyroidectomy - CLND|Procedure: Hemi-thyroidectomy + CLND|Procedure: Hemi-thyroidectomy - CLND","Short Term Hypo-calcemia|Long Term Hypocalcemia|Vocal Cord Dysfunction|Positive Nodes|Surgical Time|Length of Hospital Stay","University of Alberta","All","18 Years and older   (Adult, Older Adult)","Not Applicable","128","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","88888","February 2010","July 2013","October 2016","April 19, 2010",,"December 14, 2016","University of Alberta, Edmonton, Alberta, Canada|Dalhouise University, Halifax, Nova Scotia, Canada",,"https://ClinicalTrials.gov/show/NCT01106443"
455,"NCT02634918","Ultrasonography in Hemophilic Joint Disease and Serum Markers",,"Completed","No Results Available","Hemophilia A|Hemophilia B|Hemarthroses","Other: ultrasound","To determine the prevalence rates of synovial and cartilage changes using USG-PDS:|To determine whether the presence/absence of synovial and cartilage changes measured using USG-PDS are associated with any changes in biological surrogate marker levels.","Northwell Health|National Cancer Institute (NCI)|University of California, San Diego","Male","6 Months to 18 Years   (Child, Adult)",,"30","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","#15-145","January 2016","August 2019","December 2019","December 18, 2015",,"February 13, 2020","Feinstein Institute of Medical Research Northwell Health, New Hyde Park, New York, United States",,"https://ClinicalTrials.gov/show/NCT02634918"
456,"NCT02417558","Cognitive/Physical Computer-Game Blended Training With Personalized Brain Network Activation Technology for the Elderly","AlterniityAR","Unknown status","No Results Available","Mild Cognitive Impairment, So Stated|Mild Dementia|Healthy","Behavioral: Alterniity Augmented Reality (AAR)|Behavioral: VideoGrade","overall cognition|Physical Fitness|Episodic memory|Working Memory|Executive Function|Quality of Life|Instrumental Activities of daily living|Depressive symptoms|Overall brain function","XtremeVRI AG|Aristotle University Of Thessaloniki|Greek Alzheimer's Association and Related Disorders|Instituto Piaget|Virtual Reality Medical Center, USA","All","50 Years and older   (Adult, Older Adult)","Not Applicable","800","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention","84171-B","February 2015","September 2018","December 2018","April 15, 2015",,"June 21, 2018",,,"https://ClinicalTrials.gov/show/NCT02417558"
457,"NCT03630120","Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer",,"Terminated","Has Results","Thyroid Cancer|Thyroid Cancer, Medullary|Differentiated Thyroid Cancer|Papillary Thyroid Cancer|Follicular Thyroid Cancer|Poorly Differentiated Thyroid Gland Carcinoma","Drug: Lenvatinib|Drug: Sorafenib|Drug: Cabozantinib|Drug: Vandetanib","Time to Tyrosine Kinase Inhibitor (TKI) Treatment Discontinuation Due to Progressive Disease|Time to Tyrosine Kinase Inhibitor (TKI) Treatment Discontinuation Due to Intolerability|Time to Tyrosine Kinase Inhibitor (TKI) Treatment Discontinuation Due to Disease Related Death|Overall Response Rate (ORR)|Progression-free Survival (PFS)|Overall Survival (OS)","H. Lee Moffitt Cancer Center and Research Institute","All","18 Years and older   (Adult, Older Adult)","Phase 2","6","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","MCC-19442","August 6, 2018","November 14, 2019","December 5, 2019","August 14, 2018","January 22, 2021","July 14, 2021","H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/20/NCT03630120/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03630120"
458,"NCT01959555","Project to Update the Study of Congenital Haemophilia in Spain","PUCHS","Completed","No Results Available","Congenital Bleeding Disorder|Haemophilia A|Haemophilia B","Other: No treatment given","Prevalence of congenital haemophilia A and B in Spain in 2013, described as proportion (%) of patients in the total population (extracted from the last available census of the Spanish population for the regions considered for the study)|Severity (mild, moderate or severe) of congenital haemophilia A and B in Spain during 2013, described as proportion (%) per category of the total number of patients with haemophilia A or B|Mean current age at the time of visit to the HTC in 2013|Mean age at diagnosis|Proportion (%) of patients with/without genetic screening performed|Proportion (%) of patients who needed support of a reference Haemophilia Healthcare Centre in 2013|Proportion (%) of patients who received plasmatic or recombinant treatment|Proportion (%) of patients who received on demand or prophylaxis treatment|Mean number of bleeding episodes|Mean number of joint bleeds|Proportion (%) of patients with established arthropathy|Proportion (%) of patients with infectious complications|Proportion (%) of patients with HIV (Human immunodeficiency virus)|Proportion (%) of patients with presence of inhibitors|Proportion (%) of patients with immune tolerance induction treatment performed|Total number of surgery interventions performed|Proportion (%) of patients with quality of life questionnaire (QoLQ) performed in 2013|Mean number of days of absenteeism to school/university in children and adolescents in 2013|Mean number of days of absenteeism from work in 2013|Proportion (%) of patients with treatment administered at home","Novo Nordisk A/S","Male","Child, Adult, Older Adult",,"1157","Industry","Observational","Time Perspective: Retrospective","HAEM-4076|U1111-1136-7052|NOV-HEM-2013-01","March 2014","December 2014","December 2014","October 10, 2013",,"November 30, 2015","Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT01959555"
459,"NCT01771029","Technical Evaluation of Brahms PCT Direct",,"Completed","No Results Available","Infection",,"Correlation between BRAHMS PCT direct and reference method.|Time to result","Philipp Schuetz|Thermo Fisher Scientific|University Hospital, Basel, Switzerland","All","18 Years and older   (Adult, Older Adult)",,"150","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","POC_1","February 2013","June 2014","September 2014","January 18, 2013",,"December 12, 2014","Pitié Salpetrière. Groupement hospitalière universitaire Est, Paris, France|Klinikum Ernst von Bergmann, gemeinnützige GmbH Akademisches Lehrkrankenhaus der Humboldt-Universität Berlin (Charité), Potsdam, Germany|Kantonsspital Aarau Innere Medizin, Aarau, Aargau, Switzerland",,"https://ClinicalTrials.gov/show/NCT01771029"
460,"NCT01748201","Viscosupplementation in Patients With Hemophilic Arthropathy",,"Completed","No Results Available","Osteoarthritis|Hemarthrosis|Hemophilia A|Hemophilia B","Procedure: Joint lavage and viscosupplementation","WOMAC|VAS|Lequesne|SF-36","University of Sao Paulo General Hospital","All","Child, Adult, Older Adult","Phase 4","13","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0199/11","November 2012","March 2013","March 2013","December 12, 2012",,"September 10, 2013","Instituto de Ortopedia e Traumatologia HC-FMUSP, São Paulo, SP, Brazil",,"https://ClinicalTrials.gov/show/NCT01748201"
461,"NCT01562587","Pharmacokinetics of Single Bolus Dose of NovoSeven® in Paediatric and Adult Patients With Haemophilia A or B in a Non- Bleeding State",,"Completed","No Results Available","Congenital Bleeding Disorder|Haemophilia A|Haemophilia B","Drug: activated recombinant human factor VII","Area under the concentration curve from 0-12 hours|CL, the total body clearance|Cmax, the maximum concentration|tmax, the time to maximum concentration|t1/2, the terminal half-life|Area under the concentration curve from time 0-infinity|Vss, the apparent volume of distribution at steady state|Adverse events","Novo Nordisk A/S","Male","3 Years to 55 Years   (Child, Adult)","Phase 1","18","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","F7HAEM-1503","September 2002","May 2003","May 2003","March 26, 2012",,"January 12, 2017","Novo Nordisk Investigational Site, Bremen, Germany|Novo Nordisk Investigational Site, Frankfurt, Germany|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Firenze, Italy|Novo Nordisk Investigational Site, Milano, Italy|Novo Nordisk Investigational Site, Madrid, Spain|Novo Nordisk Investigational Site, London, United Kingdom|Novo Nordisk Investigational Site, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01562587"
462,"NCT01562457","Intra-subject Variability Following Administrations of Activated Recombinant Human Factor VII in Haemophilia Patients in a Non-bleeding State",,"Completed","No Results Available","Congenital Bleeding Disorder|Haemophilia A|Haemophilia B","Drug: activated recombinant human factor VII","TEG® (Thromboelastography) parameters after dosing of trial product|ROTEM® (Thromboelastometry) parameters after dosing of trial product|TEG® parameters obtained from blood samples spiked ex vivo with activated recombinant human factor VII|ROTEM® parameters obtained from blood samples spiked ex vivo with activated recombinant human factor VII|Serious adverse events and non-serious adverse events","Novo Nordisk A/S","Male","16 Years and older   (Child, Adult, Older Adult)","Phase 1","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NN1731-1668|2005-000891-42","November 2005","April 2006","April 2006","March 23, 2012",,"May 12, 2016","Lille, France|München, Germany|Tel Hashomer, Israel",,"https://ClinicalTrials.gov/show/NCT01562457"
463,"NCT01288391","Investigating Safety and Pharmacokinetics of 2 Different Single Doses of NNC128-0000-2011 in Haemophilia A or B Patients",,"Completed","No Results Available","Congenital Bleeding Disorder|Haemophilia A|Haemophilia B","Drug: NNC 0128-0000-2011","Frequency of Adverse Events (AEs)|Frequency of serious adverse events (SAEs)|Frequency of MESIs (Medical Event of Special Interest)|Neutralising antibodies against FVIIa and/or N7-GP","Novo Nordisk A/S","Male","18 Years and older   (Adult, Older Adult)","Phase 1","15","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NN7128-3840|2010-021127-28|U1111-1118-6995|JapicCTI-111455","January 2011","July 2011","July 2011","February 2, 2011",,"May 13, 2016","Berlin, Germany|Kitakyusyu,, Japan|Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT01288391"
464,"NCT01272206","Investigating Safety and Pharmacokinetics of NNC 0128-0000-2011 Compared to NNC 0128-0000-2021 in Healthy Male Subjects",,"Completed","No Results Available","Congenital Bleeding Disorder|Haemophilia A|Haemophilia B","Drug: NNC 0128-0000-2011|Drug: NNC 0128-0000-2021","Frequency of adverse events (AEs)|Neutralising antibodies against FVII and/or N7-GP","Novo Nordisk A/S","Male","18 Years to 49 Years   (Adult)","Phase 1","12","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","NN7128-3729|2010-021286-67|U1111-1118-0208","January 2011","March 2011","March 2011","January 7, 2011",,"August 20, 2014","Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01272206"
465,"NCT01234545","Observational Study Describing the Usual Clinical Practice Use of NovoSeven® in the Home Treatment of Joint Bleeds in Patients With Haemophilia A or B and Inhibitors",,"Completed","No Results Available","Congenital Bleeding Disorder|Haemophilia A|Haemophilia B","Drug: activated recombinant human factor VII","Number of bleeds managed at home|Number of treatments resulting in the control of bleeding episode|Number of treatments resulting in effective pain relief|Proportion of patient/caregivers with no need of any intervention from the physician to treat the bleeding episode at home|Proportion of patients who used their entire treatment at home","Novo Nordisk A/S","Male","2 Years and older   (Child, Adult, Older Adult)",,"35","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","F7HAEM-3850|U1111-1116-2488","October 2010","April 2012","April 2012","November 4, 2010",,"November 14, 2014","Algiers, Algeria|Casablanca, Morocco|Muscat, Oman|Riyadh, Saudi Arabia|Dubai, United Arab Emirates",,"https://ClinicalTrials.gov/show/NCT01234545"
466,"NCT01220141","Observational Study on Safety of Room Temperature Stable NovoSeven® in Patients With Haemophilia A or B",,"Completed","No Results Available","Congenital Bleeding Disorder|Haemophilia A|Haemophilia B","Drug: activated recombinant human factor VII","Reduced therapeutic response and neutralising antibodies to activated recombinant human factor VII as confirmed by central laboratory|Adverse events reported as potentially related to activated recombinant human factor VII","Novo Nordisk A/S","Male","Child, Adult, Older Adult",,"51","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","NN7025-3601|U1111-1116-2012","November 2010","March 2015","March 2015","October 13, 2010",,"April 16, 2015","Prov. de Buenos Aires, Argentina|Vienna, Austria|Brussels, Belgium|Paris La défense cedex, France|Mainz, Germany|Budapest, Hungary|Teheran, Iran, Islamic Republic of|Dublin 2, Ireland|Rome, Italy|Warszawa, Poland|Paco de Arcos, Portugal|Bratislava, Slovakia|Malmö, Sweden|Crawley, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01220141"
467,"NCT01748643","CURES: The Effect of Deep Curarisation and Reversal With Sugammadex on Surgical Conditions and Perioperative Morbidity","CURES","Completed","Has Results","Obesity|Laparoscopic Gastric Bypass Surgery|Surgical Conditions|Respiratory Function|Cerebral Tissue Oxygenation","Drug: deep neuromuscular blockade with rocuronium, reversal with sugammadex|Drug: normal neuromuscular blockade reversal with rocuronium, reversal with neostigmine","Subjective Evaluation of the View on the Operating Field by the Surgeon|Number of Intra-abdominal Pressure Rises > 18cmH2O|Duration of Surgery|Peak Expiratory Flow|Forced Expiratory Volume in 1 Second|Forced Vital Capacity","Ziekenhuis Oost-Limburg|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 4","60","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","PVRA-01|2012-005533-37|8616-085MISP","April 2013","January 2015","January 2015","December 12, 2012","August 3, 2017","August 3, 2017","Ziekenhuis Oost-Limburg, Genk, Limburg, Belgium",,"https://ClinicalTrials.gov/show/NCT01748643"
468,"NCT00922792","Safety and Mode of Action of a Single Dose and Multiple Doses of Long Acting Activated Recombinant Human Factor VII in Patients With Haemophilia A and B",,"Completed","No Results Available","Congenital Bleeding Disorder|Haemophilia A|Haemophilia B","Drug: activated recombinant human factor VII, long acting","Frequency of adverse events|Frequency of serious adverse events|Frequency of MESIs (Medical Event of Special Interest)|Frequency of ocurrence of neutralising antibodies against FVII and/or LA-rFVIIa|Pharmacokinetic parameters based on FVIIa activity. The pharmacokinetic parameters to be reported are: AUC(0-48h), AUC(0-t) and AUC, C10min, Vz, CL, and t½","Novo Nordisk A/S","Male","18 Years to 55 Years   (Adult)","Phase 1","8","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NN7128-3700|2009-010080-16","June 2009","September 2009","September 2009","June 17, 2009",,"May 13, 2016","Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT00922792"
469,"NCT00853086","Post-marketing Safety Surveillance of NovoSeven® in Patients With Haemophilia and Inhibitors by Means of the UK Haemophilia Database",,"Completed","No Results Available","Congenital Bleeding Disorder|Haemophilia A|Haemophilia B","Drug: activated recombinant human factor VII","Quantify number of thrombotic events in patients treated with the currently recommended dose of 90 microgram/kg compared with higher rFVIIa dose levels up to 270 microgram/kg in relation to number of treatment episodes.","Novo Nordisk A/S","Male","Child, Adult, Older Adult",,"139","Industry","Observational","Observational Model: Cohort","F7HAEM-3537|U1111-1130-5940","January 2008","June 2011","June 2011","March 2, 2009",,"November 16, 2016","Novo Nordisk Investigational Site, Crawley, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00853086"
470,"NCT04372277","Taltz in Combination With Enstilar for Psoriasis",,"Recruiting","No Results Available","Psoriasis","Drug: Enstilar","Body Surface Area 0 or 1","Psoriasis Treatment Center of Central New Jersey|Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 4","25","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PTC06","April 28, 2020","March 1, 2021","March 30, 2021","May 4, 2020",,"May 4, 2020","Psoriasis Treatment Center of Central New Jersey, East Windsor, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT04372277"
471,"NCT04347473","ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis.",,"Recruiting","No Results Available","Psoriasis","Drug: Ilumya Injectable Product","Body surface area","Psoriasis Treatment Center of Central New Jersey|Sun Pharmaceutical Industries Limited","All","18 Years and older   (Adult, Older Adult)","Phase 4","25","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PTC08","April 6, 2020","December 30, 2020","March 1, 2021","April 15, 2020",,"April 15, 2020","Psoriasis Treatment Center of Central New Jersey, East Windsor, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT04347473"
472,"NCT00486278","Haemophilia Patients With Inhibitors Being Treated for Acute Joint Bleeds",,"Completed","Has Results","Congenital Bleeding Disorder|Haemophilia A|Haemophilia B","Drug: eptacog alfa (activated)|Drug: vatreptacog alfa (activated)","Number of Adverse Events (AEs)|Activated Recombinant Human Factor VII Analogue Activity in the Blood|Prothrombin Time (PT)|F1 + 2 (Prothrombin Fragments 1+2)|Activated Partial Thromboplastin Time (aPTT)|Cessation of Bleeding: Number of Doses Needed to Control Bleeding|Number of Subjects With Need for Additional Haemostatic Agents|Pharmacokinetic Parameters Based on FVIIa Activity: AUC 0-t (Area Under the Plasma FVIIa Activity-time Curve From Time Zero to the Time (t) )|Pharmacokinetic Parameters Based on FVIIa Activity: AUC(0-inf) (Area Under the Plasma FVIIa Activity-time Curve From Time Zero to Infinity)|Pharmacokinetic Parameters Based on FVIIa Activity: MRT (Mean Residence Time)|Pharmacokinetic Parameters Based on FVIIa Activity: t½ (Terminal Half-life)|Pharmacokinetic Parameters Based on FVIIa Activity: CL (Total Clearance)|Pharmakokinetic Parameters Based on FVIIa Activity: Vss (Distribution Volume at Steady State)|Immunogenicity (Inhibitor Development)|Biochemistry: ALAT (Alanine Aminotransferase)|Biochemistry: Creatinine|Haematology: Haemoglobin|Haematology: Red Cell Count|Haematology: Packed Cell Volume|Haematology: White Cell Count|Haematology: Platelet Count","Novo Nordisk A/S","Male","12 Years and older   (Child, Adult, Older Adult)","Phase 2","51","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","NN1731-1804|2006-004879-35|CTI-080612","June 2007","June 2010","June 2010","June 14, 2007","December 25, 2014","March 7, 2017","Novo Nordisk Investigational Site, Los Angeles, California, United States|Novo Nordisk Investigational Site, Augusta, Georgia, United States|Novo Nordisk Investigational Site, Chicago, Illinois, United States|Novo Nordisk Investigational Site, Indianapolis, Indiana, United States|Novo Nordisk Investigational Site, Iowa City, Iowa, United States|Novo Nordisk Investigational Site, Boston, Massachusetts, United States|Novo Nordisk Investigational Site, Ann Arbor, Michigan, United States|Novo Nordisk Investigational Site, Minneapolis, Minnesota, United States|Novo Nordisk Investigational Site, New York, New York, United States|Novo Nordisk Investigational Site, Chapel Hill, North Carolina, United States|Novo Nordisk Investigational Site, Cincinnati, Ohio, United States|Novo Nordisk Investigational Site, Portland, Oregon, United States|Novo Nordisk Investigational Site, Ciudad Autónoma de Bs. As., Argentina|Novo Nordisk Investigational Site, Campinas, Sao Paulo, Brazil|Novo Nordisk Investigational Site, Rio de Janeiro, Brazil|Novo Nordisk Investigational Site, São Paulo, Brazil|Novo Nordisk Investigational Site, Edmonton, Alberta, Canada|Novo Nordisk Investigational Site, Zagreb, Croatia|Novo Nordisk Investigational Site, Lyon, France|Novo Nordisk Investigational Site, Budapest, Hungary|Novo Nordisk Investigational Site, Debrecen, Hungary|Novo Nordisk Investigational Site, Tel-Hashomer, Israel|Novo Nordisk Investigational Site, Castelfranco Veneto, Italy|Novo Nordisk Investigational Site, Firenze, Italy|Novo Nordisk Investigational Site, Milano, Italy|Novo Nordisk Investigational Site, Hiroshima-shi, Hiroshima, Japan|Novo Nordisk Investigational Site, Itabashi-ku, Tokyo, Japan|Novo Nordisk Investigational Site, Kashihara-shi, Nara, Japan|Novo Nordisk Investigational Site, Nagoya-shi, Aichi, Japan|Novo Nordisk Investigational Site, Nishinomiya-shi, Japan|Novo Nordisk Investigational Site, Kuala Lumpur, Malaysia|Novo Nordisk Investigational Site, Warszawa, Poland|Novo Nordisk Investigational Site, Parktown Johannesburg, Gauteng, South Africa|Novo Nordisk Investigational Site, Durban, KwaZulu-Natal, South Africa|Novo Nordisk Investigational Site, Cape Town, South Africa|Novo Nordisk Investigational Site, Madrid, Spain|Novo Nordisk Investigational Site, Changhua, Taiwan|Novo Nordisk Investigational Site, Taipei, Taiwan|Novo Nordisk Investigational Site, Bangkok, Thailand|Novo Nordisk Investigational Site, Adana, Turkey|Novo Nordisk Investigational Site, Ankara, Turkey|Novo Nordisk Investigational Site, Antalya, Turkey|Novo Nordisk Investigational Site, Bornova-IZMIR, Turkey|Novo Nordisk Investigational Site, London, United Kingdom|Novo Nordisk Investigational Site, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00486278"
473,"NCT04119102","Duobrii in Combination With Biologics",,"Recruiting","No Results Available","Psoriasis","Drug: Duobrii","Body surface area improvement","Psoriasis Treatment Center of Central New Jersey|Ortho Dermatologics","All","18 Years and older   (Adult, Older Adult)","Phase 4","25","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PTC07","October 14, 2019","August 1, 2020","September 1, 2020","October 8, 2019",,"April 30, 2020","Psoriasis Treatment Center of Central New Jersey, East Windsor, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT04119102"
474,"NCT03964168","An Outcomes Study to Determine the Reasons Patients on Biologic Therapy Discontinue Treatment and Fail to Follow-up With Their Providers",,"Completed","No Results Available","Psoriasis","Drug: Biologic Agent","Determine the most common reason for discontinuation","Psoriasis Treatment Center of Central New Jersey|Janssen Scientific Affairs, LLC","All","18 Years and older   (Adult, Older Adult)",,"3","Other|Industry","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","PTC05","July 31, 2019","March 3, 2020","March 3, 2020","May 28, 2019",,"March 11, 2020","Psoriasis Treatment Center of Central New Jersey, East Windsor, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT03964168"
475,"NCT03827876","Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis",,"Unknown status","No Results Available","Psoriasis","Drug: Enstilar 0.005%-0.064% Topical Foam","PGA x BSA improvement|BSA improvement|Dermatology Life Quality Index improvement|Itch Numerical Rating Scale","Psoriasis Treatment Center of Central New Jersey|LEO Pharma","All","18 Years and older   (Adult, Older Adult)","Phase 4","30","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PTC04","January 16, 2019","September 15, 2019","December 15, 2019","February 4, 2019",,"February 4, 2019","Psoriasis Treatment Center of Central New Jersey, East Windsor, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT03827876"
476,"NCT05086016","Multicenter Early Feasibility Trial Studying the Renata Minima Stent",,"Not yet recruiting","No Results Available","Coarctation of the Aorta|Pulmonary Artery Stenosis","Device: Catheterized Stenting","Deployment|Stenosis Relief|Free of explant|Arterial to arterial peak-to-peak pressure gradient to < 20 mmHg|Preserved vascular patency and gradient reduction|Free from a non-elective re-intervention|Successful stent re-dilation at re-catheterization","Renata Medical","All","Child, Adult, Older Adult","Not Applicable","10","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PTC-0009","December 2021","June 2022","June 2027","October 20, 2021",,"October 20, 2021",,,"https://ClinicalTrials.gov/show/NCT05086016"
477,"NCT03392337","An Open-Label, Pilot Study to Evaluate the Efficacy of Narrowband Ultraviolet-B Phototherapy Three Times Weekly for Twelve Weeks in Moderate-to-Severe Psoriasis Patients",,"Unknown status","No Results Available","Psoriasis","Device: Narrowband UVB phototherapy","Psoriasis area severity index score|Physicians Global Assessment|Body Surface Area|Physician's Global Assessments multiplied by Body surface area","Psoriasis Treatment Center of Central New Jersey","All","18 Years and older   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PTC02","November 7, 2017","December 1, 2019","January 1, 2020","January 5, 2018",,"January 30, 2019","Elise Nelson, East Windsor, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT03392337"
478,"NCT01728584","A Study Comparing the Use of Deep or Standard Neuromuscular Blockade in Combination With Low or Standard Insufflation Pressures in Participants Undergoing Laparoscopic Cholecystectomy (P07982)",,"Completed","Has Results","Gallbladder Disease","Drug: Rocuronium|Other: Insufflation|Drug: Sugammadex","Score on Surgeon's Assessment of Overall Satisfaction With the Surgical Conditions: By Depth of NMB (Standard, Deep) and Insufflation Pressure (Standard, Low)|Score on Surgeon's Assessment of Overall Satisfaction With the Surgical Conditions: By Treatment Arm|Participant's Overall Average Pain Score in the First 24 Hours After Administration of Sugammadex: By Depth of NMB (Standard, Deep) and Insufflation Pressure (Standard, Low)|Participant's Overall Average Pain Score in the First 24 Hours After Administration of Sugammadex: By Treatment Arm|Score on Surgeon's Assessment of Overall Satisfaction With the Visibility of the Surgical Field: By Depth of NMB (Standard, Deep)|Score on Surgeon's Assessment of the Overall Adequacy of Muscle Relaxation During Surgery: By Depth of NMB (Standard, Deep)|Score on Surgeon's Assessment of the Overall Adequacy of Insufflation Pressure During Surgery: By Depth of NMB (Standard, Deep)|Number of Times Participant's Movements or Increased Muscle Tone Interfered With the Surgical Conditions During Laparoscopy: By Depth of NMB (Standard, Deep)|Score on Surgeon's Assessment of the Effect Participant's Movements During Surgery Had on the Overall Surgical Procedure: By Depth of NMB (Standard, Deep)|Number of Participants With Rescue Actions Performed During Surgery in Order to Improve Insufficient Surgical Conditions: By Treatment Arm|Participant's Daily Assessment of Overall Pain at Rest During Post Operative Period: By Treatment Arm|Participant's Daily Assessment of Provoked Pain During Post Operative Period: By Treatment Arm|Participant's Daily Assessment of Shoulder Pain During Post Operative Period: By Treatment Arm|Number of Participants Using Pain/Analgesic Medication During Post Operative Period: By Treatment Arm","Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 4","127","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","P07982|MK-8616-076|2012-001886-33","November 28, 2012","April 29, 2014","April 29, 2014","November 20, 2012","March 23, 2015","October 17, 2018","Merck Sharp & Dohme GmbH, Haar, Germany|MSD Italia S.r.l., Rome, Italy",,"https://ClinicalTrials.gov/show/NCT01728584"
479,"NCT03080545","Enstilar in Combination With Biologic Agents",,"Completed","No Results Available","Psoriasis","Drug: Enstilar 0.005%-0.064% Topical Foam","Physician global assessment multiplied by body surface area improvement after 16 weeks of Enstilar® adjunctive therapy|Physician Global Assessment|Body Surface area|dermatology life quality index; TSQ-9 Treatment Satisfaction Questionnaire","Psoriasis Treatment Center of Central New Jersey|LEO Pharma","All","18 Years and older   (Adult, Older Adult)","Phase 4","25","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PTC01","May 1, 2017","October 30, 2017","October 30, 2017","March 15, 2017",,"January 3, 2018","Psoriasis Treatment Center of Central New Jersey, East Windsor, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT03080545"
480,"NCT02764489","FEIBA Reconstitution Volume Reduction and Faster Infusion Study (FEIBA STAR)",,"Completed","No Results Available","Hemophilia A or B With Inhibitors","Biological: FEIBA","Number of Participants With Serious Adverse Events (SAEs) and Non-Serious Adverse Events|Number of Participants With Adverse Events (AEs) Related to Hypersensitivity Reactions|Number of Participants With Adverse Events (AEs) Related to Thromboembolic Events|Number of Participants With Adverse Events (AEs) Related to Infusion Site Reactions|Number of Participants With Adverse Events (AEs) Leading to Discontinuation|Number of Participants With Adverse Events (AEs) Related to Change in Vital Signs|Number of Participants With Adverse Events (AEs) Related to Change in Laboratory Assessments","Baxalta now part of Shire|Baxalta Innovations GmbH, now part of Shire|Takeda","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","32","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","091501|2015-005781-39","March 13, 2019","December 27, 2021","December 27, 2021","May 6, 2016",,"January 21, 2022","University Hospital Center Zagreb, Zagreb, Croatia|PHI Institute for Transfusion Medicine of Macedonia, Skopje, North Macedonia|MV Sklifosovskyi Poltava Hematology, Poltava, Ukraine",,"https://ClinicalTrials.gov/show/NCT02764489"
481,"NCT00668811","Sutent Adjunctive Treatment of Differentiated Thyroid Cancer","IIT Sutent","Completed","Has Results","Papillary Thyroid Cancer|Follicular Thyroid Cancer|Differentiated Thyroid Cancer","Drug: SU011248, Sutent","Progression Free Survival|Overall Survival","Medstar Health Research Institute|Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 2","23","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","WCI-2007-214","April 2008","September 2015","December 2015","April 29, 2008","April 18, 2018","August 5, 2020","MedStar Washington Hospital Center, Washington, District of Columbia, United States",,"https://ClinicalTrials.gov/show/NCT00668811"
482,"NCT03247439","Safety and Effectiveness of Cartiva Implant in the Treatment of First CMC Joint Osteoarthritis Compared to LRTI (GRIP 2)","GRIP 2","Active, not recruiting","No Results Available","Osteoarthritis","Device: Cartiva","Pain measured by the Visual Analog Scale (VAS) scale|Function measured by QuickDASH|Radiographic Findings|Key Subsequent Secondary Surgical Interventions (SSSIs)","Cartiva, Inc.","All","22 Years and older   (Adult, Older Adult)","Not Applicable","74","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PTC-0290","December 22, 2017","October 30, 2020","March 2024","August 11, 2017",,"December 3, 2020","University of California, San Diego, San Diego, California, United States|Georgia Hand, Shoulder & Elbow, Atlanta, Georgia, United States|Indiana Hand to Shoulder Center, Indianapolis, Indiana, United States|Hospital for Specialty Surgery, New York, New York, United States|University of Rochester, Rochester, New York, United States|Royal Derby Hospital, Derby, Derbyshire, United Kingdom|Dorset County Hospital, Dorchester, Dorset, United Kingdom|Queen Alexandra Hospital, Portsmouth, Hampshire, United Kingdom|South Tees Hospitals, Middlesborough, North Yorkshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03247439"
483,"NCT02912143","German Pediatric Hemophilia Research Database","GEPHARD","Recruiting","No Results Available","Hemophilia A|Hemophilia B|Children|Drug Specific Antibodies","Other: documentation only","Number of patients with antibody developement to exogenous clotting factors (>0.5 BU)","Goethe University|Society for Thrombosis and Haemostasis Research (Germany)","All","up to 18 Years   (Child, Adult)",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","GEPHARD|DRKS00011101","January 1, 2017","January 1, 2022","January 1, 2022","September 23, 2016",,"August 27, 2021","Goethe University, Frankfurt, Hesse, Germany",,"https://ClinicalTrials.gov/show/NCT02912143"
484,"NCT03454477","Comparison Between Robotic, Endoscopic and Traditional Open Surgery in Thyroidectomy",,"Unknown status","No Results Available","Endoscopy|Robotics|Thyroidectomy|Papillary Thyroid Carcinoma","Procedure: conventional open surgery|Procedure: endoscopic thyroidectomy|Device: robotic thyroidectomy","operation time|recurrent laryngeal nerve palsy|thyroid volume|cosmetic effect","Fujian Medical University","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","90","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Robotic thyroidectomy","February 1, 2018","October 1, 2018","October 1, 2018","March 6, 2018",,"September 18, 2018","Wen-xin ZHAO, Fuzhou, Fujian, China",,"https://ClinicalTrials.gov/show/NCT03454477"
485,"NCT02452671","Observational Plan to Obtain Clinical Experience and Follow up Data on the Use of the ProxiFuse Hammer Toe Device",,"Terminated","No Results Available","Toe Joint Deformity",,"PROMIS Pain Interference computerized adaptive test (CAT) score|PROMIS Pain Interference CAT scores|PROMIS Physical Functioning CAT scores|Time to return to normal shoe wear|Postoperative Adverse Events that require a return to the operating room","Cartiva, Inc.","All","18 Years and older   (Adult, Older Adult)",,"15","Industry","Observational","Observational Model: Case-Control|Time Perspective: Prospective","PTC-0156","June 2015","February 2017","February 2017","May 22, 2015",,"March 22, 2017","Stanford University, Redwood City, California, United States|University of Colorado, Aurora, Colorado, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Orthopaedic Associates of Michigan, PC, Grand Rapids, Michigan, United States|University of Rochester Medical Center, Rochester, New York, United States",,"https://ClinicalTrials.gov/show/NCT02452671"
486,"NCT02391506","Safety and Effectiveness of Cartiva Implant in the Treatment of First CMC Joint Osteoarthritis","GRIP","Completed","No Results Available","Osteoarthritis","Device: Cartiva","Pain measured by the Visual Analog Scale (VAS) scale","Cartiva, Inc.","All","18 Years and older   (Adult, Older Adult)","Not Applicable","50","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PTC-0116","July 29, 2015","March 5, 2019","March 5, 2019","March 18, 2015",,"March 22, 2019","University of Calgary, Calgary, Alberta, Canada|UBC, Division of Plastic Surgery, Vancouver, British Columbia, Canada|QEII Health Sciences Center, Halifax, Nova Scotia, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Woodend Hospital, Aberdeen, Scotland, United Kingdom|Royal United Hospital, Bath, United Kingdom|Royal Derby Hospital, Derby, United Kingdom|South Tees Hospital, Middlesborough, United Kingdom|Queen Alexandra Hospital, Portsmouth, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02391506"
487,"NCT02066844","Navigator vs Standard Needle Injection for Hip",,"Completed","No Results Available","Hip Pain Etiology Unknown","Drug: Celestone|Drug: Lidocaine","Injection Pain as measured by VAS for both treatment groups|Global Patient Satisfaction|Drug Preparation Time|Hip Pain and Function","Cartiva, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","PTC-0369","February 2014","August 2014","August 2014","February 20, 2014",,"January 28, 2016","University of Rochester, Rochester, New York, United States",,"https://ClinicalTrials.gov/show/NCT02066844"
488,"NCT01764100","Mesenchymal Stromal Cells (MSCs) for the Treatment of Graft Versus Host Disease (GVHD)","MSC-GvHD","Unknown status","No Results Available","Graft vs Host Disease","Genetic: Mesenchymal stromal cells","Any toxic effect reported during MSCs infusion or in the subsequent 10 days by clinical monitoring|Feasibility as the possibility of producing adequate lots of patient dedicated MSCs for any patients presenting with steroid resistant GVHD|Number of patients with GvHD resolution|Determination of recurrence of GvHD|Relapse of haematological disease|Survival","Ettore Biagi, MD|Azienda Ospedaliera San Gerardo di Monza","All","Child, Adult, Older Adult","Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PTC-MSC|2008-007869-23","September 2009","May 2013","September 2013","January 9, 2013",,"January 9, 2013","U.O. Ematologia - Ospedali Riuniti di Bergamo, Bergamo, BG, Italy|Clinica Pediatrica CTMO - Azienda Ospedaliera San Gerardo, Monza, MB, Italy|U.O. Ematologia CTMO - Azienda Ospedaliera San Gerardo, Monza, MB, Italy",,"https://ClinicalTrials.gov/show/NCT01764100"
489,"NCT03712124","A Study of CNSA-001 in Women With Diabetic Gastroparesis",,"Completed","Has Results","Gastroparesis","Drug: CNSA-001|Drug: Placebo","Change From Baseline (Day 1) in Maximal Tolerated Volume Consumed During the Nutrient Satiety Test at Day 14|Change From Baseline (Day 1) in Maximal Tolerated Volume Consumed During the Nutrient Satiety Test at Day 28|Change From Baseline (Day 1) in the Gastroparesis Cardinal Symptom Index (GCSI) Total Score at Day 14/15 and Day 28|Change From Baseline (Day 1) in the Patient Assessment of Upper Gastrointestinal Disorders-Symptom Severity (PAGI-SYM) Subscale Scores at Day 14 and Day 28|Change Form Baseline (Day 1) in the Gastric Emptying Breath Test (GEBT) Excretion Rate at Day 14 and Day 28|Number of Participants With Adverse Events (AEs)","PTC Therapeutics","Female","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","21","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GAS-001","February 27, 2019","September 8, 2019","October 8, 2019","October 19, 2018","January 5, 2022","January 5, 2022","GW Research, Inc., Chula Vista, California, United States|LMG Research, Miami, Florida, United States|Indiana University Hospital, Indianapolis, Indiana, United States|University of Louisville, Louisville, Kentucky, United States|Johns Hopkins University, Baltimore, Maryland, United States|Clinical Research Solutions, LLC, Jackson, Tennessee, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/24/NCT03712124/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/24/NCT03712124/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03712124"
490,"NCT03196284","A Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With Inhibitors","explorer™4","Completed","Has Results","Congenital Bleeding Disorder|Haemophilia A With Inhibitors|Haemophilia B With Inhibitors","Drug: Concizumab|Drug: Eptacog alfa","The Number of Bleeding Episodes|The Number of Spontaneous Bleeding Episodes|Number of Treatment-emergent Adverse Events (TEAEs) During at Least 24 Weeks From Treatment Onset|Number of Treatment-emergent Adverse Events (TEAEs) During at Least 76 Weeks From Treatment Onset|Number of Treatment-emergent Adverse Events (TEAEs) Within 24 Hours After Eptacog Alfa Administration|Occurrence of Anti-concizumab Antibodies During at Least 24 Weeks From Treatment Onset|Occurrence of Anti-concizumab Antibodies During at Least 76 Weeks From Treatment Onset|Change in Fibrinogen|Change in D-dimer|Change in Prothrombin Fragment 1 + 2 (F1 + 2)|Change in Prothrombin Time (PT)|Change in Activated Partial Thromboplastin Time (APTT)|Change in Anti-thrombin (AT)|Concentration of Concizumab|Free Tissue Factor Pathway Inhibitor (TFPI) Concentration Value|Peak Thrombin Generation|Endogenous Thrombin Potential|Thrombin Generation Velocity Index","Novo Nordisk A/S","Male","18 Years and older   (Adult, Older Adult)","Phase 2","26","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NN7415-4310|U1111-1179-2925|2016-000510-30|JapicCTI-173681","August 10, 2017","September 19, 2018","January 31, 2020","June 22, 2017","October 22, 2021","October 22, 2021","Novo Nordisk Investigational Site, Los Angeles, California, United States|Novo Nordisk Investigational Site, Indianapolis, Indiana, United States|Novo Nordisk Investigational Site, Iowa City, Iowa, United States|Novo Nordisk Investigational Site, Wien, Austria|Novo Nordisk Investigational Site, Toronto, Ontario, Canada|Novo Nordisk Investigational Site, Zagreb, Croatia|Novo Nordisk Investigational Site, Århus N, Denmark|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Tel-Hashomer, Israel|Novo Nordisk Investigational Site, Firenze, Italy|Novo Nordisk Investigational Site, Milano, Italy|Novo Nordisk Investigational Site, Aichi, Japan|Novo Nordisk Investigational Site, Nara, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Georgetown, Penang, Malaysia|Novo Nordisk Investigational Site, Kota Kinabalu, Malaysia|Novo Nordisk Investigational Site, Madrid, Spain|Novo Nordisk Investigational Site, Sevilla, Spain|Novo Nordisk Investigational Site, Solna, Sweden|Novo Nordisk Investigational Site, Lviv, Ukraine|Novo Nordisk Investigational Site, London, United Kingdom|Novo Nordisk Investigational Site, Sheffield, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/84/NCT03196284/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/84/NCT03196284/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03196284"
491,"NCT03519711","A Study of CNSA-001 in Primary Tetrahydrobiopterin (BH4) Deficient Participants With Hyperphenylalaninemia",,"Completed","No Results Available","BH4 Deficiency|Hyperphenylalaninemia","Drug: CNSA-001","Number of Participants With Treatment-Emergent Adverse Events|Maximum Observed Plasma Concentration (Cmax) of Both CNSA-001 and BH4|Change From Baseline (Day 1) in Plasma phenylalanine Concentration at Day 7|Area Under the Plasma Concentration Versus Time Curve (AUC) of Both CNSA-001 and BH4|Time to Reach Cmax (Tmax) of Both CNSA-001 and BH4|Half-Life (t1/2) of Both CNSA-001 and BH4|Elimination Rate Constant (Ke) of Both CNSA-001 and BH4","PTC Therapeutics","All","12 Months and older   (Child, Adult, Older Adult)","Phase 1|Phase 2","6","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PBD-001","June 24, 2018","January 9, 2021","January 9, 2021","May 9, 2018",,"November 10, 2021","University of Minnesota, Minneapolis, Minnesota, United States|UT Southwestern, Dallas, Texas, United States|University of Utah Hospital, Salt Lake City, Utah, United States|Marshfield Clinic, Marshfield, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT03519711"
492,"NCT02314481","Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity","DARWINII","Recruiting","No Results Available","Non-small Cell Lung Cancer","Drug: MPDL3280A|Drug: Vemurafenib|Drug: Alectinib|Drug: Trastuzumab emtansine","Progression free survival (PFS)|Objective response rate|Overall survival|ProgressionT|Duration of response|Toxicity - Dose reductions, interruptions, modifications and exposure|Exploratory assessments","University College, London|Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 2","119","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14/0274","May 12, 2017","November 2024","November 2025","December 11, 2014",,"June 11, 2020","Univeristy College London Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02314481"
493,"NCT02541942","Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in the Adept™2 Trial",,"Completed","Has Results","Congenital Bleeding Disorder|Haemophilia A With Inhibitors|Haemophilia B With Inhibitors","Other: No treatment given","Determination of HLA Type|Determination of Polymorphisms in the FVII Gene","Novo Nordisk A/S","Male","12 Years and older   (Child, Adult, Older Adult)","Phase 2","19","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","NN1731-4214|2015-001919-13|U1111-1169-6103","April 3, 2015","April 15, 2016","April 15, 2016","September 4, 2015","January 4, 2019","January 4, 2019","Novo Nordisk Investigational Site, Tucson, Arizona, United States|Novo Nordisk Investigational Site, Tampa, Florida, United States|Novo Nordisk Investigational Site, Atlanta, Georgia, United States|Novo Nordisk Investigational Site, Iowa City, Iowa, United States|Novo Nordisk Investigational Site, Boston, Massachusetts, United States|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Thessaloniki, Greece|Novo Nordisk Investigational Site, Kashihara-shi, Nara, Japan|Novo Nordisk Investigational Site, Shinjuku-ku, Tokyo, Japan|Novo Nordisk Investigational Site, Suginami-ku, Tokyo, Japan|Novo Nordisk Investigational Site, Kuala Lumpur, Malaysia|Novo Nordisk Investigational Site, Timisoara, Timis, Romania|Novo Nordisk Investigational Site, Belgrade, Serbia|Novo Nordisk Investigational Site, Novi Sad, Serbia|Novo Nordisk Investigational Site, Bangkok, Thailand",,"https://ClinicalTrials.gov/show/NCT02541942"
494,"NCT04087954","Evaluation the Impact of Self-Stigma Reduction Program on Psychosocial Outcomes Among People Diagnosed With Schizophrenia",,"Completed","No Results Available","Stigmatization","Behavioral: Stigma reduction program","The primary outcome was stigma perception measured by the Internalised Stigma of Mental Illness Scale (ISMI)|Positive and Negative Symptom Scale (PANSS)|The Psychosocial Treatment Compliance Scale (PTCS)|The Chinese General Self-efficacy Scale (CGSS)","Fakeeh College for Medical Sciences","All","18 Years and older   (Adult, Older Adult)","Not Applicable","278","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Health Services Research","5115","November 1, 2017","December 22, 2018","December 22, 2018","September 12, 2019",,"September 12, 2019","Ministry of Health, Amman, Jordan",,"https://ClinicalTrials.gov/show/NCT04087954"
495,"NCT02592941","Deflazacort Expanded Access Program for Children, Adolescents and Adults With Duchenne Muscular Dystrophy",,"Approved for marketing","No Results Available","Duchenne Muscular Dystrophy","Drug: Deflazacort",,"PTC Therapeutics|Parexel|Dohmen Life Science Services","All","5 Years and older   (Child, Adult, Older Adult)",,,"Industry|Other","Expanded Access",,"MP-104-CL-037",,,,"October 30, 2015",,"February 28, 2018","Phoenix Children's Hospital, Phoenix, Arizona, United States|Arkansas Children's Hospital, Little Rock, Arkansas, United States|UCLA Health, Los Angeles, California, United States|Childrens Hospital of Orange County, Orange, California, United States|UC Davis Medical Center, Sacramento, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Children's National Medical Center, Washington, District of Columbia, United States|University of Florida Clinical Research Center, Gainesville, Florida, United States|Nicklaus Children's Hospital, Miami, Florida, United States|Shriner's Hospital for Children - Tampa, Tampa, Florida, United States|Children's Healthcare of Atlanta- Scottish Rite, Atlanta, Georgia, United States|Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Shriner's Hospital for Children - Chicago, Chicago, Illinois, United States|Carle Foundation Hospital, Urbana, Illinois, United States|Riley Hospital for Children at IU Health, Indianapolis, Indiana, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Kennedy Krieger Institute, Baltimore, Maryland, United States|Boston Children's Hospital, Boston, Massachusetts, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|Wayne State University- Children's Hospital of Michigan, Detroit, Michigan, United States|Helen DeVos Children's Hospital Neurology Clinic, Grand Rapids, Michigan, United States|Gillette Children's Specialty Healthcare, Saint Paul, Minnesota, United States|Las Vegas Clinic, Las Vegas, Nevada, United States|Neurosciences Institute, Neurology-Charlotte, Charlotte, North Carolina, United States|Wake Forest School of Medicine, Winston-Salem, North Carolina, United States|Oregon Health & Science University, Portland, Oregon, United States|Shriner's Hospital for Children, Portland, Oregon, United States|Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|Greenville Health System, Greenville, South Carolina, United States|Wesley Neurology Clinic, Cordova, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Children's Medical Center, Dallas, Texas, United States|Cook Children's Medical Center, Fort Worth, Texas, United States|Texas Children's Hospital, Houston, Texas, United States|University of Texas Health Science Center - San Antonio, San Antonio, Texas, United States|University of Virginia Children's Hospital, Charlottesville, Virginia, United States|Children's Specialty Group, Norfolk, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Seattle Children's Hospital, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02592941"
496,"NCT04638907","Fine Tuning of Neuro-muscular Blockade in Robot-assisted Prostatectomy","NMBUro","Completed","No Results Available","Maintenance of Deep NM Block Without Overdosing","Procedure: Assessment of NM block","Successful deep NM block|Surgeon's satisfaction","Peter Biro|University of Zurich","Male","18 Years to 90 Years   (Adult, Older Adult)",,"20","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","BASEC ID 2016-01781","January 15, 2017","July 15, 2019","December 15, 2019","November 20, 2020",,"November 20, 2020","University Hospital Zurich, Institue of Anesthesiology, Zurich, ZH, Switzerland",,"https://ClinicalTrials.gov/show/NCT04638907"
497,"NCT02485431","Food Effect and Bioavailability of Deflazacort Formulations in Healthy Volunteers",,"Completed","No Results Available","Healthy Volunteers","Drug: Deflazacort","Pharmacokinetic profile|Treatment emergent AEs and SAEs|Changes from baseline values for lab|Changes from baseline values for ECG|Changes from baseline values for physical exam|Changes from baseline values for vital signs","PTC Therapeutics|ICON Development Solutions","All","18 Years to 55 Years   (Adult)","Phase 1","45","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","MP-104-CL-026","June 2015","August 2015","August 2015","June 30, 2015",,"August 18, 2017","ICON Early Phase Services, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02485431"
498,"NCT02462603","Safety and Biomarker Study of EPI-589 in Parkinson's Disease",,"Completed","No Results Available","Parkinson's Disease","Drug: EPI-589","Safety as assessed by drug-related adverse events (AEs)|Biomarker assessments as measured in cerebrospinal fluid, blood, and urine|Clinical Disease State as assessed by the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS)|Disease morbidity as assessed by composites scales including Non-motor Symptoms Scale (NMSS), The Parkinson's Disease Questionnaire (PDQ-39) and EuroQol Group 5 Dimensions (EQ-5D)|Cognitive function as assessed by composite scales including Montreal Cognitive Assessment (MoCA) and Dementia Rating Scale-2 (DRS-2) scales|Mood as assessed by composite scales including the Beck Depression Inventory (BDI) and Montgomery Asberg Depression Rating (MADRS) scales|To evaluate changes in maximum serum concentration (Cmax) for all treated subjects pre and 3 months post treatment with EPI-589|Safety as evidenced by development of drug related adverse events after treament with EPI-589","PTC Therapeutics","All","21 Years to 75 Years   (Adult, Older Adult)","Phase 2","44","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EPI589-15-002","March 31, 2016","April 16, 2019","April 16, 2019","June 4, 2015",,"May 21, 2020","Cedar's Sinai, Los Angeles, California, United States|University of California, San Francisco, San Francisco, California, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|DZNE Site, Tuebingen, Germany|University College of London,Dept. of Clinical Neuroscience, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02462603"
499,"NCT00969969","A Study to Evaluate the Effectiveness and Safety of an Implant in the Treatment of Osteoarthritis of the Great Toe",,"Completed","No Results Available","Osteoarthritis of First Metatarsalphalangeal Joint","Device: Arthrodesis|Device: Cartiva","VAS, FAAM, Safety","Cartiva, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","236","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PTC-0031","August 2009","July 2016","July 2016","September 2, 2009",,"November 15, 2016","University of Calgary, Calgary, Alberta, Canada|University of Alberta, Edmonton, Alberta, Canada|St. Paul's Hospital, Vancouver, British Columbia, Canada|Horizon Health Network, Fredericton, New Brunswick, Canada|Queen Elizabeth Science Centre, Halifax, Nova Scotia, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Frimley Park Hospital - Surrey Foot and Ankle Clinic, Frimley, Camberley, United Kingdom|St. George's Hospital, Tooting, London, United Kingdom|Royal National Orthopaedic Hospital - Stanmore Foot & Ankle Clinic, Stanmore, Middlesex, United Kingdom|Northern General Hospital NHS Trusts - Sheffield Orthopaedics, Sheffield, South Yorkshire, United Kingdom|Royal Surrey County Hospital, Guildford, Surrey, United Kingdom|Torbay Hospital, South Devon, Torquay, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00969969"
500,"NCT02352896","Long-Term Safety and Efficacy Evaluation of EPI-743 in Children With Leigh Syndrome",,"Active, not recruiting","No Results Available","Leigh Syndrome","Drug: EPI-743","Disease Severity as Measured by Newcastle Pediatric Mitochondrial Disease Scale (NPMDS) Sections 1-3 Score|Number of Participants With Dose-Limiting Serious Adverse Events (SAEs)|Bayley Scales of Infant Development-III Score (Participants Age 0-3)|Wechsler Scale of Intelligence and Movement Assessment Battery Score for Children (Participants Age 4-18)|Barry-Albright Dystonia Scale Score|Gross Motor Function Measure|Awake Oxygen Saturation Levels|Total Ventilator Days and Total Intensive Care Unit Days|Number of Participants With Pneumonia Episodes and Tracheostomy|Total Number of Mortalities, Medical Encounters, Hospitalizations, and Hospital Days|Health-Related Quality of Life as Measured by NPMDS Section 4 Score|Glutathione Cycle Biomarkers Level","PTC Therapeutics","All","1 Year to 18 Years   (Child, Adult)","Phase 2","30","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EPI743-13-023","January 31, 2014","December 31, 2021","December 31, 2021","February 2, 2015",,"January 3, 2022","Gregory Enns, Stanford University, California, United States|Akron Children's Hospital, Akron, Ohio, United States|Baylor College of Medicine, Houston, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02352896"
501,"NCT00911417","A Study to Collect Intravascular Ultrasound Images Before and After Treatment With the Jetstream System",,"Completed","No Results Available","Peripheral Arterial Disease|Peripheral Vascular Disease","Device: Pathway Jetstream Atherectomy System","Plaque Morphology","Pathway Medical Technologies Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 4","40","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PTC09030","June 2009","July 2011","August 2011","June 1, 2009",,"September 5, 2011","Arizona Heart Institute, Phoenix, Arizona, United States|St. Luke's Hospital, Phoenix, Arizona, United States|St. John's Hospital, Springfield, Illinois, United States|St. John Hospital & Medical Ctr., Detroit, Michigan, United States|Mount Sinai Medical Center, New York City, New York, United States",,"https://ClinicalTrials.gov/show/NCT00911417"
502,"NCT02295748","An Open-Label, Long-Term Extension Study to Evaluate the Safety and Tolerability Deflazacort",,"Completed","No Results Available","Duchenne Muscular Dystrophy","Drug: Deflazacort","Number, frequency, and severity of adverse events","PTC Therapeutics","Male","4 Years and older   (Child, Adult, Older Adult)","Phase 1","24","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MP-104-CL-022OLE","December 2014","August 24, 2017","August 24, 2017","November 20, 2014",,"December 8, 2017","UCLA, Los Angeles, California, United States|Lurie Children's Hospital, Chicago, Illinois, United States|University of Rochester, Rochester, New York, United States|University of Utah, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT02295748"
503,"NCT02286635","Evaluate Effects of Multiple Doses of Rifampin and Clarithromycin on the Single Dose Pharmacokinetics of Deflazacort",,"Completed","No Results Available","Healthy Volunteers","Drug: Deflazacort and rifampin|Drug: Deflazacort and Clarithromycin","Effects of CYP3A4 inhibitors and inducers on the pharmacokinetics (PK) of deflazacort in healthy subjects including the area under the plasma concentration time curve, from time 0 to the last measurable non-zero concentration.|Safety and tolerability of one dose of deflazacort in healthy subjects receiving CYP3A4 inhibitors and inducers as measured by capturing occurrence of adverse events.","PTC Therapeutics","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","58","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MP-104-CL-025","November 2014","December 2014","December 2014","November 10, 2014",,"August 18, 2017","Celerion, Tempe, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT02286635"
504,"NCT02286622","A Single Dose Evaluation of the Effects of Renal Impairment on Deflazacort Pharmacokinetics",,"Completed","No Results Available","Renal Impairment","Drug: Deflazacort","Renal impairment on the pharmacokinetics (PK) of deflazacort in subjects with end-stage renal disease including the area under the plasma concentration time curve, from time 0 to the last measurable non-zero concentration.|Safety and tolerability of one dose of deflazacort in subjects with end stage renal disease as measured by capturing occurrence of adverse events.","PTC Therapeutics","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","16","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","MP-104-CL-024","December 2014","February 2015","February 2015","November 10, 2014",,"August 18, 2017","University of Miami Division of Clinical Pharmacology, Miami, Florida, United States|Orlando Clinical Research Center, Orlando, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02286622"
505,"NCT02286609","A Single Dose Evaluation of the Effects of Moderate Hepatic Impairment on Deflazacort Pharmacokinetics",,"Completed","No Results Available","Hepatic Impairment","Drug: Deflazacort","Hepatic impairment on the pharmacokinetics (PK) of deflazacort in subjects with moderate hepatic impairment including the area under the plasma concentration time curve, from time 0 to the last measurable non-zero concentration.|Safety and tolerability of one dose of deflazacort in subjects with hepatic impairment as measured by capturing occurrence of adverse events.","PTC Therapeutics","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","16","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","MP-104-CL-023","December 2014","February 2015","February 2015","November 10, 2014",,"August 18, 2017","University of Miami Division of Clinical Pharmacology, Miami, Florida, United States|Orlando Clinical Research Center, Orlando, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02286609"
506,"NCT02251600","A Pharmacokinetic Study of Oral Deflazacort in Children and Adolescent Subjects With Duchenne Muscular Dystrophy",,"Completed","No Results Available","Duchenne Muscular Dystrophy","Drug: Deflazacort","The area under the plasma concentration time curve, from time 0 to the last measurable concentration non-zero, for single-state pharmacokinetics on Day 1 of deflazacort and 21-desacetyl-DFZ, the active metabolite|The area under the plasma concentration versus time curve over the final dosing interval for steady state pharmacokinetics on Day 8 of deflazacort and 21-desacetyl-DFZ, the active metabolite|Number of participants with adverse events as a measure of safety and tolerability","PTC Therapeutics","Male","4 Years to 16 Years   (Child)","Phase 1","24","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","MP-104-CL-005","December 2014","October 2015","October 2015","September 29, 2014",,"August 18, 2017","UCLA, Los Angeles, California, United States|Lurie Children's Hospital, Chicago, Illinois, United States|University of Rochester Medical Center, Rochester, New York, United States|University of Utah, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT02251600"
507,"NCT04473196","The Effect of Weight Bearing on Patient Outcomes Following 1st MTP Joint Fusion",,"Not yet recruiting","No Results Available","Hallux Valgus|Hallux Rigidus","Other: weightbearing","Foot and Ankle Ability Measure (FAAM)|Visual analogue scale(VAS)|Radiographic healing","Nova Scotia Health Authority","All","18 Years and older   (Adult, Older Adult)","Not Applicable","92","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Basic Science","PTC 2020-01","September 30, 2020","August 31, 2023","August 31, 2023","July 16, 2020",,"July 16, 2020",,,"https://ClinicalTrials.gov/show/NCT04473196"
508,"NCT01830712","A Long-term Assessment of Physical Activity, Range of Motion, and Functional Status Following Elective Orthopedic Surgery in Hemophilia Patients With Inhibitors",,"Completed","No Results Available","Congenital Bleeding Disorder|Haemophilia A With Inhibitors|Haemophilia B With Inhibitors","Drug: eptacog alfa (activated)","Long-term changes in general mobility/ambulation/activity|Long-term changes in work/school attendance|Long-term changes in employment status|Long-term changes in body mass index (BMI)|Long-term changes in complications related to surgical procedure and/or prostheses|Overall frequency of bleeding episodes|Number of joint infections|Number of treatment types (on demand, prophylaxis)","Novo Nordisk A/S",,"Child, Adult, Older Adult",,"15","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","F7HAEM-3864|U1111-1114-9206","April 2011","August 2011","August 2011","April 12, 2013",,"April 15, 2014","Novo Nordisk Clinical Trial Call Center, Princeton, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT01830712"
509,"NCT02057250","To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis","SARIL-RA-EASY","Completed","Has Results","RA","Drug: Sarilumab|Device: Auto-Injector Device (AID)|Device: Pre-filled Syringe (PFS)|Drug: Methotrexate|Drug: Sulfasalazine|Drug: Leflunomide|Drug: Hydroxychloroquine","Number of Validated AID Associated Product Technical Failures (PTFs)|Area Under the Serum Concentration Versus Time Curve Calculated Using the Trapezoidal Method During a Dose Interval (AUC[0-tau]) for Sarilumab","Sanofi|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","217","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSC12665|2012-004339-21|U1111-1130-9931","March 2014","February 2015","March 2016","February 7, 2014","June 20, 2017","June 20, 2017","Investigational Site Number 840152, Huntsville, Alabama, United States|Investigational Site Number 840221, Peoria, Arizona, United States|Investigational Site Number 840226, Roseville, California, United States|Investigational Site Number 840223, Boulder, Colorado, United States|Investigational Site Number 840229, Miami, Florida, United States|Investigational Site Number 840236, Orlando, Florida, United States|Investigational Site Number 840155, Palm Harbor, Florida, United States|Investigational Site Number 840220, South Miami, Florida, United States|Investigational Site Number 840202, Hagerstown, Maryland, United States|Investigational Site Number 840232, Flint, Michigan, United States|Investigational Site Number 840233, Kalamazoo, Michigan, United States|Investigational Site Number 840037, Tupelo, Mississippi, United States|Investigational Site Number 840112, Lincoln, Nebraska, United States|Investigational Site Number 840039, Albany, New York, United States|Investigational Site Number 840224, Cincinnati, Ohio, United States|Investigational Site Number 840002, Oklahoma City, Oklahoma, United States|Investigational Site Number 840065, Tulsa, Oklahoma, United States|Investigational Site Number 840009, Duncansville, Pennsylvania, United States|Investigational Site Number 840062, Reading, Pennsylvania, United States|Investigational Site Number 840016, North Charleston, South Carolina, United States|Investigational Site Number 840025, Jackson, Tennessee, United States|Investigational Site Number 840038, Austin, Texas, United States|Investigational Site Number 840230, Carrollton, Texas, United States|Investigational Site Number 840001, Dallas, Texas, United States|Investigational Site Number 840020, Houston, Texas, United States|Investigational Site Number 840239, Houston, Texas, United States|Investigational Site Number 840241, Houston, Texas, United States|Investigational Site Number 840242, Houston, Texas, United States|Investigational Site Number 840069, Lubbock, Texas, United States|Investigational Site Number 840074, Mesquite, Texas, United States|Investigational Site Number 840237, Plano, Texas, United States|Investigational Site Number 152005, Osorno, Chile|Investigational Site Number 152050, Santiago, Chile|Investigational Site Number 152014, Talca, Chile|Investigational Site Number 152007, Viña Del Mar, Chile|Investigational Site Number 484002, Guadalajara, Mexico|Investigational Site Number 484004, Merida, Mexico|Investigational Site Number 484005, Monterrey, Mexico|Investigational Site Number 616002, Bialystok, Poland|Investigational Site Number 616005, Lublin, Poland|Investigational Site Number 616004, Warszawa, Poland|Investigational Site Number 616017, Warszawa, Poland|Investigational Site Number 616012, Wroclaw, Poland|Investigational Site Number 643006, Kemerovo, Russian Federation|Investigational Site Number 643020, Moscow, Russian Federation|Investigational Site Number 643001, Moscow, Russian Federation|Investigational Site Number 643008, Saint-Petersburg, Russian Federation|Investigational Site Number 710050, Bellville, South Africa|Investigational Site Number 710011, Cape Town, South Africa|Investigational Site Number 710007, Cape Town, South Africa|Investigational Site Number 710003, Durban, South Africa|Investigational Site Number 710001, Johannesburg, South Africa|Investigational Site Number 710051, Port Elizabeth, South Africa",,"https://ClinicalTrials.gov/show/NCT02057250"
510,"NCT04886479","Comparing Silicone Hydrogel Contact Lens Wearers to Hydrogel Contact Lens Wearers and Non-lens Wearers",,"Active, not recruiting","No Results Available","Myopia","Device: Daily Disposable Silicone Hydrogel Contact Lens|Device: Daily Disposable Hydrogel Contact Lens|Other: Non Lens Wearers","Limbal Redness|Bulbar Redness|Corneal vessel ingrowth|Number of Corneal vessel ingrowth","Coopervision, Inc.","All","17 Years to 60 Years   (Child, Adult)","Not Applicable","78","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EX-MKTG-89","May 30, 2021","January 31, 2022","March 30, 2022","May 14, 2021",,"November 2, 2021","Eurolens Research, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04886479"
511,"NCT01586936","Non-Interventional Study of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With Inhibitors",,"Completed","No Results Available","Congenital Bleeding Disorder|Haemophilia A With Inhibitors|Haemophilia B With Inhibitors","Drug: eptacog alfa (activated)","Antibody production against eptacog alpha","Novo Nordisk A/S","All","Child, Adult, Older Adult",,"9","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","F7-1949","March 10, 1999","March 9, 2010","March 9, 2010","April 27, 2012",,"February 27, 2017","Novo Nordisk Investigational Site, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT01586936"
512,"NCT01579968","Non-Interventional Study of NovoSeven® Used in Patients With Haemophilia A and B With Inhibitors When Undergoing Surgery",,"Completed","No Results Available","Congenital Bleeding Disorder|Haemophilia A With Inhibitors|Haemophilia B With Inhibitors","Drug: eptacog alfa (activated)","Physician's assessment of the evaluation for efficacy: Amount of blood at surgery, condition of haemostasis after surgery or maintenance of cessation of bleed|Number of adverse events (AEs), including serious adverse events (SAEs)","Novo Nordisk A/S","All","Child, Adult, Older Adult",,"86","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","F7-1948","March 10, 1999","March 9, 2010","March 9, 2010","April 18, 2012",,"February 24, 2017","Novo Nordisk Investigational Site, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT01579968"
513,"NCT01579955","Non-Interventional Study of NovoSeven® Used in Patients With Haemophilia A and B With Inhibitors Under Normal Clinical Practice",,"Completed","No Results Available","Congenital Bleeding Disorder|Haemophilia A With Inhibitors|Haemophilia B With Inhibitors","Drug: eptacog alfa (activated)","Percentage of bleed treatments resulting in effective bleed resolution: Markedly effective, effective, moderate or ineffective|Number of adverse events (AEs), including serious adverse events (SAEs)","Novo Nordisk A/S","All","Child, Adult, Older Adult",,"321","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","F7-1947","March 10, 1999","March 9, 2010","March 9, 2010","April 18, 2012",,"February 24, 2017","Novo Nordisk Investigational Site, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT01579955"
514,"NCT01561924","Prediction of the Efficacy of Activated Recombinant Human Factor VII in Adult Congenital Haemophilia A or B Patients With Inhibitors by Use of Thromboelastography",,"Completed","No Results Available","Congenital Bleeding Disorder|Haemophilia A With Inhibitors|Haemophilia B With Inhibitors","Drug: eptacog alfa (activated)","TEG parameters obtained at baseline and with activated recombinant human factor VII|ROTEM parameters obtained at baseline and with activated recombinant human factor VII","Novo Nordisk A/S","Male","16 Years and older   (Child, Adult, Older Adult)","Phase 1","17","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","F7HAEM-1675","November 2005","May 2006","May 2006","March 23, 2012",,"November 23, 2016","Novo Nordisk Investigational Site, Berkeley, California, United States|Novo Nordisk Investigational Site, Los Angeles, California, United States|Novo Nordisk Investigational Site, Iowa City, Iowa, United States|Novo Nordisk Investigational Site, Philadelphia, Pennsylvania, United States|Novo Nordisk Investigational Site, Århus N, Denmark|Novo Nordisk Investigational Site, Lyon, France|Novo Nordisk Investigational Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01561924"
515,"NCT04421235","Expanding Knowledge About and Evaluating Services for Incarcerated Pregnant and Postpartum Women in Arkansas",,"Enrolling by invitation","No Results Available","Health Problems in Pregnancy|Childbirth Problems|Maternal Care Patterns|Quality of Life|Emotional Stress|Health Care Acceptability|Health Risk Behaviors|Parent-Child Relations","Behavioral: Childbirth support","Program Utilization|Program Acceptability|Depressive Symptoms|PTSD Symptoms|Drug Use|Health-Related Quality of Life|Social Support|Parental Stress|Parental Sense of Competence|Pregnancy Complications|Childbirth Complications","University of Arkansas","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","500","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","260265|PTC2020-02","November 19, 2021","December 31, 2022","December 31, 2022","June 9, 2020",,"December 8, 2021","University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States",,"https://ClinicalTrials.gov/show/NCT04421235"
516,"NCT02949206","A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of JNJ-64179375 in Healthy Male Subjects",,"Completed","No Results Available","Healthy","Drug: JNJ-64179375|Drug: Placebo|Drug: 4 Factor Prothrombin Complex Concentrate (PCC)","Part 1: Number of Participants With Adverse Events (AE) as a Measure of Safety and Tolerability|Part 3: Number of Participants With Adverse Events (AE) as a Measure of Safety and Tolerability|Part 2: Change From Baseline in Potential for Reversibility of the JNJ-64179375 Induced Pharmacodynamic Effects on Coagulation Parameters|Part 2: Change From Baseline in Potential for Reversibility of the JNJ-64179375 Induced Pharmacodynamic Effects on Platelet Function|Part 1 and 3: Maximum Observed Plasma Concentration (Cmax) of JNJ-64179375|Part 1 and 3: Area Under the Plasma Concentration-Time Curve From Time Zero to Time of the Last Quantifiable Concentration (AUClast) of JNJ-64179375|Part 1 and 3: Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC [0-infinity]) of JNJ-64179375|Part 1 and 3: Terminal Half-Life (t1/2) of JNJ-64179375|Part 1: Total Systemic Clearance (CL) of JNJ-64179375|Part 1: Apparent Volume of Distribution at Terminal Phase After Intravenous Administration (Vz) of JNJ-64179375|Part 3: Time to Reach Maximum Observed Concentration (Tmax) of JNJ-64179375|Part 3: Total Systemic Clearance Over Bioavailability After Subcutaneous (SC) Administration (CL/F) of JNJ-64179375|Part 3: Apparent Volume of Distribution at Terminal Phase Over Bioavailability After Subcutaneous Administration (Vz/F) of JNJ-64179375|Part 3: Absolute Bioavailability (F) After Subcutaneous Administration of JNJ-64179375|Part 1 and 3: Immunogenicity of JNJ-64179375|Part 2: Maximum Observed Plasma Concentration (Cmax) of JNJ-64179375 in presence of 4-factor prothrombin complex concentrate (PCC)|Part 2: Area Under the Plasma ConcentrationTime Curve From Time Zero to Time of the Last Quantifiable Concentration (AUC [0-last]) of JNJ-64179375 in the presence of 4-factor PCC|Part 2: Area Under the Plasma ConcentrationTime Curve From Time Zero to Infinite Time (AUC [0-infinity]) of JNJ-64179375 in the presence of 4-factor PCC|Part 2: Terminal Half Life [t(1/2)] of JNJ-64179375 in the presence of 4-factor PCC|Part 2: Total Systemic Clearance (CL) of JNJ-64179375 in the presence of 4-factor PCC|Part 2: Apparent Volume of Distribution at Terminal Phase After Intravenous Administration (Vz) of JNJ-64179375 in the presence of 4-factor PCC|Part 2: Immunogenicity of JNJ-64179375 in the presence of 4-factor PCC|Part 2: Number of Participants With Adverse Events (AE) as a Measure of Safety and Tolerability|Part 1 and 3: Pharmacodynamic Effect of JNJ-64179375 on Platelet Function|Part 1 and 3: Pharmacodynamic Effect of JNJ-64179375 on Coagulation Parameters","Janssen Research & Development, LLC","Male","18 Years to 45 Years   (Adult)","Phase 1","80","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CR108238|64179375EDI1001|2016-003006-13","November 14, 2016","August 9, 2017","August 9, 2017","October 31, 2016",,"September 25, 2017","Merksem, Belgium",,"https://ClinicalTrials.gov/show/NCT02949206"
517,"NCT01728064","Safety and Efficacy of EPI-743 in Patients With Friedreich's Ataxia",,"Completed","No Results Available","Friedreich's Ataxia","Drug: Placebo|Drug: EPI-743 400 mg|Drug: EPI-743 200 mg","Visual Function|Color vision|Neurologic function|Neuromuscular function|Quality of life|Disease biomarkers|Cardiac function|Safety|Disease improvement","PTC Therapeutics","All","18 Years to 45 Years   (Adult)","Phase 2","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EPI2010-006","December 31, 2012","October 31, 2015","February 29, 2016","November 16, 2012",,"August 31, 2020","University of California Los Angeles, Los Angeles, California, United States|University of South Florida, Tampa, Florida, United States|Childrens Hospital of Philadelphia, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01728064"
518,"NCT00676494","The Pathway PVD Study for Percutaneous Peripheral Vascular Interventions",,"Completed","Has Results","Peripheral Artery Disease","Device: Pathway PV Atherectomy System","Major Adverse Events (MAEs) Within 30 Days|Average Rutherford Classification Score at 6 Months|Average Ankle Brachial Index (ABI) at 6 Months|Freedom From Target Lesion Revascularization (TLR) at 6 Months","Pathway Medical Technologies Inc.","All","18 Years and older   (Adult, Older Adult)","Not Applicable","172","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PTC 05003","February 2006","July 2007","February 2008","May 13, 2008","July 9, 2009","July 9, 2009",,,"https://ClinicalTrials.gov/show/NCT00676494"
519,"NCT01721733","Safety and Efficacy Study of EPI-743 in Children With Leigh Syndrome",,"Completed","No Results Available","Leigh Syndrome","Drug: Placebo|Drug: EPI-743 15 mg/kg|Drug: EPI-743 5 mg/kg","Newcastle Pediatric Mitochondrial Disease Scale (NPMDS) Sections 1-3|Neuromuscular function|Respiratory function|Disease morbidity|Glutathione cycle biomarkers|Number of dose limiting serious adverse events|Mortality","PTC Therapeutics|Axio Research. LLC","All","6 Years to 17 Years   (Child)","Phase 2","35","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EPI743-12-002","October 31, 2012","February 28, 2015","May 31, 2015","November 6, 2012",,"August 31, 2020","Stanford University, Palo Alto, California, United States|Akron Children's Hospital, Akron, Ohio, United States|Baylor College of Medicine, Houston, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01721733"
520,"NCT03639831","ACUTE AND CHRONIC EFFECTS OF A BOTANICAL EXTRACT ON ANXIETY, PERCEIVED STRESS, MOOD AND CORTISOL IN HEALTHY ADULTS",,"Completed","No Results Available","Mood Disorders","Dietary Supplement: Proprietary, standardized botanical extract|Dietary Supplement: Placebo (maltodextrin)","Mood state|POMS-2 subscores|Anxiety state State-Trait Anxiety Inventory|Anxiety state according to the Hospital Anxiety and Depression Scale|Percentage of responders|Psychological stress|Worry feeling|Coping response to stress|Depressive-like state|Quality of life score|Cognitive performances|Diurnal cortisol secretion|Diurnal cortisol metabolism|Biological response to an acute stressor|Psychological response to an acute stressor assessed through the STAI|Psychological response to an acute stressor assessed on a Visual Analogical Scale|Hemodynamic response to an acute stressor|Galvanic Skin Response to the acute stressor","Activ'inside|Northumbria University","All","18 Years to 60 Years   (Adult)","Not Applicable","65","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","PTC198-2017","November 6, 2017","November 15, 2018","March 31, 2019","August 21, 2018",,"April 10, 2019","Brain, Performance and Nutrition Research Centre, Northumbria University, Newcastle upon Tyne, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03639831"
521,"NCT04421924","Periinterventional Coagulation Management of Patients Undergoing a TIPS","TIPSprosp","Recruiting","No Results Available","Liver Cirrhosis","Procedure: thrombelastogram|Procedure: standard of care","blood product requirement|Bleeding|complications|Mortality|Modified TIPS Score (MOTS)|Factor XIII","Medical University of Graz","All","18 Years and older   (Adult, Older Adult)","Not Applicable","39","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","TIPS-prospective","May 27, 2020","May 2024","May 2025","June 9, 2020",,"September 23, 2021","Department of Internal Medicine, Medical University of Graz, Graz, Austria",,"https://ClinicalTrials.gov/show/NCT04421924"
522,"NCT01370447","EPI-743 for Mitochondrial Respiratory Chain Diseases",,"Active, not recruiting","No Results Available","Mitochondrial Diseases","Drug: EPI-743","Number of Participants Experiencing Adverse Events|Change From Baseline in Neurological Function, as Determined by Standard Neurological Examination at Week 13|Change From Baseline in Newcastle Pediatric Mitochondrial Disease Score (NPMDS) at Week 13","PTC Therapeutics","All","1 Year and older   (Child, Adult, Older Adult)","Phase 2","94","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EPI-2009-1","February 28, 2010","December 31, 2021","December 31, 2021","June 10, 2011",,"January 3, 2022","UCLA, Los Angeles, California, United States|CHOC Children's Clinic, Orange, California, United States|Lucille Packard Children's Hospital, Palo Alto, California, United States|UCSD, San Diego, California, United States|Stanford Children's Health, Stanford, California, United States|Emory University, Decatur, Georgia, United States|CUMC (Columbia University), New York, New York, United States|Carolinas Medical Center, Charlotte, North Carolina, United States|Akron Children's Hospital, Akron, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|MUSC, North Charleston, South Carolina, United States|Baylor College of Medicine, Houston, Texas, United States|UTH, Houston, Texas, United States|Naval Hospital, Bremerton, Bremerton, Washington, United States|Seattle Children's Hospital, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01370447"
523,"NCT00951405","Safety and Efficacy of 3 Different Doses of Long Acting Factor VII in Haemophilia A or B Patients With Inhibitors",,"Completed","No Results Available","Congenital Bleeding Disorder|Haemophilia A With Inhibitors|Haemophilia B With Inhibitors","Drug: activated recombinant human factor VII, long acting","Thrombogenecity|Immunogenecity: Neutralising Antibody Development|AUC(0-48h) and AUC: Area under the FVIIa activity-time profile in the given time period, which is a measure of total blood exposure|Annualized bleeding rates","Novo Nordisk A/S","Male","12 Years to 65 Years   (Child, Adult, Older Adult)","Phase 2","23","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","NN7128-1907|2008-006424-54|JapicCTI-090860|U1111-1111-8584","September 1, 2009","March 29, 2011","March 29, 2011","August 4, 2009",,"September 5, 2018","Novo Nordisk Investigational Site, Little Rock, Arkansas, United States|Novo Nordisk Investigational Site, Los Angeles, California, United States|Novo Nordisk Investigational Site, Orange, California, United States|Novo Nordisk Investigational Site, Tampa, Florida, United States|Novo Nordisk Investigational Site, Boston, Massachusetts, United States|Novo Nordisk Investigational Site, Portland, Oregon, United States|Novo Nordisk Investigational Site, Hershey, Pennsylvania, United States|Novo Nordisk Investigational Site, Rio de Janeiro, Brazil|Novo Nordisk Investigational Site, Belgrade, Former Serbia and Montenegro|Novo Nordisk Investigational Site, Le Kremlin Bicetre, France|Novo Nordisk Investigational Site, Paris, France|Novo Nordisk Investigational Site, Kashihara-shi, Nara, Japan|Novo Nordisk Investigational Site, Kitakyusyu, Fukuoka, Japan|Novo Nordisk Investigational Site, Nishinomiya-shi, Japan|Novo Nordisk Investigational Site, Shinjuku-ku, Tokyo, Japan|Novo Nordisk Investigational Site, Kuala Lumpur, Malaysia|Novo Nordisk Investigational Site, Belgrade, Serbia|Novo Nordisk Investigational Site, Parktown Johannesburg, Gauteng, South Africa|Novo Nordisk Investigational Site, Durban, KwaZulu-Natal, South Africa|Novo Nordisk Investigational Site, Malmö, Sweden|Novo Nordisk Investigational Site, Ankara, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, London, United Kingdom|Novo Nordisk Investigational Site, London, United Kingdom|Novo Nordisk Investigational Site, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00951405"
524,"NCT00882778","PROPACT: Retrospective Prophylaxis Patient Case Collection","PROPACT","Completed","Has Results","Congenital Bleeding Disorder|Haemophilia A With Inhibitors|Haemophilia B With Inhibitors","Drug: eptacog alfa (activated)","Percent Change in Total Bleed Episodes Per Month - Bleeding Population|Percent Change in Total Bleed Episodes Per Month - Frequent Bleeding Population|Percent Change in Total Bleed Episodes Per Month Per Age Categories - Bleeding Population|Percent Change in Total Bleed Episodes Per Month Per Age Categories - Frequent Bleeding Population|Percent Change in Total Bleed Episodes Per Month by Dosing and Age Categories - Bleeding Population, Infrequent Dosing|Percent Change in Total Bleed Episodes Per Month by Dosing and Age Categories - Bleeding Population, Dosing Three Times Per Week|Percent Change in Total Bleed Episodes Per Month by Dosing and Age Categories - Bleeding Population, Daily Dosing|Percent Change in Total Bleed Episodes Per Month by Dosing and Age Categories - Bleeding Population, Frequent Dosing|Percent Change in Total Bleed Episodes Per Month by Dosing and Age Categories - Frequent Bleeding Population, Infrequent Dosing|Percent Change in Total Bleed Episodes Per Month by Dosing and Age Categories - Frequent Bleeding Population, Dosing Three Times Per Week|Percent Change in Total Bleed Episodes Per Month by Dosing and Age Categories - Frequent Bleeding Population, Daily Dosing|Percent Change in Total Bleed Episodes Per Month by Dosing and Age Categories - Frequent Bleeding Population, Frequent Dosing|Individual Dose by Dose Regimen and Age Group - Bleeding Population, Paediatric|Individual Dose by Dose Regimen and Age Group - Bleeding Population, Adolescent|Individual Dose by Dose Regimen and Age Group - Bleeding Population, Adult|Individual Dose by Dose Regimen and Age Group - Frequent Bleeding Population, Paediatric|Individual Dose by Dose Regimen and Age Group - Frequent Bleeding Population, Adolescent|Individual Dose by Dose Regimen and Age Group - Frequent Bleeding Population, Adult|Total Bleed Episodes Per Month by Joint, Target Joint and Non-joint - Bleeding Population|Total Bleed Episodes Per Month by Joint, Target Joint and Non-joint - Frequent Bleeding Population|Healthcare Resource Consumption of Visits, Consultations, and Hospital Admissions Per Month - All Patients|Healthcare Resource Consumption of Visits, Consultations and Hospital Admissions Per Month - Bleeding Population|Healthcare Resource Consumption of Visits, Consultations and Hospital Admissions Per Month - Frequent Bleeding Population|Healthcare Resource Consumption of Total Hospital Length of Stay and School/Work Absences Per Month - All Patients|Healthcare Resource Consumption of Total Hospital Length of Stay and School/Work Absences Per Month - Bleeding Population|Healthcare Resource Consumption of Total Hospital Length of Stay and School/Work Absences Per Month - Frequent Bleeding Population|Physician Reported Outcome Assessment in Prophylaxis in Number of Patients|Number of Physician Reported Outcome Assessment in Prophylaxis in Percentage of Patients","Novo Nordisk A/S","Male","Child, Adult, Older Adult",,"86","Industry","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","F7HAEM-3695","April 2009","May 2010","May 2010","April 16, 2009","July 25, 2011","January 9, 2017","Novo Nordisk Investigational Site, Princeton, New Jersey, United States|Novo Nordisk Investigational Site, Prov. de Buenos Aires, Argentina|Novo Nordisk Investigational Site, Mississauga, Canada|Novo Nordisk Investigational Site, Zagreb, Croatia|Novo Nordisk Investigational Site, Prague, Czech Republic|Novo Nordisk Investigational Site, Paris La défense cedex, France|Novo Nordisk Investigational Site, Mainz, Germany|Novo Nordisk Investigational Site, Dublin 2, Ireland|Novo Nordisk Investigational Site, Rome, Italy|Novo Nordisk Investigational Site, Bratislava, Slovakia|Novo Nordisk Investigational Site, Madrid, Spain|Novo Nordisk Investigational Site, Malmö, Sweden|Novo Nordisk Investigational Site, Zurich, Switzerland|Novo Nordisk Investigational Site, Crawley, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00882778"
525,"NCT00703911","Observational Registry of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With Inhibitors","ONE","Completed","Has Results","Congenital Bleeding Disorder|Haemophilia A With Inhibitors|Haemophilia B With Inhibitors","Drug: eptacog alfa (activated)","Percentage of Bleed Treatments Resulting in Effective Bleed Resolution (All Bleed Episodes)|Percentage of Bleed Treatments Resulting in Effective Bleed Resolution (Spontaneous Bleed Episodes)|Percentage of Bleed Treatments Resulting in Effective Pain Relief (All Bleed Episodes)|Percentage of Bleed Treatments Resulting in Effective Pain Relief (Spontaneous Bleed Episodes)|Percentage of Bleed Treatments Resulting in Effective Haemostasis (Cessation of Bleeds) by Time Point (All Bleed Episodes)|Percentage of Bleed Treatments Resulting in Effective Haemostasis (Cessation of Bleeds) by Time Point (Spontaneous Bleed Episodes)|Percentage of Bleed Treatments Resulting in Effective Pain Relief by Time Point (All Bleed Episodes)|Percentage of Bleed Treatments Resulting in Effective Pain Relief by Time Point (Spontaneous Bleed Episodes)|Total Number of Injections (All Bleed Episodes)|Total Number of Injections (Spontaneous Bleed Episodes)|Total Exposure (Cumulative Dose) to Activated Recombinant Human Factor VII (All Bleed Episodes)|Total Exposure (Cumulative Dose) to Activated Recombinant Human Factor VII (Spontaneous Bleed Episodes)|Percentage of Patients Reporting Satisfaction With Symptom Relief (All Bleed Episodes)|Percentage of Bleed Treatments Resulting in Patient Satisfaction With Symptom Relief (Spontaneous Bleed Episodes)|Percentage of Bleed Treatments Resulting in Patient Satisfaction With Ease of Use (All Bleed Episodes)|Percentage of Bleed Treatments Resulting in Patient Satisfaction With Ease of Use (Spontaneous Bleed Episodes)|Overall Time to Cessation of Bleed/Achievement of Haemostasis (All Bleed Episodes)|Overall Time to Cessation of Bleed/Achievement of Haemostasis (Spontaneous Bleed Episodes)|Overall Time to Cessation/Achievement of Haemostasis (Spontaneous Bleed Episodes)|Childrens' Health Related Quality of Life (Haemo-QoL): Overall Score|Adults' Health Related Quality of Life (Haemo-QoL-A): Overall Score","Novo Nordisk A/S","Male","Child, Adult, Older Adult",,"102","Industry","Observational","Time Perspective: Prospective","F7HAEM-3507","March 2008","July 2010","July 2010","June 24, 2008","December 19, 2011","January 11, 2017","Novo Nordisk Investigational Site, Algiers, Algeria|Novo Nordisk Investigational Site, Vienna, Austria|Novo Nordisk Investigational Site, Brussels, Belgium|Novo Nordisk Investigational Site, Prague, Czech Republic|Novo Nordisk Investigational Site, Paris La défense cedex, France|Novo Nordisk Investigational Site, Mainz, Germany|Novo Nordisk Investigational Site, Rome, Italy|Novo Nordisk Investigational Site, Alphen a/d Rijn, Netherlands|Novo Nordisk Investigational Site, Warszawa, Poland|Novo Nordisk Investigational Site, Paco de Arcos, Portugal|Novo Nordisk Investigational Site, Riyadh, Saudi Arabia|Novo Nordisk Investigational Site, Sandton, South Africa|Novo Nordisk Investigational Site, Malmö, Sweden|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Crawley, United Kingdom|Novo Nordisk Investigational Site, Caracas, Venezuela",,"https://ClinicalTrials.gov/show/NCT00703911"
526,"NCT03287388","MRI Measurement of the Effects of Deep Neuromuscular Blockade on the Abdominal Working Space During Laparoscopy","RELAX-2","Unknown status","No Results Available","Neuromuscular Block|Surgery","Procedure: No Rocuronium|Drug: Rocuronium (moderate NMB)|Drug: Rocuronium (deep NMB)","Abdominal working space|Abdominal volume","Radboud University|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Not Applicable","8","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","63227.091.17","May 2019","November 2019","December 2019","September 19, 2017",,"April 2, 2019",,,"https://ClinicalTrials.gov/show/NCT03287388"
527,"NCT04274829","Predictive Factors of Lymph Node Metastasis in Patients With Papillary Microcarcinoma of the Thyroid",,"Completed","No Results Available","Thyroid Cancer|Lymph Node Metastases","Procedure: Thyroidecomt and lymphectomy","Incidence of lymph node metastasis|Predicrive factors of lymph node metastasis","University of Cagliari","All","Child, Adult, Older Adult",,"300","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","MICRO-PTC-LN","January 2010","January 2018","February 2020","February 18, 2020",,"February 18, 2020","AOU Cagliari, Cagliari, CA, Italy",,"https://ClinicalTrials.gov/show/NCT04274829"
528,"NCT00571584","High Dose of Activated Recombinant Human Factor VII for Treatment of Mild/Moderate Joint Bleeds in Haemophilia Patients With Inhibitors",,"Completed","No Results Available","Congenital Bleeding Disorder|Haemophilia A With Inhibitors|Haemophilia B With Inhibitors","Drug: activated recombinant human factor VII","Global treatment response of the patient by an algorithm based pain and joint mobility assessments|Pain assessment|Mobility assessment|Circumference of joint|Adverse events","Novo Nordisk A/S","Male","Child, Adult, Older Adult","Phase 4","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","F7HEAM-1510","November 2002","March 2004","March 2004","December 12, 2007",,"January 12, 2017","Novo Nordisk Investigational Site, Kremlin-Bicêtre, France|Novo Nordisk Investigational Site, Lille, France|Novo Nordisk Investigational Site, Lyon, France|Novo Nordisk Investigational Site, Paris, France|Novo Nordisk Investigational Site, Paris, France|Novo Nordisk Investigational Site, Budapest, Hungary|Novo Nordisk Investigational Site, Tel-Hashomer, Israel|Novo Nordisk Investigational Site, Poznan, Poland|Novo Nordisk Investigational Site, Warszawa, Poland|Novo Nordisk Investigational Site, Warszawa, Poland|Novo Nordisk Investigational Site, Wroclaw, Poland|Novo Nordisk Investigational Site, Madrid, Spain|Novo Nordisk Investigational Site, Valencia, Spain|Novo Nordisk Investigational Site, Bornova-IZMIR, Turkey|Novo Nordisk Investigational Site, Capa-ISTANBUL, Turkey|Novo Nordisk Investigational Site, Birmingham, United Kingdom|Novo Nordisk Investigational Site, Canterbury, United Kingdom|Novo Nordisk Investigational Site, Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00571584"
529,"NCT02402829","A Study Comparing Factor Level and Inhibitor Titer Testing Results Drawn From Central Venous Lines and Venipuncture","CVL#2","Terminated","No Results Available","Hemophilia A|Factor VIII Deficiency|Hemophilia|Hemophilia B|Factor IX Deficiency","Procedure: Peripheral Vein Blood draw","Evaluate the equivalence between coagulation labs drawn from central venous line to those drawn peripherally. Primary measurements will be done on factor levels resulted as percent of normal, and inhibitor titers resulted in Bethesda Units (BU).","Children's Mercy Hospital Kansas City","Male","1 Year to 21 Years   (Child, Adult)",,"3","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","14040182","November 2014","November 28, 2018","November 28, 2018","March 30, 2015",,"January 6, 2021","Children's Mercy Hospital, Kansas City, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT02402829"
530,"NCT05006807","Comparison Neuromuscular Blockade Monitors",,"Not yet recruiting","No Results Available","Neuromuscular Blockade","Device: Mechanomyograph Twitch Monitor|Device: Stimpod Twitch Monitor|Device: TetraGraph Twitch Monitor|Device: TwitchView Twitch Monitor|Device: Nihon Kohden Twitch Monitor|Other: Palpation of twitch count","Train-of-four count|Train-of-four ratio|Post tetanic count|Twitch count by palpation","University of Washington","All","18 Years to 100 Years   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","STUDY00001561","August 31, 2021","June 30, 2022","June 30, 2022","August 16, 2021",,"August 16, 2021",,,"https://ClinicalTrials.gov/show/NCT05006807"
531,"NCT00108797","Trial of NovoSeven® in Haemophilia - Joint Bleeds",,"Completed","No Results Available","Congenital Bleeding Disorder|Haemophilia A With Inhibitors|Haemophilia B With Inhibitors","Drug: eptacog alfa (activated)|Drug: Feiba VH","Comparison with FEIBA on review of pain, joint mobility and circumference|Safety variables","Novo Nordisk A/S","Male","up to 20 Years   (Child, Adult)","Phase 4","42","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","F7HAEM-2068","September 2001","February 2006","February 2006","April 19, 2005",,"January 12, 2017","Novo Nordisk Investigational Site, Little Rock, Arkansas, United States|Novo Nordisk Investigational Site, Berkeley, California, United States|Novo Nordisk Investigational Site, Los Angeles, California, United States|Novo Nordisk Investigational Site, Aurora, Colorado, United States|Novo Nordisk Investigational Site, Chicago, Illinois, United States|Novo Nordisk Investigational Site, Indianapolis, Indiana, United States|Novo Nordisk Investigational Site, Iowa City, Iowa, United States|Novo Nordisk Investigational Site, New Orleans, Louisiana, United States|Novo Nordisk Investigational Site, Boston, Massachusetts, United States|Novo Nordisk Investigational Site, Detroit, Michigan, United States|Novo Nordisk Investigational Site, Minneapolis, Minnesota, United States|Novo Nordisk Investigational Site, New Brunswick, New Jersey, United States|Novo Nordisk Investigational Site, Newark, New Jersey, United States|Novo Nordisk Investigational Site, New York, New York, United States|Novo Nordisk Investigational Site, Chapel Hill, North Carolina, United States|Novo Nordisk Investigational Site, Cincinnati, Ohio, United States|Novo Nordisk Investigational Site, Hershey, Pennsylvania, United States|Novo Nordisk Investigational Site, Philadelphia, Pennsylvania, United States|Novo Nordisk Investigational Site, Philadelphia, Pennsylvania, United States|Novo Nordisk Investigational Site, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00108797"
532,"NCT01703403","Physical Therapy Management in Degenerative Lumbar Diseases and Osteoporosis",,"Unknown status","No Results Available","Low Back Pain",,,"National Taiwan University Hospital","All","50 Years to 85 Years   (Adult, Older Adult)",,"120","Other","Observational","Observational Model: Case-Crossover|Time Perspective: Retrospective","201205036RIC","May 2012",,,"October 10, 2012",,"October 10, 2012","School & Graduate Institute of Physical Therapy, College of Medicine, National Taiwan University, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT01703403"
533,"NCT00482300","Systematic Pelvic Lymphadenectomy Versus no Lymphadenectomy in Clinical Stage I-II Endometrial Cancer",,"Completed","No Results Available","Endometrial Cancer","Procedure: Systematic pelvic lymphadenectomy",,"University of Roma La Sapienza","Female","up to 75 Years   (Child, Adult, Older Adult)","Not Applicable",,"Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PTC-CBM-15",,,,"June 5, 2007",,"June 5, 2007",,,"https://ClinicalTrials.gov/show/NCT00482300"
534,"NCT03550664","Prediction of the Recovery of Neuromuscular Transmission After Curarization",,"Completed","No Results Available","Neuromuscular Blockade","Device: Monitoring of neuromuscular transmission","TOFScan recording","Brugmann University Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","CHUB-NMB recovery","June 12, 2018","June 20, 2020","June 20, 2020","June 8, 2018",,"June 23, 2020","CHU Brugmann, Brussels, Belgium",,"https://ClinicalTrials.gov/show/NCT03550664"
535,"NCT01448603","ToleroMune Ragweed Follow up Study",,"Completed","No Results Available","Ragweed Allergy|Rhinoconjunctivitis","Biological: Placebo|Biological: ToleroMune Ragweed","Total Rhinoconjunctivitis Symptom Score|Total nasal and non-nasal symptom scores|Change in Immunoglobulin A (IgA)|Change in Immunoglobulin E (IgE)|Change in Immunoglobulin G4 (IgG4)|Adverse Events","Circassia Limited|Adiga Life Sciences, Inc.|Cetero Research, San Antonio","All","18 Years to 65 Years   (Adult, Older Adult)",,"109","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","TR002B","October 2011","March 2012","March 2012","October 7, 2011",,"May 17, 2012","Cetero Research, Mississauga, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01448603"
536,"NCT01453881","Fine Particle pMDI Formoterol/Beclomethasone in Asthmatics With and Without Spacer: Comparative Efficacy Evaluation","EFFECT-EV","Completed","No Results Available","Asthma","Device: Spacer|Device: Comparator","Change in Asthma Control Test Score|Changes in Forced Expiratory Volume in the first second (FEV1)","Universidade Federal de Pernambuco|Universidade Federal do vale do São Francisco","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","45","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","PTC 034/11","April 2011","June 2013","June 2013","October 18, 2011",,"March 31, 2015","Hospital das Clínicas - Universidade Federal de Pernambuco, Recife, Pernambuco, Brazil",,"https://ClinicalTrials.gov/show/NCT01453881"
537,"NCT02841800","Intra-luminal Radiofrequency Ablation for Inoperable Malignant Biliary Stenosis",,"Completed","No Results Available","Liver Cancer|Bile Duct Cancer|Pancreatic Cancer","Device: 'Intra-luminal radiofrequency ablation (Habib EndoHPB)","survival benefit|the recurrence of bile duct obstruction and jaundice|potential treatment-related complications|repeated biliary interventions","National Taiwan University Hospital","All","20 Years to 75 Years   (Adult, Older Adult)","Not Applicable","5","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","201604030DIPD","June 2016","August 30, 2018","May 10, 2019","July 22, 2016",,"August 5, 2019",,,"https://ClinicalTrials.gov/show/NCT02841800"
538,"NCT01570179","Sugammadex-dosing in Bariatric Patients","SugReBaCh-1","Completed","No Results Available","Neuromuscular Blockade","Drug: ideal BW based sugammadex reversal of moderate block|Drug: real body weight based sugammadex reversal of moderate block|Drug: real body weight based sugammadex reversal of deep block|Drug: ideal body weight based sugammadex reversal of deep block","100% TOF-recovery 3 min after sugammadex|impact of depth of block on surgical conditions","Central Hospital, Nancy, France","All","18 Years and older   (Adult, Older Adult)","Phase 3","34","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","2011-005504-14","May 2012","July 2012","July 2012","April 4, 2012",,"January 24, 2013","CHU Strasbourg Hôpital Civil, Strasbourg, Alsace, France|CHU Nancy, Vandoeuvre-Les-Nancy, Lorraine, France",,"https://ClinicalTrials.gov/show/NCT01570179"
539,"NCT03943264","A Biomarker-directed Study of XPro1595 in Patients With Mild to Moderate Alzheimer's",,"Unknown status","No Results Available","Alzheimer Disease","Drug: XPro1595","The number of patients with a treatment-emergent adverse event throughout 12 weeks of treatment with XPro1595|The percentage of patients with a treatment-emergent adverse event throughout 12 weeks of treatment with XPro1595|Changes from baseline in high sensitivity C-reactive protein in the blood and cerebral spinal fluid following 12 weeks of treatment with XPro1595|Changes from baseline in inflammatory cytokines in the blood and cerebral following 12 weeks of treatment with XPro1595 spinal fluid|Changes from baseline in blood and cerebral spinal fluid levels of amyloid beta following 12 weeks of treatment with XPro1595|Changes from baseline in cerebral spinal fluid levels of tau following 12 weeks of treatment with XPro1595|Change from baseline in FreeWater content (edema) using magnetic resonance imaging following 12 weeks of treatment with XPro1595|Change from baseline in the Mini-Mental State Examination (MMSE) following 12 weeks of treatment with XPro1595|Change from baseline in the Digit Symbol Substitution Test (DSST) following 12 weeks of treatment with XPro1595|Change from baseline in the Verbal Fluency Test following 12 weeks of treatment with XPro1595|Change from baseline in the Neuropsychiatric Inventory (NPI) following 12 weeks of treatment with XPro1595|Change from baseline in the Bristol Activities of Daily Living Scale (BALDS) following 12 weeks of treatment with XPro1595|Change from baseline in the Memory-Enhanced Retrospective Evaluation of Treatment Observer Reported Global Impression of Improvement (MERET OBSRO-C) following 12 weeks of treatment with XPro1595|Evaluate changes in the Memory-Enhanced Retrospective Evaluation of Change from baseline Global Impression of Improvement (MERET PGI-C) following 12 weeks of treatment with XPro1595","Inmune Bio, Inc.|Alzheimer's Association","All","18 Years and older   (Adult, Older Adult)","Phase 1","18","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","XPRO1595-AD|18PTC-R-592167","November 20, 2019","August 2020","December 2020","May 9, 2019",,"January 22, 2020","KaRa MINDS, Macquarie Park, New South Wales, Australia|Mater Medical Research Institute, Brisbane, Queensland, Australia|Central Adelaide Local Health Network, Woodville, South Australia, Australia|Alfred Heath, Melbourne, Victoria, Australia|Eastern Clinical Research Unit, Melbourne, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT03943264"
540,"NCT02978573","Post Approval Study to Evaluate the Effectiveness and Safety of Cartiva Implant in the Treatment of OA of the Great Toe","MOTION","Completed","No Results Available","Osteoarthritis of First Metatarsalphalangeal Joint","Device: Cartiva","Long Term Safety of the Cartiva Implant by demonstrating durability over the long term and no unanticipated safety concerns that arise|Pain Scale (VAS)|Foot and Ankle Ability Measure (FAAM) Activities of Daily Living (ADL)|Foot and Ankle Ability Measure (FAAM) Sports","Cartiva, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","135","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PTC-0031 (PAS)","October 2016","April 27, 2018","April 27, 2018","December 1, 2016",,"March 22, 2019",,,"https://ClinicalTrials.gov/show/NCT02978573"
541,"NCT03037385","Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors","ARROW","Recruiting","No Results Available","RET-altered Non Small Cell Lung Cancer|Medullary Thyroid Cancer|RET-altered Papillary Thyroid Cancer|RET-altered Colon Cancer|RET-altered Solid Tumors|Lung Neoplasm|Carcinoma, Non-Small-Cell Lung|Thyroid Diseases|Thyroid Neoplasm|Thyroid Cancer, Papillary|Carcinoma, Neuroendocrine|Respiratory Tract Neoplasms|Thoracic Neoplasms|Neoplasms by Site|Neoplasms|Lung Diseases|Respiratory Tract Disease|Carcinoma, Bronchogenic|Bronchial Neoplasms|Endocrine System Diseases|Endocrine Gland Neoplasm|Head and Neck Neoplasms|Adenocarcinoma, Papillary|Adenocarcinoma|Carcinoma|Neoplasms, Glandular and Epithelial|Neoplasms by Histologic Type|Neuroendocrine Tumors|Neuroectodermal Tumors|Neoplasms, Germ Cell and Embryonal|Neoplasms, Nerve Tissue|Colonic Neoplasms|Colorectal Neoplasms|Intestinal Neoplasms|Gastrointestinal Neoplasms|Digestive System Neoplasm|Digestive System Disease|Gastrointestinal Disease|Colonic Diseases|Intestinal Disease","Drug: pralsetinib (BLU-667)","(Phase 1) Determination of maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of pralsetinib|(Phase 1) Number of patients with adverse events and serious adverse events|(Phase 2) Overall response rate|(Phase 2) Number of patients with adverse events and serious adverse events|(Phase 1) Overall response rate|(Phase 1) RET gene status and correlation between RET gene status and ORR, CBR, DOR, DCR, PFS and other antineoplastic measures|(Phase 2 ) Clinical Benefit Rate (CBR)|(Phase 2 ) Duration of Response (DOR)|(Phase 2 ) Disease Control Rate (DCR)|(Phase 2 ) Progression Free Survival (PFS)|(Phase 2 ) Overall Survival (OS)|(Phase 2) RET gene status and correlation between RET gene status and ORR, CBR, DOR, DCR and other antineoplastic measures|(Phases 1 and 2) Pharmacokinetic parameters including maximum plasma drug concentration (Cmax)|(Phases 1 and 2) Pharmacokinetic parameters including area under the plasma concentration versus time curve from time 0 to 24 hours postdose (AUC0-24)|(Phases 1 and 2) Pharmacokinetic parameters including terminal elimination half-life (t1/2)|(Phase 2) Electrocardiogram (ECG) Assessment using QT analysis|(Phases 1 and 2) Pharmacodynamic parameters including changes in blood calcitonin|(Phases 1 and 2) Pharmacodynamic parameters including tumor marker, carcinoembryonic antigen (CEA)|(Phase 2) Assess intracranial response rate and time to intracranial progression in patients with NSCLC","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","647","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BO42863|2016-004390-41|BLU-667-1101","March 17, 2017","December 31, 2021","February 29, 2024","January 31, 2017",,"December 9, 2021","Mayo Clinic, Phoenix, Arizona, United States|UC Irvine Medical Center, Orange, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|Mayo Clinic, Jacksonville, Florida, United States|University of Miami Hospitals and Clinics, Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Maryland Oncology Hematology, PA - Columbia, Columbia, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University School of Medicine, Siteman Cancer Center, Saint Louis, Missouri, United States|Albany Medical Center, Albany, New York, United States|Jack D. Weiler Hospital, Bronx, New York, United States|Cornell University, New York, New York, United States|Oregon Health and Science University, Portland, Oregon, United States|University of Pennsylvania Hospital, Philadelphia, Pennsylvania, United States|UPMC CancerCenter, Pittsburgh, Pennsylvania, United States|Texas Oncology - Austin, Austin, Texas, United States|Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|University of Washington, Seattle Cancer Care Alliance, Seattle, Washington, United States|Antwerp University Hospital, Edegem, Belgium|Beijing Cancer Hospital, Beijing, China|West China Hospital, Sichuan University, Chengdu, China|Sichuan Cancer Hospital & Institute, Chongqing, China|Chongqing Cancer Hospital, Chongqing, China|Fujian Provincial Cancer Hospital, Fuzhou, China|First Affiliated Hospital of Gannan Medical University, Ganzhou, China|Sun Yat-sen University Cancer Center, Guangzhou, China|Guangdong Provincial People's Hospital, Guangzhou, China|Nanfang Hospital of Southern Medical University, Guangzhou, China|Zhejiang Provincial People's Hospital, Hangzhou, China|Zhejiang Cancer Hospital, Hangzhou, China|Anhui Provincial Cancer Hospital, Hefei, China|Jinan Central Hospital, Jinan, China|Gansu Provincial Cancer Hospital, Lanzhou, China|Fudan University Shanghai Cancer Center, Shanghai, China|Liaoning Cancer Hospital & Institute, Shenyang, China|Tianjin Medical University Cancer Institute and Hospital, Tianjin, China|Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China|Henan Cancer Hospital, Zhengzhou, China|Institut Bergonié, Bordeaux, France|CHRU de Lille - Hôpital Claude Hurier Servide d'Endocrinologie et Diabétologie, Lille, France|Centre Leon Berard, Lyon, France|Centre Antoine Lacassagne, Nice, France|Hospital Tenon, Paris, France|Institut Curie, Paris, France|CHU de Rennes - Hôpital Pontchaillou, Rennes, France|Insitut Claudius Regaud, Toulouse, France|Gustave Roussy, Villejuif, France|HELIOS Klinikum Emil von Behring, Berlin, Germany|Universitätsklinikum Essen, Essen, Germany|Thoraxklinik Heidelberg, Heidelberg, Germany|Klinikum der Universitat Munchen, Munich, Germany|Pius-Hospital Oldenberg, Oldenburg, Germany|The Chinese University of Hong Kong, Hong Kong, Hong Kong|Istituto Europeo di Oncologia Sviluppo Nuovi Farmaci per Terapie Innovative, Milano, Italy|Grande Ospedale Metropolitano Niguarda, Milan, Italy|Ospedale Santa Maria delle Croci, Ravenna, Italy|Istituto Nazionale Tumori Regina Elena, Rome, Italy|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis, Amsterdam, Netherlands|University Medical Center Groningen, Groningen, Netherlands|National Cancer Centre Singapore, Singapore, Singapore|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Clinic Barcelona, Barcelona, Spain|Hospital Duran I Reynals, Barcelona, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Universitario 12 de Octubre Servicio de Oncologia Medica, Madrid, Spain|National Taiwan University Hospital, Taipei City, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|NHS Grampian - Aberdeen Royal Infirmary, Aberdeen, United Kingdom|Sarah Cannon Research Institute, London, United Kingdom|Guy's Hospital St. Thomas NHS Foundation Trust, London, United Kingdom|NIHR UCLH Clinical Research Facility, University College of London NHS Foundation Trust, London, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03037385"
542,"NCT02698735","Gentamicin Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB) Nonsense Mutation Patients",,"Completed","Has Results","Recessive Dystrophic Epidermolysis Bullosa","Drug: Gentamicin|Drug: Placebo","Restoration of Full-length Type VII Collagen as Assessed by Immunofluorescence.|Number of Participants With Anchoring Fibrils as Assessed by Immuno-electron Microscopy","University of Southern California","All","Child, Adult, Older Adult","Phase 1|Phase 2","5","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HS-15-00821","February 25, 2016","March 31, 2017","June 30, 2017","March 4, 2016","August 14, 2019","October 29, 2019",,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/35/NCT02698735/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/35/NCT02698735/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02698735"
543,"NCT03432299","Radiofrequency Ablation of Low Risk Papillary Thyroid Microcarcinoma","RFAforPTMC","Recruiting","No Results Available","Papillary Thyroid Microcarcinoma|Thyroid Cancer","Procedure: RFA for PTMC","Change of tumor size|Development of Metastasis|Change of Quality of Life|Incidence of potential side effects from RFA","Seoul National University Hospital","All","19 Years to 60 Years   (Adult)","Not Applicable","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SNUH-RFA-PTMC","April 16, 2018","July 31, 2023","December 31, 2023","February 14, 2018",,"September 23, 2021","Seoul National University Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03432299"
544,"NCT02546843","Depth of Neuromuscular Blockade and the Perioperative Conditions in Laparoscopic Surgery in Pediatric Population","PedLapBlock","Completed","No Results Available","Neuromuscular Blockade","Drug: Rocuronium|Drug: Cisatracurium|Drug: Nonspecific Neuromuscular Blockade reversal|Drug: Specific Neuromuscular Blockade reversal|Drug: maintaining the depth of neuromuscular blockade - rocuronium|Drug: maintaining the depth of neuromuscular blockade - cisatracurium","Surgical scoring system|Number of adverse events","Brno University Hospital|KDCHOT FN Brno","All","2 Years to 18 Years   (Child, Adult)","Not Applicable","66","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","KDAR FN Brno","December 2015","September 2018","May 2019","September 11, 2015",,"May 20, 2019","University Hospital Brno - FN Brno, Brno, Czech Republic, Czechia",,"https://ClinicalTrials.gov/show/NCT02546843"
545,"NCT04076709","Cardiovascular Effects of Muscle Relaxation During Laparoscopic Surgery","RELAX-LAP","Not yet recruiting","No Results Available","Hemodynamic Instability","Procedure: goal directed anaesthesia","Blood pressure|Cardiac output","Leiden University Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 4","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","P19.042","September 1, 2020","September 1, 2021","September 1, 2021","September 3, 2019",,"June 11, 2020",,,"https://ClinicalTrials.gov/show/NCT04076709"
546,"NCT01392547","Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and Inhibitors","adept™2","Completed","Has Results","Congenital Bleeding Disorder|Haemophilia A With Inhibitors|Haemophilia B With Inhibitors","Drug: vatreptacog alfa (activated)|Drug: eptacog alfa (activated)","Effective Bleeding Control Defined as no Additional Haemostatic Medication (Other Than Trial Product) Given|Effective and Sustained Bleeding Control|Number of Doses of Trial Product Given for Each Acute Bleed|Number of Adverse Events|Immunogenicity (Inhibitor Development)","Novo Nordisk A/S","Male","12 Years and older   (Child, Adult, Older Adult)","Phase 3","72","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","NN1731-3562|2010-023803-92|U1111-1118-2228|JapicCTI-111595","July 2011","August 2012","August 2012","July 12, 2011","December 6, 2013","May 15, 2017","Novo Nordisk Clinical Trial Call Center, Tucson, Arizona, United States|Novo Nordisk Clinical Trial Call Center, Los Angeles, California, United States|Novo Nordisk Clinical Trial Call Center, Los Angeles, California, United States|Novo Nordisk Clinical Trial Call Center, Orange, California, United States|Novo Nordisk Clinical Trial Call Center, Aurora, Colorado, United States|Novo Nordisk Clinical Trial Call Center, Tampa, Florida, United States|Novo Nordisk Clinical Trial Call Center, Atlanta, Georgia, United States|Novo Nordisk Clinical Trial Call Center, Augusta, Georgia, United States|Novo Nordisk Clinical Trial Call Center, Iowa City, Iowa, United States|Novo Nordisk Clinical Trial Call Center, Boston, Massachusetts, United States|Novo Nordisk Clinical Trial Call Center, Detroit, Michigan, United States|Novo Nordisk Clinical Trial Call Center, Brooklyn, New York, United States|Novo Nordisk Clinical Trial Call Center, Portland, Oregon, United States|Novo Nordisk Clinical Trial Call Center, Richmond, Virginia, United States|Linz, Austria|Campinas, Sao Paulo, Brazil|Zagreb, Croatia|Athens, Greece|Budapest, Hungary|Milano, Italy|Shinjuku-ku, Tokyo, Japan|Kuala Lumpur, Malaysia|Warszawa, Poland|Novo Nordisk Clinical Trial Call Center, San Juan, Puerto Rico|Timisoara, Timis, Romania|Saint-Petersburg, Russian Federation|Novi Sad, Serbia|Parktown, Johannesburg, Gauteng, South Africa|Changhua, Taiwan|Bangkok, Thailand|Bornova-IZMIR, Turkey|Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01392547"
547,"NCT04609410","Bleeding in Laparoscopic Liver Surgery","MODELS","Recruiting","No Results Available","Neuromuscular Blockade|Intraoperative Bleeding|Hepatic Cancer","Procedure: Neuromuscular blockade","Total intra-operative blood loss|Number of blood product units transfused|Incidence of surgical revision|Airway peak and plateau pressures|Quality of surgical field|Surgery and hepatic resection time","Università Vita-Salute San Raffaele","All","18 Years and older   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","MODELS/22/OSR","October 30, 2020","October 2023","December 2023","October 30, 2020",,"December 22, 2021","Ospedale San Raffaele, Milano, Italy",,"https://ClinicalTrials.gov/show/NCT04609410"
548,"NCT01146652","Long Term Evaluation of Sarilumab in Rheumatoid Arthritis Patients (SARIL-RA-EXTEND)",,"Completed","Has Results","Rheumatoid Arthritis","Drug: SAR153191 (REGN88)","Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)|Sub-study: Number of Participants Reported Product Technical Complaints (PTC), Product Technical Failures (PTF) and/or Failed Drug Deliveries (FDD) With Pre-filled Syringe With Safety System|Sub-study: Number of Product Technical Complaints - Product Technical Failures With Pre-filled Syringe With Safety System|Sub-study: Number of Failed Drug Deliveries Associated With Pre-filled Syringe With Safety System|Sub-study: Number of Product Technical Complaints With Pre-filled Syringe With Safety System|Percentage of Participants Achieving American College of Rheumatology 20 (ACR20) Response|Percentage of Participants Achieving American College of Rheumatology 50 (ACR50) Response|Percentage of Participants Achieving American College of Rheumatology 70 (ACR70) Response|Percentage of Participants With Disease Activity Score for 28 Joints (DAS28) Remission|Percentage of Participants Achieving Good Response, Moderate Response or Non-response Using the European League Against Rheumatism (EULAR) Response Criteria|Change From Baseline in DAS28-CRP Score at Weeks 0, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408, 432, 456, 480, 504 and 516 of LTS11210|Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Scores at Week 0, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210|Change From Baseline in Van Der Heijde Modified Total Sharp Score (mTSS) at Week 0 and Week 48 of LTS11210: Campaign 1 X-ray Data - Participants From EFC11072 Part B|Change From Baseline in Van Der Heijde Modified Total Sharp Score (mTSS) at Week 48 and Week 96 of LTS11210: Campaign 2 X-ray Data - Participants From EFC11072 Part B|Change From Baseline in Van Der Heijde Modified Total Sharp Score (mTSS) at Week 96, Week 144 and Week 192 of LTS11210: Campaign 3 X-ray Data - Participants From EFC11072 Part B|Percentage of Participants With no Radiographic Progression of the Van Der Heijde Modified Total Sharp Score at Week 0 and 48 of LTS11210: Campaign 1 X-ray Data - Participants From EFC11072 Part B|Percentage of Participants With no Radiographic Progression of the Van Der Heijde Modified Total Sharp Score at Week 48 and Week 96 of LTS11210: Campaign 2 X-ray Data - Participants From EFC11072 Part B|Percentage of Participants With no Radiographic Progression of the Van Der Heijde Modified Total Sharp Score at Week 96, 144 and 192 of LTS11210: Campaign 3 X-ray Data - Participants From EFC11072 Part B|Change From Baseline in Tender Joint Count (TJC) at Week 0, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408, 432, 456, 480, 504 and 516 of LTS11210|Change From Baseline in Swollen Joint Count (SJC) at Week 0, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408, 432, 456, 480, 504 and 516 of LTS11210|Change From Baseline in Physician's Global Assessments of Disease Activity Visual Analogue Scale (VAS) Score at Week 0, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240, and 264 of LTS11210|Change From Baseline in Participant Global Assessment of Disease Activity Visual Analogue Scale Score at Week 0, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408, 432, 456, 480, 504 and 516 of LTS11210|Change From Baseline in Participant's Assessment of Pain Visual Analogue Scale Score at Week 0, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240, and 264 of LTS11210|Change From Baseline in Short Form 36 (SF-36; Version 2) Physical Component Summary (PCS) Score at Week 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210 - Participants From EFC11072, ACT11575 and EFC10832 Only|Change From Baseline in Short Form 36 (SF-36; Version 2) Mental Component Summary Score at Week 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210 - Participants From EFC11072, ACT11575 and EFC10832 Only|Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-fatigue) Total Score at Week 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210-Participants From EFC11072, ACT11575 and EFC10832 Only|Change From Baseline in Sleep Visual Analogue Scale Score at Week 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210 - Participants From EFC11072, and ACT11575 Only|Change From Baseline in Work Productivity and Activity Impairment (WPAI): Percent Work Time Missed Due to RA at Week 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210 - Participants From EFC11072 and ACT11575 Only|Change From Baseline in Work Productivity and Activity Impairment: Percent Impairment While Working Due to RA at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210 - Participants From EFC11072, and ACT11575 Only|Change From Baseline in Work Productivity and Activity Impairment: Percent Overall Work Impairment Due to RA at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210 - Participants From EFC11072, and ACT11575 Only|Change From Baseline in Work Productivity and Activity Impairment: Percent Activity Impairment Due to RA at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210 - Participants From EFC11072, and ACT11575 Only|Change From Baseline in Work Productivity Survey - Rheumatoid Arthritis (WPS-RA) at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210: Work Days Missed Due to Arthritis - Participants From EFC10832 Only|Change From Baseline in WPS-RA at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210: Days With Work Productivity Reduced by >=50% Due to Arthritis - Participants From EFC10832 Only|Change From Baseline in WPS-RA at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210: Arthritis Interference With Work Productivity - Participants From EFC10832 Only|Change From Baseline in WPS-RA at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210: House Work Days Missed Due to Arthritis - Participants From EFC10832 Only|Change From Baseline in WPS-RA at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210: Days With Household Work Productivity Reduced by >=50% Due to Arthritis - Participants From EFC10832 Only|Change From Baseline in WPS-RA at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210: Days With Family/Social/Leisure Activities Missed Due to Arthritis - Participants From EFC10832 Only|Change From Baseline in WPS-RA at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210: Days With Outside Help Hired Due to Arthritis- Participants From EFC10832 Only|Change From Baseline in WPS-RA at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210: Arthritis Interference With Household Work Productivity - Participants From EFC10832 Only|Sub-study: Number of Participants Who Reported Adverse Events Related to Pre-filled Syringe With Safety System","Sanofi|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","2023","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LTS11210|2010-019262-86","June 21, 2010","December 31, 2020","December 31, 2020","June 17, 2010","January 24, 2022","January 24, 2022","Investigational Site Number 840070, Anniston, Alabama, United States|Investigational Site Number 840138, Birmingham, Alabama, United States|Investigational Site Number 840152, Huntsville, Alabama, United States|Investigational Site Number 840072, Gilbert, Arizona, United States|Investigational Site Number 840141, Glendale, Arizona, United States|Investigational Site Number 840134, Fullerton, California, United States|Investigational Site Number 840008, La Jolla, California, United States|Investigational Site Number 840135, San Diego, California, United States|Investigational Site Number 840021, Santa Maria, California, United States|Investigational Site Number 840100, Stanford, California, United States|Investigational Site Number 840049, Upland, California, United States|Investigational Site Number 840151, Colorado Springs, Colorado, United States|Investigational Site Number 840130, Lewes, Delaware, United States|Investigational Site Number 840153, Aventura, Florida, United States|Investigational Site Number 840050, Clearwater, Florida, United States|Investigational Site Number 840033, Fort Lauderdale, Florida, United States|Investigational Site Number 840041, Gainesville, Florida, United States|Investigational Site Number 840067, Jupiter, Florida, United States|Investigational Site Number 840048, Miami, Florida, United States|Investigational Site Number 840024, Naples, Florida, United States|Investigational Site Number 840006, Orlando, Florida, United States|Investigational Site Number 840128, Ormond Beach, Florida, United States|Investigational Site Number 840063, Palm Harbor, Florida, United States|Investigational Site Number 840155, Palm Harbor, Florida, United States|Investigational Site Number 840060, Sarasota, Florida, United States|Investigational Site Number 840140, Tampa, Florida, United States|Investigational Site Number 840126, Vero Beach, Florida, United States|Investigational Site Number 840003, Atlanta, Georgia, United States|Investigational Site Number 840028, Decatur, Georgia, United States|Investigational Site Number 840027, Marietta, Georgia, United States|Investigational Site Number 840018, Idaho Falls, Idaho, United States|Investigational Site Number 840046, Chicago, Illinois, United States|Investigational Site Number 840052, Kansas City, Kansas, United States|Investigational Site Number 840230, Elizabethtown, Kentucky, United States|Investigational Site Number 840015, Lexington, Kentucky, United States|Investigational Site Number 840120, Baton Rouge, Louisiana, United States|Investigational Site Number 840109, Lake Charles, Louisiana, United States|Investigational Site Number 840055, Frederick, Maryland, United States|Investigational Site Number 840013, Wheaton, Maryland, United States|Investigational Site Number 840154, Boston, Massachusetts, United States|Investigational Site Number 840150, Lansing, Michigan, United States|Investigational Site Number 840137, Saint Clair Shores, Michigan, United States|Investigational Site Number 840112, Lincoln, Nebraska, United States|Investigational Site Number 840026, Freehold, New Jersey, United States|Investigational Site Number 840115, Lake Success, New York, United States|Investigational Site Number 840056, New York, New York, United States|Investigational Site Number 840043, New York, New York, United States|Investigational Site Number 840106, Orchard Park, New York, United States|Investigational Site Number 840118, Smithtown, New York, United States|Investigational Site Number 840116, Wilmington, North Carolina, United States|Investigational Site Number 840233, Minot, North Dakota, United States|Investigational Site Number 840002, Oklahoma City, Oklahoma, United States|Investigational Site Number 840127, Oklahoma City, Oklahoma, United States|Investigational Site Number 840011, Tulsa, Oklahoma, United States|Investigational Site Number 840065, Tulsa, Oklahoma, United States|Investigational Site Number 840010, Bethlehem, Pennsylvania, United States|Investigational Site Number 840009, Duncansville, Pennsylvania, United States|Investigational Site Number 840062, Reading, Pennsylvania, United States|Investigational Site Number 840058, Columbia, South Carolina, United States|Investigational Site Number 840016, North Charleston, South Carolina, United States|Investigational Site Number 840025, Jackson, Tennessee, United States|Investigational Site Number 840059, Memphis, Tennessee, United States|Investigational Site Number 840032, Amarillo, Texas, United States|Investigational Site Number 840038, Austin, Texas, United States|Investigational Site Number 840001, Dallas, Texas, United States|Investigational Site Number 840022, Dallas, Texas, United States|Investigational Site Number 840012, Dallas, Texas, United States|Investigational Site Number 840129, Houston, Texas, United States|Investigational Site Number 840069, Lubbock, Texas, United States|Investigational Site Number 840074, Mesquite, Texas, United States|Investigational Site Number 840020, Nassau Bay, Texas, United States|Investigational Site Number 840103, San Antonio, Texas, United States|Investigational Site Number 840036, Spokane, Washington, United States|Investigational Site Number 840061, Tacoma, Washington, United States|Investigational Site Number 840124, Clarksburg, West Virginia, United States|Investigational Site Number 032006, Caba, Argentina|Investigational Site Number 032007, Caba, Argentina|Investigational Site Number 032008, Caba, Argentina|Investigational Site Number 032019, Capital Federal, Argentina|Investigational Site Number 032016, Capital Federal, Argentina|Investigational Site Number 032002, Cordoba, Argentina|Investigational Site Number 032020, Cordoba, Argentina|Investigational Site Number 032003, Córdoba, Argentina|Investigational Site Number 032017, La Plata, Argentina|Investigational Site Number 032012, Mar Del Plata, Argentina|Investigational Site Number 032011, Quilmes, Argentina|Investigational Site Number 032010, Ramos Mejia, Argentina|Investigational Site Number 032001, Rosario, Argentina|Investigational Site Number 032013, Rosario, Argentina|Investigational Site Number 032015, San Fernando, Argentina|Investigational Site Number 032005, San Miguel De Tucuman, Argentina|Investigational Site Number 032004, San Miguel De Tucuman, Argentina|Investigational Site Number 032009, Zarate, Argentina|Investigational Site Number 036003, Camperdown, Australia|Investigational Site Number 036012, Fitzroy, Australia|Investigational Site Number 036010, Garran, Australia|Investigational Site Number 036004, Heidelberg West, Australia|Investigational Site Number 036001, Maroochydore, Australia|Investigational Site Number 036014, Victoria Park, Australia|Investigational Site Number 036007, Woodville, Australia|Investigational Site Number 040001, Graz, Austria|Investigational Site Number 112002, Minsk, Belarus|Investigational Site Number 112001, Minsk, Belarus|Investigational Site Number 056010, Leuven, Belgium|Investigational Site Number 076001, Curitiba, Brazil|Investigational Site Number 076006, Goiania, Brazil|Investigational Site Number 076010, Juiz De Fora, Brazil|Investigational Site Number 076004, Porto Alegre, Brazil|Investigational Site Number 076005, Rio De Janeiro, Brazil|Investigational Site Number 076015, Rio De Janeiro, Brazil|Investigational Site Number 076011, Salvador, Brazil|Investigational Site Number 076002, Sao Paulo, Brazil|Investigational Site Number 076003, Sao Paulo, Brazil|Investigational Site Number 076013, Vitoria, Brazil|Investigational Site Number 124003, Mississauga, Canada|Investigational Site Number 124002, St. Catharines, Canada|Investigational Site Number 124005, Toronto, Canada|Investigational Site Number 124009, Trois-Rivières, Canada|Investigational Site Number 124104, Victoria, Canada|Investigational Site Number 124012, Winnipeg, Canada|Investigational Site Number 152005, Osorno, Chile|Investigational Site Number 152012, Santiago, Chile|Investigational Site Number 152002, Santiago, Chile|Investigational Site Number 152011, Santiago, Chile|Investigational Site Number 152009, Santiago, Chile|Investigational Site Number 152001, Santiago, Chile|Investigational Site Number 152013, Santiago, Chile|Investigational Site Number 152008, Santiago, Chile|Investigational Site Number 152014, Talca, Chile|Investigational Site Number 152015, Temuco IX Region, Chile|Investigational Site Number 152004, Valdivia, Chile|Investigational Site Number 152006, Vina Del Mar, Chile|Investigational Site Number 152007, Viña Del Mar, Chile|Investigational Site Number 170005, Barranquilla, Colombia|Investigational Site Number 170004, Barranquilla, Colombia|Investigational Site Number 170001, Bogota, Colombia|Investigational Site Number 170008, Bogota, Colombia|Investigational Site Number 170006, Bogotá, Colombia|Investigational Site Number 170003, Bogotá, Colombia|Investigational Site Number 170007, Bucaramanga, Colombia|Investigational Site Number 170009, Bucaramanga, Colombia|Investigational Site Number 203009, Liberec, Czechia|Investigational Site Number 203004, Ostrava, Czechia|Investigational Site Number 203034, Pardubice, Czechia|Investigational Site Number 203001, Praha 2, Czechia|Investigational Site Number 203007, Praha 2, Czechia|Investigational Site Number 203011, Praha 2, Czechia|Investigational Site Number 203010, Praha 4, Czechia|Investigational Site Number 203002, Uherske Hradiste, Czechia|Investigational Site Number 203006, Zlin, Czechia|Investigational Site Number 218003, Cuenca, Ecuador|Investigational Site Number 218001, Guayaquil, Ecuador|Investigational Site Number 218002, Quito, Ecuador|Investigational Site Number 233001, Tallinn, Estonia|Investigational Site Number 233010, Tallinn, Estonia|Investigational Site Number 233002, Tallinn, Estonia|Investigational Site Number 246001, Helsinki, Finland|Investigational Site Number 246002, Hyvinkää, Finland|Investigational Site Number 246003, Pori, Finland|Investigational Site Number 246010, Riihimäki, Finland|Investigational Site Number 276011, Bad Nauheim, Germany|Investigational Site Number 276010, Berlin, Germany|Investigational Site Number 276007, Berlin, Germany|Investigational Site Number 276008, Berlin, Germany|Investigational Site Number 276014, Berlin, Germany|Investigational Site Number 276018, Deggingen, Germany|Investigational Site Number 276015, Halle/Saale, Germany|Investigational Site Number 276005, Hamburg, Germany|Investigational Site Number 276013, Hamburg, Germany|Investigational Site Number 276001, Herne, Germany|Investigational Site Number 276016, Leipzig, Germany|Investigational Site Number 276017, München, Germany|Investigational Site Number 276021, Osnabrück, Germany|Investigational Site Number 276020, Tübingen, Germany|Investigational Site Number 276019, Zerbst, Germany|Investigational Site Number 300002, Heraklion, Greece|Investigational Site Number 300003, Thessaloniki, Greece|Investigational Site Number 300005, Thessaloniki, Greece|Investigational Site Number 320002, Guatemala City, Guatemala|Investigational Site Number 320003, Guatemala City, Guatemala|Investigational Site Number 320001, Guatemala, Guatemala|Investigational Site Number 348006, Budapest, Hungary|Investigational Site Number 348014, Budapest, Hungary|Investigational Site Number 348025, Budapest, Hungary|Investigational Site Number 348022, Budapest, Hungary|Investigational Site Number 348010, Debrecen, Hungary|Investigational Site Number 348003, Debrecen, Hungary|Investigational Site Number 348021, Esztergom, Hungary|Investigational Site Number 348013, Györ, Hungary|Investigational Site Number 348009, Szolnok, Hungary|Investigational Site Number 348015, Szombathely, Hungary|Investigational Site Number 348004, Székesfehérvár, Hungary|Investigational Site Number 348005, Sátoraljaújhely, Hungary|Investigational Site Number 376001, Haifa, Israel|Investigational Site Number 376010, Haifa, Israel|Investigational Site Number 376011, Tel Aviv, Israel|Investigational Site Number 376002, Tel Hashomer, Israel|Investigational Site Number 380005, Genova, Italy|Investigational Site Number 410014, Anyang-Si, Korea, Republic of|Investigational Site Number 410006, Busan, Korea, Republic of|Investigational Site Number 410004, Daegu, Korea, Republic of|Investigational Site Number 410017, Daejeon, Korea, Republic of|Investigational Site Number 410005, Daejeon, Korea, Republic of|Investigational Site Number 410010, Gwangju, Korea, Republic of|Investigational Site Number 410001, Incheon, Korea, Republic of|Investigational Site Number 410009, Incheon, Korea, Republic of|Investigational Site Number 410011, Jeonju, Korea, Republic of|Investigational Site Number 410007, Seoul, Korea, Republic of|Investigational Site Number 410012, Seoul, Korea, Republic of|Investigational Site Number 410016, Seoul, Korea, Republic of|Investigational Site Number 410003, Seoul, Korea, Republic of|Investigational Site Number 410008, Suwon, Korea, Republic of|Investigational Site Number 440001, Kaunas, Lithuania|Investigational Site Number 440006, Klaipeda, Lithuania|Investigational Site Number 440002, Vilnius, Lithuania|Investigational Site Number 440007, Vilnius, Lithuania|Investigational Site Number 458001, Ipoh, Malaysia|Investigational Site Number 458002, Kuching, Malaysia|Investigational Site Number 484023, Chihuahua, Mexico|Investigational Site Number 484008, Durango, Mexico|Investigational Site Number 484018, Guadalajara, Mexico|Investigational Site Number 484002, Guadalajara, Mexico|Investigational Site Number 484035, Leon, Mexico|Investigational Site Number 484009, Merida, Mexico|Investigational Site Number 484007, Metepec, Mexico|Investigational Site Number 484010, Mexicali, Mexico|Investigational Site Number 484003, Mexico City, Mexico|Investigational Site Number 484019, Monterrey, Mexico|Investigational Site Number 484020, Monterrey, Mexico|Investigational Site Number 484005, Monterrey, Mexico|Investigational Site Number 484004, Mérida, Mexico|Investigational Site Number 484001, México, D.F., Mexico|Investigational Site Number 484017, México, Mexico|Investigational Site Number 484021, Queretaro, Mexico|Investigational Site Number 528010, Amsterdam, Netherlands|Investigational Site Number 554004, Christchurch, New Zealand|Investigational Site Number 554011, Nelson, New Zealand|Investigational Site Number 554007, Otahuhu, New Zealand|Investigational Site Number 554002, Rotorua, New Zealand|Investigational Site Number 554001, Timaru, New Zealand|Investigational Site Number 604001, Lima, Peru|Investigational Site Number 604010, Lima, Peru|Investigational Site Number 604008, Lima, Peru|Investigational Site Number 604009, Lima, Peru|Investigational Site Number 604006, Lima, Peru|Investigational Site Number 604012, Lima, Peru|Investigational Site Number 604013, Lima, Peru|Investigational Site Number 604007, Lima, Peru|Investigational Site Number 604005, Lima, Peru|Investigational Site Number 608003, Cebu City, Philippines|Investigational Site Number 608001, Manila, Philippines|Investigational Site Number 616014, Bialystok, Poland|Investigational Site Number 616002, Bialystok, Poland|Investigational Site Number 616003, Bialystok, Poland|Investigational Site Number 616019, Bydgoszcz, Poland|Investigational Site Number 616054, Bytom, Poland|Investigational Site Number 616015, Elblag, Poland|Investigational Site Number 616001, Krakow, Poland|Investigational Site Number 616005, Lublin, Poland|Investigational Site Number 616030, Lublin, Poland|Investigational Site Number 616018, Poznan, Poland|Investigational Site Number 616016, Szczecin, Poland|Investigational Site Number 616006, Torun, Poland|Investigational Site Number 616031, Warszawa, Poland|Investigational Site Number 616004, Warszawa, Poland|Investigational Site Number 616017, Warszawa, Poland|Investigational Site Number 616020, Wroclaw, Poland|Investigational Site Number 616012, Wroclaw, Poland|Investigational Site Number 620002, Lisboa, Portugal|Investigational Site Number 642006, Braila, Romania|Investigational Site Number 642010, Bucharest, Romania|Investigational Site Number 642021, Bucuresti, Romania|Investigational Site Number 642001, Bucuresti, Romania|Investigational Site Number 642020, Bucuresti, Romania|Investigational Site Number 642002, Bucuresti, Romania|Investigational Site Number 642005, Galati, Romania|Investigational Site Number 643006, Kemerovo, Russian Federation|Investigational Site Number 643017, Kemerovo, Russian Federation|Investigational Site Number 643020, Moscow, Russian Federation|Investigational Site Number 643001, Moscow, Russian Federation|Investigational Site Number 643002, Moscow, Russian Federation|Investigational Site Number 643021, Moscow, Russian Federation|Investigational Site Number 643004, Moscow, Russian Federation|Investigational Site Number 643012, Moscow, Russian Federation|Investigational Site Number 643031, Moscow, Russian Federation|Investigational Site Number 643030, Moscow, Russian Federation|Investigational Site Number 643009, Novosibirsk, Russian Federation|Investigational Site Number 643016, Ryazan, Russian Federation|Investigational Site Number 643008, Saint-Petersburg, Russian Federation|Investigational Site Number 643010, Samara, Russian Federation|Investigational Site Number 643011, Saratov, Russian Federation|Investigational Site Number 643007, St-Petersburg, Russian Federation|Investigational Site Number 643032, St-Petersburg, Russian Federation|Investigational Site Number 643014, St-Petersburg, Russian Federation|Investigational Site Number 643013, Ufa, Russian Federation|Investigational Site Number 710011, Cape Town, South Africa|Investigational Site Number 710007, Cape Town, South Africa|Investigational Site Number 710009, Cape Town, South Africa|Investigational Site Number 710003, Durban, South Africa|Investigational Site Number 710002, Durban, South Africa|Investigational Site Number 710001, Johannesburg, South Africa|Investigational Site Number 710004, Kempton Park, South Africa|Investigational Site Number 710005, Pretoria, South Africa|Investigational Site Number 710006, Pretoria, South Africa|Investigational Site Number 710010, Stellenbosch, South Africa|Investigational Site Number 724016, Barakaldo, Spain|Investigational Site Number 724015, Barcelona, Spain|Investigational Site Number 724014, Cádiz, Spain|Investigational Site Number 724009, La Coruña, Spain|Investigational Site Number 724001, Málaga, Spain|Investigational Site Number 724011, Sabadell, Spain|Investigational Site Number 724012, Santiago De Compostela, Spain|Investigational Site Number 724013, Santiago De Compostela, Spain|Investigational Site Number 724022, Sevilla, Spain|Investigational Site Number 724007, Sevilla, Spain|Investigational Site Number 752002, Uppsala, Sweden|Investigational Site Number 158006, Taichung, Taiwan|Investigational Site Number 158002, Taoyuan County, Taiwan|Investigational Site Number 764001, Bangkok, Thailand|Investigational Site Number 764003, Bangkok, Thailand|Investigational Site Number 792008, Gaziantep, Turkey|Investigational Site Number 804003, Dnipro, Ukraine|Investigational Site Number 804010, Kharkiv, Ukraine|Investigational Site Number 804013, Kharkiv, Ukraine|Investigational Site Number 804014, Kyiv, Ukraine|Investigational Site Number 804004, Kyiv, Ukraine|Investigational Site Number 804027, Kyiv, Ukraine|Investigational Site Number 804005, Lviv, Ukraine|Investigational Site Number 804006, Simferopol, Ukraine|Investigational Site Number 804011, Vinnytsya, Ukraine|Investigational Site Number 804009, Zaporizhzhya, Ukraine|Investigational Site Number 826004, Doncaster, United Kingdom|Investigational Site Number 826006, Edinburgh, United Kingdom|Investigational Site Number 826002, Leytonstone, United Kingdom|Investigational Site Number 826005, Southampton, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/52/NCT01146652/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/52/NCT01146652/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01146652"
549,"NCT00710619","Observational Patient Diary Study of Treatment Doses for Patients With Haemophilia With Inhibitors to Factors VIII and IX","DOSE","Completed","No Results Available","Congenital Bleeding Disorder|Haemophilia A With Inhibitors|Haemophilia B With Inhibitors","Drug: activated recombinant human factor VII|Drug: Feiba VH","Characterisation of dose and dosing intervals for each bleeding episode|Effect of type of bleed on initial dose, dosing interval and total dose|Effect of initial dose and dosing interval on total dose, time to first perceived improvement, time to perceived bleed resolution|Effect of time to first dose on dosing interval and total dose|Effect of bleeds and drug administration time on planned daily activities|Relationship of dose and dosing intervals to reported SAEs","Novo Nordisk A/S","Male","Child, Adult, Older Adult",,"52","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","F7HAEM-1965","June 2008","July 2009","July 2009","July 4, 2008",,"November 17, 2016","Novo Nordisk Investigational Site, Plainsboro, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT00710619"
550,"NCT00141973","Time Course of Procalcitonin and C Reactive Protein in Septic Patients Under Treatment With Corticosteroids",,"Completed","No Results Available","Sepsis",,,"Ospedale Regionale Bellinzona e Valli|Brahms SA, D-16761 Hennigsdorf bei Berlin","All","50 Years to 80 Years   (Adult, Older Adult)",,,"Other","Observational","Time Perspective: Prospective","CE1408","November 2004",,"December 2005","September 2, 2005",,"May 14, 2008","Ospedale Regionale Bellinzona e Valli, Bellinzona, Ticino, Switzerland",,"https://ClinicalTrials.gov/show/NCT00141973"
551,"NCT03570944","Postoperative Outcomes Within an Enhanced Recovery After Surgery Protocol (POWER2)","POWER2","Unknown status","No Results Available","Arthroplasty, Replacement, Hip|Arthroplasty, Replacement, Knee","Procedure: HRS, KRS","30 day postoperative complications|Mortality|Hospital Stay","Grupo Español de Rehabilitación Multimodal","All","18 Years to 120 Years   (Adult, Older Adult)",,"3012","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RedGerm02","October 22, 2018","February 28, 2019","March 28, 2019","June 27, 2018",,"March 6, 2019","Hospital Universitario Infanta Leonor, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT03570944"
552,"NCT00108758","Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia",,"Completed","No Results Available","Congenital Bleeding Disorder|Haemophilia A With Inhibitors|Haemophilia B With Inhibitors","Drug: activated recombinant human factor VII","Reduction of bleeds|Efficacy variables","Novo Nordisk A/S","Male","2 Years and older   (Child, Adult, Older Adult)","Phase 2","23","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","F7HAEM-1505","March 2004","November 2005","November 2005","April 19, 2005",,"January 12, 2017","Novo Nordisk Investigational Site, Berkeley, California, United States|Novo Nordisk Investigational Site, Los Angeles, California, United States|Novo Nordisk Investigational Site, Chicago, Illinois, United States|Novo Nordisk Investigational Site, Indianapolis, Indiana, United States|Novo Nordisk Investigational Site, Iowa City, Iowa, United States|Novo Nordisk Investigational Site, New Orleans, Louisiana, United States|Novo Nordisk Investigational Site, Boston, Massachusetts, United States|Novo Nordisk Investigational Site, Detroit, Michigan, United States|Novo Nordisk Investigational Site, Newark, New Jersey, United States|Novo Nordisk Investigational Site, New Hyde Park, New York, United States|Novo Nordisk Investigational Site, Philadelphia, Pennsylvania, United States|Novo Nordisk Investigational Site, Philadelphia, Pennsylvania, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Ciudad Autónoma de Bs. As., Argentina|Novo Nordisk Investigational Site, Campinas, Sao Paulo, Brazil|Novo Nordisk Investigational Site, Belo Horizonte, Brazil|Novo Nordisk Investigational Site, Recife, Brazil|Novo Nordisk Investigational Site, Ribeirao Preto, Brazil|Novo Nordisk Investigational Site, Rio de Janeiro, Brazil|Novo Nordisk Investigational Site, Sofia, Bulgaria|Novo Nordisk Investigational Site, Kremlin-Bicêtre, France|Novo Nordisk Investigational Site, Lille, France|Novo Nordisk Investigational Site, Paris, France|Novo Nordisk Investigational Site, Manila, Philippines|Novo Nordisk Investigational Site, Gdansk, Poland|Novo Nordisk Investigational Site, Lublin, Poland|Novo Nordisk Investigational Site, Warszawa, Poland|Novo Nordisk Investigational Site, Warszawa, Poland|Novo Nordisk Investigational Site, Timisoara, Timis, Romania|Novo Nordisk Investigational Site, Bucharest, Romania|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Johannesburg, Gauteng, South Africa|Novo Nordisk Investigational Site, Madrid, Spain|Novo Nordisk Investigational Site, Santander, Spain|Novo Nordisk Investigational Site, Sevilla, Spain|Novo Nordisk Investigational Site, Bornova-IZMIR, Turkey|Novo Nordisk Investigational Site, Capa-ISTANBUL, Turkey",,"https://ClinicalTrials.gov/show/NCT00108758"
553,"NCT02465229","Comparison of Diagnostic Accuracy Before or After Stricture Dilation in Biliary Stricture",,"Unknown status","No Results Available","Biliary Strictures","Procedure: Multimodal tissue-sampling methods before and after stricture dilation","Diagnostic accuracy of multimodal tissue-sampling before and after dilation|Diagnostic accuracy of individual tissue-sampling method","National Taiwan University Hospital","All","20 Years and older   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","201406071RINA","December 2015","June 2016","December 2016","June 8, 2015",,"December 18, 2015",,,"https://ClinicalTrials.gov/show/NCT02465229"
554,"NCT04040673","RAman For Thyroid cancER","RAFTER","Not yet recruiting","No Results Available","Thyroid Diseases|Thyroid Cancer","Procedure: thyroid lobectomy|Device: Raman spectroscopy probe measurement","Test the Raman needle probe on freshly exised tissue|Calculate diagnostic performance of Raman spectroscopy probe for thyroid cancer","Gloucestershire Hospitals NHS Foundation Trust","All","18 Years and older   (Adult, Older Adult)",,"40","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","18/044/GHT|245612|18/LO/1545","September 1, 2021","October 1, 2022","October 1, 2022","August 1, 2019",,"July 27, 2021","Biophotonics Research Unit, Gloucester, Gloucestershire, United Kingdom","""Study Protocol and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/73/NCT04040673/Prot_ICF_000.pdf","https://ClinicalTrials.gov/show/NCT04040673"
555,"NCT01631149","Effect of Deep BLock on Intraoperative Surgical Conditions","BLISS","Completed","Has Results","Prostate Hypertrophy|Renal Disease","Drug: Surgical block (rocuronium; atracurium/mivacurium)","Surgical Rating Scale|Breathing|Post-operative Pain|Postoperative Sedation Score|Nausea and Vomiting","Leiden University Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 4","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","bliss s","June 2012","March 2013","March 2013","June 28, 2012","October 17, 2016","October 17, 2016","Leiden University Medical Center, Leiden, ZH, Netherlands",,"https://ClinicalTrials.gov/show/NCT01631149"
556,"NCT02628340","Comprehensive Analysis of HIV Reservoirs in Chronically Infected HIV-1 Treated Patients","RESACHRON","Completed","No Results Available","HIV","Other: Ex-vivo analysis","measure of HIV reservoirs in a selected HIV chronically infected ARV treated population assessed by HIV DNA distribution in PBMCs, total and sorted CD4 T cells subsets.|measure of host molecular signatures and transcriptional activity in each subset assessed by microfluidic qRT-PCR (Fluidigm)|measure of in vitro inducibility of the HIV provirus in the different sorted CD4 subsets harboring the HIV réservoirs assessed by ultrasensitive real-time RT-PCR assay|measure of defective viral population estimated by the proportion of stop codons in the integrated HIV-DNA assessed by ultra deep sequencing and|measure of levels of unspliced HIV transcripts in total and different subsets of CD4 T cells.|measure of serum inflammatory biomarkers assessed by ELISA assay|measure of immune activation in the different sorted CD4 T cell subsets assessed by flow cytometry on fresh blood","Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida|INSERM UMR S 1136|Bristol-Myers Squibb","All","18 Years and older   (Adult, Older Adult)",,"20","Other|Industry","Observational","Time Perspective: Cross-Sectional","CREPATS 002","June 2014","June 2016","July 2016","December 11, 2015",,"August 2, 2016","Groupe Hospitalier Pitié-Salpêtrière - Service des Maladies Infectieuses et Tropicales, Paris, France",,"https://ClinicalTrials.gov/show/NCT02628340"
557,"NCT01930747","Effect of Deep Neuromuscular Block (NMB), Inhalation or TIVA on Pneumoperitoneum.","TIVA","Completed","Has Results","Muscle Relaxation","Drug: rocuronium|Drug: Sevoflurane|Drug: remifentanyl","Effect of Anesthetics on the Pressure at Zero Volume (PV0) Measured During Insufflation of the Abdomen|Effect of Anesthetics on the Abdominal Elastance (E) Measured During Insufflation of the Abdomen by|Adverse Events Difference Between the Three Groups","AZ Sint-Jan AV","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 4","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","2013JPM2","April 2013","December 2015","April 2016","August 29, 2013","May 29, 2019","May 29, 2019","Azsintjan, Brugge, Belgium",,"https://ClinicalTrials.gov/show/NCT01930747"
558,"NCT04072237","Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia",,"Completed","Has Results","Hemophilia A|Hemophilia B|Hemophilia A With Inhibitor|Hemophilia B With Inhibitor|Hemophilia A Without Inhibitor|Hemophilia B Without Inhibitor","Biological: MarzAA (marzeptacog alfa [activated])","Comparative MarzAA Activity by Dose Level/Stage - AUC0-∞ and AUC0-last|Comparative MarzAA Activity by Dose Level/Stage - AUCT1-T2 Normalized by Dose = AUC0-last/Dose|Comparative MarzAA Activity of Intravenous and Subcutaneous - Cmax|Comparative MarzAA Activity of Intravenous and Subcutaneous - Tmax|Comparative MarzAA Activity of Intravenous and Subcutaneous - T1/2eqα|Comparative MarzAA Activity of Intravenous and Subcutaneous - T1/2λ-z|Comparative MarzAA Activity of Intravenous and Subcutaneous - CL|Comparative MarzAA Activity of Intravenous and Subcutaneous - Vd1|Comparative MarzAA Activity of Intravenous and Subcutaneous - BAabs|Comparative MarzAA Activity of Intravenous and Subcutaneous - Mean Residence Time|Effect of Split Injections on MarzAA Activity by Dose Level/Stage - AUC From T1 to T2 Norm by Dose|Effect of Split Injections on MarzAA Activity by Dose Level/Stage - AUC Infinity Obs and AUC to Last Nonzero Conc|Change in Coagulation Parameters - Prothrombin Time (PT)|Change in Coagulation Parameters - Activated Partial Thromboplastin Time (aPTT)|Change in Coagulation Parameters - Thrombin Generation Time (TGT) - TGT-Peak|Change in Coagulation Parameters - Thrombin Generation Time (TGT) - TGT-Lag and TGT-Time to Peak|Change in Coagulation Parameters - Thrombin Generation Time (TGT) - TGT-Endogenous Thrombin Potential|Change in Thrombogenicity Parameter - Fibrinogen|Change in Thrombogenicity Parameter - Prothrombin Fragments 1 + 2|Change in Thrombogenicity Parameter - Thrombin/Antithrombin|Change in Thrombogenicity Parameter - D-Dimer|Occurrence of an Antibody Response to MarzAA|Occurrence of Clinical Thrombotic Event","Catalyst Biosciences","Male","18 Years and older   (Adult, Older Adult)","Phase 1","11","Industry","Interventional","Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","MAA-102","September 24, 2019","April 30, 2020","June 17, 2020","August 28, 2019","July 16, 2021","September 13, 2021","Medical Center ""Hippocrates - N"", Plovdiv, Bulgaria|Specialized Hospital for Active Treatment of Hematological Diseases, Sofia, Bulgaria|Kirov Research Institute of Hematology and Blood Transfusion, Kirov, Russian Federation|National Medical Hematology Research Center, Moscow, Russian Federation|Municipal Policlinic # 37, City Center for Hemophilia Treatment, Saint Petersburg, Russian Federation","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT04072237/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT04072237"
559,"NCT01184183","Trial Comparison of Accuseal and Bovine Pericardial Patch During Endarterectomy",,"Completed","No Results Available","Coronary Stenosis","Procedure: Comparing Accuseal Vs. Bovine Pericardial in CEA","The aim of this study is to evaluate the perioperative and long-term complications (thrombosis of the carotid artery, and the degree of restenosis of the patched artery as determined by duplex ultrasound evaluation).|We hypothesize that the Accuseal patch will have a longer hemostasis time but a lower associated stroke rate and a longer time to restenosis than the Bovine Pericardial patch.","CAMC Health System","All","18 Years to 90 Years   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","09-02-2136","September 2009","January 2012","January 2012","August 18, 2010",,"February 19, 2020","Vascular Center of Excellence, Charleston, West Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01184183"
560,"NCT00976586","Role of Pseudogene in Incontinentia Pigmenti, and Its Potential Treatment",,"Completed","No Results Available","Incontinentia Pigmenti",,"Mutation analysis result","National Taiwan University Hospital|National Science Council, Taiwan","All","Child, Adult, Older Adult",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","200812061R","August 2009","June 2012","June 2012","September 14, 2009",,"December 4, 2013","National Taiwan University Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT00976586"
561,"NCT02590354","Analytical Treatment Interruption in HIV Positive Patients","ISALA","Completed","Has Results","HIV-1 Infection","Other: ART interruption","Assessment of the Number of Participants With a HIV Plasma Viral Load Below the Lower Limit of Detection 48 Weeks Following Interruption of Antiretroviral Treatment|Number of Patients With and the Severity of Adverse Events That Are Related to the Study Intervention, Graded According to NCI CTCAE Version 4.0|Evaluation of the Reservoir Replenishment Upon Interruption of Antiretroviral Treatment (TI) by Quantifying the Viral Reservoir at Baseline (i.e. Just Before TI) and at Viral Rebound (Total HIV DNA).|Evaluation of the Reservoir Replenishment Upon Interruption of Antiretroviral Treatment (TI) by Quantifying the Viral Reservoir at Baseline (i.e. Just Before TI) and at Viral Rebound (Unspliced RNA).|Assessment of the Kinetics of HIV Viral Load Rebound After Treatment Interruption Based on the Repetitive Plasma Viral Load Measurements.","Institute of Tropical Medicine, Belgium|University Hospital, Ghent|Universitair Ziekenhuis Brussel|Saint-Pierre University Hospital|Agentschap voor Innovatie door Wetenschap en Technologie","All","18 Years to 64 Years   (Adult)","Not Applicable","114","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","ITM0714","January 25, 2016","June 22, 2018","June 22, 2018","October 29, 2015","September 24, 2019","September 24, 2019","Institute of Tropical Medicine, Antwerp, Belgium|Saint-Pierre University Hospital, Brussels, Belgium|Brussels University Hospital, Brussels, Belgium|Ghent University Hospital, Ghent, Belgium","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/54/NCT02590354/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/54/NCT02590354/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02590354"
562,"NCT02201576","Bortezomib in Rejection of Kidney Transplants","TRIBUTE","Completed","No Results Available","Chronic Antibody-mediated Transplant Rejection","Drug: Bortezomib|Drug: Plasma exchanges and intravenous immunoglobulins","histological lesions of humoral rejection and immunodominant donor specific antibody|histological lesions of humoral rejection|immunodominant donor specific antibody|all donor specific antibodies at one year|all donor specific antibodies|Histological lesions|renal function and proteinuria|Safety of bortezomib in renal transplant recipients|Patient and graft survival|T and B lymphocytes subsets with bortezomib","Assistance Publique - Hôpitaux de Paris|Fondation Centaure","All","18 Years and older   (Adult, Older Adult)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P120119","February 11, 2015","July 16, 2020","July 16, 2020","July 28, 2014",,"September 16, 2020","Hopital Necker Enfants-malades, Paris, France",,"https://ClinicalTrials.gov/show/NCT02201576"
563,"NCT03138967","Investigation of Sugammadex in Outpatient Urological Procedures",,"Completed","Has Results","Malignant Neoplasms of Urinary Tract|Bladder Cancer","Drug: Rocuronium|Drug: Sugammadex|Drug: Neostigmine|Drug: Glycopyrrolate","Muscle Recovery Time|PostOperative Complications|Overall Recovery Time","M.D. Anderson Cancer Center|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 4","54","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","2015-1007","September 18, 2017","September 1, 2018","November 24, 2019","May 3, 2017","July 26, 2019","September 22, 2020","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/67/NCT03138967/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03138967"
564,"NCT03784794","Patient Blood Management for Massive Obstetric Hemorrhage",,"Completed","No Results Available","Post Partum Hemorrhage|Fibrinogenolysis; Hemorrhage|Fibrinogen; Deficiency, Acquired|Massive Hemorrhage|Transfusion Related Complication","Diagnostic Test: Thromboelastometry|Diagnostic Test: Standard Coagulation Test|Drug: Fibrinogen Concentrate Human|Drug: Prothrombin Complex Concentrates|Other: Platelets|Other: Red Blood Cells|Other: Fresh Frozen Plasma|Other: cryoprecipitates","Number of Blood products transfused|Number of hemocomponents or fibrinogen concentrates needed to treat hypofibrinogenemia|Incidence of Red Blood Cells transfusion (RBC)|Incidence of Massive Red Blood Cells transfusion (RBC)|estimated blood loss|Time to bleeding control|Incidence of coagulopathy|Incidence of hysterectomy|Incidence of re-surgery|Incidence of Transfused associated circulatory overload|Incidence of surgical site infection or sepsis|Incidence of ICU admission|In-hospital mortality","Angel Augusto Perez Calatayud|Grupo Mexicano para el Estudio de la Medicina Intensiva","Female","18 Years to 45 Years   (Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","099/21012018/MEDCRITICAHENM","November 1, 2018","November 30, 2020","December 30, 2020","December 24, 2018",,"June 8, 2021","Hospital de Especialidades Del Niño Y La Mujer, Querétaro City, Queretaro, Mexico",,"https://ClinicalTrials.gov/show/NCT03784794"
565,"NCT01766856","Eustachian Tube Function and Myringoplasty/Tympanoplasty",,"Terminated","No Results Available","Tympanic Membrane Perforation","Other: Eustachian tube function testing","Healing of perforation|Recurrence of otitis media","University of Pittsburgh|Department of Pediatric Otolaryngology","All","3 Years to 16 Years   (Child)",,"19","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","PRO12040564","November 2012","November 2, 2017","November 2, 2017","January 11, 2013",,"January 9, 2018","ENT Research Center, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01766856"
566,"NCT05117658","Study of HA121-28 in Patients With Non-Small Cell Lung Cancer",,"Not yet recruiting","No Results Available","NSCLC","Drug: HA121-28 tablet","Objective Response Rate (ORR)|ORR|Progression-Free Survival (PFS)|PFS|Overall survival (OS)|Disease Control Rate (DCR)|DCR|Duration of Response (DOR)|DOR|Incidence of treatment-related adverse events (AEs) and serious adverse events (SAEs).","CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","83","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HA122-CSP-004","November 2021","March 2023","November 2023","November 11, 2021",,"November 19, 2021","Sun Yat-sen University Cancer Centre, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT05117658"
567,"NCT02419807","Comparison of Use of Indocyanine Green and 99mTc-labeled Radiotracer for Axillary Lymphatic Mapping in Patients With Breast Cancer",,"Completed","Has Results","Stage I Breast Cancer|Stage II Breast Cancer","Drug: Indocyanine Green Solution|Radiation: Technetium Tc-99m Sulfur Colloid|Procedure: Lymphoscintigraphy|Procedure: Axillary Lymph Node Biopsy","Proportion of Sentinel Lymph Nodes (SLNs) Flagged by the Two Methods","Case Comprehensive Cancer Center|National Cancer Institute (NCI)|Mitaka USA, Inc.","Female","Child, Adult, Older Adult","Not Applicable","102","Other|NIH|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","CASE10114","February 17, 2015","February 2019","February 2019","April 17, 2015","October 22, 2020","November 16, 2020","Cleveland Clinic Taussig Cancer Instititute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/07/NCT02419807/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/07/NCT02419807/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT02419807"
568,"NCT03946657","Anesthetics and Cerebral Oxygenation in LSG",,"Completed","No Results Available","Morbid Obesity|Bariatric Surgery Candidate|Anesthesia","Drug: Inhalational anesthetic|Drug: Intravenous anesthetic","Cerebral oxygen saturation|Arterial Blood Gas (ABG) analysis-pH|Arterial Blood Gas (ABG) analysis-Partial pressure of carbon dioxide|Arterial Blood Gas (ABG) analysis-Hemoglobin|The heart rate (HR) measurement|The oxygen saturation measurement|The mean arterial pressure measurement|The end-tidal carbon dioxide partial pressure measurement|The anesthesia time (min)|The reverse-Trendelenburg time (min)|The pneumoperitoneum time (min)|The recovery time (min)","Ondokuz Mayıs University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care","B.30.2.ODM.0.20.08/27-230","January 20, 2019","June 1, 2019","June 1, 2019","May 10, 2019",,"July 22, 2020","Ondokuz Mayis Universitesi, Samsun, Atakum, Turkey",,"https://ClinicalTrials.gov/show/NCT03946657"
569,"NCT04280081","A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation","LIBRETTO-321","Active, not recruiting","No Results Available","Solid Tumor|Medullary Thyroid Cancer","Drug: Selpercatinib","Overall Response Rate (ORR): Percentage of Participants with Complete Response (CR) or Partial Response (PR) by Independent Review Committee|Duration of Response (DoR) by IRC|Time to Response (TTR) by IRC|Clinical Benefit Rate (CBR): Percentage of Participants Who Achieve CR, PR or Stable Disease (SD) With a Duration of At Least 16 or More Weeks|Progression Free Survival (PFS) by IRC|Overall Survival (OS)|Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of Selpercatinib","Loxo Oncology, Inc.|Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 2","75","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17492|J2G-GH-JZJK","March 16, 2020","March 25, 2021","November 20, 2025","February 21, 2020",,"July 16, 2021","Nanfang Affiliated Hospital South Medical University, Guangzhou, Guangdong, China|The First Affiated Hospital Of Guangzhou Medical Collage, Guangzhou, Guangzhou, China|Hunan Cancer Hospital, Changsha, Hunan, China|Jilin Province Tumor Hospital, Changchun, Jilin, China|Jinan Central Hospital, Jinan, Shandong, China|Shanghai Chest Hospital, Shanghai, Shanghai/China, China|Zhejiang Cancer Hospital, Hang Zhou, Zhejiang, China|First Affiliated Hosp of College of Med, Zhejiang University, Hangzhou, Zhejiang, China|Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China|Beijing Cancer Hospital, Beijing, China|Fudan University Shanghai Cancer Center, Shanghai, China|Shanghai East Hospital, Shanghai, China|Tianjin Medical University Cancer Institute & Hospital, Tianjin, China",,"https://ClinicalTrials.gov/show/NCT04280081"
570,"NCT01965067","Influence of Mild Hypothermia on Reversal of Rocuronium With Sugammadex",,"Completed","Has Results","Underdosing of Other General Anesthetics","Drug: sugammadex","Reversal Time of Rocuronium|Mean Arterial Blood Pressure|Heart Rate","MSD Korea Ltd.","All","20 Years to 65 Years   (Adult, Older Adult)","Phase 4","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MK8616-099","October 2013","February 2014","April 2014","October 18, 2013","August 15, 2014","August 15, 2014","Department of Anesthesiology and Pain Medicine, Hanyang University Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01965067"
571,"NCT02726282","Impact of Papillary Microcarcinoma Terminology on Patients Treatment Preferences: a Cross Sectional Survey",,"Withdrawn","No Results Available","Thyroid Cancer",,"Treatment choice","Mayo Clinic","All","18 Years and older   (Adult, Older Adult)",,"0","Other","Observational","Observational Model: Other|Time Perspective: Prospective","15-008166","March 2016","March 2017","March 2017","April 1, 2016",,"July 28, 2017","Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT02726282"
572,"NCT03838692","Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer",,"Withdrawn","No Results Available","Medullary Thyroid Cancer","Drug: Ponatinib","Objective Response Rate (ORR)|Progression-Free Survival (PFS)","Antonio Fojo|Millennium Pharmaceuticals, Inc.|Columbia University","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AAAR5196","July 26, 2019","June 14, 2021","June 14, 2021","February 12, 2019",,"October 13, 2021",,,"https://ClinicalTrials.gov/show/NCT03838692"
573,"NCT02648503","Deep Neuromuscular Block and Sugammadex Versus Standard of Care on Quality of Recovery in Patient Undergo Elective Laparoscopic Cholecystectomy",,"Unknown status","No Results Available","Neuromuscular Block","Drug: Deep neuromuscular block|Drug: Moderate neuromuscular block","Quality of recovery|Shoulder tip pain","University of Medicine and Pharmacy at Ho Chi Minh City|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 4","120","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","8616-138","March 2016","September 2016","December 2016","January 7, 2016",,"January 7, 2016","Operation theathre, Ho Chi Minh, Vietnam",,"https://ClinicalTrials.gov/show/NCT02648503"
574,"NCT03506048","Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer",,"Terminated","No Results Available","Differentiated Thyroid Gland Carcinoma|Thyroid Gland Follicular Carcinoma|Thyroid Gland Papillary Carcinoma","Drug: Lenvatinib","Time-to-progression|Best objective response|Change in thyroglobulin levels|Change in thyroglobulin antibody levels","Emory University|Eisai Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","3","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00101617|NCI-2018-00144|Winship4271-18","January 16, 2019","June 24, 2021","June 24, 2021","April 23, 2018",,"June 29, 2021","Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT03506048"
575,"NCT03545308","Pharmacokinetics of Rocuronium for Deep Block (DeepRocu)","DeepRocu","Completed","No Results Available","Neuromuscular Blockade","Drug: Rocuronium","Onset|intubation|Post Tetanic Count recovery|Recovery Train of Four|Antagonization","Centre Hospitalier Universitaire de Nīmes","All","18 Years to 85 Years   (Adult, Older Adult)",,"250","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","2016-01-01","August 25, 2017","March 1, 2018","March 1, 2018","June 4, 2018",,"June 4, 2018","CHU Nimes, Nîmes, Gard, France",,"https://ClinicalTrials.gov/show/NCT03545308"
576,"NCT02866253","Dehydroepiandrosterone (DHEA)Supplementation Pre-IVF(In Vitro Fertilization) Cycles","IVF","Completed","No Results Available","Infertility","Drug: DHEA","Implantation rate","ShangHai Ji Ai Genetics & IVF Institute","Female","25 Years to 42 Years   (Adult)","Phase 4","78","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","ShangHaiJiAi-05","December 2014","December 2015","February 2016","August 15, 2016",,"September 19, 2019",,,"https://ClinicalTrials.gov/show/NCT02866253"
577,"NCT03753919","Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial","DUTHY","Recruiting","No Results Available","Metastatic Thyroid Papillary Carcinoma|Metastatic Thyroid Follicular Carcinoma|Metastatic Thyroid Cancer","Drug: Durvalumab|Drug: Tremelimumab","Progression-free survival rate at 6 months|Overall survival rate at 6 months|Overall response rate (ORR)|Duration of response (DoR)|Median progression-free survival|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Median Overall Survival|Response status after start of study treatment","Grupo Espanol de Tumores Neuroendocrinos|MFAR","All","18 Years and older   (Adult, Older Adult)","Phase 2","46","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GETNE-T1812|2018-001066-42","April 2, 2019","December 2021","December 2021","November 27, 2018",,"March 17, 2021","Instituto Catalán de Oncología de Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital Provincial de Castellón, Castelló, Valencia, Spain|Hospital Clínic Barcelona, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|MD Anderson Cancer Center, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario HM Sanchinarro, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital General Universitario Morales Meseguer, Murcia, Spain|Hospital Universitario Virgen de la Victoria, Málaga, Spain|Clínica Universidad de Navarra, Pamplona, Spain|Instituto Valenciano de Oncología, Valencia, Spain|Complejo Hospitalario Universitario de Vigo (CHUVI), Vigo, Spain",,"https://ClinicalTrials.gov/show/NCT03753919"
578,"NCT03159663","Assessment of Quality of Life in Hemophiliac Patients",,"Unknown status","No Results Available","Improvement of Quality of Life of Hemophiliac Patients",,"evaluation and improvement of quality of life of hemophiliac patients","Assiut University","Male","10 Years to 70 Years   (Child, Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Assiut1987","June 1, 2017","June 1, 2017","July 1, 2018","May 19, 2017",,"May 23, 2017","Assuit University, Assiut, Egypt",,"https://ClinicalTrials.gov/show/NCT03159663"
579,"NCT01555749","Investigation of the Pharmacokinetics of NNC172-2021, at Two Different Dose Levels, in Healthy Japanese Subjects",,"Completed","No Results Available","Congenital Bleeding Disorder|Haemophilia A|Haemophilia B|Healthy","Drug: NNC172-2021|Drug: placebo","Area under the curve from time point 0 to infinity (AUC0-∞) of NNC172-2021|Maximal concentration of NNC172-2021 (Cmax)|Time point for maximal concentration (tmax)|Terminal half-life (t1/2)|Number of adverse events (AEs)|Presence of antibodies against NNC172-2021|Residual tissue factor pathway inhibitor (TFPI) functionality measured by coagulation factor Xa (FXa) generation|TFPI concentration measured by tissue factor pathway inhibitor (TFPI) enzyme-linked immunosorbent assay (ELISA)","Novo Nordisk A/S","Male","20 Years to 64 Years   (Adult)","Phase 1","8","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","NN7415-3981|2011-004575-36|U1111-1124-5137","March 12, 2012","May 8, 2012","May 8, 2012","March 15, 2012",,"February 27, 2017","Novo Nordisk Investigational Site, Harrow, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01555749"
580,"NCT01228669","Safety of NNC 0172-0000-2021 in Healthy Male Subjects and Subjects With Haemophilia A or B","Explorer 1","Completed","No Results Available","Congenital Bleeding Disorder|Haemophilia A|Haemophilia B|Healthy","Drug: NNC 0172-0000-2021|Drug: placebo","Number of adverse Events (AEs), including Serious Adverse Events (SAEs)|Area under the concentration-time curve|Adverse Events (AEs), including Serious Adverse Events (SAEs)","Novo Nordisk A/S","Male","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","52","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","NN7415-3813|2010-020465-24|U1111-1116-2356","October 25, 2010","September 10, 2012","September 10, 2012","October 26, 2010",,"May 15, 2019","Novo Nordisk Investigational Site, Wien, Austria|Novo Nordisk Investigational Site, København, Denmark|Novo Nordisk Investigational Site, Berlin, Germany|Novo Nordisk Investigational Site, Frankfurt/M., Germany|Novo Nordisk Investigational Site, Milano, Italy|Novo Nordisk Investigational Site, Kuala Lumpur, Malaysia|Novo Nordisk Investigational Site, Polokwane, Limpopo, South Africa|Novo Nordisk Investigational Site, Madrid, Spain|Novo Nordisk Investigational Site, Malmö, Sweden|Novo Nordisk Investigational Site, Zürich, Switzerland|Novo Nordisk Investigational Site, Bangkok, Thailand|Novo Nordisk Investigational Site, Harrow, United Kingdom|Novo Nordisk Investigational Site, London, United Kingdom|Novo Nordisk Investigational Site, London, United Kingdom|Novo Nordisk Investigational Site, London, United Kingdom|Novo Nordisk Investigational Site, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01228669"
581,"NCT00923481","A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...",,"Completed","Has Results","Head and Neck Neoplasms|Pheochromocytoma|Colorectal Neoplasms|Carcinoma, Non-Small-Cell Lung|Carcinoma, Renal Cell","Drug: Fostamatinib disodium","Response Rate|Number of Participants With Adverse Events","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)","Phase 2","37","NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","090138|09-C-0138","April 2009","April 2009","January 2012","June 18, 2009","August 29, 2012","September 30, 2015","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00923481"
582,"NCT00951873","A Single Dose Trial Investigating Safety and Local Tolerability of Ascending Doses of Long Acting Activated Recombinant Human Factor VII in Healthy Male Volunteers",,"Completed","No Results Available","Congenital Bleeding Disorder|Haemophilia A|Haemophilia B|Healthy","Drug: activated recombinant human factor VII, long acting|Drug: placebo","Number of adverse events|Area under activity concentration-time curve from time zero to infinity","Novo Nordisk A/S","Male","18 Years to 45 Years   (Adult)","Phase 1","38","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","NN7129-3754|2009-011267-37","July 2009","April 2010","April 2010","August 4, 2009",,"May 13, 2016","Harrow, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00951873"
583,"NCT03372993","Prospective, Non-interventional Study to Evaluate Immunogenicity of AryoSeven",,"Enrolling by invitation","No Results Available","Hemophilia A With Inhibitor|Hemophilia B With Inhibitor|Factor VII Deficiency|Glanzmann's Thrombasthenia",,"Immunogenicity (neutralising antibodies toward FVII)|Adverse Drug Reactions","AryoGen Pharmed Co.","All","Child, Adult, Older Adult",,"200","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ARY2016-01","June 13, 2016","March 2021","April 2021","December 14, 2017",,"January 8, 2021","Iranian Blood Transfusion Organization (IBTO), Tehran, Iran, Islamic Republic of|MAHTA (Iranian Hemophilia and Thrombophilia Association), Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT03372993"
584,"NCT01630538","Cyclophosphamide Therapy for Refractory Antibody-Mediated Rejection (AMR) in Kidney Transplants",,"Terminated","No Results Available","Antibody Mediated Rejection","Drug: Cyclophosphamide","Microvascular inflammation|titre of donor specific antibody (DSA)|antibody-mediated tissue injury|Urine Albumin/Creatinine ratios|Creatinine Clearance and estimated GFR|Graft Survival|Patient Survival","University of Manitoba","All","18 Years and older   (Adult, Older Adult)","Phase 2","4","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TMCT-01","June 2013","January 18, 2018","January 18, 2018","June 28, 2012",,"April 19, 2018","Transplant Manitoba Adult Kidney Transplant Program, Health Sciences Centre, Winnipeg, Manitoba, Canada",,"https://ClinicalTrials.gov/show/NCT01630538"
585,"NCT04194944","A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer","LIBRETTO-431","Recruiting","No Results Available","Non-Small Cell Lung Cancer","Drug: Selpercatinib|Drug: Carboplatin|Drug: Cisplatin|Drug: Pemetrexed|Drug: Pembrolizumab","Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) (with Pembrolizumab)|PFS by BICR (with or without Pembrolizumab)|Disease Control Rate (DCR) by BICR (with Pembrolizumab)|DCR by BICR (with or without Pembrolizumab)|PFS2 (with Pembrolizumab)|PFS2 (with or without Pembrolizumab)|Overall Response Rate (ORR): Percentage of Participants with Complete Response (CR) or Partial Response (PR) by BICR (with Pembrolizumab)|ORR: Percentage of Participants with CR or PR by BICR (with or without Pembrolizumab)|Duration of Response (DoR) by BICR (with Pembrolizumab)|DOR by BICR (with or without Pembrolizumab)|Overall Survival (OS) (with Pembrolizumab)|OS (with or without Pembrolizumab)|Intracranial ORR: Percentage of Participants with Intracranial CR or PR per RECIST (Response Evaluation Criteria in Solid Tumors) 1.1 by BICR (with Pembrolizumab)|Intracranial ORR: Percentage of Participants with Intracranial CR or PR per RECIST 1.1 by BICR (with or without Pembrolizumab)|Intracranial DOR per RECIST 1.1 by BICR (with Pembrolizumab)|Intracranial DOR per RECIST 1.1 by BICR (with or without Pembrolizumab)|Time to Deterioration of Pulmonary Symptoms (with Pembrolizumab)|Time to Deterioration of Pulmonary Symptoms (with or without Pembrolizumab)|The Concordance of the Local Lab and the Central Lab RET Results: Percentage of Participants with RET-Positive Specimens as Called by the Central Lab, which is also RET-Positive as Called by a Local Lab (Positive Percent Agreement)|Time to CNS Progression per RECIST 1.1 by BICR (with Pembrolizumab)|Time to CNS Progression per RECIST 1.1 by BICR (with or without Pembrolizumab)|Intracranial ORR: Percentage of Participants with Intracranial CR or PR per Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) by BICR (with Pembrolizumab)|Intracranial ORR: Percentage of Participants with Intracranial CR or PR per RANO-BM by BICR (with or without Pembrolizumab)|Intracranial DOR per RANO-BM by BICR (with Pembrolizumab)|Intracranial DOR per RANO-BM by BICR (with or without Pembrolizumab)","Loxo Oncology, Inc.|Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 3","250","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17479|J2G-MC-JZJC|2019-001979-36","February 17, 2020","January 15, 2023","August 18, 2025","December 11, 2019",,"January 19, 2022","Centro de Oncología e Investigación de Buenos Aires, Berazategui, Buenos Aires, Argentina|Fundacion CENIT para la Investigacion en Neurociencias, Caba, Buenos Aires, Argentina|Clinica Viedma, Viedma, Río Negro, Argentina|Instituto Alexander Fleming, Ciudad de Buenos Aires, Argentina|Clínica El Castaño, San Juan, Argentina|Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia|Calvary Mater Newcastle, Waratah, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Monash Medical Centre, Clayton, Victoria, Australia|Slade Pharmacy, Frankston, Victoria, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|St. Vincent's Hospital, Melbourne, Victoria, Australia|Peninsula & South Eastern Haematology and Oncology Group, Frankston, Australia|ZNA Middelheim, Antwerp, Antwerpen, Belgium|Universitair Ziekenhuis Brussel, Jette, Brussel, Belgium|UZ Gent Hospital, Gent, Belgium|Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg, Leuven, Belgium|AZ Sint-Maarten, Campus Leopoldstraat 2, Mechelen, Belgium|CHU UCL Namur/Site Sainte Elisabeth, Namur, Belgium|AZ Delta, Roeselare, Belgium|AZ Nikolaas, Campus Moerland, Sint Niklaas, Belgium|Núcleo de Oncologia da Bahia, Salvador, Bahia, Brazil|Oncocentro BH, Belo Horizonte, Minas Gerais, Brazil|Hospital de Cancer de Londrina, Londrina, Paraná, Brazil|Hospital São Lucas da PUCRS, Porto Alegre, Rio Grande Do Sul, Brazil|Grupo COI - Clínicas Oncológicas Integradas, Rio de Janeiro, RJ, Brazil|Fundação Pio XII - Hospital de Câncer de Barretos, Barretos, Sao Paulo, Brazil|Clinica Onco Star, Sao Paulo, SP, Brazil|Hospital PUC-CAMPINAS, Campinas, São Paulo, Brazil|Hospital das Clinicas da FMRP, Ribeirao Preto, São Paulo, Brazil|INCA Hospital do Câncer III, Rio de Janeiro, Brazil|Oncoclinicas Rio de Janeiro S.A., Rio de Janeiro, Brazil|Soc. Beneficente de Senhoras Hospital Sirio Libanes-Oncology, Sao Paolo, Brazil|Icesp - Instituto Do Câncer Do Estado de São Paulo, Sao Paulo, Brazil|Centro Paulista de Oncologia, São Paulo, Brazil|Cross Cancer Institute, Edmonton, Alberta, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|Beijing Cancer hospital, Beijing, Beijing, China|First affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China|The First Affiated Hospital Of Guangzhou Medical Collage, Guangzhou, Guangzhou, China|Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China|Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China|Hunan Cancer Hospital, Changsha, Hunan, China|Changzhou No.2 People's Hospital, Changzhou, Jiangsu, China|Xuzhou central Hospital, Xuzhou, Jiangsu, China|Jilin Cancer Hospital, Changchun, Jilin, China|Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China|Shanghai Pulmonary Hospital, Shanghai, Shanghai, China|West China Hospital of Sichuan University, Cheng Du, Sichuan, China|Xinjiang Medical University Cancer Hospital, Urumqi, Xinjiang, China|Sir Run Run Shaw Hospital, Hangzhou, Zhejiang, China|Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China|People's Hospital of Hunan Province, Changsha, China|First Affiliated Hosp of College of Med, Zhejiang University, Hangzhou, China|Shanghai Chest Hospital, Shanghai, China|Fakultni nemocnice Olomouc, Olomouc, Czechia|Nemocnice AGEL Ostrava-Vitkovice a.s.-Plicni oddeleni, Ostrava - Vitkovice, Czechia|Fakultni nemocnice Bulovka, Praha 8, Czechia|Centre Jean Perrin - Centre Régional de Lutte contre le Cancer d'Auvergne, Clermont-Ferrand, Puy-de-Dôme, France|Centre Leon Berard, Lyon, Rhône-Alpes, France|CHU Grenoble Alpes- Hopital Albert Michallon, Cs10217 Grenoble Cedex 9, France|Assistance Publique Hôpitaux de Marseille - Hôpital Nord, Marseille Cedex 20, France|Institut du Cancer de Montpellier - Val d'aurelle, Montpellier Cedex 5, France|Hopital Cochin, Paris, France|Thoraxklinik-Heidelberg gGmbH, Heidelberg, Baden-Württemberg, Germany|Asklepios Fachkliniken München-Gauting, Gauting, Bayern, Germany|Klinikverbund Kempten-Oberallgäu, Immenstadt, Bayern, Germany|Franziskus-Hospital Harderberg, Georgsmarienhütte, Niedersachsen, Germany|Universitätsmedizin Göttingen, Göttingen, Niedersachsen, Germany|Universitätsklinikum Köln, Köln, Nordrhein-Westfalen, Germany|LungenClinic Grosshansdorf, Grosshansdorf, Schleswig-Holstein, Germany|Charité Campus Virchow-Klinikum, Berlin, Germany|Sotiria Thoracic Diseases Hospital of Athens, Athens, Attikí, Greece|University General Hospital of Heraklion, Heraklion, Irakleío, Greece|European Interbalkan Medical Center, Thessaloniki, Thessaloníki, Greece|G. Papanikolaou General Hospital, Thessaloniki, Thessaloníki, Greece|Hong Kong United Oncology Centre, Jordan, Kowloon, Hong Kong|Prince of Wales Hospital, Shatin, Hong Kong|Soroka Medical Center - Pediatric Outpatient Clinic, Beer-Sheva, Israel|Rambam Medical Center, Haifa, Israel|Shaare Zedek Medical Center, Jerusalem, Israel|Hadassah Medical Center, Jerusalem, Israel|Sheba Medical Center, Ramat Gan, Israel|Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, Italy|Azienda Ospedaliera San Camillo Forlanini, Roma, Lazio, Italy|Policlinico Gemelli - Università Cattolica del Sacro Cuore, Roma, Lazio, Italy|ASST Grande Ospedale Metropolitano Niguarda, Milan, Milano, Italy|Azienda Ospedaliera San Gerardo, Monza, Milano, Italy|Istituto Clinico Humanitas, Rozzano, Milano, Italy|Centro di Riferimento Oncologico, Aviano, Pordenone, Italy|Azienda Sanitaria Ospedaliera S Luigi Gonzaga, Orbassano, Torino, Italy|Ospedale G. Moscati, Avellino, Italy|IRCCS - AOU di Bologna, Bologna, Italy|Azienda Ospedlaliero-Univeristaria Pisana, Stabilimento Ospedaliero di Cisanello, Pisa, Italy|Ospedale Santa Maria delle Croci, Ravenna, Italy|I.F.O. Istituto Nazionale Tumori Regina Elena, Roma, Italy|National Cancer Center Hospital East, Kashiwa, Chiba, Japan|Hokkaido University Hospital, Sapporo, Hokkaido, Japan|Kanazawa University Hospital, Kanazawa, Ishikawa, Japan|Kanagawa cancer center, Yokohama, Kanagawa, Japan|Kindai University Hospital, Osaka Sayama-shi, Osaka, Japan|Shizuoka Cancer Center, Nagaizumi-cho,Sunto-gun, Shizuoka, Japan|National Cancer Center Hospital, Chuo-ku, Tokyo, Japan|Japanese Foundation for Cancer Research, Koto, Tokyo, Japan|Tottori University Hospital, Yonago, Tottori, Japan|Okayama University Hospital, Okayama, Japan|Osaka International Cancer Institute, Osaka, Japan|National Cancer Center, Goyang-si, Gyeonggi-do, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of|Gyeongsang National University Hospital, Jin-ju-si, Gyeongsangnam-do, Korea, Republic of|Gachon University Gil Hospital, Incheon, Korea, Korea, Republic of|Asan Medical Center, Seoul, Korea, Korea, Republic of|Seoul St. Mary's Hospital, Seoul, Korea, Korea, Republic of|Seoul National University Hospital, Seoul, Seoul, Korea, Korea, Republic of|Konyang University Hospital, Daejon, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul Municipal Boramae Hospital, Seoul, Korea, Republic of|Health Pharma Professional Research S.A. de C.V:, Mexico City, Federal District, Mexico|Actualidad Basada en la Investigación del Cáncer, Guadalajara, Jalisco, Mexico|Oncologico Potosino, S.C., San Luis Potosí, Mexico|Ziekenhuis St. Jansdal, Harderwijk, Gelderland, Netherlands|Jeroen Bosch Hospital, Den Bosch, Noord-Brabant, Netherlands|Vrije Universiteit Medisch Centrum Amsterdam, Amsterdam, Netherlands|Erasmus Medisch Centrum, Rotterdam, Netherlands|Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy, Warszawa, Poland|Institutul Oncologic, Bucharest, București, Romania|Centrul de Oncologie ""Sfântul Nectarie"", Craiova, Dolj, Romania|Cabinet Medical Oncomed, Timișoara, Timiș, Romania|Spitalul Universitar de Urgență București, Bucuresti, Romania|Gral Medical SRL, București, Romania|Institutul Oncologic ""Prof. Dr. Ion Chiricuta"" Cluj-Napoca, Cluj-Napoca, Romania|Spitalul Clinic Judetean de Urgenta Sf.Apostol Andrei Constanta, Constanta, Romania|Spitalul Judetean de Urgenta ""Sf. Ioan cel Nou"", Suceava, Romania|GBUZ Republican Clinical Oncological Dispensary, Ufa, Baškortostan, Respublika, Russian Federation|Samara Regional Clinical Oncology Center, Samara, Samarskaya Oblast', Russian Federation|N.N.Petrov Research Institute of Oncology, Saint Petersburg, Sankt-Peterburg, Russian Federation|Arkhangelsk Clinical Oncological Dispensary, Arkhangelsk, Russian Federation|SHI Kaluga Regional Hospital, Kaluga, Russian Federation|Republic Oncology Dispensary of MoH of Republic Tatarstan, Kazan, Russian Federation|First Moscow State Medical University n.a. Sechenov, Moscow, Russian Federation|Hadassah Medical LTD, Moscow, Russian Federation|Murmansk Regional Clinical Hospital, Murmansk, Russian Federation|St-Petersburg scientifical practical cente spec medical care, St. Petersburg, Russian Federation|National Cancer Centre Singapore, Singapore, Central Singapore, Singapore|Tan Tock Seng Hospital, Singapore, Singapore|CHUS - Hospital Clinico Universitario, Santiago de Compostela, A Coruña [La Coruña], Spain|Hospital Fundacion Son Llatzer, Palma de Mallorca, Baleares, Spain|Complejo Hospitalario de Jaén, Jaen, Jaén, Spain|Hospital Insular de Gran Canaria, Las palmas de gran canaria, Las Palmas, Spain|Hospital Puerta De Hierro, Majadahonda, Madrid, Spain|Clinica Universitaria De Navarra, Pamplona, Navarra, Spain|Hospital General Universitario de Alicante, Alicante, Spain|Hospital Germans Trias i Pujol, Badalona, Spain|Hospital del Mar, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitari Dexeusa, Barcelona, Spain|Institut Catala d'Oncologia, Barcelona, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Regional Universitario, Malaga, Spain|Hospital De Navarra, Pamplona, Spain|Hospital Universitario de Salamanca - Complejo Asistencial Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Hospital Universitario Virgen Del Rocio, Sevilla, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hospital Universitario La Fe de Valencia, Valencia, Spain|Changhua Christian Hospital, Changhua County, Changhua, Taiwan|Buddhist Dalin Tzu Chi General Hospital, Dalin Town, Chiayi, Taiwan|Chang Gung Memorial Hospital - Linkou, Guei Shan Township, Taoyuan County, Taiwan|E-Da hospital, Kaohsiung, Taiwan|Chang Gung Memorial Hospital - Kaohsiung Branch, Kaohsiung, Taiwan|Tri-Service General Hospital, Neihu Taipei, Taiwan|Taipei Medical University Shuang Ho Hospital, New Taipei, Taiwan|Chung Shan Medical University Hospital, Taichung, Taiwan|China Medical University Hospital, Taichung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|Chi Mei Hospital - Liouying Branch, Tainan City, Taiwan|National Cheng-Kung Uni. Hosp., Tainan, Taiwan|National Taiwan University Hospital, Taipei City, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Dicle Üniversitesi, SUR, Diyarbakır, Turkey|Ege University Medicine of Faculty, Bornova, İzmir, Turkey|Baskent University Dr. Turgut Noyan Research and Training Center, Adana, Turkey|Abdurrahman Yurtaslan Ankara Oncology, education and Research Hospital, Ankara, Turkey|Hacettepe University Faculty of Medicine, Ankara, Turkey|Trakya University, Edirne, Turkey|Istanbul Medeniyet University, Istanbul, Turkey|Izmir Ataturk Training and Research Hospital, Izmir, Turkey|Izmir Medical Park Hospital, Izmir, Turkey|Memorial Antalya Hastanesi, Kepez, Turkey|Inonu Universitesi, Malatya, Turkey|Maslak Acıbadem Hstanesi, Sarıyer, Turkey|Municipal Non-profit Enterprise ""City Clinical Hospital #4"" of Dnipro City Council, Dnipro, Dnipropetrovska Oblast, Ukraine|CNPE ""Regional Center of Oncology"", Kharkiv, Kharkivska Oblast, Ukraine|Sumy regional clinical oncological dispensary, Sumy, Sumska Oblast, Ukraine|Communal Noncommercial Enterprise ""Podillia Regional Oncology Center Of Vinnytsia Regional Council"", Vinnytsia, Vinnytska Oblast, Ukraine|Municipal Enterprise ""Volyn Regional Medical Oncology Centre"" of the Volyn Regional Council, Lutsk, Volynska Oblast, Ukraine|Chernivtsi Regional Oncological Dispensary, Chernivtsi, Ukraine|ACINUS Medical and Diagnostic Center, Kropyvnytskyi, Ukraine|Medical Center ""Mriya Med-Service"", LLC, Kryvyi Rig, Ukraine|Kyiv City Clinical Oncological Center, Kyiv, Ukraine|Odessa Regional Oncology Dispensary, Odesa, Ukraine|CI Odesa Regional Clinical Hospital, Odesa, Ukraine|Medical center ""Oncolife"", Zaporizhya, Ukraine|City Hospital, Nottingham University Hospitals, Nottingham, Nottinghamshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04194944"
586,"NCT04211337","A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer","LIBRETTO-531","Recruiting","No Results Available","Medullary Thyroid Cancer","Drug: Selpercatinib|Drug: Cabozantinib|Drug: Vandetanib","Treatment Failure-Free Survival (TFFS) by Blinded Independent Committee Review (BICR)|Progression Free Survival (PFS) by BICR|Overall Response Rate (ORR): Percentage of Participants with Complete Response (CR) or Partial Response (PR) by BICR|Duration of Response (DoR) by BICR|Overall Survival (OS)|PFS2 by Investigator|Comparative Tolerability: Percentage of Time with High Side Effect Bother Based on the Functional Assessment of Cancer Therapy-Side Effects (FACT-GP5)|The Concordance of the Local Lab and the Central Lab RET Results: Percentage of Participants with RET-Positive Specimens as Called by the Central Lab, which is also RET-Positive as Called by a Local Lab (Positive Percent Agreement)","Loxo Oncology, Inc.|Eli Lilly and Company","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","400","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17478|J2G-MC-JZJB|2019-001978-28","February 11, 2020","May 20, 2024","November 13, 2026","December 26, 2019",,"December 9, 2021","University of Alabama at Birmingham, Birmingham, Alabama, United States|Mayo Clinic Hospital, Phoenix, Arizona, United States|City of Hope National Medical Center, Duarte, California, United States|University of California San Diego, La Jolla, California, United States|UCLA Medical Center, Los Angeles, California, United States|University of California, Davis - Health Systems, Sacramento, California, United States|UCSF Medical Center at Mission Bay, San Francisco, California, United States|Los Angeles Biomedical Research Institute at Harbor - UCLA Medical, Torrance, California, United States|Mayo Clinic-Jacksonville, Jacksonville, Florida, United States|Emory University, Atlanta, Georgia, United States|University of Chi Med Center, Chicago, Illinois, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University Medical School, Saint Louis, Missouri, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University of Cincinnati Cancer Institute, Cincinnati, Ohio, United States|Ohio State University Medical Center, Columbus, Ohio, United States|University of Pennsylvania Hospital, Philadelphia, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|University of Wisconsin-Madison Hospital and Health Clinic, Madison, Wisconsin, United States|Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia|Royal North Shore Hospital, St. Leonards, New South Wales, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|Universitair Ziekenhuis Antwerpen, Edegem, Belgium|Centre Hospitalier Universitaire Sart Tilman, Liege, Belgium|Oncocentro BH, Belo Horizonte, Minas Gerais, Brazil|Hospital de Cancer de Londrina, Londrina, Paraná, Brazil|Hospital de Clinicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|INCA - Instituto Nacional Do Cancer, Rio De Janeiro, RJ, Brazil|Grupo COI - Clínicas Oncológicas Integradas, Rio de Janeiro, RJ, Brazil|Fundação Pio XII - Hospital de Câncer de Barretos, Barretos, Sao Paulo, Brazil|Clinica Onco Star, Sao Paulo, SP, Brazil|Hospital PUC-CAMPINAS, Campinas, São Paulo, Brazil|Hospital das Clinicas da FMRP, Ribeirão Preto, São Paulo, Brazil|Oncoclinicas Rio de Janeiro S.A., Rio de Janeiro, Brazil|Soc. Beneficente de Senhoras Hospital Sirio Libanes-Oncology, Sao Paolo, Brazil|Icesp - Instituto Do Câncer Do Estado de São Paulo, Sao Paulo, Brazil|Centro Paulista de Oncologia, São Paulo, Brazil|London Health Science Centre - Victoria Hospital, London, Ontario, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|Anhui Provincial Hospital, Hefei, Anhui, China|Beijing Tongren Hospital affiliated to Capital Medical Unive, Beijing, Beijing, China|The First Affiliated Hospital of Fujian Medical University, Fujian, Fuzhou, China|Gansu Province Cancer Hospital, Lanzhou, Gansu, China|Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China|Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China|Henan Cancer Hospital, Zhengzhou, Henan, China|Hunan Cancer Hospital, Changsha, Hunan, China|Jilin Cancer Hospital, Chang Chun, Ji Lin, China|Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China|Jinan Central Hospital, Jinan, Shandong, China|Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China|West China Hospital Sichuan University, Cheng Du, Sichuan, China|First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China|Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China|Sir Run Run Shaw Hospital, Hangzhou, Zhejiang, China|Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China|Chongqing Cancer Hospital, Chongqing, China|Tianjin Medical University Cancer Institute & Hospital, Tianjin, China|Tianjin People's Hospital, Tianjin, China|Fakultni nemocnice Brno, Brno, Czechia|Fakultni nemocnice Olomouc, Olomouc, Czechia|Fakultni Nemocnice v Motole, Praha 5, Czechia|Centre Georges François Leclerc, Dijon, Côte-d'Or, France|Centre Hospitalier Universitaire d'Angers, Angers, Maine-et-Loire, France|Centre Jean Perrin - Centre Régional de Lutte contre le Cancer d'Auvergne, Clermont-Ferrand, Puy-de-Dôme, France|Centre Leon Berard, Lyon, Rhône, France|Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest, Bordeaux, France|Centre Francois Baclesse, Caen Cedex 5, France|Hôpital C. HURIEZ, Lille, France|Hopital Nord de Marseille, Marseille Cedex 20, France|Hopital Pitie Salpetriere -Unité Thyroïde-Tumeurs Endocrines, PARIS- cedex 13, France|Institut de cancérologie Strasbourg Europe, Strasbourg, France|Institut Claudius Regaud, Toulouse cedex 9, France|Gustave Roussy, Villejuif Cedex, France|Klinikum der Universität München, München, Bayern, Germany|Universitätsklinikum Würzburg A. ö. R., Würzburg, Bayern, Germany|Medizinische Hochschule Hanover, Hannover, Niedersachsen, Germany|Universitatsmedizin der Johannes Gutenberg-Universitat Mainz, Mainz, Rheinland-Pfalz, Germany|Charité Campus Mitte, Berlin, Germany|Universitaetsklinikum Essen, Essen, Germany|Studiengesellschaft Hämato-Onkologie Hamburg - Prof Laack & Partner, Hamburg, Germany|Otto-von-Guericke-Universität, Magdeburg, Germany|Alexandra Hospital, Athens, Attikí, Greece|University General Hospital of Heraklion, Heraklion, Irakleío, Greece|European Interbalkan Medical Center, Thessaloniki, Thessaloníki, Greece|Regional Cancer Centre, Trivandrum, Kerala, India|HCG Manavata Cancer Centre, Nashik, Maharashtra, India|Ruby Hall Clinic and Grant Medical Foundation, Pune, Maharashtra, India|Deenanath Mangeshkar Hospital & Research Centre, Pune, Maharashtra, India|Apollo Gleneagles Hospitals Kolkata, Kolkata, West Bengal, India|Postgraduate Institute of Medical Education & Research, Chandigarh, India|Hadassah Medical Center, Jerusalem, Israel|Rabin Medical Center, Petach Tikva, Israel|Sheba Medical Center, Ramat Gan, Israel|Istituto Nazionale dei Tumori, Milano, Lombardie, Italy|Ospedale San Luca, IRCCS Istituto Auxologico, Milano, Milan, Italy|Polic.Umberto I -Univ. La Sapienza, Roma, Rome, Italy|A.O.U. Senese Policlinico Santa Maria alle Scotte, Siena, SI, Italy|Ospedale Garibaldi-Nesima, Catania, Italy|Azienda Ospedaliera Universitaria Federico II, Napoli, Italy|Istituto Oncologico Veneto IRCCS, Padova, Italy|Azienda Ospedlaliero-Univeristaria Pisana, Stabilimento Ospedaliero di Cisanello, Pisa, Italy|I.F.O. Istituto Nazionale Tumori Regina Elena, Roma, Italy|Azienda Ospedaliero-Universitaria S.Giovanni Battista, Torino, Italy|Aichi Cancer Center Hospital, Nagoya, Aichi, Japan|National Cancer Center Hospital East, Kashiwa, Chiba, Japan|Hokkaido University Hospital, Sapporo, Hokkaido, Japan|Kobe University Hospital, Kobe, Hyogo, Japan|Yokohama City University Hospital, Yokohama, Kanagawa, Japan|Osaka University Hospital, Suita-shi, Osaka, Japan|Japanese Foundation for Cancer Research, Koto, Tokyo, Japan|National Hospital Organization Kyushu Medical Center, Fukuoka, Japan|National Cancer Center, Goyang-si, Gyeonggi-do, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of|Chonnam National University Hwasun Hospital, Hwasun-gun, Jeollanam Do, Korea, Republic of|Asan Medical Center, Seoul, Korea, Korea, Republic of|Seoul National University Hospital, Seoul, Seoul, Korea, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Nederlands Kanker Instituut - Antoni van Leeuwenhoek, Amsterdam, Netherlands|Universitair Medisch Centrum Groningen, Groningen, Netherlands|Leids Universitair Medisch Centrum, Leiden, Netherlands|Maastricht UMC+, Maastricht, Netherlands|Erasmus Medisch Centrum, Rotterdam, Netherlands|Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie, Gliwice, Poland|Swietokrzyskie Centrum Onkologii w Kielcach, Kielce, Poland|National medical research center of radiology Obninsk, Obninsk, Kaluga Region, Russian Federation|Clinic of advanced medical technologies n. a. Nicolay I. Pirogov (policlinic, hospital), Saint-Petersburg, Northwestern Federal District, Russian Federation|LLC Evimed, Chelyabinsk, Russian Federation|Blokhin Cancer Research Center, Moscow, Russian Federation|National Medical Research Center of Endocrinology of Ministry of Health Dept, Moscow, Russian Federation|Saint-Petersburg City Clinical Oncology Dispensary, Saint-Petersburg, Russian Federation|Hospital Universitario Virgen de la Victoria, Malaga, Andalucia, Spain|Hospital Universitari de Girona Dr. Josep Trueta, Girona, Barcelona, Spain|Hospital Universitario Ramón y Cajal, Madrid, Madrid, Comunidad De, Spain|Clinica Universitaria De Navarra, Pamplona, Navarra, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Institut Catala d'Oncologia, Barcelona, Spain|Hospital General Universitario Gregorio Marañon, Madrid, Spain|Clinica Universidad de Navarra, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain|China Medical University Hospital, Taichung, Taiwan|National Cheng-Kung Uni. Hosp., Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|University College Hospital - London, London, Greater London, United Kingdom|Royal Marsden NHS Trust, London, Greater London, United Kingdom|Beatson West of Scotland Cancer Center, Glasgow, Scotland, United Kingdom|Velindre Hospital, Cardiff, South Glamorgan, United Kingdom|Weston Park Hospital, Sheffield, South Yorkshire, United Kingdom|Royal Marsden Hospital, Sutton, Surrey, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04211337"
587,"NCT03570021","ESTIMation of the ABiLity of Prophylactic Central Compartment Neck Dissection to Modify Outcomes in Low-risk Differentiated Thyroid Cancer","ESTIMABL3","Recruiting","No Results Available","Thyroid Cancer","Procedure: total thyroidectomy with bilateral prophylactic central compartment (level VI) neck dissection|Procedure: total thyroidectomy alone without neck dissection","Rate of patients in complete remission","Gustave Roussy, Cancer Campus, Grand Paris","All","18 Years and older   (Adult, Older Adult)","Phase 3","1000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2017-A01779-44|2017/2581","August 29, 2018","June 2026","June 2026","June 26, 2018",,"January 11, 2022","Gustave Roussy, Villejuif, Val De Marne, France",,"https://ClinicalTrials.gov/show/NCT03570021"
588,"NCT01988532","Impact of Pain on Functional Impairment and Quality of Life in Adults With Hemophilia",,"Completed","No Results Available","Congenital Bleeding Disorder|Haemophilia A|Haemophilia A With Inhibitors|Haemophilia B|Haemophilia B With Inhibitors","Other: No treatment given","Prevalence of acute (bleed-related) pain (percentage)|Prevalence of chronic (arthritic) pain (percentage)","Novo Nordisk A/S","Male","Child, Adult, Older Adult",,"381","Industry","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","HAEM-4073|U1111-1138-3464","October 2013","October 2014","October 2014","November 20, 2013",,"January 18, 2017","Novo Nordisk Investigational Site, Plainsboro, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT01988532"
589,"NCT01949792","A Trial Investigating the Pharmacokinetics and Pharmacodynamics of rFVIIa in Patients With Haemophilia A or B With or Without Inhibitors",,"Completed","No Results Available","Congenital Bleeding Disorder|Haemophilia A|Haemophilia A With Inhibitors|Haemophilia B|Haemophilia B With Inhibitors","Drug: eptacog alfa (activated)","Thromboelastography (TEG) parameter Maximum Thrombosis Generation (MTG;'maximum velocity')|TEG parameters r-time, MTG, alpha angle, and maximum amplitude (MA)","Novo Nordisk A/S","Male","18 Years and older   (Adult, Older Adult)","Phase 1","6","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NN7777-4086|2013-000040-26|U1111-1138-2521","September 2013","November 2013","November 2013","September 25, 2013",,"November 14, 2014","Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT01949792"
590,"NCT01503567","Epidemiological Study on Haemophilia Care and Orthopaedic Status in Developing Countries","HAEMOcare","Completed","No Results Available","Congenital Bleeding Disorder|Haemophilia A|Haemophilia A With Inhibitors|Haemophilia B|Haemophilia B With Inhibitors","Other: No treatment given","Type of haemophilia and inhibitor characteristics: Against FVIII or FIX; high or low titre; anamnestic response (high or low responder)|Clinical (using Haemophilia joint score) and radiological (using Pettersson score) orthopaedic status of defined joints: Elbow, knees and ankles in relation to haemophilia A or B|Mean orthopaedic score in the 4 groups according to the Pettersson and Haemophilia joint scores|Usage of anti haemophilic treatment in IU/kg|Quality of Life - EQ-5D (Euro Quality - 5 Domains) questionnaire|Economic aspects of the management of haemophiliacs and its burden on patient/family and community resources|Living characteristics of the patient's household","Novo Nordisk A/S","Male","6 Years to 18 Years   (Child, Adult)",,"282","Industry","Observational","Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional","HAEM-3971|U1111-1124-6665","January 2012","September 2012","September 2012","January 4, 2012",,"January 18, 2017","Novo Nordisk Investigational Site, Bangalore, India|Novo Nordisk Investigational Site, Casablanca, Morocco|Novo Nordisk Investigational Site, Muscat, Oman|Novo Nordisk Investigational Site, Sandton, South Africa",,"https://ClinicalTrials.gov/show/NCT01503567"
591,"NCT02609685","Active Surveillance of Papillary Thyroid Microcarcinoma","PMCAS","Recruiting","No Results Available","Papillary Thyroid Microcarcinoma","Other: Active Surveillance","Rate of disease progression|Percentage of subjects that will elect surgery despite absence of clinical progression|Impact of TSH suppression on thyroid nodule growth (in cm) as measured by ultrasound|Identify the clinicopathologic features associated with disease progression in papillary thyroid microcarcinoma patients followed with active surveillance|Identify the genetic factors associated with an increased risk of disease progression|Quality of life score as measured by City of Hope Quality of Life Scale|Anxiety score as measured by Memorial Anxiety Scale","Cedars-Sinai Medical Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","216","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","IIT2014-13-Ho-PMCAS","May 13, 2016","December 2030","December 2030","November 20, 2015",,"December 8, 2021","Cedars-Sinai Medical Center, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT02609685"
592,"NCT05138367","Effects of UCA-PSCs in Women With POF",,"Completed","No Results Available","Premature Ovarian Failure","Procedure: transplantation of human UCA-PSCs or WJ-MSCs into ovaries of POF patients","blood perfusion in the ovary|Antral Follicle Diameter|blood flow index in the ovaries","Li-jun Ding|Nanjing University","Female","18 Years to 39 Years   (Adult)","Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SZ-POF-2018-12","December 1, 2018","December 1, 2019","December 1, 2019","December 1, 2021",,"December 1, 2021","Reproductive Medicine Center, The affiliated Drum Towel Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China",,"https://ClinicalTrials.gov/show/NCT05138367"
593,"NCT02548143","LR769 in Congenital Hemophilia Patients With Inhibitors Undergoing Elective Surgery or Invasive Procedures","PerSept3","Completed","Has Results","Hemophilia","Biological: Coagulation Factor VIIa (Recombinant)","Percentage of Surgical or Other Invasive Procedures Defined as ""Good"" or ""Excellent"" Response to LR769 Treatment as Assessed by the Investigator, Based on the Totality of the Assessments Performed on the Patient|Percentages of Success as Defined as the Combination of ""Good"" and ""Excellent"" Responses by the Investigator or Designee","LFB USA, Inc.|Laboratoire français de Fractionnement et de Biotechnologies","Male","6 Months to 75 Years   (Child, Adult, Older Adult)","Phase 3","12","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LFB-FVIIa-008-14","August 25, 2016","August 6, 2017","August 31, 2017","September 14, 2015","September 6, 2019","May 14, 2020","UT Southwestern Medical Center, Dallas, Texas, United States|Dr. Jose Eleuterio Gonzalez Monterrey University Hospital, Monterrey, Nuevo Leon, Mexico|Hematology Research Center of the Russian Academy of Medical Sciences, Moscow, Russian Federation|Charlotte Maxeke Johannesburg Academic Hospital, Hemophilia Comprehensive Care, Parktown, Gauteng, South Africa|Worthwhile Clinical Trials, Lakeview Hospital, Benoni, South Africa|University and Polytechnic Hospital La Fe, Hemostasis and Thrombosis Unit, Valencia, Spain|City Scientific-Practical center for diagnosics, Kiev, Ukraine|National Specialized Children's Hospital OKHMATDYT, Centre for Hemostatic Pathology, Kyiv, Ukraine|Institute of Blood Pathology and Transfusion Medicine, Lviv, Ukraine","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT02548143/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT02548143/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02548143"
594,"NCT03034577","Deep Neuromuscular Block for Laparoscopic Surgery","DEEPBLOCK","Completed","Has Results","Laparoscopy|Anesthesia Recovery Period","Drug: Sugammadex|Drug: Neostigmine","Percentage of Patients Recovered Cognitively at 1 Week|Percentage of Patients Recovered in All Domains of the Postoperative Quality of Recovery Scale at 3 Months After the Operation|Number of Participants With Full Reversal of Neuromuscular Blockade Prior to Extubation|Duration of Anesthesia From Induction to Cessation of the Anesthetic|Number of Participants Categorized by Level of Surgical Satisfaction|Duration of Hospital Length of Stay","University of Melbourne|Melbourne Health|Peter MacCallum Cancer Centre, Australia|Royal Hospital For Women|Northpark Private Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 4","350","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2016.343","June 16, 2017","February 15, 2019","April 1, 2019","January 27, 2017","October 21, 2019","April 22, 2020","Northpark Private Hospital, Bundoora, Victoria, Australia|Melbourne Health, Parkville, Victoria, Australia|The Royal Womens Hospital, Parkville, Victoria, Australia|Victorian Comprehensive Cancer Centre, Parkville, Victoria, Australia","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/77/NCT03034577/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/77/NCT03034577/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03034577"
595,"NCT01563471","Safety and Tolerability of Intravenous Doses of Activated Recombinant Human Factor VII in Healthy Volunteers",,"Completed","No Results Available","Congenital Bleeding Disorder|Haemophilia A With Inhibitors|Haemophilia B With Inhibitors|Healthy","Drug: activated recombinant human factor VII|Drug: placebo","Area under the Curve (AUC) of FVII:C (Factor VII clotting activity) from 0-24 hours|Mean residence time (MRT)|Maximum plasma concentration (Cmax)|Time to reach maximum plasma concentration (tmax)|Area under the Curve (AUC) from 0-24 hours of the PT (Prothrombin Time)|Adverse events","Novo Nordisk A/S","All","18 Years to 45 Years   (Adult)","Phase 1","39","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","F7LIVER-1465","October 2001","July 2002","July 2002","March 27, 2012",,"January 13, 2017","Novo Nordisk Investigational Site, Paris, France",,"https://ClinicalTrials.gov/show/NCT01563471"
596,"NCT03591289","Does Depth of Neuromuscular Blockade (NMB) Affect Surgical Conditions in Obese Patients Undergoing Robotic Surgery","NMB","Withdrawn","No Results Available","GYN Disorders|Urologic Diseases","Drug: NMB with rocuronium bromide","Assessment of surgical conditions during deep versus moderate NMB in patients undergoing robotic abdominal surgery|Assessment of PVI changes to predict fluid responsiveness in robotic surgery|Incidence of good and optimal surgical conditions in obese and non-obese patients undergoing robotic abdominal surgery|Assessment of postoperative pain after deep versus moderate NMB in patients undergoing robotic abdominal surgery. Does depth of neuromuscular block (NMB) affect postoperative pain ?","Rainer Lenhardt|University of Louisville","All","18 Years and older   (Adult, Older Adult)","Phase 4","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","17.1119","February 2018","February 2018","July 12, 2018","July 19, 2018",,"July 21, 2021","University of Louisville Medical School, Department of Anesthesiology and Perioperative Medicine, Louisville, Kentucky, United States",,"https://ClinicalTrials.gov/show/NCT03591289"
597,"NCT04760288","A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).","AcceleRET-MTC","Not yet recruiting","No Results Available","Thyroid Cancer","Drug: Pralsetinib|Drug: Cabozantinib|Drug: Vandetanib","Progression-Free Survival (PFS)|Time-To-Treatment Failure (TTF)|Objective Response Rate (ORR)|Overall Survival (OS)|Percentage of Participants With Adverse Events (AEs)|Duration of Response (DOR)|Disease Control Rate (DCR)|Clinical Benefit Rate (CBR)|Time to deterioration of function|Quality of Life (QoL)|Acceptability and Palatability of Pralsetinib capsules","Hoffmann-La Roche","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","198","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CO42865|2020-005269-15","July 1, 2022","April 15, 2026","April 15, 2028","February 18, 2021",,"January 18, 2022","The Lundquist Institute for BioMedical Innovation at Harbor-UCLA Medical Cente, Torrance, California, United States|Instituto de Investigaciones Metabolicas (Idim), Ciudad Autonoma de Buenos Aires, Argentina|Centro Médico Privado CEMAIC, Córdoba, Argentina|Instituto Medico de la Fundacion Estudios Clinicos, Rosario, Argentina|Sanatorio Britanico de Rosario, Rosario, Argentina|Centro de Investigación Clínica - Clínica Viedma, Viedma, Argentina|Macquarie University Hospital, Macquarie Park, New South Wales, Australia|Royal North Shore Hospital, St. Leonards, New South Wales, Australia|Ashford Cancer Center Research, Kurralta Park, South Australia, Australia|The Alfred Hospital;Clinical Trial Pharmacy, Melbourne, Victoria, Australia|Medizinische Universität Graz; Klinische Abteilung für Allgemeine HNO, Graz, Austria|CETUS Hospital Dia Oncologia, Uberaba, MG, Brazil|Hospital de Clinicas de Porto Alegre (HCPA) - PPDS, Porto Alegre, PA, Brazil|Irmandade Da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, RS, Brazil|Fundação Pio XII Hospital de Câncer de Barretos, Barretos, SP, Brazil|Instituto Do Câncer Do Estado de São Paulo Octávio Frias de Oliveira, São Paulo, SP, Brazil|Multiprofile Hospital for Active Treatment Uni Hospital; Department of medicinal oncology, Panagyurishte, Bulgaria|Complex Oncology Center Plovdiv; Department of Medical Oncology and Oncology Diseases in Pneumology, Plovdiv, Bulgaria|University Multiprofile Hospital For Active Treatment ""Sveti Ivan Rilski"" EAD; clinical hematology, Sofia, Bulgaria|Tom Baker Cancer Centre; Dept of Pathology, Calgary, Alberta, Canada|Cross Cancer Institute; Clinical Trials, Edmonton, Alberta, Canada|McGill University Health Center; Glen-Cedars Cancer Centre, Oncology Pharmacy, Montreal, Quebec, Canada|Centre Hospitalier Universitaire de Sherbrooke; Pharmacie de Chimiotherapie, Sherbrooke, Quebec, Canada|Clinical Hospital Centre Osijek; Hematology, Osijek, Croatia|Clinical Hospital Sestre Milosrdnice, Zagreb, Croatia|Klinicki bolnicki centar Zagreb, Zagreb, Croatia|Odense Universitetshospital, Onkologisk Afdeling, Klinisk Forsknings Enhed, Odense C, Denmark|Hôtel Dieu -Angers; Pharmacie / Secteur Essais Cliniques, Angers, France|EDOG - Institut Bergonie - PPDS, Bordeaux, France|Centre Hospitalier Universitaire Lyon; Institut Hématologique et d'Oncologie Pédiatrique, Lyon, France|CHU Nantes, Nantes, France|Centre Antoine Lacassagne Centre Régional de Lutte Contre Le Cancer, Nice, France|Hopital Cochin, Paris, France|Institut Curie; Pharmacie, Paris, France|Hôpital Saint-Louis, Paris, France|ICANS, Strasbourg, France|Institut Universitaire de Cancer de Toulouse Oncopole; IUCT- Oncopole, Toulouse, France|Attikon University General Hospital, Ahens, Greece|University of Athens Medical School - Regional General Hospital Alexandra, Athens, Greece|Kianous Stavros, Thessaloniki, Greece|Semmelweis Egyetem, II. Belgyógyászati Klinika, Budapest, Hungary|Debreceni Egyetem Klinikai Kozpont, Debrecen, Hungary|Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont, Szeged, Hungary|Panchshil Hospital, Ahmadabad CITY, Gujarat, India|Unity Hospital-Surat, Surat CITY, Gujarat, India|Tata Memorial Hospital; Dept of Medical Oncology, Mumbai, Maharashtra, India|HCG NCHRI Cancer Center, Nagpur, Maharashtra, India|Deenanath Mangeshkar Hospital & Research Centre, Pune, Maharashtra, India|Sparsh Hospitals & Critical Care (P) Ltd., Bhubaneswar, Odisha, India|Dayanand Medical College and Hospital, Ludhiana, Punjab, India|Hadassah Medical Center, Jerusalem, Israel|C.H. Regional Reina Sofia - PPDS, Cordoba, Calabria, Italy|National Cancer Center, Goyang-si, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Samsung Medical Center - PPDS, Seoul, Korea, Republic of|VU Medisch Centrum, Amsterdam, Netherlands|Saint Louis University Hospital of Sacred Heart, Baguio City, Philippines|St. Luke's Medical Center - Quezon City, Quezon City, Philippines|Centrum Onkologii-Instytut Im. Marii Skłodowskiej Curie; I Klinika Radioterapii i Chemioterapii, Gliwice, Poland|Centrum Onkologii Instytut im. Marii Sklodowskiej-Curie w Krakowie - Apteka/Pharmacy; Pharmacy, Warszawa, Poland|Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E., Lisbon, Portugal|Instituto Portugues de Oncologia Do Porto Francisco Gentil Epe, Porto, Portugal|Institutul National de Endocrinologie ""C. I. Parhon""; Sectorul 1 BUCUREȘTI, Bucuresti, Romania|Prof Dr I Chiricuta Institute of Oncology; Oncology Department, Cluj-napoca, Romania|Onco Clinic Consult SA, Craiova, Romania|CHUS - H. Clinico U. de Santiago, Santiago de Compostela, LA Coruña, Spain|Clinica Universidad Navarra; Servicio de Farmacia, Pamplona, Navarra, Spain|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|MD Anderson Cancer Center Madrid - España; Servicio de Farmacia, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Universitario HM Sanchinarro - CIOCC; Farmacia - Ensayos Clínicos, Madrid, Spain|Hospital Regional Universitario de Malaga, Malaga, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Phramongkutklao Hospital, Bangkok, Thailand|Siriraj Hospital, Mahidol Uni ; Division of Rheumatology, Dept. of Medicine, Bangkok, Thailand|Chulalongkorn University Hospital; Hematology, Pathum Wan, Thailand|SI Institute for general and urgent surgery n.a. V.T.Zaitseva of NAMS of Ukraine, Kharkiv, Kharkiv Governorate, Ukraine|Municipal Non-profit Enterprise ""City Clinical Hospital # 4"" of Dnipro City Council - PPDS, Dnipro, KIEV Governorate, Ukraine|Ukr. Scientific Practical Center of Endocrine Surgery,Transplantation of Endocrine organs&Tissues, Kyiv, KIEV Governorate, Ukraine|Clinic Verum Expert LLC, Kyiv, KIEV Governorate, Ukraine|Treatment and Diagnostic Center of LLC Specialized Clinic Prognosis Optima, Kyiv, KIEV Governorate, Ukraine|St Bartholomew's Hospital, London, United Kingdom|Guys Hospital; Guys Cancer Center, London, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom|The Royal Marsden NHS Foundation Trust - Royal Marsden Hospital (RMH) - Sutton, Sutton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04760288"
598,"NCT00098813","Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine",,"Completed","Has Results","Recurrent Thyroid Cancer|Stage IV Follicular Thyroid Cancer|Stage IV Papillary Thyroid Cancer","Drug: romidepsin|Other: laboratory biomarker analysis|Procedure: positron emission tomography","Tumor Major Response Rate (Including Stable Disease) as Measured by RECIST Criteria","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","20","NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2012-01458|04-059|N01CM62206|CDR0000396783","October 2004","August 2009","August 2009","December 9, 2004","December 19, 2013","May 28, 2014","Memorial Sloan-Kettering Cancer Center at Suffolk, Commack, New York, United States",,"https://ClinicalTrials.gov/show/NCT00098813"
599,"NCT05124938","Assessment of CA 19-9 in Patients' With Thyroid Malignancies",,"Not yet recruiting","No Results Available","Thyroid Cancer","Diagnostic Test: Laboratory investigations for control: a-Complete blood count. b-Liver function test. c-kidney function test. d-thyroid-stimulating hormone,T3 and T4. e-Assessment of levels of CA19-9.","Serum levels of CA19-9 in patients' with thyroid malignancies.","Sohag University","All","1 Year to 80 Years   (Child, Adult, Older Adult)",,"120","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","Soh-Med-21-10-11","December 1, 2021","June 1, 2022","December 1, 2022","November 18, 2021",,"November 18, 2021","Sohag faculty of medicine, Sohag, Egypt",,"https://ClinicalTrials.gov/show/NCT05124938"
600,"NCT03380936","Pilot Study of Treatment for Subclinical AMR (Antibody-mediated Rejection) in Kidney Transplant Recipients",,"Terminated","No Results Available","Kidney Transplant Rejection","Drug: Tacrolimus Extended Release Oral Tablet [Envarsus]|Other: Plasma Exchange and IVIG (Intravenous Immunoglobulin )","Change in Acute Inflammatory Histologic Parameters|Change in MDRD GFR (Modification of Diet in Renal Disease Glomerular Filtration Rate)|Change in Donor-Specific Antibody (DSA) Mean Fluorescence Intensity (MFI) Level|Change in serum creatinine|Graft Survival|Patient Survival|Evaluation of Adverse Events","University of Colorado, Denver|Veloxis Pharmaceuticals","All","18 Years to 79 Years   (Adult, Older Adult)","Early Phase 1","4","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17-1812","January 17, 2018","October 16, 2019","October 16, 2019","December 21, 2017",,"October 27, 2020","University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT03380936"
601,"NCT04583930","Clinical and Health-related Outcome of rFVIIIFc Prophylaxis","CLHEAR","Recruiting","No Results Available","Hemophilia A",,"total annual bleeding rate|orthopaedic joint status (Haemophilia health joint score)|pressure pain thresholds|spontaneous joint ABR|subjective quality of life (SF-36)|subjective physical performance (HEP-Test-Q)|self-perceived functional abilities (Haemophilia Activities List)","Prof. Dr. Dr. Thomas Hilberg|University of Wuppertal","Male","18 Years and older   (Adult, Older Adult)",,"48","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Hae-Ger-2019-251-Hil","February 1, 2021","March 31, 2023","April 20, 2023","October 12, 2020",,"May 11, 2021","Department of Sports Medicine, University of Wuppertal, Wuppertal, North Rhine-Westphalia, Germany|Department of Sports Medicine, Wuppertal, Northwest, Germany",,"https://ClinicalTrials.gov/show/NCT04583930"
602,"NCT01440933","Efficacy of Sugammadex in Magnesium Pretreated Patients","MagSug","Completed","No Results Available","Neuromuscular Block","Drug: Magnesium Sulfate|Drug: Placebo comparator","Time from start administration of sugammadex to recovery T4/T1 ratio to 0.9|Time from start administration of sugammadex to recovery T4/T1 ratio to 0.7|Time from start administration of sugammadex to recovery T4/T1 ratio to 0.8.","University Hospital, Geneva","Male","18 Years to 60 Years   (Adult)","Phase 2","32","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CER 10-093","September 2011","June 2012","June 2012","September 27, 2011",,"July 10, 2012","University Hospitals of Geneva, Geneva, Switzerland",,"https://ClinicalTrials.gov/show/NCT01440933"
603,"NCT01524978","A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers",,"Completed","Has Results","Multiple Myeloma, Neoplasms","Drug: cetuximab|Drug: vemurafenib","Confirmed Best Overall Response Rate (BORR)|Percentage of Participants With Confirmed Clinical Benefit|Overall Response Rate (ORR)|Duration of Response (DOR)|Time to Response|Time to Tumor Progression (TTP)|Progression Free Survival (PFS)|Overall Survival (OS)|Maximum Tolerated Dose for Vemurafenib in Combination With Cetuximab|Number of Dose-limiting Toxicities of Vemurafenib in Combination With Cetuximab|Safety: Percentage of Participants With Adverse Event","Hoffmann-La Roche","All","16 Years and older   (Child, Adult, Older Adult)","Phase 2","208","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MO28072|2011-004426-10","April 12, 2012","October 28, 2016","October 28, 2016","February 2, 2012","November 20, 2017","November 20, 2017","Arizona Oncology, Tucson, Arizona, United States|Rocky Mountain Cancer Centers, LLP, Aurora, Colorado, United States|Massachusetts General Hospital;Oncology, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Washington University, Saint Louis, Missouri, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Vanderbilt, Nashville, Tennessee, United States|University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States|Yakima Valley Memorial Hospital/North Star Lodge, Yakima, Washington, United States|Tianjin Cancer Hospital, Tianjin, China|Institut Bergonie; Oncologie, Bordeaux, France|Centre Francois Baclesse; Oncologie, Caen, France|Centre Georges François Leclerc, Dijon, France|Centre Leon Berard; Departement Oncologie Medicale, Lyon, France|Institut Paoli-Calmettes; Oncologie Medicale 1, Marseille Cedex 09, France|Centre Rene Gauducheau, Saint Herblain, France|Institut Claudius Regaud; Departement Oncologie Medicale, Toulouse, France|Institut Gustave Roussy; Sitep, VILLEJUIF Cedex, France|Universitätsklinikum Essen; Innere Klinik und Poliklinik für Tumorforschung, Essen, Germany|Klinik der Uni zu Koeln; Klinik I für Innere Medizin; Onkologie, Köln, Germany|Universitätsklinikum Mannheim, Tagestherapiezentrum, Interdisziplinäres Tumorzentrum, Mannheim, Germany|Hospital Univ. Central de Asturias; Servicio de Oncologia, Oviedo, Asturias, Spain|Hospital del Mar; Servicio de Oncologia, Barcelona, Spain|Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain|Hospital General Universitario Gregorio Marañon; Servicio de Oncologia, Madrid, Spain|Fundacion Jimenez Diaz; Servicio de Oncologia, Madrid, Spain|Centro Integral Oncologico Clara Campal (CIOCC); Dirección Médica, Madrid, Spain|Hospital Clinico Universitario de Salamanca; Servicio de Oncologia, Salamanca, Spain|Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia, Valencia, Spain|Aberdeen Royal Infirmary, Aberdeen, United Kingdom|The Royal Marsden Hospital; Dept of Medicine, London, United Kingdom|The Royal Marsden Hospital, Sutton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01524978"
604,"NCT01800435","A Comparison Study of Bypassing Agent Therapy With and Without Tranexamic Acid in Haemophilia A Patients With Inhibitor","BPATXAS","Completed","No Results Available","Hereditary Factor VIII Deficiency Disease With Inhibitor","Drug: aPCC, aPCC + TXA|Drug: rFVIIa, rFVIIa + TXA","Clot stability and thrombin generation capacity following treatment with bypassing agents with and without tranexamic acid.|DIC or thrombosis events associated with different treatment regimens.","Oslo University Hospital","Male","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","6","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EudraCTnr. 2010-022668-11|2010-022668-11","October 2011","October 2012","October 2012","February 27, 2013",,"March 1, 2013","Oslo University Hospital, Oslo, Norway",,"https://ClinicalTrials.gov/show/NCT01800435"
605,"NCT01804140","A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)",,"Completed","Has Results","Multiple Myeloma, Neoplasms",,"Percentage of Participants With BRAF V600 Mutation Positivity in Tumor Samples by Cancer Type|Number of Participants Classified Based on Different Types of BRAF V600 Mutation Patterns in Tumor Samples","Genentech, Inc.","All","18 Years and older   (Adult, Older Adult)",,"662","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ML28560","December 2012","September 2013","September 2013","March 5, 2013","July 31, 2015","November 2, 2016","Sedona, Arizona, United States|Tucson, Arizona, United States|Burbank, California, United States|Rancho Cucamonga, California, United States|Denver, Colorado, United States|Ocala, Florida, United States|Woodbury, Minnesota, United States|Columbia, Missouri, United States|Las Vegas, Nevada, United States|Nashville, Tennessee, United States|Amarillo, Texas, United States|Austin, Texas, United States|Dallas, Texas, United States|Dallas, Texas, United States|Dallas, Texas, United States|Denton, Texas, United States|McAllen, Texas, United States|Tyler, Texas, United States|Spokane, Washington, United States|Yakima, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01804140"
606,"NCT03608436","The Effect of Low Pressure Pneumoperitoneum During Laparoscopic Colorectal Surgery on Early Quality of Recovery","RECOVER","Completed","No Results Available","Pneumoperitoneum|Neuromuscular Blockade|Surgery","Procedure: Low pressure pneumoperitoneum|Drug: Rocuronium Bromide","Total score on the Quality of Recovery-40 questionnaire|McGill pain Questionnaire|RAND-36 general health questionnaire|Pain scores|Post-operative nausea and vomiting (PONV)|Cumulative use of analgesics and anti-emetics|Length of hospital stay|Surgical conditions|Intraoperative complications|Postoperative complications|Time to reach discharge criteria","Radboud University|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 4","178","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","NL65290.091.18","October 24, 2018","March 3, 2021","June 3, 2021","August 1, 2018",,"October 28, 2021","Canisius Wilhelmina Hospital, Nijmegen, Gelderland, Netherlands|Martini general hospital, Groningen, Netherlands|Maxima Medisch Centrum, Veldhoven, Netherlands",,"https://ClinicalTrials.gov/show/NCT03608436"
607,"NCT03572413","The Effect of Low Pressure Pneumoperitoneum During Laparoscopic Colorectal Surgery on Innate Immune Homeostasis.","RECOVER-PLUS","Completed","No Results Available","Pneumoperitoneum|Neuromuscular Blockade|Surgery|Immune Suppression","Procedure: Low pressure pneumoperitoneum|Drug: Rocuronium bromide","Mononuclear cell responsiveness ex vivo|Mononuclear cell responsiveness ex-vivo|Serum DAMPs and cytokines|HLA-DR mRNA expression|Peritoneal histology and HIF1alpha expression","Radboud University|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 4","100","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","NL65290.091.18 substudy","October 24, 2018","August 31, 2020","December 1, 2020","June 28, 2018",,"November 3, 2021","Canisius Wilhelmina Hospital, Nijmegen, Gelderland, Netherlands",,"https://ClinicalTrials.gov/show/NCT03572413"
608,"NCT02507609","Deep Neuromuscular Block on Cytokines Release and Postoperative Delirium",,"Completed","No Results Available","Hip Fractures","Other: Moderate neuromuscular blockade|Other: Deep neuromuscular blockade","Interleukin 6|postoperative delirium","Konkuk University Medical Center","All","50 Years and older   (Adult, Older Adult)","Not Applicable","82","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","KUH1160087","September 8, 2015","April 26, 2018","April 26, 2018","July 24, 2015",,"June 20, 2018","Konkuk University Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02507609"
609,"NCT03469544","Long Non Coding RNA HOTAIR and Midkine as Biomarkers in Thyroid Cancer",,"Unknown status","No Results Available","Thyroid Cancer","Other: complete blood picture ,serum urea and creatinine,liver function test,T3,T4,thyroid stimulating hormone,thyroglobuline and thyroglobuline anti body specific test Real time polymerase chain reaction","Expression of long non coding RNA HOTAIR|level of serum midkine in thyroid cancer","Assiut University","All","20 Years and older   (Adult, Older Adult)",,"90","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","LNCRHAMBTC","March 29, 2018","December 29, 2019","March 29, 2020","March 19, 2018",,"March 19, 2018",,,"https://ClinicalTrials.gov/show/NCT03469544"
610,"NCT04666103","Function Integrity of Neck Anatomy in Thyroid Surgery",,"Recruiting","No Results Available","Thyroid Carcinoma|Thyroid Nodule (Benign)|Ablation; Retina","Procedure: Intraoperative thermal ablation","Rate of complications|Scores of hospital anxiety and depression scale (HADS)|Scores of fear of progression questionnaire-short form(FPQS)|Scores of thyroid cancer- specific quality of life (THYCA-QoL) questionnaire|Rate of recurrence","Wuhan University","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","1264","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","lycf202007","December 11, 2020","December 31, 2021","December 12, 2026","December 14, 2020",,"December 14, 2020","Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04666103"
611,"NCT02601508","Compare of Surgical Condition and Complications With Moderate and Deep NM Block","MISPCNUHH","Unknown status","No Results Available","Neuromuscular Blockade","Drug: Rocuronium|Drug: cis-atracurium","Surgical rating SCORE(SRS)|Respiratory rate|peripheral arterial oxygen saturation|visual analogue scale (VAS) for pain|occurrence of nausea or vomiting|the level of sedation or alertness|Postoperative Quality Recovery Scale (PQRS)","Chonnam National University Hospital","All","20 Years and older   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","CNUHH-2015-135","November 2015","August 2016","August 2017","November 10, 2015",,"November 10, 2015","Chonnam University Hwasun Hospital, Hwasun, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02601508"
612,"NCT02185339","Effects of Deep Neuromuscular Blockade on Intraoperative Respiratory Mechanics",,"Completed","Has Results","Laparoscopic Renal Surgery|Laparoscopy|Muscle Relaxation","Drug: Rocuronium","Thoracopulmonary Compliance|Arterial Oxygen Tension/Inspired Oxygen Fraction|Arterial to End-tidal Partial Pressure of Carbon Dioxide Difference|Estimated Dead Space|Pulmonary Shunt","Seoul St. Mary's Hospital|Merck Sharp & Dohme Corp.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 4","61","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Supportive Care","dNMBonResp","July 2014","January 2015","January 2015","July 9, 2014","June 24, 2016","July 25, 2016","Seoul St. Mary's Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02185339"
613,"NCT01187030","Appropriateness of Frozen Plasma Use in Canada",,"Completed","No Results Available","Blood Component Transfusion",,"The primary outcome for the appropriateness of Frozen Plasma transfusions will be the proportion of appropriate transfusion episodes.|The number of units transfused per patient will be the secondary outcome.","Ottawa Hospital Research Institute|Canadian Blood Services|Canadian Institutes of Health Research (CIHR)","All","16 Years and older   (Child, Adult, Older Adult)",,"2580","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","200766101","May 2008","March 2011","March 2011","August 23, 2010",,"May 23, 2012",,,"https://ClinicalTrials.gov/show/NCT01187030"
614,"NCT02736305","Use of Regorafenib in Recurrent Epithelial Ovarian Cancer",,"Active, not recruiting","No Results Available","Ovarian Neoplasms","Drug: Regorafenib","Investigator assessed progression free survival (PFS)|Overall survival (OS)|Overall tumour response rate (ORR) as per Gynecological Cancer Intergroup (GCIG) and RECIST v1.1 criteria|Treatment Emergent Adverse Events","National Cancer Centre, Singapore","Female","21 Years to 99 Years   (Adult, Older Adult)","Phase 2","43","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCC OV-01","February 3, 2016","June 2021","June 2021","April 13, 2016",,"April 28, 2021","National Cancer Centre Singapore, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT02736305"
615,"NCT04384341","Haemophilia and Bone Loss - PHILEOS Study","PHILEOS","Recruiting","No Results Available","Hemophilia","Radiation: Bone densitometry (BMD)|Biological: Blood sampling for patients only","Osteoporosis defined by a T-score < -2.5 in severe haemophilic patients without prophylaxis and in healthy subjects.|Osteoporosis defined by a T-score < -2.5 in the different groups of haemophilic patients and in in healthy subjects.|Osteopenia defined by a T-score < -1 in the different groups of haemophilic patients and in in healthy subjects.|Bone mineral density (expressed as a T-score) in the different groups of haemophilic patients and in healthy subjects.|Basal level of fVIII/fIX (expressed as an Ag level or as a %) or thrombin generation potential (expressed as an endogenous thrombin potential (ETP), nmol/min) and Bone mineral density (expressed as a T-score and Z-score)|Markers influencing bone metabolism in all haemophilic patients included","Centre Hospitalier Universitaire de Saint Etienne|Ministry of Health, France","Male","20 Years to 60 Years   (Adult)","Not Applicable","480","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","19PH224|2019-A03358-49","June 2, 2020","December 2023","March 2024","May 12, 2020",,"January 24, 2022","BELGIUM - Brussels, Brussel, Belgium|Chu de Bordeaux, Bordeaux, France|Chu Brest Hopital Morvan, Brest, France|HCL - Groupement Hospitalier Est (Hôpital Louis Pradel), Bron, France|CHU Caen, Caen, France|Centre Hospitalier Metropole Savoie, Chambéry, France|Chu Cth Estaing Clermont Ferrand, Clermont-Ferrand, France|Chu de Dijon, Dijon, France|Chu Grenoble Alpes, Grenoble, France|CHU Lille, Lille, France|Chu La Timone Marseille, Marseille, France|CHU Nancy, Nancy, France|Chu Necker Paris, Paris, France|Chu Rennes Hopital Pontchaillou, Rennes, France|CHU de ROUEN, Rouen, France|CHU de Saint-Etienne, Saint-Étienne, France|Chu Strasbourg - Hôpital de Hautepierre, Strasbourg, France|ROMANIA - Bucharest, Bucharest, Romania",,"https://ClinicalTrials.gov/show/NCT04384341"
616,"NCT04211064","Comparison of the Effects of Deep and Moderate Neuromuscular Blockade on Optic Nerve Sheath Diameter","MBLONDE","Not yet recruiting","No Results Available","Intracranial Hypertension","Diagnostic Test: Ultrasonographic measurement of optic nerve sheath diameter|Procedure: Deep neuromuscular block|Procedure: Moderate neuromuscular block","Optic nerve sheath diameter|Headache|Postoperative nausea and vomiting score|Patient satisfaction score","Bezmialem Vakif University","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Diagnostic","54022451-050.05.04-","September 2021","January 2022","February 2022","December 26, 2019",,"September 13, 2021",,,"https://ClinicalTrials.gov/show/NCT04211064"
617,"NCT05158712","Genetic Factors and Pheochromocytomas in Neoplasia Type 2","NEM2A-Pheo","Not yet recruiting","No Results Available","Neoplasia|Pheochromocytoma",,"Genetic profile","Assistance Publique Hopitaux De Marseille","All","18 Years and older   (Adult, Older Adult)",,"14","Other","Observational","Observational Model: Family-Based|Time Perspective: Prospective","2020-65","January 15, 2022","January 14, 2023","December 14, 2023","December 15, 2021",,"January 6, 2022",,,"https://ClinicalTrials.gov/show/NCT05158712"
618,"NCT02952612","Active Surveillance of Papillary Thyroid Microcarcinoma",,"Unknown status","No Results Available","Thyroid Cancer, Papillary",,"Progression of papillary thyroid microcarcinoma","Dong Jun Lim|Seoul St. Mary's Hospital","All","18 Years and older   (Adult, Older Adult)",,"300","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","KC16OISI0414","October 2016","October 2017","October 2021","November 2, 2016",,"November 8, 2016","Seoul St Mary's Hospital, Seoul, Seocho-Gu, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02952612"
619,"NCT01515540","Brain Imaging of Lidoderm for Chronic Back Pain",,"Completed","Has Results","Low Back Pain","Drug: lidocaine|Drug: placebo","Pain Intensity on a Visual Analog Scale (VAS) The Scale Had Values From 0-100, Where 0 Represents ""no Pain"" and 100 Was the ""Worst Pain Imaginable"".","Northwestern University|Endo Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 4","38","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","STU00022968","January 2004","June 2010","June 2010","January 24, 2012","July 30, 2013","July 30, 2013","Northwestern University, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT01515540"
620,"NCT01823068","Vandetanib in Advanced NSCLC With RET Rearrangement",,"Completed","No Results Available","Non Small Cell Lung Cancer","Drug: Vandetanib","Objective response rate (ORR)|Progression-free survival (PFS)|Disease-control rate (DCR)|Overall survival (OS)|Number of Participants with Adverse Events","Samsung Medical Center|AstraZeneca","All","18 Years and older   (Adult, Older Adult)","Phase 2","17","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2013-09-089-01","November 3, 2014","December 29, 2014","March 16, 2018","April 4, 2013",,"December 7, 2020","Seoul National University Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01823068"
621,"NCT01210755","Study in Healthy Volunteers of the Reversion by Haemostatic Drugs of the Anticoagulant Effect of New Anti-thrombotics","REVNEWANTICO","Completed","No Results Available","Venous Thromboembolism","Drug: Rivaroxaban, Dabigatran|Drug: Dabigatran; Rivaroxaban","In vitro Reversal of anticoagulation|In vitro, activated partial thromboplastin time","University Hospital, Grenoble","Male","18 Years to 35 Years   (Adult)","Phase 4","10","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","DCIC 10 09","November 2010","March 2011","June 2011","September 28, 2010",,"July 1, 2011","Clinical Research Centre, University Hospital Grenoble, Grenoble, France",,"https://ClinicalTrials.gov/show/NCT01210755"
622,"NCT04354311","Prediction of Hemodynamic Response to Intubation by ANI Variation During Standardized Stimulation","ANI_LARYNGO","Completed","No Results Available","Tracheal Intubation Morbidity|Pain","Device: ANI","predictability of hemodynamic impact during laryngoscopy by tetanus-induced ANI variation,|predictability of somatic impact during laryngoscopy by tetanus-induced ANI variation,","University Hospital, Lille","All","18 Years to 99 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2012_34|2013-A01127-38","February 2, 2014","December 2014","December 2014","April 21, 2020",,"April 21, 2020","Hopital Roger Salengro, CHU Lille, Lille, France",,"https://ClinicalTrials.gov/show/NCT04354311"
623,"NCT02363595","Genomic Predictors of Papillary Microcarcinoma Disease Progression",,"Recruiting","No Results Available","Papillary Microcarcinoma",,"estimate the disease progression rate","Memorial Sloan Kettering Cancer Center|Ohio State University","All","18 Years and older   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","14-277","December 2014","December 2023","December 2023","February 16, 2015",,"February 17, 2021","Memorial Sloan Kettering Cancer Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02363595"
624,"NCT04161391","Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations",,"Recruiting","No Results Available","Non Small Cell Lung Cancer|Medullary Thyroid Cancer|RET Gene Mutation|Metastatic Solid Tumor|Advanced Solid Tumor","Drug: TPX-0046","Incidence of first cycle dose-limiting toxicities (DLTs) of TPX-0046|Define the Recommended Phase 2 Dose|Define the objective response rate (ORR)|Adverse events (AEs)|Cmax (maximum plasma concentration) of TPX-0046|AUC (area under plasma concentration time curve) of TPX-0046|Cmax (maximum plasma concentration) of TPX-0046 under different food intake conditions|AUC (area under plasma concentration time curve) of TPX-0046 under different food intake conditions|Preliminary Objective Response Rate (ORR)|Clinical benefit rate (CBR)|Time to response (TTR)|Duration of Response (DOR)|Progression free survival (PFS)|Intracranial tumor response|Overall survival (OS)","Turning Point Therapeutics, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","362","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TPX-0046-01","December 16, 2019","May 2024","March 2025","November 13, 2019",,"August 9, 2021","UCI Health - Chao Family Comprehensive Cancer Center, Irvine, California, United States|UC San Diego Moores Cancer Center, San Diego, California, United States|University of Colorado, Denver, Aurora, Colorado, United States|Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|Moffitt Cancer Center, Tampa, Florida, United States|Winship Cancer Institute, Emory University, Atlanta, Georgia, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|MD Anderson Cancer Center, Houston, Texas, United States|Virginia Cancer Specialists, Fairfax, Virginia, United States|The University of Washington, Seattle Cancer Care Alliance, Seattle, Washington, United States|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04161391"
625,"NCT02097810","Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations.","STARTRK-1","Completed","No Results Available","Locally Advanced Solid Tumors|Metastatic Solid Tumors","Drug: Entrectinib","Dose-Limiting Toxicity (DLT)|Maximum Tolerated Dose (MTD)|Recommended Phase 2 Dose (RP2D)|Overall Response Rate (ORR) in Dose Expansion|Plasma Concentrations of Entrectinib|Disease Control|Duration of Response|Overall Survival (OS)|Progression-Free Survival (PFS)","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 1","84","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RXDX-101-01|GO40784","July 28, 2014","June 2, 2020","June 2, 2020","March 27, 2014",,"June 9, 2021","UC Irvine Medical Center, Orange, California, United States|University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States|University Of Colorado, Aurora, Colorado, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|Florida Cancer Specialists - Sarasota, Sarasota, Florida, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Tennessee Oncology, Nashville, Tennessee, United States|University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States|Samsung Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02097810"
626,"NCT01980069","A Double-blind, Randomized, Parallel Design Study to Compare the Effectiveness of Sugammadex Versus Neostigmine in Improving Surgical Condition in Subjects Undergoing Laryngeal Microsurgery",,"Completed","No Results Available","General Anesthesia","Drug: Sugammadex|Drug: Neostigmine","surgical condition","Yonsei University","All","20 Years to 90 Years   (Adult, Older Adult)","Not Applicable","72","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","4-2013-0451","November 2013","October 2014","October 2014","November 8, 2013",,"April 23, 2015","Severance Hospital, Seoul, Seodaemun-gu, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01980069"
627,"NCT00890812","Factor XI Levels in Acute Ischemic Stroke",,"Completed","No Results Available","Stroke",,"To determine the relationship between elevated factors VIII, IX and XI and acute ischemic stroke as compared to other emergent events.|To determine the relationship between elevated factors VIII, IX and XI and stroke subtype.|To determine if a relationship exists between elevated factors VIII, IX and XI and the clinical severity and stroke outcome.|To determine if factors VIII, IX and XI level are different in the acute phase of ischemic stroke relative to chronic phase.|To determine if a relationship exists between factors VIII, IX and XI levels and early stroke/TIA recurrence.","University of Utah|Sheila B. Terry Memorial Research Fund","All","18 Years and older   (Adult, Older Adult)",,"450","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","14363|ACC: 46499140|IRB: 00014363","May 2009","July 2011","July 2011","April 30, 2009",,"August 4, 2011","University of Utah Health Sciences Center, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT00890812"
628,"NCT03428997","Human Comedogenicity Test",,"Completed","Has Results","Comedogenicity","Device: Lotion|Other: Negative Control","Microcomedone Score of Follicular Biopsies","Johnson & Johnson Consumer Inc. (J&JCI)|Johnson & Johnson Consumer and Personal Products Worldwide","All","18 Years to 45 Years   (Adult)","Not Applicable","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Other","CO-171106085430-SACT","November 20, 2017","February 5, 2018","February 5, 2018","February 12, 2018","August 2, 2019","November 17, 2020","Stephens and Associates, Richardson, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/97/NCT03428997/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03428997"
629,"NCT00803101","An Open-label, Randomized, Multicenter Phase IIIb Study to Assess the Efficacy, Safety and Tolerance of BERIPLEX® P/N (Kcentra) Compared With Plasma for Rapid Reversal of Coagulopathy Induced by Vitamin K Antagonists in Subjects Requiring an Urgent Surgical Procedure","BE1116_3003","Completed","Has Results","Reversal of Coagulopathy","Biological: Beriplex® P/N (Kcentra)|Biological: Fresh frozen plasma","Percentage of Participants Achieving Hemostatic Efficacy During Surgery|Percentage of Participants Who Had a Rapid Decrease of the INR|Plasma Levels of Factors II, VII, IX, and X, Protein C, and Protein S|Transfusion of Packed Red Blood Cells (PRBCs) or Whole Blood|Percentage of Participants With INR Correction at Various Times After the Start of Infusion|Percentage of Participants Who Received Red Blood Cells|Overall Treatment-emergent Adverse Events (TEAEs)","CSL Behring","All","18 Years and older   (Adult, Older Adult)","Phase 3","176","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BE1116_3003|1474|2007-007862-39","February 2009","November 2012","February 2013","December 5, 2008","February 25, 2014","April 6, 2015","Study Site, Newark, Delaware, United States|Study site, Lexington, Kentucky, United States|Study Site, Boston, Massachusetts, United States|Study Site, Duluth, Minnesota, United States|Study Site, Minneapolis, Minnesota, United States|Study Site, Albuquerque, New Mexico, United States|Study Site, Rochester, New York, United States|Study Site, Winston-Salem, North Carolina, United States|Study Site, Philadelphia, Pennsylvania, United States|Study Site, West Reading, Pennsylvania, United States|Study Site, Wilkes Barre, Pennsylvania, United States|Study Site, Memphis, Tennessee, United States|Study Site, Austin, Texas, United States|Study site, Bryan, Texas, United States|Study Site, El Paso, Texas, United States|Study Site, Houston, Texas, United States|Study Site 1, Minsk, Belarus|Study Site 2, Minsk, Belarus|Study Site, Rousse, Bulgaria|Study Site 4, Sofia, Bulgaria|Study Site, Varna, Bulgaria|Study Site, Beirut, Lebanon|Study Site, Saida, Lebanon|Study Site, Timisoara, Romania|Study Site 2, Barnaul, Russian Federation|Study Site, Kazan, Russian Federation|Study Site 1, Moscow, Russian Federation|Study Site 2, Moscow, Russian Federation|Study Site, Novosibirsk, Russian Federation|Study Site, Saint Petersburg, Russian Federation",,"https://ClinicalTrials.gov/show/NCT00803101"
630,"NCT00284193","Combination Therapy of Low Doses of rFVIIa and FEIBA for Severe Hemophilia A Patients With an Inhibitor to Factor VIII",,"Completed","No Results Available","Hemophilia A","Drug: rFVIIa-FEIBA therapy for hemophilia A inhibitors|Drug: FEIBA- Activated Prothrombin Complexes","Hemostasis achieved post therapy|Safety|Time to Hemostasis","Sheba Medical Center","Male","16 Years to 65 Years   (Child, Adult, Older Adult)","Phase 4","5","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SHEBA-05-3768-UM-CTIL","January 2005","November 2008","November 2009","January 31, 2006",,"July 27, 2012",,,"https://ClinicalTrials.gov/show/NCT00284193"
631,"NCT02469831","Respiratory Mechanics and Metabolic Changes During Low Pressure Laparoscopic Cholecystectomy",,"Completed","No Results Available","Laparoscopic Cholecystectomy","Drug: Rocuronium","respiratory mechanics (Dynamic compliance)|surgeon satisfaction (scale from 1 to 5)|postoperative pain (VAS score)|postoperative nausea and vomiting|completion of surgical procedure|metabolic changes (blood lactate)","Assiut University","All","18 Years to 60 Years   (Adult)","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","low pressure lap chole.","October 2014","December 2015","January 2016","June 12, 2015",,"March 28, 2017","Al Rajhy liver hospital, Assuit, اسيوط, Egypt",,"https://ClinicalTrials.gov/show/NCT02469831"
632,"NCT04403893","Feasibility and Safety of a Dedicated Biliary Stent for Transmural EUS-guided Hepatico-gastrostomy: the FIT Study","FIT","Recruiting","No Results Available","Malignant Bilio-pancreatic Diseases","Other: HANARO biliary stent placement","AE and SAE events","Istituto Clinico Humanitas","All","18 Years and older   (Adult, Older Adult)",,"20","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2753","June 17, 2020","December 31, 2021","December 31, 2021","May 27, 2020",,"January 22, 2021","Endoscopy Unit, Humanitas Research Hospital, Rozzano, Milano, Italy",,"https://ClinicalTrials.gov/show/NCT04403893"
633,"NCT04784988","Intensive Replacement Treatment in Haemophilia Patients With Synovitis",,"Not yet recruiting","No Results Available","Hemophilia A","Drug: Adynovate|Drug: plasma derived or recombinant products containing FVIII","changes in synovitis","Federico II University","Male","12 Years to 70 Years   (Child, Adult, Older Adult)","Phase 4","40","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IISR-2020-103302","March 1, 2021","March 1, 2022","May 1, 2022","March 5, 2021",,"March 5, 2021",,,"https://ClinicalTrials.gov/show/NCT04784988"
634,"NCT03503565","Intraoperative Neuromuscular Blockade and Postoperative Atelectasis",,"Completed","Has Results","Thoracic Surgery|One-lung Ventilation","Procedure: intraoperative neuromuscular blockade","Atelectasis Area on Chest CT|Number of Patients Defined as Acute Respiratory Distress Syndrome|Number of Patients Defined as Pneumonia|Number of Patients Showing Pleural Effusion|Number of Patients Showing Postoperative Desaturation|Number of Patients Requiring Postoperative Re-intubation|Intraoperative Lung Compliance (ml/cmH2O)|Patient Demographic Data","Kyung Hee University Hospital at Gangdong|Merck Sharp & Dohme Corp.","All","19 Years and older   (Adult, Older Adult)",,"118","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","2018-03-015","October 11, 2018","May 14, 2020","May 18, 2021","April 20, 2018","August 20, 2021","August 20, 2021","Kyung Hee University Gangdong Hospital, Seoul, Korea, Republic of","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/65/NCT03503565/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT03503565"
635,"NCT02754102","Human Phototoxicity Test",,"Completed","No Results Available","Sunscreening Agents","Other: Sunscreen Spray- Liquid (BAY987516)","Intensity of skin reactions will be evaluated using the 5 point grading scale","Bayer","All","18 Years to 60 Years   (Adult)","Not Applicable","35","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Other","18775","May 3, 2016","May 6, 2016","May 6, 2016","April 28, 2016",,"May 1, 2017","Piscataway, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02754102"
636,"NCT02751489","Human Phototoxicity Test",,"Completed","No Results Available","Sunscreening Agents","Other: Bain De Soliel - Solid","Intensity of skin reactions is evaluated by 5 point scale","Bayer","All","18 Years to 60 Years   (Adult)","Not Applicable","35","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)","18600","May 2016","May 2016","May 2016","April 26, 2016",,"June 17, 2016","Piscataway, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02751489"
637,"NCT04096391","Post-market, Randomized, Controlled, Prospective Study Evaluating Intrathecal Pain Medication (IT) Versus Conventional Medical Management (CMM) in the Non-cancer, Refractory, Chronic Pain Population","Prosper-001","Recruiting","No Results Available","Chronic Nonmalignant Pain|Pain, Intractable|Pain, Chronic","Device: Flowonix Prometra® II Programmable Infusion System|Drug: Pain Medicine","Compare the change in Numeric Pain Rating Scale between the IDDS group and the CMM group|Compare the change in PROMIS 29 scores between the IDDS group and CMM group|Comparison of the accrued cost of therapy for pain|Comparison of other concurrent treatments","Evolve Restorative Center|Flowonix Medical|Celéri Health, Inc.|Advanced Infusion Solutions","All","22 Years and older   (Adult, Older Adult)","Not Applicable","82","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","Prosper-001","June 5, 2019","January 31, 2022","July 31, 2022","September 19, 2019",,"June 9, 2020","Evolve Restorative Center, Santa Rosa, California, United States",,"https://ClinicalTrials.gov/show/NCT04096391"
638,"NCT04570696","TFPI Levels in Haemophilia A and B Patients",,"Recruiting","No Results Available","Haemophilia A and B","Other: NON INTERVENTIONAL","Concentration of TFPI plasma level","CHU de Reims","Male","18 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","PO19085","July 1, 2019","June 2021","June 2021","September 30, 2020",,"September 30, 2020","Damien JOLLY, Reims, France",,"https://ClinicalTrials.gov/show/NCT04570696"
639,"NCT02838134","Deep Versus Moderate Muscle Relaxation During Laparoscopic Donor Nephrectomy in Enhancing Postoperative Recovery","RELAX","Completed","Has Results","Neuromuscular Block|Renal Transplant Donor of Left Kidney|Renal Transplant Donor of Right Kidney|Surgery","Other: Rocuronium|Other: No additional Rocuronium","Total Score of the Quality of Recovery-40 Questionnaire (QoR-40)|Surgical Conditions|Length of Pneumoperitoneum|Warm Ischemia Time|Estimated Blood Loss|Conversion|Intra-operative Complications|Cumulative Use of Rocuronium|Total Score of the Quality of Recovery-40 Questionnaire|Postoperative Pain|Postoperative Complications|Discharge Criteria|Pain Scores","Radboud University|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 4","101","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NL58160.091.16","November 2016","November 2, 2017","December 2, 2017","July 20, 2016","September 19, 2019","September 19, 2019","LUMC, Leiden, Netherlands|Radboudumc, Nijmegen, Netherlands","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/34/NCT02838134/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02838134"
640,"NCT02771236","Clinical and Molecular Studies in Families With Inherited Eye Disease",,"Recruiting","No Results Available","Inherited Eye Disease",,"Statistically Significant Linkage or association","National Eye Institute (NEI)|National Institutes of Health Clinical Center (CC)","All","4 Years and older   (Child, Adult, Older Adult)",,"5000","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","160104|16-EI-0104","October 4, 2016","January 1, 2032","January 1, 2032","May 13, 2016",,"December 16, 2021","University of California, San Diego, La Jolla, California, United States|University of California, Los Angeles, Los Angeles, California, United States|National Institutes of Health Clinical Center, Bethesda, Maryland, United States|Zhongshan Ophthalmic Center, Guangzhou, China|Seconda Universita di Napoli, Napoli, Italy|University of the Punjab, Lahore, Pakistan|University of the Philippines, Manila, Philippines|The National Academy of Medical Sciences of Ukraine, Odessa, Ukraine",,"https://ClinicalTrials.gov/show/NCT02771236"
641,"NCT03105648","Diagnostic and Prognostic Significance of Computerized Cytologic Morphometry of the Thyroid Neoplasm",,"Recruiting","No Results Available","Computerized Cytomorphometry","Other: computerized cytomorphometry","cytomorphometry of the cells","National Taiwan University Hospital","All","20 Years and older   (Adult, Older Adult)",,"3000","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","201603064RIPB","July 1, 2016","April 20, 2026","April 20, 2026","April 10, 2017",,"February 18, 2021","National Taiwan University Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT03105648"
642,"NCT01529450","Pilot LDE225 in Locally Advanced or Metastatic BCC + Previously Tx Non-LDE225 Smoothened Inhibitors",,"Completed","Has Results","Basal Cell Carcinoma","Drug: LDE225","Progression Free Survival (PFS) of All Participants|Molecular Markers Associated With Clinical Response","Anne Chang|Novartis|Stanford University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","11","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SKIN0009|SU-09022011-8371|21759","February 2012","August 2013","August 2013","February 8, 2012","November 2, 2016","January 16, 2017","Stanford University, School of Medicine, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT01529450"
643,"NCT01856751","Use of a TGA and TEM in the Assessment of the Efficacy of Treatment With APCC or rFVIIa","Thrombus","Unknown status","No Results Available","Haemophilia",,"Assessment of patient's individual response to therapy with by-passing agents by simultaneous use of TGA and TEM methods.","Stowarzyszenie Pomocy Chorym na Zakrzepicę i Skazy Krwotoczne Thrombus","All","18 Years and older   (Adult, Older Adult)",,"80","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","TGA-TEM","April 2014","April 2016","June 2016","May 17, 2013",,"December 18, 2015","Katedra i Klinika Hematologii i Transplantologii Gdanski Uniwersytet Medyczny, Gdansk, Poland|Szpital Uniwersytecki w Krakowie, Oddzial Kliniczny Alergii i Immunologii, Krakow, Poland|Klinika Hematologii Uniwersytetu Medycznego w Lodzi Wojewodzki Szpital Specjalistyczny im. M. Kopernika, Lodz, Poland|Centrum Diagnostyczno - Lecznicze INTERLAB, Poznan, Poland|Instytut Hematologii i Transfuzjologii w Warszawie, Warszawa, Poland|Katedra i Klinika Hematologii, Nowotworow Krwi i Transplantacji Szpiku, Akademia Medyczna, Wroclaw, Poland",,"https://ClinicalTrials.gov/show/NCT01856751"
644,"NCT04883294","Validation of the Diagnostic Accuracy of the Electronic Nose in the Detection of Thyroid Cancer",,"Not yet recruiting","No Results Available","Thyroid Neoplasm","Diagnostic Test: Electronic Nose","Sensitivity|Specificity|Positive Predictive Value|Negative Predictive Value|Area Under the Curve of the Receiver Operating Characteristics Curve|Quality of Life|Burden Thermometer/Problem List|Surgical Complications|Number of unnecessary surgeries|Ease of use of electronic nose|Sensitivity and Specificity of Molecular Diagnostics","Maastricht University Medical Center","All","18 Years and older   (Adult, Older Adult)",,"1500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","NL76036.068.21","May 1, 2021","January 1, 2024","January 1, 2025","May 12, 2021",,"May 12, 2021",,,"https://ClinicalTrials.gov/show/NCT04883294"
645,"NCT03479463","Use of Human Dehydrated Amnion Chorion Allograft in Laryngectomy/Pharyngectomy",,"Terminated","No Results Available","Larynx Cancer|Pharynx Cancer|Pharyngocutaneous Fistula","Biological: Dehydrated human amnion/chorion membrane","Incidence of Pharayngocutaneous Fistula Development (PCF)","MiMedx Group, Inc.","All","18 Years and older   (Adult, Older Adult)",,"8","Industry","Observational","Observational Model: Case-Control|Time Perspective: Other","AFSUR003","March 19, 2018","March 30, 2019","March 30, 2019","March 27, 2018",,"November 13, 2020","Mount Sinai Hospital, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03479463"
646,"NCT00459043","Docetaxel in Combination With Zactima (ZD6474) in Patients With Locally Advanced Squamous Cell Carcinoma of the the Head and Neck",,"Completed","Has Results","Squamous Cell Carcinoma of Head and Neck","Drug: ZD6474|Drug: Docetaxel","Partial Response Rate in Both Groups of Patients.|Progression Free Survival|Overall Survival","Dana-Farber Cancer Institute|Brigham and Women's Hospital|Massachusetts General Hospital|Loyola University|AstraZeneca","All","18 Years and older   (Adult, Older Adult)","Phase 2","30","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","06-283","March 2007","March 2010","February 2012","April 11, 2007","July 3, 2013","July 3, 2013","Loyola University Medical Center/Cardinal Bernadin Cancer Center, Maywood, Illinois, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00459043"
647,"NCT04591483","Stargardt-like Macular Dystrophy (STDG3) Secondary to Mutations in ELOVL4",,"Not yet recruiting","No Results Available","Stargardt-Like Macular Dystrophy",,"Growth rate in square root area of loss of the inner segment/outer segment band (EZband)|Growth rate of square root area of atrophy measured from short-wavelength autofluorescence|The change in BCVA total letters read from baseline to Year 3|The rate of loss of retinal sensitivity measured with perimetry","National Eye Institute (NEI)|National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","10 Years and older   (Child, Adult, Older Adult)",,"25","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","10000108|000108-EI","January 27, 2022","July 16, 2025","July 16, 2025","October 19, 2020",,"January 24, 2022","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04591483"
648,"NCT01848106","A Study To Determine the Efficacy and Safety of REG1 Compared to Bivalirudin in Patients Undergoing PCI","Regulate","Terminated","No Results Available","Coronary Artery Disease","Drug: pegnivacogin/anivamersen|Drug: Bivalirudin","Ischemic composite","Regado Biosciences, Inc.|The Cleveland Clinic|Duke Clinical Research Institute|Canadian VIGOUR Centre|Icahn School of Medicine at Mount Sinai|Parexel","All","18 Years and older   (Adult, Older Adult)","Phase 3","3232","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","REG1-CLIN310|2013-001384-23","September 2013","August 2014","August 2014","May 7, 2013",,"October 23, 2014","Black Hills Cardiovascular Research, Rapid City, South Dakota, United States",,"https://ClinicalTrials.gov/show/NCT01848106"
649,"NCT04567511","Hemlibra in Mild Hemophilia A",,"Recruiting","No Results Available","Factor VIII Deficiency, Congenital","Drug: Emicizumab","Interaction of Hemlibra (emicizumab) binding with endogenous altered FVIII protein in an individual with mild hemophilia A and the combined effect on thrombin generation and hemostatic characteristics|Breakthrough bleeds|Factor VIII alteration and coagulation|Change from baseline joint disease annually|AE, SAE, and ADA|ADA development|Alternate hemostatic therapies with surgery|Change in quality of life: questionnaire|Change in activity: questionnaire","Indiana Hemophilia &Thrombosis Center, Inc.|Genentech, Inc.","Male","5 Years to 45 Years   (Child, Adult)","Phase 4","40","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RO-IIS-2019-20049","September 1, 2021","February 2024","February 2024","September 28, 2020",,"October 14, 2021","Indiana Hemophila @Thrombosis Center, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT04567511"
650,"NCT04665752","Ocular Findings and Viral Persistence in Ocular Fluids in COVID-19 Survivors",,"Recruiting","No Results Available","COVID-19",,"Percentage of participants|Correlation of findings|Proportion of patients","National Eye Institute (NEI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)",,"150","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","10000078|000078-EI","February 2, 2021","June 30, 2023","June 30, 2023","December 14, 2020",,"December 16, 2021","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04665752"
651,"NCT04205175","A Study to Evaluate the Safest Dose Range for FEIBA in Hemophilia A Patients With Inhibitors on Emicizumab",,"Active, not recruiting","No Results Available","Hemophilia A With Inhibitor","Drug: Feiba","Thrombin generation","Children's Hospital Los Angeles|Takeda","Male","Child, Adult, Older Adult","Phase 4","20","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19 00367","July 1, 2020","October 2021","October 2021","December 19, 2019",,"October 21, 2021","Childrens Hospital Los Angeles, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT04205175"
652,"NCT04289571","Virtual Reality Mobility Assessment of Functional Vision in Retinal Disease",,"Not yet recruiting","No Results Available","Cone-Rod Degeneration|Rod-Cone Degeneration","Diagnostic Test: VR Motility Tool","VR mobility test parameters|Feasibility of the tool|Effect of prior game play","National Eye Institute (NEI)|National Institutes of Health Clinical Center (CC)","All","5 Years and older   (Child, Adult, Older Adult)","Phase 1","165","NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","200026|20-EI-0026","January 27, 2022","December 31, 2030","December 31, 2030","February 28, 2020",,"January 24, 2022","National Institutes of Health Clinical Center, Bethesda, Maryland, United States|Sydney Eye Hospital at the University of Sydney, Sydney, Australia",,"https://ClinicalTrials.gov/show/NCT04289571"
653,"NCT05033236","Platelets and Complement Activation in Coronary Artery Bypass Graft Surgery (CABG)","PAC","Recruiting","No Results Available","Cardiopulmonary Bypass|Inflammatory Response|Platelet Dysfunction",,"correlation between complement activation (c5b-9) and platelet decline|A secondary aim of the study is to investigate the specific pathway of complement activation, the mtDNA levels and the interaction with platelet function.","Medical University Innsbruck","All","18 Years to 85 Years   (Adult, Older Adult)",,"190","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","1097/2018","November 23, 2018","January 31, 2022","August 30, 2022","September 2, 2021",,"September 2, 2021","University Hospital Innsbruck, Innsbruck, Tyrol, Austria","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/36/NCT05033236/Prot_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/36/NCT05033236/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT05033236"
654,"NCT03845218","Retinitis Pigmentosa Clinical Measures and Repeatability Testing of Potential Outcome Measures",,"Recruiting","No Results Available","Retinitis Pigmentosa",,"Macular thickness as measured by OCT, EZ band length; functional testing including photopic/scotopic perimetry and kinetics, mfERG|Secondary outcome measures will include analysis of parameter testing based on absolute measures to categorize testing results into severity groups","National Eye Institute (NEI)|National Institutes of Health Clinical Center (CC)","All","12 Years and older   (Child, Adult, Older Adult)",,"150","NIH","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","190056|19-EI-0056","September 27, 2019","October 30, 2022","October 30, 2022","February 19, 2019",,"December 16, 2021","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03845218"
655,"NCT03921294","HemLibra Prophylaxis in Patients With Hemophilic Pseudotumor",,"Recruiting","No Results Available","Haemophilic Pseudotumour","Drug: Emicizumab","Hemostatic efficacy of prophylactic weekly injections of Hemlibra (emicizumab) based on hemoglobin|Hemostatic efficacy of prophylactic weekly injections of Hemlibra (emicizumab) based on blood transfusions|Breakthrough bleeds|Pseudotumor Status|Patient Quality of Life based on Haem-A-QOL|Patient Quality of Life based on EQ-5D-5L|Adverse Events|Serious Adverse Events|Number of participants with adverse events|Anti-Drug Antibodies (ADA)|ADA and Activated Partial Thromboplastin Time (APTT)|ADA and Factor VIII (FVIII)|Planned or unplanned surgery|Hemostatic agents in surgery|Blood loss in surgery","Indiana Hemophilia &Thrombosis Center, Inc.|Genentech, Inc.","All","Child, Adult, Older Adult","Phase 4","10","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RO-IIS-2018-10581","May 15, 2019","May 2023","May 2023","April 19, 2019",,"June 14, 2021","Indiana Hemophila @Thrombosis Center, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT03921294"
656,"NCT04107688","Taste Perception, Salivary Proteins & the Oral Microbiome",,"Active, not recruiting","No Results Available","Saliva Altered|Taste, Altered","Other: Control|Other: CPE","Taste and Flavor Intensity Ratings|Levels of Salivary Proteins|Composition of Oral Microbiome","Rutgers University|Rutgers, The State University of New Jersey","All","18 Years to 45 Years   (Adult)","Not Applicable","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","13309M","March 25, 2019","March 31, 2022","March 31, 2022","September 27, 2019",,"August 24, 2021","Rutgers University, Department of Food Science, New Brunswick, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT04107688"
657,"NCT02821767","Natural History, Pathogenesis, and Outcome of Ocular Disorders",,"Recruiting","No Results Available","Eye Disease",,"No formal outcomes will be measured; however, the clinical assessments of enrolled participants can be used to measure the response to standard treatment.","National Eye Institute (NEI)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult",,"1000","NIH","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","160134|16-EI-0134","November 2, 2016","July 1, 2026","July 1, 2026","July 4, 2016",,"January 5, 2022","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02821767"
658,"NCT02617966","Rod and Cone Mediated Function in Retinal Disease",,"Recruiting","No Results Available","Retinal Degeneration|Retinitis Pigmentosa|Stargardt's Disease",,"The primary outcomes for this study are to establish normal ranges for the kinetics of dark adaptation and dark-adapted retinal sensitivity for the fundus guided and non-guided perimeters and for RF hyperacuity on the Display++.","National Eye Institute (NEI)|National Institutes of Health Clinical Center (CC)","All","5 Years and older   (Child, Adult, Older Adult)",,"370","NIH","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","160024|16-EI-0024","March 24, 2016","December 30, 2024","December 30, 2024","December 1, 2015",,"January 19, 2022","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02617966"
659,"NCT01829217","Sunitinib in Never-Smokers With Lung Adenocarcinoma",,"Completed","Has Results","Lung Cancer","Drug: Sunitinib","Objective Response Rate (ORR)","Dana-Farber Cancer Institute","All","18 Years and older   (Adult, Older Adult)","Phase 2","13","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","13-086","May 2013","August 2017","January 2018","April 11, 2013","September 4, 2018","October 31, 2018","Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Isreal Deaconess Medical Center, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/17/NCT01829217/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01829217"
660,"NCT04128631","Thyroid Cancer and (FDG)PET/CT Scan",,"Unknown status","No Results Available","Thyroid Cancer",,"Recurrence and metastasis|Improve survival rate","Assiut University","All","10 Years to 80 Years   (Child, Adult, Older Adult)",,"35","Other","Observational","Observational Model: Other|Time Perspective: Prospective","FDGPET","October 30, 2019","September 1, 2020","December 1, 2020","October 16, 2019",,"October 16, 2019",,,"https://ClinicalTrials.gov/show/NCT04128631"
661,"NCT02741440","Natural History of Spinocerebellar Ataxia Type 7 (SCA7)",,"Recruiting","No Results Available","Spinocerebellar Ataxia",,"Amplitude and time of photopic and scotopic responses on electroretinogram|changes in visual acuity, microperimetry, color vision, macular thickness, neurologic (including neuroimaging) outcome variables, eye movement recordings (e.g., saccadic velocity) and results of neuropsychologic testing","National Eye Institute (NEI)|National Institutes of Health Clinical Center (CC)","All","12 Years and older   (Child, Adult, Older Adult)",,"25","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","160090|16-EI-0090","July 11, 2016","January 1, 2027","January 1, 2027","April 18, 2016",,"January 4, 2022","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02741440"
662,"NCT03488134","Predicting Prognosis and Recurrence of Thyroid Cancer Via New Biomarkers, Urinary Exosomal Thyroglobulin and Galectin-3",,"Active, not recruiting","No Results Available","Thyroid Cancer",,"Prognostic biological markers via this prospective study","National Taiwan University Hospital","All","20 Years to 80 Years   (Adult, Older Adult)",,"74","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","201711082RINA","August 3, 2018","January 31, 2022","July 31, 2023","April 4, 2018",,"November 16, 2021","National Taiwan University Hospital, Taipei, Taipei City, Taiwan",,"https://ClinicalTrials.gov/show/NCT03488134"
663,"NCT02229331","Biomechanical Determinants and Patterns Associated to the Pathophysiological Cascade of Ankle Arthropathy in Children With Haemophilia: Non-invasive In-vivo Measurement of Foot Joints in Children With Haemophilia During Gait.","3DMKFM","Unknown status","No Results Available","Haemophilia|Arthropathy","Other: Gait analysis","Kinetic Joint Classification System outcome measure|Instrumentation implementation outcome measure|MRI and Haemophilia Joint Health Score correlation outcome measure","Universitaire Ziekenhuizen Leuven|Cliniques universitaires Saint-Luc- Université Catholique de Louvain","Male","6 Years to 18 Years   (Child, Adult)",,"70","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","3DMKFM_haemo1","September 2014","September 2014","September 2016","September 1, 2014",,"September 1, 2014",,,"https://ClinicalTrials.gov/show/NCT02229331"
664,"NCT04424485","Near-infrared Fluorescence With Indocyanine Green for Identification of Sentinels and Parathyroids During Thyroidectomy",,"Recruiting","No Results Available","Thyroid Cancer|Thyroid Carcinoma, Papillary|Thyroid Metastases|Thyroid Neoplasms|Sentinel Lymph Node|Lymph Node Metastases","Procedure: Total thyroidectomy (TT)|Procedure: Central lymph node dissection (CLND)|Diagnostic Test: Sentinel lymph node (SLN) bopsy|Diagnostic Test: Identification of parathyroid glands (PGs)","Involvement of sentinel lymph node (presence/absence of tumor cell: positive or negative) by histopathological examinatiion|Identification of parathyroid glands (PGs) by NIR/ICG camera detected high-contrast|Central lymph node dissetion (CLND)","Umraniye Education and Research Hospital","All","17 Years to 80 Years   (Child, Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","B.10.1.TKH.4.34.H.GP.0.01/213","June 1, 2020","June 1, 2021","June 1, 2021","June 11, 2020",,"June 11, 2020","Umraniye Education and Research Hospital, Department of General Surgery, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT04424485"
665,"NCT04425512","Delta Neutrophil Index and Neutrophil Lymphocyte Ratio in Thyroid Malignancy",,"Completed","No Results Available","Thyroid Cancer|Thyroid Nodule|Thyroid Diseases|Delta Neutrophyl Index|Immature Granulocyte Count|Neutrophyl to Lymphocyte Ratio","Diagnostic Test: Complete Blood Count","Delta neutrophyl index for thyroid malignancies|Immature granulocyte count for thyroid malignancies|Neutrophyl to lymphocyte ratio for thyroid malignancies","Kahramanmaras Sutcu Imam University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","333","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","355","November 1, 2014","November 1, 2019","November 1, 2019","June 11, 2020",,"June 11, 2020",,,"https://ClinicalTrials.gov/show/NCT04425512"
666,"NCT00514046","Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer",,"Completed","Has Results","Medullary Thyroid Carcinoma|Multiple Endocrine Neoplasia Type 2A|Multiple Endocrine Neoplasia Type 2B","Drug: Vandetanib","Maximum Tolerated Dose (MTD)|Overall Percentage of Participants With an Objective Response Defined as a Complete Response (CR) or Partial Response (PR)|Number of Participants With an Increase or Decrease in Carcinoembryonic Antigen (CEA) Biomarker Response|Percent Change in Calcitonin (CTN) Biomarker Response After Cycle 1|Area Under the Concentration Time Curve (AUC 0-24h)|Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v3.0)","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","5 Years to 18 Years   (Child, Adult)","Phase 1|Phase 2","17","NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","070189|07-C-0189","July 20, 2007","December 10, 2019","November 1, 2020","August 9, 2007","December 22, 2020","December 22, 2020","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/46/NCT00514046/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/46/NCT00514046/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT00514046"
667,"NCT02911233","Evaluation of Clot Stability Induced by Solulin: Evaluation of New Solulin Mutants Lacking Protein C Activation Capacity","SOLUCLOT","Completed","No Results Available","Hemophilia A","Biological: Thromboelastograpgy","Evaluation of blood clot firmness in ROTEM experiments using mutant Solulin|Evaluation of fibrinolysis in ROTEM experiments using mutant Solulin","University Hospital, Caen","Male","18 Years and older   (Adult, Older Adult)",,"10","Other","Observational","Time Perspective: Prospective","13-136","March 2014","September 2015","September 2015","September 22, 2016",,"September 22, 2016","University Hospital, Caen, Calvados, France",,"https://ClinicalTrials.gov/show/NCT02911233"
668,"NCT02656381","Uveitis/Intraocular Inflammatory Disease Biobank (iBank)",,"Recruiting","No Results Available","Uveitis",,"The clinical data and samples from this study will be used to test for interaction of key parameters of phenotype with genetic variants and other biomarkers identified from biospecimens.|Secondary outcomes will include the number and severity of systemic and ocular adverse events among participants who use systemic immunosuppression.","National Eye Institute (NEI)|National Institutes of Health Clinical Center (CC)","All","8 Years and older   (Child, Adult, Older Adult)",,"650","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","160046|16-EI-0046","July 26, 2016","December 31, 2029","December 31, 2029","January 14, 2016",,"December 16, 2021","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02656381"
669,"NCT02774629","Efficacy of Local Food Extracts at Different Storage Times",,"Unknown status","No Results Available","Food Allergy","Other: prick and patch test","Mean wheal diameter of skin prick test|Result of atopy patch test","Mahidol University","All","3 Years to 18 Years   (Child, Adult)",,"60","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","619/2556(EC3)","January 1, 2017","August 31, 2019","August 31, 2019","May 17, 2016",,"March 14, 2019","Siriraj hospital, Bangkok, Thailand",,"https://ClinicalTrials.gov/show/NCT02774629"
670,"NCT01424878","Study of Molecular Pathways in Medullary Thyroid Carcinoma and Correlation of Molecular Data With Clinical Behavior of the MTC in Individuals Patients",,"Completed","No Results Available","Medullary Thyroid Carcinoma|Multiple Endocrine Neoplasia Type 2",,,"National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","2 Years to 80 Years   (Child, Adult, Older Adult)",,"150","NIH","Observational","Time Perspective: Retrospective","999910167|10-C-N167","July 5, 2010",,"February 12, 2014","August 29, 2011",,"April 5, 2018","National Cancer Institute (NCI), 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01424878"
671,"NCT00795951","Clinical Evaluation of T.R.U.E. TEST in Children and Adolescents",,"Completed","Has Results","Dermatitis, Contact","Biological: T.R.U.E. Test","Positive Reactions: Nickel Sulfate|Positive Reactions: Neomycin Sulfate|Positive Reactions: Wool Alcohol|Positive Reactions: Potassium Dichromate|Positive Reactions: Caine Mix|Positive Reactions: Fragrance Mix|Positive Reactions: Colophony|Positive Reactions: Paraben Mix|Positive Reactions: Negative Control|Positive Reactions: Balsam of Peru|Positive Reactions: Ethylenediamine Dihydrochloride|Positive Reactions: Cobalt Dichloride|Positive Reactions: P-tert Butylphenol Formadehyde Resin|Positive Reactions: Epoxy Resin|Positive Reactions: Carba Mix|Positive Reactions: Black Rubber Mix|Positive Reactions: Cl+Me-Isothiazolinone|Positive Reactions: Quaternium-15|Positive Reactions: Mercaptobenzothiazole|Positive Reactions: p-Phenylenediamine|Positive Reactions: Formaldehyde|Positive Reactions: Mercapto Mix|Positive Reactions: Thimerosal|Positive Reactions: Thiuram Mix|Positive Reactions: Diazolidinyl Urea|Positive Reactions: Imidazolidinyl Urea|Positive Reactions: Budesonide|Positive Reactions: Tixocortol-21-pivalate|Positive Reactions: Quinoline Mix|Late Reactions: Nickel Sulfate|Late Reactions: Neomycin Sulfate|Late Reactions: Wool Alcohol|Late Reactions: Potassium Dichromate|Late Reactions: Caine Mix|Late Reactions: Fragrance Mix|Late Reactions: Colophony|Late Reactions: Paraben Mix|Late Reactions: Negative Control|Late Reactions: Balsam of Peru|Late Reactions: Ethylenediamine Dihydrochloride|Late Reactions: Cobalt Dichloride|Late Reactions: P-tert Butylphenol Formadehyde Resin|Late Reactions: Epoxy Resin|Late Reactions: Carba Mix|Late Reactions: Black Rubber Mix|Late Reactions: Cl+Me-Isothiazolinone|Late Reactions: Quaternium-15|Late Reactions: Mercaptobenzothiazole|Late Reactions: p-Phenylenediamine|Late Reactions: Formaldehyde|Late Reactions: Mercapto Mix|Late Reactions: Thimerosal|Late Reactions: Thiuram Mix|Late Reactions: Diazolidinyl Urea|Late Reactions: Imidazolidinyl Urea|Late Reactions: Budesonide|Late Reactions: Tixocortol-21-pivalate|Late Reactions: Quinoline Mix|Persistent Reactions: Nickel Sulfate|Persistent Reactions: Neomycin Sulfate|Persistent Reactions: Wool Alcohol|Persistent Reactions: Potassium Dichromate|Persistent Reactions: Caine Mix|Persistent Reactions: Fragrance Mix|Persistent Reactions: Colophony|Persistent Reactions: Paraben Mix|Persistent Reactions: Negative Control|Persistent Reactions: Balsam of Peru|Persistent Reactions: Ethylenediamine Dihydrochloride|Persistent Reactions: Cobalt Dichloride|Persistent Reactions: P-tert Butylphenol Formadehyde Resin|Persistent Reactions: Epoxy Resin|Persistent Reactions: Carba Mix|Persistent Reactions: Black Rubber Mix|Persistent Reactions: Cl+Me-Isothiazolinone|Persistent Reactions: Quaternium-15|Persistent Reactions: p-Phenylenediamine|Persistent Reactions: Formaldehyde|Persistent Reactions: Mercapto Mix|Persistent Reactions: Thimerosal|Persistent Reactions: Thiuram Mix|Persistent Reactions: Diazolidinyl Urea|Persistent Reactions: Imidazolidinyl Urea|Persistent Reactions: Budesonide|Persistent Reactions: Tixocortol-21-pivalate|Persistent Reactions: Quinoline Mix|Persistent Reactions: Mercaptobenzothiazole|Panel Adhesion Evaluation|Panel Irritation|Subject Reported Itching and Burning","Allerderm","All","6 Years to 18 Years   (Child, Adult)","Phase 4","102","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","MEKOS 07 29P1/2/3/401","November 2008","October 2009","November 2009","November 21, 2008","February 11, 2014","August 6, 2020","Rady Children's Hospital, San Diego, California, United States",,"https://ClinicalTrials.gov/show/NCT00795951"
672,"NCT04157946","The Role of Morphological Phenotype in ARDS","MPARDS","Completed","No Results Available","Respiratory Distress Syndrome, Adult","Diagnostic Test: CT","Measuring the level of pulmonary stress caused by mechanical ventilation|Measurement of pulmonary strain caused by mechanical ventilation|Measurement of injury due to cyclic opening and closing of the most unstable caused by mechanical ventilation .|Measurement of pulmonary hyperinflation caused by mechanical ventilation","Hospital El Cruce","All","18 Years and older   (Adult, Older Adult)",,"12","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","HElCruce","August 7, 2017","July 10, 2019","July 20, 2019","November 8, 2019",,"November 8, 2019","Hospital El Cruce, Florencio Varela, Buenos Aires, Argentina",,"https://ClinicalTrials.gov/show/NCT04157946"
673,"NCT01739465","Comparison of Endoscopic Radiofrequency Ablation Versus Photodynamic Therapy for Inoperable Cholangiocarcinoma",,"Unknown status","No Results Available","Cholangiocarcinoma","Procedure: Self expanding metallic stent (SEMS)|Procedure: Endoscopic radiofrequency ablation (ERFA)|Procedure: Photodynamic therapy (PDT)","stent patency|overall survival rate","Guangzhou Medical University","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2|Phase 3","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RFA2012","November 2012","December 2015",,"December 3, 2012",,"February 26, 2013","The Second Hospital of Guangzhou Medical College, Guangzhou, Guangdong, China|The second hospital of Guangzhou Medical college, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT01739465"
674,"NCT00647439","Genetics and Markers of Degenerative and Inflammatory Eye Diseases",,"Completed","No Results Available","Diabetic Retinopathy|Age-Related Macular Degeneration (AMD)|Uveitis",,,"National Eye Institute (NEI)|National Institutes of Health Clinical Center (CC)","All","4 Years and older   (Child, Adult, Older Adult)",,"609","NIH","Observational","Observational Model: Case-Control|Time Perspective: Other","080099|08-EI-0099","March 27, 2008",,"December 4, 2018","March 31, 2008",,"December 10, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00647439"
675,"NCT01358045","Topical Vitamin D3, Diclofenac or a Combination of Both to Treat Basal Cell Carcinoma",,"Completed","No Results Available","Basal Cell Carcinoma","Drug: Diclofenac|Drug: Diclofenac + Calcitriol|Drug: Calcitriol","Histological changes in different proliferation and apoptosis markers.|Macroscopic tumour changes|Toleration|Compliance","Maastricht University Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","128","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","MEC 10-2-088","November 2011","February 2013","May 2013","May 23, 2011",,"January 13, 2015","Maastricht University Medical Center, Maastricht, Limburg, Netherlands",,"https://ClinicalTrials.gov/show/NCT01358045"
676,"NCT02185027","Observatory of Invasive Procedures and Bleeding in Patients Treated With New Oral Anticoagulants","GIHP-NACO","Completed","No Results Available","Venous Thromboembolism|Atrial Fibrillation","Other: complications and compliance with GIHP recommendations","complications and compliance with GIHP recommendations|NOAC management|reversal strategies description|Coagulation test results","University Hospital, Grenoble|Floralis","All","18 Years and older   (Adult, Older Adult)",,"1166","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","DCIC 13 18","June 2013","March 2016","December 2016","July 9, 2014",,"October 6, 2021","CHU Brugmann, Brussels, Belgium|Hôpitaux du Léman, Thonon-les-Bains, haute-Savoie, France|CH Agen, Agen, France|CHU d'Amiens, Amiens, France|CHR Annecy, Annecy, France|CHU Besançon, Besançon, France|CHU Bordeaux, Bordeaux, France|CH Castres, Castres, France|CH Chambéry, Chambery, France|CHU Clermont-Ferrand, Clermont-ferrand, France|CH Alpes leman, Contamine-sur-Arve, France|CHU Dijon, Dijon, France|CH Gap, GAP, France|CHU de Grenoble, Grenoble, France|Groupe Hospitalier Mutualiste Grenoble, Grenoble, France|CHRU Lille, Lille, France|HCL - Edouard Herriot, Lyon, France|HCL - Hôpital de la Croix-Rousse, Lyon, France|HCL - Lyon Sud, Lyon, France|CHU Marseille, Marseille, France|CHU Montpellier, Montpellier, France|Centre Emile Gallé - SINCAL, Nancy, France|CHU Nancy, Nancy, France|CHU Nantes, Nantes, France|CHU Nimes, Nimes, France|CH de Niort, Niort, France|APHP - Antoine Beclere, Paris, France|APHP - Tenon, Paris, France|APHP Henri Mondor, Paris, France|APHP Hôpital Bichat, Paris, France|APHP Hôpital Cochin, Paris, France|APHP Site St Antoine, Paris, France|Aphp-Hegp, Paris, France|APHP-Hôpital Beaujon, Paris, France|Centre Hôpital Américain, Paris, France|CHU Bicêtre, Paris, France|CHU Rennes, Rennes, France|CHRU Strasbourg - Hôpital Civil, Strasbourg, France|Hôpital d'Instruction des Armées Sainte-Anne, Toulon, France|CHU Toulouse, Toulouse, France|CH Voiron, Voiron, France",,"https://ClinicalTrials.gov/show/NCT02185027"
677,"NCT00655096","Screening for Research Participants",,"Recruiting","No Results Available","Eye Diseases",,"ascertain eligibility","National Eye Institute (NEI)|National Institutes of Health Clinical Center (CC)","All","2 Years and older   (Child, Adult, Older Adult)",,"10000","NIH","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","080102|08-EI-0102","August 20, 2008",,,"April 9, 2008",,"January 18, 2022","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00655096"
678,"NCT00946634","Ozone Therapy in Endodontic Practice, in Vivo Study",,"Completed","No Results Available","Primary Apical Periodontite","Drug: Ozone|Drug: Control (no last irrigation)|Drug: Aqueous Ozone","Acceleration in repair by healing of apical periodontite","University of Sao Paulo|Fundação de Amparo à Pesquisa do Estado de São Paulo","All","13 Years to 60 Years   (Child, Adult)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","CEP 154/06","January 2009","March 2009","March 2011","July 27, 2009",,"October 4, 2011","Fundação para o Desenvolvimento Científico e Tecnológico da Odontologia of University of Sao Paulo, Sao Paulo, SP, Brazil",,"https://ClinicalTrials.gov/show/NCT00946634"
679,"NCT00055029","Clinical and Genetic Studies of X-Linked Juvenile Retinoschisis",,"Recruiting","No Results Available","Retinoschisis",,"The primary outcome is the categorization of the proband's genotype and phenotype and determination of the relationship between the two.","National Eye Institute (NEI)|National Institutes of Health Clinical Center (CC)","All","1 Year and older   (Child, Adult, Older Adult)",,"500","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","030033|03-EI-0033","May 19, 2003",,,"February 17, 2003",,"December 16, 2021","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00055029"
680,"NCT00113997","Safety and Dosing Evaluation of REG1 Anticoagulation System",,"Completed","No Results Available","Healthy","Drug: REG1",,"National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult","Phase 1","106","NIH","Interventional","Primary Purpose: Treatment","050164|05-H-0164","June 2005",,"October 2005","June 13, 2005",,"March 4, 2008","National Heart, Lung and Blood Institute (NHLBI), Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00113997"
681,"NCT02241694","To Quantify the Range of Main Psychosocial Factors Affecting Patients and Caregivers in Their Daily Lives","HERO","Completed","No Results Available","Congenital Bleeding Disorder|Haemophilia A|Haemophilia B|Haemophilia A With Inhibitors|Haemophilia B With Inhibitors|Relatives to/Carers of Patients","Other: No treatment given","Qualitative assessments of perceived impact on daily life|Perceived disease control|Carrier status and reactions to haemophilia diagnosis|Genetic counselling and testing|Impact of haemophilia in siblings|Satisfaction with support from partners, family, friends, others|Sexual intimacy with partners in long-term relationships|Treatment method, compliance and location|Modified WHO-5 (World Health Organization-Five Well Being Index)|Knowledge and information about haemophilia|Improvements in haemophilia care","Novo Nordisk A/S","Male","18 Years and older   (Adult, Older Adult)",,"200","Industry","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","F7HAEM-4146|U1111-1147-4202","November 2014","July 2015","July 2015","September 16, 2014",,"July 10, 2015","Säo Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT02241694"
682,"NCT00076271","Evaluation and Treatment of Pediatric, Developmental, and Genetic Eye Diseases",,"Completed","No Results Available","Eye Diseases",,,"National Eye Institute (NEI)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult",,"350","NIH","Observational",,"040039|04-EI-0039","January 14, 2004",,"October 28, 2008","January 19, 2004",,"July 2, 2017","Rocky Mountain Lions Eye Institute, Denver, Colorado, United States|National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00076271"
683,"NCT03937440","The Effect of Deep Neuromuscular Block on the Perioperative Stress Response Reduction and Postoperative Recovery Enhancement in Robot-assisted Stomach Cancer Surgery",,"Completed","No Results Available","Stomach Cancer","Drug: Deep neuromuscular block with 'rocunium®'|Drug: Moderate neuromuscular block with 'rocunium®'","Difference of stress responses between deep block and moderate block","Yonsei University","All","20 Years to 65 Years   (Adult, Older Adult)","Not Applicable","46","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","4-2019-0205","July 3, 2019","December 15, 2019","December 15, 2019","May 3, 2019",,"December 18, 2019","Department of Anesthesiology and Pain Medicine, Anesthesia and Pain Research Institute, Yonsei University College of Medicine, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03937440"
684,"NCT02084810","Investigating the Bioequivalence of Eptacog Alfa A 6 mg and NovoSeven® in Healthy Male Subjects",,"Withdrawn","No Results Available","Congenital Bleeding Disorder|Haemophilia A|Haemophilia A With Inhibitors|Haemophilia B|Haemophilia B With Inhibitors|Healthy","Drug: activated recombinant human factor VII|Drug: eptacog alfa (activated)","Area under the curve|Maximum concentration|Frequency of adverse events (including serious adverse events)|Incidence of antibodies","Novo Nordisk A/S","Male","18 Years to 55 Years   (Adult)","Phase 1","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","NN7777-4087|2013-003163-63|U1111-1145-6620","March 2014","July 2014","July 2014","March 12, 2014",,"March 26, 2014",,,"https://ClinicalTrials.gov/show/NCT02084810"
685,"NCT01322620","Survey Evaluating the Psychosocial Effects of Living With Haemophilia","HERO","Completed","No Results Available","Congenital Bleeding Disorder|Haemophilia A|Haemophilia B|Haemophilia A With Inhibitors|Haemophilia B With Inhibitors|Relatives to/Carers of Patients","Other: No treatment given","To quantify the extent of key psychosocial factors affecting patients with haemophilia in their daily lives|To quantify how psychosocial factors are associated with treatment outcomes, compliance, health and general well-being","Novo Nordisk A/S","Male","18 Years and older   (Adult, Older Adult)",,"1236","Industry","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","F7HAEM-3911|U1111-1119-7128","June 3, 2011","February 29, 2012","February 29, 2012","March 24, 2011",,"February 23, 2017","Novo Nordisk Investigational Site, Mississauga, Canada|Novo Nordisk Investigational Site, Madrid, Spain|Novo Nordisk Investigational Site, Crawley, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01322620"
686,"NCT00231010","Molecular Genetics of Retinal Degenerations",,"Completed","No Results Available","Retinal Degeneration|Retinitis Pigmentosa",,"V","National Eye Institute (NEI)|National Institutes of Health Clinical Center (CC)","All","4 Years and older   (Child, Adult, Older Adult)",,"3549","NIH","Observational","Observational Model: Family-Based|Time Perspective: Other","050143|05-EI-0143","September 26, 2005",,"June 23, 2016","October 3, 2005",,"April 5, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States|Harvard Medical School, Boston, Massachusetts, United States|Cleveland Clinic Foundation Childrens Hospital, Cleveland, Ohio, United States|Sun Yat-Sen University, Guangzhou, China|Aravind Eye Hospital, Maduri, India|University of Punjab, Lahore, Pakistan",,"https://ClinicalTrials.gov/show/NCT00231010"
687,"NCT01892657","Cetaphil® Daily Facial Moisturizer With Sunscreen SPF 50+ - Human Repeat Insult Patch Test",,"Completed","Has Results","Skin Irritation","Drug: Facial Moisturizer with SPF 50+","Area of Erythema and Elevated Responses of Skin to Product","Galderma Laboratories, L.P.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 4","128","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","GLI.04.SRE.US10093","March 2008","May 2008","August 2008","July 4, 2013","September 25, 2013","September 25, 2013","Thomas J. Stephens and Associates, Inc., Colorado Springs, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT01892657"
688,"NCT02484651","Can Adequacy of Anesthesia Depth and Quality of Recovery be Influenced by the Level of Neuromuscular Blockade?",,"Completed","Has Results","Neuromuscular Block","Drug: Sugammadex|Drug: Rocuronium","BIS Signal Variability Using the Measured Standard Deviation During the Maintenance Phase of Anesthesia|Required Effect-site Concentrations of Propofol and Remifentanil|PQRS Results at 15 and 40 Minutes After Surgery (Taking Into Account the Patient Baseline Values of the PQRS Test Done on the Preanesthetic Visit)|PQRS Satisfaction Results at Day 3 After Surgery","Centro Hospitalar do Porto|Merck Sharp & Dohme Corp.","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","70","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2014.145|2014-005238-76","September 2016","June 28, 2017","July 1, 2017","June 29, 2015","September 16, 2019","September 16, 2019","Centro Hospitalar do Porto, Porto, Portugal","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/51/NCT02484651/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02484651"
689,"NCT00089765","Ranibizumab Injections to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome",,"Completed","No Results Available","Von Hippel-Lindau Syndrome","Drug: Ranibizumab",,"National Eye Institute (NEI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)","Phase 1","5","NIH","Interventional","Primary Purpose: Treatment","040240|04-EI-0240","August 10, 2004",,"August 15, 2007","August 13, 2004",,"July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00089765"
690,"NCT00056199","EYE001 to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome",,"Completed","No Results Available","Hippel-Lindau Disease","Drug: EYE001",,"National Eye Institute (NEI)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult","Phase 1","5","NIH","Interventional","Primary Purpose: Treatment","030101|03-EI-0101","March 2003",,"November 2005","March 7, 2003",,"March 4, 2008","National Eye Institute (NEI), Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00056199"
691,"NCT03598907","Point-of-care Management of Coagulopathy in Lung Transplantation",,"Terminated","No Results Available","Lung Transplantation","Other: Fresh frozen plasma","Compare the incidence of PGD in the group of patients with POC approach to treatment of coagulopathy versus existing standard ,,blind"" approach to treatment of coagulopathy|Compare the the amount of perioperative blood loss|Compare the consumption of transfusion products between groups|Compare the incidence of thrombotic complications between groups|Compare the length of invasive mechanical ventilation|Compare morbidity and mortality between investigated groups (30, 90 and 365 days)|Compare incidence of lung graft rejection","University Hospital, Motol","All","18 Years to 80 Years   (Adult, Older Adult)",,"67","Other","Observational","Observational Model: Other|Time Perspective: Prospective","NV19-06-00471","January 1, 2018","June 30, 2020","June 30, 2020","July 26, 2018",,"July 2, 2020","Unoversity Hospital Motol, Department of Anaesthesiology and Intensive Care, Prague, Czechia",,"https://ClinicalTrials.gov/show/NCT03598907"
692,"NCT02724111","Effect of Neuromuscular Blockade on Operating Conditions and Overall Satisfaction During Spinal Surgery",,"Completed","Has Results","Neuromuscular Blockade|Surgery|Anesthesia|Spinal Diseases","Drug: sufficient dose of rocuronium|Drug: sugammadex 10 min after position change","Mean Value of Peak Inspiratory Pressure|Mean Value of Pressure of Back Muscle Retractor|Overall Satisfaction of Surgeons for the Surgical Condition|The Muscle Tone|The Number of Body Movements|The Degree of Bleeding|Recovery Time (Time to Reach Sedation Score 5 at Postanesthesia Care Unit (PACU).|Adverse Events : The Postoperative Nausea and Vomiting Occurrence in Subject","Korea University Guro Hospital|Merck Sharp & Dohme Corp.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","90","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Supportive Care","KUGH15297-002","May 15, 2016","February 16, 2017","February 16, 2017","March 31, 2016","October 13, 2017","October 13, 2017","Korea University Guro Hospital, Seoul, Korea, Republic of","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT02724111/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT02724111/SAP_001.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT02724111/ICF_002.pdf","https://ClinicalTrials.gov/show/NCT02724111"
693,"NCT02773173","Individualized Pneumoperitoneum Pressure in Colorectal Laparoscopic Surgery Versus Standard Therapy (IPPCollapse-II)",,"Completed","No Results Available","Colorectal Surgery|Laparoscopy","Procedure: IPP in colorectal laparoscopic surgery|Procedure: SPP in colorectal laparoscopic surgery","Change in Postoperative Quality of Recovery Scale (PQRS) Physiologic Domain|Chnge Postoperative Quality of Recovery Scale (PQRS)|Daily postoperative complications until hospital discharge (Clavien-Dindo)|Basic features of airway pressures (plateauP, peakP, pulmonary Compliance)|Intraabdominal pressure|Intraabdominal volume|Spontaneous / coughing movements .|Substudy- Hepatic perfusion during pneumoperitoneum.Plasma disappearance rate of indocyanine green (PDRICG)|Change in Surgical stress and inflammatory markers","Instituto de Investigacion Sanitaria La Fe","All","18 Years and older   (Adult, Older Adult)","Phase 4","204","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care","IPPCollapse-II","January 25, 2017","November 19, 2018","November 19, 2018","May 16, 2016",,"April 15, 2020","Hospital universitario y Politécnico La Fe, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT02773173"
694,"NCT02485210","Effectiveness of Photodynamic Therapy for Endodontic Treatment of Deciduous Teeth",,"Unknown status","No Results Available","Tooth, Nonvital","Procedure: Endodontic treatment","Clinical evaluation.|Radiographic evaluation|Microbiological evaluation","University of Nove de Julho","All","3 Years to 6 Years   (Child)","Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","832.657","April 29, 2017","October 2017","April 2018","June 30, 2015",,"May 8, 2017","University of Nove de Julho, São Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT02485210"
695,"NCT03292965","Monitoring of Postoperative Residual Neuromuscular Blockade in Laparoscopic Surgery",,"Completed","No Results Available","Neuromuscular Block, Residual","Drug: Neostigmine|Drug: Sugammadex","the incidence of postoperative residual curarization","Seoul National University Bundang Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","B-1609-363-002","September 28, 2017","November 29, 2017","November 29, 2017","September 26, 2017",,"October 9, 2018","Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03292965"
696,"NCT00867906","Safety of Cat-PAD to Treat Cat Allergy in Cat Allergic Subjects With Controlled Asthma",,"Completed","No Results Available","Cat Allergy","Biological: Cat-PAD|Biological: Placebo","Safety and tolerability of multiple intradermal injections of Cat-PAD in cat allergic subjects with controlled asthma|Mean change from baseline in area of the LPSR 8 hours after intradermal challenge with whole cat allergen at PTC after Cat-PAD injection compared to placebo|Mean change from baseline in area of the EPSR 15 minutes after intradermal challenge with whole cat allergen at PTC after Cat-PAD injection compared to placebo|Mean change from baseline in CPT score at PTC after Cat-PAD injection compared to placebo|Mean change from baseline in concentration of cat specific IgE at PTC after Cat-PAD injection compared to placebo","Circassia Limited|Adiga Life Sciences, Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","48","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","CP003","March 2009","April 2010","April 2010","March 24, 2009",,"May 6, 2010","Alpha Medical Research, Mississauga, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00867906"
697,"NCT01008332","Safety of ToleroMune House Dust Mite (HDM) to Treat House Dust Mite Allergy in HDM Allergic Subjects With Rhinoconjunctivitis",,"Completed","No Results Available","Allergy","Biological: Toleromune HDM|Biological: Placebo","Safety and tolerability of multiple intradermal injections of ToleroMune HDM in HDM allergic subjects with allergic rhinoconjunctivitis|Mean change from baseline in area of the LPSR 8 hours after intradermal challenge with whole HDM allergen at PTC after ToleroMune HDM injection compared to placebo|Mean change from baseline in area of the EPSR 15 minutes after intradermal challenge with whole HDM allergen at PTC after ToleroMune HDM injection compared to placebo|Mean change from baseline in CPT score at PTC after ToleroMune HDM injection compared to placebo|Mean change from baseline in concentration of HDM specific IgE at PTC after ToleroMune HDM injection compared to placebo","Circassia Limited|Adiga Life Sciences, Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","50","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","TH001","November 2009","August 2010","August 2010","November 5, 2009",,"November 10, 2010","Centre de Recherche Appliqué en Allergie de Québec, Quebec City, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT01008332"
698,"NCT02082522","Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)",,"Terminated","Has Results","Hilar Cholangiocarcinoma","Drug: Photodynamic therapy-Photofrin|Procedure: Stenting procedure|Drug: Chemotherapy regimen","Overall Survival Time|Time-to-bilirubin Response|Best Overall Tumor Response as Measured by the RECIST 1.1 Criteria (Response Evaluation Criteria in Solid Tumors)|Time-to-tumor Progression|Change From Baseline on Karnofsky Performance Scale (KPS)|Change From Baseline in Performance Status on the Karnofsky Performance Scale (KPS)|Change From Baseline in Health-related Quality of Life on the 4- and 7-point European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30)|Change From Baseline in Health-related Quality of Life on the 4- and 7-point EORTC QLQ-C30","Concordia Laboratories Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","28","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","PIN-PHO1201","November 12, 2014","January 12, 2017","January 12, 2017","March 10, 2014","August 28, 2019","August 28, 2019","Western Regional Medical Center, Inc., Goodyear, Arizona, United States|Mayo Clinic Cancer Center, Scottsdale, Arizona, United States|University of Southern California Keck School of Medicine, Los Angeles, California, United States|UC Davis Medical Center, Sacramento, California, United States|University of Colorado Denver, Aurora, Colorado, United States|Oschner Medical Center, Kenner, Louisiana, United States|Henry Ford Health System, Detroit, Michigan, United States|SUNY Downstate Medical Center, Brooklyn, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Weill Cornell Medical College, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Southwestern Regional Medical Center, Inc., Tulsa, Oklahoma, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Allegheny Center for Digestive Health - AHN ASRI, Pittsburgh, Pennsylvania, United States|Methodist Dallas Medical Center, Dallas, Texas, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Providence Sacred Heart Medical Center and Children's Hospital, Spokane, Washington, United States|St. Michael's Hospital, Toronto, Ontario, Canada|CHUM Hôpital St-Luc, Montreal, Quebec, Canada|Klinikum Ludwigsburg, Ludwigsburg, Baden Wuerttemberg, Germany|Klinikum Mannheim GmbH, Mannheim, Baden Wuerttemberg, Germany|Johann-Wolfgang-Goethe Universität Frankfurt, Frankfurt, Hessen, Germany|Medizinische Hochschule Hannover, Hannover, Niedersachsen, Germany|Universitätsklinikum Essen (AöR), Essen, Nordrhein Westfalen, Germany|Konkuk University Medical Center, Seoul, Gwangjin-gu, Korea, Republic of|Soonchunhyang University Bucheon Hospital, Bucheon City, Gyeonggi-do, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Seodaemun-gu, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|UniversitätsSpital Zürich, Zürich, Switzerland",,"https://ClinicalTrials.gov/show/NCT02082522"
699,"NCT04563520","SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis","SAFE","Not yet recruiting","No Results Available","Hemophilia A","Drug: aPCC-emicizumab|Drug: FEIBA|Drug: rFVIIa","Number of serious adverse events|Number of serious bleeding episodes|Number of episodes of thrombotic events including thrombotic microangiopathy (TMA)|Number of infusions of aPCC required to achieve hemostatic efficacy for treatment of an acute bleeding episode, or prevention of bleeding with emergent and non-emergent procedures","Emory University|Takeda Pharmaceuticals North America, Inc.","All","6 Years and older   (Child, Adult, Older Adult)","Phase 3","20","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STUDY00000804","March 2022","December 2022","December 2022","September 24, 2020",,"January 13, 2022","Children's Healthcare of Atlanta, Atlanta, Georgia, United States|Emory University Hospital, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT04563520"
700,"NCT00878774","Safety of ToleroMune Ragweed to Treat Ragweed Allergy in Ragweed Allergic Subjects With Rhinoconjunctivitis",,"Completed","No Results Available","Allergy","Biological: ToleroMune Ragweed|Biological: Placebo","Safety and tolerability of multiple intradermal injections of ToleroMune Ragweed in ragweed allergic subjects with allergic rhinoconjunctivitis|Mean change from baseline in area of the LPSR 8 hours after intradermal challenge with whole ragweed allergen at PTC after ToleroMune Ragweed injection compared to placebo|Mean change from baseline in area of the EPSR 15 minutes after intradermal challenge with whole ragweed allergen at PTC after ToleroMune Ragweed injection compared to placebo|Mean change from baseline in CPT score at PTC after ToleroMune Ragweed injection compared to placebo|Mean change from baseline in concentration of ragweed specific IgE at PTC after ToleroMune Ragweed injection compared to placebo","Circassia Limited|Adiga Life Sciences, Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","50","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","TR001","April 2009","November 2009","November 2009","April 9, 2009",,"November 10, 2010","Centre de Recherche Appliqué en Allergie de Québec, Quebec City, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00878774"
701,"NCT04476329","Optimization for Regorafenib in HCC","ReDos HCC","Terminated","No Results Available","Hepatocellular Carcinoma","Drug: Regorafenib 40 MG","Overall Survival|Regorafenib treatment cycles|Tumor Progression|Dosing Patterns|EORTC QOL-C30 Quality of Life Measurements|Optional CD14-16 cell sub-study|FACIT FACT-Hep Quality of Life Measurements","SC Liver Research Consortium, LLC|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","7","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","21305","January 21, 2021","October 13, 2021","December 10, 2021","July 20, 2020",,"December 30, 2021","Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|VA Long Beach Health System, Long Beach, California, United States|Tulane University, New Orleans, Louisiana, United States|Henry Ford Health Systems, Detroit, Michigan, United States|Cancer and Hematology Centers of Western Michigan, Grand Rapids, Michigan, United States|Saint Louis University, Saint Louis, Missouri, United States|Comprehensive Cancer Centers of Nevada, Henderson, Nevada, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|Albert Einstein Medical Center, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04476329"
702,"NCT02646514","Efficacy and Safety of Endobiliary Radiofrequency Ablation by Using a Novel RF Catheter (ELRA®) on Maintaining the Patency of Endobiliary Metal Drainage in Patients With Malignant Biliary Strictures : A Double-arm Comparable Study",,"Unknown status","No Results Available","Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer","Device: Radiofrequency ablation with stenting|Device: stenting","Patency of metal stent|Overall Survival|Complication rate","Yonsei University","All","19 Years and older   (Adult, Older Adult)","Not Applicable","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1-2015-0053","September 2015","September 2019","September 2019","January 5, 2016",,"January 28, 2019","Severance Hospital, Yonsei University, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02646514"
703,"NCT02148016","Corneal Epithelium Repair and Therapy Using Autologous Limbal Stem Cell Transplantation",,"Unknown status","No Results Available","Corneal Disease|Pterygium|Myopia|Hyperopia","Procedure: LSCs and amniotic membrane (Modified Technique)|Procedure: Amniotic membrane only (Traditional Technique)|Procedure: PRK, LSCs, and amniotic membrane (Modified Technique)|Procedure: PRK only (Traditional Technique)|Drug: Levofloxacin|Drug: Betamethasone|Drug: Limbal stem cells (LSCs)","Composite measure of visual function in eyes treated for corneal ocular surface disease.|Composite measure of visual function in eyes after photo-refractive keratectomy (PRK)|Incidence of transparency of the cornea","Sun Yat-sen University","All","10 Years to 70 Years   (Child, Adult, Older Adult)","Phase 1|Phase 2","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2013SKL005","December 2012","June 2014","September 2014","May 28, 2014",,"May 28, 2014","Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China",,"https://ClinicalTrials.gov/show/NCT02148016"
704,"NCT02410590","Rocuronium + Sugammadex vs. Succinylcholine + Cisatracurium + Neostigmine/Atropine in Obese Participants (MK-8616-104)","BENN","Withdrawn","No Results Available","Neuromuscular Blockade","Drug: Rocuronium|Drug: Sugammadex|Drug: Cisatracurium|Drug: Neostigmine/Atropine|Drug: Succinylcholine","Number of Surgeons who prefer Rocuronium + Sugammadex vs. Succinylcholine + Cisatracurium + Neostigmine/Atropine for neuromuscular blocking/reversal in obese participants undergoing laparoscopic abdominal surgery|Time elapsed from end of surgery to extubation|Time elapsed from start of reversal drug administration to train-of-four (TOF) ratio ≥0.9","Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 4","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)","8616-104|2013-004423-36","July 2015","October 2016","October 2016","April 7, 2015",,"July 13, 2015",,,"https://ClinicalTrials.gov/show/NCT02410590"
705,"NCT03411187","Study on the Application of Convenient Foot-control Exhaust Method in Endoscopic Thyroidectomy",,"Unknown status","No Results Available","Thyroid Cancer|Papillary Thyroid Carcinoma|Thyroidectomy|Endoscopy","Device: used of the Pressure adjustable foot-control method|Device: direct exhaust","Flap separation time|Glandular excision time|Central lymph node dissection time|Times of wiping lens|Volume of intraoperative blood loss|Volume of Postoperative drainage|The number of identifying parathyroid glands|Blood PTH level|Blood calcium level","Bo Wang,MD|Fujian Medical University","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","exhaust","January 1, 2018","June 30, 2018","December 30, 2018","January 26, 2018",,"September 18, 2018","Wen-xin ZHAO, Fuzhou, Fujian, China",,"https://ClinicalTrials.gov/show/NCT03411187"
706,"NCT01100619","A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors",,"Completed","No Results Available","Papillary Thyroid Cancer|Follicular Thyroid Cancer|Huerthle Cell Thyroid Cancer|Renal Cell Carcinoma","Drug: rosiglitazone|Drug: XL184","Pharmacokinetics of XL184 and rosiglitazone|Safety and tolerability of repeated administration of XL184|Pharmacokinetics of XL184 after co-administration of rosiglitazone","Exelixis","All","18 Years and older   (Adult, Older Adult)","Phase 1","40","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","XL184-008","April 2010","August 2012",,"April 9, 2010",,"September 19, 2013","City of Hope Comprehensive Cancer Center, Duarte, California, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Montefiore Medical Center, Bronx, New York, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01100619"
707,"NCT01771068","Trial of a Parenting Discussion Group in Panama, Central America",,"Completed","No Results Available","Child Behavioural and Emotional Difficulties|Parenting Practices","Behavioral: Triple P Positive Parenting Program Discussion Group ""Dealing with Disobedience""","Change in Eyberg Child Behaviour Inventory (ECBI)|Change in Depression Anxiety Stress Scale 21 (DASS 21)|Change in Parenting Scale (PS)|Change in Parenting Task Checklist (PTC)","University of Manchester|National Secretariat of Science, Technology and Innovation in Panama (SENACYT)","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","108","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","PTY12","April 2012","December 2012","December 2012","January 18, 2013",,"January 18, 2013","Ministry of Education, District of Panama, Panama, Panama",,"https://ClinicalTrials.gov/show/NCT01771068"
708,"NCT02168478","Neo-Synalar Modified 48 Hour Patch Test",,"Completed","Has Results","Allergy","Drug: Neo-Synalar Cream|Other: Sodium Lauryl Sulfate Aqueous Solution (0.40%)|Other: Saline","Evidence of Pre-Existing Sensitization by Use of the Erythemal Scoring Scale (ESS)","Noah Rosenberg, MD|Medimetriks Pharmaceuticals, Inc","All","18 Years to 79 Years   (Adult, Older Adult)","Phase 4","206","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MTWC01-001","June 2014","June 2014","June 2014","June 20, 2014","December 11, 2015","December 11, 2015","Michael Caswell PhD., CCRC,CCRA, Fairfield, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02168478"
709,"NCT04237766","Movement Visualization in Patients With Hemophilic Arthropathy",,"Unknown status","No Results Available","Hemophilia","Other: Experimental group","Change from baseline joint bleeding frequency after treatment and at 6 months|Change from baseline joint pain after treatment and at 6 months|Change from baseline joint pain perception after treatment and at 6 months|Change from baseline muscle strength after treatment and at 6 months|Change from baseline electrical muscle activity after treatment and at 6 months|Change from baseline perception of quality of life after treatment and at 6 months|Change from baseline anxiety perception after treatment and at 6 months|Change from baseline fear of movement after treatment and at 6 months|Change from baseline catastrophism after treatment and at 6 months|Change from baseline anxiety perceived after treatment and at 6 months|Change from baseline endogenous pain inhibitory system after treatment and at 6 months|Change from baseline joint status after treatment and at 6 months","Real Fundación Victoria Eugenia","Male","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","140","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","He-Mirror","May 1, 2020","October 1, 2020","May 1, 2021","January 23, 2020",,"January 27, 2020",,,"https://ClinicalTrials.gov/show/NCT04237766"
710,"NCT05028088","Diaphragm Ultrasound to Evaluate the Antagonistic Effect of Sugammadex",,"Recruiting","No Results Available","Diaphragm Ultrasonography|Liver Dysfunction|Sugammadex|Rocuronium","Drug: sugammadex","the recovery rate of muscle relaxation|muscle relaxation onset time|intraoperative rocuronium dosage|PACU monitoring time|the incidence of postoperative pulmonary complications","Wuhan Union Hospital, China","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","99","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","2016Summer","July 1, 2021","December 2022","December 2022","August 31, 2021",,"September 5, 2021","Union Hospital of Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT05028088"
711,"NCT01723202","Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer",,"Active, not recruiting","No Results Available","Follicular Thyroid Cancer|Insular Thyroid Cancer|Papillary Thyroid Cancer|Recurrent Thyroid Cancer","Drug: dabrafenib|Drug: trametinib|Other: Correlative Studies","Overall objective response rate, defined as the proportion of patients who have a minor response (MR), partial response (PR), or complete response(CR)assessed according to RECIST.|Portion of patients with progression-free survival (PFS)|Overall survival|Number of patients with Adverse events of GSK2118436 (BRAFi) as a single agent and adverse events of GSK2118436 (BRAFi) and GSK1120212 (MEKi) in combination.|Tolerability of the regimens in terms of the number of patients who required dose modifications and/or dose delays.","Manisha Shah|National Comprehensive Cancer Network|Ohio State University Comprehensive Cancer Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","53","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OSU-12064|NCI-2012-01700|NCCNGSK20008","November 7, 2012","December 31, 2021","December 31, 2021","November 7, 2012",,"February 25, 2021","University of California, San Diego, San Diego, California, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States|Ohio State University Medical Center, Columbus, Ohio, United States|The University of Texas-MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01723202"
712,"NCT01910168","A Study to Collect Blood Samples From Patients With Spinal Muscular Atrophy for Biomarker Analysis",,"Completed","No Results Available","Muscular Atrophy, Spinal",,"SMN1/SMN2 detection in blood by mRNA assay|SMN protein level in blood/lymphocytes","Hoffmann-La Roche|PTC Therapeutics","All","Child, Adult, Older Adult",,"36","Industry","Observational","Observational Model: Case-Control|Time Perspective: Prospective","BE29002","August 2013","February 2014","February 2014","July 29, 2013",,"November 2, 2016","Kalamazoo, Michigan, United States|Salt Lake, Utah, United States",,"https://ClinicalTrials.gov/show/NCT01910168"
713,"NCT01797562","Clinical Evaluation of T.R.U.E. Test Allergens in Children an Adolescents",,"Completed","Has Results","Allergic Contact Dermatitis","Diagnostic Test: Panels 1.3, 2.2 and 3.2 experimental allergens","Number of Participants With Negative, Positive, Irritant or Doubtful Reaction Scores|Number of Participants With Late or Persistent Positive Patch Test Reactions","Allerderm","All","6 Years to 17 Years   (Child)","Not Applicable","116","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","SP 12 7NEW 401","December 10, 2012","September 8, 2015","September 8, 2015","February 22, 2013","August 12, 2020","August 21, 2020","Rady Children's Hospital, San Diego, California, United States|Anschutz Health and Wellness Center, University of Colorado, Aurora, Colorado, United States|Dermatology Specialists, Louisville, Kentucky, United States|Oregon Health & Science University, Portland, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT01797562"
714,"NCT02852759","A Cold Physical Treatment to Manage Insulin Resistance","CTPMIR","Completed","No Results Available","Insulin Resistance|Hyperglycemia|Hyperinsulinemia|Diabetes|Obesity","Procedure: Selective Cold|Device: Electroacupuncture","Change of Glucose Tolerance measured by OGTT|Change of serum insulin levels|Change of Body weight|Change of 2-deoxy-2-[fluorine-18]fluoro- D-glucose (FDG) uptake by PET/CT-scans|Change of glucose infusion rate by hyperinsulinemic euglycemic clamp","First Affiliated Hospital Xi'an Jiaotong University|Columbia University","All","18 Years to 60 Years   (Adult)","Not Applicable","33","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","XJTU1AF-CRS-2016-018","July 2016","October 2018","August 2019","August 2, 2016",,"April 30, 2020","First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi, China",,"https://ClinicalTrials.gov/show/NCT02852759"
715,"NCT04115696","Biodegradable Stent Implantation in Biliary Benign Strictures.","BiELLA","Completed","No Results Available","Biliary Tract|Biliary Tract Diseases|Stenosis|Follow-Up Studies|Stents","Device: Percutaneous placement of biodegradable biliary stents","Biliary duct patency: bilirubin alterations (> 2.2)|Stent reabsorption: radiographic persistence of stent radiopaque marks","Group of Research in Minimally Invasive Techniques","All","18 Years and older   (Adult, Older Adult)",,"150","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","GITMI-03","March 1, 2012","February 3, 2018","July 4, 2019","October 4, 2019",,"October 9, 2019","Lozano Blesa Universitary Hospital, Zaragoza, Aragon, Spain|Hospital Parc Tauli, Sabadell, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT04115696"
716,"NCT01143831","Evaluation of Factors II, VII, IX, X, and Proteins C and S, Following High-dose Vitamin K Supplementation",,"Completed","No Results Available","Thrombosis","Dietary Supplement: Vitamin K, 20mg","Change in levels and activities due to vitamin K supplementation","Stephan Moll, MD|University of North Carolina, Chapel Hill","Male","20 Years to 85 Years   (Adult, Older Adult)","Not Applicable","8","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","09-1240","November 2009","March 2012","March 2012","June 14, 2010",,"June 12, 2012","University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01143831"
717,"NCT00004062","Azacitidine to Restore Thyroid Function in Patients With Persistent or Metastatic Thyroid Cancer",,"Completed","No Results Available","Head and Neck Cancer","Drug: azacitidine|Drug: liothyronine sodium|Radiation: iodine I 131",,"Lucille P. Markey Cancer Center at University of Kentucky|National Cancer Institute (NCI)","All","Child, Adult, Older Adult","Phase 1",,"Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000067262|UKMC-9700053|NCI-T99-0045","July 1999",,"August 2006","June 4, 2004",,"December 19, 2013","Albert B. Chandler Medical Center, University of Kentucky, Lexington, Kentucky, United States",,"https://ClinicalTrials.gov/show/NCT00004062"
718,"NCT01905748","Acute Phase Reactions and Thrombophilia in Pediatric Patients With Migraine",,"Unknown status","No Results Available","Migraine|Thrombophilia","Other: Laboratory tests","Proportion of patients with activation of the coagulation system.","HaEmek Medical Center, Israel","All","5 Years to 20 Years   (Child, Adult)","Not Applicable","15","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","0040-09-EMC","August 2011","December 31, 2020","December 31, 2020","July 23, 2013",,"October 31, 2019","Ha'Emek Medical Center, Afula, Israel",,"https://ClinicalTrials.gov/show/NCT01905748"
719,"NCT02716883","Early Amniotic Membrane Transplantation in Bacterial Keratitis",,"Unknown status","No Results Available","Keratitis of Both Eyes","Procedure: AMT","Time to scar formation","Farabi Eye Hospital","All","Child, Adult, Older Adult","Not Applicable","14","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","23345","January 2014","April 2016","April 2016","March 23, 2016",,"March 29, 2016",,,"https://ClinicalTrials.gov/show/NCT02716883"
720,"NCT03323021","Use of Human Dehydrated Amnion/Chorion (DHACM) Allograft in Partial Nephrectomy",,"Completed","No Results Available","Partial Nephrectomy|Kidney Cancer|Renal Function Aggravated","Other: Dehydrated human amnion/chorion membrane|Other: Standard of Care","Recovery of Renal Function|Preservation of Renal Parenchymal Volume|Cancer Control Rates","MiMedx Group, Inc.","All","18 Years and older   (Adult, Older Adult)","Not Applicable","61","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","AFSUR001","May 23, 2017","February 21, 2019","February 21, 2019","October 26, 2017",,"November 13, 2020","The Mount Sinai Hospital, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03323021"
721,"NCT03538782","Patients Radiation Exposure in Percutaneous Transhepatic Biliary Drainage (PTBD) Procedures",,"Completed","No Results Available","Radiation Exposure","Procedure: Percutaneous biliary drainage","Radiation Exposure|Fluoroscopy time|Number of images","Theresienkrankenhaus und St. Hedwig-Klinik GmbH|The Federal Office for Radiation Protection, Germany","All","18 Years and older   (Adult, Older Adult)",,"600","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","Rad Exp PTBD 2018 V1.0","March 15, 2018","August 15, 2018","October 15, 2018","May 29, 2018",,"October 30, 2018","Universitätsklinikum des Saarlandes und Medizinische Fakultät der Universität des Saarlandes Klinik für Innere Medizin II - Gastroenterologie und Endokrinologie, Bad Homburg, Germany",,"https://ClinicalTrials.gov/show/NCT03538782"
722,"NCT02803502","Does the Thrombin Generation Test Performed During the Pharmacokinetic Profile of the Substitutive Factor VIII Bring Benefits to the Personalized Treatment of Pediatric Patients and Adult Hemophilia A Patients Under Prophylaxis ?",,"Unknown status","No Results Available","Hemophilia","Device: Chronometric method|Device: Chromogenic method|Device: Thrombin generation test (TGT)","Factor VIII blood concentration - chronometric method|Factor VIII blood concentration - Chromogenic method|total thrombin generation","Brugmann University Hospital","All","Child, Adult, Older Adult","Not Applicable","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","CHUB-PK TGT","January 2017","July 2020","July 2020","June 17, 2016",,"November 30, 2017","CHU Brugmann, Brussels, Belgium|HUDERF, Brussels, Belgium|Centre Hospitalier Régional de la Citadelle de Liège, Liège, Belgium|CHC de Liège, Liège, Belgium|CHU Liège Sart Tilman, Liège, Belgium",,"https://ClinicalTrials.gov/show/NCT02803502"
723,"NCT04491006","A Translational Study of ATH-1017 in Mild to Moderate Alzheimer's Disease","ACT-AD","Active, not recruiting","No Results Available","Alzheimer Disease|Dementia of Alzheimer Type","Drug: ATH-1017|Drug: Placebo","Event-Related Potential|Cognition","Athira Pharma|National Institute on Aging (NIA)","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 2","77","Industry|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ATH-1017-AD-0202|U1111-1255-9714|18PTC-R-589358|1R01AG068268-01","November 23, 2020","April 2022","May 2022","July 29, 2020",,"November 2, 2021","Syrentis Clinical Research, Santa Ana, California, United States|Premiere Research Institute, West Palm Beach, Florida, United States|iResearch Atlanta, Decatur, Georgia, United States|Neurological Associates of Albany, Albany, New York, United States|Center for Cognitive Health, Portland, Oregon, United States|Evergreen Health Research Program, Kirkland, Washington, United States|University of Washington, Seattle, Washington, United States|Central Coast Neurosciences Research, Central Coast, New South Wales, Australia|St Vincent's Centre for Applied Medical Research, Translational Research Centre, Darlinghurst, New South Wales, Australia|Hammondcare Greenwich Hospital, Greenwich, New South Wales, Australia|KaRa MINDS, Macquarie Park, New South Wales, Australia|HammondCare, Malvern, Victoria, Australia|Australian Alzheimer's Research Organization, Nedlands, Western Australia, Australia",,"https://ClinicalTrials.gov/show/NCT04491006"
724,"NCT00118248","Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer",,"Completed","Has Results","Recurrent Thyroid Cancer|Stage IV Follicular Thyroid Cancer|Stage IV Papillary Thyroid Cancer|Thyroid Gland Medullary Carcinoma","Drug: tanespimycin","Proportion of Patients Who Have Remained on Treatment and Progression-free at Least One Year After Start of 17-AAG (Tanespimycin)|Overall Response|Progression-Free Survival|Overall Survival|Toxicity","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","41","NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2009-00063|JHOC-B/06/174|NCI-6482|JHOC-JS0652|CDR0000433150|MC0476|6482|N01CM62205|P30CA015083|N01CM62207","December 2004","August 2009","April 2012","July 11, 2005","May 6, 2014","February 15, 2017","Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT00118248"
725,"NCT01249235","Bandage Contact Lens and Oral Analgesics Versus Patching and Oral Analgesics for Pain Following Pterygium Surgery",,"Unknown status","No Results Available","Pterygium","Procedure: Patch or bandage contact lens","Visual Analog Pain Score|Sensitivity to light, tearing, foreign body sensation|Postoperative Complications|Number of Tylenol #3 tablets required","University Health Network, Toronto","All","19 Years and older   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","REB-10-0538","October 2010","October 2010","October 2011","November 29, 2010",,"November 29, 2010","Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01249235"
726,"NCT03084068","Use of Human Dehydrated Umbilical Cord Allograft in Supraspinatus Tendon Repair",,"Completed","No Results Available","Shoulder Injury|Shoulder Sprain|Supraspinatus Tear","Other: Human dehydrated umbilical cord allograft|Other: Placebo","ASES score|Constant Murley Score|Shoulder range of motion|VAS Pain scores|Incidence of tendon re-tear|Incidence of adverse events","MiMedx Group, Inc.","All","18 Years and older   (Adult, Older Adult)","Not Applicable","25","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","ACORT001","February 1, 2017","January 17, 2019","January 17, 2019","March 20, 2017",,"December 18, 2019","Hand & UpperEx Center, Wexford, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03084068"
727,"NCT04478136","Can Blood Panels Provide Early Warning of Bleeding in Patients on ECMO?",,"Not yet recruiting","No Results Available","ECMO|Bleeding","Diagnostic Test: Blood test of factor levels","Number of participants with changes in extended blood panel (EBP) for each of the bleeding and non-bleeding patient groups.|Number of participants designated as major bleeders (MB)|Number of participants designated as non-major bleeders (NMB)","Montefiore Medical Center","All","18 Years to 70 Years   (Adult, Older Adult)",,"60","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2019-10472","December 1, 2021","December 1, 2022","June 1, 2023","July 20, 2020",,"February 26, 2021",,,"https://ClinicalTrials.gov/show/NCT04478136"
728,"NCT03809481","Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study to Evaluate Safety and Efficacy of Danaparoid vs Argatroban","HITSOVA","Active, not recruiting","No Results Available","Heparin-induced Thrombocytopenia","Drug: Danaparoid Sodium|Drug: Argatroban","Composite Efficacy Response|Consistent increases in platelet count|Death due to TE or bleeding|Major Bleeding|New or extended thrombosis|Unplanned amputation|All-cause mortality","Aspen Global Incorporated","All","up to 100 Years   (Child, Adult, Older Adult)","Phase 3","508","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","ERGCR-18-ORGHIT-001","May 16, 2019","December 2023","December 2023","January 18, 2019",,"February 15, 2021","Shands University of Florida, Gainesville, Florida, United States|Minneapolis Heart Institute Foundation at Abbott Northwestern Hospital, Minneapolis, Minnesota, United States|University of Minnesota Medical Center, Minneapolis, Minnesota, United States|Duke University Medical Center, Durham, North Carolina, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Clinical Center of the Republic of Srpska, Medical Intesnive Care Unit, Banja Luka, Republika Srpska, Bosnia and Herzegovina|University Clinical Centre of the Republic of Srpska, Clinic for cardiology, Banja Luka, Bosnia and Herzegovina|University Clinical Centre of the Republic of Srpska, Lung Clinic, Banja Luka, Bosnia and Herzegovina|Clinical Center University of Sarajevo, Clinic for Heart, Blood Vessels and Rheumatic Diseases, Sarajevo, Bosnia and Herzegovina|Clinical Center University of Sarajevo, Clinic for Lung Diseases, Sarajevo, Bosnia and Herzegovina|Hamilton General Hospital, Hamilton, Ontario, Canada|The Ottawa Hospital; 501 Smyth Road, Ottawa, Ottowa, Canada|Jewish General Hospital, Montréal, Canada|DIJON University Hospital, Dijon, Burgundy, France|CHU St Etienne; Avenue Albert Raimond, Saint-Priest-en-Jarez, Rhone- Alpes, France|Centre Hospitalier Universitaire Amiens Picardie, Amiens, Somme, France|Vivantes Klinikum im Friedrichhain Hämophiliezentrum, Gerinnungssprechstunde Landsberger Allee 49, Berlin, Berlin-Brandenburg, Germany|Vivantes Klinikum im Friedrichhain Hämophiliezentrum, Berlin, Brandenburg, Germany|Universitätsklinikum Gießen und Marburg GmbH, Klinik für Herz-, Kinderherz- und Gefäßchirurgie Standort Gießen, Gießen, Hesse, Germany|Universitätsklinikum Gießen und Marburg GmbH, Klinik für Herz-, Kinderherz- und Gefäßchirurgie Standort Gießen, Giesen, Lower Saxony, Germany|Universitatstklinikum Halle (Saale), Medizinische Klinik III, Halle (Saale), Saxony-Anhalt, Germany|Städtisches Klinkum Dresden, Dresden, Saxony, Germany|University Hospital Greifswald Dpt. of Hematology, Greifswald, Germany|Zentrum für Klinische Transfusionsmedizin, Tübingen, Germany|Azienda Ospedaliero Universitaria S.Orsola-Malpighi - UO Angiologia e Malattie della Coagulazione, Bologna, Emilia-Romagna, Italy|AOU Careggi, SOD Malattie Aterotrombotiche, Firenze, Florence, Italy|ASST Papa Giovanni XIII, Servizio di Immunoematologia e Medicina Trasfusionale, Bergamo, Lombardy, Italy|Humanitas Research Hospital- Thrombosis Center, Milano, Italy|Instituto Scientifico San Raffaele- Servizio Coagulazione e Centro Trombosi, Milano, Italy|Centrum Medyczne HCP Sp. z o.o. Szpital im. Św. Jana Pawła II, Poznań, Poland|Wojewódzki Szpital Zespolony im. L. Rydygiera, Toruń, Poland|First City Hospital N.A. E.E. Volosevich, Arkhangelsk, Russian Federation|Moscow City Hospital 67, Moscow, Russian Federation|Oncology Center, Omsk, Russian Federation|Regional Hospital after N.N Burdenko, Penza, Russian Federation|Clinical Hospital № 122 N. A. L.G. Sokolov, Saint Petersburg, Russian Federation|Institute of Cardiovasklar Diseases of Vojvodina, Cardiac Surgery ICU, Sremska Kamenica, Novi Sad, Serbia|The Institute for Pulmonary Disease of Vojvodina, Pulmonary thromboembolism department, Novi Sad, Sremska Kamenica, Serbia|Clinical Centre of Serbia, Clinic for Emergency Internal Medicine, Belgrade, Serbia|Clinical centre of Serbia, Clinic for Pulmonology, Belgrade, Serbia|Instiute of Cardiovascular Diseases ""Dedinje"", Belgrade, Serbia",,"https://ClinicalTrials.gov/show/NCT03809481"
729,"NCT00729157","Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy",,"Completed","Has Results","Recurrent Thyroid Gland Carcinoma|Stage III Thyroid Gland Follicular Carcinoma|Stage III Thyroid Gland Papillary Carcinoma|Stage IV Thyroid Gland Follicular Carcinoma|Stage IV Thyroid Gland Papillary Carcinoma","Radiation: Fludeoxyglucose F-18|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Procedure: Positron Emission Tomography|Biological: Ziv-Aflibercept","Progression-free Survival to Determine the 6-month Progression-free-survival (PFS) Rate|Radiographic Response Rate of Aflibercept in Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy|The Safety and Toxicity Profile of IV VEGF Trap in Patients With Recurrent and/or Metastatic TC-FCO|To Determine the Biologic Effect of IV VEGF Trap on FDG Avidity After Four Cycles (Approximately 8 Weeks) of Therapy Through Pre- and Post-treatment FDG-PET Scans in Patients With Recurrent and/or Metastatic D-TC-FCO.|Effect of Thyroglobulin Concentration on Progression-free Survival","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","41","NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2009-00178|MSKCC-08066|CDR0000608163|08-066|7508|N01CM62206|P30CA008748","August 2008","October 2012","November 2012","August 7, 2008","March 15, 2017","March 15, 2017","Memorial Sloan-Kettering Cancer Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00729157"
730,"NCT03676686","Study With Nåva Foot Cream in Patients With Tinea Pedis Interdigitalis",,"Completed","No Results Available","Tinea Pedis","Device: Nåva Foot Cream","Effective clinical treatment rate|Frequency of negative fungal culture|Frequency of negative KOH test|Tolerability to the device used|Other clinical signs and symptoms|Dermatology Quality of life","Natumin Pharma AB","All","18 Years and older   (Adult, Older Adult)","Not Applicable","46","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Nåva Foot Cream_1","October 1, 2018","November 4, 2019","November 4, 2019","September 19, 2018",,"February 25, 2020","Carlanderska sjukhuset, Göteborg, Sweden|PTC, Skövde, Sweden|Univeristetssjukhuset, Örebro, Sweden",,"https://ClinicalTrials.gov/show/NCT03676686"
731,"NCT01382862","PHANTOM-S: The Pre-Hospital Acute Neurological Therapy and Optimization of Medical Care in Stroke Patients - Study","PHANTOM-S","Completed","No Results Available","Acute Stroke","Other: Stroke Emergency Mobile Unit (STEMO)","alarm-to-needle time|Functional outcomes|other times|Costs effectiveness will be assessed|Proportion of stroke patients receiving tissue Plasminogen Activator (tPA)|Special referral|symptomatic intracerebral hemorrhage|Serious adverse events|Mortality","Charite University, Berlin, Germany|Berlin Firebrigade|MEYTEC GmbH|B.R.A.H.M.S GmbH ThermoFisher Scientific|Federal Ministry of Education and Research via Center for Stroke Research Berlin (CSB)|European Union|Berlin Technology Foundation (EFRE)|The Volkswagen Foundation|German Research Foundation","All","18 Years and older   (Adult, Older Adult)","Phase 2","614","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PHANTOM-S","May 2011","January 2013","May 2013","June 27, 2011",,"September 15, 2015","Charite - Universitätsmedizin Berlin, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT01382862"
732,"NCT05127681","Bone Microarchitecture in Men With Hemophilia","HEMOS","Not yet recruiting","No Results Available","Severe Hemophilia A|Osteoporosis","Radiation: HR-pQCT|Biological: Blood sample|Radiation: Dual energy X-ray absorptiometry|Other: medical data collection","number of trabecular at distal tibia|number of trabecular at distal radius|Sera bone remodeling biomarkers|reflection of bone strength|Trabecular Bone Score (TBS)","Hospices Civils de Lyon","Male","20 Years to 60 Years   (Adult)","Not Applicable","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","69HCL19_0390|2019-A03281-56","January 1, 2022","April 1, 2024","April 1, 2024","November 19, 2021",,"December 2, 2021","Hôpital Cardio-Vasculaire et Pneumologique, Bron, France",,"https://ClinicalTrials.gov/show/NCT05127681"
733,"NCT03218722","Early Administration of Prothrombin Concentrate Complex in Patients With Acute Hemorrhage Following Severe Trauma","PROCOAG","Active, not recruiting","No Results Available","Shock, Hemorrhagic","Drug: Pro-Thrombin Concentrate Complex|Drug: NaCl 0.9%","Labile blood products transfused in the first 24 hours|RBC (Red Blood Cells) transfused in the first 24 hours|FFP transfused in the first 24 hours|Platelets transfused in the first 24 hours|Time to achieve Prothrombin ratio < 1.5|Time to hemostasis|Thrombo-embolic events|Mortality|ICU-free days|Ventilator-Free Days|Hospital-free days|Glasgow Outcome Scale Extended (GOSE)|Hospitalisation status|Cost of the strategy","University Hospital, Grenoble","All","18 Years and older   (Adult, Older Adult)","Phase 3","350","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","38RC16.046","December 29, 2017","August 31, 2021","July 2022","July 14, 2017",,"October 1, 2021","Annecy University Hospital, Annecy, France|AP-HP Beaujon, Clichy, France|Grenoble University Hospital, Grenoble, France|AP-HP Kremlin Bicêtre, Le Kremlin-Bicêtre, France|Lille University Hospital, Lille, France|HCL - Hôpital Edouard Herriot, Lyon, France|AP-HM - Marseille Nord, Marseille, France|Montpellier University Hospital, Montpellier, France|Nantes University Hospital, Nantes, France|AP-HP Pitié Salpetrière, Paris, France|HCL - Lyon Sud, Pierre-Bénite, France|Strasbourg University Hospital, Strasbourg, France",,"https://ClinicalTrials.gov/show/NCT03218722"
734,"NCT00381641","Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery",,"Active, not recruiting","Has Results","Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Carcinoma|Refractory Thyroid Gland Carcinoma|Stage III Thyroid Gland Follicular Carcinoma AJCC v7|Stage III Thyroid Gland Medullary Carcinoma AJCC v7|Stage IV Thyroid Gland Follicular Carcinoma AJCC v7|Stage IV Thyroid Gland Medullary Carcinoma AJCC v7|Stage IV Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVA Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVB Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVC Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7|Thyroid Gland Hurthle Cell Carcinoma|Unresectable Thyroid Gland Carcinoma","Other: Laboratory Biomarker Analysis|Other: Pharmacogenomic Study|Drug: Sunitinib|Drug: Sunitinib Malate","Objective Response Rate, Assessed Using the Response Evaluation Criteria in Solid Tumors (RECIST)|Incidence of Toxicity, Graded According to the Common Terminology Criteria for Adverse Events Version 3.0|Overall Survival|Time to Progression or Death Evaluated Using the RECIST","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","63","NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2009-00213|UCCRC-14696A|CDR0000502260|NCI-7735|14696A|7735|N01CM62201|N01CM62202|P30CA014599","August 8, 2006","December 31, 2016",,"September 28, 2006","September 15, 2017","October 26, 2021","University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|Duly Health and Care Joliet, Joliet, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|Central Illinois Hematology Oncology Center, Springfield, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Fort Wayne Medical Oncology and Hematology Inc-Parkview, Fort Wayne, Indiana, United States|Northern Indiana Cancer Research Consortium, South Bend, Indiana, United States|University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Oncology Care Associates PLLC, Saint Joseph, Michigan, United States|Mercy Hospital Saint Louis, Saint Louis, Missouri, United States|M D Anderson Cancer Center, Houston, Texas, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00381641"
735,"NCT00708435","Efficacy and Safety Study of BERIPLEX® P/N (Kcentra) Compared With Plasma in Patients With Acute Major Bleeding Caused by Anticoagulant Therapy",,"Completed","Has Results","Blood Coagulation Disorders|Acute Major Bleeding","Biological: Beriplex® P/N (Kcentra)|Biological: Fresh frozen plasma","Percentage of Participants Achieving Hemostatic Efficacy of Stopping an Ongoing Major Bleed|Percentage of Participants Who Had a Rapid Decrease of the International Normalized Ratio (INR)|Percentage of Participants Who Had Hemostatic Efficacy for Visible or Non-visible Musculoskeletal Bleeding|Incremental in Vivo Recovery (IVR) (Response) of Factors II, VII, IX, and X, Protein C, and Protein S for Beriplex|Plasma Levels of Factors II, VII, IX, and X, Protein C, and Protein S|Percentage of Participants With INR Correction at Various Times After the Start of Infusion|Percentage of Participants With INR Correction at Various Times After Randomization|Transfusion of Red Blood Cells|Use of Other Blood Products and Hemostatic Agents|45-Day All-cause Mortality|Overall Treatment-emergent Adverse Events (TEAEs)","CSL Behring","All","18 Years and older   (Adult, Older Adult)","Phase 3","216","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BE1116_3002|1462|2007-007861-19","June 2008","November 2010","November 2010","July 2, 2008","August 13, 2013","February 3, 2014","Study Site, Birmingham, Alabama, United States|Study Site, Los Angeles, California, United States|Study Site, San Franciso, California, United States|Study Site, Newark, Delaware, United States|Study Site, Orlando, Florida, United States|Study Site, Tampa, Florida, United States|Study Site, Chicago, Illinois, United States|Study Site, Oak Park, Illinois, United States|Study Site, Hazard, Kentucky, United States|Study Site, Baltimore, Maryland, United States|Study Site, Baltimore, Maryland, United States|Study Site, Boston, Massachusetts, United States|Study Site, Worchester, Massachusetts, United States|Study Site, Ann Arbor, Michigan, United States|Study Site, Royal Oak, Michigan, United States|Study Site, Duluth, Minnesota, United States|Study Site, Minneapolis, Minnesota, United States|Study Site, Jackson, Mississippi, United States|Study Site, St. Louis, Missouri, United States|Study Site, Albuquerque, New Mexico, United States|Study Site, Albany, New York, United States|Study Site, Johnson City, New York, United States|Study Site, New York, New York, United States|Study Site, New York, New York, United States|Study Site, New York, New York, United States|Study Site, Rochester, New York, United States|Study Site, Staten Island, New York, United States|Study Site, Durham, North Carolina, United States|Study Site, Allentown, Pennsylvania, United States|Study Site, Hershey, Pennsylvania, United States|Study Site, Philadelphia, Pennsylvania, United States|Study Site, Philadelphia, Pennsylvania, United States|Study Site, West Reading, Pennsylvania, United States|Study Site, Austin, Texas, United States|Study Site, El Paso, Texas, United States|Study Site 2, Houston, Texas, United States|Study Site, Houston, Texas, United States|Study Site, Temple, Texas, United States|Study Site, Salt Lake City, Utah, United States|Study Site, Charlottesville, Virginia, United States|Study Site, Richmond, Virginia, United States|Study Site 1, Minsk, Belarus|Study Site 2, Minsk, Belarus|Study Site, Pleven, Bulgaria|Study Site, Plovdiv, Bulgaria|Study Site, Rousse, Bulgaria|Study Site 1, Sofia, Bulgaria|Study Site 2, Sofia, Bulgaria|Study Site 3, Sofia, Bulgaria|Study Site 4, Sofia, Bulgaria|Study Site, Brasov, Romania|Study Site 1, Bucharest, Romania|Study Site 2, Bucharest, Romania|Study Site 3, Bucharest, Romania|Study Site, Cluj-Napoca, Romania|Study Site, Timisoara, Romania|Study Site, Arkhangelsk, Russian Federation|Study Site 1, Barnaul, Russian Federation|Study Site 2, Barnaul, Russian Federation|Study Site, Kazan, Russian Federation|Study Site, Kemerovo, Russian Federation|Study Site 1, Moscow, Russian Federation|Study Site 2, Moscow, Russian Federation|Study Site 1, Nizhny Novgorod, Russian Federation|Study Site 2, Nizhny Novgorod, Russian Federation|Study Site 1, St. Petersburg, Russian Federation|Study Site 2, St. Petersburg, Russian Federation|Study Site, Kharkov, Ukraine|Study Site, Vinnytsa, Ukraine",,"https://ClinicalTrials.gov/show/NCT00708435"
736,"NCT00275509","Induction Therapy Study in Live Donor Kidney Transplant Recipients With a Positive Crossmatch",,"Completed","Has Results","Kidney Failure, Chronic","Drug: Thymoglobulin|Drug: Daclizumab|Other: Plasmapheresis|Drug: Mycophenolate mofetil|Drug: Tacrolimus|Drug: Dexamethasone|Drug: Prednisone|Drug: Cytogam","6-month Acute Cellular-mediated Rejection Rate (CMR)|6-month Acute Antibody-mediated Rejection Rate (AMR)|6-month Cumulative Rejection Incidence (Either CMR, AMR or Both)","Johns Hopkins University","All","18 Years and older   (Adult, Older Adult)","Phase 3","56","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IRB00078055","January 2007","June 2010","June 2010","January 12, 2006","December 20, 2017","January 18, 2018","The Johns Hopkins University, School of Medicine, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00275509"
737,"NCT04784728","Pharmacokinetics and Adhesion of Lidocaine Topical System 1.8% With Water Exposure",,"Completed","No Results Available","Healthy","Drug: Lidocaine topical system 1.8%","Mean cumulative adhesion score|Peak plasma concentration (Cmax) of lidocaine|Area under the plasma concentration-time curve (AUC) from Time 0 to Time 24 hours|Area under the plasma concentration-time curve (AUC) from Time 0 to Time Infinity|Dermal Response Score","Scilex Pharmaceuticals, Inc.","All","18 Years to 60 Years   (Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCI-LIDO-ADH-004","August 21, 2019","August 31, 2019","August 31, 2019","March 5, 2021",,"March 5, 2021","AXIS Clinicals, Dilworth, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT04784728"
738,"NCT03987607","Comparison of Two Monitors That Measure Neuromuscular Function During Surgeries",,"Completed","No Results Available","Neuromuscular Blockade","Device: neuromuscular blockade monitoring","Agreement between acceleromyography and electromyography derived TOF ratios in the recovery range of 0.8-1.0|o Agreement between acceleromyography and electromyography derived TOF ratios in the recovery range of 0.6-0.79|o Agreement between acceleromyography and electromyography derived TOF ratios in the recovery range of 0.4-0.59|o Agreement between acceleromyography and electromyography derived TOF ratios in the recovery range of 0.2-0.39|o Agreement between acceleromyography and electromyography derived TOF counts|o Agreement between acceleromyography and electromyography derived PTC counts","Tamas Vegh, MD|Senzime AB|University of Debrecen","All","18 Years to 65 Years   (Adult, Older Adult)",,"50","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","AITT2017/3","June 17, 2019","December 18, 2019","December 18, 2019","June 17, 2019",,"January 2, 2020","University of Debrecen, Department of Anesthesiology and Intensive Care, Debrecen, Hungary",,"https://ClinicalTrials.gov/show/NCT03987607"
739,"NCT04312750","Adhesion of Lidocaine Topical System 1.8%",,"Completed","No Results Available","Healthy","Drug: Lidocaine topical system 1.8%","Mean Cumulative Adhesion Score|Dermal Response Score","Scilex Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","54","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","SCI-LIDO-ADH-001","December 2015","December 2015","December 2015","March 18, 2020",,"March 18, 2020",,,"https://ClinicalTrials.gov/show/NCT04312750"
740,"NCT04207086","A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III Melanoma","Neo PeLe","Active, not recruiting","No Results Available","Melanoma Stage III","Drug: Pembrolizumab|Drug: Lenvatinib","Pathological response rate|The anti-tumoural immune response|Objective clinical (RECIST) response rate|Metabolic response rate|Relapse free survival|Treatment free survival|Overall survival|Incidence of post operative infection|Incidence of post operative seroma formation|Duration of post operative wound drainage time|Incidence of post operative bleeding requiring return to theatre or transfusion|Comparison of surgeon's opinion of operability evaluated at baseline to time of surgery|Incidence of any treatment-emergent adverse events|Description of the morphological assessment of melanoma tissue|Description of the RNA expression profile of melanoma tumour|Measurement of leucocyte subpopulations in peripheral blood|Measurement of circulating tumour DNA|Concordance of metabolic response measured by pathological response|Concordance of metabolic response measured by RECIST response|Concordance of pathological response measured by RECIST response|Concordance of metabolic response with RECIST response at relapse|Quality of life scores","Melanoma Institute Australia|Merck Sharp & Dohme Corp.","All","18 Years to 115 Years   (Adult, Older Adult)","Phase 2","20","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MIA/CT2019/281|OTSP 57111","November 11, 2020","July 1, 2022","March 1, 2024","December 20, 2019",,"November 23, 2021","Melanoma Institute Australia, North Sydney, New South Wales, Australia",,"https://ClinicalTrials.gov/show/NCT04207086"
741,"NCT04648462","Proton Therapy Research Infrastructure- ProTRAIT- Neuro-oncology",,"Recruiting","No Results Available","Astrocytoma|Ependymoma|Ganglioglioma|Oligodendroglioma|Optic Nerve Glioma|Meningioma|Nerve Sheath Neoplasms|Adenoma|Craniopharyngioma|Hemangiopericytoma|Germinoma|Neurilemmoma","Other: ProTRAIT","Neurocognitive failure at 5 years|HVLT- delayed recall decline at 5 years|HVLT total recall decline at 5 years|TMT a decline at 5 years|TMT b decline at 5 years|COWA total decline at 5 years","Maastricht Radiation Oncology|University Medical Center Groningen|HollandPTC|Erasmus Medical Center|Leiden University Medical Center|Medical Center Haaglanden|Maastro Clinic, The Netherlands","All","18 Years and older   (Adult, Older Adult)",,"1500","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ProTRAIT-neuro","January 1, 2018","January 1, 2030","January 1, 2035","December 1, 2020",,"December 1, 2020","Maastricht Radiation Oncology, Maastricht, Limburg, Netherlands|Holland PTC, Delft, Zuid-Holland, Netherlands|Universitair Medisch Centrum Groningen, Groningen, Netherlands",,"https://ClinicalTrials.gov/show/NCT04648462"
742,"NCT00751179","Rocuronium Plus Sugammadex Versus Succinylcholine Alone in Participants Undergoing Short Surgical Procedures (19.4.319)(P05700 AM2)(COMPLETED)",,"Completed","Has Results","Neuromuscular Blockade","Drug: rocuronium|Drug: sugammadex|Drug: succinylcholine","Change From Baseline in Plasma Potassium Levels at 5 Minutes After Treatment With Rocuronium or Succinylcholine|Change From Baseline in Plasma Potassium Levels at 5 Minutes After Treatment With Sugammadex|Change From Baseline in Plasma Potassium Levels at 2 Minutes After Treatment With Rocuronium or Succinylcholine|Change From Baseline in Plasma Potassium Levels at 2 Minutes After Treatment With Sugammadex|Change From Baseline in Plasma Potassium Levels at 10 Minutes After Treatment With Rocuronium or Succinylcholine|Change From Baseline in Plasma Potassium Levels at 10 Minutes After Treatment With Sugammadex|Change From Baseline in Plasma Potassium Levels at 15 Minutes After Treatment With Rocuronium or Succinylcholine|Change From Baseline in Plasma Potassium Levels at 15 Minutes After Treatment With Sugammadex|Number of Participants With at Least One Adverse Event (AE) in Rocuronium - Sugammadex and Succinylcholine Treatment Groups|Time to Recovery of the Fourth Twitch/First Twitch (T4/T1) Ratio to 0.9 Following Administration of 4.0 mg/kg of Sugammadex After Neuromuscular Blockade Induced by Rocuronium|Time to Recovery of T1 to 90% of Baseline Following Neuromuscular Blockade Induced by Succinylcholine","Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 3","161","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","P05700|19.4.319","November 2008","December 2009","December 2009","September 11, 2008","March 20, 2012","June 30, 2015",,,"https://ClinicalTrials.gov/show/NCT00751179"
743,"NCT02908243","Outcomes of Prophylaxis and On-demand Treatment for Severe Hemophiliacs and Collection of Baseline Data in Hemophiliacs in Taiwan",,"Unknown status","No Results Available","Hemophilia","Other: collection of baseline data","annual bleeding rate","Taiwan Society of Thrombosis and Hemostasis|Changhua Christian Hospital|Taipei Medical University Hospital|Taipei Veterans General Hospital, Taiwan|Taipei Medical University Shuang Ho Hospital|Taichung Veterans General Hospital|China Medical University Hospital|Kaohsiung Medical University Chung-Ho Memorial Hospital","Male","2 Years to 80 Years   (Child, Adult, Older Adult)",,"350","Other","Observational","Observational Model: Cohort","141115","February 2015","December 2018","December 2018","September 20, 2016",,"September 20, 2016",,,"https://ClinicalTrials.gov/show/NCT02908243"
744,"NCT02530411","Fulvestrant +/- Vandetanib in Advanced Aromatase Inhibitor Resistant Breast Cancer","FURVA","Unknown status","No Results Available","Neoplasms","Drug: Fulvestrant|Drug: Vandetanib","Progression-Free Survival (PFS)|Objective Response Rate|Overall Survival|Exploratory analysis: The influence of RET signalling pathway components expression on vandetanib activity.|Safety and tolerability of the fulvestrant/vandetanib trial drug regime measured by the number of participants with reported serious adverse events (composite outcome measure).|Feasibility of use of the combined vandetanib/fulvestrant trial drug regime measured by the number of participants requiring dose delays, reductions and/or study withdrawal to manage reported serious adverse events.|Clinical Benefit Rate (measuring the proportion of patients with no disease progression after six months of treatment)","Velindre NHS Trust|Cancer Research UK|AstraZeneca","Female","18 Years and older   (Adult, Older Adult)","Phase 2","160","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2014/VCC/0013|2014-001208-23","April 2015","December 2018","December 2020","August 21, 2015",,"August 21, 2015","Royal Bournemouth Hospital, Bournemouth, Dorset, United Kingdom|Royal Devon and Exeter Hospital, Exeter, England, United Kingdom|Royal Cornwall Hospital, Truro, Cornwall, England, United Kingdom|Velindre Cancer Center, Velindre Hospital, Cardiff, Wales, United Kingdom|Royal United Hospital Bath, Bath, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02530411"
745,"NCT02955771","Efficacy and Safety Study of PDT Using Deuteporfin for Unresectable Advanced Perihilar Cholangiocarcinoma",,"Terminated","No Results Available","Hilar Cholangiocarcinoma","Combination Product: PDT-Deuteporfin（6 hour)|Combination Product: PDT-Deuteporfin（9 hour)|Device: stenting","Overallsurvival|1-year survival rate|The change rate of Bile duct stricture|The change rate of serum bilirubin|The change rate of carbohydrate antigen 199(CA199)|The change rate of Karnofsky Performance Scale(KPS)|The change rate of European Organization for Research and Treatment of Cancer Quality Of Life Questionnaire C30 (EORTC QLQ-C30)","Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 2","7","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FDZJDTBF-NCC201512","May 17, 2017","December 26, 2018","December 26, 2018","November 4, 2016",,"July 17, 2019","The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China|The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China|Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China|Shanghai Eastern Hepatobiliary Surgery Hospital, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT02955771"
746,"NCT04023019","Treatment of Hemophilia A Patients With FVIII Inhibitors","MOTIVATE","Recruiting","No Results Available","Hemophilia A","Biological: Nuwiq|Biological: Octanate|Biological: Wilate|Biological: Emicizumab|Biological: Recombinant factor VIIa (rFVIIa)|Biological: Activated prothrombin complex concentrate (aPCC)","Proportion of participants achieving inhibitor titer < 0.6 Bethesda units (BU)/mL|Proportion of participants achieving FVIII recovery ≥ 66% of the predefined reference value of 1.5% IU/kg body weight (Groups 1 and 2)|Proportion of participants achieving FVIII half-life ≥ 6 h (Groups 1 and 2)|Annualized bleeding rate|Time to achieve immune tolerance induction outcome|Frequency of emicizumab, aPCC, and rFVIIa use during immune tolerance induction|Rate of FVIII inhibitor relapse|Frequency of bleeding episodes|Severity of bleeding episodes|Number of infusions required to control bleeding episodes|Frequency of bleeding with surgical procedures|Severity of bleeding with surgical procedures|Proportion of participants experiencing adverse drug reactions|Number of thrombotic events|Treatment costs","Emory University|Octapharma","Male","Child, Adult, Older Adult",,"120","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB00113316","March 17, 2020","December 2028","June 2029","July 17, 2019",,"July 7, 2021","Children's Healthcare of Altanta, Atlanta, Georgia, United States|HZRM Hämophilie-Zentrum Rhein Main, Morfelden-Walldorf, Germany",,"https://ClinicalTrials.gov/show/NCT04023019"
747,"NCT02461251","Thromboelastometry-guided Treatment Protocol Versus Standard Care of Major Haemorrhage in Obstetric Patients","ROTEM-PPH","Completed","No Results Available","Obstetric Labor Complications|Hemorrhage","Device: Rotational Thromboelastometry (ROTEM)","Reduction in blood transfusions|Reduction of transfusion related side-effects|Number of thromboembolic events","Tampere University Hospital","Female","18 Years to 60 Years   (Adult)","Not Applicable","59","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ETL R15054","January 2016","January 2020","January 2020","June 3, 2015",,"January 29, 2020","Tampere University Hospital, Tampere, Finland",,"https://ClinicalTrials.gov/show/NCT02461251"
748,"NCT04614090","Fast Reversal of Warfarin and Early Surgery in Patients With Trochanteric Hip Fracture A Case-control Study",,"Completed","No Results Available","Trochanteric Hip Fractures|Warfarin Medication|Early Surgery",,"Transfusion rates|adverse events|mortality","Karolinska Institutet|Stockholm South General Hospital","All","60 Years and older   (Adult, Older Adult)",,"198","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","Leif Mattisson","October 1, 2017","February 1, 2018","June 26, 2018","November 3, 2020",,"November 3, 2020","Södersjukhuset, Stockholm, Sjukhusbacken 10, Sweden",,"https://ClinicalTrials.gov/show/NCT04614090"
749,"NCT04142918","Diagnostic Markers of Neuropathic Odontalgia","DIAMOND-1","Not yet recruiting","No Results Available","Oral Mucosa","Other: Immunostaining","Patched-1 Western Blot concentration|Patched-1 immunohistochemistry concentration|Patched-1 ELISA concentration|Frizzled-7 Western Blot concentration|Frizzled-7 immunohistochemistry concentration|Frizzled-7 ELISA concentration|Claudin-5 Western Blot concentration|Claudin-5 immunohistochemistry concentration|Claudin-5 ELISA concentration","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)",,"45","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","AP-HP190545","June 1, 2020","December 1, 2020","March 1, 2021","October 29, 2019",,"March 25, 2020","Bretonneau Hospital, Paris, France",,"https://ClinicalTrials.gov/show/NCT04142918"
750,"NCT04014530","Pembrolizumab With Ataluren in Patients With Metastatic pMMR and dMMR Colorectal Carcinoma or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO Study","ATAPEMBRO","Recruiting","No Results Available","Colorectal Cancer|Endometrium Cancer","Drug: Ataluren + Pembrolizumab","Incidence of treatment-Emergent Adverse Event and the determination of the maximum tolerable dose of Ataluren.|Objective response rate|Immune-related progression free survival|Overall survival|Progression free survival|Overall response rate|Historic case matching","Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Merck Sharp & Dohme Corp.|PTC Therapeutics","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","47","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NL64152.018.18|2017-004752-34","August 1, 2019","December 1, 2021","August 1, 2023","July 10, 2019",,"January 13, 2021","Amsterdam UMC, AMC, Amsterdam, Noord-Holland, Netherlands",,"https://ClinicalTrials.gov/show/NCT04014530"
751,"NCT02066051","IPL and Meibomian Gland Expression to Treat Ocular Rosacea Ocular GVHD",,"Completed","Has Results","GVHD|Ocular Rosacea|Dry Eye Syndrome","Device: IPL|Procedure: Meibomian Gland Expression","Number of Participants Who Responded to Intense Pulsed Light (IPL)|Number of Participants Who Experienced Adverse Events","Mayo Clinic","All","18 Years to 99 Years   (Adult, Older Adult)","Not Applicable","8","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","13-003814","October 2013","November 2014","November 2014","February 19, 2014","November 25, 2015","November 25, 2015","Mayo Clinic Arizona, Scottsdale, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT02066051"
752,"NCT03186651","An Investigation With an Intra-vaginal Device for Stress Urinary Incontinence",,"Completed","No Results Available","Stress Urinary Incontinence","Device: TVS","Absolute reduction in leakage as measured by pad weight in gram|Success rate in % in reducing urinary leakage measured by pad weight|Reduction of urinary leakage episodes measured by subjective observations|General impact on quality of life parameters|Impact on disease specific qulity of life parameters","Invent Medic Sweden AB","Female","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","97","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","TVS1000","February 27, 2017","February 14, 2018","March 28, 2018","June 14, 2017",,"April 4, 2018","Ladulaas Kliniska Studier, Boras, Sweden|Kvinnokliniken Karolinska Sjukhuset, Huddinge, Sweden|PTC-Skaraborg, Skovde, Sweden|PTC-Göteborg, Västra Frölunda, Sweden",,"https://ClinicalTrials.gov/show/NCT03186651"
753,"NCT04873310","Behavior Problems Prevention Using the Online Triple P Parenting Program","TriplePChile","Recruiting","No Results Available","Parenting","Other: Triple P online with professional support|Other: Triple P online without professional support","Acceptability of the program by parents/main caregivers using the Acceptability Scale (AS)|Feasibility of the program using the Feasibility Inventory (FI)|Parenting Scale (PS)|Parenting Task Checklist (PTC)|Alabama Parenting Questionnaire (APQ)|The Strengths and Difficulties Questionnaire (SDQ)","Universidad de los Andes, Chile|Municipalidad de Lo Barnechea, Chile","All","18 Years and older   (Adult, Older Adult)","Not Applicable","1920","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention","MLB-TripleP-2021","April 6, 2021","December 30, 2022","December 30, 2022","May 5, 2021",,"November 1, 2021","Universidad de los Andes, Santiago, Las Condes, Chile",,"https://ClinicalTrials.gov/show/NCT04873310"
754,"NCT02113891","Eculizumab Therapy for Subclinical Antibody-mediated Rejection in Kidney Transplantation","TAMARCIN","Withdrawn","No Results Available","Subclinical Acute Antibody-mediated Rejection in Kidney Transplantation","Drug: Eculizumab","Microcirculation inflammation|Transplant glomerulopathy|Measured Glomerular Filtration Rate (Iohexol clearance)|Incidence of adverse effects|Incidence of biopsy-proven acute rejection|CH50|Endothelial Microparticles and Progenitors|Molecular diagnosis of AMR|Donor Specific Antibody titers (Luminex SA)","Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France|Alexion Pharmaceuticals","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","0","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P101004","February 2015","July 2017","November 2017","April 15, 2014",,"February 25, 2015",,,"https://ClinicalTrials.gov/show/NCT02113891"
755,"NCT02668081","Comparing the Effects of EST and EPBD in Patients With Acute Biliary Pancreatitis",,"Unknown status","No Results Available","Acute Biliary Pancreatitis","Procedure: Endoscopic papillary balloon dilation|Procedure: Endoscopic sphincterotomy","Complete removal of common bile duct stones|Evaluation of adverse events","Kaohsiung Veterans General Hospital.","All","20 Years to 100 Years   (Adult, Older Adult)","Not Applicable","39","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VGHKS15-CT7-13","January 2016","December 2017","December 2017","January 29, 2016",,"January 29, 2016","Kaohsiung Veterans General Hospital., Kaohsiung, Taiwan",,"https://ClinicalTrials.gov/show/NCT02668081"
756,"NCT02723591","To Compare the Effects of Immediate-release Tacrolimus and Astagraf XL on Donor-Specific Antibody (DSA) Formation and the Development of Immune Activation (IA) in de Novo Kidney Transplant Recipients","ASTOUND","Completed","Has Results","Kidney Transplantation","Drug: Tacrolimus|Drug: Tacrolimus immediate release","Percentage of Participants Who Were Positive for de Novo DSA (dnDSA) or Immune Activation (IA) Occurrence|Percentage of Participants Who Were Positive, Negative or Indeterminate for dnDSA Occurrence|Peak Mean Fluorescence Intensity (MFI) of DSA Positive Participants|Percentage of DSA Positive Participants With Weak, Moderate and Strong Antibody Strentgh|Percentage of DSA Positive Participants With DSA Persistence|Percentage of Participants Who Were Positive or Negative for Complement Component 1, Q Subcomponent (C1q)-Binding DSA|Percentage of Participants Who Were Positive or Negative for DSA Immunoglobulin G (IgG3) Isotype|Percentage of DSA Positive Participants With Human Leukocyte Antigen, Class II, DQ Locus (HLA-DQ)|Percentage of Participants Who Were Positive for IA Occurrence From Day 1 to Day 365 Visit|Percentage of Participants Who Were Positive for IA Occurrence From Day 30 to Day 365 Visit|Percentage of Participants With IA Persistence|Percentage of Participants With Presence of Transplant Glomerulopathy (TG) on Biopsy|Percentage of Participants With Presence of Microcirculatory Inflammation (MI) on Biopsy|Percentage of Participants With Presence of Interstitial Fibrosis and Tubular Atrophy (IFTA) and Inflammation on Biopsy|Percentage of Participants With Estimated Glomerular Filtration Rate (eGFR) Threshold of <30 Millimetre Per Minute Per 1.73 Meter Square (mL/Min/1.73m^2)|Percentage of Participants With eGFR Threshold of <40 mL/Min/1.73m^2|Percentage of Participants With eGFR Threshold of <50 mL/Min/1.73m^2|Percentage of Participants With a Five-point Decline in eGFR|eGFR at Day 30, Day 90, Day 180, Day 270 and Day 365|Percentage of Participants With Graft Loss|Percentage of Participants Who Died|Percentage of Participants With Biopsy-Proven Acute Rejection (BPAR)|Percentage of Participants Who Were Lost to Follow-up|Percentage of Participants With Either Graft Loss, Death, BPAR or Lost to Follow-up|Percentage of Participants With Any Antibody-Mediated Rejection (ABMR)|Percentage of Participants With Normal Biopsy Findings|Percentage of Participants With C4d Deposition Without Active Rejection|Percentage of Participants With Acute ABMR|Percentage of Participants With Grade I, II and III Acute ABMR|Percentage of Participants With Chronic ABMR|Percentage of Participants With Borderline Changes|Percentage of Participants With Acute T-cell Mediated Rejection (TCMR)|Percentage of Participants With Chronic TCMR|Percentage of Participants With Grade I, II and III IFTA|Percentage of Participants With Any Additional Findings|Percentage of Participants With Glomerulitis (g) Biopsy Score Assessed Using Banff Lesion Scores|Percentage of Participants With Tubulitis (t) Biopsy Score Assessed Using Banff Lesion Scores|Percentage of Participants With Intimal Arteritis (v) Biopsy Score Assessed Using Banff Lesion Scores|Percentage of Participants With Mononuclear Cell Interstitial Inflammation (i) Biopsy Score Assessed Using Banff Lesion Scores|Percentage of Participants With Glomerular Basement Membrane Double Contours (cg) Biopsy Score Assessed Using Banff Lesion Scores|Percentage of Participants With Tubular Atrophy (ct) Biopsy Score Assessed Using Banff Lesion Scores|Percentage of Participants With Interstitial Fibrosis (ci) Biopsy Score Assessed Using Banff Lesion Scores|Percentage of Participants With Vascular Fibrous Intimal Thickening (cv) Biopsy Score Assessed Using Banff Lesion Scores|Percentage of Participants With Arteriolar Hyalinosis (ah) Biopsy Score Assessed Using Banff Lesion Scores|Percentage of Participants With Peritubular Capillaritis (Ptc) Biopsy Score Assessed Using Banff Lesion Scores|Percentage of Participants With Mesangial Matrix Expansion (mm) Biopsy Score Assessed Using Banff Lesion Scores|Time to First Occurrence of DSA|Time to First Occurrence of HLA-DQ DSA|Time to First Occurrence of C1q-binding DSA|Time to First Occurrence of DSA IgG3 Isotype|Time to First Occurrence of IA|Time to First Occurrence of TG on Biopsy|Time to Occurrence of Death|Time to First Occurrence of Local BPAR|Time to First Occurrence of Acute Forms of ABMR|Time to First Occurrence of Chronic Forms of ABMR|Time to First Occurrence of Acute TCMR|Time to First Occurrence of Chronic TCMR|Time to First Occurrence of Borderline Changes|Time to First Occurrence of IFTA|Percentage of Participants With Treatment-emergent Adverse Event(TEAEs), Related TEAEs, Treatment-emergent Serious Adverse Event (TESAEs), Related TESAEs, TEAEs Leading to Discontinuation of Study Treatment and TEAEs Leading to Death","Astellas Pharma Global Development, Inc.|Astellas Pharma Inc","All","16 Years to 70 Years   (Child, Adult, Older Adult)","Phase 4","599","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IDTX-MA-3004|2018-003867-79","September 9, 2016","June 14, 2019","June 14, 2019","March 30, 2016","June 29, 2020","August 4, 2020","Site US10006, Birmingham, Alabama, United States|Site US10025, Scottsdale, Arizona, United States|Site US10031, Los Angeles, California, United States|Site US10005, Sacramento, California, United States|Site US10016, San Francisco, California, United States|Site US10024, Aurora, Colorado, United States|Site US10003, New Haven, Connecticut, United States|Site US10014, Washington, District of Columbia, United States|Site US10030, Jacksonville, Florida, United States|Site US10020, Chicago, Illinois, United States|Site US10010, Chicago, Illinois, United States|Site US10001, Baltimore, Maryland, United States|Site US10007, Boston, Massachusetts, United States|Site US10013, Ann Arbor, Michigan, United States|Site US10032, Detroit, Michigan, United States|Site US10029, Minneapolis, Minnesota, United States|Site US10027, Rochester, Minnesota, United States|Site US10019, Livingston, New Jersey, United States|Site US10004, Buffalo, New York, United States|Site US10037, New York, New York, United States|Site US10022, New York, New York, United States|Site US10028, New York, New York, United States|Site US10021, Syracuse, New York, United States|Site US10026, Portland, Oregon, United States|Site US10002, Charleston, South Carolina, United States|Site US10036, Houston, Texas, United States|Site US10018, Salt Lake City, Utah, United States|Site US10012, Charlottesville, Virginia, United States|Site US10008, Falls Church, Virginia, United States|Site US10023, Madison, Wisconsin, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/91/NCT02723591/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/91/NCT02723591/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02723591"
757,"NCT01267955","Vismodegib in Treating Patients With Advanced Chondrosarcomas",,"Active, not recruiting","Has Results","Clear Cell Chondrosarcoma|Dedifferentiated Chondrosarcoma|Locally Advanced Chondrosarcoma|Mesenchymal Chondrosarcoma|Metastatic Chondrosarcoma|Primary Central Chondrosarcoma|Unresectable Primary Central Chondrosarcoma","Other: Laboratory Biomarker Analysis|Other: Pharmacogenomic Study|Drug: Vismodegib","Clinical Benefit Rate (CBR) Based on Centralized Imaging Review as Per RECIST 1.1|Progression-free Survival|Overall Survival Per Response Evaluation Criteria in Solid Tumors Criteria 2009|Duration of Response|Mutational Status of Patched 1 and Smoothened|Expression Pattern of Hedgehog Signaling Molecules by Using Quantitative Reverse Transcription-polymerase Chain Reaction and Immunohistochemistry","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","45","NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2011-02564|CDR0000691728|IB-CHONDROG|CHONDROG|8408","December 21, 2010","June 30, 2018",,"December 29, 2010","November 15, 2019","September 16, 2021","Institut Bergonie Cancer Center, Bordeaux, France|Centre Oscar Lambert, Lille, France|Centre Leon Berard, Lyon, France|Hopital De La Timone, Marseille, France|Institut Curie Paris, Paris, France|Gustave Roussy, Villejuif, France","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/55/NCT01267955/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01267955"
758,"NCT01398085","IoN- Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients","IoN","Active, not recruiting","No Results Available","Thyroid Cancer","Radiation: I131 1.1 GBq","Phase II: monthly patient accrual rates|Phase III: Disease-free thyroid specific survival|Phase III: Mortality (cause and date of death)|Phase III: Occurrence of loco-regional recurrence or metastatic disease|Phase III: Stage of cancer at the time of recurrence, and the ability to treat this successfully|Phase III: Health-related quality of life|Phase III: Adverse events for all patients|Phase III: Further neck surgery|Phase III: Further RAI ablations|Phase III: Cost-effectiveness","University College, London|Cancer Research UK","All","16 Years and older   (Child, Adult, Older Adult)","Phase 2|Phase 3","504","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UCL/10/0299|2011-000144-21|Cancer Research UK|ISRCTN","May 2012","March 2023","March 2031","July 20, 2011",,"November 5, 2020","University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom|Brighton and Sussex University Hospitals NHS Trust, Brighton, United Kingdom|University Hospital Bristol NHS Foundation Trust, Bristol, United Kingdom|Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom|East Kent Hospitals University NHS Foundation Trust, Canterbury, United Kingdom|Mid Essex Hospitals Services NHS Trust, Chelmsford, United Kingdom|Gloucestershire Hospitals NHS Trust, Cheltenham, United Kingdom|Royal Derby hospital NHS foundation trust, Derby, United Kingdom|NHS Lothian, Edinburgh, United Kingdom|Royal Devon and Exeter NHS Trust, Exeter, United Kingdom|Glasgow and Clyde NHS Trust, Glasgow, United Kingdom|The Royal Surrey County Hospital NHS Foundation Trust, Guildford, United Kingdom|Ipswich Hospital NHS Trust, Ipswich, United Kingdom|Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom|University Hospitals of Leicester NHS Trust, Leicester, United Kingdom|Royal Marsden NHS Foundation Trust, London, United Kingdom|Imperial College Healthcare NHS Trust, London, United Kingdom|Barts Health NHS Trust, London, United Kingdom|Guys and St Thomas' NHS Foundation Trust, London, United Kingdom|University College London Hospitals NHS Foundation Trust, London, United Kingdom|Maidstone and Tunbridge Wells NHS Trust, Maidstone, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom|South Tees Hospitals NHS Trust, Middlesbrough, United Kingdom|Velindre NHS Trust, Nantgarw, United Kingdom|Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, United Kingdom|Norfolk and Norwich University Hospitals NHS Trust, Norwich, United Kingdom|Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom|Portsmouth Hospitals NHS Trust, Portsmouth, United Kingdom|Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom|Southend University Hospitals NHS Trust, Southend, United Kingdom|East and North Herts, Stevenage, United Kingdom|Royal Wolverhampton NHS Trust, Wolverhampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01398085"
759,"NCT02568267","Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)","STARTRK-2","Recruiting","No Results Available","Breast Cancer|Cholangiocarcinoma|Colorectal Cancer|Head and Neck Neoplasms|Lymphoma, Large-Cell, Anaplastic|Melanoma|Neuroendocrine Tumors|Non-Small Cell Lung Cancer|Ovarian Cancer|Pancreatic Cancer|Papillary Thyroid Cancer|Primary Brain Tumors|Renal Cell Carcinoma|Sarcomas|Salivary Gland Cancers|Adult Solid Tumor","Drug: Entrectinib","Objective Response Rate|Duration of Response|Time to Response|Clinical Benefit Rate|Intracranial Tumor Response|CNS Progression-free Survival|Progression-free Survival|Overall Survival|Population PK|Adverse Events|Quality of Life|Bone Growth and Bone Mineral Density|Bone Biomarkers","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 2","700","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RXDX-101-02|2015-003385-84|GO40782","November 19, 2015","December 1, 2022","December 2, 2024","October 5, 2015",,"January 11, 2022","Western Regional Medical Center at Cancer Treatment Centers of America, Goodyear, Arizona, United States|Dignity Health St Joseph's Hospital and Medical Center, Phoenix, Arizona, United States|Mayo Clinic, Scottsdale, Arizona, United States|City of Hope Cancer Center; Division of Medical Oncology & Experimental Therapeutics, Duarte, California, United States|Scripps Clinic, La Jolla, California, United States|University of California San Diego Moores Cancer Center; Dept of Lung Cancer, La Jolla, California, United States|University of Southern California Medical Center, Los Angeles, California, United States|Univ Of California Irvine College Of Medicine; 300194620, Orange, California, United States|Southern California Kaiser Permanente, San Diego, California, United States|UCSF Mount Zion Medical Ctr, San Francisco, California, United States|Sarcoma Oncology Center, Santa Monica, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|Yale University, New Haven, Connecticut, United States|Georgetown University Medical Center Lombardi Cancer Center, Washington, District of Columbia, United States|Florida Cancer Specialists - Sarasota, Sarasota, Florida, United States|H. Lee Moffitt Cancer Center and Research Inst., Tampa, Florida, United States|Cleveland Clinic Florida, Weston, Florida, United States|University Cancer & Blood Center, LLC; Research, Athens, Georgia, United States|Winship Cancer Institute, Atlanta, Georgia, United States|Southeastern Regional Medical Center, Inc., Newnan, Georgia, United States|University of Hawaii Cancer Center, Honolulu, Hawaii, United States|Northwestern University, Chicago, Illinois, United States|Advocate Medical Group - Park Ridge, Luther Lane - Oncology, Park Ridge, Illinois, United States|Midwestern Regional Medical Center, Zion, Illinois, United States|Weinberg Cancer Institution at Franklin Square, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Karmanos Cancer Center, Detroit, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Regents of the University of Minnesota, Minneapolis, Minnesota, United States|Washington University, Saint Louis, Missouri, United States|Comprehensive Cancer Centers of Nevada (CCCN) - Central Valley, Las Vegas, Nevada, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|North Shore Hem Onc Associates, East Setauket, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Duke Cancer Institute, Durham, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|OSU, James Cancer Hospital, Columbus, Ohio, United States|Cancer Treatment Centers of America; Tulsa, Tulsa, Oklahoma, United States|Providence Portland Medical Center, Portland, Oregon, United States|Oregon Health & Science Univ, Portland, Oregon, United States|Cancer Treatment Centers of America - Eastern Regional Medical Center, Philadelphia, Pennsylvania, United States|Mary Crowley Medical Research Center, Dallas, Texas, United States|University Hospital Medical Oncology Clinic; Harold C. Simmons Comprehensive Cancer Center, Dallas, Texas, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Baylor Scott & White Health, Temple, Texas, United States|University of Utah Hospitals & Clinics, Salt Lake City, Utah, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, United States|Virginia Oncology Associates - Hampton, Hampton, Virginia, United States|University of Washington Seattle Cancer Care Alliance, Seattle, Washington, United States|Wheaton Franciscan Cancer Care-All Saints, Franklin, Wisconsin, United States|Border Medical Oncology Research Unit, Albury, New South Wales, Australia|Liverpool Hospital, Liverpool, New South Wales, Australia|Newcastle Private Hospital, New Lambton Heights, New South Wales, Australia|Flinders Medical Centre, Bedford Park, South Australia, Australia|Austin Hospital, Heidelberg, Victoria, Australia|Antwerp University Hospital, Edegem, Belgium|Beijing Cancer Hospital, Beijing, China|Sichuan Provincial Cancer Hospital, Chengdu, China|Cancer Center of Guangzhou Medical University, Guangzhou, China|Harbin Medical University Cancer Hospital, Harbin, China|Fudan University Shanghai Cancer Center, Shanghai City, China|Shanghai chest hospital, Shanghai, China|Shenzhen People's Hospital, Shenzhen, China|Tianjin Cancer Hospital, Tianjin, China|Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan City, China|Zhejiang Cancer Hospital, Zhejiang, China|Institut de Cancerologie de l Ouest, Angers, France|Institut Bergonie; Oncologie, Bordeaux, France|Centre Oscar Lambret; Chir Cancerologie General, Lille, France|Centre Leon Berard; Departement Oncologie Medicale, Lyon, France|Hôpital de la Timone; Oncologie Médicale Hématologie & Soins Palliatifs, Marseille cedex 5, France|Hôpital Nord - AP-HM Marseille#; Service d'Oncologie Multidisciplinaire, Marseille, France|Institut de Recherche en Cancérologie de Montpellier, Montpellier cedex 5, France|Hôpital Européen Georges Pompidou; Hématologie Oncologie, Paris cedex 15, France|Institut Curie; Oncologie Medicale, Paris, France|Institut De Cancerologie De L'ouest - Rene Gauducheau - Biology, Saint Herblain, France|Institut Claudius Regaud; Departement Oncologie Medicale, Toulouse, France|Institut Gustave Roussy; Pathologie Thoracique, Villejuif cedex, France|Charite Universitaetsmedizin Berlin - Campus Charite Mitte ; Charite Comprehensive Cancer Center, Berlin, Germany|Evang. Lungenklinik Berlin Klinik für Pneumologie, Berlin, Germany|Universitaetsklinikum Carl Gustav Carus TU Dresden, Dresden, Germany|Asklepios-Fachkliniken Muenchen-Gauting; Onkologie, Gauting, Germany|Universitaetsmedizin Goettingen; Abteilung Haematologie und Onkologie, Göttingen, Germany|NCT Uniklinikum Heidelberg; Medizinische Onkologie, Heidelberg, Germany|Universitaetsklinikum Koeln; Innere Medizin I, Haematologie, Köln, Germany|Hong Kong Integrated Oncology Centre, Hong Kong, Hong Kong|Princess Margaret Hospital, Hong Kong, Hong Kong|The University of Hong Kong, Hong Kong, Hong Kong|Queen Elizabeth Hospital, Kowloon, Hong Kong|The Chinese University of Hong Kong, Shatin, Hong Kong|Seconda Università degli Studi di Napoli; Servizio Epato-Gastroenterologia, Napoli, Campania, Italy|Università Campus Bio-Medico di Roma; Oncologia Medica, Roma, Lazio, Italy|Azienda Ospedaliero Universitaria San Martino; Lung Cancer Unit, Genova, Liguria, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Lombardia, Italy|Azienda Socio Sanitaria Territoriale Niguarda (Ospedale Niguarda Ca' Granda); Oncologico -Onc.Falck, Milano, Lombardia, Italy|Fondazione del Piemonte per l'Oncologia - IRCCS;Ematologia, Candiolo, Piemonte, Italy|Azienda Ospedaliero-Universitaria S.Luigi Gonzaga; SSD Oncologia Polmonare, Orbassano, Piemonte, Italy|A.O Città della Salute e della Scienza di Torino; Colorectal Cancer Unit (CRCU) - SSCVD, Torino, Piemonte, Italy|Azienda Ospedaliero - Universitaria Pisana U.O. Oncologia Medica 2 Universitaria - Polo Oncologico, Pisa, Toscana, Italy|Azienda Ospedaliera di Perugia Ospedale S. Maria della Misericordia ; S.C. Oncologia Medica, Perugia, Umbria, Italy|IOV - Istituto Oncologico Veneto - IRCCS; Oncologia Medica II, Padova, Veneto, Italy|Aichi Cancer Center Hospital; Respiratory Medicine, Aichi, Japan|NHO Shikoku Cancer Center; Dept of Respiratory Medicine, Ehime, Japan|NHO Kyushu Cancer Center, Fukuoka, Japan|Hyogo Cancer Center, Dept of Respiratory Medicine, Hyogo, Japan|National Cancer Center Hospital; Dept of Respiratory Medicine, Kashiwa-shi, Japan|Miyagi Cancer Center; Respiratory Medicine, Miyagi, Japan|Niigata Cancer Center Hospital; Internal Medicine, Niigata, Japan|OSAKA CITY GENERAL HOSPITAL;Medical Oncology, Osaka, Japan|Kindai University Hospital; Medical Oncology, Osaka, Japan|Shizuoka Cancer Center; Respiratory Internal Medicine, Shizuoka, Japan|Chungbuk National University Hospital, Cheongju-si, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Asan Medical Center., Seoul, Korea, Republic of|NKI The Netherlands Cancer Institute, Amsterdam, Netherlands|Leids Universitair Medisch Centrum, Leiden, Netherlands|Uniwersyteckie Centrum Kliniczne; Klinika Onkologii i Radioterapii, Gdańsk, Poland|Centrum Onkologii-Instytut im.M.Sklodowskiej Curie; Dept of Nuclear Med. and Endocrine Oncology, Gliwice, Poland|Mazowieckie Centrum Leczenia Chorob Pluc i Gruzlicy; Dept of Pulmonology & subdiv. of oncology, Otwock, Poland|Szpital Kliniczny Przemienienia Panskiego Uni. Medycznego im. Karola Marcinkowskiego; Chemotherapy, Poznań, Poland|Centrum Onkologii Instytut im. M. Sklodowskiej-Curie, Klinika Nowotworow Ukladu Chlonnego, Warszawa, Poland|National University Hospital; Haematology/Oncology, Singapore, Singapore|National Cancer Centre, Singapore, Singapore|Centro Nacional de Investigaciones Oncológicas(CNIO); Gastrointestinal Cancer Clinical Research Unit, Fuenlabrada, Madrid, Spain|Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Barcelona, Spain|Hospital Universitario de La Princesa; Servicio de Oncologia, Madrid, Spain|Hospital Universitario Ramon y Cajal; Servicio de Farmacia, Madrid, Spain|Hospital Universitario Clínico San Carlos; Servicio de Oncologia, Madrid, Spain|Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid, Spain|Hospital Universitario La Paz; Servicio de Oncologia, Madrid, Spain|Centro Integral Oncologico Clara Campal; Servicio de Oncología, Madrid, Spain|Hospital Clinico Universitario Virgen de la Victoria; Servicio de Oncologia, Malaga, Spain|Hospital Universitario Virgen del Rocio; Servicio de Oncologia, Sevilla, Spain|Changhua Christian Hospital, Chang Hua, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|Taipei Veterans General Hospital, Taipei City, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Taichung Veterans General Hospital, Xitun Dist., Taiwan|Cambridge University Hospitals NHS Foundation Trust - Addenbrookes Hospital, Cambridge, United Kingdom|Sarah Cannon Research Institute, London, United Kingdom|Christie Hospital Nhs Trust; Medical Oncology, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02568267"
760,"NCT04282213","Neuromuscular Monitoring:TOFCuff Versus EMG",,"Completed","No Results Available","Neuromuscular Blockade",,"TOFR (Train Of Four Ratio)|Counts|PTC|T1|T2|T3|T4|PID|PIS|PIM|Temperature","Servei Central d' Anestesiologia","All","18 Years to 65 Years   (Adult, Older Adult)",,"32","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","NMT2020","January 15, 2020","May 10, 2020","May 10, 2020","February 24, 2020",,"September 22, 2021","Centro Médico Teknon, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT04282213"
761,"NCT02234076","A Study on the Efficacy of Virtual Reality Exposure Therapy (VRET) for Survivors of Childhood Sexual Abuse and War Related Trauma",,"Unknown status","No Results Available","Posttraumatic Stress Disorder (PTSD)|Depression","Behavioral: VRET|Behavioral: TAU","Posttraumatic Stress Disorder (PTSD) Checklist Diagnostic & Statistical Manual of Mental Disorders (DSM) 5 (PCL-5) to measure change from baseline self-reported symptoms of PTSD at the endpoint of the therapy (after completing 12 sessions) and follow-ups|Beck Depression Inventory-II (BDI-II) to measure change from baseline self-reported symptoms of depression at the endpoint of the therapy (after completing 12 sessions) and follow-ups|The Outcome Questionnaire-45-2 (OQ-45-2) to measure change from baseline self-reported symptoms and well-being at the endpoint of the therapy (after completing 12 sessions) and follow-ups","Erasmus Medical Center|Netherlands Organisation for Scientific Research|Erasmus Universiteit Rotterdam (EUR) (Erasmus University Rotterdam)|Delft University of Technology|University of Amsterdam|PsyQ|Reinier van Arkel Groep, Psychotraumacentrum Zuid-Nederland","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","144","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CI1-12-S028-1","October 2014","October 2016","October 2016","September 9, 2014",,"August 17, 2016","Reinier van Arkel Groep PTC ZN, Den Bosch, Noord-Brabant, Netherlands|PsyQ, Rotterdam/The Hague, Zuid-Holland, Netherlands|Erasmus University Rotterdam, Rotterdam, Zuid-Holland, Netherlands",,"https://ClinicalTrials.gov/show/NCT02234076"
762,"NCT00952731","4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ",,"Completed","Has Results","Ductal Breast Carcinoma in Situ|Estrogen Receptor-positive Breast Cancer","Drug: oral placebo|Drug: afimoxifene|Drug: tamoxifen citrate|Drug: placebo gel","Difference Between Ki-67 Labeling Index in Tissue Samples Taken at Baseline and Post-treatment|Difference in Mean Score for Vasomotor Symptoms Including Hot Flashes From Baseline to Time of Surgery|Difference in vWF Coagulation Protein in Blood Collected at Baseline and Just Prior to Surgery|Difference in Factor VIII Coagulation Protein in Blood Collected at Baseline and Just Prior to Surgery|Difference in Factor IX Coagulation Protein in Blood Collected at Baseline and Just Prior to Surgery|Difference in Protein S Coagulation Protein in Blood Collected at Baseline and Just Prior to Surgery","Northwestern University|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Older Adult)","Phase 2","27","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","NWU07-9-02|NCI-2013-00452|NCI 07-9-02|P30CA060553|N01CN35157","December 2009","September 2011",,"August 6, 2009","July 21, 2015","July 21, 2015","Northwestern University, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT00952731"
763,"NCT01441154","Metabolic Effects of Synthetic Thyroid Hormone for Thyroid Cancer Treatment",,"Completed","No Results Available","Malignant Struma Ovarii|Papillary Thyroid Cancer|Hurthle Cell Thyroid Cancer|Follicular Thyroid Cancer|Tall Cell Variant Thyroid Cancer",,"1. To assess the pharmacokinetics of T3 in patients devoid of endogenous or exogenous T4 during acute L-T3 withdrawal at steady- state and after the first L-T3 dose administration|2. To estimate the minimal duration of L-T3 therapy withdrawal required to achieve a serum TSH level, equal or greater than 30 uIU/mL, to assure effective 131I therapy for treatment of differentiated thyroid cancer|3. To correlate clinical and biochemical parameters of thyroid hormone action, with circulating levels of T3 during L-T3 therapy withdrawal","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC)","All","18 Years to 99 Years   (Adult, Older Adult)",,"16","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","110256|11-DK-0256","September 20, 2011","December 12, 2013","December 12, 2013","September 27, 2011",,"September 28, 2020","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01441154"
764,"NCT02955264","Using D-Galactose as a Food Supplement in Congenital Disorders of Glycosylation",,"Completed","No Results Available","Congenital Disorders of Glycosylation","Dietary Supplement: D-Galactose","Metabolic Function|Biomarkers for protein glycosylation","Tulane University","All","up to 21 Years   (Child, Adult)","Not Applicable","8","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14-517339","July 2014","November 2017","January 2018","November 4, 2016",,"January 8, 2021","Tulane University, New Orleans, Louisiana, United States",,"https://ClinicalTrials.gov/show/NCT02955264"
765,"NCT03209258","The Third, Intensive Care Bundle With Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial","INTERACT3","Recruiting","No Results Available","Cerebral Hemorrhage|Stroke|Hypertension|Diabetes|Anticoagulant-induced Bleeding|Cerebral Vascular Disorder|Brain Disorder|Hemorrhage|Intracranial Hemorrhages|Cardiovascular Diseases|Central Nervous System Diseases","Other: Care bundle of active management|Other: Usual care","Shift ('improvement') in functional recovery (death or disability) defined by the modified Rankin Scale (mRS)|Shift ('improvement') in survival and neurological impairment defined by scores on the National Institutes of Health Stroke Scale (NIHSS)|Death or disability defined by scores of 3-6 on the mRS|Death|Disability defined by scores 3-5 on the mRS|Health-related quality of life (HRQoL)|Duration of initial hospitalization|Residence","The George Institute for Global Health, China|West China Hospital|SICHUAN CREDIT PHARMACEUTICAL CO., LTD.|Takeda|National Institute for Health Research, United Kingdom|Department for International Development, United Kingdom|UK Research and Innovation|Medical Research Council","All","18 Years and older   (Adult, Older Adult)","Not Applicable","8360","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","ICH-WCH&GI","December 12, 2017","May 30, 2022","May 30, 2022","July 6, 2017",,"August 2, 2021","West China Hospital, Chengdu, Sichuan, China",,"https://ClinicalTrials.gov/show/NCT03209258"
766,"NCT01844258","Modified Surgical Techniques for Pediatric Cataract Treatment",,"Completed","No Results Available","Cataract","Procedure: Modified technique|Procedure: Traditional technique","Incidence of opacification of the visual axis|Visual function in eyes treated for cataract","Sun Yat-sen University","All","1 Month to 24 Months   (Child)","Not Applicable","37","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CCPMOH2010-China3","March 2013","December 2013","January 2014","May 1, 2013",,"December 22, 2015","Zhongshan Ophthalmic Center,Sun Yat-sen U, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT01844258"
767,"NCT04541875","Medication Adherence and Non-adherence in Adults With Rare Disease",,"Not yet recruiting","No Results Available","Cystic Fibrosis|Hemophilia A|Hemophilia B|Idiopathic Pulmonary Fibrosis|Myasthenia Gravis|Sickle Cell Disease","Other: MAR-Scale","To use the MAR-Scale to determine the extent of non-adherence to specific medications indicated to treat a range of rare diseases.|To use the MAR-Scale to identify the top patient-reported reasons for non-adherence to specific medications indicated to treat these rare diseases.|To perform psychometric analysis of the MAR-Scale questionnaire based on data collected from rare disease patients.","Xperiome|The Touro College and University System","All","18 Years and older   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RM-RP005","January 2021","September 2022","September 2022","September 9, 2020",,"December 16, 2020",,,"https://ClinicalTrials.gov/show/NCT04541875"
768,"NCT05027646","Study to Assess Bioequivalence and Adhesion Properties Between Two Granisetron Transdermal Patches.",,"Recruiting","No Results Available","Healthy Volunteers","Drug: Sancuso - Part 1|Drug: Sancuso - Part 2","Area under the plasma concentration versus time curve AUC (0-t)|Area under the plasma concentration versus time curve AUC (0-inf)|Peak Plasma Concentration (Cmax)|Maximum concentration (Tmax)|T1/2|CL/F|Vz/F|Mean adhesion score (FDA scale)|Number of subjects with treatment related adverse events will be as assessed as mild, moderate or severe and will be summarized descriptively and presented as frequency and percentage.|Adhesion performance score (FDA Scale)","Kyowa Kirin, Inc.|PPD","All","18 Years to 55 Years   (Adult)","Phase 1","132","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","392MD/48/C","July 27, 2021","April 2022","May 2022","August 30, 2021",,"August 30, 2021","PPD Development, Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT05027646"
769,"NCT05003856","Radiofrequency Ablation for the Treatment of Benign or Low Risk Thyroid Nodule",,"Not yet recruiting","No Results Available","Benign Thyroid Gland Neoplasm|Recurrent Thyroid Gland Carcinoma|Thyroid Gland Follicular Tumor of Uncertain Malignant Potential|Thyroid Gland Nodule|Thyroid Gland Papillary Carcinoma","Other: Quality-of-Life Assessment|Procedure: Radiofrequency Ablation","Changes in thyroid nodule size|Treatment response that affect quality of life|Sonographic features of nodules|Cost of ultrasound-guided radiofrequency ablation (RFA)","M.D. Anderson Cancer Center","All","18 Years and older   (Adult, Older Adult)","Phase 4","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2021-0542|NCI-2021-08354","September 30, 2021","June 30, 2025","June 30, 2025","August 12, 2021",,"August 12, 2021","M D Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT05003856"
770,"NCT03996486","Study to Test the Safety of an Investigational Drug Given Repeatedly to Adult Men With Severe Hemophilia",,"Withdrawn","No Results Available","Hemophilia","Drug: BAY1093884","Frequency of drug-related adverse events|Frequency of drug-related serious adverse events|Frequency of adverse events of special interest","Bayer","Male","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","0","Industry","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Other","20414|2018-004566-34","October 28, 2019","May 29, 2020","July 31, 2020","June 24, 2019",,"October 22, 2019",,,"https://ClinicalTrials.gov/show/NCT03996486"
771,"NCT04709406","Determinants on Rocuronium Dose for Deep Block in Bariatric Surgery",,"Not yet recruiting","No Results Available","Bariatric Surgery","Drug: deep neuromuscular blockade in bariatric surgery","the highest correlation coefficient|onset time of rocuronium|time to deep neuromuscular blockade|Recovery time","Seoul National University Bundang Hospital","All","20 Years to 80 Years   (Adult, Older Adult)",,"90","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","B-2009/639-301","January 2021","October 2021","October 2021","January 14, 2021",,"January 14, 2021",,,"https://ClinicalTrials.gov/show/NCT04709406"
772,"NCT04688268","Dose for Deep Neuromuscular Blockade Deciding Factor of Neuromuscular Blocker Dose for Deep Neuromuscular Blockade",,"Not yet recruiting","No Results Available","Laparoscopic Surgery","Drug: deep neuromuscular blockade","the highest correlation coefficient|onset time of rocuronium|Time to deep neuromuscular blockade|Recovery time","Seoul National University Bundang Hospital","All","20 Years to 80 Years   (Adult, Older Adult)",,"90","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","B-2008/633-302","January 10, 2021","July 30, 2021","July 30, 2021","December 29, 2020",,"December 30, 2020",,,"https://ClinicalTrials.gov/show/NCT04688268"
773,"NCT00451880","Study of XL281 in Adults With Solid Tumors",,"Completed","No Results Available","Cancer|Non-small-cell Lung Cancer|Colorectal Cancer|Papillary Thyroid Cancer|Melanoma","Drug: XL281|Drug: famotidine","Safety, tolerability, and maximum tolerated dose (MTD) of once daily or twice daily oral administration of XL281|To assess the pharmacokinetic/pharmacodynamic/preliminary clinical activity relationship following XL281 administration in different tumor types from subjects treated at the MTD|To determine the bioavailability of XL281 under fed and fasted conditions, and with or without the concomitant use of a single dose of famotidine in subjects with solid tumors|Plasma pharmacokinetics of once daily or twice daily oral administration of XL281","Exelixis","All","18 Years and older   (Adult, Older Adult)","Phase 1","180","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","XL281-001","February 2007","October 2011","October 2011","March 26, 2007",,"October 13, 2011","Premiere Oncology of Arizona, Scottsdale, Arizona, United States|H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Mary Crowley Cancer Research Center, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00451880"
774,"NCT01269138","Treatment of Inherited Factor VII Deficiency","STER","Completed","No Results Available","Factor VII Deficiency","Drug: plasma derived Factor VII|Drug: recombinant FVIIa|Drug: Fresh Frozen Plasma|Drug: Activated Prothrombin Complex Concentrates|Drug: Virus Inactivated plasma","Changes in Factor VII levels|Evaluation of Inhibitor Development","University of L'Aquila|TRIB s.r.l.","All","up to 90 Years   (Child, Adult, Older Adult)",,"223","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","STERProtocol7.0","January 2007",,"November 2012","January 4, 2011",,"November 27, 2012","San Salvatore Hospital, L'Aquila, AQ, Italy",,"https://ClinicalTrials.gov/show/NCT01269138"
775,"NCT04195113","Perioperative Anticoagulant Use for Surgery Evaluation Emergency Registry","PAUSE-ER","Recruiting","No Results Available","Atrial Fibrillation|Venous Thromboembolism|Arterial Vascular Disease",,"Number of patients who had arterial thromboembolism (ATE)|Number of patients who had venous thromboembolism (VTE)|Number of patients who had major bleeding|Number of patients who died|Number of patients who received adjunctive hemostatic therapies|Number of patients who received specific anticoagulant reversal agents|Number of patients who received blood products","McMaster University|Hamilton Health Sciences Corporation|St. Joseph's Healthcare Hamilton","All","18 Years and older   (Adult, Older Adult)",,"400","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","PAUSE-ER-2019","August 7, 2019","August 2022","August 2022","December 11, 2019",,"December 19, 2019","Hamilton General Hospital, Hamilton, Ontario, Canada|Juravinski Hospital, Hamilton, Ontario, Canada|St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04195113"
776,"NCT00001160","Studies on Tumors of the Thyroid",,"Recruiting","No Results Available","Hurthle Cell Thyroid Cancer|Tall Cell Variant Thyroid Cancer|Follicular Thyroid Cancer|Thyroid Cancer|Papillary Thyroid Cancer",,"Evaluation of thyroid cancer|Evaluation of thyroid disorders","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC)","All","6 Months and older   (Child, Adult, Older Adult)",,"2500","NIH","Observational","Observational Model: Case-Only|Time Perspective: Prospective","770096|77-DK-0096","June 1, 1977",,,"November 4, 1999",,"December 16, 2021","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00001160"
777,"NCT00307125","Rituximab in Renal Allograft Recipients Who Develop Early De Novo Anti-HLA Alloantibodies",,"Completed","Has Results","Kidney Transplant|Kidney Transplant Recipient|Graft Function/Survival|de Novo HLA Antibodies Development","Drug: Rituximab plus immunosuppression|Drug: Placebo plus immunosuppression","During Screening Phase: Incidence of Alloantibody Development|During Screening Phase: Timing of Alloantibody Development|Number of Participants With 50 Percent (%) Decrease in Circulating Anti-Human Leukocyte Antigen (HLA) Antibodies|Number of Deaths 12 Months Post Treatment Initiation|Number of Participants Experiencing Graft Loss 12 Months Post Treatment Initiation|Number of Participants Experiencing Biopsy-proven Post-Transplant Lymphoproliferative Disease (PTLD)|Number of Participants Experiencing Loss of Peritubular Capillary (PTC) C4d Staining on Kidney Biopsy|Number of Participants With Viral Replication of Cytomegalovirus (CMV)|Number of Participants With Evidence of Viral Replication of Epstein-Barr Virus (EBV)|Number of Participants With Viral Replication of Polyomavirus (BKV)","National Institute of Allergy and Infectious Diseases (NIAID)|Clinical Trials in Organ Transplantation|Cooperative Clinical Trials in Pediatric Transplantation (CCTPT)","All","5 Years to 70 Years   (Child, Adult, Older Adult)","Phase 2","757","NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DAIT CTOT-02|CCTPT-02","March 2006","December 2012","December 2012","March 27, 2006","March 23, 2015","March 23, 2015","University of Alabama, Pediatric Nephrology, Birmingham, Alabama, United States|University of Alabama, Birmingham, Alabama, United States|University of California, San Francisco, San Francisco, California, United States|University of Florida, Gainesville, Florida, United States|University of Illinois, Chicago, Illinois, United States|Northwestern University, Chicago, Illinois, United States|University of Maryland, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Children's Hospital Boston, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Saint Barnabas Medical Center, Livingston, New Jersey, United States|Legacy Transplant Services, Portland, Oregon, United States|Oregon Health Science University, Portland, Oregon, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|The Methodist Hospital, Houston, Texas, United States|Children's Hospital and Regional Medical Center, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00307125"
778,"NCT02973997","Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)",,"Active, not recruiting","No Results Available","Columnar Cell Variant Thyroid Gland Papillary Carcinoma|Follicular Variant Thyroid Gland Papillary Carcinoma|Metastatic Thyroid Gland Follicular Carcinoma|Metastatic Thyroid Gland Papillary Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Follicular Carcinoma|Recurrent Thyroid Gland Papillary Carcinoma|Stage III Differentiated Thyroid Gland Carcinoma AJCC v7|Stage III Thyroid Gland Follicular Carcinoma AJCC v7|Stage III Thyroid Gland Papillary Carcinoma AJCC v7|Stage IV Thyroid Gland Follicular Carcinoma AJCC v7|Stage IV Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v7|Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v7|Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVC Differentiated Thyroid Gland Carcinoma AJCC v7|Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7|Tall Cell Variant Thyroid Gland Papillary Carcinoma|Thyroid Gland Hurthle Cell Carcinoma|Unresectable Differentiated Thyroid Gland Carcinoma|Unresectable Thyroid Gland Carcinoma","Other: Laboratory Biomarker Analysis|Drug: Lenvatinib|Drug: Lenvatinib Mesylate|Biological: Pembrolizumab","Complete response rate (Cohort 1)|Confirmed response rate (Cohort 2)|Incidence of adverse events|Progression free survival (PFS)|Overall survival (OS)","Academic and Community Cancer Research United|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","60","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACCRU-ITOG-1504|NCI-2016-01752|P30CA015083","February 7, 2018","October 8, 2022","September 30, 2024","November 28, 2016",,"January 6, 2022","Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, United States|University of Colorado Hospital, Aurora, Colorado, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|M D Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02973997"
779,"NCT04927416","The Role of 68-Gallium-DOTATATE-PET/CT in the Imaging of Metastatic Thyroid Cancer",,"Recruiting","No Results Available","Metastic Thyroid Cancer","Drug: 68-Gallium-DOTATATE-PET/CT","Prevalence of patients with metastatic RAI-non-avid or RAI-non-responsive thyroid cancer whose tumors are characterized by a high SSTR2 expression by imaging with 68Ga-DOTATATE PET/CT|Correlation between tumor volume and SUV max for each participant|Maximum standard uptake value (SUVmax) of 68Ga-DOTATATE","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)","Phase 2","54","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","10000079|000079-DK","October 25, 2021","November 30, 2030","November 30, 2030","June 16, 2021",,"January 11, 2022","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04927416"
780,"NCT01208051","Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer",,"Completed","Has Results","Refractory Differentiated Thyroid Gland Carcinoma|Refractory Thyroid Gland Follicular Carcinoma|Refractory Thyroid Gland Hurthle Cell Carcinoma|Refractory Thyroid Gland Papillary Carcinoma|Unresectable Thyroid Gland Carcinoma","Drug: Cediranib|Drug: Cediranib Maleate|Other: Laboratory Biomarker Analysis|Drug: Lenalidomide","Dose Limiting Toxicity|Progression-free Survival (Phase II Futility Analysis)|Progression-free Survival (Final Results After Crossover)|Objective Response Rate|Overall Survival (Final Results After Crossover)|Percent Change in Tumor Size (Phase II)|Serial Measurements of Thyroid Stimulating Hormone and Thyroglobulin|Presence or Absence of B-RAF and RAS Mutations and Outcomes","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","127","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2011-02530|10-182-B|CDR0000685236|10-182|P8317_A23PAMDREVW02|UCCRC-10-182-B|8317|N01CM00032|N01CM00038|N01CM00071|N01CM00099|N01CM00100|N01CM62201|P30CA014599|U10CA180821","September 9, 2010","February 1, 2020","February 1, 2020","September 23, 2010","July 15, 2021","July 15, 2021","City of Hope Comprehensive Cancer Center, Duarte, California, United States|USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States|University of California Davis Comprehensive Cancer Center P2C, Sacramento, California, United States|University of California Davis Comprehensive Cancer Center, Sacramento, California, United States|City of Hope South Pasadena, South Pasadena, California, United States|University of Colorado Hospital, Aurora, Colorado, United States|Moffitt Cancer Center, Tampa, Florida, United States|Northwestern University, Chicago, Illinois, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|UC Comprehensive Cancer Center at Silver Cross, New Lenox, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|Fort Wayne Medical Oncology and Hematology Inc-Parkview, Fort Wayne, Indiana, United States|Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States|Minnesota Oncology Hematology PA-Minneapolis, Minneapolis, Minnesota, United States|Metro Minnesota Community Oncology Research Consortium, Saint Louis Park, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Mercy Hospital Saint Louis, Saint Louis, Missouri, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Penn State Children's Hospital, Hershey, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States|M D Anderson Cancer Center, Houston, Texas, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Tom Baker Cancer Centre, Calgary, Alberta, Canada|London Regional Cancer Program, London, Ontario, Canada|University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/51/NCT01208051/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01208051"
781,"NCT01407939","Efficacy of Bitter Blockers on Taste Perception in Children and Adults","BL","Completed","No Results Available","Healthy",,"Proportion of subjects who rate bitter solutions with added bitter blockers as less bitter than the bitter solution alone.|Biometrics and Genotype|Differences in bitterness ratings obtained via different pediatric taste-assessment methodologies.","Monell Chemical Senses Center|National Institute on Deafness and Other Communication Disorders (NIDCD)","All","3 Years and older   (Child, Adult, Older Adult)",,"215","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","809789|1R01DC011287-01","April 2011","March 2016","March 2016","August 2, 2011",,"March 16, 2016","Monell Chemical Senses Center, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01407939"
782,"NCT04762576","Thrombin in Cardiac Surgery",,"Not yet recruiting","No Results Available","Thrombin|Hemostatic Disorder|Surgical Blood Loss|Coagulation Disorder|Cardiovascular Surgical Procedures",,"Thrombin Generation, as assessed by the Endogenous Thrombin Potential (ETP)|Thrombin Generation, as assessed by the Lag Time|Thrombin Generation, as assessed by the Time to Peak|Thrombin Generation, as assessed by the Peak Height|Total Units of Red Blood Cells Transfused|Total Units of Platelets Transfused|Total Units of Frozen Plasma Transfused|Total amount of Prothrombin Complex Concentrates transfused|Total amount of Fibrinogen Concentrate transfused","University Health Network, Toronto|McMaster University","All","18 Years and older   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20-5726","June 1, 2021","March 1, 2022","March 1, 2022","February 21, 2021",,"May 4, 2021","Toronto General Hospital - University Health Network, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04762576"
783,"NCT04320173","Adhesion Performance Study of Lidocaine Topical System 1.8% Compared to Lidocaine Patch 5% and Lidocaine Medicated Plaster 5% in Healthy, Adult, Human Subjects",,"Completed","No Results Available","Healthy","Drug: Lidocaine patch 1.8%|Drug: Lidocaine patch 5%|Drug: Lidocaine medicated plaster 5%","Mean Adhesion Score (FDA scale)|Mean Adhesion Score (EMA scale)|Dermal Response Score","Scilex Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","47","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCI-LIDO-ADH-002","February 14, 2017","March 22, 2017","March 22, 2017","March 24, 2020",,"March 24, 2020","TKL Research, Inc., Fair Lawn, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT04320173"
784,"NCT03754868","Evaluation of Coagulation Factors and Point-of-care Devices During Veno-venous ECMO Therapy",,"Completed","No Results Available","Extracorporeal Membrane Oxygenation Complication|Coagulation Factor Deficiency","Diagnostic Test: Detailed coagulation monitoring","Changes in the activity of coagulation factor II [%] during Veno-venous ECMO therapy|Changes in the activity of coagulation factor V [%] during Veno-venous ECMO|Changes in the activity of coagulation factor VII [%] during Veno-venous ECMO|Changes in the activity of coagulation factor VIII [%] during Veno-venous ECMO|Changes in the activity of coagulation factor IX [%] during Veno-venous ECMO|Changes in the activity of coagulation factor X [%] during Veno-venous ECMO|Changes in the activity of coagulation factor XII [%] during Veno-venous ECMO|Changes in the activity of coagulation factor XIII [%] during Veno-venous ECMO|vWF-Antigen|Changes in the vWF:Ristocetin-Cofaktor-Activity in % during Veno-venous ECMO therapy|Changes in CT-EXTEM|Changes in CT-INTEM|Changes in CT-FIBTEM|Changes in CT-HEPTEM|Changes in CFT-EXTEM|Changes in CFT-INTEM|Changes in CFT-FIBTEM|Changes in CFT-HEPTEM|Changes in MCF-EXTEM|Changes in MCF-INTEM|Changes in MCF-FIBTEM|Changes in MCF-HEPTEM|Changes in Alpha angle-EXTEM|Changes in Alpha angle-INTEM|Changes in Alpha angle-FIBTEM|Changes in Alpha angle-HEPTEM|Changes in arachidonic acid induced platelet aggregation assessed by multiple elcetrode aggregometry (MEA)(ASPItest)|Changes in adenosine diphosphate (ADP) induced platelet aggregation assessed by multiple elcetrode aggregometry (MEA)(ADPtest)|Changes in thrombin-receptor activating peptide (TRAP) induced platelet aggregation assessed by multiple elcetrode aggregometry (MEA)(TRAPtest)|Light transmission aggregometry|Quick|activated partial thromboplastin time (aPTT)|Fibrinogen|Platelet count|activated clotting time (ACT)|Antithrombin III (ATIII)|Measurement of Anti-Xa-Activity in %|D-Dimers|hemoglobin|leucocyte count|Hemorrhagic complications|Thrombotic complications|Oxygenator State","University Hospital Goettingen","All","18 Years to 90 Years   (Adult, Older Adult)",,"20","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","19/5/13","July 2014","June 2015","June 2015","November 27, 2018",,"November 27, 2018","University Medical Center Goettingen, Goettingen, Germany",,"https://ClinicalTrials.gov/show/NCT03754868"
785,"NCT00098852","Rosiglitazone in Treating Patients With Locoregionally Extensive or Metastatic Thyroid Cancer",,"Unknown status","No Results Available","Head and Neck Cancer","Drug: rosiglitazone maleate","Radioiodine uptake and thyroglobulin level at 6 months and 1 year|Side effects of drug at 2 months","University of California, San Francisco|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","25","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000398114|UCSF-03201|UCSF-H28355-22994-01|GSK-UCSF-H28355-22994-01","October 2004","June 2010",,"December 9, 2004",,"January 6, 2014","UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT00098852"
786,"NCT00859937","Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors",,"Completed","Has Results","Malignant Salivary Gland Neoplasm|Recurrent Salivary Gland Carcinoma|Salivary Gland Adenoid Cystic Carcinoma|Stage IV Major Salivary Gland Cancer AJCC v7","Drug: Dasatinib|Other: Laboratory Biomarker Analysis","Response Rate|Progression-free Survival|Overall Survival|Changes in Laboratory Correlates","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","55","NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2009-01165|CDR0000636685|UCCRC-16691B|16691B|8271|N01CM00032|N01CM00038|N01CM00071|P30CA014599","March 16, 2009","January 30, 2013",,"March 11, 2009","April 3, 2015","April 20, 2018","Tower Cancer Research Foundation, Beverly Hills, California, United States|City of Hope Comprehensive Cancer Center, Duarte, California, United States|USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States|Mercy UC Davis Cancer Center, Merced, California, United States|Moffitt Cancer Center, Tampa, Florida, United States|Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|Joliet Oncology-Hematology Associates Limited, Joliet, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|Central Illinois Hematology Oncology Center, Springfield, Illinois, United States|Fort Wayne Medical Oncology and Hematology Inc-Parkview, Fort Wayne, Indiana, United States|Northern Indiana Cancer Research Consortium, South Bend, Indiana, United States|University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Oncology Care Associates PLLC, Saint Joseph, Michigan, United States|Mercy Hospital Saint Louis, Saint Louis, Missouri, United States|Montefiore Medical Center-Wakefield Campus, Bronx, New York, United States|Montefiore Medical Center - Moses Campus, Bronx, New York, United States|Mount Sinai Hospital, New York, New York, United States|UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States|M D Anderson Cancer Center, Houston, Texas, United States|Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States|Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States|London Regional Cancer Program, London, Ontario, Canada|University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada|CHUM-Hotel Dieu de Montreal, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00859937"
787,"NCT02923908","Recording Facial Expressions to Assess Taste in Children and Teenagers",,"Completed","No Results Available","Facial Expression","Other: Noldus Facereader 7|Other: Voice Recording|Other: 5-Point Facial Hedonic Scale|Other: Follow-Up Questionnaire","Evidence that recording of facial expressions can reliably distinguish between liquids that taste bitter, sweet, or have no taste","Arkansas Children's Hospital Research Institute","All","7 Years to 16 Years   (Child)",,"12","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","GK003|20162192","December 2016","June 1, 2017","June 1, 2017","October 5, 2016",,"April 10, 2018","Arkansas Children's Hospital, Little Rock, Arkansas, United States",,"https://ClinicalTrials.gov/show/NCT02923908"
788,"NCT01811212","Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer",,"Completed","Has Results","Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Carcinoma|Stage I Thyroid Gland Follicular Carcinoma|Stage I Thyroid Gland Papillary Carcinoma|Stage II Thyroid Gland Follicular Carcinoma|Stage II Thyroid Gland Papillary Carcinoma|Stage III Thyroid Gland Follicular Carcinoma|Stage III Thyroid Gland Papillary Carcinoma|Stage IVA Thyroid Gland Follicular Carcinoma|Stage IVA Thyroid Gland Papillary Carcinoma|Stage IVB Thyroid Gland Follicular Carcinoma|Stage IVB Thyroid Gland Papillary Carcinoma|Stage IVC Thyroid Gland Follicular Carcinoma|Stage IVC Thyroid Gland Papillary Carcinoma|Tall Cell Variant Thyroid Gland Papillary Carcinoma|Thyroid Gland Oncocytic Follicular Carcinoma","Drug: Cabozantinib S-malate|Other: Laboratory Biomarker Analysis","Objective Response Rate, Defined as the Proportion of Patients Who Have Had a PR or CR as Assessed by the RECIST Version (v)1.1|Bone Turnover, as Measured by Serum and Urinary Markers of Bone Turnover|Duration of Objective Response as Assessed by the RECIST v1.1|Expression Levels of Predictive Biomarkers of Response by Immunohistochemistry in Archived Tumor Tissue|Genotype of Biomarkers Potentially Predictive of Response|Incidence of Severe (Grade 3+) Adverse Events, Graded According to the National Cancer Institute CTCAE v4.0|Overall Survival|Percent Change in Serum Tumor Marker Thyroglobulin Levels|Progression-free Survival|Response of Cabozantinib-s-malate in Bone Metastasis (Bone Metastasis-specific Progression Free Survival) as Evaluated by Functional Imaging","National Cancer Institute (NCI)|Exelixis","All","18 Years and older   (Adult, Older Adult)","Phase 2","25","NIH|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2013-00554|2012C0101|RU241210I|OSU 12154|9312|N01CM00039|N01CM00070|N01CM00071|N01CM00099|P30CA016058|UM1CA186705","May 8, 2013","July 13, 2015","October 9, 2017","March 14, 2013","April 3, 2018","April 3, 2018","MedStar Georgetown University Hospital, Washington, District of Columbia, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|M D Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01811212"
789,"NCT03914300","Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer",,"Suspended","No Results Available","Differentiated Thyroid Gland Carcinoma|Follicular Variant Thyroid Gland Papillary Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Refractory Differentiated Thyroid Gland Carcinoma|Refractory Thyroid Gland Carcinoma|Tall Cell Variant Thyroid Gland Papillary Carcinoma|Thyroid Gland Follicular Carcinoma|Thyroid Gland Hurthle Cell Carcinoma|Thyroid Gland Papillary Carcinoma","Drug: Cabozantinib S-malate|Biological: Ipilimumab|Biological: Nivolumab","Objective response rate|Incidence of adverse events (AEs)|Duration of response|Progression-free survival|Overall survival","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","24","NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2019-02220|10240|UM1CA186712","July 15, 2019","January 15, 2023","January 15, 2023","April 16, 2019",,"January 19, 2022","City of Hope Comprehensive Cancer Center, Duarte, California, United States|Los Angeles County-USC Medical Center, Los Angeles, California, United States|USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States|USC Norris Oncology/Hematology-Newport Beach, Newport Beach, California, United States|Moffitt Cancer Center-International Plaza, Tampa, Florida, United States|Moffitt Cancer Center - McKinley Campus, Tampa, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|University of Kansas Clinical Research Center, Fairway, Kansas, United States|HaysMed University of Kansas Health System, Hays, Kansas, United States|University of Kansas Cancer Center, Kansas City, Kansas, United States|Olathe Health Cancer Center, Olathe, Kansas, United States|University of Kansas Cancer Center-Overland Park, Overland Park, Kansas, United States|Ascension Via Christi - Pittsburg, Pittsburg, Kansas, United States|Salina Regional Health Center, Salina, Kansas, United States|University of Kansas Health System Saint Francis Campus, Topeka, Kansas, United States|University of Kansas Hospital-Westwood Cancer Center, Westwood, Kansas, United States|University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States|Truman Medical Centers, Kansas City, Missouri, United States|University of Kansas Cancer Center - North, Kansas City, Missouri, United States|University of Kansas Cancer Center - Lee's Summit, Lee's Summit, Missouri, United States|University of Kansas Cancer Center at North Kansas City Hospital, North Kansas City, Missouri, United States|Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States|Memorial Sloan Kettering Commack, Commack, New York, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Nassau, Uniondale, New York, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States|University of Utah Sugarhouse Health Center, Salt Lake City, Utah, United States|Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT03914300"
790,"NCT04970134","Spanish Study for Molecular Characterization of Thyroid Carcinoma","MOLTHY","Recruiting","No Results Available","Differentiated Thyroid Carcinoma|Medullary Thyroid Carcinoma","Other: Immunohistochemistry (IHC)|Other: Fluorescence In-Situ Hybridization (FISH)|Other: Oncomine Focus Assay Platform with 52 genes","Progression free survival (PFS)|Overall survival (OS)|Objective response rate|Prevalence of genetic alterations","Grupo Español de Tratamiento de Tumores de Cabeza y Cuello","All","18 Years and older   (Adult, Older Adult)",,"150","Other","Observational","Observational Model: Other|Time Perspective: Retrospective","TTCC-2020-02","June 14, 2021","March 2023","March 2024","July 21, 2021",,"July 28, 2021","Hospital Universitario Durán i Reinals, L'Hospitalet De Llobregat, Barcelona, Spain|Fundació Althaia, Manresa, Barcelona, Spain|Consorci Corporació Sanitària Parc Taulí de Sabadell, Sabadell, Barcelona, Spain|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Hospital Clínic de Barcelona, Barcelona, Spain|Institut Català d'Oncologia Girona - ICO Girona, Girona, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital universitario Marqués de Valdecilla, Santander, Spain|Hospital General Universitario de Valencia, Valencia, Spain|Hospital Universitario y Politécnico La Fe, Valencia, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain",,"https://ClinicalTrials.gov/show/NCT04970134"
791,"NCT00933231","Comparison of Standard Versus Low Dose Advagraf® With or Without Angiotensin-converting Enzyme Inhibitor (ACEi)/Angiotensin Receptor Blocker (ARB) on Histology and Function of Renal Allografts",,"Completed","No Results Available","Kidney Transplantation","Drug: tacrolimus|Biological: Simulect|Drug: Cellcept|Drug: Corticosteroids|Drug: Ramipril|Drug: Irbesartan","Percentage of Participants with the Presence of Allograft Interstitial Fibrosis and Tubular Atrophy (IF/TA) as Assessed at a Central Pathology Lab|Progression of IF/TA from Month 6 to Month 24|Time to T-cell Banff Mediated Rejection as Assessed at a Central Pathology Lab|Percentage of Participants in Each Category of Banff 2007 Diagnostic Classification of Renal Allograft Pathology|Percentage of Participants with Humoral Rejections|Percentage of Participants with Acute Rejections|Time to First Any Acute Rejection|Banff 2007 Individual Sub-scores|Change from Baseline in Chronic Allograft Damage Index|Percentage of Participants with Circulating Anti-Donor Antibody|Number of Participants with Cellular Immune Response (ELISPOT)|Urine Renal Biomarkers|Graft Survival|Patient Survival|Renal Function as Measured by Glomerular Filtration Rate (GFR)|Renal Function as Measured by Serum Creatinine|Renal Function as Measured by Ratio of Urine Protein and Creatinine Concentrations|12-Item Short Form (SF-12) Health Survey: Physical Composite Score (PCS) and Mental Health Composite Score (MCS)|Kidney Transplant Recipient Opinions of Immunosuppressive Medications Questionnaire|Percentage of Participants with Polyomavirus Infection","Astellas Pharma Inc|Astellas Pharma Canada, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","281","Industry","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FKC-014","August 17, 2009","May 11, 2015","April 3, 2018","July 7, 2009",,"April 5, 2019","Site CA133 Foothills Medical Centre, Calgary, Alberta, Canada|Site CA54 University of Alberta Hospital, Edmonton, Alberta, Canada|Site CA141 Health Sciences Centre, Winnipeg, Manitoba, Canada|Site CA114 Capital District Health Authority- QEII Health Sciences Centre, Halifax, Nova Scotia, Canada|Site CA150 St. Joseph's Healthcare, Hamilton, Ontario, Canada|Site CA27 London Health Sciences Centre, London, Ontario, Canada|Site CA165 St. Michael's Hospital, Toronto, Ontario, Canada|Site CA238 Hôpital Maisonneuve-Rosemont, Montreal, Quebec, Canada|Site CA172 Hôpital Notre-Dame du CHUM, Montreal, Quebec, Canada|Site CA144 McGill University Health Centre, Montreal, Quebec, Canada|Site CA116 Centre Hospitalier Universitaire de Sherbrooke- Hôpital Fleuirmont, Sherbrooke, Quebec, Canada|Site CA142 St. Paul's Hospital, Saskatoon, Saskatchewan, Canada|Site CA64 Centre Hospitalier Universitaire de Québec- L'Hôtel-dieu de Québec, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00933231"
792,"NCT02113709","Determining the Efficacy of Full-time Occlusion Therapy in Severe Amblyopia at Different Ages",,"Unknown status","No Results Available","Amblyopia|Strabismus","Device: Occlusion therapy by Eye Patch|Device: Occlusion therapy","Visual Acuity improvement|improvement in stereopsis","Mughal Eye Trust Hospital","All","3 Years and older   (Child, Adult, Older Adult)","Not Applicable","115","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SIrfanMEHT","January 2010","October 2012","June 2014","April 15, 2014",,"April 15, 2014","Mughal Eye Trust Hospital, Lahore, Punjab, Pakistan",,"https://ClinicalTrials.gov/show/NCT02113709"
793,"NCT02192203","A Safety Study to Investigate the Skin Sensitization Potential of MFC51123",,"Completed","No Results Available","Pain","Drug: Diclofenac + Menthol Gel|Drug: Diclofenac Only Gel|Drug: Menthol Only Gel|Drug: Placebo Only Gel","Skin irritation|Effects on Superficial Layers of the Skin|Response notation","GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)","Phase 1","227","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","202186|RH02169","April 1, 2014","July 15, 2014","July 15, 2014","July 16, 2014",,"June 28, 2017","TKL Research Inc, Paramus, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02192203"
794,"NCT01413113","Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery",,"Completed","No Results Available","Recurrent Thyroid Cancer|Stage IVA Follicular Thyroid Cancer|Stage IVA Papillary Thyroid Cancer|Stage IVB Follicular Thyroid Cancer|Stage IVB Papillary Thyroid Cancer|Stage IVC Follicular Thyroid Cancer|Stage IVC Papillary Thyroid Cancer","Drug: pazopanib hydrochloride|Radiation: iodine I 131","Toxicity and the occurrence of dose limiting toxicity (DLT) when pazopanib is given in conjunction with radioiodine to establish the MTD and RP2D in combination|Tumor response|TTP","University of Washington|GlaxoSmithKline|National Cancer Institute (NCI)|National Comprehensive Cancer Network","All","18 Years and older   (Adult, Older Adult)","Phase 1","6","Other|Industry|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","7529|NCI-2011-01139|P30CA015704","December 2011","November 2013","October 2015","August 10, 2011",,"November 5, 2015","Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01413113"
795,"NCT00068497","Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer",,"Completed","No Results Available","Anaplastic Thyroid Cancer|Insular Thyroid Cancer|Metastatic Parathyroid Cancer|Recurrent Adenoid Cystic Carcinoma of the Oral Cavity|Recurrent Basal Cell Carcinoma of the Lip|Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Recurrent Lymphoepithelioma of the Nasopharynx|Recurrent Lymphoepithelioma of the Oropharynx|Recurrent Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Recurrent Mucoepidermoid Carcinoma of the Oral Cavity|Recurrent Non-small Cell Lung Cancer|Recurrent Parathyroid Cancer|Recurrent Salivary Gland Cancer|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Recurrent Thyroid Cancer|Recurrent Verrucous Carcinoma of the Larynx|Stage III Follicular Thyroid Cancer|Stage III Papillary Thyroid Cancer|Stage III Salivary Gland Cancer|Stage III Squamous Cell Carcinoma of the Hypopharynx|Stage III Squamous Cell Carcinoma of the Larynx|Stage III Verrucous Carcinoma of the Larynx|Stage IIIB Non-small Cell Lung Cancer|Stage IV Lymphoepithelioma of the Nasopharynx|Stage IV Non-small Cell Lung Cancer|Stage IV Squamous Cell Carcinoma of the Hypopharynx|Stage IV Squamous Cell Carcinoma of the Nasopharynx|Stage IVA Adenoid Cystic Carcinoma of the Oral Cavity|Stage IVA Basal Cell Carcinoma of the Lip|Stage IVA Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage IVA Follicular Thyroid Cancer|Stage IVA Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage IVA Lymphoepithelioma of the Oropharynx|Stage IVA Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage IVA Mucoepidermoid Carcinoma of the Oral Cavity|Stage IVA Papillary Thyroid Cancer|Stage IVA Salivary Gland Cancer|Stage IVA Squamous Cell Carcinoma of the Larynx|Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVA Squamous Cell Carcinoma of the Oropharynx|Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVA Verrucous Carcinoma of the Larynx|Stage IVA Verrucous Carcinoma of the Oral Cavity|Stage IVB Adenoid Cystic Carcinoma of the Oral Cavity|Stage IVB Basal Cell Carcinoma of the Lip|Stage IVB Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage IVB Follicular Thyroid Cancer|Stage IVB Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage IVB Lymphoepithelioma of the Oropharynx|Stage IVB Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage IVB Mucoepidermoid Carcinoma of the Oral Cavity|Stage IVB Papillary Thyroid Cancer|Stage IVB Salivary Gland Cancer|Stage IVB Squamous Cell Carcinoma of the Larynx|Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVB Squamous Cell Carcinoma of the Oropharynx|Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVB Verrucous Carcinoma of the Larynx|Stage IVB Verrucous Carcinoma of the Oral Cavity|Stage IVC Adenoid Cystic Carcinoma of the Oral Cavity|Stage IVC Basal Cell Carcinoma of the Lip|Stage IVC Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage IVC Follicular Thyroid Cancer|Stage IVC Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage IVC Lymphoepithelioma of the Oropharynx|Stage IVC Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage IVC Mucoepidermoid Carcinoma of the Oral Cavity|Stage IVC Papillary Thyroid Cancer|Stage IVC Salivary Gland Cancer|Stage IVC Squamous Cell Carcinoma of the Larynx|Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVC Squamous Cell Carcinoma of the Oropharynx|Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVC Verrucous Carcinoma of the Larynx|Stage IVC Verrucous Carcinoma of the Oral Cavity|Thryoid Gland Nonmedullary Carcinoma|Thyroid Gland Medullary Carcinoma|Tongue Cancer|Untreated Metastatic Squamous Neck Cancer With Occult Primary","Drug: gefitinib","Feasibility of enrolling patients aged 75 or older and 50 or younger to the study setting|Peak ZD1839 concentration level|Elimination half-life|Toxicity rates between the two age groups by CTCAE version 3.0|Responses observed|Survival for each tumor type","National Cancer Institute (NCI)","All","Child, Adult, Older Adult","Not Applicable","40","NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2012-03171|S0322|U10CA032102|CDR0000322890","August 2003","December 2007",,"September 11, 2003",,"January 14, 2013","Southwest Oncology Group, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00068497"
796,"NCT00519896","Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer",,"Completed","Has Results","Recurrent Thyroid Cancer|Stage IVA Follicular Thyroid Cancer|Stage IVA Papillary Thyroid Cancer|Stage IVB Follicular Thyroid Cancer|Stage IVB Papillary Thyroid Cancer|Stage IVC Follicular Thyroid Cancer|Stage IVC Papillary Thyroid Cancer|Thyroid Gland Medullary Carcinoma","Drug: sunitinib malate","Overall Response Rate|Safety and Toxicity of Sunitinib Malate Given as a Continuous Treatment Rated for Toxicity Using the NCI Common Toxicity Criteria (CTC) Version 3.0|Time-to-tumor Progression Measured From the Date of Enrollment to the First Date of Progression of Disease","University of Washington|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","35","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","6494|NCI-2011-01305","July 2007","May 2015","September 2015","August 23, 2007","April 25, 2017","April 25, 2017","Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00519896"
797,"NCT02249585","Effects of Neuromuscular Blockade Level and Intra-abdominal Pressure on Surgical Conditions and Cardiopulmonary Responses During Laparoscopic Colon Surgery With the Trendelenburg Position",,"Completed","Has Results","Cardiac Index","Device: Standard abdominal pressure|Device: Low abdominal pressure|Drug: Conventional neuromuscular blockade|Drug: Deep neuromuscular blockade","Cardiac Index|Mean Arterial Blood Pressure (MBP)|Stroke Volume Index (SVI)|PaO2|Pulmonary Compliance|Surgical Rating Scale","Seoul National University Hospital","All","20 Years to 90 Years   (Adult, Older Adult)","Not Applicable","131","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","1405-010-576","September 2014","October 2016","October 2016","September 25, 2014","August 6, 2018","August 6, 2018","Seoul National University Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02249585"
798,"NCT04645199","National Longitudinal Cohort of Hematological Diseases","NICHE","Recruiting","No Results Available","Multiple Myeloma|Myeloma, Multiple|Myelomas, Multiple|Acute Myeloid Leukemia|Leukemias, Acute Myeloid|Myeloid Leukemias, Acute|Hemophilia|Hemophilia A|Hemophilia As|Hemophilia B|Hemophilia Bs|Myelodysplastic Syndrome|MDS|Lymphoma|Leukemia|Aplastic Anemia|Bleeding Disorder|Bone Marrow Transplantation",,"Incidence and distribution|Therapeutic evaluation|Health economic evaluation","Institute of Hematology & Blood Diseases Hospital","All","Child, Adult, Older Adult",,"2300","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IHBDH-IIT2020025","December 1, 2020","December 1, 2025","December 1, 2030","November 27, 2020",,"January 14, 2022","Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China","""Study Protocol: NICHE-AML"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT04645199/Prot_000.pdf|""Study Protocol: NICHE-MM"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT04645199/Prot_001.pdf|""Study Protocol: NICHE-Hemophilia"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT04645199/Prot_002.pdf|""Study Protocol: NICHE-AA"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT04645199/Prot_003.pdf|""Study Protocol and Statistical Analysis Plan: NICHE-Leukemia/MDS/Lymphoma/BD"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT04645199/Prot_SAP_004.pdf|""Study Protocol and Statistical Analysis Plan: NICHE-BMT/Pediatrics"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT04645199/Prot_SAP_005.pdf|""Statistical Analysis Plan: NICHE-AA/Hemophilia/AML/MM_SAP"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT04645199/SAP_006.pdf","https://ClinicalTrials.gov/show/NCT04645199"
799,"NCT01619501","Dysregulation of the C/EBPa Pathway in Human Lung Cancer and Search for New Biomarkers and/or Therapeutic Targets",,"Unknown status","No Results Available","Lung Cancer",,"Define the C/EBPa-Bmi-1 axis in human lung cancer|Validate the relevance of the C/EBPa-SHH pathway in human NSCLC|Identify new downstream targets of C/EBPa in murine lung cancer and test their involvement in human pathogenesis","National University Hospital, Singapore","All","Child, Adult, Older Adult",,,"Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","2012/00117","April 2012","March 2014",,"June 14, 2012",,"December 11, 2013","Nationa University Hospital, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT01619501"
800,"NCT02393690","Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer",,"Active, not recruiting","Has Results","Metastatic Thyroid Gland Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Carcinoma|Stage IV Thyroid Gland Follicular Carcinoma AJCC v7|Stage IV Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7","Radiation: Iodine I-131|Other: Placebo Administration|Drug: Selumetinib","Response at 6 Months|Best Overall Response|Progression Free Survival (PFS)|Changes in Serum Thyroglobulin Levels|Incidence of Adverse Events","Academic and Community Cancer Research United|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","60","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","RU241306I|NCI-2015-00277|14-008494|P30CA015083","May 4, 2015","July 17, 2020","February 20, 2022","March 19, 2015","August 3, 2021","August 3, 2021","UC San Diego Moores Cancer Center, La Jolla, California, United States|Hoag Memorial Hospital, Newport Beach, California, United States|University of Colorado Hospital, Aurora, Colorado, United States|MedStar Georgetown University Hospital, Washington, District of Columbia, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States|M D Anderson Cancer Center, Houston, Texas, United States","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/90/NCT02393690/Prot_SAP_ICF_000.pdf","https://ClinicalTrials.gov/show/NCT02393690"
801,"NCT04215588","Heparin and Protamine Titration in Cardiac Surgery Under Minimal Invasive Extracorporeal Circulation",,"Unknown status","No Results Available","Cardiopulmonary Bypass","Device: Hemostasis Management System Plus|Device: Activated Coagulation Timer System Plus","Total heparin dose|Total protamine dose|Red Blood Cells transfusion|Fibrinogen concentrate transfusion|Prothrombin Complex Concentrate transfusion|Platelets transfusion","Aristotle University Of Thessaloniki","All","18 Years to 79 Years   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Other","7774/16.07.2019","January 1, 2020","January 1, 2021","April 30, 2021","January 2, 2020",,"January 3, 2020",,,"https://ClinicalTrials.gov/show/NCT04215588"
802,"NCT02152995","Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer",,"Active, not recruiting","No Results Available","Metastatic Thyroid Gland Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Carcinoma|Refractory Thyroid Gland Carcinoma|Stage IV Thyroid Gland Follicular Carcinoma AJCC v7|Stage IV Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7","Procedure: Computed Tomography|Other: Iodine I 124|Radiation: Iodine I-131|Other: Laboratory Biomarker Analysis|Other: Pharmacodynamic Study|Procedure: Positron Emission Tomography|Drug: Trametinib","Proportion of patients alive following treatment with trametinib and I-124 (Cohort A)|Progression free survival (Cohort A)|Objective response rate (ORR) (complete response or partial response) (Cohort A)|Iodine incorporation in thyroid cancer metastases to a predicted lesional absorbed radiation dose equal to or exceeding 2,000 cGy with the administration of =< 300 mCi radioiodine (RAI) (Cohort B)|Adequate increase in iodine corporation (Cohort A)|Changes in thyroglobulin|Incidence of toxicity (Cohort A)|ORR (Cohort B)|Proportion of patients alive without disease progression (Cohort B)|Change in thyroglobulin (Cohort B)|Incidence of toxicity (Cohort B)|Proportion of patients alive without disease progression (Cohort C)|Best objective response (Cohort C)|Incidence of toxicity (Cohort C)|Change in thyroglobulin (Cohort C)","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","34","NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2014-01106|13-157|9446|P30CA008748|P50CA172012|R01CA184724","August 14, 2014","August 25, 2021","January 12, 2023","June 2, 2014",,"January 14, 2022","Memorial Sloan Kettering Cancer Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02152995"
803,"NCT03730415","The Effects of Viscoelastometry Guided Resuscitation During Burn Excision on Post Resuscitation Infections",,"Completed","No Results Available","Burns","Procedure: Viscoelastic (VE) Guided Transfusion","Number of blood products transfused|Coagulation factors|Inflammatory Mediators - plasminogen activator inhibitor 1","University of Texas Southwestern Medical Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","032014-072","May 2016","August 12, 2019","August 12, 2019","November 5, 2018",,"April 23, 2021","Parkland Memorial Hospital, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03730415"
804,"NCT04819581","Pharmacokinetic Study of SP-103 in Healthy Adult Human Subjects",,"Completed","No Results Available","Healthy","Drug: SP-103|Drug: ZTlido","Peak plasma concentration (Cmax) of lidocaine|Area under the Plasma-Concentration Time Curve (AUC) from Time 0 to Time 48 hours|Area under the Plasma-Concentration Time Curve (AUC) from Time 0 to Time Infinity|Mean adhesion score|Dermal response score","Scilex Pharmaceuticals, Inc.","All","18 Years to 60 Years   (Adult)","Phase 1","15","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCI-LIDO-PK-005","August 3, 2019","August 27, 2019","August 27, 2019","March 29, 2021",,"March 29, 2021","AXIS Clinicals, Dilworth, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT04819581"
805,"NCT02815605","Risk Factors, Management and Complications of Severe Post-partum Hemorrhage","PPH-REG","Completed","No Results Available","Post-partum Hemorrhage|Blood Transfusion",,"Total amount of bleeding|Blood component usage|Use of procoagulant medication|Number of emergency hysterectomies|Number of Intensive care admissions|Transfusion-related side effects and thromboembolic complications","Tampere University Hospital","Female","18 Years and older   (Adult, Older Adult)",,"9000","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","ETL R16092","June 1, 2016","August 1, 2017","November 4, 2019","June 28, 2016",,"November 5, 2019","Tampere University Hospital, Tampere, Finland",,"https://ClinicalTrials.gov/show/NCT02815605"
806,"NCT04587089","Effectiveness of Antimicrobial Photodynamic Therapy and Guedes-Pinto Paste for Endodontic Treatment of Deciduous Teeth",,"Not yet recruiting","No Results Available","Necrotic Pulp","Procedure: Conventional Endodontic Treatment|Procedure: Irrigation|Radiation: Antimicrobial Photodynamic Therapy (aPDT)|Procedure: Filling with Guedes-Pinto Paste","Clinical Investigation of the Change in the Presence of Fistulas|Clinical Investigation of Changes in Tooth Mobility|Radiographic Evaluation of the Changes in the Presence of Periapical Lesions|Microbiological Analysis - change in colony forming units","University of Nove de Julho|Universidade Metropolitana de Santos","All","3 Years to 6 Years   (Child)","Phase 1|Phase 2","45","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","EndoPDT","January 20, 2021","September 20, 2021","December 20, 2021","October 14, 2020",,"October 14, 2020",,,"https://ClinicalTrials.gov/show/NCT04587089"
807,"NCT01561417","Bioequivalence of NovoSeven® and a NovoSeven® Formulation Stable at Room Temperature in Healthy Male Subjects",,"Completed","No Results Available","Acquired Bleeding Disorder|Acquired Haemophilia|Congenital Bleeding Disorder|Congenital FVII Deficiency|Glanzmann's Disease|Haemophilia A With Inhibitors|Haemophilia B With Inhibitors|Healthy","Drug: activated recombinant human factor VII","Area under the plasma concentration versus time curve for FVIIa clot activity|The maximum plasma concentration (Cmax)|Terminal half-life (t½)","Novo Nordisk A/S","Male","18 Years to 45 Years   (Adult)","Phase 1","28","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","NN1007-1744|2005-005379-14","April 2006","September 2006","September 2006","March 23, 2012",,"January 19, 2017","Novo Nordisk Investigational Site, Paris, France",,"https://ClinicalTrials.gov/show/NCT01561417"
808,"NCT04055051","ATHN 11: Liver Transplantation Outcomes Study","HOT","Recruiting","No Results Available","Hemophilia A and B|Liver Transplantation",,"Quality of life (Haem-A-QoL)|Quality of life (PROMIS-29)|Quality of Life (HOT)|Clotting factor protein","American Thrombosis and Hemostasis Network|BioMarin Pharmaceutical","All","18 Years and older   (Adult, Older Adult)",,"112","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ATHN 11: Liver Transplantation","June 18, 2020","December 31, 2022","June 2023","August 13, 2019",,"January 6, 2022","Orthopaedic Institute for Children Hemophilia Program, Los Angeles, California, United States|University of California, San Francisco, San Francisco, California, United States|Bleeding and Clotting Disorders Institute, Peoria, Illinois, United States|Indiana Hemophilia and Thrombosis Center (IHTC), Indianapolis, Indiana, United States|Maine Hemophilia and Thrombosis Center, Scarborough, Maine, United States|Henry Ford Health System, Detroit, Michigan, United States|Mayo Comprehensive Hemophilia Center, Rochester, Minnesota, United States|Mary M. Gooley Hemophilia Center, Inc., Rochester, New York, United States|Comprehensive Hemophilia Treatment Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Ohio State University Medical Center Hemophilia Treatment Center, Columbus, Ohio, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Gulf States Hemophilia and Thrombophilia Center, Houston, Texas, United States|Utah Center for Bleeding and Clotting Disorders, Salt Lake City, Utah, United States|Hemophilia Outreach Center Green Bay, Green Bay, Wisconsin, United States|Comprehensive Center for Bleeding Disorders, Milwaukee, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT04055051"
809,"NCT04031339","Study of Clinical Outcomes of Thyroid Cancer","ITCO","Recruiting","No Results Available","Thyroid Neoplasms","Procedure: Standard treatment","Disease persistence or recurrence|Disease persistence after 12-18 months from the primary treatment|Disease recurrence after 3, 5 and 10 years from the primary treatment|Response to primary therapy|Response to secondary treatments","University of Roma La Sapienza|Italian Thyroid Cancer Observatory (ITCO) Foundation|Catholic University of the Sacred Heart","All","Child, Adult, Older Adult",,"15000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","3366","January 1, 2013","January 2025","January 2025","July 24, 2019",,"November 5, 2021","Ospedali Riuniti di Ancona, Ancona, Italy|Università degli Studi di Bari, Bari, Italy|Azienda Unità Sanitaria di Bologna - Ospedale Maggiore, Bologna, Italy|University of Bologna, S. Orsola Malpighi Hospital, Bologna, Italy|ASST Valle Olona - Ospedale di Busto Arsizio, Busto Arsizio, Italy|University of Florence, Firenze, Italy|Ente Ospedaliero Ospedali Galliera, Genova, Italy|Sapienza University of Rome, Santa Maria Goretti Hospital, Latina, Italy|Tinchi Pisticci Hospital, Matera, Italy|University of Milan, Fondazione IRCCS, National Cancer Institute of Milan, Milano, Italy|University of Modena and Reggio Emilia, Modena, Italy|University of Naples Federico II, Napoli, Italy|University of Parma, Parma, Italy|Bio-Medical Campus University, Roma, Italy|Sapienza University of Rome, Sant'Andrea Hospital, Roma, Italy|Sapienza University of Rome, Rome, Italy|University of Siena, Siena, Italy|University of Turin, Gradenigo Hospital, Torino, Italy|University of Turin, Molinette Hospital, Torino, Italy",,"https://ClinicalTrials.gov/show/NCT04031339"
810,"NCT02303041","Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma",,"Terminated","Has Results","Carcinoma, Basal Cell|Recurrent Skin Cancer|Skin Neoplasms|Basal Cell Nevus Syndrome","Drug: Buparlisib|Drug: Sonidegib","Overall Response Rate (ORR)|Median Duration of Response|Adverse Event Frequency|Changes in Gene Expression Profiles of BCCs Including Hedgehog Pathway and PI3K Pathways|Gene Expression Profiles (Correlation of Particular Gene Expression Profiles and Response to LB Therapy Will be Assessed.)","Anne Chang|Novartis Pharmaceuticals|Stanford University","All","18 Years and older   (Adult, Older Adult)","Phase 2","10","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB-29839|NCI-2014-02200|SKIN0020","February 2015","April 2017","June 2017","November 27, 2014","January 29, 2019","January 29, 2019","Stanford University School of Medicine, Stanford, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/41/NCT02303041/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02303041"
811,"NCT03140514","Urine CXCL10 Chemokine Monitoring Post-renal Transplant",,"Recruiting","No Results Available","Renal Transplant Rejection","Drug: Rejection treatment according to clinical standard-of-care","Graft loss not due to death of the patient|Biopsy-proven clinical acute rejection|Subclinical T-cell mediated rejection in 1-year surveillance biopsy defined by t>0 and/or v>0|Interstitial fibrosis / tubular atrophy with inflammation (IFTA+i defined by the Mayo Clinic criteria) in 1-year surveillance biopsy|Efficacy assessed by microvascular inflammation at 1-year (ptc, g, c4d, cg)|Efficacy assessed by development of IFTA from implantation to 1-year (∆ ci, ct, cv)|Efficacy assessed by number of days from transplantation to biopsy-proven clinical acute rejection|Efficacy assessed by Proteinuria >500mg/day at 6- and 12-months post-transplant|Safety assessed by total number of biopsies, indication for biopsy and CXCL10-triggered biopsies within the first year post-transplant|Safety assessed by biopsy-related complications within the first year post-transplant|Safety assessed by immunosuppression-related complications as infections and cancer within the first year post-transplant|Graft and its cause|Death and its cause|Allograft function measured by creatinine and eGFR|Proteinuria|Biopsy-proven rejection","University Hospital, Basel, Switzerland","All","18 Years and older   (Adult, Older Adult)","Not Applicable","178","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","Urine chemokine monitoring","September 28, 2017","September 2022","September 2022","May 4, 2017",,"October 6, 2020","University Hospital Basel, Transplantation Immunology & Nephrology, Basel, Switzerland",,"https://ClinicalTrials.gov/show/NCT03140514"
812,"NCT05078853","Thyroglobulin Point of Care Assay for Rapid Detection of Metastatic Differentiated Thyroid Carcinoma",,"Recruiting","No Results Available","Differentiated Thyroid Cancer|Lymph Node Metastases","Device: Point of care assay for thyroglobulin (POC-Tg) evaluation of a suspected cervical lymph node","Accurate diagnosis of cervical lymph node in the FNA clinic being benign or malignant|Accurate diagnosis of suspicious cervical lymph node in the operating room being benign or malignant","Soroka University Medical Center","All","18 Years to 120 Years   (Adult, Older Adult)",,"250","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","SCRC21021CTIL","October 6, 2021","December 31, 2022","December 31, 2022","October 15, 2021",,"December 28, 2021","Soroka University Medical Center, Beer Sheva, Israel",,"https://ClinicalTrials.gov/show/NCT05078853"
813,"NCT01191372","First-in-Human and Proof-of-Mechanism Study of ARC19499 Administered to Hemophilia Patients",,"Terminated","No Results Available","Hemophilia","Drug: placebo control|Drug: ARC19499","Pharmacokinetics (PK) of ARC19499|Coagulation system pharmacodynamic (PD) effects of ARC19499.","Baxalta now part of Shire|Takeda","Male","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","17","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ARC19499-001|2010-020373-17|271101","September 15, 2010","December 28, 2011","December 28, 2011","August 30, 2010",,"May 5, 2021","London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01191372"
814,"NCT02199704","Self Directed Positive Parenting Program (Triple P) for Psychosis: A Clinical Case Series",,"Completed","No Results Available","Schizophrenia|Spectrum|Disorders","Other: Self Directed Positive Parenting Program","The Psychotic Symptom Rating Scales (PSYRATS)|Parenting and Family Adjustment Scale (PAFAS)|Eyberg Child Behaviour Inventory (ECBI)|Parenting Task Checklist (PTC)|Depression Anxiety and Stress Scale (DASS-21)|Work and Social Adjustment Scale (WSAS)|Warwick-Edinburgh Mental Well-being Scale (WEMWBS)","University of Manchester|Lancashire Care NHS Foundation Trust","All","18 Years to 35 Years   (Adult)","Not Applicable","1","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)","14/NW/0126","June 2014","November 2014","November 2014","July 24, 2014",,"August 2, 2016","University of Manchester, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02199704"
815,"NCT00134043","Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer",,"Completed","Has Results","Insular Thyroid Cancer|Recurrent Thyroid Cancer|Stage II Follicular Thyroid Cancer|Stage II Papillary Thyroid Cancer|Stage IV Follicular Thyroid Cancer|Stage IV Papillary Thyroid Cancer|Thyroid Gland Medullary Carcinoma","Drug: vorinostat","Objective Response Rate (PR + CR) Using RECIST/WHO Response Criteria","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","19","NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2012-01468|04110|CDR0000439450|NCI-6902|OSU-04110|N01CM62207","December 2005","March 2009","March 2009","August 24, 2005","August 11, 2014","August 11, 2014","Ohio State University Medical Center, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00134043"
816,"NCT00795782","Prophylactic Central Lymph Node Dissection in Papillary Thyroid Microcarcinoma",,"Completed","No Results Available","Thyroid Cancer","Procedure: Prophylactic central lymph node dissection","Recurrence (Thyroglobulin level, antiTG level, results of follow-up imaging tools)|Postoperative complications(hypocalcemia, hoarseness)","Samsung Medical Center","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","258","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","2008-09-048","January 2009","June 2012","June 2014","November 21, 2008",,"April 15, 2016","Samsung Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT00795782"
817,"NCT00470496","Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer",,"Completed","No Results Available","Recurrent Adenoid Cystic Carcinoma of the Oral Cavity|Recurrent Basal Cell Carcinoma of the Lip|Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Recurrent Lymphoepithelioma of the Nasopharynx|Recurrent Lymphoepithelioma of the Oropharynx|Recurrent Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Recurrent Mucoepidermoid Carcinoma of the Oral Cavity|Recurrent Salivary Gland Cancer|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Recurrent Thyroid Cancer|Recurrent Verrucous Carcinoma of the Larynx|Recurrent Verrucous Carcinoma of the Oral Cavity|Stage I Adenoid Cystic Carcinoma of the Oral Cavity|Stage I Basal Cell Carcinoma of the Lip|Stage I Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage I Follicular Thyroid Cancer|Stage I Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage I Lymphoepithelioma of the Nasopharynx|Stage I Lymphoepithelioma of the Oropharynx|Stage I Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage I Mucoepidermoid Carcinoma of the Oral Cavity|Stage I Papillary Thyroid Cancer|Stage I Salivary Gland Cancer|Stage I Squamous Cell Carcinoma of the Hypopharynx|Stage I Squamous Cell Carcinoma of the Larynx|Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage I Squamous Cell Carcinoma of the Oropharynx|Stage I Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage I Verrucous Carcinoma of the Larynx|Stage I Verrucous Carcinoma of the Oral Cavity|Stage II Adenoid Cystic Carcinoma of the Oral Cavity|Stage II Basal Cell Carcinoma of the Lip|Stage II Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage II Follicular Thyroid Cancer|Stage II Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage II Lymphoepithelioma of the Nasopharynx|Stage II Lymphoepithelioma of the Oropharynx|Stage II Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage II Mucoepidermoid Carcinoma of the Oral Cavity|Stage II Papillary Thyroid Cancer|Stage II Salivary Gland Cancer|Stage II Squamous Cell Carcinoma of the Hypopharynx|Stage II Squamous Cell Carcinoma of the Larynx|Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage II Squamous Cell Carcinoma of the Oropharynx|Stage II Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage II Verrucous Carcinoma of the Larynx|Stage II Verrucous Carcinoma of the Oral Cavity","Drug: HPPH|Drug: photodynamic therapy|Procedure: conventional surgery","Maximum tolerated dose of photodynamic therapy in which 1 of 6 patients experience dose-limiting toxicity|Time to tumor progression or recurrence|Uptake and distribution of HPPH in resected tumor tissue","Roswell Park Cancer Institute|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1","15","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","I 74606|NCI-2010-01941|P30CA016056","October 19, 2006","October 28, 2011","August 30, 2018","May 7, 2007",,"October 5, 2018","Roswell Park Cancer Institute, Buffalo, New York, United States",,"https://ClinicalTrials.gov/show/NCT00470496"
818,"NCT00095693","Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer",,"Terminated","No Results Available","Anaplastic Thyroid Cancer|Insular Thyroid Cancer|Recurrent Thyroid Cancer|Stage III Follicular Thyroid Cancer|Stage III Papillary Thyroid Cancer|Stage IV Follicular Thyroid Cancer|Stage IV Papillary Thyroid Cancer","Drug: sorafenib tosylate|Other: laboratory biomarker analysis|Other: pharmacological study|Radiation: fludeoxyglucose F 18|Procedure: positron emission tomography|Procedure: dynamic contrast-enhanced magnetic resonance imaging","Objective response rate|Incidence of toxicity","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","25","NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2012-01457|OSU-0441|CDR0000393968|NCI-6608|OSU-2004C0068|OSU 0441|6608|N01CM62207|P30CA016058|N01CM62206|U01CA076576","October 2004","August 2005","December 2011","November 8, 2004",,"January 16, 2014","Ohio State University Medical Center, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00095693"
819,"NCT00004074","Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu",,"Completed","No Results Available","Advanced Adult Primary Liver Cancer|Anaplastic Thyroid Cancer|Bone Metastases|Carcinoma of the Appendix|Distal Urethral Cancer|Fallopian Tube Cancer|Gastrinoma|Glucagonoma|Inflammatory Breast Cancer|Insulinoma|Liver Metastases|Localized Unresectable Adult Primary Liver Cancer|Lung Metastases|Male Breast Cancer|Malignant Pericardial Effusion|Malignant Pleural Effusion|Metastatic Gastrointestinal Carcinoid Tumor|Metastatic Parathyroid Cancer|Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter|Newly Diagnosed Carcinoma of Unknown Primary|Occult Non-small Cell Lung Cancer|Pancreatic Polypeptide Tumor|Primary Peritoneal Cavity Cancer|Proximal Urethral Cancer|Pulmonary Carcinoid Tumor|Recurrent Adenoid Cystic Carcinoma of the Oral Cavity|Recurrent Adrenocortical Carcinoma|Recurrent Adult Primary Liver Cancer|Recurrent Anal Cancer|Recurrent Bladder Cancer|Recurrent Breast Cancer|Recurrent Carcinoma of Unknown Primary|Recurrent Cervical Cancer|Recurrent Colon Cancer|Recurrent Endometrial Carcinoma|Recurrent Esophageal Cancer|Recurrent Extrahepatic Bile Duct Cancer|Recurrent Gallbladder Cancer|Recurrent Gastric Cancer|Recurrent Gastrointestinal Carcinoid Tumor|Recurrent Islet Cell Carcinoma|Recurrent Malignant Testicular Germ Cell Tumor|Recurrent Mucoepidermoid Carcinoma of the Oral Cavity|Recurrent Non-small Cell Lung Cancer|Recurrent Ovarian Epithelial Cancer|Recurrent Pancreatic Cancer|Recurrent Parathyroid Cancer|Recurrent Prostate Cancer|Recurrent Rectal Cancer|Recurrent Renal Cell Cancer|Recurrent Salivary Gland Cancer|Recurrent Small Intestine Cancer|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Thyroid Cancer|Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter|Recurrent Urethral Cancer|Recurrent Vaginal Cancer|Recurrent Vulvar Cancer|Skin Metastases|Small Intestine Adenocarcinoma|Somatostatinoma|Stage III Adenoid Cystic Carcinoma of the Oral Cavity|Stage III Adrenocortical Carcinoma|Stage III Bladder Cancer|Stage III Cervical Cancer|Stage III Colon Cancer|Stage III Endometrial Carcinoma|Stage III Esophageal Cancer|Stage III Follicular Thyroid Cancer|Stage III Gastric Cancer|Stage III Malignant Testicular Germ Cell Tumor|Stage III Mucoepidermoid Carcinoma of the Oral Cavity|Stage III Ovarian Epithelial Cancer|Stage III Pancreatic Cancer|Stage III Papillary Thyroid Cancer|Stage III Prostate Cancer|Stage III Rectal Cancer|Stage III Renal Cell Cancer|Stage III Salivary Gland Cancer|Stage III Squamous Cell Carcinoma of the Larynx|Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage III Squamous Cell Carcinoma of the Nasopharynx|Stage III Squamous Cell Carcinoma of the Oropharynx|Stage III Vaginal Cancer|Stage III Vulvar Cancer|Stage IIIA Anal Cancer|Stage IIIA Breast Cancer|Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Anal Cancer|Stage IIIB Breast Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Adenoid Cystic Carcinoma of the Oral Cavity|Stage IV Adrenocortical Carcinoma|Stage IV Anal Cancer|Stage IV Bladder Cancer|Stage IV Breast Cancer|Stage IV Colon Cancer|Stage IV Endometrial Carcinoma|Stage IV Esophageal Cancer|Stage IV Follicular Thyroid Cancer|Stage IV Gastric Cancer|Stage IV Mucoepidermoid Carcinoma of the Oral Cavity|Stage IV Non-small Cell Lung Cancer|Stage IV Ovarian Epithelial Cancer|Stage IV Pancreatic Cancer|Stage IV Papillary Thyroid Cancer|Stage IV Prostate Cancer|Stage IV Rectal Cancer|Stage IV Renal Cell Cancer|Stage IV Salivary Gland Cancer|Stage IV Squamous Cell Carcinoma of the Larynx|Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IV Squamous Cell Carcinoma of the Nasopharynx|Stage IV Squamous Cell Carcinoma of the Oropharynx|Stage IVA Cervical Cancer|Stage IVA Vaginal Cancer|Stage IVB Cervical Cancer|Stage IVB Vaginal Cancer|Stage IVB Vulvar Cancer|Thyroid Gland Medullary Carcinoma|Unresectable Extrahepatic Bile Duct Cancer|Unresectable Gallbladder Cancer|Urethral Cancer Associated With Invasive Bladder Cancer|WDHA Syndrome","Biological: recombinant interleukin-12|Biological: ABI-007/carboplatin/trastuzumab","Maximum tolerated dose (MTD) determined according to dose-limiting toxicities (DLTs) graded using Common Terminology Criteria for Adverse Events version 2.0 (CTCAE v2.0)","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1","15","NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2012-01398|99H0185|U01CA076576|CDR0000067282","August 1999","February 2009",,"October 29, 2003",,"February 28, 2013","Ohio State University Medical Center, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00004074"
820,"NCT00456547","Coagulation Factor Changes Associated With Postpartum Hysterectomies",,"Completed","Has Results","Obstetric Labor Complications|Hemorrhage|Complications; Cesarean Section","Procedure: Blood Draw","Fibrinogen Level at 2 Hours After Delivery|Platelet Counts at 2 Hours After Delivery|Plasminogen Levels 2 Hours After Delivery|Antithrombin III Levels at 2 Hours Post Delivery","Northwestern University","Female","18 Years to 60 Years   (Adult)",,"24","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","0524-020","December 2003","December 2006","December 2006","April 5, 2007","February 20, 2012","April 14, 2014","Northwestern University, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT00456547"
821,"NCT02030730","RCT of Brief Universal Parenting Program to Prevent Child Behavioural and Emotional Difficulties in Greece",,"Completed","No Results Available","Child Behavior Disorders|Parenting","Behavioral: Triple P Seminar Series","Eyberg Child Behaviour Inventory- Intensity scale (ECBI; Eyberg & Pincus, 1999)|Eyberg Child Behaviour Inventory- Problem scale (ECBI; Eyberg & Pincus, 1999)|The Conners Parent Rating Scale (CPRS; Goyette, Conners, & Ulrich, 1978)|Parenting Scale (PS; Arnold, O'Leary, Wolff, & Acker, 1993)|Parenting Tasks Checklist (PTC; Sanders & Wooley, 2005)|General Health Questionnaire (GHQ; Goldberg & Williams, 1988)","University of Oxford","All","Child, Adult, Older Adult","Not Applicable","124","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","UOXSIKF01|F-ZC 092/2 2010-2011","March 2012","March 2013","April 2013","January 8, 2014",,"January 8, 2014","Department of Social Policy and Intervention, University of Oxford, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02030730"
822,"NCT01677741","A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects",,"Completed","Has Results","Neoplasms, Brain","Drug: Dabrafenib","Incidence of Treatment Emergent Adverse Events (AEs) in Part 1 (Dose Escalation)|Maximum Concentration (Cmax) of Dabrafenib|Area Under the Concentration-time Curve Over the Dosing Interval (AUC(0-τ)) and AUC From Zero to Infinity (AUC(0-inf)) of Dabrafenib|Pre-dose (Trough) Concentration (C Tau) of Dabrafenib and Its Metabolites|The AUC(0-t) of Dabrafenib Metabolites|The AUC(0-tau) of Dabrafenib and Its Metabolites|Apparent Total Clearance of the Drug From Plasma After Oral Administration (CL/F) of Dabrafenib|Maximum Concentration (Cmax) of Dabrafenib Metabolites|Time to Reach Maximum (Peak) Plasma Concentration Following Drug Administration (Tmax) of Dabrafenib and Its Metabolites|Elimination Half Life (T½) of Dabrafenib and Its Metabolites|Incidence of Treatment Emergent Adverse Events (AEs) in Part 2 (Tumor Specific Expansion)|Best Overall Response Based on Investigator Assessment Per Response Assessment in Neuro-Oncology (RANO) Criteria for Low Grade Glioma (LLG) Subjects|Best Overall Response Based on Investigator Assessment Per Response Assessment in Neuro-Oncology (RANO) Criteria for High Grade Glioma (HGG) Subjects|Effect of Weight on Total Apparent Clearance (CL/F) of Dabrafenib Estimated With a PopPK Model|Effect of Weight on Volume of Distribution (V/F) of Dabrafenib Estimated With a PopPK Model|Effect of Weight on Absorption Rate (ka) of Dabrafenib Estimated With a PopPK Model|Effect of Weight on Coefficients for Significant Covariates of Dabrafenib Estimated With a PopPK Model","Novartis Pharmaceuticals|Novartis","All","12 Months to 17 Years   (Child)","Phase 1|Phase 2","85","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","116013|2012-001499-12|CDRB436A2102","May 23, 2013","December 4, 2020","December 4, 2020","September 3, 2012","November 24, 2021","November 24, 2021","Novartis Investigative Site, Phoenix, Arizona, United States|Novartis Investigative Site, Orange, California, United States|Novartis Investigative Site, Baltimore, Maryland, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, New York, New York, United States|Novartis Investigative Site, Cincinnati, Ohio, United States|Novartis Investigative Site, Memphis, Tennessee, United States|Novartis Investigative Site, Seattle, Washington, United States|Novartis Investigative Site, Parkville, Victoria, Australia|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Copenhagen, Denmark|Novartis Investigative Site, Marseille Cedex 5, France|Novartis Investigative Site, Paris cedex 05, France|Novartis Investigative Site, Paris cedex 12, France|Novartis Investigative Site, Toulouse cedex 9, France|Novartis Investigative Site, Villejuif Cedex, France|Novartis Investigative Site, Heidelberg, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Regensburg, Bayern, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Jerusalem, Israel|Novartis Investigative Site, Ramat-Gan, Israel|Novartis Investigative Site, Milan, Italy|Novartis Investigative Site, Esplugues De Llobregat. Barcelona, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Sutton, Surrey, United Kingdom|Novartis Investigative Site, London, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/41/NCT01677741/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/41/NCT01677741/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01677741"
823,"NCT02416817","Strategy of Transfusion in Trauma Patients - STATA Trial","STATA","Completed","No Results Available","Wounds and Injuries","Other: Blood Products only|Other: Point of Care guided","SOFA Score - 5 days","University of Sao Paulo General Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","156","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STATA","July 2014","July 2016","July 2016","April 15, 2015",,"November 2, 2016","Hospital das Clínicas FMUSP, Sao Paulo, SP, Brazil",,"https://ClinicalTrials.gov/show/NCT02416817"
824,"NCT03050151","Study of Dupilumab Auto-injector Device When Used by Patients With Atopic Dermatitis",,"Completed","No Results Available","Atopic Disorders|Eczema, Atopic","Drug: Dupilumab|Device: Auto-injector Device|Device: Prefilled syringe","Number of validated AI device-associated product technical failures (PTFs) during the treatment period divided by total number of actual injections|Type of validated AI device-associated PTFs during the treatment period divided by total number of actual injections.|Number of patients with an AI device-associated PTF|Percentage of patients with an AI device-associated PTF|Number of AI device-associated product technical complaints (PTCs) divided by total number of actual injections|Type of AI device-associated PTCs divided by total number of actual injections|Number of patients with an AI device-associated PTC|Percentage of patients with an AI device-associated PTC|Number of AI device-associated failed drug deliveries (defined as patient failure to administer the full dose at a given attempt, excluding PTF) divided by total number of actual injections|Type of AI device-associated failed drug deliveries (defined as patient failure to administer the full dose at a given attempt, excluding PTF) divided by total number of actual injections|Number of patients with an AI device-associated failure to deliver dose|Percentage of patients with an AI device-associated failure to deliver dose|Number of patients with response to patient satisfaction questions with the AI device|Percentage of patients with response to patient satisfaction questions with the AI device","Regeneron Pharmaceuticals|Sanofi","All","12 Years and older   (Child, Adult, Older Adult)","Phase 1","176","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R668-AD-1607","February 28, 2017","November 14, 2017","February 12, 2018","February 10, 2017",,"August 1, 2018","Regeneron Investigational Site, Birmingham, Alabama, United States|Regeneron Investigational Site, Birmingham, Alabama, United States|Regeneron Investigational Site, Fort Smith, Arkansas, United States|Regeneron Investigational Site, Long Beach, California, United States|Regeneron Investigational Site, Los Angeles, California, United States|Regeneron Investigational Site, Murrieta, California, United States|Regeneron Investigational Site, Oceanside, California, United States|Regeneron Investigational Site, Orange, California, United States|Regeneron Investigational Site, Rolling Hills Estates, California, United States|Regeneron Investigational Site, Santa Monica, California, United States|Regeneron Investigational Site, Denver, Colorado, United States|Regeneron Investigational Site, Coral Gables, Florida, United States|Regeneron Investigational Site, Tampa, Florida, United States|Regeneron Investigational Site, Normal, Illinois, United States|Regeneron Investigational Site, Skokie, Illinois, United States|Regeneron Investigational Site, Indianapolis, Indiana, United States|Regeneron Investigational Site, Rockville, Maryland, United States|Regeneron Investigational Site, Plymouth, Minnesota, United States|Regeneron Investigational Site, Saint Joseph, Missouri, United States|Regeneron Investigational Site, Berlin, New Jersey, United States|Regeneron Investigational Site, Windsor, New Jersey, United States|Regeneron Investigational Site, Corning, New York, United States|Regeneron Investigational Site, Forest Hills, New York, United States|Regeneron Investigational Site, New York, New York, United States|Regeneron Investigational Site, High Point, North Carolina, United States|Regeneron Investigational Site, Raleigh, North Carolina, United States|Regeneron Investigational Site, Tulsa, Oklahoma, United States|Regeneron Investigational Site, Portland, Oregon, United States|Regeneron Investigational Site, Charleston, South Carolina, United States|Regeneron Investigational Site, Greer, South Carolina, United States|Regeneron Investigational Site, Bellaire, Texas, United States|Regeneron Investigational Site, Fort Worth, Texas, United States|Regeneron Investigational Site, San Antonio, Texas, United States|Regeneron Investigational Site, San Antonio, Texas, United States|Regeneron Investigational Site, Webster, Texas, United States|Regeneron Investigational Site, Norfolk, Virginia, United States|Regeneron Investigational Site, Tacoma, Washington, United States",,"https://ClinicalTrials.gov/show/NCT03050151"
825,"NCT00026533","Thalidomide in Treating Patients With Thyroid Cancer",,"Completed","No Results Available","Head and Neck Cancer","Drug: thalidomide",,"Kenneth Ain|National Cancer Institute (NCI)|University of Kentucky","All","18 Years to 120 Years   (Adult, Older Adult)","Phase 2",,"Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000069053|UKMC-IRB-010069","June 2001","November 2003","December 2005","January 27, 2003",,"June 6, 2017","Albert B. Chandler Medical Center, University of Kentucky, Lexington, Kentucky, United States",,"https://ClinicalTrials.gov/show/NCT00026533"
826,"NCT04268563","Comparing the Effect of Sitagliptin/Metformin and Metformin in PCOS Patients",,"Recruiting","No Results Available","Polycystic Ovary Syndrome|Infertility|ART","Drug: placebo|Drug: metformin|Drug: Sitagliptin|Drug: Sitagliptin/metformin","Fasting insulin|Growth differentiation factor-9(GDF-9) expression|Bone morphogenetic protein-15(BMP-15) expression|Total Testosterone|Follicle-stimulating hormone(FSH)","Shahid Beheshti University of Medical Sciences","Female","25 Years to 35 Years   (Adult)","Phase 1|Phase 2","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","11367","January 10, 2020","July 19, 2021","July 30, 2021","February 13, 2020",,"March 22, 2021","Mahdiyeh educational hospital, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT04268563"
827,"NCT00061906","Celecoxib in Treating Patients With Progressive Metastatic Differentiated Thyroid Cancer",,"Completed","No Results Available","Head and Neck Cancer","Drug: celecoxib","Examine efficacy of celecoxib in patients with progressive metastatic differentiated thyroid carcinoma by assessing progression free survival.|Quantifying gene expression and protein levels of angiogenic markers[vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), and tumor necrosis factor (TNF)-α] in peripheral blood mononuclear cells (PBMCs) from pre-,during-|Quantifying gene expression and protein levels of cytokines [interleukin (IL)-10, IL-12, IL-6 and interferon (IFN)-γ] in peripheral blood mononuclear cells from pre-,during-, and post-treatment blood samples.|Evaluate cyclooxygenase (COX)-2 protein expression by immunohistochemistry in tumor biopsies to correlate with clinical response.","Ohio State University Comprehensive Cancer Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","25","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OSU-0239","January 2003","June 2006","June 2006","June 6, 2003",,"February 11, 2014","Ohio State University Comrehensive Cancer Center, Columbus, Ohio, United States|University of Texas - MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00061906"
828,"NCT00415233","High Dose vs Low Dose I 131 +/- rhTSH for Differentiated Thyroid Cancer","HiLo","Active, not recruiting","No Results Available","Head and Neck Cancer","Biological: recombinant thyroid-stimulating hormone|Radiation: Radiodine ablation without rhTSH","Proportion of patients with successful remnant ablation at 6-9 months|Quality of life as measured by the SF-36 questionnaire at baseline, the day of ablation, and at 3 months|Locoregional recurrence|Distant metastases|Survival|Incidence of second primary malignancy","University College, London","All","16 Years to 80 Years   (Child, Adult, Older Adult)","Phase 3","438","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","UCL/05/83|CRUK-HILO-BRD/05/83|ISRCTN56078540|EU-20665|CTA-20363/0217/001/0001|2005-003687-37","November 2006","June 2011","July 2025","December 22, 2006",,"October 14, 2021","Sussex Cancer Centre at Royal Sussex County Hospital, Brighton, England, United Kingdom|Addenbrooke's Hospital, Cambridge, England, United Kingdom|Kent and Canterbury Hospital, Canterbury, England, United Kingdom|Castle Hill Hospital, Cottingham, England, United Kingdom|Derbyshire Royal Infirmary, Derby, England, United Kingdom|Royal Devon and Exeter Hospital, Exeter, England, United Kingdom|Gloucestershire Royal Hospital, Gloucester, England, United Kingdom|St. Luke's Cancer Centre at Royal Surrey County Hospital, Guildford, England, United Kingdom|Ipswich Hospital, Ipswich, England, United Kingdom|Leeds Cancer Centre at St. James's University Hospital, Leeds, England, United Kingdom|Leicester Royal Infirmary, Leicester, England, United Kingdom|Guy's Hospital, London, England, United Kingdom|Royal Marsden - London, London, England, United Kingdom|Maidstone Hospital, Maidstone, England, United Kingdom|Christie Hospital, Manchester, England, United Kingdom|James Cook University Hospital, Middlesbrough, England, United Kingdom|Newcastle Upon Tyne Hospitals NHS Trust, Newcastle-Upon-Tyne, England, United Kingdom|Northampton General Hospital, Northampton, England, United Kingdom|Mount Vernon Cancer Centre at Mount Vernon Hospital, Northwood, England, United Kingdom|Norfolk and Norwich University Hospital, Norwich, England, United Kingdom|Dorset Cancer Centre, Poole Dorset, England, United Kingdom|Cancer Research Centre at Weston Park Hospital, Sheffield, England, United Kingdom|University Hospital of North Staffordshire, Stoke-On-Trent, England, United Kingdom|Velindre Cancer Center at Velindre Hospital, Cardiff, Wales, United Kingdom|Glan Clwyd Hospital, Rhyl, Denbighshire, Wales, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00415233"
829,"NCT04133220","Endothelial Activation Hemostasis Disturbances and Severe Bleeding Events in Hyperleukocytic Acute Myeloid Leukemia","HEAL","Not yet recruiting","No Results Available","Leukemia, Myeloid, Acute",,"Hemostasis / platelet and endothelial dysfunction assessed by plasma concentration of ICAM-|Hemostasis / platelet and endothelial dysfunction parameter assessed by plasma concentration of Syndecan-1|Hemostasis / platelet and endothelial dysfunction parameter assessed by plasma concentration of vWF Ag|Hemostasis / platelet and endothelial dysfunction assessed by vWF activity|Hemostasis / platelet and endothelial dysfunction assessed by plasma concentration of Fg|Hemostasis / platelet and endothelial dysfunction assessed by plasma concentration of t-PA|Hemostasis / platelet and endothelial dysfunction assessed by plasma concentration of u-PA|Hemostasis / platelet and endothelial dysfunction assessed by plasma concentration of e-Selectin|Hemostasis / platelet and endothelial dysfunction assessed by plasma concentration of sCD40L|Hemostasis / platelet and endothelial dysfunction parameter assessed by plasma concentration of IL6|Hemostasis / platelet and endothelial dysfunction assessed by plasma concentration of AT|Hemostasis / platelet and endothelial dysfunction assessed by plasma concentration of Fragments thrombin 1+2|Hemostasis / platelet and endothelial dysfunction assessed by plasma concentration of TAT complex|Hemostasis / platelet and endothelial dysfunction assessed by plasma concentration of plasmin-antiplasmin complex|Hemostasis / platelet and endothelial dysfunction assessed by plasma concentration of PAI-1 Ag|Hemostasis / platelet and endothelial dysfunction assessed by plasma concentration of PAI-1 activity|Hemostasis / platelet and endothelial dysfunction assessed by plasma concentration of t-PA-PAI-1 complex|Hemostasis / platelet and endothelial dysfunction assessed by plasma concentration of ADAMTS13 Ag|Hemostasis / platelet and endothelial dysfunction assessed by ADAMTS13 activity|Hemostasis / platelet and endothelial dysfunction assessed by plasma concentration of vWF:CB|Hemostasis / platelet and endothelial dysfunction assessed by plasma concentration of Fibrin monomers|Hemostasis / platelet and endothelial dysfunction assessed by Prothrombine Time|Hemostasis / platelet and endothelial dysfunction assessed by Activated Partial Thromboplastin Time [APTT]|Hemostasis / platelet and endothelial dysfunction assessed by plasma concentration of Factor IX|Hemostasis / platelet and endothelial dysfunction assessed by plasma concentration of Factor II|Hemostasis / platelet and endothelial dysfunction assessed by plasma concentration of Factor VIII|Hemostasis / platelet and endothelial dysfunction assessed by plasma concentration of Factor XII|Hemostasis / platelet and endothelial dysfunction assessed by plasma concentration of Factor X|Cumulative incidence of serious bleeding events|Cumulative incidence of thrombotic events|Overall survival|ICU length of stay","Assistance Publique - Hôpitaux de Paris","All","18 Years to 65 Years   (Adult, Older Adult)",,"60","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","190002","October 2019","February 2022","July 2022","October 21, 2019",,"October 21, 2019",,,"https://ClinicalTrials.gov/show/NCT04133220"
830,"NCT00416949","Iodine I 131 in Treating Patients With Thyroid Cancer",,"Terminated","Has Results","Head and Neck Cancer","Device: Patient-specific dosimetry","Tumor Absorbed Dose","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI)","All","18 Years to 100 Years   (Adult, Older Adult)","Not Applicable","9","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","J0628|CDR0000522716|R01CA116477-01A1|NA_00002264","April 2006","October 2009","October 2009","December 28, 2006","July 18, 2018","July 18, 2018","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00416949"
831,"NCT00062348","Boronophenylalanine-Fructose Complex (BPA-F) and/or Sodium Borocaptate (BSH) Followed By Surgery in Treating Patients With Thyroid Cancer, Head and Neck Cancer, or Liver Metastases",,"Completed","No Results Available","Colorectal Cancer|Head and Neck Cancer|Metastatic Cancer","Drug: boronophenylalanine-fructose complex|Drug: sodium borocaptate|Procedure: conventional surgery","Boron uptake ratio in tumor vs normal tissue|Toxicity measured by NCI-CTC v2.0 up to 28 days after injections","European Organisation for Research and Treatment of Cancer - EORTC","All","18 Years and older   (Adult, Older Adult)","Phase 1","27","Other","Interventional","Masking: None (Open Label)|Primary Purpose: Treatment","EORTC-11001","April 2003","December 2007",,"June 6, 2003",,"January 20, 2012","Universitaetsklinikum Essen, Essen, Germany",,"https://ClinicalTrials.gov/show/NCT00062348"
832,"NCT04411290","Malignancy Predictors, Bethesda and TI-RADS Scores Correlated With Final Histopathology in Thyroid Diseases",,"Enrolling by invitation","No Results Available","Thyroid Carcinoma|Thyroid Papillary Carcinoma|Multinodular Goiter, Adolescent|Solitary Thyroid Nodule|Thyroid Diseases|Multifocal Dysplasia|Aspiration|Thyroid Nodule|Thyroid Cancer, Papillary|Thyroid Neoplasms|Thyroid Goiter","Procedure: Total thyroidectomy (TT)","Preoperative Evaluation of Malignancy Risk Factors-How many risk factors are present?|Preoperative Bethesda category, Fine needle aspiration (FNA) cytology report|Preoperative ultrasound evaluation with Thyroid Imaging Reporting and Data System (TI-RADS)|Total thyroidectomy for both benign and malign thyroid diseases","Umraniye Education and Research Hospital","All","17 Years and older   (Child, Adult, Older Adult)",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","B.10.1.TKH.4.34.H.GP.0.01/172","May 15, 2020","June 1, 2021","June 1, 2021","June 2, 2020",,"June 2, 2020","Umraniye Education and Research Hospital, Health Sciences Universit, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT04411290"
833,"NCT03491904","To Assess the Patients' Ability to Self-Administer Fasinumab","FACT DEVICE","Completed","No Results Available","Osteoarthritis, Knee|Osteoarthritis, Hip","Drug: Fasinumab AI|Drug: Fasinumab PFS","Percentage of device-associated product technical failure (PTF) for the AI based on the total number of fasinumab injections administered by patients/caregivers in an unsupervised setting|Proportion of successful fasinumab injections administered by patients or their caregivers using an AI in an unsupervised setting (per patient report)|Number of AI associated product technical complaint (PTCs)|Number of validated AI associated PTFs|Number of patients with an AI associated PTC|Number of AI use-related errors|Patient satisfaction with the AI as assessed using the Self-Injection Assessment Questionnaire (SIAQ)|Number of participants who experience Adjudicated arthropathy (AA)|Number of participants who experience Destructive arthropathy (DA)|Number of participants who experience treatment-emergent adverse events (TEAEs)|Number of participants who experience sympathetic nervous system dysfunction|Number of participants who experience peripheral sensory adverse events (AEs) that require a neurology or other specialty consultation|Number of participants who experience all-cause Joint replacement (JR)s|Number of participants who experienced JR at the telephone survey|Maximum observed drug concentration (Cmax)|Area under the curve from the time of dosing to the end of dosing interval (AUC)|Geometric mean ratio of Cmax and AUC for the AI device (CI) of the geometric mean ratio|Geometric mean ratio of Cmax and AUC for the PFS device (CI) of the geometric mean ratio|Incidence of anti-drug antibody (ADA)","Regeneron Pharmaceuticals|Teva Pharmaceutical Industries, Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 1","100","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R475-PN-1602","January 23, 2019","January 15, 2020","December 15, 2020","April 9, 2018",,"March 3, 2021","Regeneron Research Facility, Gilbert, Arizona, United States|Regeneron Research Facility, Glendale, Arizona, United States|Regeneron Research Facility, Los Angeles, California, United States|Regeneron Research Facility, Wheat Ridge, Colorado, United States|Regeneron Research Facility, Ocala, Florida, United States|Regeneron Research Facility, Orlando, Florida, United States|Regeneron Research Facility, Pinellas Park, Florida, United States|Regeneron Research Facility, Port Orange, Florida, United States|Regeneron Research Facility, Atlanta, Georgia, United States|Regeneron Research Facility, West Des Moines, Iowa, United States|Regeneron Research Facility, Wichita, Kansas, United States|Regeneron Research Facility, Lexington, Kentucky, United States|Regeneron Research Facility, Lexington, Kentucky, United States|Regeneron Research Facility, Jamaica, New York, United States|Regeneron Research Facility, Statesville, North Carolina, United States|Regeneron Research Facility, Wilmington, North Carolina, United States|Regeneron Research Facility, Oklahoma City, Oklahoma, United States|Regeneron Research Facility, Bristol, Tennessee, United States|Regeneron Research Facility, Knoxville, Tennessee, United States|Regeneron Research Facility, Dallas, Texas, United States|Regeneron Research Facility, Houston, Texas, United States|Regeneron Research Facility, Houston, Texas, United States|Regeneron Research Facility, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03491904"
834,"NCT04544111","PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer",,"Recruiting","No Results Available","Thyroid Cancer|Thyroid Cancer, Follicular|Papillary Thyroid Cancer|Follicular Thyroid Cancer|Hurthle Cell Tumor|Poorly Differentiated Thyroid Gland Carcinoma|Hurthle Cell Thyroid Neoplasia","Drug: Trametinib|Drug: Dabrafenib|Drug: PDR001","Overall response rate","Memorial Sloan Kettering Cancer Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20-258","September 2, 2020","September 2, 2022","September 2, 2022","September 10, 2020",,"December 8, 2021","Memoral Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States|Memoral Sloan Kettering Monmouth (Limited protocol activities), Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States|Memorial Sloan Kettering Cancer Center @ Suffolk - Commack (Limited Protocol Activities), Commack, New York, United States|Memoral Sloan Kettering Westchester (Limited protocol activities), Harrison, New York, United States|Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States|Memorial Sloan Kettering Nassau (Limited protocol activities), Rockville Centre, New York, United States",,"https://ClinicalTrials.gov/show/NCT04544111"
835,"NCT00002386","Effect of Indinavir Plus Two Other Anti-HIV Drugs on Blood Clotting in HIV-Positive Males With Hemophilia",,"Completed","No Results Available","HIV Infections|Hemophilia A","Drug: Indinavir sulfate|Drug: Lamivudine|Drug: Stavudine|Drug: Zidovudine|Drug: Zalcitabine|Drug: Didanosine",,"Merck Sharp & Dohme Corp.|NIH AIDS Clinical Trials Information Service","Male","16 Years and older   (Child, Adult, Older Adult)","Phase 4","55","Industry","Interventional","Primary Purpose: Treatment","246J|065-00",,,,"August 31, 2001",,"June 24, 2005","USCF, San Francisco, California, United States|Georgetown U Med Ctr / Div of Hematology / Oncology, Washington, District of Columbia, United States|Emory Univ, Atlanta, Georgia, United States|Riley Hosp for Children, Indianapolis, Indiana, United States|Tulane Univ School of Medicine / Hematology / Oncology, New Orleans, Louisiana, United States|Univ of North Carolina School of Medicine / Div Hemat / Onco, Chapel Hill, North Carolina, United States|Milton Hershey Med Ctr, Hershey, Pennsylvania, United States|Montreal Gen Hosp, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00002386"
836,"NCT04731467","A Study of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors",,"Recruiting","No Results Available","Solid Tumor|Non Small Cell Lung Cancer|Pancreatic Cancer|Ovarian Cancer|Papillary Thyroid Cancer|Melanoma|Colorectal Adenocarcinoma","Drug: CM-24 and Nivolumab - Dose Escalation|Drug: CM-24 and Nivolumab - Expansion|Drug: CM-24, Nivolumab, and Nab paclitaxel - Expansion","Part A: Incidence of treatment emergent adverse events|Part B: Objective Response Rate|Part C: Objective Response Rate|Maximum serum concentration [Cmax]|Time of maximum concentration [Tmax]|Area under the serum concentration curve [AUC]|Half life|Drug clearance|Volume of distribution|Serum ADA parameters|Objective Response Rate when CM24 is used in combination with nivolumab|Disease Control Rate when CM24 is used in combination with nivolumab|Median Duration of Response when CM24 is used in combination with nivolumab|Median Time to Response when CM24 is used in combination with nivolumab|Progression Free Survival when CM24 is used in combination with nivolumab|Overall Survival when CM24 is used in combination with nivolumab|Population pharmacokinetics when CM24 is used in combination with nivolumab as measured by the maximum plasma concentration [Cmax]|Population pharmacokinetics when CM24 is used in combination with nivolumab as measured by the average area under the concentration curve [AUC]|Population pharmacokinetics when CM24 is used in combination with nivolumab as measured by the median area under the concentration curve [AUC]|Population pharmacokinetics when CM24 is used in combination with nivolumab and nab-paclitaxel as measured by the maximum plasma concentration [Cmax]|Population pharmacokinetics when CM24 is used in combination with nivolumab and nab-paclitaxel as measured by the average area under the concentration curve [AUC]|Population pharmacokinetics when CM24 is used in combination with nivolumab and nab-paclitaxel as measured by the median area under the concentration curve [AUC]|Disease Control Rate when CM24 is used in combination with nivolumab and nab-paclitaxel|Duration of Response when CM24 is used in combination with nivolumab and nab-paclitaxel|Time to Response when CM24 is used in combination with nivolumab and nab-paclitaxel|Progression Free Survival when CM24 is used in combination with nivolumab and nab-paclitaxel|Overall Survival when CM24 is used in combination with nivolumab and nab-paclitaxel","Famewave Ltd.|Bristol-Myers Squibb|Purple Biotech Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","74","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FW-2020-1","March 19, 2021","February 2024","March 2024","February 1, 2021",,"October 22, 2021","HonorHealth Research Institute, Scottsdale, Arizona, United States|Yale University, New Haven, Connecticut, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States|Rambam Health Care Campus, Haifa, Israel|Sheba Medical Center, Ramat Gan, Israel",,"https://ClinicalTrials.gov/show/NCT04731467"
837,"NCT04759911","Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer",,"Recruiting","No Results Available","Malignant Thyroid Gland Neoplasm|Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Carcinoma|Thyroid Gland Anaplastic Carcinoma|Thyroid Gland Medullary Carcinoma|Thyroid Gland Papillary Carcinoma|Thyroid Gland Squamous Cell Carcinoma","Other: Quality-of-Life Assessment|Other: Questionnaire Administration|Drug: Selpercatinib|Procedure: Therapeutic Conventional Surgery","Objective response rate (ORR)|Tumor response|R0/R1 resection rates|Progression free survival (PFS)|Locoregional PFS|Surgical morbidity/complexity score|Overall survival (OS)|Incidence of adverse events|Quality of life|Patient-reported outcomes","M.D. Anderson Cancer Center","All","12 Years and older   (Child, Adult, Older Adult)","Phase 2","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020-0570|NCI-2021-00535","February 26, 2021","September 10, 2024","September 10, 2024","February 18, 2021",,"May 17, 2021","M D Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04759911"
838,"NCT02227212","Ease of Use and Safety of the New U300 Pen Injector in Insulin-Naïve Patients With T2DM",,"Completed","No Results Available","Diabetes Mellitus Type 2","Drug: Insulin glargine U300 (new formulation of insulin glargine) HOE901","Ease-of-use / ease of learning questionnaire|Change in treatment satisfaction score (sum of items 1, 4, 5, 6, 7, and 8 from Diabetes Treatment Satisfaction Questionnaire [status]) from baseline to Week 4|Change in perception of hyper- and hypoglycemia score (items 2 and 3 from Diabetes Treatment Satisfaction Questionnaire [status]) from baseline to Week 4|Change in fasting plasma glucose (FPG) (mmol/L) from baseline to Week 4|Number of participants with Product Technical Complaints (PTC)|Number of participants with adverse events and hypoglycemic events related to PTC|Change in daily insulin dose (U and U/kg) from Day 1 to Week 4 (patient diary)|Number of participants with adverse events|Incidence and frequency of hypoglycemia episodes. Hypoglycemia will be analyzed by hypoglycemia categories as defined by American Diabetes Association|Potentially clinically significant changes in laboratory evaluations, vital signs, electrocardiogram (ECG)|Number of participants with site injection site reactions / hypersensitivity reactions","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 3","40","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PDY14065|2014-001253-16|U1111-1155-7309","August 2014","November 2014","November 2014","August 28, 2014",,"December 3, 2014","Investigational Site Number 276011, Augsburg, Germany|Investigational Site Number 276008, Berlin, Germany|Investigational Site Number 276009, Essen, Germany|Investigational Site Number 276002, Hamburg, Germany|Investigational Site Number 276001, Münster, Germany|Investigational Site Number 276007, Potsdam, Germany|Investigational Site Number 276004, Wangen, Germany",,"https://ClinicalTrials.gov/show/NCT02227212"
839,"NCT04921553","Real Word European Registry of NTRK Fusions and Other Rare Actionable Fusions (TRacKING)","TRacKING","Recruiting","No Results Available","Cancer|Cancer Metastatic|NTRK Gene Fusion Overexpression|NTRK Family Gene Mutation|ATIC-ALK Fusion Protein Expression|ALK Fusion Protein Expression|BCR-FGFR1 Fusion Protein Expression|ROS1 Gene Translocation|COL1A1-PDGFB Fusion Protein Expression|RET Gene Translocation|Gene Fusion|ROS Gene Translocation|BRAF Gene Rearrangement|FGFR2 Gene Translocation|FGFR3 Gene Translocation|NTRK1 Gene Translocation","Other: Data collection and quality of life questionnaire","Overall Survival|Management of patient with actionable fusion|Time to relapse|Progression Free Survival (PFS)|Incidence of long-term responders|Quality of life of patient|Time to relapse for fusion-targeting treatments|Overall survival for patient treated by fusion-targeting treatments|PFS for patient treated by fusion-targeting treatments|Incidence of long-term responders for patient treated by fusion-targeting treatments|Quality of life of patient treated by fusion-targeting treatments|Safety : Nature of adverse reaction (for treatment targeting a fusion)|Safety : Frequency of adverse reaction (for treatment targeting a fusion)|Safety : Severity of adverse reaction (for treatment targeting a fusion)","Centre Leon Berard","All","18 Years and older   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","ET20000258 TRacKING","June 22, 2021","June 2025","June 2025","June 10, 2021",,"August 2, 2021","University Hospital Graz, Graz, Austria|Medical University of Vienna, Vienna, Austria|Masaryk Memorial Cancer Institute (Masarykuv Onkologicky Ustav), Brno, Czechia|Aarhus University Hospital, Aarhus, Denmark|Chu Jean Minjoz, Besançon, France|Institut Bergonie, Bordeaux, France|Centre Georges Francois Leclerc, Dijon, France|Centre Oscar Lambret, Lille, France|Chu Dupuytren, Limoges, France|Centre Léon Bérard, Lyon, France|Assistance Publique Hopitaux de Marseille (AP-HM), Marseille, France|Centre Antoine Lacassagne, Nice, France|Institut Curie, Paris, France|Aphp - Hopital de La Pitie Salpetriere, Paris, France|Aphp - Hopital Cohin, Paris, France|Aphp - Hopital Tenon, Paris, France|Centre Henri Becquerel, Rouen, France|Institut Claudius Regaud, Toulouse, France|""Hämato-Onkologischer Studienkreis MVZ am Klinikum Aschaffenburg / Onkologie"", Aschaffenburg, Germany|Charité - Universitätsmedizin Berlin, Berlin, Germany|""Klinik für Innere Medizin III, Hämatologie, Onkologie Klinikum Chemnitz"", Chemnitz, Germany|""Medizinische Klinik 1- Gastroenterologie, Hepatologie, Pneumologie Universitätsklinikum Frankfurt"", Frankfurt am main, Germany|""Hämatologisch-onkologische Ambulanz Universitätsklinikum Halle"", Halle, Germany|""Klinik für Gastroenterologie, Hepatologie und Infekt Universitätsklinikum Magdeburg"", Magdeburg, Germany|Mannheim University Medical Center (UniversitatsMedizin Mannheim), Mannheim, Germany|""Medizinische Klinik und Poliklinik III LMU - Klinikum der Universität München"", München, Germany|""Klinik für Innere Medizin III, Hämatologie, Onkologie Südharzklinikum"", Nordhausen, Germany|Universitätsklinikum Tübingen Medizinische Universitätsklinik;, Tübingen, Germany|University Hospital Würzburg (UniversitätsKlinikum Würzburg), Würzburg, Germany|Azienda Ospedaliera - Universitaria - Policlinico S Orsola-Malpighi Univertsita di Bologna, Bologna, Italy|Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy|Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy|IRCCS Ospedale San Raffale, Milano, Italy|CRTR-AOU Federico II, Napoli, Italy|Azienda Ospedaliero - Universitaria Cita della Salute e della Scienza di Torino, Torino, Italy|Leiden University Medical Center, Leiden, Netherlands|Maria Sklodowska Curie National Research Institute of Oncology, Warsaw, Poland|Institute of Oncology of Ljubljana, Ljubljana, Slovenia|Complejo Hospitalario regional Virgen del Rocio, Sevilla, Spain|The Royal Marsden NHS Foundation Trust, London, United Kingdom|University College London NHS Foundation Trust, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04921553"
840,"NCT03596814","MOTHIF II : THERAPEUTIC MANAGEMENT AND USE OF CLOTTING FACTORS IN HEMOPHILIA A & B IN FRANCE II","MOTHIF II","Completed","No Results Available","Hemophilia","Other: No Interventional study","A comparison of the consumptions of CF before and after the laucnh of EHL CF is an assessment of the the impact of EHL CF on the treatment of haemophiliacs patients","Nantes University Hospital","All","Child, Adult, Older Adult",,"2072","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","RC17_0288","November 13, 2019","December 31, 2019","December 31, 2019","July 24, 2018",,"May 18, 2020","Angers University Hospital, Angers, France|Brest University Hospital, Brest, France|Caen university Hospital, Caen, France|Le Mans University Hospital, Le Mans, France|Nantes University Hospital, Nantes, France|Rennes University Hospital, Rennes, France|Tours University Hospital, Tours, France",,"https://ClinicalTrials.gov/show/NCT03596814"
841,"NCT03468985","Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer",,"Active, not recruiting","No Results Available","Metastatic Lung Non-Squamous Non-Small Cell Carcinoma|Recurrent Lung Non-Squamous Non-Small Cell Carcinoma|Stage IV Lung Non-Small Cell Cancer AJCC v7","Drug: Cabozantinib|Drug: Cabozantinib S-malate|Biological: Ipilimumab|Other: Laboratory Biomarker Analysis|Biological: Nivolumab|Other: Questionnaire Administration","Progression-free survival (PFS)|Overall survival|Best objective response evaluated|Incidence of toxicity","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","169","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2017-01008|EA5152|U10CA180820","March 1, 2018","December 31, 2022","December 31, 2022","March 19, 2018",,"January 6, 2022","Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States|Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States|Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States|Alaska Women's Cancer Care, Anchorage, Alaska, United States|Anchorage Oncology Centre, Anchorage, Alaska, United States|Katmai Oncology Group, Anchorage, Alaska, United States|Providence Alaska Medical Center, Anchorage, Alaska, United States|CHI Saint Vincent Cancer Center Hot Springs, Hot Springs, Arkansas, United States|Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro, Jonesboro, Arkansas, United States|PCR Oncology, Arroyo Grande, California, United States|Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California, United States|Penrose-Saint Francis Healthcare, Colorado Springs, Colorado, United States|Rocky Mountain Cancer Centers-Penrose, Colorado Springs, Colorado, United States|Porter Adventist Hospital, Denver, Colorado, United States|Mercy Medical Center, Durango, Colorado, United States|Southwest Oncology PC, Durango, Colorado, United States|Mountain Blue Cancer Care Center, Golden, Colorado, United States|Rocky Mountain Cancer Centers-Lakewood, Lakewood, Colorado, United States|Saint Anthony Hospital, Lakewood, Colorado, United States|Littleton Adventist Hospital, Littleton, Colorado, United States|Longmont United Hospital, Longmont, Colorado, United States|Rocky Mountain Cancer Centers-Longmont, Longmont, Colorado, United States|Parker Adventist Hospital, Parker, Colorado, United States|Rocky Mountain Cancer Centers-Parker, Parker, Colorado, United States|Saint Mary Corwin Medical Center, Pueblo, Colorado, United States|Rocky Mountain Cancer Centers - Pueblo, Pueblo, Colorado, United States|Rocky Mountain Cancer Centers-Thornton, Thornton, Colorado, United States|Broward Health Medical Center, Fort Lauderdale, Florida, United States|University Cancer and Blood Center LLC, Athens, Georgia, United States|Dekalb Medical Center, Decatur, Georgia, United States|Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States|Saint Luke's Cancer Institute - Boise, Boise, Idaho, United States|Saint Alphonsus Cancer Care Center-Caldwell, Caldwell, Idaho, United States|Kootenai Health - Coeur d'Alene, Coeur d'Alene, Idaho, United States|Walter Knox Memorial Hospital, Emmett, Idaho, United States|Saint Luke's Cancer Institute - Fruitland, Fruitland, Idaho, United States|Idaho Urologic Institute-Meridian, Meridian, Idaho, United States|Saint Luke's Cancer Institute - Meridian, Meridian, Idaho, United States|Saint Alphonsus Medical Center-Nampa, Nampa, Idaho, United States|Saint Luke's Cancer Institute - Nampa, Nampa, Idaho, United States|Kootenai Clinic Cancer Services - Post Falls, Post Falls, Idaho, United States|Kootenai Cancer Clinic, Sandpoint, Idaho, United States|Saint Luke's Cancer Institute - Twin Falls, Twin Falls, Idaho, United States|Rush - Copley Medical Center, Aurora, Illinois, United States|Illinois CancerCare-Bloomington, Bloomington, Illinois, United States|Illinois CancerCare-Canton, Canton, Illinois, United States|Memorial Hospital of Carbondale, Carbondale, Illinois, United States|SIH Cancer Institute, Carterville, Illinois, United States|Illinois CancerCare-Carthage, Carthage, Illinois, United States|Centralia Oncology Clinic, Centralia, Illinois, United States|Carle on Vermilion, Danville, Illinois, United States|Cancer Care Specialists of Illinois - Decatur, Decatur, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Carle Physician Group-Effingham, Effingham, Illinois, United States|Crossroads Cancer Center, Effingham, Illinois, United States|Illinois CancerCare-Eureka, Eureka, Illinois, United States|NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois, United States|Illinois CancerCare-Galesburg, Galesburg, Illinois, United States|Western Illinois Cancer Treatment Center, Galesburg, Illinois, United States|NorthShore University HealthSystem-Glenbrook Hospital, Glenview, Illinois, United States|NorthShore University HealthSystem-Highland Park Hospital, Highland Park, Illinois, United States|Edward Hines Jr VA Hospital, Hines, Illinois, United States|Illinois CancerCare-Kewanee Clinic, Kewanee, Illinois, United States|Illinois CancerCare-Macomb, Macomb, Illinois, United States|Carle Physician Group-Mattoon/Charleston, Mattoon, Illinois, United States|Trinity Medical Center, Moline, Illinois, United States|Cancer Care Center of O'Fallon, O'Fallon, Illinois, United States|Illinois CancerCare-Ottawa Clinic, Ottawa, Illinois, United States|Illinois CancerCare-Pekin, Pekin, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|Illinois CancerCare-Peru, Peru, Illinois, United States|Valley Radiation Oncology, Peru, Illinois, United States|Illinois CancerCare-Princeton, Princeton, Illinois, United States|SwedishAmerican Regional Cancer Center/ACT, Rockford, Illinois, United States|North Shore Medical Center, Skokie, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Springfield Clinic, Springfield, Illinois, United States|Memorial Medical Center, Springfield, Illinois, United States|Southwest Illinois Health Services LLP, Swansea, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|The Carle Foundation Hospital, Urbana, Illinois, United States|Rush-Copley Healthcare Center, Yorkville, Illinois, United States|Parkview Hospital Randallia, Fort Wayne, Indiana, United States|Parkview Regional Medical Center, Fort Wayne, Indiana, United States|Reid Health, Richmond, Indiana, United States|Mary Greeley Medical Center, Ames, Iowa, United States|McFarland Clinic PC - Ames, Ames, Iowa, United States|McFarland Clinic PC-Boone, Boone, Iowa, United States|Medical Oncology and Hematology Associates-West Des Moines, Clive, Iowa, United States|Mercy Cancer Center-West Lakes, Clive, Iowa, United States|Alegent Health Mercy Hospital, Council Bluffs, Iowa, United States|Greater Regional Medical Center, Creston, Iowa, United States|Iowa Methodist Medical Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates-Des Moines, Des Moines, Iowa, United States|Broadlawns Medical Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates-Laurel, Des Moines, Iowa, United States|Mercy Medical Center - Des Moines, Des Moines, Iowa, United States|Iowa Lutheran Hospital, Des Moines, Iowa, United States|McFarland Clinic PC-Trinity Cancer Center, Fort Dodge, Iowa, United States|Trinity Regional Medical Center, Fort Dodge, Iowa, United States|McFarland Clinic PC-Jefferson, Jefferson, Iowa, United States|McFarland Clinic PC-Marshalltown, Marshalltown, Iowa, United States|Methodist West Hospital, West Des Moines, Iowa, United States|Mercy Medical Center-West Lakes, West Des Moines, Iowa, United States|Central Care Cancer Center - Garden City, Garden City, Kansas, United States|Central Care Cancer Center - Great Bend, Great Bend, Kansas, United States|Lawrence Memorial Hospital, Lawrence, Kansas, United States|Kansas Institute of Medicine Cancer and Blood Center, Lenexa, Kansas, United States|Minimally Invasive Surgery Hospital, Lenexa, Kansas, United States|Menorah Medical Center, Overland Park, Kansas, United States|Cancer Center of Kansas-Wichita Medical Arts Tower, Wichita, Kansas, United States|Cancer Center of Kansas - Wichita, Wichita, Kansas, United States|Flaget Memorial Hospital, Bardstown, Kentucky, United States|Baptist Health Corbin, Corbin, Kentucky, United States|Commonwealth Cancer Center-Corbin, Corbin, Kentucky, United States|Baptist Health Lexington, Lexington, Kentucky, United States|Saint Joseph Radiation Oncology Resource Center, Lexington, Kentucky, United States|Saint Joseph Hospital East, Lexington, Kentucky, United States|Saint Joseph London, London, Kentucky, United States|Jewish Hospital, Louisville, Kentucky, United States|Baptist Health Louisville, Louisville, Kentucky, United States|Saints Mary and Elizabeth Hospital, Louisville, Kentucky, United States|Jewish Hospital Medical Center Northeast, Louisville, Kentucky, United States|Baptist Health Madisonville/Merle Mahr Cancer Center, Madisonville, Kentucky, United States|Baptist Health Paducah, Paducah, Kentucky, United States|Jewish Hospital Medical Center South, Shepherdsville, Kentucky, United States|Ochsner Health Center-Summa, Baton Rouge, Louisiana, United States|Medical Center of Baton Rouge, Baton Rouge, Louisiana, United States|Ochsner Medical Center Jefferson, New Orleans, Louisiana, United States|University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States|Greater Baltimore Medical Center, Baltimore, Maryland, United States|Western Maryland Regional Medical Center, Cumberland, Maryland, United States|TidalHealth Peninsula Regional, Salisbury, Maryland, United States|Hickman Cancer Center, Adrian, Michigan, United States|Saint Joseph Mercy Hospital, Ann Arbor, Michigan, United States|IHA Hematology Oncology Consultants-Brighton, Brighton, Michigan, United States|Saint Joseph Mercy Brighton, Brighton, Michigan, United States|IHA Hematology Oncology Consultants-Canton, Canton, Michigan, United States|Saint Joseph Mercy Canton, Canton, Michigan, United States|Caro Cancer Center, Caro, Michigan, United States|IHA Hematology Oncology Consultants-Chelsea, Chelsea, Michigan, United States|Saint Joseph Mercy Chelsea, Chelsea, Michigan, United States|Hematology Oncology Consultants-Clarkston, Clarkston, Michigan, United States|Newland Medical Associates-Clarkston, Clarkston, Michigan, United States|Ascension Saint John Hospital, Detroit, Michigan, United States|Great Lakes Cancer Management Specialists-Doctors Park, East China Township, Michigan, United States|Genesee Cancer and Blood Disease Treatment Center, Flint, Michigan, United States|Genesee Hematology Oncology PC, Flint, Michigan, United States|Genesys Hurley Cancer Institute, Flint, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|Academic Hematology Oncology Specialists, Grosse Pointe Woods, Michigan, United States|Great Lakes Cancer Management Specialists-Van Elslander Cancer Center, Grosse Pointe Woods, Michigan, United States|Michigan Breast Specialists-Grosse Pointe Woods, Grosse Pointe Woods, Michigan, United States|Sparrow Hospital, Lansing, Michigan, United States|Hope Cancer Clinic, Livonia, Michigan, United States|Saint Mary Mercy Hospital, Livonia, Michigan, United States|Great Lakes Cancer Management Specialists-Macomb Medical Campus, Macomb, Michigan, United States|Michigan Breast Specialists-Macomb Township, Macomb, Michigan, United States|Saint Mary's Oncology/Hematology Associates of Marlette, Marlette, Michigan, United States|Toledo Clinic Cancer Centers-Monroe, Monroe, Michigan, United States|21st Century Oncology-Pontiac, Pontiac, Michigan, United States|Hope Cancer Center, Pontiac, Michigan, United States|Newland Medical Associates-Pontiac, Pontiac, Michigan, United States|Saint Joseph Mercy Oakland, Pontiac, Michigan, United States|Huron Medical Center PC, Port Huron, Michigan, United States|Lake Huron Medical Center, Port Huron, Michigan, United States|Great Lakes Cancer Management Specialists-Rochester Hills, Rochester Hills, Michigan, United States|Ascension Saint Mary's Hospital, Saginaw, Michigan, United States|Oncology Hematology Associates of Saginaw Valley PC, Saginaw, Michigan, United States|Bhadresh Nayak MD PC-Sterling Heights, Sterling Heights, Michigan, United States|Ascension Saint Joseph Hospital, Tawas City, Michigan, United States|Advanced Breast Care Center PLLC, Warren, Michigan, United States|Great Lakes Cancer Management Specialists-Macomb Professional Building, Warren, Michigan, United States|Macomb Hematology Oncology PC, Warren, Michigan, United States|Michigan Breast Specialists-Warren, Warren, Michigan, United States|Saint John Macomb-Oakland Hospital, Warren, Michigan, United States|Saint Mary's Oncology/Hematology Associates of West Branch, West Branch, Michigan, United States|Huron Gastroenterology PC, Ypsilanti, Michigan, United States|IHA Hematology Oncology Consultants-Ann Arbor, Ypsilanti, Michigan, United States|Sanford Joe Lueken Cancer Center, Bemidji, Minnesota, United States|Fairview Ridges Hospital, Burnsville, Minnesota, United States|Mercy Hospital, Coon Rapids, Minnesota, United States|Fairview Southdale Hospital, Edina, Minnesota, United States|Unity Hospital, Fridley, Minnesota, United States|Fairview Clinics and Surgery Center Maple Grove, Maple Grove, Minnesota, United States|Minnesota Oncology Hematology PA-Maplewood, Maplewood, Minnesota, United States|Saint John's Hospital - Healtheast, Maplewood, Minnesota, United States|Abbott-Northwestern Hospital, Minneapolis, Minnesota, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|Health Partners Inc, Minneapolis, Minnesota, United States|New Ulm Medical Center, New Ulm, Minnesota, United States|North Memorial Medical Health Center, Robbinsdale, Minnesota, United States|Park Nicollet Clinic - Saint Louis Park, Saint Louis Park, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|Saint Francis Regional Medical Center, Shakopee, Minnesota, United States|Lakeview Hospital, Stillwater, Minnesota, United States|Sanford Thief River Falls Medical Center, Thief River Falls, Minnesota, United States|Ridgeview Medical Center, Waconia, Minnesota, United States|Rice Memorial Hospital, Willmar, Minnesota, United States|Minnesota Oncology Hematology PA-Woodbury, Woodbury, Minnesota, United States|Sanford Cancer Center Worthington, Worthington, Minnesota, United States|Fairview Lakes Medical Center, Wyoming, Minnesota, United States|Singing River Hospital, Pascagoula, Mississippi, United States|Central Care Cancer Center - Bolivar, Bolivar, Missouri, United States|Parkland Health Center-Bonne Terre, Bonne Terre, Missouri, United States|Saint Francis Medical Center, Cape Girardeau, Missouri, United States|Southeast Cancer Center, Cape Girardeau, Missouri, United States|Centerpoint Medical Center LLC, Independence, Missouri, United States|Capital Region Southwest Campus, Jefferson City, Missouri, United States|Research Medical Center, Kansas City, Missouri, United States|Missouri Baptist Medical Center, Saint Louis, Missouri, United States|Sainte Genevieve County Memorial Hospital, Sainte Genevieve, Missouri, United States|Missouri Baptist Sullivan Hospital, Sullivan, Missouri, United States|Missouri Baptist Outpatient Center-Sunset Hills, Sunset Hills, Missouri, United States|Community Hospital of Anaconda, Anaconda, Montana, United States|Billings Clinic Cancer Center, Billings, Montana, United States|Bozeman Deaconess Hospital, Bozeman, Montana, United States|Benefis Healthcare- Sletten Cancer Institute, Great Falls, Montana, United States|Great Falls Clinic, Great Falls, Montana, United States|Saint Peter's Community Hospital, Helena, Montana, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|Saint Patrick Hospital - Community Hospital, Missoula, Montana, United States|Community Medical Hospital, Missoula, Montana, United States|CHI Health Saint Francis, Grand Island, Nebraska, United States|Heartland Hematology and Oncology, Kearney, Nebraska, United States|CHI Health Good Samaritan, Kearney, Nebraska, United States|Saint Elizabeth Regional Medical Center, Lincoln, Nebraska, United States|Nebraska Methodist Hospital, Omaha, Nebraska, United States|Alegent Health Immanuel Medical Center, Omaha, Nebraska, United States|Hematology and Oncology Consultants PC, Omaha, Nebraska, United States|Alegent Health Bergan Mercy Medical Center, Omaha, Nebraska, United States|Alegent Health Lakeside Hospital, Omaha, Nebraska, United States|Creighton University Medical Center, Omaha, Nebraska, United States|Midlands Community Hospital, Papillion, Nebraska, United States|Carson Tahoe Regional Medical Center, Carson City, Nevada, United States|Cancer and Blood Specialists-Henderson, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada - Henderson, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada-Horizon Ridge, Henderson, Nevada, United States|Las Vegas Cancer Center-Henderson, Henderson, Nevada, United States|OptumCare Cancer Care at Seven Hills, Henderson, Nevada, United States|21st Century Oncology-Henderson, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada-Southeast Henderson, Henderson, Nevada, United States|Desert West Surgery, Las Vegas, Nevada, United States|OptumCare Cancer Care at Charleston, Las Vegas, Nevada, United States|University Medical Center of Southern Nevada, Las Vegas, Nevada, United States|Hope Cancer Care of Nevada, Las Vegas, Nevada, United States|Cancer and Blood Specialists-Shadow, Las Vegas, Nevada, United States|Radiation Oncology Centers of Nevada Central, Las Vegas, Nevada, United States|21st Century Oncology, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-San Martin, Las Vegas, Nevada, United States|Radiation Oncology Centers of Nevada Southeast, Las Vegas, Nevada, United States|Cancer Therapy and Integrative Medicine, Las Vegas, Nevada, United States|21st Century Oncology-Vegas Tenaya, Las Vegas, Nevada, United States|Ann M Wierman MD LTD, Las Vegas, Nevada, United States|Cancer and Blood Specialists-Tenaya, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada - Northwest, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-Tenaya, Las Vegas, Nevada, United States|OptumCare Cancer Care at MountainView, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada-Summerlin, Las Vegas, Nevada, United States|Summerlin Hospital Medical Center, Las Vegas, Nevada, United States|Las Vegas Cancer Center-Medical Center, Las Vegas, Nevada, United States|21st Century Oncology-Fort Apache, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|OptumCare Cancer Care at Fort Apache, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada - Central Valley, Las Vegas, Nevada, United States|University Cancer Center, Las Vegas, Nevada, United States|Hope Cancer Care of Nevada-Pahrump, Pahrump, Nevada, United States|Renown Regional Medical Center, Reno, Nevada, United States|Saint Mary's Regional Medical Center, Reno, Nevada, United States|Radiation Oncology Associates, Reno, Nevada, United States|New Hampshire Oncology Hematology PA-Concord, Concord, New Hampshire, United States|Solinsky Center for Cancer Care, Manchester, New Hampshire, United States|Virtua Memorial, Mount Holly, New Jersey, United States|Virtua Voorhees, Voorhees, New Jersey, United States|Montefiore Medical Center-Einstein Campus, Bronx, New York, United States|Montefiore Medical Center-Weiler Hospital, Bronx, New York, United States|Montefiore Medical Center - Moses Campus, Bronx, New York, United States|Randolph Hospital, Asheboro, North Carolina, United States|Cone Health Cancer Center at Alamance Regional, Burlington, North Carolina, United States|Southeastern Medical Oncology Center-Clinton, Clinton, North Carolina, United States|Southeastern Medical Oncology Center-Goldsboro, Goldsboro, North Carolina, United States|Wayne Memorial Hospital, Goldsboro, North Carolina, United States|Cone Health Cancer Center, Greensboro, North Carolina, United States|Margaret R Pardee Memorial Hospital, Hendersonville, North Carolina, United States|Onslow Memorial Hospital, Jacksonville, North Carolina, United States|Southeastern Medical Oncology Center-Jacksonville, Jacksonville, North Carolina, United States|Vidant Oncology-Kinston, Kinston, North Carolina, United States|Cone Heath Cancer Center at Mebane, Mebane, North Carolina, United States|Annie Penn Memorial Hospital, Reidsville, North Carolina, United States|Sanford Bismarck Medical Center, Bismarck, North Dakota, United States|Sanford South University Medical Center, Fargo, North Dakota, United States|Sanford Broadway Medical Center, Fargo, North Dakota, United States|Sanford Roger Maris Cancer Center, Fargo, North Dakota, United States|Trinity Cancer Care Center, Minot, North Dakota, United States|Indu and Raj Soin Medical Center, Beavercreek, Ohio, United States|Strecker Cancer Center-Belpre, Belpre, Ohio, United States|Aultman Health Foundation, Canton, Ohio, United States|Dayton Physicians LLC-Miami Valley South, Centerville, Ohio, United States|Miami Valley Hospital South, Centerville, Ohio, United States|Geauga Hospital, Chardon, Ohio, United States|Adena Regional Medical Center, Chillicothe, Ohio, United States|University of Cincinnati Cancer Center-UC Medical Center, Cincinnati, Ohio, United States|Good Samaritan Hospital - Cincinnati, Cincinnati, Ohio, United States|Oncology Hematology Care Inc-Kenwood, Cincinnati, Ohio, United States|Bethesda North Hospital, Cincinnati, Ohio, United States|TriHealth Cancer Institute-Westside, Cincinnati, Ohio, United States|TriHealth Cancer Institute-Anderson, Cincinnati, Ohio, United States|Case Western Reserve University, Cleveland, Ohio, United States|MetroHealth Medical Center, Cleveland, Ohio, United States|Mount Carmel East Hospital, Columbus, Ohio, United States|Columbus Oncology and Hematology Associates Inc, Columbus, Ohio, United States|Riverside Methodist Hospital, Columbus, Ohio, United States|Grant Medical Center, Columbus, Ohio, United States|The Mark H Zangmeister Center, Columbus, Ohio, United States|Mount Carmel Health Center West, Columbus, Ohio, United States|Doctors Hospital, Columbus, Ohio, United States|Good Samaritan Hospital - Dayton, Dayton, Ohio, United States|Miami Valley Hospital, Dayton, Ohio, United States|Dayton Physician LLC-Miami Valley Hospital North, Dayton, Ohio, United States|Miami Valley Hospital North, Dayton, Ohio, United States|Delaware Health Center-Grady Cancer Center, Delaware, Ohio, United States|Delaware Radiation Oncology, Delaware, Ohio, United States|Grady Memorial Hospital, Delaware, Ohio, United States|Mercy Cancer Center-Elyria, Elyria, Ohio, United States|Armes Family Cancer Center, Findlay, Ohio, United States|Blanchard Valley Hospital, Findlay, Ohio, United States|Orion Cancer Care, Findlay, Ohio, United States|Atrium Medical Center-Middletown Regional Hospital, Franklin, Ohio, United States|Dayton Physicians LLC-Atrium, Franklin, Ohio, United States|Dayton Physicians LLC-Wayne, Greenville, Ohio, United States|Wayne Hospital, Greenville, Ohio, United States|Greater Dayton Cancer Center, Kettering, Ohio, United States|First Dayton Cancer Care, Kettering, Ohio, United States|Kettering Medical Center, Kettering, Ohio, United States|Fairfield Medical Center, Lancaster, Ohio, United States|OhioHealth Mansfield Hospital, Mansfield, Ohio, United States|Marietta Memorial Hospital, Marietta, Ohio, United States|OhioHealth Marion General Hospital, Marion, Ohio, United States|Toledo Clinic Cancer Centers-Maumee, Maumee, Ohio, United States|Toledo Radiation Oncology at Northwest Ohio Onocolgy Center, Maumee, Ohio, United States|UH Seidman Cancer Center at Lake Health Mentor Campus, Mentor, Ohio, United States|UH Seidman Cancer Center at Southwest General Hospital, Middleburg Heights, Ohio, United States|Knox Community Hospital, Mount Vernon, Ohio, United States|Licking Memorial Hospital, Newark, Ohio, United States|Newark Radiation Oncology, Newark, Ohio, United States|University Hospitals Parma Medical Center, Parma, Ohio, United States|Mercy Health Perrysburg Cancer Center, Perrysburg, Ohio, United States|Southern Ohio Medical Center, Portsmouth, Ohio, United States|UH Seidman Cancer Center at Firelands Regional Medical Center, Sandusky, Ohio, United States|Springfield Regional Cancer Center, Springfield, Ohio, United States|Springfield Regional Medical Center, Springfield, Ohio, United States|Mercy Health - Saint Anne Hospital, Toledo, Ohio, United States|Toledo Clinic Cancer Centers-Toledo, Toledo, Ohio, United States|Dayton Physicians LLC-Upper Valley, Troy, Ohio, United States|Upper Valley Medical Center, Troy, Ohio, United States|University of Cincinnati Cancer Center-West Chester, West Chester, Ohio, United States|Saint Ann's Hospital, Westerville, Ohio, United States|UH Seidman Cancer Center at Saint John Medical Center, Westlake, Ohio, United States|Genesis Healthcare System Cancer Care Center, Zanesville, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Integris Southwest Medical Center, Oklahoma City, Oklahoma, United States|Integris Cancer Institute of Oklahoma, Oklahoma City, Oklahoma, United States|Oklahoma Cancer Specialists and Research Institute-Tulsa, Tulsa, Oklahoma, United States|Saint Alphonsus Medical Center-Baker City, Baker City, Oregon, United States|Saint Charles Health System, Bend, Oregon, United States|Clackamas Radiation Oncology Center, Clackamas, Oregon, United States|Providence Cancer Institute Clackamas Clinic, Clackamas, Oregon, United States|Bay Area Hospital, Coos Bay, Oregon, United States|Providence Newberg Medical Center, Newberg, Oregon, United States|Saint Alphonsus Medical Center-Ontario, Ontario, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence Saint Vincent Medical Center, Portland, Oregon, United States|Saint Charles Health System-Redmond, Redmond, Oregon, United States|Lehigh Valley Hospital-Cedar Crest, Allentown, Pennsylvania, United States|Lehigh Valley Hospital - Muhlenberg, Bethlehem, Pennsylvania, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Pocono Medical Center, East Stroudsburg, Pennsylvania, United States|Geisinger Medical Center-Cancer Center Hazleton, Hazleton, Pennsylvania, United States|Lehigh Valley Hospital-Hazleton, Hazleton, Pennsylvania, United States|Geisinger Medical Oncology-Lewisburg, Lewisburg, Pennsylvania, United States|Lewistown Hospital, Lewistown, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|Pottstown Hospital, Pottstown, Pennsylvania, United States|Geisinger Cancer Services-Pottsville, Pottsville, Pennsylvania, United States|Community Medical Center, Scranton, Pennsylvania, United States|Geisinger Medical Group, State College, Pennsylvania, United States|Reading Hospital, West Reading, Pennsylvania, United States|Geisinger Wyoming Valley/Henry Cancer Center, Wilkes-Barre, Pennsylvania, United States|Prisma Health Cancer Institute - Spartanburg, Boiling Springs, South Carolina, United States|Prisma Health Cancer Institute - Laurens, Clinton, South Carolina, United States|Prisma Health Cancer Institute - Easley, Easley, South Carolina, United States|Prisma Health Cancer Institute - Butternut, Greenville, South Carolina, United States|Prisma Health Cancer Institute - Faris, Greenville, South Carolina, United States|Prisma Health Greenville Memorial Hospital, Greenville, South Carolina, United States|Prisma Health Cancer Institute - Eastside, Greenville, South Carolina, United States|Prisma Health Cancer Institute - Greer, Greer, South Carolina, United States|Prisma Health Cancer Institute - Seneca, Seneca, South Carolina, United States|Sanford Cancer Center Oncology Clinic, Sioux Falls, South Dakota, United States|Sanford USD Medical Center - Sioux Falls, Sioux Falls, South Dakota, United States|Wellmont Bristol Regional Medical Center, Bristol, Tennessee, United States|Memorial Hospital, Chattanooga, Tennessee, United States|Pulmonary Medicine Center of Chattanooga-Hixson, Hixson, Tennessee, United States|Wellmont Medical Associates Oncology and Hematology-Johnson City, Johnson City, Tennessee, United States|Regional Cancer Center at Indian Path Community Hospital, Kingsport, Tennessee, United States|Wellmont Holston Valley Hospital and Medical Center, Kingsport, Tennessee, United States|Memorial GYN Plus, Ooltewah, Tennessee, United States|Saint Joseph Regional Cancer Center, Bryan, Texas, United States|Parkland Memorial Hospital, Dallas, Texas, United States|UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States|UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth, Texas, United States|Wellmont Medical Associates-Bristol, Bristol, Virginia, United States|Southwest VA Regional Cancer Center, Norton, Virginia, United States|Providence Regional Cancer System-Aberdeen, Aberdeen, Washington, United States|PeaceHealth Saint Joseph Medical Center, Bellingham, Washington, United States|Harrison HealthPartners Hematology and Oncology-Bremerton, Bremerton, Washington, United States|Harrison Medical Center, Bremerton, Washington, United States|Highline Medical Center-Main Campus, Burien, Washington, United States|Providence Regional Cancer System-Centralia, Centralia, Washington, United States|Swedish Cancer Institute-Edmonds, Edmonds, Washington, United States|Saint Elizabeth Hospital, Enumclaw, Washington, United States|Providence Regional Cancer Partnership, Everett, Washington, United States|Saint Francis Hospital, Federal Way, Washington, United States|Swedish Cancer Institute-Issaquah, Issaquah, Washington, United States|Kadlec Clinic Hematology and Oncology, Kennewick, Washington, United States|Providence Regional Cancer System-Lacey, Lacey, Washington, United States|Saint Clare Hospital, Lakewood, Washington, United States|PeaceHealth Saint John Medical Center, Longview, Washington, United States|Harrison HealthPartners Hematology and Oncology-Poulsbo, Poulsbo, Washington, United States|Pacific Gynecology Specialists, Seattle, Washington, United States|Swedish Medical Center-Ballard Campus, Seattle, Washington, United States|Kaiser Permanente Washington, Seattle, Washington, United States|Swedish Medical Center-First Hill, Seattle, Washington, United States|Swedish Medical Center-Cherry Hill, Seattle, Washington, United States|PeaceHealth United General Medical Center, Sedro-Woolley, Washington, United States|Providence Regional Cancer System-Shelton, Shelton, Washington, United States|Franciscan Research Center-Northwest Medical Plaza, Tacoma, Washington, United States|Northwest Medical Specialties PLLC, Tacoma, Washington, United States|PeaceHealth Southwest Medical Center, Vancouver, Washington, United States|Providence Saint Mary Regional Cancer Center, Walla Walla, Washington, United States|Providence Regional Cancer System-Yelm, Yelm, Washington, United States|Langlade Hospital and Cancer Center, Antigo, Wisconsin, United States|Aurora Cancer Care-Southern Lakes VLCC, Burlington, Wisconsin, United States|Aurora Health Center-Fond du Lac, Fond Du Lac, Wisconsin, United States|Aurora Health Care Germantown Health Center, Germantown, Wisconsin, United States|Aurora Cancer Care-Grafton, Grafton, Wisconsin, United States|Aurora BayCare Medical Center, Green Bay, Wisconsin, United States|Aurora Cancer Care-Kenosha South, Kenosha, Wisconsin, United States|Gundersen Lutheran Medical Center, La Crosse, Wisconsin, United States|Aurora Bay Area Medical Group-Marinette, Marinette, Wisconsin, United States|Aurora Cancer Care-Milwaukee, Milwaukee, Wisconsin, United States|Aurora Saint Luke's Medical Center, Milwaukee, Wisconsin, United States|Aurora Sinai Medical Center, Milwaukee, Wisconsin, United States|Cancer Center of Western Wisconsin, New Richmond, Wisconsin, United States|Vince Lombardi Cancer Clinic - Oshkosh, Oshkosh, Wisconsin, United States|Aurora Cancer Care-Racine, Racine, Wisconsin, United States|Vince Lombardi Cancer Clinic-Sheboygan, Sheboygan, Wisconsin, United States|Aurora Medical Center in Summit, Summit, Wisconsin, United States|Vince Lombardi Cancer Clinic-Two Rivers, Two Rivers, Wisconsin, United States|Aspirus Regional Cancer Center, Wausau, Wisconsin, United States|Aurora Cancer Care-Milwaukee West, Wauwatosa, Wisconsin, United States|Aurora West Allis Medical Center, West Allis, Wisconsin, United States|Aspirus Cancer Care - Wisconsin Rapids, Wisconsin Rapids, Wisconsin, United States|Billings Clinic-Cody, Cody, Wyoming, United States|Welch Cancer Center, Sheridan, Wyoming, United States",,"https://ClinicalTrials.gov/show/NCT03468985"
842,"NCT01118065","Everolimus in Treating Patients With Progressive or Recurrent, Unresectable, or Metastatic Thyroid Cancer",,"Unknown status","No Results Available","Head and Neck Cancer","Drug: everolimus","Efficacy|Maximum percentage of tumor reduction|Activity time to event endpoints|Toxicity","Leiden University Medical Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","42","Other","Interventional","Masking: None (Open Label)|Primary Purpose: Treatment","DUT-LUMC-CRAD001CNL08T|CDR0000672171|EUDRACT-2009-016669-27|EU-21037|NL-31245-058-10","May 2010","May 2012",,"May 6, 2010",,"August 12, 2013","Leiden University Medical Center, Leiden, Netherlands",,"https://ClinicalTrials.gov/show/NCT01118065"
843,"NCT00095836","Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy",,"Completed","Has Results","Head and Neck Cancer","Drug: Gefitinib","Objective Tumor Response Rate at 3, 6, and 12 Months|Toxicity|Median Progression-free Survival|Overall Survival","Massachusetts General Hospital|National Cancer Institute (NCI)|Dana-Farber Cancer Institute|Brigham and Women's Hospital|AstraZeneca","All","18 Years and older   (Adult, Older Adult)","Phase 2","27","Other|NIH|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","02-220|P30CA006516|ZENECA-IRUSIRES0165|CDR0000393510","March 2003","March 2011","March 2011","November 9, 2004","May 31, 2017","May 31, 2017","Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00095836"
844,"NCT01164176","Everolimus in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer",,"Completed","No Results Available","Head and Neck Cancer","Drug: everolimus|Other: laboratory biomarker analysis","Response rate|Overall survival|Progression-free survival|Toxicity profile","Yonsei University","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","4-2009-0542|YONSEI-CRAD001CKR12T|KCSG-HN-10-03","March 2010","October 2014","October 2014","July 16, 2010",,"December 2, 2014","Hallym University Sacred Heart Hospital, Anyang, Gyeonggi-do, Korea, Republic of|Yeungnam University Medical Center, Daegu, Korea, Republic of|National Cancer Center - Korea, Goyang, Korea, Republic of|Kosin Medical Center Gospel Hospital, Pusan, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Yonsei Cancer Center at Yonsei University Medical Center, Seoul, Korea, Republic of|Gangnam Severance Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01164176"
845,"NCT03346070","Efficacy and Safety of Sugammadex Dosed According to Actual Body Weight (ABW) or Ideal Body Weight (IBW) in Reversal of Neuromuscular Blockade (NMB) in Morbidly Obese Participants (MK-8616-146)",,"Completed","Has Results","Neuromuscular Blockade","Drug: Sugammadex 2 mg/kg ABW|Drug: Sugammadex 2 mg/kg IBW|Drug: Sugammadex 4 mg/kg ABW|Drug: Sugammadex 4 mg/kg IBW|Drug: Neostigmine + Glycopyrrolate|Drug: Rocuronium or Vecuronium","Time to Recovery (TTR) of Participant Train Of Four (TOF) Ratio to ≥0.9: Primary Kaplan-Meier Analysis|Percentage of Participants With Treatment-Emergent Sinus Bradycardia Events|Percentage of Participants With Treatment-Emergent Sinus Tachycardia Events|Percentage of Participants With Other Treatment-Emergent Cardiac Arrhythmia Events|Percentage of Participants Experiencing an Adverse Event (AE) After Administration of Study Intervention|Percentage of Participants Experiencing a Serious Adverse Event (SAE) After Administration of Study Intervention|Percentage of Participants Experiencing an Event of Clinical Interest (ECI) After Administration of Study Intervention|Percentage of Participants With Prolonged (>10 Minutes) Time to Recovery (TTR) of the Train Of Four (TOF) Ratio to ≥0.9|Time to Recovery (TTR) of Participant Train of Four (TOF) Ratio to ≥0.9: Secondary Geometric Mean Analysis|Time to Recovery (TTR) of Participant Train of Four (TOF) Ratio to ≥0.8: Geometric Mean Analysis|Time to Recovery (TTR) of Participant Train of Four (TOF) Ratio to ≥0.7: Geometric Mean Analysis","Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 4","207","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","8616-146|2017-000188-33|MK-8616-146","January 1, 2018","January 29, 2019","January 29, 2019","November 17, 2017","December 23, 2019","January 28, 2021","University California / Davis ( Site 2001), Sacramento, California, United States|Jackson Memorial Hospital/University of Miami ( Site 2007), Miami, Florida, United States|University of Kansas Medical Center ( Site 2049), Kansas City, Kansas, United States|William Beaumont Hospital - Royal Oak ( Site 2033), Royal Oak, Michigan, United States|University Hospital- Columbia MO ( Site 2060), Columbia, Missouri, United States|Robert Wood Johnson University Hospital ( Site 2037), New Brunswick, New Jersey, United States|Mission Hospital - St. Joseph ( Site 2015), Asheville, North Carolina, United States|Cleveland Clinic Foundation ( Site 2031), Cleveland, Ohio, United States|Temple University Hospital ( Site 2004), Philadelphia, Pennsylvania, United States|Vanderbilt University Medical Center ( Site 2032), Nashville, Tennessee, United States|Hermann Drive Surgical Center ( Site 2020), Houston, Texas, United States|Hermann Drive Surgical Center ( Site 2059), Houston, Texas, United States|Zablocki VA Medical Center ( Site 2011), Milwaukee, Wisconsin, United States|Sozialmedizinisches Zentrum Ost - Donauspital ( Site 2150), Wien, Austria|Universitaire Ziekenhuis Antwerpen - UZA ( Site 2200), Edegem, Belgium|Bispebjerg og Frederiksberg Hospital ( Site 2250), Copenhagen NV, Denmark|Rigshospitalet ( Site 2253), Copenhagen, Denmark|Johanniter Krankenhaus Bonn ( Site 2353), Bonn, Germany|Diakovere Annastift gGmbH ( Site 2355), Hannover, Germany|Universitatsklinikum Giessen und Marburg GmbH ( Site 2356), Marburg, Germany|Klinikum Rechts der Isar Technische Universitaet Muenchen ( Site 2350), Muenchen, Germany|St. Franziskus-Hospital ( Site 2354), Muenster, Germany|Klinikum am Steinenberg Reutlingen ( Site 2352), Reutlingen, Germany|Josephs-Hospitals Warendorf ( Site 2351), Warendorf, Germany","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/70/NCT03346070/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/70/NCT03346070/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03346070"
846,"NCT00005842","Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer",,"Completed","No Results Available","Cancer","Biological: trastuzumab|Drug: tipifarnib",,"National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1","24","NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000067858|UTHSC-IDD-99-26|SACI-IDD-99-26|NCI-62","June 2000","February 2004",,"April 26, 2004",,"February 11, 2013","Brooke Army Medical Center, Fort Sam Houston, Texas, United States|Institute for Drug Development, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00005842"
847,"NCT04819100","A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)","LIBRETTO-432","Recruiting","No Results Available","Carcinoma, Non-Small-Cell Lung","Drug: Selpercatinib|Drug: Placebo","Event-Free Survival (EFS)|EFS|Overall Survival (OS)|Time to Distant Disease Recurrence in the Central Nervous System (CNS)|Progression Free Survival on the Next Line of Treatment (PFS2)|Positive Predictive Value (PPV) of Local Lab Tests Compared to Central Lab Test to Detect Rearranged during Transfection (RET) Gene Fusion|Mean Change from Baseline over Time in NSCLC Symptoms|Mean Change from Baseline over Time in Physical Function","Loxo Oncology, Inc.|Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 3","170","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","18126|J2G-MC-JZJX|2020-005191-35","December 20, 2021","August 31, 2028","November 30, 2032","March 26, 2021",,"January 19, 2022","UCLA Hematology Oncology, Santa Monica, California, United States|Stockton Hematology Oncology Medical Group, Stockton, California, United States|UCLA Medical Center, Torrance, California, United States|GenesisCare, Aventura, Florida, United States|GenesisCare - Boca Raton, Boca Raton, Florida, United States|Florida Cancer Specialists, Fort Myers, Florida, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Florida Cancer Specialists, Saint Petersburg, Florida, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|New York Oncology Hematology, P.C, Clifton Park, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Sarah Cannon Research Institute SCRI, Nashville, Tennessee, United States|Tennessee Oncology PLLC, Nashville, Tennessee, United States|US Oncology, The Woodlands, Texas, United States|University of Vermont Medical Center, Burlington, Vermont, United States|Border Medical Oncology, Albury, New South Wales, Australia|Sunshine Coast University Hospital, Birtinya, Queensland, Australia|The Townsville Hospital, Douglas, Queensland, Australia|Rockhampton Hospital, Rockhampton, Queensland, Australia|Ballarat Health Services, Ballarat, Victoria, Australia|Bendigo Health, Bendigo, Victoria, Australia|Goulburn Valley Health, Shepparton, Victoria, Australia|South West Healthcare, Warrambool, Victoria, Australia|Landeskrankenhaus Feldkirch, Feldkirch, Austria|Klinik Floridsdorf - Abteilung für INNERE MEDIZIN UND PNEUMOLOGIE, Wien, Austria|Cliniques Universitaires Saint-Luc, Bruxelles, Brussel, Belgium|Université Catholique de Louvain-Namur - Centre Hospitalier Universitaire Dinant-Godinne - Site Godinne, Yvoir, Namur, Belgium|Universitair Ziekenhuis Antwerpen, Edegem, Belgium|Clinique Saint Pierre Ottignies, Ottignies, Belgium|Núcleo de Oncologia da Bahia, Salvador, Bahia, Brazil|Oncocentro BH, Belo Horizonte, Minas Gerais, Brazil|COT - Centro Oncológico do Triângulo S.A., Uberlândia, Minas Gerais, Brazil|Multihemo Servicos Medicos S/A, Recife, Pernambuco, Brazil|Hospital São Lucas da PUCRS, Porto Alegre, Rio Grande Do Sul, Brazil|Grupo COI - Clínicas Oncológicas Integradas, Rio de Janeiro, RJ, Brazil|IBCC - Instituto Brasileiro de Controle do Câncer, São Paulo, Brazil|Centro Paulista de Oncologia, São Paulo, Brazil|Princess Margaret Hospital, Toronto, Ontario, Canada|Beijing Friendship Hospital, Beijing, Beijing, China|Beijing Cancer hospital, Haidian District, Beijing, China|The First Affiliated Hospital Chongqing Medical University, Chongqing, Chongqing, China|Fujian Provincial Hospital, Fuzhou, Fujian, China|Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China|Southern Medical University Nanfang Hospital, Guangzhou, Guangdong, China|Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China|Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China|Xiangya Hospital, Central South University, Changsha, Hunan, China|Hunan Cancer Hospital, Changsha, Hunan, China|Hunan Cancer Hospital, Changsha, Hunan, China|Jilin Cancer Hospital, Changchun, Jilin, China|Jinan Central Hospital, Jinan, Shandong, China|Shanghai Chest Hospital, Shanghai, Shanghai, China|Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China|Shanghai Pulmonary Hospital, Shanghai, Shanghai, China|Tang Du Hospital, The Second Teaching Hospital of FMMU, Xi'an, Shanxi, China|the Third People's Hospital of Chengdu, Chengdu, Sichuan, China|West China Hospital of Sichuan University, Chengdu, Sichuan, China|First Affiliated Hosp of College of Med, Zhejiang University, Hangzhou, Zhejiang, China|Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China|Beijing Peking Union Medical College Hospital, Beijing, China|Masarykuv onkologicky ustav, Brno, Czech Republic, Czechia|Nemocnice AGEL Ostrava-Vitkovice a.s.-Plicni oddeleni, Ostrava - Vitkovice, Czechia|Fakultni nemocnice Bulovka, Praha 8, Czechia|Odense Universitetshospital, Odense C, Syd, Denmark|HCL-Hôpital Louis Pradel, Lyon (Bron), France|Centre Leon Berard, Lyon Cedex 08, France|Assistance Publique Hôpitaux de Marseille - Hôpital Nord, Marseille Cedex 20, France|Hopital Cochin, Paris, France|CHU Charles Nicolle in Rouen, Rouen cedex, France|Gustave Roussy, Villejuif Cedex, France|Thoraxklinik-Heidelberg gGmbH, Heidelberg, Baden-Württemberg, Germany|Asklepios Fachkliniken München-Gauting, Gauting, Bayern, Germany|Lungenfachklinik Immenhausen, Immenhausen, Hessen, Germany|Franziskus-Hospital Harderberg, Georgsmarienhütte, Lower Saxony, Germany|LungenClinic Grosshansdorf, Grosshansdorf, Schleswig-Holstein, Germany|Charité-Campus Benjamin Franklin-Hematology and Oncology, Berlin, Germany|University Hospital of Patras, Patras, Achaḯa, Greece|Agios Savvas Regional Cancer Hospital, Athens, Attikí, Greece|Sotiria Thoracic Diseases Hospital of Athens, Athens, Attikí, Greece|University General Hospital of Heraklion, Heraklion, Krete, Greece|European Interbalkan Medical Center, Thessaloniki, Thessaloníki, Greece|G. Papanikolaou General Hospital, Thessaloniki, Thessaloníki, Greece|Princess Margaret Hospital, Lai Chi Kok, Kowloon, Hong Kong|Queen Elizabeth Hospital, Hong Kong, Hong Kong|Hong Kong United Oncology Centre, Kowloon, Hong Kong|Regional Cancer Centre, Thiruvananthapuram, Kerala, India|Tata Memorial Hospital, Mumbai, Maharashtra, India|Rashtrasant Tukdoji Regional Cancer Hospital and Research Centre (RSTRCH), Nagpur, Maharashtra, India|HCG Manavata Cancer Centre, Nashik, Maharashtra, India|Rambam Medical Center, Haifa, Israel|Hadassah Medical Center, Jerusalem, Israel|Sheba Medical Center, Ramat Gan, Israel|ASST Grande Ospedale Metropolitano Niguarda, Milan, Milano, Italy|Istituto Clinico Humanitas, Rozzano, Milano, Italy|Azienda Sanitaria Ospedaliera S Luigi Gonzaga, Orbassano, Torino, Italy|IRCCS Ospedale Oncologico di Bari, Bari, Italy|Ospedale V. Monaldi, Napoli, Italy|Istituto Oncologico Veneto IRCCS, Padova, Italy|Aichi Cancer Center Hospital, Nagoya, Aichi, Japan|National Cancer Center Hospital East, Kashiwa, Chiba, Japan|Himeji Medical Center, Himeji, Hyogo, Japan|Kanagawa cancer center, Yokohama, Kanagawa, Japan|Niigata Cancer Center Hospital, Niigata-shi, Niigata, Japan|Kinki University Hospital, Osaka-Sayama, Osaka, Japan|Shizuoka Cancer Center, Nagaizumi-cho,Sunto-gun, Shizuoka, Japan|Juntendo University Hospital, Bunkyo-ku, Tokyo, Japan|Japanese Foundation for Cancer Research, Koto, Tokyo, Japan|Tottori University Hospital, Yonago, Tottori, Japan|Hiroshima University Hospital, Hiroshima, Japan|Osaka International Cancer Institute, Osaka, Japan|National Cancer Center, Goyang-si, Gyeonggi-do, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of|Chonnam National University Hwasun Hospital, Hwasun-gun, Jeollanam Do, Korea, Republic of|Asan Medical Center, Seoul, Korea, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Korea, Republic of|Seoul National University Hospital, Seoul, Seoul, Korea, Korea, Republic of|Kyungpook National University Medical Center Chilgok Hospital, Daegu, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Actualidad Basada en la Investigación del Cáncer, Guadalajara, Jalisco, Mexico|ONCARE Viaducto Nápoles, Delegación Benito Juárez, Mexico City, Federal District, Mexico|Hospital Universitario ""Dr. Jose Eleuterio Gonzalez"", Monterrey, Nuevo León, Mexico|Avix Investigación Clinica, S.C., Monterrey, Nuevo León, Mexico|Ziekenhuis St. Jansdal, Harderwijk, Gelderland, Netherlands|Universitair Medisch Centrum St Radboud Nijmegen, Nijmegen, Netherlands|Krakowski Szpital Specjalistyczny im. Jana Pawa II, Krakow, Małopolskie, Poland|Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Wojewodzki Zespol Specjalistyczny Chorob Pluc, Poznan, Poland|Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy, Warszawa, Poland|Pan American Center for Oncology Trials, LLC, Rio Piedras, Puerto Rico|Institutul Oncologic ""Prof. Dr. Ion Chiricuta"" Cluj-Napoca, Cluj-Napoca, Romania|Arkhangelsk Clinical Oncological Dispensary, Arkhangelsk, Arkhangel'skaya Oblast', Russian Federation|Hadassah Medical LTD, Moscow, Russian Federation|National medical research center of oncology n. a. N. N. Petrov, Saint Petersburg, Russian Federation|EuroCityClinic, Saint-Petersburg, Russian Federation|Parkway Cancer Centre, Singapore, Singapore|Tan Tock Seng Hospital, Singapore, Singapore|CHUS - Hospital Clinico Universitario, Santiago de Compostela, A Coruña [La Coruña], Spain|Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain|Hospital de Mataró, Mataró, Barcelona, Spain|Hospital Universitario Virgen de la Arrixaca, El Palmar, Murcia, Spain|Hospital Álvaro Cunqueiro, Vigo, Pontevedra, Spain|Hospital Universitario de Canarias, Santa Cruz de Tenerife, Tenerife, Spain|Hospital General de Albacete, Albacete, Spain|Hospital Germans Trias i Pujol, Badalona, Spain|Hospital del Mar, Barcelona, Spain|Hospital Universitari Dexeusa, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Clinic I Provincial, Barcelona, Spain|Institut Catala d'Oncologia, Barcelona, Spain|Hospital Universitario Puerta del Mar, Cadiz, Spain|Hospital Reina Sofia, Cordoba, Spain|Complejo Asistencial de Leon, Leon, Spain|Hospital Lucus Augusti, Lugo, Spain|MD Anderson, Madrid, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Regional Universitario, Malaga, Spain|Hospital Santa Maria Nai, Ourense, Spain|Hospital Son Llàtzer-ONCOLOGY, Palma de Mallorca, Spain|Hospital Univ Sant Joan de Reus, S.A., Reus, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Hospital Universitario La Fe de Valencia, Valencia, Spain|Sahlgrenska Universitetssjukhuset, Göteborg, Sweden|Changhua Christian Hospital, Changhua City, Changhua County, Taiwan|Chi Mei Hospital - Liouying Branch, Tainan City, Tainan, Taiwan|Kaohsiung Medical University Hospital, Kaohsiung, Taiwan|Chang Gung Memorial Hospital - Kaohsiung Branch, Kaohsiung, Taiwan|Chung Shan Medical University Hospital, Taichung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|National Taiwan University Cancer Centre, Taipei City, Taiwan|National Taiwan University Hospital, Taipei City, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Chang Gung Memorial Hospital - Linkou, Taoyuan City, Taiwan|Izmir Medical Park Hospital, Izmir, Karşıyaka/İzmir, Turkey|Baskent University Dr. Turgut Noyan Research and Training Center, Adana, Turkey|Adana Sehir Hastanesi, Adana, Turkey|Abdurrahman Yurtaslan Ankara Oncology, education and Research Hospital, Ankara, Turkey|Ankara City Hospital, Ankara, Turkey|Uludag University Medical Faculty, Bursa, Turkey|Dicle University, Diyarbakir, Turkey|Trakya University, Edirne, Turkey|Medipol Mega University Hospital, Istanbul, Turkey|Goztepe Prof Dr Suleyman Yalcin Sehir Hastanesi, Istanbul, Turkey|Ege University Medicine of Faculty, Izmir, Turkey|Izmir Katip Celebi University Training and Research Hospital Oncology, Izmir, Turkey|Memorial Antalya Hastanesi, Kepez, Turkey|Inonu University Medical Faculty Oncology, Malatya, Turkey|Maslak Acıbadem Hstanesi, Sarıyer, Turkey|CNPE ""Regional Center of Oncology"", Kharkiv, Kharkivska Oblast, Ukraine|Communal Noncommercial Enterprise ""Podillia Regional Oncology Center Of Vinnytsia Regional Council"", Vinnytsia, Vinnytska Oblast, Ukraine|Medical Center ""Mriya Med-Service"", LLC, Kryvyi Rig, Ukraine|Kyiv City Clinical Oncological Center, Kyiv, Ukraine|Communal Enterprise ""Odesa Regional Clinical Hospital"", Odesa, Ukraine|University clinic of Sumy State University, Sumy, Ukraine|Medical center ""Oncolife"", Zaporizhya, Ukraine|University College Hospital - London, London, Greater London, United Kingdom|The Clatterbridge Cancer Centre, Bebbington, Merseyside, United Kingdom|New Cross Hospital, Wolverhampton, West Midlands, United Kingdom|City Hospital, Nottingham University Hospitals, Nottingham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04819100"
848,"NCT04444700","A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care as a Rapid Response to (SARS-CoV-2) COVID-19 Pandemic","RAPID-BRAZIL","Completed","No Results Available","COVID|Coronavirus Infection|Severe Acute Respiratory Syndrome|Thromboembolism, Venous|Anticoagulants and Bleeding Disorders","Drug: Therapeutic anticoagulation","Composite outcome of ICU admission (yes/no), non-invasive positive pressure ventilation (yes/no), invasive mechanical ventilation (yes/no), or all-cause death (yes/no) up to 28 days.|All-cause death|Composite outcome of ICU admission or all-cause death|Composite outcome of mechanical ventilation or all-cause death|Major bleeding|Red blood cell transfusion|Transfusion of platelets, frozen plasma, prothrombin complex concentrate, cryoprecipiate and/or fibrinogen concentrate|Renal replacement therapy|Hospital-free days alive up to day 28|ICU-free days alive up to day 28|Ventilator-free days alive up to day 28|Organ support-free days alive up to day 28|Venous thromboembolism|Arterial thromboembolism|Heparin induced thrombocytopenia|Changes in D-dimer up to day 3","University of Sao Paulo General Hospital|Unity Health Toronto|University of Vermont Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 3","465","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CAAE: 33109220.7.0000.0068","July 4, 2020","May 10, 2021","October 14, 2021","June 23, 2020",,"October 26, 2021","Hospital das Clínicas da FMUSP, São Paulo, SP, Brazil",,"https://ClinicalTrials.gov/show/NCT04444700"
849,"NCT04362085","Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care",,"Completed","No Results Available","COVID-19","Drug: Therapeutic Anticoagulation","Composite outcome of ICU admission (yes/no), non-invasive positive pressure ventilation (yes/no), invasive mechanical ventilation (yes/no), or all-cause death (yes/no) up to 28 days.|All-cause death|Composite outcome of ICU admission or all-cause death|Composite outcome of mechanical ventilation or all-cause death|Major bleeding|Red blood cell transfusion|Transfusion of platelets, frozen plasma, prothrombin complex concentrate, cryoprecipiate and/or fibrinogen concentrate|Renal replacement therapy|Hospital-free days alive up to day 28|ICU-free days alive up to day 28|Ventilator-free days alive up to day 28|Organ support-free days alive up to day 28|Venous thromboembolism|Arterial thromboembolism|Heparin induced thrombocytopenia|Changes in D-dimer up to day 3","Unity Health Toronto|University of Vermont Medical Center|University of Sao Paulo|Hôpital Charles Lemoyne|William Osler Health System|MOUNT SINAI HOSPITAL|Trillium Health Partners|St. Joseph's Health Centre|The Ottawa Hospital|Hopital du Sacre-Coeur de Montreal|Michael Garron Hospital|University of Alberta|Southlake Regional Health Centre|Hospital Maisonneuve-Rosemont|Queen Elizabeth II Health Sciences Centre|Foothills Medical Centre|Rockyview General Hospital|Peter Lougheed Centre|Mater Misericordiae University Hospital|King Saud University Medical City|King Fahad Medical City|King Faisal Specialist Hospital|Versiti|Barnes-Jewish Hospital|Al Ain Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 3","465","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RAPID COVID-COAG","May 11, 2020","May 10, 2021","October 14, 2021","April 24, 2020",,"October 26, 2021","St. Michael's Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04362085"
850,"NCT01511393","An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC)",,"Enrolling by invitation","No Results Available","Diabetes|Diabetes Mellitus, Type 2|Medullary Thyroid Carcinoma|Weight Management","Other: No treatment given","Annual incidence of MTC in the US to identify any possible increase related to the introduction of liraglutide, exenatide once-weekly, and other GLP-1 receptor agonists into the US market.|Family history of cancer (including history of MEN2A or MEN 2B, history of FMTC, history of RET proto-oncogene mutations), Patient demographic characteristics, Patient prior history of thyroid diseases|Dose and Duration of use of all previous diabetes medication exposures (including long acting and short acting GLP-1 receptor agonists, DPP4 inhibitors, and insulin)|Dose and Duration of use of all previous weight management drugs (including long acting GLP-1 receptor agonists).|Lifestyle factors such as smoking and alcohol use|Environmental exposures (occupational history, radioiodine exposure, nuclear fallout)","Novo Nordisk A/S|AstraZeneca|Eli Lilly and Company|United BioSource, LLC","All","18 Years and older   (Adult, Older Adult)",,"6750","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","NN2211-3965|U1111-1125-4362","January 2012","December 2035","December 2035","January 18, 2012",,"January 26, 2021","United BioSource, LLC, Morgantown, West Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01511393"
851,"NCT01934335","Effect of Vandetanib on Cellular Markers in Invasive Breast Cancer",,"Terminated","Has Results","Invasive Breast Cancer","Drug: Vandetanib|Other: Placebo","Percent Change From Baseline in Ki-67 Cells Observed 2 Weeks Post-treatment|Percent Change From Baseline in TUNEL Observed 2 Weeks Post-treatment","Ronald Weigel|AstraZeneca|University of Iowa","Female","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","12","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","201301763","October 2013","December 21, 2018","December 21, 2018","September 4, 2013","November 1, 2021","November 1, 2021","University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/35/NCT01934335/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/35/NCT01934335/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT01934335"
852,"NCT04188639","Emicizumab in Acquired Hemophilia A",,"Recruiting","No Results Available","Hemophilia A, Acquired","Drug: Emicizumab Injection","The number of clinically significant bleeds per patient-week until death or week 12 after starting emicizumab treatment, whatever occurs first|Incidence and severity of adverse events, thromboembolic events, thrombotic microangiopathy in the 12 weeks after starting emicizumab|Incidence of mortality and cause of death in the 24 weeks after starting emicizumab treatment|Days of treatment with and total dose of bypassing agents (recombinant factor VIIa, activated prothrombin complex concentrate) or recombinant porcine factor VIII (susoctocag alfa) or other factor VIII concentrates|Days in hospital during 12 weeks of emicizumab treatment|Number of patients achieving partial remission in the 24 weeks after starting emicizumab treatment","GWT-TUD GmbH|Hoffmann-La Roche|Hannover Medical School","All","18 Years and older   (Adult, Older Adult)","Phase 2","51","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AHA-EMI (MO41153)","March 23, 2021","September 2023","September 2024","December 6, 2019",,"August 19, 2021","LMU Klinikum, München, Bayern, Germany|Universitätsklinikum Regensburg, Regensburg, Bayern, Germany|Vivantes Klinikum im Friedrichshain, Berlin-Friedrichshain, Berlin, Germany|Universitätsklinikum Frankfurt, Frankfurt, Hessen, Germany|Medizinische Hochschule Hannover, Hannover, Niedersachsen, Germany|Universitätsklinikum des Saarlandes, Institut für Klinische Hämostaseologie und Transfusionsmedizin, Homburg / Saar, Saarland, Germany|Universitätsklinikum Dresden, Dresden, Sachsen, Germany|Universitätsklinikum Leipzig, Medizinische Klinik und Poliklinik I, Bereich Hämostaseologie, Leipzig, Sachsen, Germany|Universitätsklinikum Schleswig-Holstein, Kiel, Schleswig-Holstein, Germany|Universitätsklinikum Jena, Klinik für Innere Medizin II, Jena, Thüringen, Germany",,"https://ClinicalTrials.gov/show/NCT04188639"
853,"NCT02745041","Fibrinogen Early In Severe Trauma studY","FEISTY","Completed","No Results Available","Trauma|Haemorrhage|Coagulopathy","Drug: Fibrinogen Concentrate|Other: Cryoprecipitate","Time to administration of Fibrinogen Replacement from time of ROTEM analysis indicating fibrinogen supplementation is required First dose of Fibrinogen Concentrate or Cryoprecipitate required|Feasibility of administering FC within 30 mins of clinical scenario and ROTEM analysis suggesting Fibrinogen replacement is required|Effects on Fibrinogen levels during traumatic haemorrhage as measured by Clauss Fibrinogen|Effects on Fibrinogen levels during traumatic haemorrhage as measured by FIBTEM|Transfusion Requirements|Duration of bleeding episode or time until surgical control|Intensive Care Unit Length of stay|Hospital Length of Stay|Adverse Events|All cause Mortality","Gold Coast Hospital and Health Service|Emergency Medicine Foundation|National Blood Authority|Australian Red Cross","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 2","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FEISTY-1","December 2016","January 20, 2018","February 20, 2018","April 20, 2016",,"March 5, 2018","Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia|Princess Alexandra Hospital, Brisbane, Queensland, Australia|Gold Coast University Hospital, Gold Coast, Queensland, Australia|Townsville Hospital, Townsville, Queensland, Australia",,"https://ClinicalTrials.gov/show/NCT02745041"
854,"NCT04150536","Pharmacokinetics and Adhesion of Lidocaine Topical System 1.8% Under Conditions of Heat and Exercise",,"Completed","No Results Available","Healthy","Drug: Lidocaine topical system 1.8%","Peak plasma concentration (Cmax) of lidocaine|Area under the Plasma Concentration-Time Curve (AUC) from Time 0 to Time 48 hours|Area under the Plasma Concentration-Time Curve (AUC) from Time 0 to Time Infinity|Cumulative Adhesion Score|Dermal Response Score","Scilex Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","12","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","SCI-LIDO-HEX-001","January 8, 2016","January 25, 2016","January 25, 2016","November 4, 2019",,"November 4, 2019",,,"https://ClinicalTrials.gov/show/NCT04150536"
855,"NCT03486392","A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese Participants",,"Completed","Has Results","Obesity","Drug: JNJ-64565111 Dose Level 1|Drug: JNJ-64565111 Dose Level 2|Drug: JNJ-64565111 Dose Level 3|Drug: Liraglutide|Drug: Placebo","Percent Change From Baseline in Body Weight at Week 26|Number of Participants With Treatment Emergent Adverse Events (TEAEs)|Number of Participants With Greater Than or Equal to (>=) 5 Percent (%) Body Weight Loss at Week 26|Number of Participants With Greater Than or Equal to 10 % Body Weight Loss at Week 26|Change From Baseline in Body Weight at Week 26","Janssen Research & Development, LLC","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","474","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CR108314|64565111OBE2001|2017-003616-39","March 26, 2018","March 8, 2019","March 8, 2019","April 3, 2018","February 5, 2020","February 5, 2020","Central Phoenix Medical Clinic, Phoenix, Arizona, United States|Diablo Clinical Research, Inc., Walnut Creek, California, United States|Care Partners Clinical Research, Jacksonville, Florida, United States|Advanced Clinical Research, Boise, Idaho, United States|Medisphere Medical Research Center, Llc, Evansville, Indiana, United States|L-Marc Research Center, Louisville, Kentucky, United States|Milford Emergency Associates, Inc., Marlborough, Massachusetts, United States|Central New York Clinical Research, Manlius, New York, United States|Weill Cornell Medicine, New York, New York, United States|Rapid Medical Research, Cleveland, Ohio, United States|Omega Medical Research, Warwick, Rhode Island, United States|Coastal Carolina Research Center, Mount Pleasant, South Carolina, United States|Dallas Diabetes Research Center, Dallas, Texas, United States|Permian Research Foundation, Odessa, Texas, United States|Advanced Clinical Research, West Jordan, Utah, United States|Rainier Clinical Research Center, Renton, Washington, United States|Allegiance Reserach Specialists, LLC, Wauwatosa, Wisconsin, United States|OLV Ziekenhuis Aalst, Aalst, Belgium|CSL Arlon, Arlon, Belgium|UZ Antwerpen, Edegem, Belgium|UZ Leuven, Leuven, Belgium|CHU de Liège, Liège, Belgium|AZ Delta, Roeselare, Belgium|AZ Glorieux Ronse, Ronse, Belgium|Practimed Medical Center, Tessenderlo, Belgium|Joanne F. Liutkus Medicine Professional Corporation, Cambridge, Ontario, Canada|Canadian Phase Onward, Toronto, Ontario, Canada|Dr. Anil K Gupta Medicine Professional Corporation, Toronto, Ontario, Canada|Manna Research, Toronto, Ontario, Canada|Manna Research, Levis, Quebec, Canada|Manna Research, Pointe Claire, Quebec, Canada|Clinique des Maladies Lipidiques de Québec, Québec, Quebec, Canada|Indywidualna Praktyka Lekarska, Gabinet Leczenia Otyłości i Chorób Dietozależnych, Białystok, Poland|Centrum Badań Klinicznych PI-House sp. z o.o., Gdańsk, Poland|Nzoz Salvia, Katowice-Ligota, Poland|NZOZ 'Linia' Centrum Leczenia Zaburzeń Metabolicznych Magdalena Olszanecka-Glinianowicz, Katowice, Poland|Centrum Zdrowia Metabolicznego Paweł Bogdański, Poznan, Poland|Katarina Berndtsson-Blom Ladulaaskliniken, Borås, Sweden|PTC,Primary care Trial Center, Goteborg, Sweden|Intern Medicin, Göteborg, Sweden|PharmaSite, Helsingborg, Sweden|PharmaSite, Malmo, Sweden|PTC- Skaraborg, Skövde, Sweden|Avdelningen för kliniska prövningar, Örebro, Sweden|Southmead Hospital, Bristol, United Kingdom|Ashgate Medical Practice, Chesterfield, United Kingdom|Hathaway Medical Centre, Chippenham, United Kingdom|Aintree University Hospital NHS Trust, Liverpool, United Kingdom|Clifton Medical Centre, Rotherham, United Kingdom|Albany House Medical Centre, Wellingborough, United Kingdom|Bradford on Avon and Melksham Health Partnership, Wiltshire, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/92/NCT03486392/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/92/NCT03486392/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03486392"
856,"NCT03690388","A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy",,"Active, not recruiting","No Results Available","Differentiated Thyroid Cancer","Drug: Cabozantinib|Drug: Placebo","Progression Free Survival (PFS)|Objective Response Rate (ORR)","Exelixis","All","16 Years and older   (Child, Adult, Older Adult)","Phase 3","258","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","XL184-311","October 5, 2018","August 19, 2020","December 2022","October 1, 2018",,"July 15, 2021","Exelixis Clinical Site #2, Newport Beach, California, United States|Exelixis Clinical Site #98, Sacramento, California, United States|Exelixis Clinical Site #69, San Francisco, California, United States|Exelixis Clinical Site #10, Stanford, California, United States|Exelixis Clinical Site #3, Torrance, California, United States|Exelixis Clinical Site #9, Aurora, Colorado, United States|Exelixis Clinical Site #21, New Haven, Connecticut, United States|Exelixis Clinical Site #4, Washington, District of Columbia, United States|Exelixis Clinical Site #94, Miami, Florida, United States|Exelixis Clinical Site #93, Orlando, Florida, United States|Exelixis Clinical Site #6, Tampa, Florida, United States|Exelixis Clinical Site #164, Chicago, Illinois, United States|Exelixis Clinical Site #54, Lexington, Kentucky, United States|Exelixis Clinical Site #153, Boston, Massachusetts, United States|Exelixis Clinical Site #80, Ann Arbor, Michigan, United States|Exelixis Clinical Site #78, Detroit, Michigan, United States|Exelixis Clinical Site #22, Detroit, Michigan, United States|Exelixis Clinical Site #63, Columbia, Missouri, United States|Exelixis Clinical Site #42, Saint Louis, Missouri, United States|Exelixis Clinical Site #11, Omaha, Nebraska, United States|Exelixis Clinical Site #118, Morristown, New Jersey, United States|Exelixis Clinical Site #76, Charlotte, North Carolina, United States|Exelixis Clinical Site #19, Durham, North Carolina, United States|Exelixis Clinical Site #7, Cincinnati, Ohio, United States|Exelixis Clinical Site #5, Easton, Pennsylvania, United States|Exelixis Clinical Site #1, Philadelphia, Pennsylvania, United States|Exelixis Clinical Site #75, Pittsburgh, Pennsylvania, United States|Exelixis Clinical Site #134, Charleston, South Carolina, United States|Exelixis Clinical Site #68, Nashville, Tennessee, United States|Exelixis Clinical Site #8, Houston, Texas, United States|Exelixis Clinical Site #113, Seattle, Washington, United States|Exelixis Clinical Site #96, Pergamino, Buenos Aires, Argentina|Exelixis Clinical Site #97, Caba, Argentina|Exelixis Clinical Site #129, Córdoba, Argentina|Exelixis Clinical Site #17, St. Leonards, New South Wales, Australia|Exelixis Clinical Site #25, Waratah, New South Wales, Australia|Exelixis Clinical Site #86, Bedford Park, South Australia, Australia|Exelixis Clinical Site #24, Melbourne, Victoria, Australia|Exelixis Clinical Site #12, Herston, Australia|Exelixis Clinical Site #62, Salzburg, Austria|Exelixis Clinical Site #119, Vienna, Austria|Exelixis Clinical Site #90, Brussels, Belgium|Exelixis Clinical Site #31, Brussels, Belgium|Exelixis Clinical Site #26, Edegem, Belgium|Exelixis Clinical Site #74, Edegem, Belgium|Exelixis Clinical Site #100, Gent, Belgium|Exelixis Clinical Site #27, Namur, Belgium|Exelixis Clinical Site #35, Cascavel, Parana, Brazil|Exelixis Clinical Site #39, Porto Alegre, Rio Grande Do Sul, Brazil|Exelixis Clinical Site #140, Porto Alegre, Rio Grande Do Sul, Brazil|Exelixis Clinical Site #38, Porto Alegre, Rio Grande Do Sul, Brazil|Exelixis Clinical Site #40, Sao Jose do Rio Preto, Sao Paulo, Brazil|Exelixis Clinical Site #116, Ribeirão Preto, São Paulo, Brazil|Exelixis Clinical Site #92, Rio De Janeiro, Brazil|Exelixis Clinical Site #47, Sao Paulo, Brazil|Exelixis Clinical Site #20, Calgary, Alberta, Canada|Exelixis Clinical Site #18, Edmonton, Alberta, Canada|Exelixis Clinical Site #107, London, Ontario, Canada|Exelixis Clinical Site #83, Toronto, Ontario, Canada|Exelixis Clinical Site #145, Osijek, Croatia|Exelixis Clinical Site #137, Zagreb, Croatia|Exelixis Clinical Site #138, Zagreb, Croatia|Exelixis Clinical Site #105, Brno, Czechia|Exelixis Clinical Site #104, Olomouc, Czechia|Exelixis Clinical Site #32, Dijon, Bourgogne-Franche-Comte, France|Exelixis Clinical Site #44, Villejuif, Ile De France, France|Exelixis Clinical Site #67, Bordeaux, Nouvelle - Aquitaine, France|Exelixis Clinical Site #45, Angers, Pays De La Loire, France|Exelixis Clinical Site #72, Marseille, Provence-Alpes-Cote d'Azur, France|Exelixis Clinical Site #102, Besançon, France|Exelixis Clinical Site #91, Lyon Cedex 08, France|Exelixis Clinical Site #82, Nice, France|Exelixis Clinical Site #152, Paris, France|Exelixis Clinical Site #95, Strasbourg Cedex, France|Exelixis Clinical Site #121, Tübingen, Baden-Württemberg, Germany|Exelixis Clinical Site #156, Würzburg, Bayern, Germany|Exelixis Clinical Site #125, Marburg, Hesse, Germany|Exelixis Clinical Site #163, Hannover, Lower Saxony, Germany|Exelixis Clinical Site #124, Magdeburg, Sachsen-Anhalt, Germany|Exelixis Clinical Site #151, Dresden, Saxony, Germany|Exelixis Clinical Site #155, Aachen, Germany|Exelixis Clinical Site #131, Bonn, Germany|Exelixis Clinical Site #154, Essen, Germany|Exelixis Clinical Site #160, Freiburg, Germany|Exelixis Clinical Site #159, Hamburg, Germany|Exelixis Clinical Site #139, München, Germany|Exelixis Clinical Site #28, Hong Kong, Hong Kong|Exelixis Clinical Site #46, Budapest, Hungary|Exelixis Clinical Site #37, Pecs, Hungary|Exelixis Clinical Site #43, Haifa, Israel|Exelixis Clinical Site #41, Jerusalem, Israel|Exelixis Clinical Site #58, Petah tikva, Israel|Exelixis Clinical Site #109, Viagrande, Catania, Italy|Exelixis Clinical Site #135, Catania, CT, Italy|Exelixis Clinical Site #132, Meldola, Forlì - Cesena, Italy|Exelixis Clinical Site #144, Genova, GE, Italy|Exelixis Clinical Site #143, Rozzano, Milano, Italy|Exelixis Clinical Site #29, Pisa, PI, Italy|Exelixis Clinical Site #120, Torino, TO, Italy|Exelixis Clinical Site #103, Milano, Italy|Exelixis Clinical Site #110, Milano, Italy|Exelixis Clinical Site #115, Milano, Italy|Exelixis Clinical Site #108, Napoli, Italy|Exelixis Clinical Site #56, Napoli, Italy|Exelixis Clinical Site #123, Padova, Italy|Exelixis Clinical Site #87, Roma, Italy|Exelixis Clinical Site #127, Roma, Italy|Exelixis Clinical Site #111, Siena, Italy|Exelixis Clinical Site #70, Busan, Korea, Republic of|Exelixis Clinical Site #79, Gyeonggi-do, Korea, Republic of|Exelixis Clinical Site #36, Seoul, Korea, Republic of|Exelixis Clinical Site #34, Seoul, Korea, Republic of|Exelixis Clinical Site #158, Tuxtla Gutiérrez, Chiapas, Mexico|Exelixis Clinical Site #133, Ciudad de Mèxico, Mexico|Exelixis Clinical Site #147, Ciudad de México, Mexico|Exelixis Clinical Site #148, Ciudad de México, Mexico|Exelixis Clinical Site #161, San Luis Potosí, Mexico|Exelixis Clinical Site #128, Amsterdam, Noord-Holland, Netherlands|Exelixis Clinical Site #117, Leiden, Zuid-Holland, Netherlands|Exelixis Clinical Site #15, Warszawa, Mazowieckie, Poland|Exelixis Clinical Site #61, Gliwice, Slaskie, Poland|Exelixis Clinical Site #59, Poznan, Wielkopolskie, Poland|Exelixis Clinical Site #149, Cluj-Napoca, Cluj, Romania|Exelixis Clinical Site #150, Craiova, Dolj, Romania|Exelixis Clinical Site #142, Timişoara, Timis, Romania|Exelixis Clinical Site #146, Bucuresti, Romania|Exelixis Clinical Site #48, Obninsk, Kaluzhiskiy Region, Russian Federation|Exelixis Clinical Site #55, Kislino, Kursk Region, Russian Federation|Exelixis Clinical Site #157, Tyumen, Tyumen Region, Russian Federation|Exelixis Clinical Site #49, Moscow, Russian Federation|Exelixis Clinical Site #53, Moscow, Russian Federation|Exelixis Clinical Site #84, Moscow, Russian Federation|Exelixis Clinical Site #85, Moscow, Russian Federation|Exelixis Clinical Site #106, Omsk, Russian Federation|Exelixis Clinical Site #89, Saint Petersburg, Russian Federation|Exelixis Clinical Site #52, Samara, Russian Federation|Exelixis Clinical Site #66, Yaroslavl, Russian Federation|Exelixis Clinical Site #14, Barcelona, Spain|Exelixis Clinical Site #99, Barcelona, Spain|Exelixis Clinical Site #114, Madrid, Spain|Exelixis Clinical Site #30, Madrid, Spain|Exelixis Clinical Site #13, Madrid, Spain|Exelixis Clinical Site #16, Madrid, Spain|Exelixis Clinical Site #33, Madrid, Spain|Exelixis Clinical Site #73, Madrid, Spain|Exelixis Clinical Site #23, Madrid, Spain|Exelixis Clinical Site #81, Málaga, Spain|Exelixis Clinical Site #136, Tainan, Taiwan|Exelixis Clinical Site #112, Tainan, Taiwan|Exelixis Clinical Site #77, Taipei, Taiwan|Exelixis Clinical Site #101, Taipei, Taiwan|Exelixis Clinical Site #126, Bangkok Noi, Bangkok, Thailand|Exelixis Clinical Site #122, Pathum Wan, Bangkok, Thailand|Exelixis Clinical Site #141, Ratchathewi, Bangkok, Thailand|Exelixis Clinical Site #130, Hat Yai, Songkla, Thailand|Exelixis Clinical Site #88, Birmingham, England, United Kingdom|Exelixis Clinical Site #71, Bristol, England, United Kingdom|Exelixis Clinical Site #162, London, England, United Kingdom|Exelixis Clinical Site #51, Oxford, England, United Kingdom|Exelixis Clinical Site #64, Aberdeen, Scotland, United Kingdom|Exelixis Clinical Site #50, Glasgow, Scotland, United Kingdom|Exelixis Clinical Site #60, Cardiff, Wales, United Kingdom|Exelixis Clinical Site #65, Manchester, United Kingdom|Exelixis Clinical Site #57, Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03690388"
857,"NCT00295763","A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen.",,"Completed","No Results Available","Differentiated Thyroid Cancer","Drug: Thyrogen (thyrotropin alfa for injection)","To confirm the status of thyroid remnant ablation by using Thyrogen stimulated radioiodine whole body scans (WBS) in patients previously treated in THYR-008-00.|To learn if there was recurrence of thyroid cancer in any of the patients previously treated in the THYR-008-00 study.|To assess Thyrogen-stimulated serum Tg measurements in patients previously treated in the THYR-008-00 study.|To assess safety information on repeat exposure to Thyrogen in patients previously treated in the THYR-008-00 study.","Genzyme, a Sanofi Company|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 3","61","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","THYR01605","May 2006","July 2006","September 2006","February 24, 2006",,"March 18, 2015","University of Colorado Health Sciences Centre, Aurora, Colorado, United States|Johns Hopkins University, Baltimore, Maryland, United States|Ohio State University, Columbus, Ohio, United States|MD Anderson Cancer Centre, Houston, Texas, United States|LHRI Research Services, London, Ontario, Canada|Centre Rene Huguenin, Saint Cloud, France|Institut Gustave Roussy, Villejuif, France|University of Wurzburg, Wurzburg, Germany|University of Pisa, Pisa, Italy",,"https://ClinicalTrials.gov/show/NCT00295763"
858,"NCT02013089","A Pilot Study of Genomic Sequencing Guided Individualized Therapy in Gastrointestinal Cancers, GITIC Study","GITIC","Unknown status","No Results Available","Gastrointestinal Cancers","Drug: Erlotinib or Gefitinib|Drug: Everolimus|Drug: Imatinib|Drug: Sorafenib or Sunitinib|Drug: Vandetanib","Overall survival|Response rate","Sun Yat-sen University","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GIHSYSU04","December 2013","May 2017","December 2017","December 17, 2013",,"August 30, 2016","Gastrointestinal Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT02013089"
859,"NCT04644315","A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors","ALpha-T","Recruiting","No Results Available","Neoplasms|Colorectal Neoplasms|Melanoma|Pancreatic Neoplasms|Sarcoma|Ovarian Neoplasms|Brain Neoplasms|Thyroid Neoplasms|Neuroendocrine Tumors|Cholangiocarcinoma|Salivary Gland Neoplasms|Head and Neck Neoplasms|Thyroid Cancer, Papillary|Lymphoma, Large-Cell, Anaplastic|Neoplasms by Site|Respiratory Tract Neoplasms|Thoracic Neoplasms|Respiratory Tract Diseases|Carcinoma, Bronchogenic|Bronchial Neoplasms|Intestinal Neoplasms|Gastrointestinal Neoplasms|Digestive System Neoplasms|Digestive System Diseases|Gastrointestinal Diseases|Colonic Diseases|Intestinal Diseases|Central Nervous System","Drug: Alectinib","Confirmed Objective Response Rate (ORR) as Determined by the Investigator per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)|Confirmed ORR as Determined by Blinded Independent Center Review (BICR) per RECIST v1.1|Duration of Response (DOR) as Determined by both the Investigator and by BICR per RECIST v1.1|Progression-Free Survival (PFS) as Determined by both the Investigator and by BICR per RECIST v1.1|Central Nervous System (CNS) ORR by BICR per RECIST v1.1|CNS DOR by BICR per RECIST v1.1|Overall Survival (OS)|Percentage of Participants with Adverse Events (AEs)|Percentage of Participants with Serious Adverse Events (SAEs)|Plasma Concentration of Alectinib|ORR in Participants with Primary CNS Tumors as Determined by both BICR and the Investigator per Response Assessment in Neuro-Oncology (RANO) Criteria|DOR in Participants with Primary CNS Tumors as Determined by both BICR and the Investigator per RANO Criteria|PFS in Participants with Primary CNS Tumors as Determined by both BICR and the Investigator per RANO Criteria|OS in Participants with Primary CNS Tumors","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 2","50","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BO41929","May 24, 2021","December 1, 2025","December 1, 2025","November 25, 2020",,"January 11, 2022","Science 37, Inc, Culver City, California, United States|Science 37, Inc, Culver City, California, United States|Science 37, Inc, Culver City, California, United States|Homebased Telemedicine, Los Angeles, California, United States|Homebased Telemedicine, Sacramento, California, United States|Homebased Telemedicine, San Diego, California, United States|Homebased Telemedicine, San Francisco, California, United States|Homebased Telemedicine, San Jose, California, United States|Homebased Telemedicine, Jacksonville, Florida, United States|Homebased Telemedicine, Miami, Florida, United States|Homebased Telemedicine, Orlando, Florida, United States|Homebased Telemedicine, Tampa, Florida, United States|Homebased Telemedicine, Fort Wayne, Indiana, United States|Homebased Telemedicine, Indianapolis, Indiana, United States|Homebased Telemedicine, Minneapolis, Minnesota, United States|Homebased Telemedicine, Saint Paul, Minnesota, United States|Homebased Telemedicine, Saint Louis, Missouri, United States|Homebased Telemedicine, Buffalo, New York, United States|Homebased Telemedicine, New York, New York, United States|Homebased Telemedicine, Philadelphia, Pennsylvania, United States|Homebased Telemedicine, Pittsburgh, Pennsylvania, United States|Homebased Telemedicine, Austin, Texas, United States|Homebased Telemedicine, Dallas, Texas, United States|Homebased Telemedicine, Houston, Texas, United States|Homebased Telemedicine, Richmond, Virginia, United States|Homebased Telemedicine, Virginia Beach, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT04644315"
860,"NCT02650401","Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options","STARTRK-NG","Recruiting","No Results Available","Solid Tumors|CNS Tumors","Drug: Entrectinib","Maximum Tolerated Dose (MTD)|Recommended Phase 2 Dose (RP2D) of F1 Formulation In Pediatric Participants Able To Swallow Intact Capsules|Recommended Phase 2 Dose (RP2D) of F06 Formulation In Pediatric Participants Able To Swallow Intact Capsules|Recommended Phase 2 Dose (RP2D) of F06 Formulation In Pediatric In Participants Dosed Via Feeding Tube (Nasogastric Tube Or Gastric Tube)|Recommended Phase 2 Dose (RP2D) Of Minitablets/F15 Formulation In Pediatric Participants Unable To Swallow Intact Capsules|Objective Response Rate (ORR)|Safety and Tolerability - AE, ECG and Labs assessed by NCI CTCAE v4.03|Maximum observed plasma drug concentration (Cmax) using F1 Formulation|Maximum observed plasma drug concentration (Cmax) using F06 Formulation given intact|Maximum observed plasma drug concentration (Cmax) using F06 Formulation administered via feeding tube|Maximum observed plasma drug concentration (Cmax) using minitablets/F15|Time to Cmax, by inspection (Tmax) using F1 Formulation|Time to Cmax, by inspection (Tmax) using F06 Formulation given intact|Time to Cmax, by inspection (Tmax) using F06 Formulation administered via feeding tube|Time to Cmax, by inspection (Tmax) using minitablets/F15|AUC at steady state (AUCss) using F1 Formulation|AUC at steady state (AUCss) using F06 Formulation given intact|AUC at steady state (AUCss) using F06 Formulation administered via feeding tube|AUC at steady state (AUCss) using minitablets/F15|Terminal half life (t½) using F1 Formulation|Terminal half life (t½) using F06 Formulation given intact|Terminal half life (t½) using F06 Formulation administered via feeding tube|Terminal half life (t½) using minitablets/F15|Area under the drug concentration by time curve (AUC) using F1 Formulation|Area under the drug concentration by time curve (AUC) using F06 Formulation given intact|Area under the drug concentration by time curve (AUC) using F06 Formulation administered via feeding tube|Area under the drug concentration by time curve (AUC) using minitablets/F15|Progression-free Survival (PFS)|Overall Survival (OS)|Duration of Response (DOR)|Time to response (TTR)|Clinical Benefit Rate (CBR)","Hoffmann-La Roche","All","up to 18 Years   (Child, Adult)","Phase 1|Phase 2","68","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RXDX-101-03|CO40778","May 3, 2016","August 30, 2029","August 30, 2029","January 8, 2016",,"January 19, 2022","Children'S Hospital of Orange County, Orange, California, United States|Rady Childrens Hospital, San Diego, California, United States|UCSF Benioff Children's Hospital; UCSF Pediatrics Hematology Oncology, San Francisco, California, United States|Children's Hospital Colorado; Center For Cancer/Blood Disorder, Aurora, Colorado, United States|Children's National Medical Center; Department of Pediatrics, Washington, District of Columbia, United States|Egleston Children's Hospital at Emory University Atlanta; Pediatric Hematology/Oncology, Atlanta, Georgia, United States|University of Chicago; Comer Children's Hospital/Department of Pediatrics, Chicago, Illinois, United States|Johns Hopkins University, Baltimore, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|University of Minnesota Childrens' Hospital, Minneapolis, Minnesota, United States|Washington University,St. Louis Children's Hospital; Neurology, Movement Disorder, Saint Louis, Missouri, United States|Morgan Stanley Children's Hospital; Herbert Irving Cancer Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center; Pediatrics, New York, New York, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Nationwide Children's Hospital; Dept. of Pulmonology, Columbus, Ohio, United States|Oregon Health & Science Uni, Portland, Oregon, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|St. Jude Children'S Research Hospital, Memphis, Tennessee, United States|Cook Childrens Medical Center, Fort Worth, Texas, United States|Texas Children's Cancer and Hematology Center, Houston, Texas, United States|Primary Children's Hospital, Salt Lake City, Utah, United States|The Hospital for Sick Children, Toronto, Ontario, Canada|Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China|Centre Leon Berard; Pediatrie, Lyon, France|Hôpital de la Timone, Oncologie Pédiatrique, Marseille, France|Hopital Purpan; Pédiatrie - Hématologie - Oncologie pédiatrique, Toulouse, France|Institut Gustave Roussy; Service de Pathologie Morphologique, Villejuif, France|Universitätsklinikum Heidelberg, Heidelberg, Germany|Hong Kong Children's Hospital, Hong Kong, Hong Kong|Fondazione IRCCS Istituto Nazionale dei Tumori; Struttura Complessa di Pediatria Oncologica, Milano, Lombardia, Italy|A. O. Città della Salute e della Scienza di Torino; SC Oncoematologia e Centro Trapianti AOOIRM, Torino, Piemonte, Italy|Seoul National University Hospital, Seoul, Korea, Republic of|Hospital Sant Joan de Deu; Servicio de Oncologia y Hematologia, Esplugues de Llobregat, Barcelona, Spain|Hospital Infantil Universitario Niño Jesus; Servicio de Onco-hematologia, Madrid, Spain|National Taiwan University Hospital; Department of Paediatrics, Taipei, Taiwan|Chang Gung Memorial Hospital, Linkou; Department of Pediatric Internal Medicine, Taoyuan City, Taiwan|Leeds General Infirmary, Leeds, United Kingdom|Royal Victoria Infirmary; Pharmacy, Newcastle upon Tyne, United Kingdom|Royal Marsden NHS Foundation Trust, Sutton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02650401"
861,"NCT04222972","A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)","AcceleRET-Lung","Recruiting","No Results Available","RET-fusion Non Small Cell Lung Cancer|Lung Neoplasm|Carcinoma, Non-Small-Cell Lung|Respiratory Tract Neoplasms|Thoracic Neoplasms|Neoplasms by Site|Neoplasms|Lung Diseases|Respiratory Tract Disease|Carcinoma, Bronchogenic|Bronchial Diseases|Head and Neck Neoplasms|Adenocarcinoma|Carcinoma|Neoplasms by Histologic Type|Neoplasms, Germ Cell and Embryonal|Neoplasms, Nerve Tissue","Drug: Pralsetinib|Drug: Carboplatin|Drug: Cisplatin|Drug: Pemetrexed|Drug: Pembrolizumab|Drug: Gemcitabine|Drug: Paclitaxel|Drug: Nab-Paclitaxel","Progression Free Survival (PFS)|Overall Response Rate (ORR)|Overall Survival (OS)|Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|Changes in Eastern Cooperative Oncology Group Performance Status (ECOG PS)|Duration of Response (DOR)|Clinical Benefit Rate (CBR)|Disease Control Rate (DCR)|European Organization for Research and Treatment of Cancer Quality of Life (EORTC-QLQ)-C30 Questionnaires|European Organization for Research and Treatment of Cancer Quality of Life (EORTC-QLQ)-LC13 Scores","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 3","226","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BO42864|2019-002463-10|BLU-667-2303","July 24, 2020","September 30, 2023","December 31, 2024","January 10, 2020",,"May 27, 2021","UC Irvine Medical Center, Orange, California, United States|Southern California Kaiser Permanente, San Diego, California, United States|Sylvester Comprehensive Cancer Center; University of Miami School of Medicine, Miami, Florida, United States|University of Maryland Marlene and Stewart Greenebaum Cancer Center, Baltimore, Maryland, United States|University of Michigan Hospital, Ann Arbor, Michigan, United States|UPMC - Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States|University of Texas Health Science Center, Dallas, Texas, United States|Millennium Oncology, Houston, Texas, United States|Royal North Shore Hospital; Department of Medical Oncology, St Leonards, New South Wales, Australia|Flinders Medical Centre, Bedford Park, South Australia, Australia|Institut Jules Bordet; Pulmonary Oncology, Bruxelles, Belgium|UZ Antwerpen, Edegem, Belgium|Rigshospitalet, Onkologisk Klinik; Klinisk Forskningsenhed, København Ø, Denmark|Helsinki University Central Hospital; Dept of Oncology, Helsinki, Finland|Institut Bergonie CLCC Bordeaux, Bordeaux, France|Hôpital Ambroise Paré - Boulogne-Billancourt, Boulogne Billancourt, France|Hôpital Louis Pradel, Hospices Civils de Lyon, Bron, France|CHRU Lille Service de Pneumologie et Oncologie Thoracique, Lille, France|Institut Paoli Calmettes; Oncologie Medicale, Marseille, France|Hopital Bichat Claude Bernard; Oncologie Serv., Paris, France|Institut Curie; Oncologie Medicale, Paris, France|Hopital Tenon;Pneumologie, Paris, France|Hopital de Pontchaillou; Service de Pneumologie, Rennes, France|Ico Rene Gauducheau; Oncologie, Saint Herblain, France|CHU Strasbourg - Nouvel Hopital Civil, Strasbourg, France|CHU de Toulouse - Hôpital Larrey; Service de pneumologie et oncologie pneumologique, Toulouse cedex 9, France|Institut Gustave Roussy; Departement Oncologie Medicale, Villejuif, France|Helios Klinikum Emil von Behring GmbH, Berlin, Germany|Universitätsklinikum Carl Gustav Carus, Medizinische Klinik I, Pneumologie MK1-A13, Dresden, Germany|Universitaetsklinikum Essen; Westdeutsches Tumorzentrum; Innere Klinik (Tumorforschung), Essen, Germany|Klinikum Esslingen, Esslingen, Germany|Universitätsklinikum Frankfurt; Medizinische Klinik II; Onkologie, Frankfurt, Germany|Asklepios-Fachkliniken Muenchen-Gauting; Onkologie, Gauting, Germany|Universitätsklinikum Hamburg-Eppendorf; Med. II. Klinik, Hamburg, Germany|Thoraxklinik Heidelberg gGmbH, Heidelberg, Germany|Klinikum der Universität München; Campus Großhadern; Med. Klinik und Poliklinik V, München, Germany|Pius-Hospital; Klinik fuer Haematologie und Onkologie, Oldenburg, Germany|Leopoldina-Krankenhaus Medizinische Klinik II, Schweinfurt, Germany|Klinik Schillerhöhe; Pneumologische Onkologie, Stuttgart, Germany|St. James Hospital; Oncology, Dublin, Ireland|Ospedale Clinicizzato SS Annunziata, Chieti, Abruzzo, Italy|Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G. Pascale, Napoli, Campania, Italy|Università degli Studi della Campania Luigi Vanvitelli, Napoli, Campania, Italy|Ospedale Provinciale Santa Maria Delle Croci; Oncologia Medica, Ravenna, Emilia-Romagna, Italy|Istituto Nazionale Tumori Regina Elena, Roma, Lazio, Italy|AZ. Ospedaliera San Giovanni - Addolorata, Roma, Lazio, Italy|Azienda Ospedaliera Sant'Andrea, Roma, Lazio, Italy|Irccs Ospedale San Raffaele, Milano, Lombardia, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Lombardia, Italy|Istituto Europeo Di Oncologia, Milano, Lombardia, Italy|A.O.U. Maggiore della Carità, Novara, Piemonte, Italy|IRCCS Giovanni Paolo II Istituto Oncologico, Bari, Puglia, Italy|Azienda Ospedaliera Universitaria Pisana - Ospedale Cisanello; Dipartimento Cardio Toraco Vascolare, Pisa, Toscana, Italy|IOV - Istituto Oncologico Veneto - IRCCS; Oncologia Medica II, Padova, Veneto, Italy|Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Borgo Roma, Verona, Veneto, Italy|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|NKI/AvL, Amsterdam, Netherlands|Universitair Medisch Centrum Groningen, Groningen, Netherlands|Maastricht University Medical Center, Maastricht, Netherlands|Oslo universitetssykehus HF, Ullevål, Kreftsenteret, Oslo, Norway|Narod.Inst.Onkol. im. M.Sklodowskiej - Curie-Panst.Inst.Bad; Klinika Nowot.Pluca i Klatki Piers, Warszawa, Poland|Hospital Garcia de Orta; Servico de Pneumologia, Almada, Portugal|Hospital de Braga; Serviço de Pneumologia, Braga, Portugal|IPO do Porto; Servico de Oncologia Medica, Porto, Portugal|Centro Hospitalar de Vila Nova de Gaia / Espinho E.P.E, Vila Nova de Gaia, Portugal|Hospital Univ. Central de Asturias; Servicio de Oncologia, Oviedo, Asturias, Spain|Hospital Universitario Germans Trias i Pujol, Badalona, Barcelona, Spain|Hospital Universitario Marques de Valdecilla; Servicio de Oncologia, Santander, Cantabria, Spain|Complejo Hospitalario Universitario A Coruña, A Coruña, LA Coruña, Spain|Hospital Universitario Puerta de Hierro; Servicio de Oncologia, Majadahonda, Madrid, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Clínic. Barcelona, Barcelona, Spain|Hospital General Universitario Gregorio Marañon; Servicio de Oncologia, Madrid, Spain|Hospital Ramon y Cajal; Servicio de Oncologia, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|HOSPITAL DE MADRID NORTE SANCHINARRO- CENTRO INTEGRAL ONCOLOGICO CLARA CAMPAL; Servicio de Oncologia, Madrid, Spain|Hospital Regional Universitario de Malaga, Malaga, Spain|Hospital Universitario Virgen del Rocio; Servicio de Oncologia, Sevilla, Spain|Hospital General Universitario de Valencia; Servicio de oncologia, Valencia, Spain|Hosp Clinico Univ Lozano Blesa; División De Oncología Médica, Zaragoza, Spain|Karolinska Universitetssjukhuset, Solna; Kliniska prövningsenheten Z:4:01, Stockholm, Sweden|UniversitätsSpital Zürich; Zentrum für Hämatologie und Onkologie, Klinik für Onkologie, Zürich, Switzerland|Adana City Hospital, Medical Oncology, Adana, Turkey|Velindre Cancer Centre; Oncology Dept, Cardiff, United Kingdom|Leicester Royal Infirmary; Dept. of Medical Oncology, Leicester, United Kingdom|University College Hospital; Department of Oncology, London, United Kingdom|Guys & St Thomas Hospital; Department of Oncology, London, United Kingdom|Royal Marsden Hospital; Dept of Med-Onc, London, United Kingdom|Christie Hospital Nhs Trust; Medical Oncology, Manchester, United Kingdom|Royal Marsden Hospital; Dept of Medical Oncology, Sutton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04222972"
862,"NCT03535090","Coagulation After Intravenous Methylprednisolone Administration",,"Completed","No Results Available","Graves' Disease|Graves Ophthalmopathy|Blood Coagulation|Venous Thromboembolism","Drug: Methylprednisolone","Change in activity of coagulation factor VIII from baseline (before administration of methylprednisolone) to 24 hours after first intravenous pulse|Change in activity of coagulation factor VIII from baseline (before therapy) to the end of the course of therapy with methylprednisolone|Change in of activated partial thromboplastin time (seconds) from baseline (before administration of methylprednisolone) to 24 hours after first intravenous pulse|Change in activated partial thromboplastin time (seconds) from baseline (before therapy) to the end of the course of therapy with methylprednisolone|Change in activity of coagulation factor II from baseline (before administration of methylprednisolone) to 24 hours after first intravenous pulse|Change in activity of coagulation factor V from baseline (before administration of methylprednisolone) to 24 hours after first intravenous pulse|Change in activity of coagulation factor VII from baseline (before administration of methylprednisolone) to 24 hours after first intravenous pulse|Change in prothrombin time (seconds) from baseline (before administration of methylprednisolone) to 24 hours after first intravenous pulse|Change in fibrinogen (mg/dl) from baseline (before administration of methylprednisolone) to 24 hours after first intravenous pulse|Change in D-Dimer (ng/dl) from baseline (before administration of methylprednisolone) to 24 hours after first intravenous pulse|Change in PLT count from baseline (before administration of methylprednisolone) to 24 hours after first intravenous pulse|Change in activity of coagulation factor II from baseline (before therapy) to the end of the course of therapy with methylprednisolone|Change in activity of coagulation factor V from baseline (before therapy) to the end of the course of therapy with methylprednisolone|Change in activity of coagulation factor VII from baseline (before therapy) to the end of the course of therapy with methylprednisolone|Change in prothrombin time (seconds) from baseline (before therapy) to the end of the course of therapy with methylprednisolone|Change in fibrinogen (mg/dl) from baseline (before therapy) to the end of the course of therapy with methylprednisolone|Change in D-Dimer (ng/dl) from baseline (before therapy) to the end of the course of therapy with methylprednisolone|Change in PLT count from baseline (before therapy) to the end of the course of therapy with methylprednisolone","Piotr Miskiewicz|Medical University of Warsaw","All","18 Years and older   (Adult, Older Adult)",,"26","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IVMPCoagulation","January 1, 2011","December 31, 2014","December 31, 2014","May 24, 2018",,"May 24, 2018",,,"https://ClinicalTrials.gov/show/NCT03535090"
863,"NCT02698969","Recovery of Muscle Function After Deep Neuromuscular Block by Means of Diaphragm Ultrasonography",,"Unknown status","No Results Available","Post-operative Residual Curarization","Drug: Sugammadex|Device: Diaphragm Ultrasonography|Drug: Neostigmine|Drug: Atropine|Device: Neurumuscual monitoring|Drug: Rocuronium|Drug: Fentanyl|Drug: Propofol|Drug: Sevoflurane","Number of participants with post-operative residual curarization (PORC) as assessed by diaphragm ultrasonography in order to determine its muscle strenght|Number of participants with post-operative complications related to PORC such as pneumonia as assessed chest x ray, drop of SpO2 by means of pulse oximeter and blood gas sample.|Number of participants with post-operative nausea and vomiting (PONV) as assessed by postoperative nause and vomiting visual analogic scale (PONV VAS)","University of Florence|Merck Sharp & Dohme Corp.","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","58","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","EUDRACT 2013-004-787-62","November 2014","February 2017","July 2017","March 4, 2016",,"October 25, 2016","Azienda Ospdaliero Universitaria Careggi, Florence, Italy",,"https://ClinicalTrials.gov/show/NCT02698969"
864,"NCT02012231","Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.",,"Terminated","No Results Available","Melanoma|Thyroid Cancer|Colorectal Cancer|Non-small Cell Lung Cancer|Cholangiocarcinoma|Histiocytosis|Hairy Cell Leukemia","Drug: PLX8394","Phase 1 dose escalation: Identification of Recommended Phase 2 Dose Safety of PLX8394|Identification of Recommended Phase 2 dose (RP2D)","Fore Biotherapeutics","All","18 Years and older   (Adult, Older Adult)","Phase 1","5","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PLX120-01","February 2014","September 2014","June 2015","December 16, 2013",,"October 19, 2020","Scottsdale Healthcare, Scottsdale, Arizona, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Evergreen Hematology & Oncology, Spokane, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02012231"
865,"NCT00121628","A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer",,"Completed","No Results Available","Thyroid Cancer","Drug: AMG 706","Objective Response Rate (complete response and partial response) as defined by modified RECIST|Duration of response|Progression Free Survival|Changes in tumor markers|overall survival time|time to response|Tumour Related Symptoms (medullary thyroid cancer arm)|AMG 706 pharmacokinetic profile|patient reported outcome (EQ-5D)|Safety Endpoint: Incidence of treatment-emergent adverse events (including all, serious, treatment-related, and each by maximum severity).|Pharmacokinetic Enpoint: AMG 706 pharmacokinetic parameters (Cmax, t1/2, AUC0-24,C24)","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 2","184","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20040273","July 2005","November 2006","October 2010","July 21, 2005",,"October 9, 2013",,,"https://ClinicalTrials.gov/show/NCT00121628"
866,"NCT03561220","A Prospective Comparative Study of Outcomes With Proton and Photon Radiation in Prostate Cancer","COMPPARE","Recruiting","No Results Available","Prostate Cancer","Radiation: Standard of Care IMRT (Photon)|Radiation: Standard of Care Proton Therapy|Radiation: Proton Arm 1: Standard Proton Therapy|Radiation: Proton Arm 2: Hypofractionated Proton Therapy","Bowel urgency and bowel frequency Expanded Prostate Cancer Index Composite (EPIC) item scores|Grade 2 or higher toxicity for each adverse event assessed by CTCAE|Grade 2 or higher toxicity for each adverse event assessed by PRO-CTCAE.|Freedom from biochemical progression using PSA results.","University of Florida|Patient-Centered Outcomes Research Institute","Male","30 Years to 85 Years   (Adult, Older Adult)","Not Applicable","3000","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","COMPPARE|PCORI-6312|IRB201801001|OCR17881","July 5, 2018","February 15, 2026","April 1, 2026","June 19, 2018",,"January 20, 2022","University of Alabama at Birmingham (UAB), Birmingham, Alabama, United States|University of Arizona, Tucson, Arizona, United States|University of California San Diego, La Jolla, California, United States|Proton Therapy Treatment Center - Loma Linda University, Loma Linda, California, United States|Sutter Health, Roseville, California, United States|California Protons Cancer Therapy Center, San Diego, California, United States|Department of Radiation Oncology Davis Cancer Pavilion, Gainesville, Florida, United States|University of Florida Proton Therapy Institute, Jacksonville, Florida, United States|Ackerman Cancer Center, Jacksonville, Florida, United States|Mayo Clinic, Jacksonville, Florida, United States|University of Miami School of Medicine, Miami, Florida, United States|Miami Cancer Institute, Miami, Florida, United States|Orlando Health UF Health Center, Orlando, Florida, United States|Winship Cancer Institute - Emory University, Atlanta, Georgia, United States|University of Chicago, Chicago, Illinois, United States|Northwestern Medicine Proton Center, Warrenville, Illinois, United States|University of Kansas Medical Center, Lawrence, Kansas, United States|University of Louisville, Louisville, Kentucky, United States|Willis-Knighton Medical Center PTC, Shreveport, Louisiana, United States|Johns Hopkins University, Baltimore, Maryland, United States|University of Maryland, College Park, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Mayo Clinic Health System, Mankato, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|S Lee Kling Proton Therapy Center - Washington University Medical Center, Saint Louis, Missouri, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|ProCure Proton Therapy Center, Somerset, New Jersey, United States|New York Proton Center, New York, New York, United States|Weill Cornell, New York, New York, United States|The Univeristy of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|The Duke University Health System, Durham, North Carolina, United States|UNC- Rex Hospital, Raleigh, North Carolina, United States|University of Cincinnati Medical PTC, Cincinnati, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|University Hospitals- Seidman Cancer Center, Cleveland, Ohio, United States|Stephenson Cancer Center, Oklahoma City, Oklahoma, United States|Oregon Health & Science University, Portland, Oregon, United States|University of Pennsylvania--Penn Medicine, Philadelphia, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Provision CARES Proton Therapy Center Knoxville, Knoxville, Tennessee, United States|Texas Oncology, Austin, Texas, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Texas Center for Proton Therapy, Irving, Texas, United States|Texas Oncology - Longview, Longview, Texas, United States|Texas Oncology - McKinney, McKinney, Texas, United States|Texas Oncology - Plano West, Plano, Texas, United States|Texas Oncology - Waco, Waco, Texas, United States|University of Virginia, Charlottesville, Virginia, United States|Inova Schar Cancer Institute, Fairfax, Virginia, United States|Hampton University Proton Therapy Institute, Hampton, Virginia, United States|Seattle Care Alliance/University of Washington, Seattle, Washington, United States|Mayo Clinic Health System, Eau Claire, Wisconsin, United States|Mayo Clinic Health System-Franciscan Healthcare, Sparta, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT03561220"
867,"NCT05024747","A Bioequivalence Study of 21 Milligram (mg) Nicotine Transdermal Patches (NicoDerm CQ, GlaxoSmithKline [GSK] Dungarvan) Compared to the Current Marketed 21 mg Nicotine Transdermal Patches (NicoDerm CQ, Alza) in Healthy Adult Smokers",,"Completed","No Results Available","Tobacco Use Disorder","Drug: NicoDerm CQ patch (GSK Dungarvan)|Drug: NicoDerm CQ (Alza)","Assessment of Bioequivalence of NicoDerm CQ, GSK Dungarvan with NicoDerm CQ, Alza by Measuring Maximum Observed Plasma Nicotine Concentration (Cmax)|Assessment of Bioequivalence of NicoDerm CQ (GSK Dungarvan) with NicoDerm CQ (Alza) by Measuring Area Under the Plasma Concentration Versus Time Curve From Time Zero to Time t (AUC [0-t])|Assessment of Bioequivalence of NicoDerm CQ (GSK Dungarvan) with NicoDerm CQ (Alza) by Measuring Area Under the Plasma Concentration Versus Time Curve Calculated from Time Zero to Infinity (AUC [(0-inf])|Assessment of Pharmacokinetic Profile of the Patches by Measuring Lambda z (λz)|Assessment of Pharmacokinetic Profile of the Patches by Measuring Time of Maximum Plasma Nicotine Concentration (tmax)|Assessment of Pharmacokinetic Profile of the Patches by Measuring Elimination Half-Life (t1/2)|Mean Adhesion Score","GlaxoSmithKline","All","21 Years to 55 Years   (Adult)","Phase 1","22","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","217756","September 1, 2021","October 25, 2021","October 25, 2021","August 27, 2021",,"November 10, 2021","GSK Investigational Site, Springfield, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT05024747"
868,"NCT00937417","S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors",,"Withdrawn","No Results Available","Breast Cancer|Head and Neck Cancer|Lung Cancer|Prostate Cancer|Unspecified Adult Solid Tumor, Protocol Specific","Drug: docetaxel|Drug: vandetanib|Genetic: proteomic profiling|Other: laboratory biomarker analysis|Other: pharmacological study","Pharmacodynamic parameters (percent inhibition of pERK, pKDR, and pEGFR)|Correlation of pharmacokinetic profile with pharmacodynamic data and treatment-related toxicities|Association between scientific correlates (microvessel density, cell death, circulating endothelial cells, ERK and pERK, and serum proteomics) and treatment outcomes and other patient characteristics|Objective tumor response and clinically stable disease in patients with measurable disease at baseline","Southwest Oncology Group|National Cancer Institute (NCI)","All","18 Years to 120 Years   (Adult, Older Adult)","Phase 1","0","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","S0716|SWOG-S0716","September 2008","September 2009","September 2009","July 13, 2009",,"April 24, 2017",,,"https://ClinicalTrials.gov/show/NCT00937417"
869,"NCT00667641","Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors",,"Completed","No Results Available","Breast Cancer|Colorectal Cancer|Head and Neck Cancer|Lung Cancer|Melanoma (Skin)|Ovarian Cancer|Pancreatic Cancer|Prostate Cancer|Unspecified Adult Solid Tumor, Protocol Specific","Drug: bortezomib|Drug: paclitaxel","Maximum tolerated dose of paclitaxel in combination with bortezomib","University of Medicine and Dentistry of New Jersey|National Cancer Institute (NCI)|Rutgers, The State University of New Jersey","All","18 Years and older   (Adult, Older Adult)","Phase 1","16","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000592905|P30CA072720|CINJ-050608|MILLENNIUM-CINJ-050608|CINJ-IRB-0220060270","March 2007","February 2009","February 2009","April 28, 2008",,"May 10, 2011","Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT00667641"
870,"NCT00637637","External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases",,"Unknown status","No Results Available","Cancer","Drug: indinavir sulfate|Drug: ritonavir|Radiation: radiation therapy","Time to treatment failure in the brain (TTF) as determined by the radiological response rate|Overall survival (OS)|Radiological volumetric response to treatment|Local intracranial disease progression at 4 months|Progression-free survival at 6 months|Improvement of symptoms|Time to symptom relapse or symptom progression|Duration of use of steroids|Duration of use of anticonvulsive drugs","Oncology Institute of Southern Switzerland|National Cancer Institute (NCI)","All","Child, Adult, Older Adult","Phase 2","60","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","IOSI-RO0402|CDR0000587517","September 2007","June 2009",,"March 18, 2008",,"August 12, 2013","Hopital Cantonal Universitaire de Geneve, Geneva, Switzerland|Oncology Institute of Southern Switzerland - Lugano, Lugano, Switzerland|UniversitaetsSpital Zuerich, Zurich, Switzerland",,"https://ClinicalTrials.gov/show/NCT00637637"
871,"NCT01166503","Early Versus Delayed Surgery for Infantile Esotropia",,"Completed","No Results Available","Esotropia","Procedure: mVEP Testing|Procedure: Stereoacuity Testing|Procedure: Optokinetic nystagmus testing|Procedure: Motion detection testing|Procedure: Motion discrimination testing","Motion visual evoked potential (mVEPs) asymmetry|Stereopsis|Optokinetic nystagmus (OKN) asymmetry|Global Motion Perception","The Hospital for Sick Children","All","3 Months to 23 Months   (Child)",,"71","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","1000005134","May 2004","April 2, 2018","April 26, 2018","July 21, 2010",,"June 12, 2018","The Hospital for Sick Children, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01166503"
872,"NCT00390325","Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer",,"Active, not recruiting","Has Results","Hereditary Thyroid Gland Medullary Carcinoma|Locally Advanced Thyroid Gland Medullary Carcinoma|Multiple Endocrine Neoplasia Type 2A|Multiple Endocrine Neoplasia Type 2B|Recurrent Thyroid Gland Medullary Carcinoma|Sporadic Thyroid Gland Medullary Carcinoma|Stage III Thyroid Gland Medullary Carcinoma AJCC v7|Stage IV Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVA Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVB Thyroid Gland Medullary Carcinoma AJCC v7|Stage IVC Thyroid Gland Medullary Carcinoma AJCC v7","Drug: Sorafenib Tosylate","Objective Response Rate of Sorafenib Tosylate in Metastatic Medullary Thyroid Carcinoma in Setting of Inherited Tumor Syndromes as Well as in Setting of Sporadic Medullary Thyroid Cancer|Number of Patients With Decreased Calcitonin Levels|Patient With Decreased Carcinoembryonic Antigen (CEA) Levels|Percent of Baseline Dynamic-Contrast Enhanced Magnetic Resonance Imaging (DCE-MRI) Exchange Rate Constant (Kep)|Degree of Ras-MAPK Signaling Inhibition in the Tumor|Degree of Vascular Endothelial Growth Factor (VEGF) Expression in the Tumor|Standardized Uptake Value (SUV Max) as Measured by Fludeoxyglucose F-18 Positron Emission Tomography (PET)|Number of Patients With Toxicity, Graded Using the Revised National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0|Number of Participants With Ret Proto-Oncogene (RET) Gene Defects in the Tumor|Selected Polymorphisms of Genes Influencing Sorafenib Tosylate Metabolism and/or Resistance Genes That May Predict Response or Toxicity","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","21","NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2009-00196|2006C0050|NCI-7609|CDR0000507441|OSU 06054 / IRB 2006C0050|7609|N01CM00070|N01CM62207|P30CA016058","October 5, 2006","January 30, 2017",,"October 19, 2006","December 21, 2018","November 4, 2021","Washington University School of Medicine, Saint Louis, Missouri, United States|Duke University Medical Center, Durham, North Carolina, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/25/NCT00390325/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT00390325"
873,"NCT00098943","NGR-TNF in Treating Patients With Advanced Solid Tumors",,"Completed","No Results Available","Colorectal Cancer|Head and Neck Cancer|Kidney Cancer|Unspecified Adult Solid Tumor, Protocol Specific","Biological: CNGRC peptide-TNF alpha conjugate","Dose-limiting toxicity and maximum tolerated dose as measured by CTC v 3.0|Clinical response as measured by RECIST criteria|Mechanism of action as measured by Dynamic Imaging","European Organisation for Research and Treatment of Cancer - EORTC","All","18 Years and older   (Adult, Older Adult)","Phase 1","70","Other","Interventional","Masking: None (Open Label)|Primary Purpose: Treatment","EORTC-16041|MOLMED-EORTC-16041|EUDRACT-2004-000950-21","September 2004","November 2007",,"December 9, 2004",,"September 24, 2012","University Medical Center Hamburg - Eppendorf, Hamburg, Germany|Universitair Medisch Centrum St. Radboud - Nijmegen, Nijmegen, Netherlands",,"https://ClinicalTrials.gov/show/NCT00098943"
874,"NCT00019331","Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors",,"Completed","No Results Available","Colorectal Cancer|Endometrial Cancer|Head and Neck Cancer|Liver Cancer|Lung Cancer|Melanoma (Skin)|Pancreatic Cancer|Testicular Germ Cell Tumor|Unspecified Adult Solid Tumor, Protocol Specific","Biological: aldesleukin|Biological: ras peptide cancer vaccine|Biological: sargramostim|Drug: DetoxPC",,"National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2",,"NIH","Interventional","Primary Purpose: Treatment","CDR0000065656|NCI-97-C-0141F|NCI-T96-0078","October 1997",,"May 2007","January 27, 2003",,"June 20, 2013","Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00019331"
875,"NCT00002608","Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors",,"Completed","No Results Available","Adrenocortical Carcinoma|Brain and Central Nervous System Tumors|Head and Neck Cancer|Liver Cancer|Malignant Mesothelioma|Pheochromocytoma|Sarcoma","Drug: cisplatin|Drug: doxorubicin hydrochloride|Drug: tamoxifen citrate|Procedure: conventional surgery|Radiation: radiation therapy",,"Ottawa Regional Cancer Centre|National Cancer Institute (NCI)","All","up to 65 Years   (Child, Adult, Older Adult)","Phase 2","30","Other","Interventional","Masking: None (Open Label)|Primary Purpose: Treatment","CAN-OTT-9401|CDR0000063892|NCI-V94-0566","May 1994",,"April 2005","January 27, 2003",,"July 10, 2013","Ottawa Regional Cancer Centre at Ottawa Hospital - General Campus, Ottawa, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00002608"
876,"NCT00872469","World Maternal Antifibrinolytic Trial","WOMAN","Completed","No Results Available","Postpartum Haemorrhage","Drug: Tranexamic acid|Drug: Placebo [Saline]","The primary outcome is the proportion of women who die or undergo hysterectomy. The primary cause of death will be described.|Surgical Interventions including hysterectomy; brace suture; selective arterial embolisation; laparotomy for other reasons; manual removal of placenta; intrauterine tamponade; artery ligation, to achieve haemostasis.|Need for blood transfusion - blood or blood component units transfused.|Health Status measured using the EQ-5D.|Thromboembolic events (myocardial infarction, strokes, pulmonary embolism, DVT).|Other relevant medical events|Length of stay at hospital/time spent at an intensive care unit|Need for mechanical ventilation.|Status of baby/ies","London School of Hygiene and Tropical Medicine","Female","16 Years and older   (Child, Adult, Older Adult)","Phase 3","20060","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ISRCTN76912190","May 2009","June 2016","April 2017","March 31, 2009",,"February 26, 2018","University College Hospital, Ibadan, Nigeria",,"https://ClinicalTrials.gov/show/NCT00872469"
877,"NCT01097915","Gustin Gene Polymorphism and 6-n-propylthiouracil (PROP) Taste","gustinprop","Completed","Has Results","Dysgeusia",,"Association Between Gustin Gene Polymorphism and PROP Sensitivity|Association Between PROP Sensitivity and Saliva Zinc Ion Concentration|Association Between PROP Sensitivity and BMI|Electrophysiological Recordings From the Tongue for the Objective Evaluation of Individual Variations of 6-n-propylthiouracil (PROP) Sensitivity|Association Between PROP Sensitivity and Fungiform Papilla Density|Taste Perception of Sweet, Sour, Salty, Bitter and Umami and Changes Due to L-Arginine Supplementation, as a Functin of Genetic Ability to Taste PROP.","University of Cagliari","All","20 Years to 30 Years   (Adult)",,"170","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","UNICADBSITB-1","October 2009","December 2009","June 2016","April 2, 2010","December 21, 2016","December 21, 2018","Sezione di Farmacologia Clinica del Dipartimento di Neuroscienze, San Giovanni di Dio Azienda Ospedaliero Universitaria di Cagliari, Cagliari, Ca, Italy",,"https://ClinicalTrials.gov/show/NCT01097915"
878,"NCT04360824","Covid-19 Associated Coagulopathy",,"Recruiting","No Results Available","COVID 19 Associated Coagulopathy","Drug: Intermediate dose thromboprophylaxis|Drug: Standard of Care thromboprophylaxis","Mortality|Major Bleeding|Arterial Thrombosis|Venous Thromboembolism|ICU admission, intubation/ventilation|Packed Red Blood Cell Transfusions|Platelet Transfusions|Fresh Frozen Plasma Transfusions|Cryoprecipitate Transfusions|Prothrombin Complex Concentrate Transfusions","University of Iowa","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 4","170","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","202004235","May 6, 2020","April 16, 2021","April 16, 2021","April 24, 2020",,"June 19, 2020","University of Iowa, Iowa City, Iowa, United States|Gundersen Health System, La Crosse, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT04360824"
879,"NCT01546038","A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome",,"Completed","Has Results","Acute Myeloid Leukemia","Drug: PF-04449913|Drug: Low dose ARA-C (LDAC)|Drug: Decitabine|Drug: Daunorubicin|Drug: Cytarabine","Number of Participants With Dose-limiting Toxicities (DLTs) at Phase 1B|Percentage of Participants With Complete Response (CR) at Phase 2 Fit|Overall Survival (OS) at Phase 2 Unfit|Overall Survival (OS) at Phase 1B|Overall Survival (OS) at Phase 2 Fit|Percentage of Participants With CR / Complete Response With Incomplete Blood Count Recovery (CRi) at Phase 1B|Percentage of Participants With Complete Response (CR) at Phase 2 Unfit|Percentage of Participants With Disease-specific Efficacy for Acute Myeloid Leukemia (AML) at Phase 2 Fit and Unfit|Percentage of Participants With Disease-specific Efficacy for Myelodysplastic Syndrome (MDS) at Phase 2 Fit and Unfit|Maximum Observed Plasma Concentration (Cmax) of Glasdegib in Participants Receiving Glasdegib and LDAC at Phase 1B on Cycle 1/Day 10 and Cycle 1/Day 21|Time to Cmax (Tmax) of Glasdegib in Participants Receiving Glasdegib and LDAC at Phase 1B on Cycle 1/Day 10 and Cycle 1/Day 21|Area Under the Plasma Concentration-time Profile From Time 0 to Dosing Interval (AUCtau) of Glasdegib in Participants Receiving Glasdegib and LDAC at Phase 1B on Cycle 1/Day 10 and Cycle 1/Day 21|Cmax of Glasdegib in Participants Receiving Glasdegib and Decitabine at Phase 1B on Cycle 1/Day 10 and Cycle 2/Day 1|Tmax of Glasdegib in Participants Receiving Glasdegib and Decitabine at Phase 1B on Cycle 1/Day 10 and Cycle 2/Day 1|AUCtau of Glasdegib in Participants Receiving Glasdegib and Decitabine at Phase 1B on Cycle 1/Day 10 and Cycle 2/Day 1|Cmax of Glasdegib in Participants Receiving Glasdegib and Cytarabine/Daunorubicin at Phase 1B on Induction Cycle 1/Day 3 and Day 10|Tmax of Glasdegib in Participants Receiving Glasdegib and Cytarabine/Daunorubicin at Phase 1B on Induction Cycle 1/Day 3 and Day 10|AUCtau of Glasdegib in Participants Receiving Glasdegib and Cytarabine/Daunorubicin at Phase 1B on Induction Cycle 1/Day 3 and Day 10|Cmax of LDAC and Ara-U in Participants Receiving Glasdegib and LDAC at Phase 1B on Cycle 1/Day 2 and Cycle 1/Day 10|Tmax of LDAC and Ara-U in Participants Receiving Glasdegib and LDAC at Phase 1B on Cycle 1/Day 2 and Cycle 1/Day 10|Area Under the Plasma Concentration-time Profile From Time 0 to Infinity (AUCinf) of LDAC in Participants Receiving Glasdegib and LDAC at Phase 1B on Cycle 1/Day 2 and Cycle 1/Day 10|Area Under the Plasma Concentration-time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of LDAC and Ara-U in Participants Receiving Glasdegib and LDAC at Phase 1B on Cycle 1/Day 2 and Cycle 1/Day 10|Cmax of Decitabine in Participants Receiving Glasdegib and Decitabine at Phase 1B on Cycle 1/Day 1 and Cycle 1/Day 2|Tmax of Decitabine in Participants Receiving Glasdegib and Decitabine at Phase 1B on Cycle 1/Day 1 and Cycle 1/Day 2|AUCinf of Decitabine in Participants Receiving Glasdegib and Decitabine at Phase 1B on Cycle 1/Day 1 and Cycle 1/Day 2|AUCtau of Cytarabine and Ara-U in Participants Receiving Glasdegib and Cytarabine/Daunorubicin at Phase 1B on Induction Cycle 1/Day 3|Cmax of Daunorubicin and Daunorubicinol in Participants Receiving Glasdegib and Cytarabine/Daunorubicin at Phase 1B on Induction Cycle 1/Day 3|Tmax of Daunorubicin and Daunorubicinol in Participants Receiving Glasdegib and Cytarabine/Daunorubicin at Phase 1B on Induction Cycle 1/Day 3|AUCtau of Daunorubicin and Daunorubicinol in Participants Receiving Glasdegib and Cytarabine/Daunorubicin at Phase 1B on Induction Cycle 1/Day 3|Pre-dose Plasma Concentration (Ctrough) of Glasdegib in Phase 2 Fit on Induction Cycle 1/Day 10|Cmax of Glasdegib in Participants Receiving Glasdegib and LDAC at Phase 2 Unfit on Cycle 1/Day 10|Tmax of Glasdegib in Participants Receiving Glasdegib and LDAC at Phase 2 Unfit on Cycle 1/Day 10|AUCtau of Glasdegib in Participants Receiving Glasdegib and LDAC at Phase 2 Unfit on Cycle 1/Day 10|Number of Participants With Disease-related Gene Mutations at Phase 1B|Serum Levels of Circulating Protein Analytes at Phase 1B - Baseline|Serum Levels of Circulating Protein Analytes at Phase 1B - Induction Cycle 1/Day 3|Serum Levels of Circulating Protein Analytes at Phase 1B - Induction Cycle 1/Day 10|Baseline Levels of Serum Circulating Protein Analytes Associated With Best Overall Response at Phase 1B|Post-baseline Levels of Serum Circulating Protein Analytes Associated With Best Overall Response at Phase 1B - Induction Cycle 1/Lead-In|Post-baseline Levels of Serum Circulating Protein Analytes Associated With Best Overall Response at Phase 1B - Induction Cycle 1/Day 3|Number of Participants With Disease-related Gene Mutations at Phase 2 Fit and Unfit|Serum Levels of Circulating Protein Analytes at Phase 2 Fit - Induction Cycle 1/Day 3|Serum Levels of Circulating Protein Analytes at Phase 2 Fit - Induction Cycle 1/Day 10|Serum Levels of Circulating Protein Analytes at Phase 2 Fit - Consolidation Cycle 1/Day 1|Serum Levels of Circulating Protein Analytes at Phase 2 Fit - Consolidation Cycle 1/Day 10|Serum Levels of Circulating Protein Analytes at Phase 2 Fit - End of Treatment|Baseline Levels of Serum Circulating Protein Analytes Associated With Best Overall Response at Phase 2 Fit|Post-baseline Levels of Serum Circulating Protein Analytes Associated With Best Overall Response at Phase 2 Fit - Induction Cycle 1/Day 3|Post-baseline Levels of Serum Circulating Protein Analytes Associated With Best Overall Response at Phase 2 Fit - Induction Cycle 1/Day 10|Post-baseline Levels of Serum Circulating Protein Analytes Associated With Best Overall Response at Phase 2 Fit - End of Treatment|Serum Levels of Circulating Protein Analytes at Phase 2 Unfit - Cycle 1/Day 1|Serum Levels of Circulating Protein Analytes at Phase 2 Unfit - Cycle 1/Day 10|Baseline Levels of Serum Circulating Protein Analytes Associated With Best Overall Response at Phase 2 Unfit|Post-baseline Levels of Serum Circulating Protein Analytes Associated With Best Overall Response at Phase 2 Unfit - Cycle 1/Day 1|Post-baseline Levels of Serum Circulating Protein Analytes Associated With Best Overall Response at Phase 2 Unfit - End of Treatment|Ratios of mRNA Levels to Baseline at Phase 2 Fit - Induction Cycle 1/Day 3|Ratios of mRNA Levels to Baseline at Phase 2 Fit - End of Treatment|Ratios of mRNA Levels to Baseline at Phase 2 Unfit - End of Treatment|Baseline mRNA Levels Associated With Best Overall Response at Phase 2 Fit|Baseline mRNA Levels Associated With Best Overall Response at Phase 2 Unfit|Ratios of mRNA Levels to Baseline Associated With Best Overall Response at Phase 2 Fit|Ratios of mRNA Levels Associated With Best Overall Response at Phase 2 Unfit|Number of Participants With Corrected QT Interval Using Fridericia's Formula (QTcF) Values Meeting Predefined Criteria at Phase 1B|Number of Participants With Corrected QT Interval Using Fridericia's Formula (QTcF) Values Meeting Predefined Criteria at Phase 2 Fit and Unfit|Number of Participants With Treatment-emergent Adverse Events (AEs) at Phase 1B (All Causality)|Number of Participants With Treatment-emergent AEs at Phase 1B (Treatment-related)|Number of Participants With Treatment-emergent AEs Categorized by Seriousness at Phase 1B|Number of Participants With Treatment-emergent AEs at Phase 2 Fit and Unfit (All Causality)|Number of Participants With Treatment-emergent AEs at Phase 2 Fit and Unfit (Treatment-related)|Number of Participants With Treatment-emergent AEs Categorized by Seriousness at Phase 2 Fit and Unfit","Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 2","255","Industry","Interventional","Allocation: Randomized|Masking: None (Open Label)|Primary Purpose: Treatment","B1371003|2012-000684-24","June 27, 2012","January 3, 2017","March 4, 2019","March 7, 2012","May 23, 2018","March 3, 2020","University of Alabama at Birmingham, Birmingham, Alabama, United States|University of Alabama at Birmingham, Birmingham, Alabama, United States|University of Alabama at Birmingham, Birmingham, Alabama, United States|UC San Diego Moores Cancer Center - Investigational Drug Services, La Jolla, California, United States|UC San Diego Medical Center - La Jolla, La Jolla, California, United States|UC San Diego Moores Cancer Center, La Jolla, California, United States|Keck Hospital of USC, Los Angeles, California, United States|LAC & USC Medical Center, Los Angeles, California, United States|USC/Norris Comprehensive Cancer Center / Investigational Drug Services, Los Angeles, California, United States|USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States|Ronald Reagan UCLA Medical Center Drug Information Center, Los Angeles, California, United States|Ronald Reagan UCLA Medical Center, Los Angeles, California, United States|UCLA Drug lnformation/lnvestigational Drugs, Los Angeles, California, United States|UCLA Hematology/Oncology Clinic, Los Angeles, California, United States|UC San Diego Medical Center - Hillcrest, San Diego, California, United States|University of Colorado Denver, Aurora, Colorado, United States|University of Colorado Hospital, Aurora, Colorado, United States|H.Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Emory University Hospital, Atlanta, Georgia, United States|Investigational Drug Service, Emory University Clinic, Atlanta, Georgia, United States|The Emory Clinic, Atlanta, Georgia, United States|Winship Cancer Institute, Emory University, Atlanta, Georgia, United States|Northwestern Medical Faculty Foundation, Chicago, Illinois, United States|Northwestern Medicine Developmental Therapeutics Institute, Chicago, Illinois, United States|Northwestern Memorial Hospital, Chicago, Illinois, United States|The University of Chicago Medical Center, Chicago, Illinois, United States|The University of Chicago's Medical Center, Chicago, Illinois, United States|University of Kansas Clinical Research Center, Fairway, Kansas, United States|University of Kansas Hospital, Kansas City, Kansas, United States|University of Kansas Cancer Center and Medical Pavilion, Westwood, Kansas, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute (DFCI), Boston, Massachusetts, United States|University of Michigan Comprehensive Cancer Center Clinical Trials Office, Ann Arbor, Michigan, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|Siteman Cancer Center - West County, Creve Coeur, Missouri, United States|Barnes Jewish Hospital North Campus, Saint Louis, Missouri, United States|Barnes-Jewish Hospital, Saint Louis, Missouri, United States|Washington University School of Medicine - Division of Bone Marrow Transplant & Leukemia, Saint Louis, Missouri, United States|Washington University School of Medicine, Siteman Cancer Center, Saint Louis, Missouri, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Cleveland Clinic Cancer Institute, Cleveland, Ohio, United States|Centennial Medical Center, Nashville, Tennessee, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|The University of Texas, MD Anderson Cancer Center, Houston, Texas, United States|University of Washington-Seattle Cancer Care Alliance, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States|Juravinski Cancer Centre @ Hamilton Health Sciences, Hamilton, Ontario, Canada|Centre de Sante et de Services Sociaux (CSSS) Champlain - Charles-Le Moyne, Greenfield Park, Quebec, Canada|Universitaetsklinikum Ulm, Ulm, Baden-wuerttemberg, Germany|Johann Wolfgang Goethe University, Frankfurt am Main, Hessen, Germany|Medizinische Hochschule Hannover, Hannover, Lower Saxony, Germany|Charite -Universitatsmedizin Berlin - Campus Benjamin Franklin, Berlin, Germany|Charite - Universitatsmedizin Berlin, Berlin, Germany|Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany|Universitaetsklinikum Schleswig-Holstein, Kiel, Germany|Universitaetsklinikum Magdeburg A.oe.R., Magdeburg, Germany|Johannes Gutenberg-Universitaet Mainz, Mainz, Germany|Universitaetsklinikum Muenster, Muenster, Germany|Universitaetsklinikum Ulm, Ulm, Germany|Policlinico S. Orsola-Malpighi, Bologna, Province OF Bologna, Italy|ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy|Policlinico Universitario ""Umberto I"" Universita degli Studi ""La Sapienza"" Sezione di Ematologia, Rome, Italy|A.O. Citta della Salute e della Scienza di Torino - S.C. Ematologia, Torino, Italy|Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy|Uniwersyteckie Centrum Kliniczne Gdanskiego Uniwersytetu Medycznego, Gdansk, Pomorskie, Poland|Oddzial Hematologii Z pododzialem chemioterapii-Klinika Hematologii Wojewodzkie Wielospecjalistyczne, Lodz, Poland|Dolnoslaskie Centrum Transplantacji Komorkowych z Krajowym Bankiem Dawcow Szpiku, Wroclaw, Poland|Hospital Universitario Virgen del Rocio, Sevilla, Andalucia, Spain|Hospital Universitario Germans Trias i Pujol, Badalona, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Ramon y Cajal, Madrid, Spain|Hospital Universitario y Politecnico La Fe, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT01546038"
880,"NCT02251795","Effects of Steady State Tipranavir/Ritonavir or Darunavir/Ritonavir or Ritonavir on Platelet Function, Coagulation and Fibrinolysis Biomarkers in Healthy Subjects",,"Completed","No Results Available","Healthy","Drug: Tipranavir|Drug: Ritonavir|Drug: Darunavir|Drug: Aspirin","Percent change from baseline in the area under the curve (AUC) of platelet aggregation in response to arachidonic acid (AA)|Changes in platelet aggregation in response to AA|Changes in platelet aggregation in response to collagen|Changes in platelet aggregation in response adenosine diphosphate (ADP)|Changes in closure Time (CT)|Changes in urinary thromboxane B2 metabolites|Changes in bleeding time|Changes in activated partial thromboplastin time (aPTT)|Changes in prothrombin time (PT)|Changes in fibrinogen|Changes in von Willebrand antigen|Changes in von anti-thrombin III antigen|Changes in anti-thrombin III activity|Changes in factor II|Changes in factor VII|Changes in factor IX|Changes in factor X|Changes in plasminogen activity|Changes in alpha 2-antiplasmin|Changes in D-dimer|Changes in Plasminogen Activator Inhibitor (PAI-1)|Maximum measured concentration of the analyte in plasma (Cmax)|Serum concentration at 12 hours (Cp12h)|Area under the curve from 0-12 hours (AUC0-12h)|Time from dosing to the maximum measured concentration of the analyte in plasma (Tmax)|Total clearance of the analyte in plasma (CL/F)|Apparent volume of distribution (V/F)|Terminal half-life (t1/2)|Number of subjects with abnormal findings in laboratory tests|Number of subjects with treatment-emergent adverse events","Boehringer Ingelheim","All","18 Years to 50 Years   (Adult)","Phase 1","52","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1182.117","August 2007","June 2008",,"September 29, 2014",,"September 29, 2014",,,"https://ClinicalTrials.gov/show/NCT02251795"
881,"NCT00945100","Increasing Patching for Amblyopia in Children 3 to < 8 Years Old","ATS15","Completed","Has Results","Amblyopia","Device: Eye Patch","Distribution of 10-week Amblyopic Eye Visual Acuity|Mean 10-week Amblyopic Eye Visual Acuity|Distribution of the Change in Amblyopic Eye Visual Acuity at 10 Weeks From Randomization|Mean Change in Amblyopic Eye Visual Acuity at 10 Weeks From Randomization|Compliance With Prescribed Patching by Treatment Group at 10 Weeks|Average Compliance With Prescribed Patching by Treatment Group|Treatment Group Comparison of the Proportion of Participants Who Have Improved by 2 or More logMAR Visual Acuity Lines at 10 Weeks Since Randomization|Treatment Group Comparison of 10-week Interocular Difference|Distribution of Baseline Characteristics at the 10-week Outcome|Mean Amblyopic Eye Visual at Randomization According to Baseline Characteristics for 10-week Outcome|Treatment Comparison of Mean Amblyopic Eye Visual Acuity Change at 10-weeks According to Baseline Characteristics|Distribution of Amblyopic Eye Visual Acuity at Visit of Best Post-randomization Visual Acuity|Mean Amblyopic Eye Visual Acuity at Visit of Best Post-randomization Visual Acuity|Distribution of the Change in Best Post-randomization Visual Acuity in the Amblyopic Eye|Mean Change in Amblyopic Eye Visual Acuity Since Randomization at Visit of Best Post-randomization Visual Acuity|Treatment Group Comparison of the Proportion of Participants Who Have Improved by 2 or More logMAR Visual Acuity Lines Based on Visual Acuity at Best Post-randomization Visit|Distribution of Best Fellow Eye Visual Acuity at 10-week Outcome|Mean Best Fellow Eye Visual Acuity at 10-week Outcome|Distribution of Best Fellow Eye Visual Acuity at Final Visit|Mean Best Fellow Eye Visual Acuity at Final Visit|Distribution of Change in Best Fellow Eye Visual Acuity Since Randomization at 10 Weeks|Mean Change in Best Fellow Eye Visual Acuity Since Randomization at 10 Weeks|Distribution of Change in Best Fellow Eye Visual Acuity Since Randomization at Final Visit|Mean Change in Best Fellow Eye Visual Acuity Since Randomization at Final Visit|Distribution of Randot Preschool Stereoacuity Scores at Randomization|Distribution of Randot Preschool Stereoacuity Scores at 10 Weeks|Change in Randot Preschool Stereoacuity Level at 10-week Outcome Since Randomization|Distribution of Randot Preschool Stereoacuity Scores at Randomization for Participants With Anisometropic Amblyopia|Distribution of Randot Preschool Stereoacuity Scores at 10 Weeks for Participants With Anisometropic Amblyopia|Change in Randot Preschool Stereoacuity Level at 10-week Outcome Since Randomization for Participants With Anisometropic Amblyopia","Jaeb Center for Health Research|National Eye Institute (NEI)","All","3 Years to 7 Years   (Child)","Phase 3","169","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NEI-143|2U10EY011751","August 2009","March 2013","March 2013","July 23, 2009","November 13, 2013","July 13, 2016","Southern California College of Optometry, Fullerton, California, United States|Duke University Eye Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00945100"
882,"NCT04794348","Clinical Trial Assessing Non-Inferiority of Freeze Dried Plasma to Fresh Frozen Plasma in Reversing Warfarin",,"Not yet recruiting","No Results Available","Anticoagulant Reversal","Biological: Fresh Frozen Plasma (FFP)|Biological: Freeze Dried Plasma (FDP)","Relative change in International Normalized Ratio (INR)|Occurrence of treatment emergent adverse events (TEAE)|Changes in INR|Changes in aPTT|Changes in Factor II (FII)|Changes in Factor VII (FVII)|Changes in Factor IX (FIX)|Changes in Factor X (FX)|Changes in protein C|Changes in protein S|Factor VII (FVII) kinetics area under the curve (AUC)|Factor VII (FVII) kinetics maximum concentration (Cmax)|Factor VII (FVII) kinetics half-life (t1/2)|Thrombin generation assay (TGA)","Vascular Solutions LLC|United States Army Medical Materiel Development Activity|Westat","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","28","Industry|U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","S-18-04","May 2021","March 2022","March 2022","March 12, 2021",,"March 12, 2021","Hoxworth Blood Center, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT04794348"
883,"NCT05013008","An add-on Study to the FIGARO-DKD Study Called FIGARO-BM to Learn About the Link Between Biomarkers (Substances in the Blood Used as Indicators of Biological Processes, Disease Processes or Responses to Medication) and Finerenone in FIGARO-DKD Participants","FIGARO-BM","Completed","No Results Available","Chronic Kidney Disease|Type 2 Diabetes Mellitus","Drug: Finerenone (BAY94-8862)|Drug: Placebo","Change in plasma biomarker levels after 36 months (Visit 11) of treatment versus 4 months (Visit 3) of treatment in a set of 27 pre-defined biomarkers","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","951","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","21952|2021-003053-37","August 18, 2021","December 31, 2021","December 31, 2021","August 19, 2021",,"January 11, 2022","Valley Clinical Trials, Inc., Northridge, California, United States|Saviers Medical Group, Port Hueneme, California, United States|Chase Medical Research, LLC, Waterbury, Connecticut, United States|Florida Kidney Physicians, Fort Lauderdale, Florida, United States|Indago Research & Health Center, Inc., Hialeah, Florida, United States|San Marcus Research Clinic, Inc., Miami Lakes, Florida, United States|Floridian Clinical Research, LLC, Miami Lakes, Florida, United States|East-West Medical Research Institute, Honolulu, Hawaii, United States|Crescent City Clinical Research Center, LLC, Metairie, Louisiana, United States|Joslin Diabetes Center, Boston, Massachusetts, United States|Kansas City VA Medical Center, Kansas City, Missouri, United States|Randolph Medical Associates, Asheboro, North Carolina, United States|Clinical Advancement Center, PLLC, San Antonio, Texas, United States|Illawarra Diabetes Service, Wollongong, New South Wales, Australia|Melbourne Renal Research Group, Reservoir, Victoria, Australia|Medizinische Universität Graz, Graz, Steiermark, Austria|Klinik Landstraße - Krankenhaus Rudolfstiftung, Wien, Austria|Zentrum f. klinische Studien Dr. Hanusch GmbH, Wien, Austria|UZ Gent, Gent, Belgium|AZ Delta, Roeselaere, Belgium|MHAT St. Ivan Rilski, Gorna Oryahovitsa, Bulgaria|DCC 2 - Plovdiv EOOD, Plovdiv, Bulgaria|MHAT Sveti Pantaleymon, Yambol, Bulgaria|Fraser Clinical Trials, Inc., New Westminster, British Columbia, Canada|Hopital Charles LeMoyne, Greenfield Park, Quebec, Canada|Manna Research, Mirabel, Quebec, Canada|Clinique des Maladies Lipidques de Quebec, Quebec, Canada|Nefrologicka ambulance, Praha 4, Czechia|Aarhus Universitetshospital, Skejby, Aarhus N, Denmark|Sydvestjysk Sygehus Esbjerg, Esbjerg, Denmark|Steno Diabetes Center Copenhagen, Gentofte, Denmark|Gentofte Hospital, Hellerup, Denmark|Herlev Hospital, Herlev, Denmark|Holbæk Sygehus, Holbæk, Denmark|Holstebro Hospital, Holstebro, Denmark|Bispebjerg Hospital, København NV, Denmark|Viborg Sygehus, Viborg, Denmark|Terveystalo Oulu, Oulu, Finland|Lääkärikeskus Minerva, Rauma, Finland|Turun yliopistollinen keskussairaala, kantasairaala, Turku, Finland|Queen Mary Hospital, Hong Kong, Hong Kong|Prince of Wales Hospital, Shatin, Hong Kong|Tung Wah Hospital, Sheung Wan, Hong Kong|Barzilai Medical Center, Ashkelon, Israel|Edith Wolfson Medical Center, Holon, Israel|Hadassah Hebrew University Hospital Ein Kerem, Jerusalem, Israel|Meir Medical Center, Kfar Saba, Israel|The Nazareth Trust Hospital EMMS, Nazareth, Israel|Clalit Health Services, Midgal Hamea, Tel Aviv, Israel|DMC - Diabetes Medical Center, Tel Aviv, Israel|A.O.U. di Bologna Policlinico S.Orsola Malpighi, Bologna, Emilia-Romagna, Italy|Istituto Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Lombardia, Italy|ASST Papa Giovanni XXIII, Bergamo, Lombardia, Italy|ASST Santi Paolo e Carlo, Milano, Lombardia, Italy|Kohnodai Hospital, NC for Global Health and Medicine, Ichikawa, Chiba, Japan|Saiseikai Matsuyama Hospital, Matsuyama, Ehime, Japan|Fukuoka University Chikushi Hospital, Chikushino, Fukuoka, Japan|Fukuoka Tokushukai Hospital, Kasuga, Fukuoka, Japan|Kokura Memorial Hospital, Kitakyushu, Fukuoka, Japan|Steel Memorial Yawata Hospital, Kitakyushu, Fukuoka, Japan|Shirakawa Kosei General Hospital, Shirakawa, Fukushima, Japan|Higashihiroshima Medical Center, Higashihiroshima, Hiroshima, Japan|Jiyugaoka YAMADA Clinic, Obihiro, Hokkaido, Japan|Naka Kinen Clinic, Naka, Ibaraki, Japan|Noritake Clinic, Ushiku, Ibaraki, Japan|Komatsu Municipal Hospital, Komatsu, Ishikawa, Japan|Shonan Fujisawa Tokushukai Hospital, Fujisawa, Kanagawa, Japan|Shonan Kamakura General Hospital, Kamakura, Kanagawa, Japan|Osaka Saiseikai Senri Hospital, Suita, Osaka, Japan|Sugiura Clinic, Kawaguchi, Saitama, Japan|Association of healthcare corporation, Oyama East Clinic, Oyama, Tochigi, Japan|Fukuoka University Hospital, Fukuoka, Japan|Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan|Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan|Medical Corporation Kyosokai AMC Nishi-umeda Clinic, Osaka, Japan|Kitano Hospital, Osaka, Japan|Yonsei University Wonju Christian Hospital, Wonju, Gang''weondo, Korea, Republic of|Hallym University Sacred Heart Hospital, Anyang-si, Gyeonggido, Korea, Republic of|Seoul National University Hospital, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Kyung Hee University Hospital at Gangdong, Seoul, Korea, Republic of|Kangbuk Samsung Hospital, Seoul, Korea, Republic of|Albert Schweitzer Ziekenhuis, locatie Zwijndrecht, Zwijndrecht, Netherlands|Hospital de Braga, Braga, Portugal|First City Clinical Hospital n.a. E.E. Volosevich, Arkhangelsk, Russian Federation|Izhevsk City Clinical Hospital #9, Izhevsk, Russian Federation|Sci-Res. Institute of Complex Cardiovascular Disorders, Kemerovo, Russian Federation|Kemerovo Regional Clinical Hospital, Kemerovo, Russian Federation|Center of cardiology and neurology, Kirov, Russian Federation|Regional Clinical Hospital #1 n.a. prof. S.V. Ochapovsky, Krasnodar, Russian Federation|Moscow State University n.a. M.V. Lomonosov, Moscow, Russian Federation|Moscow State Univ. of Med. & Stomatology n.a. A.I. Evdokimov, Moscow, Russian Federation|PHI ""Central Clinical Hospital ""RZD-Medicine"", Moscow, Russian Federation|City Clinical Hospital #13, Nizhny Novgorod, Russian Federation|Saratov City Clinical Hospital #9, Saratov, Russian Federation|Voronezh Regional Clinical Consultancy-Diagnostic Center, Voronezh, Russian Federation|City Outpatient Clinic #4, Voronezh, Russian Federation|Clinical Hospital for Emergency Care n.a. N.V.Solovyov, Yaroslavl, Russian Federation|Singapore General Hospital, Singapore, Singapore|National Heart Centre Singapore, Singapore, Singapore|Complexo Hospitalario Universitario de Ferrol, Lugar Da Pega, A Coruña, Spain|Hospital SAS de Jerez de la Frontera, Jerez de la Frontera, Cádiz, Spain|Complejo Hospitalario Universitario A Coruña, A Coruña, Spain|Hospital del Mar, Barcelona, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|PTC-Primary care Trial Center, Göteborg, Sweden|ClinSmart, Uppsala, Sweden|Avdelningen för kliniska prövningar AKP, Örebro, Sweden|Chang Gung Mem Hosp. Kaohsiung, Taiwan, Taiwan|Changhua Christian Hospital, Taiwan, Taiwan|Far Eastern Memorial Hospital, Taiwan, Taiwan|Taichung Veterans General Hosp, Taiwan, Taiwan|Taipei Medical University Hosp, Taiwan, Taiwan|Taipei Veterans General Hos., Taiwan, Taiwan",,"https://ClinicalTrials.gov/show/NCT05013008"
884,"NCT03206801","Urine CXCL10 Monitoring Trial in Kidney Transplant",,"Recruiting","No Results Available","Kidney Transplant; Complications|Rejection of Renal Transplant","Procedure: Kidney transplant biopsy","Death-censored graft loss|Clinical indication biopsy-proven acute rejection|De novo donor specific antibody development|Subclinical tubulitis|Interstitial fibrosis and inflammation (IFTA + i)|Renal allograft function|Microvascular inflammation|Development IFTA from implantation to 12-months|Days from transplantation to clinical-biopsy proven rejection|Albuminuria >300mg/day|Cost-effectiveness of urine CXCL10 monitoring strategy|Quality of life|Urine CXCL10 kinetics","University of Manitoba|Canadian Institutes of Health Research (CIHR)|Canadian National Transplant Research Program","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","420","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Screening","B2017:076|364003|TMCT-04","April 3, 2018","December 1, 2022","December 1, 2023","July 2, 2017",,"April 27, 2021","Royal Adelaide Hospital, Adelaide, South Australia, Australia|University of Manitoba, Transplant Manitoba Adult Kidney Program, Winnipeg, Manitoba, Canada|Western University, London, Ontario, Canada|University of Ottawa, Ottawa, Ontario, Canada|Centre de recherche du CHUM (CRCHUM), Montréal, Quebec, Canada|Université Laval, Québec City, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT03206801"
885,"NCT04641273","A 2-part Trial to Learn More About How BAY1817080 Works, How Safe it is, and What the Right Dose is for Participants With Diabetic Neuropathic Pain",,"Recruiting","No Results Available","Neuropathic Pain Associated With Diabetic Peripheral Neuropathy","Drug: BAY1817080|Drug: Placebo for BAY1817080|Drug: Placebo for Pregabalin|Drug: Pregabalin","Change in weekly mean 24-hour average pain intensity score using the 11-point Numeric Rating Scale (NRS) from baseline to the end of intervention|Change in Neuropathic Pain Symptom Inventory (NPSI) score from baseline to the end of intervention|Patient Global Impression of Change (PGI-C) at the end of intervention|The proportion of participants achieving a ≥30% and a ≥50% reduction in weekly mean 24-hour average pain intensity score (i.e. responder rates using NRS)|Number of participants with treatment emergent adverse events (TEAE)","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","441","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20887|2020-002066-14","January 22, 2021","June 26, 2023","July 24, 2023","November 23, 2020",,"December 2, 2021","Landeskrankenhaus Feldkirch, Feldkirch, Vorarlberg, Austria|Medizinische Universität Innsbruck, Innsbruck, Austria|Zentrum f. klinische Studien Dr. Hanusch GmbH, Wien, Austria|Universitätsklinikum AKH Wien, Wien, Austria|Klinik Hietzing, Wien, Austria|NEUROHK s.r.o, Chocen, Czechia|Nemocnice Pardubickeho kraje, a.s., Pardubicka nemocnice, Pardubice, Czechia|Clintrial s.r.o., Praha 10, Czechia|Diabet2, s.r.o., Praha 1, Czechia|VFN, Fakultni poliklinika, Praha 2, Czechia|Diabetologicka a endokrinologicka ambulance, Milan Kvapil, Praha 4, Czechia|Praglandia, Praha 5, Czechia|Diabetologicka a endokrinologicka ambulance, Milan Kvapil,, Pribram, Czechia|Vestra Clinics s.r.o., Rychnov nad Kneznou, Czechia|Aalborg Universitetshospital, Aalborg, Denmark|Aarhus Universitetshospital, Skejby, Aarhus N, Denmark|Steno Diabetes Center Copenhagen, Gentofte, Denmark|Holbæk Sygehus, Holbæk, Denmark|Kolding Sygehus, Kolding, Denmark|Diagnos Klaukkalan Lääkäriasema, Klaukkala, Finland|Health Step Finland Oy, Kuopio, Finland|Tampereen yliopistollinen sairaala, keskussairaala, Tampere, Finland|Turun yliopistollinen keskussairaala, kantasairaala, Turku, Finland|Hopital Ambroise Pare, Boulogne billancourt, France|Hôpital Gabriel Montpied - Clermont Ferrand, Clermont Ferrand, France|Hôpital François Mitterrand - Dijon, Dijon, France|Hopital Carémeau - Nîmes, NIMES cedex 9, France|Hôpital Lariboisière - Paris, Paris, France|Cochin - Paris, Paris, France|St. Josefskrankenhaus, Heidelberg, Baden-Württemberg, Germany|Siteworks GmbH, Hannover, Niedersachsen, Germany|InnoDiab Forschung GmbH, Essen, Nordrhein-Westfalen, Germany|Medamed Studienambulanz, Leipzig, Sachsen, Germany|Private Diabetologik Praxis Dr. Täschner / Dr. Bonigut, Leipzig, Sachsen, Germany|Praxis Hr. Dr. med. Jens Taggeselle, Markkleeberg, Sachsen, Germany|Friedrich-Schiller-Uni. Jena, Jena, Thüringen, Germany|emovis GmbH, Berlin, Germany|Diabetespraxis Dr. Braun, Berlin, Germany|DKD Helios Klinik Wiesbaden, Wiesbaden, Germany|Trial Pharma Kft., Bekescsaba, Hungary|Obudai Egeszsegugyi Centrum, Budapest, Hungary|ClinDiab Kft., Budapest, Hungary|DPCKh Orszagos Hematologiai es Infektologiai Intezet, Budapest, Hungary|Belinus Bt., Debrecen, Hungary|Trial Pharma Kft., Gyula, Hungary|Kanizsai Dorottya Hospital, Nagykanizsa, Hungary|Trial Pharma Kft., Oroshaza, Hungary|Coromed Smo Kft, Pecs, Hungary|SZTE ÁOK Szent Györgyi Albert Klinikai Kozpont, Szeged, Hungary|Meitetsu Hospital, Nagoya, Aichi, Japan|Nakayama Clinic, Nagoya, Aichi, Japan|Seino Internal Medicine Clinic, Koriyama, Fukushima, Japan|Asahikawa City Hospital, Asahikawa, Hokkaido, Japan|Jiyugaoka YAMADA Clinic, Obihiro, Hokkaido, Japan|Naka Kinen Clinic, Naka, Ibaraki, Japan|Yokohama City Minato Red Cross Hospital, Yokohama, Kanagawa, Japan|Japan Red Cross Society Azumino Hospital, Azumino, Nagano, Japan|Saiki Central Hospital, Saiki, Oita, Japan|Otsu City Hospital, Otsu, Shiga, Japan|Dokkyo Medical University Hospital, Shimotsuga-gun, Tochigi, Japan|JCHO Shimonoseki Medical Center, Shimonoseki, Yamaguchi, Japan|Fukuoka Wajiro Hospital, Fukuoka, Japan|Kunisaki Makoto Clinic, Fukuoka, Japan|Kagoshima University Hospital, Kagoshima, Japan|Nagano Municipal Hospital, Nagano, Japan|Medical Corporation Kyosokai AMC Nishi-umeda Clinic, Osaka, Japan|Osaka General Medical Center, Osaka, Japan|AKTIMED Helse AS, Hamar, Norway|Sykehuset Innlandet HF Hamar, Hamar, Norway|Oslo Universitetssykehus HF, Ullevål, Oslo, Norway|Oslo universitetssykehus HF, Aker, Oslo, Norway|Centrum Badan Klinicznych PI-House, Gdansk, Poland|Vita Longa Sp. z o.o., Katowice, Poland|LANDA - Specjalist. Gabinety Lekarskie, Krakow, Poland|Diamond Clinic Specjalistyczne Poradnie Lekarskie, Krakow, Poland|Twoja Przychodnia-Centrum Medyczne Nowa Sol, Nowa Sol, Poland|Instytut Diabetologii w Warszawie, Warszawa, Poland|Futuremeds sp. z o. o., Wroclaw, Poland|DIABEDA s.r.o., Bratislava, Slovakia|MEDISPEKTRUM s.r.o., Bratislava, Slovakia|KONZILIUM s.r.o., Dubnica nad Vahom, Slovakia|NEURES, s.r.o., Krompachy, Slovakia|Liptovska nemocnica s poliklinikou MUDr. Ivana Stodolu, Liptovsky Mikulas, Slovakia|Fakultna nemocnica Nitra, Nitra, Slovakia|Tatratrial s. r. o., Roznava, Slovakia|MEDI-DIA s.r.o., Sabinov, Slovakia|Fakultna nemocnica s poliklinikou Skalica, a.s., Skalica, Slovakia|PTC-Primary care Trial Center, Göteborg, Sweden|Öbackakliniken, Härnösand, Sweden|Universitetssjukhuset Linköping, Linköping, Sweden|Center For Diabetes, Academic Specialist Center, Stockholm, Sweden|Bragee Clinics, Stockholm, Sweden|ClinSmart, Uppsala, Sweden|Avdelningen för kliniska prövningar AKP, Örebro, Sweden",,"https://ClinicalTrials.gov/show/NCT04641273"
886,"NCT04507061","Study on the Safety of the Drug Runcaciguat and How Well it Works When Given at the Highest Dose as Tolerated by Individual Patient Whose Kidneys Are Not Working Properly and Suffering at the Same Time From High Blood Sugar and/or High Blood Pressure and a Disease of the Heart and the Blood Vessels.","CONCORD","Recruiting","No Results Available","Chronic Kidney Disease","Drug: runcaciguat|Other: Placebo","Mean change in urinary albumin-to-creatinine ratio (UACR) from baseline to the average of multiple time points during treatment|Number of subjects with treatment emergent adverse event (TEAE)|Number of subjects with early discontinuations","Bayer","All","45 Years and older   (Adult, Older Adult)","Phase 2","216","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","18748|2019-003297-53","September 1, 2020","March 29, 2022","May 2, 2022","August 10, 2020",,"January 11, 2022","Medizinische Universität Graz, Graz, Austria|Medizinische Universität Innsbruck, Innsbruck, Austria|Uniklinikum Salzburg - Landeskrankenhaus, Salzburg, Austria|Klinik Landstraße - Krankenhaus Rudolfstiftung, Wien, Austria|Zentrum f. klinische Studien Dr. Hanusch GmbH, Wien, Austria|Universitätsklinikum AKH Wien, Wien, Austria|Klinik Hietzing, Wien, Austria|OL Vrouwziekenhuis - Campus Aalst, Aalst, Belgium|Hôpital Erasme/Erasmus Ziekenhuis, Bruxelles - Brussel, Belgium|UZ Gent, Gent, Belgium|UZ Leuven Gasthuisberg, Leuven, Belgium|Med Centre Diamedical 2013, Dimitrovgrad, Bulgaria|Multiprofile Hospital for Active Treatment Medline Clinic, Plovdiv, Bulgaria|MHAT Sveta Karidad, Plovdiv, Bulgaria|MHAT Dr. Bratan Shukerov AD, Smolyan, Bulgaria|MHAT ""Knyaginya Klementina - Sofia""EAD, Sofia, Bulgaria|MC Kalimat, Sofia, Bulgaria|MHAT Sveta Anna, Sofia, Bulgaria|MCOMH Preventsia-2000, Stara Zagora, Bulgaria|Aalborg Universitetshospital, Aalborg, Denmark|Steno Diabetes Center Copenhagen, Gentofte, Denmark|Holbæk Sygehus, Holbæk, Denmark|Holstebro Hospital, Holstebro, Denmark|Kolding Sygehus, Kolding, Denmark|Odense Universitetshospital, Odense C, Denmark|StudyCor Oy, Jyväskylä, Finland|Diagnos Klaukkalan Lääkäriasema, Klaukkala, Finland|Satucon / Kuopion Työterveys, Kuopio, Finland|Omena Terveys Oy, Seinäjoki, Finland|Turun yliopistollinen keskussairaala, kantasairaala, Turku, Finland|Klinikum der Universität Würzburg, Wuerzburg, Bayern, Germany|Medizinische Hochschule Hannover (MHH), Hannover, Niedersachsen, Germany|Herz- und Diabeteszentrum Nordrhein-Westfalen (HDZ NRW), Bad Oeynhausen, Nordrhein-Westfalen, Germany|DaVita Clinical Research Deutschland GmbH, Düsseldorf, Nordrhein-Westfalen, Germany|InnoDiab Forschung GmbH, Essen, Nordrhein-Westfalen, Germany|Medamed Studienambulanz, Leipzig, Sachsen, Germany|Barzilai Medical Center, Ashkelon, Israel|Lady Davis Carmel Medical Center, Haifa, Israel|Edith Wolfson Medical Center, Holon, Israel|Hadassah Hebrew University Hospital Ein Kerem, Jerusalem, Israel|Health Corporation of Galilee Medical Center, Nahariya, Israel|Clalit Health Services Rabin Medical Center-Beilinson Campus, Petah Tikva, Israel|Chaim Sheba Medical Center, Ramat Gan, Israel|The Baruch Padeh Medical Center, Poriya, Tiberias, Israel|A.O.U. Luigi Vanvitelli, Napoli, Campania, Italy|A.O.U. di Bologna Policlinico S.Orsola Malpighi, Bologna, Emilia-Romagna, Italy|IRCCS Ospedale Policlinico San Martino, Genova, Liguria, Italy|Istituto Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Lombardia, Italy|Ospedale San Raffaele s.r.l., Milano, Lombardia, Italy|IRCCS Centro Cardiologico Monzino, Milano, Lombardia, Italy|B_Serwis Popenda Spólka Jawna, Chorzow, Poland|Uniwersyteckie Centrum Kliniczne Warszawskiego UM, Warszawa, Poland|Centralny Szpital Kliniczny MSWiA w Warszawie, Warszawa, Poland|Miedzyleski Szpital Specjalistyczny, Warszawa, Poland|FMC-dialyzacne sluzby, s.r.o., Bratislava, Slovakia|FMC-dialyzacne sluzby, s.r.o., Kosice, Slovakia|BIODIAL, spol. s r.o., Puchov, Slovakia|Medivasa s.r.o., Zilina, Slovakia|Complexo Hospitalario Universitario de Ferrol, Ferrol, A Coruña, Spain|Complejo Hospitalario Universitario A Coruña, A Coruña, Spain|Hospital del Mar, Barcelona, Spain|Hospital Quirón, Barcelona, Spain|Ciutat Sanitària i Universitaria de la Vall d'Hebron, Barcelona, Spain|Hospital Universitario Virgen de las Nieves, Granada, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hospital Universitario Dr. Peset, Valencia, Spain|PTC-Primary care Trial Center, Göteborg, Sweden|Clemenstorget Hjärtmottagning, Lund, Sweden|Akademiska Sjukhuset, Uppsala, Sweden|ClinSmart, Uppsala, Sweden|Avdelningen för kliniska prövningar AKP, Örebro, Sweden|Medical center LLC "" Fresenius medical care Ukraine"", Cherkasy, Ukraine|Dnepropetrovsk regional hospital n.a. I. I. Mechnikov, Dnipro, Ukraine|Private enterprise private production company "" Acinus"", Kropyvnytskyi, Ukraine|Kyiv City Center of Nephrology and Dialysis, Kyiv, Ukraine|Medical Center of Edelweiss Medics LLC, Kyiv, Ukraine|Kyiv City Center of Nephrology and Dialysis, Kyiv, Ukraine|Volyn Regional Clinical Hospital, Lutsk, Ukraine|Ternopil University Hospital, Ternopil, Ukraine|Zaporizhzhia Regional Clinical Hospital, Zaporizhzhya, Ukraine",,"https://ClinicalTrials.gov/show/NCT04507061"
887,"NCT02547220","A Multicenter Study to Evaluate the Efficacy and Safety of Cinryze® for the Treatment of Acute Antibody-mediated Rejection in Participants With Kidney Transplant",,"Terminated","Has Results","Acute Antibody-Mediated Rejection (AMR)","Biological: Cinryze®|Drug: Placebo","Percentage of Participants With New or Worsening Transplant Glomerulopathy (TG) at Month 6 Post-Treatment|Number of Participants With All-Cause Graft Failure at Month 48|Change From Baseline in Renal Function up to Month 48|Change From Baseline With Pre-Antibody-Mediated Rejection (AMR) in Renal Function up to Month 48|Number of Participants With Proteinuria Levels at Month 48|Change From Pre-Antibody-Mediated Rejection (AMR) Baseline in Histopathology Per Banff Criteria at Month 6|Number of Participants With All-Cause Graft Failure at Month 6|Number of Participants With Graft Failure Due to Antibody-Mediated Rejection (AMR) Episodes at Month 48|Time to All-Cause Graft Failure up to Month 48|Time to Graft Failure Due to Antibody-Mediated Rejection (AMR) Episodes up to Month 48|Number of Participants With Resolution of the Qualifying Antibody-Mediated Rejection (AMR) Episodes at Month 48|Time to Resolution of Qualifying Antibody-Mediated Rejection (AMR) Episodes up to Month 48|Number of Participants Who Were Alive at Month 36|Time to All-Cause Mortality up to Month 48|Number of Participants With Treatment-emergent Adverse Events (TEAEs)","Shire|Takeda","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","39","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SHP616-302|2015-000726-11","May 20, 2016","May 31, 2019","May 31, 2019","September 11, 2015","July 13, 2020","July 13, 2020","Kidney Transplant Research Office at UCLA, Los Angeles, California, United States|Keck School of Medicine at USC, Los Angeles, California, United States|University of California San Francisco, San Francisco, California, United States|University Of Colorado School Of Medicine, Aurora, Colorado, United States|MedStar Georgetown University Hospital, Washington, District of Columbia, United States|Jackson Memorial Hospital, Miami, Florida, United States|Florida Hospital Transplant Institute, Orlando, Florida, United States|Piedmont Hospital, Atlanta, Georgia, United States|Northwestern Memorial Hospital, Chicago, Illinois, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Johns Hopkins University, Baltimore, Maryland, United States|Brigham and Womens Hospital, Boston, Massachusetts, United States|University of Minnesota, Minneapolis, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Saint Barnabas Medical Center, Livingston, New Jersey, United States|Mount Sinai Hospital, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|New York Presbyterian Hospital - Weill-Cornell, New York, New York, United States|NYU Longone Medical Center, White Plains, New York, United States|University of Cincinnati, Cincinnati, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Ohio State University Medical Center, Columbus, Ohio, United States|INTEGRIS Nazih Zuhdi Transplant Institute, Oklahoma City, Oklahoma, United States|University of Pittsburgh Medical Center, Monroeville, Pennsylvania, United States|University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Baylor All Saints Medical Center, Fort Worth, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|University of Utah Health Sciences Center, Salt Lake City, Utah, United States|Providence Health Care Research Institute, Vancouver, British Columbia, Canada|Royal Victoria Hospital, Montreal, Quebec, Canada|Hotel Dieu, Nantes, Loire-Atlantique, France|Hopital Henri Mondor, Créteil, Val-De-Marne, France|CHU Michallon, Grenoble, France|Centre Hospitalier Universitaire de Bicêtre, Le Kremlin-Bicêtre, France|Hôpital Saint Louis, Paris, France|Groupe Hospitalier Necker Enfants Malades, Paris, France|Hôpital de Rangueil, Toulouse, France|Universität Heidelberg, Heidelberg, Baden-Württemberg, Germany|Universitätsklinikum Frankfurt, Steinbach, Hessen, Germany|Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany|Universitair Medisch Centrum Groningen, Groningen, Netherlands|Erasmus MC, Rotterdam, Netherlands|Hospital Universitario Germans Trias i Pujol, Badalona, Barcelona, Spain|Hospital Universitari de Bellvitge, Barcelona, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/20/NCT02547220/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/20/NCT02547220/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02547220"
888,"NCT02404779","Treatment of Intracranial Hypertension of Severe Tramatic Brain Injured Patients. Physiopathologic Effects of Neuromuscular Blocking Agents","THIC Cu","Recruiting","No Results Available","Traumatic Brain Injury|Intracranial Hypertension","Drug: cisatracurium besilate|Other: Placebo","area under the curve of the temporal evolution of intracranial pressure|Course of intracranial and cerebral perfusion pressures and various cerebral monitoring data if available (SvjO2, PtiO2)|Monitoring of the time spent by intracranial pressure above 20 mmHg using continuous recording|Course of intracranial pressure based on the type of brain injury|Monitoring of the curare effect|Course of ventilation parameters|Course of transcranial Doppler data|Course of arterial blood gas data|Course of plasma and cerebrospinal fluid concentrations of cistracurium and laudanosine|Cerebrospinal fluid concentrations of cisatracurium and laudanosin in case of cerebrospinal fluid derivation|Occurrence of cardiovascular complications|Occurrence of pulmonary complications|Occurrence of renal complications|Occurrence of infectious complications|Doses of vasopressors or catecholamines|Need to increase therapeutics","University Hospital, Clermont-Ferrand","All","18 Years and older   (Adult, Older Adult)","Phase 4","34","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CHU-0225|2014-004951-30","March 19, 2015","March 19, 2022","June 18, 2022","April 1, 2015",,"July 7, 2020","CHU de Clermont-Ferrand, Clermont-Ferrand, France",,"https://ClinicalTrials.gov/show/NCT02404779"
889,"NCT02187120","Pre-hospital Anti-fibrinolytics for Traumatic Coagulopathy and Haemorrhage (The PATCH Study)","PATCH","Recruiting","No Results Available","Wounds and Injuries|Acute Coagulopathy","Drug: Tranexamic Acid|Drug: Placebo","The proportion of patients with a favourable outcome (moderate disability or good recovery, GOSE scores 5-8) compared to those who have died (GOSE 1), or have severe disability (GOSE 2-4).|Units of blood products used (red blood cells, plasma, platelets, prothrombin complex concentrate, fibrinogen, Factor VIIa, cryoprecipitate)|Coagulation assessed using the international normalised ratio (INR)|Coagulation assessed by activated partial thromboplastin time (APTT)|Platelet count|Vascular occlusive events (myocardial infarction, stroke, deep venous thrombosis (DVT), pulmonary embolus (PE))|Ventilator-free days|Mortality|Proportion of deaths due to bleeding, vascular occlusion (pulmonary embolus, stroke, acute myocardial infarction), multi-organ failure, or head injury|Cumulative incidence of sepsis|Quality of life measured using WHODAS 2.0|Quality of life measured using the EuroQOL 5 dimensions questionnaire (EQ-5D)|Number of participants with serious adverse events|Coagulation assessed by fibrinogen","Monash University|National Health and Medical Research Council, Australia|Health Research Council, New Zealand","All","18 Years and older   (Adult, Older Adult)","Phase 3","1316","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","APP1044894|U1111-1160-6738","July 2014","January 2021","January 2021","July 10, 2014",,"March 11, 2020","Lismore Base Hospital, Lismore, New South Wales, Australia|NNSW Medical Retrieval Service, Lismore, New South Wales, Australia|John Hunter Hospital, Newcastle, New South Wales, Australia|CareFlight, Northmead, New South Wales, Australia|Orange Base Hospital, Orange, New South Wales, Australia|Ambulance Service of New South Wales, Rozelle, New South Wales, Australia|Royal North Shore Hospital, St Leonards, New South Wales, Australia|Liverpool Hospital, Sydney, New South Wales, Australia|Wagga Wagga Base Hospital, Wagga Wagga, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|St John Ambulance, Darwin, Northern Territory, Australia|Royal Darwin Hospital, Darwin, Northern Territory, Australia|Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia|Princess Alexandra Hospital, Brisbane, Queensland, Australia|Gold Coast Hospital, Gold Coast, Queensland, Australia|Queensland Ambulance Service, Kedron, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Flinders Medical Centre, Bedford Park, South Australia, Australia|South Australia Ambulance Service, Eastwood, South Australia, Australia|Ambulance Tasmania, Hobart, Tasmania, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|Ambulance Victoria, Melbourne, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Melbourne, Victoria, Australia|St John Ambulance Western Australia, Geraldton, Western Australia, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|St John Ambulance, Albany, New Zealand|Auckland City Hospital, Auckland, New Zealand|Middlemore Hospital, Auckland, New Zealand|Waikato Hospital, Hamilton West, New Zealand|Hawke's Bay, Hastings, New Zealand|Wellington Free Ambulance, Wellington, New Zealand|Wellington Hospital, Wellington, New Zealand",,"https://ClinicalTrials.gov/show/NCT02187120"
890,"NCT04386603","Risk Factors for Postoperative Shoulder-tip Pain After Laparoscopic Surgery Undergoing General Anesthesia",,"Completed","No Results Available","Laparoscopic Surgery|Anesthesia",,"inpatient department|sex|age|body mass index(BMI)|ASA grade|operative position|peritoneal drainage|operative duration|the use of sufentanil|the use of fentanyl|the use of remifentanil|the use of morphine|the use of butophanol|the use of sevoflurane|the use of flubiprofen|the use of parecoxib|the use of dezocine|the use of tramadol|the use of intravenous lidocaine|the use of dexamethasone|the use of methylprednisolone|the use of deep neuromuscular block|the use of peripheral nerve block|the use of tracer-site infiltration with ropinvacaine|the use of patient-controlled intravenous analgesia|incidence of postoperative shoulder-tip pain after laparoscopic surgery undergoing general anesthesia","Shenzhen Second People's Hospital|Shenzhen Third People's Hospital","All","18 Years and older   (Adult, Older Adult)",,"1311","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","KS20190903004-FS02","June 1, 2019","December 31, 2019","December 31, 2019","May 13, 2020",,"May 19, 2020","Shenzhen Second People's Hospital, Shenzhen, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT04386603"
891,"NCT01147302","A Pilot Study to Evaluate the Use of C1 Esterase Inhibitor (Human) in Patients With Acute Antibody-Mediated Rejection",,"Completed","Has Results","Graft Rejection","Biological: Placebo|Biological: C1 Esterase Inhibitor (Human)","Change From Baseline in Histopathology Endpoints|Number of Participants With Resolution of The Qualifying Episode of Antibody-Mediated Rejection (AMR)|Change From Baseline in Serum Creatinine|Change From Baseline in Creatinine Clearance|Number of Plasmapheresis Sessions|Number of Participants Who Required Salvage Splenectomy|Number of Deaths|Number of Participants With Allograft Failure|Serum Concentrations of C1 Inhibitor (C1 INH) Antigen|Serum Concentrations of C1 INH Functional Activity|Time to Maximum Plasma Concentration (Tmax) of C1 INH|Area Under The Concentration-Time Curve (AUC) of C1 INH Antigen|Area Under The Concentration-Time Curve (AUC) of C1 INH Functional Activity","Shire|Takeda","All","18 Years and older   (Adult, Older Adult)","Phase 2","18","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","0624-201|2012-000441-12","August 24, 2011","April 19, 2013","June 28, 2013","June 22, 2010","July 9, 2015","June 11, 2021","ViroPharma Investigative Site, Los Angeles, California, United States|ViroPharma Investigative Site, Baltimore, Maryland, United States|ViroPharma Investigative Site, Minneapolis, Minnesota, United States|ViroPharma Investigative Site, Cincinnati, Ohio, United States|ViroPharma Investigative Site, Heidelberg, Germany",,"https://ClinicalTrials.gov/show/NCT01147302"
892,"NCT01713218","Effect on Tumor Perfusion of a Chemotherapy Combining Gemcitabine and Vismodegib Before Surgery in Pancreatic Cancer","NEOPACHI-001","Unknown status","No Results Available","Pancreatic Adenocarcinoma Resectable","Drug: gemcitabine|Drug: Vismodegib|Procedure: Neoadjuvant chemotherapy","""Dynamic"" tumor response rate as defined by a 20% modification of tumoral perfusion and cellular density parameters.|Number of participants with adverse events as assessed by National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Effects (CTCAE) V4.0.","Jean-Luc Van Laethem|Roche Pharma AG|Erasme University Hospital","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","21","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2012-003516-31","December 2012","June 2014","December 2016","October 24, 2012",,"October 24, 2012","Antwerp University Hospital (UZA), Edegem, Antwerpen, Belgium|Erasme University Hospital (ULB), Brussels, Belgium",,"https://ClinicalTrials.gov/show/NCT01713218"
893,"NCT03444103","A Pilot Trial of Clazakizumab in Late ABMR",,"Completed","No Results Available","Antibody-mediated Rejection","Drug: Clazakizumab / Clazakizumab|Drug: Placebo / Clazakizumab","Number of adverse events and severe adverse events (AE's, SAE's)|Anti-clazakizumab antibodies in serum|Clazakizumab serum concentration|Pantoprazole serum concentration|Protocol biopsy results - microcirculation inflammation|Protocol biopsy results - chronic damage|Protocol biopsy results - molecular signs of ABMR|Protocol biopsy results - ABMR phenotype|Anti-HLA antibody levels - antibody strength|Anti-HLA antibody levels - number of DSA|Anti-HLA antibody levels - broadness of antibody reactivity|Allograft function - eGFR|Allograft function - protein excretion in spot urine|Total IgG concentration|Total IgM concentration|Total IgA concentration|IgG subclass 1 (IgG1)|IgG subclass 2 (IgG2)|IgG subclass 3 (IgG3)|IgG subclass 4 (IgG4)|Effect on leukocyte subsets in peripheral blood|Cytokine patterns and endothelial activation/injury markers in serum|Effect on IL-6 gene expression in peripheral blood cells|Effect on IL-6R gene expression in peripheral blood cells|Patient survival|Graft survival|Occurrence of biopsy-proven acute rejection necessitating rejection treatment","Medical University of Vienna|CSL Behring|University of Alberta|Charite University, Berlin, Germany","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 2","20","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","EK1428/2017|2017-001604-30","January 16, 2018","June 30, 2020","June 30, 2020","February 23, 2018",,"September 9, 2020","Medical University of Vienna, Vienna, Austria|Charité University, Berlin, Germany","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/03/NCT03444103/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03444103"
894,"NCT03859388","Longitudinal Changes in Donor-Derived Cell-Free DNA With Tocilizumab Treatment for Chronic Antibody-Mediated Rejection",,"Enrolling by invitation","No Results Available","Rejection Chronic Renal|Kidney Transplant Rejection",,"Change in the percentage of donor-derived cell-free DNA|Difference in Change in Donor-Derived Cell-Free DNA Between Responders and Non-Responders|Change in estimated glomerular filtration rate (GFR)|Change in glomerulitis histology score with treatment|Change in peritubular capillaritis histology score with treatment|Change in C4d score with treatment|Change in glomerular double contours score with treatment|Change in interstitial fibrosis score with treatment|Change in tubular atrophy score with treatment","Cedars-Sinai Medical Center","All","18 Years and older   (Adult, Older Adult)",,"10","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Pro00053105","March 1, 2019","December 2021","December 2021","March 1, 2019",,"January 27, 2021","Cedars-Sinai Medical Center, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT03859388"
895,"NCT05021484","Felzartamab in Late Antibody-Mediated Rejection",,"Not yet recruiting","No Results Available","Antibody-mediated Rejection","Drug: Felzartamab|Drug: Placebo","Incidence of treatment-emergent adverse events|Felzartamab serum concentration|Anti-Felzartamab antibodies|Morphologic ABMR categories|Serum donor-specific antibody (DSA) levels|Serum immunoglobulin levels|Leukocyte subsets in peripheral blood|Immunologic biomarkers|Torque Teno virus|eGFR|Proteinuria|Graft loss|Death|Glomerulitis plus peritubular capillaritis sum score|Transplant glomerulopathy score|C4d score|Molecular ABMR score|Molecular ABMR categories","Farsad Eskandary|Charite University, Berlin, Germany|University of Alberta|MorphoSys AG|Medical University of Vienna","All","19 Years to 80 Years   (Adult, Older Adult)","Phase 2","20","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EK1161/2021|2021-000545-40","October 2021","October 2024","December 2024","August 25, 2021",,"August 25, 2021","Medical University of Vienna, Vienna, Austria|Charité University, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT05021484"
896,"NCT05058170","Renal Allograft Fibrosis Study",,"Not yet recruiting","No Results Available","Renal Allograft Fibrosis",,"Presence of renal allograft fibrosis|Banff scoring system for fibrosis|Presence of renal allograft inflammation|Banff scoring system for inflammation|4-gene fibrosis signature score|3-gene inflammation score|Change in estimated Glomerular filtration rate (eGFR)|Change in Protein level in urine|Change in Interstitial fibrosis and tubular atrophy (IFTA) stage","Icahn School of Medicine at Mount Sinai|Weill Medical College of Cornell University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","18 Years and older   (Adult, Older Adult)",,"280","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","GCO 20-2690|R01DK129888","October 2021","April 30, 2026","October 30, 2026","September 27, 2021",,"September 27, 2021","Weill Cornell Medicine, New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT05058170"
897,"NCT02357836","Neoadjuvant Itraconazole in Non-small Cell Lung Cancer",,"Completed","Has Results","Non-small Cell Lung Cancer","Drug: Itraconazole","Changes in Tumor Tissue Microvessel Density [MVD] From Baseline|Change in HIF1α From Baseline|Change in VEGFR2 From Baseline|Change in Phospho-VEGFR2 From Baseline|Mean Percent Change in Other Plasma Cytokine From Baseline to Post-Treatment|Mean Percent Change in Angiogenic Cytokines From Baseline|Changes in Perfusion (Ktrans)|Number of Participants With Tumor SMO (Smoothened) Gene Mutations, GLI2 and CCND1 Copy Number, PI3K-mTOR Pathway Activation|Change in Tumor Tissue GLI1, SHH and PTCH1 Levels From Baseline|Change in Skin Biopsy GLI1 Levels From Baseline|Change in Skin Biopsy SHH Levels From Baseline|Change in Skin Biopsy PTCH1 Levels From Baseline|Number of Participants With Tumor Cell Proliferation/Apoptosis|Itraconazole Levels in Post-treatment Serum|Itraconazole Levels in Tumor Tissue|Itraconazole Levels in Skin Biopsy","University of Texas Southwestern Medical Center|United States Department of Defense","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","13","Other|U.S. Fed","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STU 122014-038","June 2015","July 2018","July 2018","February 6, 2015","May 3, 2021","May 3, 2021","UT Southwestern Medical Center, Dallas, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/36/NCT02357836/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02357836"
898,"NCT02444429","3-month Screening Biopsy to Optimize the Immunosuppression in Renal Transplantation","I4BiS","Recruiting","No Results Available","Renal Transplantation","Drug: Corticosteroid boluses Methylprednisolone|Other: No therapeutic modification|Other: Stop maintenance corticotherapy","Evolution of graft inflammatory lesions|Graft function at 1 year post-transplantation|Evolution of chronic histological lesions|Evaluation of the immunological risk associated with the different strategies of corticosteroid treatment adaptation|Evaluation of the metabolic tolerance profile associated with the different strategies of corticosteroid treatment adaptation|Evaluation of the infectious tolerance profile associated with the different strategies of corticosteroid treatment adaptation|Evaluation of the impact of the different strategies for corticosteroid use on quality of life.","Hospices Civils de Lyon","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","346","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","2014.848","September 2015","June 2023","June 2023","May 14, 2015",,"June 4, 2021","Service de Néphrologie,Transplantation, Dialyse I - Hôpital Pellegrin - CHU Bordeaux, Bordeaux, France|Service de Néphrologie, Hémodialyse, Transplantations Rénales - Hôpital de la Cavale Blanche - CHU de Brest, BREST Cedex, France|Service de Néphrologie - Hôpital Claude Huriez - CHU de Lille, Lille, France|Service de Néphrologie, Transplantation et Immunologie Clinique - Hôpital Edouard Herriot - Hospices Civils de Lyon, LYON Cedex 03, France|Institut de Transplantation, Urologie et Néphrologie (ITUN) - CHU de Nantes, NANTES cedex 01, France|Unité de Transplantation Rénale - Hôpital Pasteur - CHU de Nice, Nice, France|Service de Néphrologie et Transplantation - Hôpital Saint-Louis, PARIS Cedex 10, France|Service de Transplantation - Hôpital Universitaire Necker, Paris, France|Service Urgences Néphrologiques et Transplantation Rénale - Hôpital Tenon, Paris, France|Service de Néphrologie et Transplantation - Nouvel Hôpital Civil - CHRU Strasbourg, Strasbourg, France|Département de Néphrologie et Transplantation d'Organes - Hôpital Rangueil - CHU de Toulouse, TOULOUSE Cedex 9, France",,"https://ClinicalTrials.gov/show/NCT02444429"
899,"NCT03191799","A Study to Evaluate the Safety and Tolerability of Prophylactic Emicizumab in Hemophilia A Patients With Inhibitors","STASEY","Completed","Has Results","Hemophilia A","Drug: Emicizumab","Overall Summary of the Number of Participants With Adverse Events, Severity Assessed According to the World Health Organization (WHO) Toxicity Grading Scale|Adverse Events (AEs) Rates Per 100 Patient-Years for All-Grade AEs, Serious AEs, and Grade ≥3 AEs|Number of Participants by Hematology and Biochemistry Laboratory Parameter Test Results as Shifts From the WHO Toxicity Grade at Baseline to the Worst WHO Toxicity Grade Post-Baseline|Change From Baseline in Body Temperature at Specified Timepoints|Change From Baseline in Systolic Blood Pressure at Specified Timepoints|Change From Baseline in Diastolic Blood Pressure at Specified Timepoints|Change From Baseline in Pulse Rate at Specified Timepoints|Change From Baseline in Respiratory Rate at Specified Timepoints|Change From Baseline in Body Weight at Specified Timepoints|Model-Based Annualized Bleed Rates (ABR) for Treated Bleeds, All Bleeds, Treated Joint Bleeds, Treated Target Joint Bleeds, and Treated Spontaneous Bleeds|Mean Calculated Annualized Bleed Rates (ABR) for Treated Bleeds, All Bleeds, Treated Joint Bleeds, Treated Target Joint Bleeds, and Treated Spontaneous Bleeds|Median Calculated Annualized Bleed Rates (ABR) for Treated Bleeds, All Bleeds, Treated Joint Bleeds, Treated Target Joint Bleeds, and Treated Spontaneous Bleeds|Percentage of Participants by the Categorized Number of Bleeds for Treated Bleeds|Percentage of Participants by the Categorized Number of Bleeds for All Bleeds|Percentage of Participants by the Categorized Number of Bleeds for Treated Spontaneous Bleeds|Percentage of Participants by the Categorized Calculated Annualized Bleed Rates (ABR) for Treated Bleeds|Percentage of Participants by the Categorized Calculated Annualized Bleed Rates (ABR) for All Bleeds|Percentage of Participants by the Categorized Calculated Annualized Bleed Rates (ABR) for Treated Spontaneous Bleeds|Change From Baseline in the Hemophilia Adult Quality of Life (Haem-A-QoL) Questionnaire Total Score at Specified Timepoints, Adult Participants|Percentage of Participants With an Improvement From Baseline Greater Than the Responder Threshold for the Hemophilia Adult Quality of Life (Haem-A-QoL) Questionnaire Total Score at Specified Timepoints|Change From Baseline in the Hemophilia Adult Quality of Life (Haem-A-QoL) Questionnaire Physical Health Domain Score at Specified Timepoints, Adult Participants|Percentage of Participants With an Improvement From Baseline Greater Than the Responder Threshold for the Hemophilia Adult Quality of Life (Haem-A-QoL) Questionnaire Physical Health Domain Score at Specified Timepoints|Change From Baseline in the Hemophilia Adult Quality of Life (Haem-A-QoL) Questionnaire Treatment Domain Score at Specified Timepoints, Adult Participants|Change From Baseline in the Hemophilia Adult Quality of Life (Haem-A-QoL) Questionnaire Work and School Domain Score at Specified Timepoints, Adult Participants|Change From Baseline in the Hemophilia Adult Quality of Life (Haem-A-QoL) Questionnaire Dealing With Hemophilia Domain Score at Specified Timepoints, Adult Participants|Change From Baseline in the Hemophilia Adult Quality of Life (Haem-A-QoL) Questionnaire Feelings Domain Score at Specified Timepoints, Adult Participants|Change From Baseline in the Hemophilia Adult Quality of Life (Haem-A-QoL) Questionnaire Family Planning Domain Score at Specified Timepoints, Adult Participants|Change From Baseline in the Hemophilia Adult Quality of Life (Haem-A-QoL) Questionnaire Future Domain Score at Specified Timepoints, Adult Participants|Change From Baseline in the Hemophilia Adult Quality of Life (Haem-A-QoL) Questionnaire Partnership and Sexuality Domain Score at Specified Timepoints, Adult Participants|Change From Baseline in the Hemophilia Adult Quality of Life (Haem-A-QoL) Questionnaire Sports and Leisure Domain Score at Specified Timepoints, Adult Participants|Change From Baseline in the Hemophilia Adult Quality of Life (Haem-A-QoL) Questionnaire View of Yourself Domain Score at Specified Timepoints, Adult Participants|Change From Baseline in the Hemophilia Quality of Life Short Form (Haemo-QoL-SF) Questionnaire Total Score at Specified Timepoints, Adolescent Participants|Percentage of Participants With an Improvement From Baseline Greater Than the Responder Threshold for the Hemophilia Quality of Life Short Form (Haemo-QoL-SF) Questionnaire Total Score at Specified Timepoints|Change From Baseline in the Hemophilia Quality of Life Short Form (Haemo-QoL-SF) Questionnaire Physical Health Domain Score at Specified Timepoints, Adolescent Participants|Percentage of Participants With an Improvement From Baseline Greater Than the Responder Threshold for the Hemophilia Quality of Life Short Form (Haemo-QoL-SF) Questionnaire Physical Health Domain Score at Specified Timepoints|Change From Baseline in the Hemophilia Quality of Life Short Form (Haemo-QoL-SF) Questionnaire Treatment Domain Score at Specified Timepoints, Adolescent Participants|Change From Baseline in the Hemophilia Quality of Life Short Form (Haemo-QoL-SF) Questionnaire Sports and School Domain Score at Specified Timepoints, Adolescent Participants|Change From Baseline in the Hemophilia Quality of Life Short Form (Haemo-QoL-SF) Questionnaire Dealing With Hemophilia Domain Score at Specified Timepoints, Adolescent Participants|Change From Baseline in the Hemophilia Quality of Life Short Form (Haemo-QoL-SF) Questionnaire Feelings Domain Score at Specified Timepoints, Adolescent Participants|Change From Baseline in the Hemophilia Quality of Life Short Form (Haemo-QoL-SF) Questionnaire Family Domain Score at Specified Timepoints, Adolescent Participants|Change From Baseline in the Hemophilia Quality of Life Short Form (Haemo-QoL-SF) Questionnaire Friends Domain Score at Specified Timepoints, Adolescent Participants|Change From Baseline in the Hemophilia Quality of Life Short Form (Haemo-QoL-SF) Questionnaire Other People Domain Score at Specified Timepoints, Adolescent Participants|Change From Baseline in the Hemophilia Quality of Life Short Form (Haemo-QoL-SF) Questionnaire View of Yourself Domain Score at Specified Timepoints, Adolescent Participants|Change From Baseline in the EuroQoL Five-Dimension-Five Levels Questionnaire (EQ-5D-5L) Index Utility Score at Specified Timepoints|Change From Baseline in the EuroQoL Five-Dimension-Five Levels Questionnaire (EQ-5D-5L) Quality-of-Life Visual Analogue Scale (VAS) Score at Specified Timepoints|Percentage of Participants Who Preferred the New Emicizumab Treatment or the Old Hemophilia Treatment, or Without Treatment Preference, as Assessed by the EmiPref Questionnaire|Number and Percentage of Participants With Anti-Drug Antibodies (ADAs) Against Emicizumab at Anytime Post-Baseline|Mean Trough Plasma Concentrations of Emicizumab at Specified Timepoints","Hoffmann-La Roche","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","195","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MO39129|2016-004366-25","September 5, 2017","November 19, 2020","November 19, 2020","June 19, 2017","June 11, 2021","June 11, 2021","Royal Prince Alfred Hospital; Haematology, Camperdown, New South Wales, Australia|Alfred Hospital, Melbourne, Victoria, Australia|Fiona Stanley Hospital, Murdoch, Western Australia, Australia|UZ Leuven Gasthuisberg, Leuven, Belgium|Centro de Hematologia E Hemoterapia Do Parana - Hemepar, Curitiba, PR, Brazil|Instituto Estadual de Hema, Rio de Janeiro, RJ, Brazil|Hospital das Clinicas - UNICAMP, Campinas, SP, Brazil|Faculdade de Medicina de Ribeirão Preto - Universidade de Sao Paulo, Ribeirao Preto, SP, Brazil|Kaye Edmonton Clinic, Edmonton, Alberta, Canada|CancerCare Manitoba; Neuro-Oncology, Winnipeg, Manitoba, Canada|McMaster University Health Sciences Center, Hamilton, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Centro de Atención e Investigación Médica CAIMED S.A.S, Localidad Puente Aranda, Colombia|Hospital Pablo Tobon Uribe, Medellin, Colombia|Helsingin yliopistollinen keskussairaala, Meilahden sairaala, Helsinki, Finland|Vivantes Klinikum im Friedrichshain - Landsberger Allee, Angiologie und Hämostaseologie, Berlin, Germany|Universitätsklinikum Bonn; Institut für Experimentelle Hämatologie und Transfusionsmedizin, Bonn, Germany|Hämophiliezentrum Med. Klinik III/Institut für Transfusionsmedizin; Johann Wolfgang Goethe-Univers., Frankfurt/M., Germany|Universitätsklinikum Leipzig, Innere Medizin, Neurologie, Dermatologie; Zentrum für Hämostaseologie, Leipzig, Germany|Hämophilie-Zentrum Rhein Main GmbH, Mörfelden-Walldorf, Germany|Klinikum der Universität München, Campus Innenstadt; Hämostaseologische Ambulanz/Hämophiliezentrum, München, Germany|Oncomedica, Guatemala, Guatemala|Magyar Honvédség Egészségügyi Központ; Országos Haemophilia Központ, Budapest, Hungary|Országos Vérellátó Szolgálat - Győri Regionális Vérellátó Központ, Győr, Hungary|University of Pecs, I st Dept of Internal Medicine, Pecs, Hungary|St. John's Medical College & Hospital; Department of Medicine, Bengaluru, Karnataka, India|King Edward Memorial Hospital and Seth G.S. Medical College; Department of Hematology, Mumbai, Maharashtra, India|Fortis Hospitals Limited, Mumbai, Maharashtra, India|Sahyadri Speciality Hospital; Hematology & Bone Marrow Unit, Pune, Maharashtra, India|Christian Medical College & Hospital; Department of Haematology, Vellore, Maharashtra, India|Nil Ratan Sircar Medical College and Hospital; Department of Hematology, Kolkata, WEST Bengal, India|Grant Medical Foundation, Ruby Hall Clinic, Pune, India|Sheba Medical Center - National Hemophilia Center, Tel Hashomer, Israel|AOU Federico II; Medicina Clinica Chirurgia Centro Emocoaugulopatie e Emofilia, Napoli, Campania, Italy|AOU Policlinico S. Orsola Malpighi; U.O. Angiologia e Malattie della Coagulazione Marino Golinelli, Bologna, Emilia-Romagna, Italy|AOU di Parma; Dip Emergenza-Urgenza Centro Riferimento Regionale per l'emofilia, Parma, Emilia-Romagna, Italy|Universita' Degli Studi La Sapienza-Ist.Di Ematologia; Dip Biot Cel e Ematol, Roma, Lazio, Italy|IRCCS Ca' Granda Ospedale Maggiore Policlinico; Centro Emofilia e Trombosi ""Angelo Bianchi e Bonomi"", Milano, Lombardia, Italy|AO Città Salute e Scienza D-Osp S. G. Battista Molinette; SSCVD Malattie Tromboti e Emorragiche, Torino, Piemonte, Italy|Azienda Uni Ria Policlinico P. Giaccone ; Divisione Di Ematologia E Trapianto, Palermo, Sicilia, Italy|AOU Careggi; SOD Malattie Emorragiche, Firenze, Toscana, Italy|Azienda Ospedaliera di Padova; Centro Emofilia, Padova, Veneto, Italy|Hospital General de México, Distrito Federal, Mexico CITY (federal District), Mexico|CENTRO MEDICO NACIONAL SIGLO XXI; Banco de Sangre, Mexico City, Mexico CITY (federal District), Mexico|Hospital de Especialidades Centro Medico Nacional La Raza; Haematology, Mexico City, Mexico|Erasmus MC / location Sophia Kinderziekenhuis, Rotterdam, Netherlands|Universitair Medisch Centrum Utrecht, Utrecht, Netherlands|Complejo Hospitalario Arnulfo Arias Madrid; Servicio de Hematología, Panama City, Panama|Instytut Hematologii i Transfuzjologii; Klinika Zaburzeń Hemostazy i Chorób Wewnętrznych, Warsaw, Poland|Hospital Geral; Servico de Imuno-Hemoterapia, Coimbra, Portugal|Hospital de Santa Maria; Servico de Imuno-Hemoterapia; Servico de Imuno-Hemoterapia, Lisboa, Portugal|Hospital de Sao Joao; Servico de Imuno-Hemoterapia; Servico de Imuno-Hemoterapia, Porto, Portugal|Louis Turcanu Emergency Clinical Hospital for Children; First Pediatric Clinic, Timisoara, Romania|Regional State Budgetary Institution of Healthcare ""Regional Cinilcal Hospital""; Pulmonology, Barnaul, Altaj, Russian Federation|Morozov Children's Municipal Clinical Hospital. Haematology department, Moscow, Russian Federation|""Hematological Scientific Center, Moscow, Russian Federation|City Outpatient Clinic #37, City Hemophilia Treatment Center, Saint Petersburg, Russian Federation|Samara State Medical University, Samara, Russian Federation|King Faisal Specialist Hospital & Research Centre; Oncology, Riyadh, Saudi Arabia|Hospital Universitario Vall de Hebron; Unidad de Hemofília, Barcelona, Spain|Hospital Universitario la Paz; Servicio de Hematologia, Madrid, Spain|Hospital Regional Universitario Carlos Haya; Servicio de Hematologia, Malaga, Spain|Hospital Universitario Virgen del Rocio; Servicio de Hematologia, Sevilla, Spain|Hospital Universitario la Fe; Servicio de Hematologia, Valencia, Spain|Sahlgrenska Universitetssjukhuset; Koagulationscentrum, Göteborg, Sweden|Karolinska Universitetssjukhuset; Koagulationsmottagningen, Solna, Sweden|Inselspital Bern; Hämatologie und Hämatologisches Zentrallabor, Bern, Switzerland|University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom|The Royal London Hospital, London, United Kingdom|Royal Free Hospital, London, United Kingdom|Royal Victoria Infirmary; Non-Malignant Haematology Research, Newcastle upon Tyne, United Kingdom|Royal Hallamshire Hospital Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT03191799/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT03191799/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03191799"
900,"NCT05010707","Transgender Estradiol Affirming Therapy","TREAT","Recruiting","No Results Available","Transgenderism","Drug: Transdermal patch|Diagnostic Test: Pro-thrombotic markers|Diagnostic Test: Metabolic markers|Diagnostic Test: Hormone Profile|Drug: Sublingual Tablet|Drug: Spironolactone","Degree of testosterone suppression by measuring total testosterone level in transgender female patients undergoing hormonal affirming therapy|Coagulation factors II, IX, XI, Protein C, Protein S, von Willebrand factor, and activated protein C resistance in transgender female patients undergoing|von Willebrand factor in transgender female patients undergoing|Llipid panel|Homeostatic Model Assessment for Insulin Resistance","Washington University School of Medicine","Male","18 Years to 30 Years   (Adult)","Phase 3","45","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","202104092","August 2, 2021","July 2024","July 2024","August 18, 2021",,"August 18, 2021","Washington University Transgender Center, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT05010707"
901,"NCT00195442","Study Evaluating Refacto For Pharmacovigilance",,"Completed","Has Results","Hemophilia A","Drug: Moroctocog alfa","Mean Number of Bleeding Episodes Per Patient Year|Mean Number of Bleeding-related Exposure Days Per Patient Year|Mean Number of Exposure Days Per Patient Year|Number of Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With de Novo Inhibitor Formation|Mean Annual ReFacto Consumption Per Patient Year|Number of Participants for Physicians' Assessment of Satisfaction With Treatment Success|Number of Participants for Physicians' Assessment of Efficacy|Number of Participants for Patients' Assessment of Efficacy|Number of Participants for Physicians' Assessment of Tolerance|Number of Participants for Patients' Assessment of Tolerance|Number of Participants for Physicians' Assessment of Handling of ReFacto|Number of Participants for Patients' Assessment of Handling of ReFacto|Number of Participants for Days of Sick Leave Per Month","Wyeth is now a wholly owned subsidiary of Pfizer","Male","Child, Adult, Older Adult",,"288","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","3082A-100690","July 1999","January 2010","January 2010","September 19, 2005","February 7, 2011","February 11, 2011","Pfizer Investigational Site, Vienna, Austria|Pfizer Investigational Site, Frankfurt, Hessen, Germany|Pfizer Investigational Site, Giessen, Hessen, Germany|Pfizer Investigational Site, Rostock, Mecklenburg-Vorpommern, Germany|Pfizer Investigational Site, Hannover, Niedersachsen, Germany|Pfizer Investigational Site, Bonn, Nordrhein-Westfalen, Germany|Pfizer Investigational Site, Halle, Sachsen-Anhalt, Germany|Pfizer Investigational Site, Stadtroda, Thuringen, Germany|Pfizer Investigational Site, Berlin, Germany|Pfizer Investigational Site, Berlin, Germany|Pfizer Investigational Site, Bermen, Germany|Pfizer Investigational Site, Erlangen, Germany|Pfizer Investigational Site, Frankfurt a. M., Germany|Pfizer Investigational Site, Hamburg, Germany|Pfizer Investigational Site, Heidelberg, Germany|Pfizer Investigational Site, Homburg, Germany|Pfizer Investigational Site, Klipphausen, Germany|Pfizer Investigational Site, Leipzig, Germany|Pfizer Investigational Site, Lubeck, Germany|Pfizer Investigational Site, Muenchen, Germany|Pfizer Investigational Site, Muenchen, Germany|Pfizer Investigational Site, Muenster, Germany|Pfizer Investigational Site, Potsdam, Germany|Pfizer Investigational Site, Schwerin, Germany|Pfizer Investigational Site, Ulm, Germany|Pfizer Investigational Site, Wiesbaden, Germany",,"https://ClinicalTrials.gov/show/NCT00195442"
902,"NCT02745054","Safety of Oral Anticoagulants Registry","SOAR","Unknown status","No Results Available","Blood Coagulation","Other: mgt of bleeding concerns/complications of oral anticoagulants","DESCRIPTIVE: timing endpoints: hours after presentation before any observed intervention|hospital length of stay|disposition after emergency care|DESCRIPTIVE: blood products utilization: # units|DESCRIPTIVE: reversal products given (with doses and timing)|DESCRIPTIVE: in-hospital complications: incidence, description|DESCRIPTIVE: costs of treatment","Hospital Quality Foundation|Boehringer Ingelheim|Daiichi Sankyo, Inc.|CSL Behring|Janssen Scientific Affairs, LLC|Portola Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)",,"1500","Other|Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","HQF-2016-SOAR-1","August 2016","August 2018","October 2018","April 20, 2016",,"May 22, 2018","University of Alabama at Birmingham, Birmingham, Alabama, United States|Hartford Hospital, Hartford, Connecticut, United States|Henry Ford Hospital, Detroit, Michigan, United States|Beaumont Hospital, Royal Oak, Michigan, United States|Washington University, Saint Louis, Missouri, United States|Kings County Hospital, Brooklyn, New York, United States|The Cleveland Clinic Foundation, Cleveland, Ohio, United States|Genesis HealthCare, Zanesville, Ohio, United States|Reading Hospital, West Reading, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02745054"
903,"NCT03155620","Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)",,"Suspended","No Results Available","Advanced Malignant Solid Neoplasm|Ann Arbor Stage III Non-Hodgkin Lymphoma|Ann Arbor Stage IV Non-Hodgkin Lymphoma|Histiocytic Sarcoma|Juvenile Xanthogranuloma|Langerhans Cell Histiocytosis|Malignant Glioma|Recurrent Childhood Rhabdomyosarcoma|Recurrent Ependymoma|Recurrent Ewing Sarcoma|Recurrent Glioma|Recurrent Hepatoblastoma|Recurrent Langerhans Cell Histiocytosis|Recurrent Malignant Germ Cell Tumor|Recurrent Malignant Solid Neoplasm|Recurrent Medulloblastoma|Recurrent Neuroblastoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Osteosarcoma|Recurrent Peripheral Primitive Neuroectodermal Tumor|Recurrent Primary Central Nervous System Neoplasm|Recurrent Rhabdoid Tumor|Recurrent Soft Tissue Sarcoma|Refractory Ewing Sarcoma|Refractory Glioma|Refractory Hepatoblastoma|Refractory Langerhans Cell Histiocytosis|Refractory Malignant Germ Cell Tumor|Refractory Malignant Solid Neoplasm|Refractory Medulloblastoma|Refractory Neuroblastoma|Refractory Non-Hodgkin Lymphoma|Refractory Osteosarcoma|Refractory Peripheral Primitive Neuroectodermal Tumor|Refractory Primary Central Nervous System Neoplasm|Refractory Rhabdoid Tumor|Refractory Rhabdomyosarcoma|Rhabdoid Tumor|Stage III Osteosarcoma AJCC v7|Stage III Soft Tissue Sarcoma AJCC v7|Stage IV Osteosarcoma AJCC v7|Stage IV Soft Tissue Sarcoma AJCC v7|Stage IVA Osteosarcoma AJCC v7|Stage IVB Osteosarcoma AJCC v7|Wilms Tumor","Procedure: Biopsy|Procedure: Biospecimen Collection|Drug: Ensartinib|Drug: Erdafitinib|Other: Laboratory Biomarker Analysis|Drug: Larotrectinib Sulfate|Procedure: Mutation Carrier Screening|Drug: Olaparib|Drug: Palbociclib|Other: Pharmacological Study|Drug: Samotolisib|Drug: Selpercatinib|Drug: Selumetinib Sulfate|Drug: Tazemetostat|Drug: Tipifarnib|Drug: Ulixertinib|Drug: Vemurafenib","Objective response rate (complete response/partial response)|Proportion of pediatric patients whose advanced tumors have pathway alterations that can be targeted by select anti-cancer drugs|Percentage of patients with grade 3 or 4 adverse events|Incidence of research biopsy related target toxicity|Progression free survival (PFS)|Pharmacokinetic (PK) parameters","National Cancer Institute (NCI)","All","12 Months to 21 Years   (Child, Adult)","Phase 2","2316","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2017-01251|APEC1621SC|U10CA180886","July 24, 2017","September 30, 2027","September 30, 2027","May 16, 2017",,"January 10, 2022","Children's Hospital of Alabama, Birmingham, Alabama, United States|Providence Alaska Medical Center, Anchorage, Alaska, United States|Banner Children's at Desert, Mesa, Arizona, United States|Phoenix Childrens Hospital, Phoenix, Arizona, United States|Banner University Medical Center - Tucson, Tucson, Arizona, United States|Arkansas Children's Hospital, Little Rock, Arkansas, United States|Kaiser Permanente Downey Medical Center, Downey, California, United States|City of Hope Comprehensive Cancer Center, Duarte, California, United States|Loma Linda University Medical Center, Loma Linda, California, United States|Miller Children's and Women's Hospital Long Beach, Long Beach, California, United States|Children's Hospital Los Angeles, Los Angeles, California, United States|Cedars Sinai Medical Center, Los Angeles, California, United States|Mattel Children's Hospital UCLA, Los Angeles, California, United States|Valley Children's Hospital, Madera, California, United States|UCSF Benioff Children's Hospital Oakland, Oakland, California, United States|Kaiser Permanente-Oakland, Oakland, California, United States|Children's Hospital of Orange County, Orange, California, United States|Lucile Packard Children's Hospital Stanford University, Palo Alto, California, United States|University of California Davis Comprehensive Cancer Center, Sacramento, California, United States|Rady Children's Hospital - San Diego, San Diego, California, United States|Naval Medical Center -San Diego, San Diego, California, United States|UCSF Medical Center-Mission Bay, San Francisco, California, United States|Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center, Denver, Colorado, United States|Connecticut Children's Medical Center, Hartford, Connecticut, United States|Yale University, New Haven, Connecticut, United States|Alfred I duPont Hospital for Children, Wilmington, Delaware, United States|MedStar Georgetown University Hospital, Washington, District of Columbia, United States|Children's National Medical Center, Washington, District of Columbia, United States|Broward Health Medical Center, Fort Lauderdale, Florida, United States|Golisano Children's Hospital of Southwest Florida, Fort Myers, Florida, United States|University of Florida Health Science Center - Gainesville, Gainesville, Florida, United States|Memorial Regional Hospital/Joe DiMaggio Children's Hospital, Hollywood, Florida, United States|Nemours Children's Clinic-Jacksonville, Jacksonville, Florida, United States|University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States|Nicklaus Children's Hospital, Miami, Florida, United States|AdventHealth Orlando, Orlando, Florida, United States|Arnold Palmer Hospital for Children, Orlando, Florida, United States|Nemours Children's Hospital, Orlando, Florida, United States|Nemours Children's Clinic - Pensacola, Pensacola, Florida, United States|Johns Hopkins All Children's Hospital, Saint Petersburg, Florida, United States|Tampa General Hospital, Tampa, Florida, United States|Saint Joseph's Hospital/Children's Hospital-Tampa, Tampa, Florida, United States|Saint Mary's Hospital, West Palm Beach, Florida, United States|Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States|Memorial Health University Medical Center, Savannah, Georgia, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States|Saint Luke's Cancer Institute - Boise, Boise, Idaho, United States|Lurie Children's Hospital-Chicago, Chicago, Illinois, United States|University of Illinois, Chicago, Illinois, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Saint Jude Midwest Affiliate, Peoria, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|Saint Vincent Hospital and Health Care Center, Indianapolis, Indiana, United States|Blank Children's Hospital, Des Moines, Iowa, United States|University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States|University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States|Norton Children's Hospital, Louisville, Kentucky, United States|Children's Hospital New Orleans, New Orleans, Louisiana, United States|Ochsner Medical Center Jefferson, New Orleans, Louisiana, United States|Eastern Maine Medical Center, Bangor, Maine, United States|Maine Children's Cancer Program, Scarborough, Maine, United States|University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States|Sinai Hospital of Baltimore, Baltimore, Maryland, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|National Institutes of Health Clinical Center, Bethesda, Maryland, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|UMass Memorial Medical Center - University Campus, Worcester, Massachusetts, United States|C S Mott Children's Hospital, Ann Arbor, Michigan, United States|Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States|Helen DeVos Children's Hospital at Spectrum Health, Grand Rapids, Michigan, United States|Bronson Methodist Hospital, Kalamazoo, Michigan, United States|Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis, Minnesota, United States|University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Children's Mercy Hospitals and Clinics, Kansas City, Missouri, United States|Cardinal Glennon Children's Medical Center, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Mercy Hospital Saint Louis, Saint Louis, Missouri, United States|Children's Hospital and Medical Center of Omaha, Omaha, Nebraska, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|University Medical Center of Southern Nevada, Las Vegas, Nevada, United States|Sunrise Hospital and Medical Center, Las Vegas, Nevada, United States|Alliance for Childhood Diseases/Cure 4 the Kids Foundation, Las Vegas, Nevada, United States|Summerlin Hospital Medical Center, Las Vegas, Nevada, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Morristown Medical Center, Morristown, New Jersey, United States|Saint Peter's University Hospital, New Brunswick, New Jersey, United States|Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States|Albany Medical Center, Albany, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|NYU Winthrop Hospital, Mineola, New York, United States|The Steven and Alexandra Cohen Children's Medical Center of New York, New Hyde Park, New York, United States|Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States|NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|NYP/Weill Cornell Medical Center, New York, New York, United States|University of Rochester, Rochester, New York, United States|Stony Brook University Medical Center, Stony Brook, New York, United States|State University of New York Upstate Medical University, Syracuse, New York, United States|New York Medical College, Valhalla, New York, United States|Mission Hospital, Asheville, North Carolina, United States|UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Carolinas Medical Center/Levine Cancer Institute, Charlotte, North Carolina, United States|Novant Health Presbyterian Medical Center, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|East Carolina University, Greenville, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Children's Hospital Medical Center of Akron, Akron, Ohio, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Rainbow Babies and Childrens Hospital, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Dayton Children's Hospital, Dayton, Ohio, United States|ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital, Toledo, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Legacy Emanuel Children's Hospital, Portland, Oregon, United States|Oregon Health and Science University, Portland, Oregon, United States|Lehigh Valley Hospital-Cedar Crest, Allentown, Pennsylvania, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Prisma Health Richland Hospital, Columbia, South Carolina, United States|BI-LO Charities Children's Cancer Center, Greenville, South Carolina, United States|Sanford USD Medical Center - Sioux Falls, Sioux Falls, South Dakota, United States|East Tennessee Childrens Hospital, Knoxville, Tennessee, United States|Saint Jude Children's Research Hospital, Memphis, Tennessee, United States|The Children's Hospital at TriStar Centennial, Nashville, Tennessee, United States|Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States|Dell Children's Medical Center of Central Texas, Austin, Texas, United States|Driscoll Children's Hospital, Corpus Christi, Texas, United States|Medical City Dallas Hospital, Dallas, Texas, United States|UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States|El Paso Children's Hospital, El Paso, Texas, United States|Cook Children's Medical Center, Fort Worth, Texas, United States|Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, United States|M D Anderson Cancer Center, Houston, Texas, United States|Covenant Children's Hospital, Lubbock, Texas, United States|UMC Cancer Center / UMC Health System, Lubbock, Texas, United States|Children's Hospital of San Antonio, San Antonio, Texas, United States|Methodist Children's Hospital of South Texas, San Antonio, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Scott and White Memorial Hospital, Temple, Texas, United States|Primary Children's Hospital, Salt Lake City, Utah, United States|University of Vermont and State Agricultural College, Burlington, Vermont, United States|Children's Hospital of The King's Daughters, Norfolk, Virginia, United States|Naval Medical Center - Portsmouth, Portsmouth, Virginia, United States|Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States|Seattle Children's Hospital, Seattle, Washington, United States|Providence Sacred Heart Medical Center and Children's Hospital, Spokane, Washington, United States|Mary Bridge Children's Hospital and Health Center, Tacoma, Washington, United States|Madigan Army Medical Center, Tacoma, Washington, United States|West Virginia University Healthcare, Morgantown, West Virginia, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States|San Jorge Children's Hospital, San Juan, Puerto Rico|University Pediatric Hospital, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT03155620"
904,"NCT02974855","PF-06741086 Multiple Dose Study in Severe Hemophilia",,"Completed","Has Results","Hemophilia A or B","Biological: PF-06741086","Number of Participants With Treatment Emergent Adverse Events (TEAEs)|Number of Participants Discontinued From Study Due to TEAEs|Number of Participants With Abnormal Laboratory Findings-Hematology|Number of Participants With Abnormal Laboratory Findings-Clinical Chemistry|Number of Participants With Abnormal Laboratory Findings-Urinalysis|Change From Baseline for Globulin by Dose Cohort|Change From Baseline for Prothrombin International Normalized Ratio (PT/INR) by Dose Cohort|Change From Baseline for Activated Partial Thromboplastin Time (aPTT) by Dose Cohort|Change From Baseline for Fibrinogen by Dose Cohort|Change From Baseline for Antithrombin III by Dose Cohort|Change From Baseline for Troponin I by Dose Cohort|Number of Participants With Vital Signs Data Meeting Pre-specified Criteria|Number of Participants With Electrocardiogram (ECG) Change Meeting Pre-specified Criteria|Number of Participants With Clinically Significant Changes in Physical Examination Findings|Number of Participants With Infusion and Injection Site Reactions|Annualized Bleeding Rate (ABR)|Plasma PF-06741086 Concentrations|Area Under the Concentration-time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of PF-06741086|Maximum Plasma Concentration (Cmax) of PF-06741086|Lowest Concentration Observed During the Dosing Interval (Cmin) of PF-06741086|Time to Reach Maximum Plasma Concentration (Tmax) of PF-06741086|Area Under the Serum Concentration-time Curve Over the Dosing Interval Tau (AUCtau) of PF-06741086|Apparent Clearance After Oral Dose (CL/F) of PF-06741086|Change From Baseline in Total Tissue Factor Pathway Inhibitor (TFPI)|Change From Baseline in Thrombin Generation (TGA) Lag Time|Change From Baseline in Thrombin Generation (TGA) Peak|Change From Baseline in Endogenous Thrombin Generation (TGA) Potential|Change From Baseline in Prothrombin Fragments 1 + 2|Change From Baseline in D-Dimer|Change From Baseline in Dilute Prothrombin Time|Number of Participants Who Tested Positive for Anti-PF-06741086 Antibody (ADA)|Number of Participants Who Tested Positive for Neutralizing Antibody (NAb)","Pfizer","Male","18 Years to 64 Years   (Adult)","Phase 2","27","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","B7841002|2016-001885-27","March 8, 2017","December 3, 2018","December 3, 2018","November 29, 2016","December 4, 2019","December 4, 2019","UC Denver Hemophilia and Thrombosis Center - Pharmacy, Aurora, Colorado, United States|UC Denver Hemophilia and Thrombosis Center, Aurora, Colorado, United States|Pharmacy, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Hospital Dr. Sotero del Rio, Santiago, Chile|Klinicki bolnicki centar Zagreb, Zagreb, Croatia|Klinika Hematologii i Transplantologii Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Phoenix Pharma (Pty) Ltd, Port Elizabeth, Eastern CAPE, South Africa|Haemophilia Comprehensive Care Centre, Johannesburg, Gauteng, South Africa|UniversitatsSpital Zurich, Klinik fur Hamatologie, Zurich, Switzerland","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/55/NCT02974855/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/55/NCT02974855/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02974855"
905,"NCT03178552","A Study to Evaluate Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)","B-FAST","Recruiting","No Results Available","Non-Small Cell Lung Cancer","Drug: Alectinib|Drug: Atezolizumab|Drug: Pemetrexed|Drug: Cisplatin|Drug: Carboplatin|Drug: Gemcitabine|Drug: Entrectinib|Drug: Cobimetinib|Drug: Vemurafenib|Drug: Bevacizumab","Cohort A: Percentage of Participants with Confirmed Objective Response as Assessed by the Investigator Based on the Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1|Cohort B: Percentage of Participants with Confirmed Objective Response as Assessed by the Investigator Based on RECIST v1.1|Cohort C: Progression Free Survival (PFS) as Assessed by the Investigator Based on RECIST v1.1 in bTMB PP1|Cohort D: Percentage of Participants with Confirmed Objective Response as Assessed by the Investigator Based on RECIST v1.1|Cohort E: Time in Response (TIR) as Assessed by the Investigator Based on RECIST v1.1|Cohort F: Investigator-Assessed Objective Response Rate (ORR) Based on RECIST v1.1|All Cohorts: Duration of Response (DOR) as Assessed by the Investigator Based on RECIST v1.1|Cohorts A, B and D: Percentage of Participants with Clinical Benefit Response as Assessed by the Investigator Based on RECIST v1.1|Cohorts A, B, D, F: PFS as Assessed by the Investigator Based on RECIST v1.1|All Cohorts: Duration of Response as Assessed by the Independent Review Facility (IRF) Based on RECIST v1.1|Cohorts A, B and D: Percentage of Participants with Clinical Benefit Response as Assessed by IRF Based on RECIST v1.1|All Cohorts: PFS as Assessed by IRF Based on RECIST v1.1|All Cohorts: Percentage of Participants with Confirmed Objective Response as Assessed by IRF Based on RECIST v1.1|All Cohorts: Overall Survival (OS)|All Cohorts: Percentage of Participants with Adverse Events (AEs)|Cohorts A, B, D, E, F: Percentage of Participants with Improvement Compared with Baseline in Total Severity Symptom Score as Measured by Symptoms in Lung Cancer (SILC) Scale in Patient-Reported Lung Cancer Symptoms (Cough, Dyspnea and Chest Pain)|All Cohorts: Time to Deterioration in Patient-Reported Lung Cancer Symptoms (Cough, Dyspnea and Chest Pain) as Measured by the SILC Scale|Cohorts C, E, F: Change from Baseline in Patient-Reported Lung Cancer Symptom (Cough, Dyspnea, Chest pain) Score as Measured by the SILC Scale|All Cohorts: Change from Baseline in Health Related Quality of Life (HRQoL) Scores as Measured by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - C30 (EORTC QLQ-C30)|Cohorts A, B, D, E, F: Change from Baseline in HRQoL Scores as Measured by the SILC Scale|All Cohorts: Change from Baseline in Patient Functioning and Symptoms Score as Measured by the EORTC QLQ-C30|Cohorts A, B, D, E, F: Change from Baseline in Patient Functioning and Symptoms Score as Measured by the SILC Scale|All Cohorts: Health Status Assessed as an Index Score Using the European Quality of Life 5-Dimension 5-Level (EQ-5D-5L) Questionnaire|Cohort B: Percentage of Participants with Dose-Limiting Toxicities (DLTs)|Cohort B: Maximum Plasma Concentration (Cmax) of Alectinib|Cohort B: Area Under the Concentration-Time Curve from Time Zero to the Last Measurable Concentration (AUC0-last) of Alectinib|Cohort B: Time to Reach Cmax (Tmax) of Alectinib|Cohort B: Half-Life (t1/2) of Alectinib|Cohort B: Metabolite to Parent Exposure Ratio for AUC0-last|Cohort B: Metabolite to Parent Exposure Ratio for Cmax|Cohort C: Percentage of Participants with Objective Response as Assessed by the Investigator Based on RECIST v1.1|Cohort C: Percentage of Participants Free from Disease Progression as Assessed by the Investigator Based on RECIST v1.1 at Months 6 and 12|Cohort C: PFS as Assessed by the Investigator based on RECIST v1.1 in bTMB PP2|Cohort C: OS in bTMB PP2|Cohort D: Time to CNS progression as Assessed by the Investigator Based on RECIST v1.1|Cohort D: Time to CNS progression as Assessed by the IRF Based on RECIST v1.1|Cohorts D: Percentage of Participants who have shown improvement compared with Baseline in patient-reported cognitive function, fatigue, HRQoL, headache and vision disorder per the EORTC QLQ-C30|Cohorts D: Percentage of Participants who have shown improvement compared with Baseline in patient-reported cognitive function, fatigue, HRQoL, headache and vision disorder per the EORTC QLQ-BN20|Cohort D: Mean Plasma Concentration of Entrectinib|Cohort D: Mean Plasma Concentration of Entrectinib Metabolite M5|Cohort E: TIR as Assessed by the Investigator Based on RECIST v1.1|Cohort E: TIR as Assessed by IRF|Cohorts E, F: Serum Concentration of Atezolizumab|Cohort E, F: Change from Baseline in Anti-Drug Antibodies (ADAs)","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","700","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BO29554|2017-000076-28","September 22, 2017","April 27, 2024","April 27, 2024","June 7, 2017",,"January 12, 2022","University of California San Diego, La Jolla, California, United States|UC Davis; Comprehensive Cancer Center, Sacramento, California, United States|Rocky Mountain Cancer Center, Denver, Colorado, United States|Eastern Connecticut Hematology and Oncology Associates; (ECHO), Norwich, Connecticut, United States|SCRI Florida Cancer Specialists South, Fort Myers, Florida, United States|Florida Cancer Specialist, North Region, Saint Petersburg, Florida, United States|University Cancer & Blood Center, LLC; Research, Athens, Georgia, United States|Illinois Cancer Care, Peoria, Illinois, United States|University of Kentucky; Markey Cancer Center, Lexington, Kentucky, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Henry Ford Health System; Hematology/Oncology, Detroit, Michigan, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Cancer Inst. of New Jersey, New Brunswick, New Jersey, United States|Montefiore Medical Center, Bronx, New York, United States|Weill Cornell Medical College-New York Presbyterian Hospital, New York, New York, United States|Ohio State University, Columbus, Ohio, United States|Oregon HSU, Portland, Oregon, United States|St. Luke's University Health network, Bethlehem, Pennsylvania, United States|SCRI Tennessee Oncology Chattanooga, Chattanooga, Tennessee, United States|Tennessee Oncology PLLC - Nashville (20th Ave), Nashville, Tennessee, United States|Texas Oncology - South Austin, Austin, Texas, United States|Oncology Consultants PA, Houston, Texas, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, United States|University of Washington Seattle Cancer Care Alliance, Seattle, Washington, United States|Fundación CENIT para la Investigación en Neurociencias, Buenos Aires, Argentina|Hospital Italiano, Buenos Aires, Argentina|Hospital Britanico de Buenos Aires, Ciudad Autonoma Buenos Aires, Argentina|Centro Oncologico Riojano Integral (CORI), La Rioja, Argentina|Royal North Shore Hospital; Department of Medical Oncology, St Leonards, New South Wales, Australia|The Prince Charles Hospital; Oncology Dept., Chermside, Queensland, Australia|Ashford Cancer Center Research, Kurralta Park, South Australia, Australia|Austin Hospital; Medical Oncology, Heidelberg, Victoria, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|UZ Brussel, Brussel, Belgium|Cliniques Universitaires St-Luc, Bruxelles, Belgium|UZ Leuven Gasthuisberg, Leuven, Belgium|Instituto Nacional de Cancer - INCa; Oncologia, Rio de Janeiro, RJ, Brazil|Hospital de Caridade de Ijui; Oncologia, Ijui, RS, Brazil|Hospital Sao Lucas - PUCRS, Porto Alegre, RS, Brazil|Instituto do Cancer do Estado de Sao Paulo - ICESP, Sao Paulo, SP, Brazil|Cross Cancer Institute, Edmonton, Alberta, Canada|CancerCare Manitoba; Department of Medical Oncology, Winnipeg, Manitoba, Canada|Royal Victoria Regional Health Centre; c/o Oncology Clinical Trials, Barrie, Ontario, Canada|William Osler Health System Brampton Civic Hospital, Brampton, Ontario, Canada|London Health Sciences Centre · Victoria Hospital; Department of Medicine, London, Ontario, Canada|Lakeridge Health Center; R. S. MacLaughlin Durham Regional Cancer Center, Oshawa, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Princess Margaret Cancer Center, Toronto, Ontario, Canada|Jewish General Hospital, Montreal, Quebec, Canada|IUCPQ (Hôpital Laval), Quebec City, Quebec, Canada|Saskatoon Cancer Centre, Saskatoon, Saskatchewan, Canada|Bradford Hill Centro de Investigaciones Clinicas; Bradford Hill Centro de Investigaciones Clinicas, Recoleta, Chile|Clinica CIMCA, San Jose, Costa Rica|Institut Bergonie CLCC Bordeaux, Bordeaux, France|Centre Francois Baclesse; Radiologie, Caen, France|Centre Oscar Lambret, Lille, France|Centre Léon Bérard, Lyon, France|Hopital Caremeau; Pneumologie, Nimes, France|Hopital Bichat Claude Bernard; Oncologie Serv., Paris, France|Hôpital Européen Georges Pompidou, Paris, France|Hopital Tenon; Oncologie Radiotherapie, Paris, France|CHU Poitiers, Poitiers, France|Hopital Pontchaillou, Rennes, France|CHU de Toulouse - Hôpital Larrey; Service de pneumologie et oncologie pneumologique, Toulouse cedex 9, France|Hopital Bretonneau; Pneumologie Oncologie, Tours, France|Hopital Robert Schuman; Pneumologie, Vantoux, France|Klinikum Chemnitz gGmbH, Chemnitz, Germany|Universitätsklinikum Düsseldorf; Klinik für Kardiologie, Pneumologie und Angiologie, Düsseldorf, Germany|Universitätsklinikum Essen; Innere Klinik (Tumorforschung), Essen, Germany|Klinikum Esslingen; Klinik für Kardiologie, Angiologie und Pneumologie, Esslingen, Germany|Asklepios-Fachklinik Muenchen-Gauting; Klinik Für Pneumologie, Gauting, Germany|Robert Bosch Krankenhaus; Pneumologie und pneumologische Onkologie, Gerlingen, Germany|Thoraxklinik Heidelberg gGmbH, Heidelberg, Germany|HSK Dr.-Horst-Schmidt-Kliniken Klinik für Innere Medizin III Onkologie Hämatologie und Palliativmed, Wiesbaden, Germany|Pamela Youde Nethersole Eastern Hospital, Hong Kong, Hong Kong|Queen Mary Hospital; Medicine & Respiratory, Hong Kong, Hong Kong|Prince of Wales Hosp; Dept. Of Clinical Onc, Shatin, Hong Kong|Soroka Medical Center; Oncology Dept, Beer Sheva, Israel|Rambam Health Care Campus; Oncology, Haifa, Israel|Meir Medical Center; Oncology, Kfar-Saba, Israel|Rabin MC; Davidof Center - Oncology Institute, Petach Tikva, Israel|Chaim Sheba Medical Center; Oncology Dept, Ramat Gan, Israel|Sourasky / Ichilov Hospital; Dept. of Oncology, Tel Aviv, Israel|Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G. Pascale, Napoli, Campania, Italy|IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica, Meldola, Emilia-Romagna, Italy|Irccs Centro Di Riferimento Oncologico (CRO), Aviano, Friuli-Venezia Giulia, Italy|Azienda Ospedaliera San Camillo Forlanini, Roma, Lazio, Italy|Asst Papa Giovanni XXIII; Oncologia Medica, Bergamo, Lombardia, Italy|ASST di Cremona - Azienda Socio Sanitaria Territoriale di Cremona, Cremona, Lombardia, Italy|Irccs Istituto Europeo di Oncologia (IEO); Divisione di Oncologia, Milano, Lombardia, Italy|Asst Di Monza, Monza, Lombardia, Italy|Azienda Sanitaria Ospedaliera S Luigi Gonzaga; S.C.D.U. di Oncologia Toracica, Orbassano (TO), Piemonte, Italy|Fujita Health University Hospital, Aichi, Japan|National Cancer Center Hospital East, Chiba, Japan|Shikoku Cancer Center, Ehime, Japan|National Hospital Organization Kyushu Medical Center, Fukuoka, Japan|National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan|Kyushu University Hospital, Fukuoka, Japan|Hiroshima University Hospital, Hiroshima, Japan|Kanazawa University Hospital, Ishikawa, Japan|Kanagawa Cancer Center, Kanagawa, Japan|University Hospital Kyoto Prefectural University of Medicine, Kyoto, Japan|Kyoto University Hospital, Kyoto, Japan|Sendai Kousei Hospital, Miyagi, Japan|Tohoku University Hospital, Miyagi, Japan|Niigata University Medical & Dental Hospital, Niigata, Japan|Niigata Cancer Center Hospital, Niigata, Japan|Okayama University Hospital, Okayama, Japan|Kindai University Hospital, Osaka, Japan|Saga University Hospital, Saga, Japan|Shizuoka Cancer Center, Shizuoka, Japan|Juntendo University Hospital, Tokyo, Japan|Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, Tokyo, Japan|The Cancer Institute Hospital of JFCR, Tokyo, Japan|Kyorin University Hospital, Tokyo, Japan|Wakayama Medical University Hospital, Wakayama, Japan|National Hospital Organization Yamaguchi - Ube Medical Center, Yamaguchi, Japan|National Cancer Center, Goyang-si, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Yonsei University Health System/Severance Hospital, Seoul, Korea, Republic of|Health Pharma Professional Research, Cdmx, Mexico CITY (federal District), Mexico|Oncologico Potosino, San Luis Potosí, SAN LUIS Potosi, Mexico|AVIX Investigación Clínica S.C, Monterrey, Mexico|Hospital Angeles Tijuana, Tijuana, Mexico|UMCG, NL -groningen, Netherlands|Erasmus MC, Rotterdam, Netherlands|Auckland City Hospital, Auckland, New Zealand|Hemato Oncología de Panamá Especializada, Panama City, Panama|Hospital Nacional Edgardo Rebagliati Martins; Oncologia, Lima, Peru|Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru|Clinica Ricardo Palma, San Isidro, Peru|Uniwersyteckie Centrum Kliniczne, Klinika Onkologii i Radioterapii, Gdansk, Poland|Krakowski Szpital Specjalistyczny im.Jana Pawla II, Krakow, Poland|Samodzielny Publiczny Zespol Gruzlicy i Chorob Pluc; Oddzial V Chemioterapii Nowotworow Pluc, Olsztyn, Poland|Mazowieckie Centrum Leczenia Chorob Pluc I Gruzlicy; Oddzial Iii, Otwock, Poland|Wielkopolskie Centrum Pulmonologii i Torakochirurgii w Poznaniu, Poznan, Poland|Narod.Inst.Onkol. im. M.Sklodowskiej - Curie-Panst.Inst.Bad; Klinika Nowot.Pluca i Klatki Piers, Warszawa, Poland|Moscow City Oncology Hospital #62, Moscovskaya Oblast, Moskovskaja Oblast, Russian Federation|Principal Military Clinical Hospital n.a. N.N. Burdenko, Moscow, Moskovskaja Oblast, Russian Federation|FSBI Russian Oncology Research Center n.a. Blokhin of MOH RF, Moscow, Russian Federation|Clinical Oncology Dispensary; Chemotherapy, Omsk, Russian Federation|S-Pb clinical scientific practical center of specialized kinds of medical care (oncological), Saint-Petersburg, Russian Federation|Saint-Petersburg City Clinical Oncology Dispensary, St Petersburg, Russian Federation|Clinical Center of Serbia, Belgrade, Serbia|University Hospital Medical Center Bezanijska kosa, Belgrade, Serbia|Clinical Center Nis, NIS, Serbia|Institute for Pulmonary Diseases of Vojvodina, Sremska Kamenica, Serbia|National University Hospital; National University Cancer Institute, Singapore (NCIS), Singapore, Singapore|National Cancer Centre; Medical Oncology, Singapore, Singapore|Insititut Catala D'Oncologia, Hospitalet de Llobregat, Barcelona, Spain|Complejo Hospitalario Universitario de Santiago (CHUS) ; Servicio de Oncologia, Santiago de Compostela, LA Coruña, Spain|Hospital Universitario Puerta de Hierro; Servicio de Oncologia, Majadahonda, Madrid, Spain|Hospital Quiron de Madrid; Servicio de Oncologia, Pozuelo de Alarcon, Madrid, Spain|Clinica Universitaria de Navarra; Servicio de Oncologia, Pamplona, Navarra, Spain|Hospital General Univ. de Alicante, Alicante, Spain|Hospital Universitari Vall d'Hebron; Oncology, Barcelona, Spain|Hospital Clínic i Provincial; Servicio de Hematología y Oncología, Barcelona, Spain|ICO Badalona - Hospital Germans Trias i Pujol, Barcelona, Spain|Hospital General Universitario Gregorio Marañon; Servicio de Oncologia, Madrid, Spain|Hospital Ramon y Cajal; Servicio de Oncologia, Madrid, Spain|Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid, Spain|Centro Integral Oncologico Clara Campal; Servicio de Oncología, Madrid, Spain|Hospital Regional Universitario Carlos Haya; Servicio de Oncologia, Malaga, Spain|Hospital Universitario Virgen del Rocio; Servicio de Oncologia, Sevilla, Spain|Hospital Clínico Universitario de Valencia; Servicio de Oncología, Valencia, Spain|Kaohsiung Chang Gung Memorial Hospital; Dept of Internal Medicine, Kaohsiung, Taiwan|National Taiwan Uni Hospital; Internal Medicine, Taipei, Taiwan|Taipei Veterans General Hospital; Chest Dept , Section of Thoracic Oncology, Taipei, Taiwan|Chang Gung Medical Foundation - Linkou; Chest Dept, Taoyuan, Taiwan|Chulalongkorn Hospital; Medical Oncology, Bangkok, Thailand|Ramathibodi Hospital; Dept of Med.-Div. of Med. Onc, Bangkok, Thailand|Faculty of Med. Siriraj Hosp.; Med.-Div. of Med. Oncology, Bangkok, Thailand|Prince of Songkla University; Division of Pulmonary Disease, Department of Medicine, Hat Yai, Thailand|Baskent University Adana Dr. Turgut Noyan Practice and Research Hospital; Medical Oncology, Adana, Turkey|Akdeniz University Medical Faculty; Medical Oncology Department, Antalya, Turkey|Trakya University Medical Faculty Research And Practice Hospital Medical Oncology Department, Edirne, Turkey|Medipol University MF; Oncology Department, Istanbul, Turkey|Pendik Training and Research Hospital; Medical Oncology, Istanbul, Turkey|Medikal Park Izmir Hospital, Karşıyaka, Turkey|Hacettepe Uni Medical Faculty Hospital; Oncology Dept, Sihhiye/Ankara, Turkey",,"https://ClinicalTrials.gov/show/NCT03178552"
906,"NCT00265317","A Study In Patients With Non-Small Cell Lung Cancer Testing If Erlotinib Plus SU011248 (Sunitinib) Is Better Than Erlotinib Alone","SUN1058","Completed","Has Results","Carcinoma, Non-Small-Cell Lung","Drug: erlotinib|Drug: sunitinib|Drug: placebo","Progression-Free Survival (PFS)|Percentage of Participants With Objective Response|Time to Tumor Progression (TTP)|Duration of Response (DR)|Overall Survival (OS)|Percentage of Participants Surviving at 1 Year|Area Under the Curve From Time Zero to 24 Hours [AUC(0-24)] of Erlotinib|AUC(0-24) of Sunitinib|AUC(0-24) of SU-012662 (Metabolite of Sunitinib)|AUC(0-24) of Total Drug (Sunitinib + SU-012662)|Maximum Observed Plasma Concentration (Cmax) of Erlotinib|Cmax of Sunitinib|Cmax of SU-012662 (Metabolite of Sunitinib)|Cmax of Total Drug (Sunitinib + SU-012662)|Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC0-inf) for Erlotinib|AUC(0-inf) for Sunitinib|AUC(0-inf) for SU-012662 (Metabolite of Sunitinib)|AUC(0-inf) for Total Drug (Sunitinib + SU-012662)|Plasma Decay Half-life (t1/2) of Erlotinib|Plasma Decay Half-life (t1/2) of Sunitinib|Erlotinib Clearance at Steady State After Oral Administration (CL/F)|Sunitinib Clearance at Steady State After Oral Administration (CL/F)|Time to Reach Maximum Observed Plasma Concentration (Tmax) for Erlotinib|Tmax for Sunitinib|Tmax for SU-012662 (Metabolite of Sunitinib)|Tmax for Total Drug (Sunitinib + SU-012662)|Dose-Corrected Observed Plasma Trough Concentrations (Ctrough) for Erlotinib on Day 1 of Cycles 3-13 (Original and Amended, Arms A and B), and Day 1 of Cycles 1-18 (Randomized)|Dose-Corrected Ctrough for Erlotinib on Day 15 Cycle 1 (Original), Day 1 of Cycle 3 (Original and Amended, Arms A and B), and Day 1 of Cycles 1-18 (Randomized)|Dose-Corrected Ctrough for Sunitinib on Day 1 of Cycles 3-13 (Original and Amended, Arms A and B), and Day 1 of Cycles 1-18 (Randomized)|Dose-Corrected Ctrough for Sunitinib on Day 15 Cycle 1 (Original), Day 1 of Cycle 3 (Original and Amended, Arms A and B), and Day 1 of Cycles 1-18 (Randomized)|Dose-Corrected Ctrough for SU-012662 (Metabolite of Sunitinib) on Day 1 of Cycles 3-13 (Original and Amended, Arms A and B), and Day 1 of Cycles 1-18 (Randomized)|Dose-Corrected Ctrough for SU-012662 (Metabolite of Sunitinib) on Day 15 Cycle 1 (Original), Day 1 of Cycle 3 (Original and Amended, Arms A and B), and Day 1 of Cycles 1-18 (Randomized)|Percentage of Participants With Epidermal Growth Factor Receptor (EGFR) Expression by Immunohistochemistry (IHC) Using 0 Percent [%] Cutoff|PFS in Subgroups That Were Defined by EGFR Expression (Using 0% Cutoff)|Percentage of Participants With EGFR Expression by IHC (Using 10% Cutoff)|PFS in Subgroups That Were Defined by EGFR Expression (Using 10% Cutoff)|Percentage of Participants With EGFR Gene Copy Number Increase|PFS in Subgroups That Were Defined by EGFR Gene Copy Number Increase|Percentage of Participants With EGFR Gene Amplification|PFS in Subgroups That Were Defined by EGFR Gene Amplification|Percentage of Participants With EGFR Gene Mutation|PFS in Subgroups That Were Defined by EGFR Gene Mutation|Percentage of Participants With KRAS (V-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog) Gene Mutations|PFS in Subgroups That Were Defined by KRAS Gene Mutation|Percentage of Participants With Germline Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Polymorphisms|PFS in Subgroups That Were Defined by Germline VEGFR2 Polymorphisms|Overall Survival (OS) in Subgroups That Were Defined by Germline VEGFR2 Polymorphisms|Percentage of Participants With Germline Platelet-derived Growth Factor Receptor Beta (PDGFRB) Polymorphisms|PFS in Subgroups That Were Defined by Germline PDGFRB Polymorphisms|OS in Subgroups That Were Defined by Germline PDGFRB Polymorphisms|Percentage of Participants by Tumor VEGFR Mutation|Correlation of Polymorphisms in Stem Cell Factor Receptor (c-Kit), FMS-like Tyrosine Kinase 3 Receptor (FLT-3), and c-FMS With Blood Counts|Percentage of Participants by Ribonucleic Acid (RNA) Expression Profile|PFS in Subgroups That Were Defined by RNA Expression Profile|Health Related Quality of Life (HRQoL) and Lung Cancer Related Symptoms as Assessed With European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30) Score|EORTC-QLQ-C30 Lung Cancer Module (LC13) Score|Number of Participants With Blood Pressure (BP) Greater Than 150/100 Millimeters of Mercury (mmHg)|Number of Participants With BP Greater Than 200/110 mmHg|Number of Participants on Anti-hypertensive Medications|Plasma Concentration of VEGF-C at Baseline|Plasma Concentration of Soluble VEGFR-2 at Baseline|Plasma Concentration of Soluble VEGFR-3 at Baseline|Plasma Concentration of Soluble KIT (sKIT) at Baseline","Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 2","162","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","A6181058","June 2006","January 2010","January 2012","December 14, 2005","June 10, 2011","February 6, 2013","Pfizer Investigational Site, Birmingham, Alabama, United States|Pfizer Investigational Site, Birmingham, Alabama, United States|Pfizer Investigational Site, Mobile, Alabama, United States|Pfizer Investigational Site, Antioch, California, United States|Pfizer Investigational Site, Palm Springs, California, United States|Pfizer Investigational Site, Pleasant Hill, California, United States|Pfizer Investigational Site, San Leandro, California, United States|Pfizer Investigational Site, Chicago, Illinois, United States|Pfizer Investigational Site, Creve Coeur, Missouri, United States|Pfizer Investigational Site, St. Louis, Missouri, United States|Pfizer Investigational Site, St. Louis, Missouri, United States|Pfizer Investigational Site, St. Peters, Missouri, United States|Pfizer Investigational Site, Chapel Hill, North Carolina, United States|Pfizer Investigational Site, Clinton, North Carolina, United States|Pfizer Investigational Site, Goldsboro, North Carolina, United States|Pfizer Investigational Site, Wilson, North Carolina, United States|Pfizer Investigational Site, Cleveland, Ohio, United States|Pfizer Investigational Site, Houston, Texas, United States|Pfizer Investigational Site, Edmonton, Alberta, Canada|Pfizer Investigational Site, Hamilton, Ontario, Canada|Pfizer Investigational Site, Budapest, Hungary|Pfizer Investigational Site, Torokbalint, Hungary|Pfizer Investigational Site, Genova, Italy|Pfizer Investigational Site, Monteforte Irpino, AV, Italy|Pfizer Investigational Site, Amsterdam, Netherlands|Pfizer Investigational Site, Groningen, Netherlands|Pfizer Investigational Site, Bydgoszcz, Poland|Pfizer Investigational Site, Gdansk, Poland|Pfizer Investigational Site, Cluj-Napoca, Cluj, Romania|Pfizer Investigational Site, Bucuresti, Sector 2, Romania|Pfizer Investigational Site, Bucuresti, Romania|Pfizer Investigational Site, Santander, Cantabria, Spain",,"https://ClinicalTrials.gov/show/NCT00265317"
907,"NCT03707418","Bivalirudin vs Heparin in ECMO Patients",,"Withdrawn","No Results Available","Extracorporeal Membrane Oxygenation Complication","Drug: Heparin Sodium|Drug: Bivalirudin Injection [Angiomax]","Number of heparin-induced thrombocytopenia (HIT) events|Number of Cross-overs between arms|Number of circuit failures requiring a circuit exchange|Thrombotic events|Bleeding events|Renal failure|Number of Transfusions|Number of emergent decannulations|Number of patients surviving to discharge","Johns Hopkins University","All","18 Years and older   (Adult, Older Adult)","Phase 1","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00176475","April 2021","June 2021","June 2021","October 16, 2018",,"January 19, 2021","Johns Hopkins University, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03707418"
908,"NCT00372775","Study Tests The Safety And Effectiveness Of SU011248 In Patients With Non-Small Cell Lung Cancer Having Brain Metastases",,"Completed","Has Results","Non-Small Cell Lung Cancer","Drug: Sunitinib","Progression-Free Survival (PFS)|Time to Tumor Progression (TTP)|Time to Neurological Progression (TNP)|Number of Participants With Objective Disease Response|Time to Objective Intracranial Progression|Number of Participants With Intracranial Objective Disease Response|Duration of Response (DR)|Overall Survival (OS)|Percentage of Participants Surviving at 1 Year|Number of Deaths Due to Intracranial Versus Systemic Progression|Change From Baseline in Functional Assessment of Cancer Therapy/National Comprehensive Cancer Network (FACT/NCCN) Lung Symptom Index (FLSI) Score|Change From Baseline in FACT/NCCN Brain Symptom Index (FBrSI) Score|Trough Plasma Concentrations (Ctrough) of Sunitinib|Ctrough of Sunitinib Metabolite (SU012662)|Correlation of Polymorphisms in c-Kit, Flt-3 and c-Fms With Blood Counts|Percentage of Participants by Ribonucleic Acid (RNA) Expression Profile|PFS in Subgroups Defined by RNA Expression Profiles of Tumors","Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 2","66","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","A6181092","March 2007","December 2009","December 2009","September 7, 2006","February 24, 2011","February 24, 2011","Pfizer Investigational Site, Norwalk, Connecticut, United States|Pfizer Investigational Site, Cocoa Beach, Florida, United States|Pfizer Investigational Site, Merritt Island, Florida, United States|Pfizer Investigational Site, Titusville, Florida, United States|Pfizer Investigational Site, Creve Coeur, Missouri, United States|Pfizer Investigational Site, St. Louis, Missouri, United States|Pfizer Investigational Site, St. Louis, Missouri, United States|Pfizer Investigational Site, St. Peters, Missouri, United States|Pfizer Investigational Site, Basking Ridge, New Jersey, United States|Pfizer Investigational Site, Commack, New York, United States|Pfizer Investigational Site, New York, New York, United States|Pfizer Investigational Site, Sayre, Pennsylvania, United States|Pfizer Investigational Site, Austin, Texas, United States|Pfizer Investigational Site, Austin, Texas, United States|Pfizer Investigational Site, Austin, Texas, United States|Pfizer Investigational Site, Austin, Texas, United States|Pfizer Investigational Site, Round Rock, Texas, United States|Pfizer Investigational Site, Pessac, Be1 04495, France|Pfizer Investigational Site, Marseille Cedex 09, France|Pfizer Investigational Site, Saint-Priest en Jarez Cedex, France|Pfizer Investigational Site, Toulouse cedex 9, France|Pfizer Investigational Site, Bologna, Italy|Pfizer Investigational Site, Genova, Italy|Pfizer Investigational Site, Orbassano (TO), Italy|Pfizer Investigational Site, Roma, Italy|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT00372775"
909,"NCT04111497","Glasdegib for Chronic Graft-Versus-Host Disease",,"Recruiting","No Results Available","Chronic Graft Versus Host Disease|Fasciitis","Drug: Glasdegib","Incidence of adverse events|Overall response rate (ORR) in sclerotic manifestations|ORR in all chronic graft versus host disease (cGVHD) manifestations|Failure-free survival|Symptom Burden Assessment|Quality of Life Assessment|Biologic impact of hedgehog pathway inhibition","Fred Hutchinson Cancer Research Center|Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","20","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RG1005365|NCI-2019-03244|8771","December 3, 2019","June 30, 2024","June 30, 2024","October 1, 2019",,"September 5, 2021","Duke University Medical Center, Durham, North Carolina, United States|Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States|Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT04111497"
910,"NCT05058352","A Study of HS269 in Patients With Advanced Solid Tumors",,"Not yet recruiting","No Results Available","Advanced Solid Tumor","Drug: HS269","Dose limiting toxicities (DLT)|Adverse Event(s) and Serious Adverse Event(s)|Peak Plasma Concentration (Cmax)|Area Under the Plasma Concentration versus Time Curve (AUC)|Calcitonin in Peripheral Blood|Thyroglobulin in Peripheral Blood|ORR|DCR|PFS|Peripheral blood ctDNA","Zhejiang Hisun Pharmaceutical Co. Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 1","36","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HS269-Ⅰ-01","October 2021","October 2022","April 2023","September 27, 2021",,"September 27, 2021","Shanghai Pulmonary Hospital, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT05058352"
911,"NCT03508141","Fibrinogen Early In Severe Trauma studY Junior","FEISTY Jnr","Recruiting","No Results Available","Trauma|Hemorrhage|Coagulopathy|Pediatrics","Drug: Fibrinogen Concentrate|Drug: Cryoprecipitate","Time to administration of fibrinogen replacement from time of identification of hypofibrinogenaemia requiring fibrinogen replacement|Transfusion Requirements|Duration of bleeding episode or time until surgical control|Intensive Care Unit LOS|Hospital LOS|Adverse Events|All Cause Mortality|Functional Outcomes GOS-E Paediatrics","Gold Coast Hospital and Health Service|Emergency Medicine Foundation|National Blood Authority|Australian Red Cross","All","3 Months to 18 Years   (Child, Adult)","Phase 2","44","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","FEISTY Jnr 1","July 1, 2018","June 30, 2021","June 30, 2021","April 25, 2018",,"June 29, 2020","Westmead Childrens Hospital, Sydney, New South Wales, Australia|Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia|Lady Cilento Children's Hospital, Brisbane, Queensland, Australia|Princess Alexandra Hospital, Brisbane, Queensland, Australia|Cairns Hospital, Cairns, Queensland, Australia|Gold Coast University Hospital, Gold Coast, Queensland, Australia|Mackay Base Hospital, Mackay, Queensland, Australia|Rockhampton Hospital, Rockhampton, Queensland, Australia|Townsville Hospital, Townsville, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia",,"https://ClinicalTrials.gov/show/NCT03508141"
912,"NCT02622321","A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors","HAVEN 1","Completed","Has Results","Hemophilia A","Drug: Emicizumab|Drug: rFVIIa|Drug: aPCC","Model-Based Annualized Bleed Rate (ABR) for Treated Bleeds, Arm A: Emicizumab Versus Arm B: No Prophylaxis|Model-Based Annualized Bleed Rate (ABR) for All Bleeds, Arm A: Emicizumab Versus Arm B: No Prophylaxis|Intra-Participant Comparison of the Model-Based Annualized Bleed Rate (ABR) for All Bleeds in Arm A: Emicizumab Versus Previous Episodic Bypassing Agents|Intra-Participant Comparison of the Model-Based Annualized Bleed Rate (ABR) for Treated Bleeds in Arm A: Emicizumab Versus Previous Episodic Bypassing Agents|Model-Based Annualized Bleed Rate (ABR) for Treated Joint Bleeds, Arm A: Emicizumab Versus Arm B: No Prophylaxis|Intra-Participant Comparison of the Model-Based Annualized Bleed Rate (ABR) for All Bleeds in Arm C: Emicizumab Versus Previous Prophylactic Bypassing Agents|Intra-Participant Comparison of the Model-Based Annualized Bleed Rate (ABR) for Treated Bleeds in Arm C: Emicizumab Versus Previous Prophylactic Bypassing Agents|Model-Based Annualized Bleed Rate (ABR) for Treated Spontaneous Bleeds, Arm A: Emicizumab Versus Arm B: No Prophylaxis|Model-Based Annualized Bleed Rate (ABR) for Treated Target Joint Bleeds, Arm A: Emicizumab Versus Arm B: No Prophylaxis|Mean Calculated Annualized Bleed Rates (ABR) for Treated Bleeds, All Bleeds, Treated Spontaneous Bleeds, Treated Joint Bleeds, and Treated Target Joint Bleeds, Arm A: Emicizumab Versus Arm B: No Prophylaxis|Median Calculated Annualized Bleed Rates (ABR) for Treated Bleeds, All Bleeds, Treated Spontaneous Bleeds, Treated Joint Bleeds, and Treated Target Joint Bleeds, Arm A: Emicizumab Versus Arm B: No Prophylaxis|Percentage of Participants With 0 Bleeds for Treated Bleeds, All Bleeds, Treated Spontaneous Bleeds, Treated Joint Bleeds, and Treated Target Joint Bleeds, Arm A: Emicizumab Versus Arm B: No Prophylaxis|Hemophilia-Specific Quality of Life (Haem-A-QoL) Questionnaire Physical Health Score at Week 25 in Adult Participants (>/=18 Years Old), Arm A: Emicizumab Versus Arm B: No Prophylaxis|Haem-A-QoL Questionnaire Total Score at Week 25 in Adult Participants (>/=18 Years Old), Arm A: Emicizumab Versus Arm B: No Prophylaxis|European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Visual Analog Scale Score at Week 25, Arm A: Emicizumab Versus Arm B: No Prophylaxis|EQ-5D-5L Index Utility Score at Week 25, Arm A: Emicizumab Versus Arm B: No Prophylaxis|Hemophilia-Specific Quality of Life - Short Form (Haemo-Qol-SF) Questionnaire Total Score at Baseline and Week 25 in Adolescent Participants (12-17 Years Old)|Long-Term Efficacy of Emicizumab: Model-Based Annualized Bleed Rates (ABR) for Treated Bleeds, All Bleeds, Treated Spontaneous Bleeds, Treated Joint Bleeds, and Treated Target Joint Bleeds, All Enrolled Participants|Long-Term Efficacy of Emicizumab: Mean Calculated Annualized Bleed Rates (ABR) for Treated Bleeds, All Bleeds, Treated Spontaneous Bleeds, Treated Joint Bleeds, and Treated Target Joint Bleeds, All Enrolled Participants|Long-Term Efficacy of Emicizumab: Median Calculated Annualized Bleed Rates (ABR) for Treated Bleeds, All Bleeds, Treated Spontaneous Bleeds, Treated Joint Bleeds, and Treated Target Joint Bleeds, All Enrolled Participants|Long-Term Efficacy of Emicizumab: Mean Calculated Annualized Bleed Rates (ABR) for Treated Bleeds Per 12-Week Intervals Over Time, All Enrolled Participants|Long-Term Efficacy of Emicizumab: Median Calculated Annualized Bleed Rates (ABR) for Treated Bleeds Per 12-Week Intervals Over Time, All Enrolled Participants|Long-Term Efficacy of Emicizumab: Mean Calculated Annualized Bleed Rates (ABR) for All Bleeds Per 12-Week Intervals Over Time, All Enrolled Participants|Long-Term Efficacy of Emicizumab: Median Calculated Annualized Bleed Rates (ABR) for All Bleeds Per 12-Week Intervals Over Time, All Enrolled Participants|Long-Term Efficacy of Emicizumab: Mean Calculated Annualized Bleed Rates (ABR) for Treated Spontaneous Bleeds Per 12-Week Intervals Over Time, All Enrolled Participants|Long-Term Efficacy of Emicizumab: Median Calculated Annualized Bleed Rates (ABR) for Treated Spontaneous Bleeds Per 12-Week Intervals Over Time, All Enrolled Participants|Safety Summary of the Overall Number and Percentage of Participants With at Least One Adverse Event, Severity Assessed According to the WHO Toxicity Grading Scale|Number of Participants Testing Negative or Positive for the Presence of Anti-Drug Antibodies (ADAs), Including Neutralizing ADAs, During the Study|Plasma Trough Concentrations of Emicizumab at Specified Timepoints","Hoffmann-La Roche|Chugai Pharmaceutical","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","113","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BH29884|2015-002866-21","November 18, 2015","October 25, 2016","December 1, 2020","December 4, 2015","November 24, 2017","June 24, 2021","Children's Hospital Los Angeles, Los Angeles, California, United States|Santa Monica Oncology Center, Santa Monica, California, United States|University of Colorado Denver, Children's Hospital, Aurora, Colorado, United States|Winship Cancer Institute, Atlanta, Georgia, United States|Boston Childrens Hospital, Boston, Massachusetts, United States|Children's Hospital of Michigan; Pediatrics, Detroit, Michigan, United States|Cornell Univ Medical College; Hematology-Oncolog, New York, New York, United States|Oregon Health & Science Uni ; Dept of Pediatrics, Portland, Oregon, United States|Pennsylvania State Hershey Medical Center; Division of Hematology/Oncology, H046, Hershey, Pennsylvania, United States|Univ of TX Health Science Ctr; Gulf States Hemo and Throm Ctr, Houston, Texas, United States|Bloodworks Northwest (formerly Puget Sound Blood Center); Hemophilia, Seattle, Washington, United States|Royal Prince Alfred Hospital; Haematology, Camperdown, New South Wales, Australia|The Alfred Hospital, Melbourne; Thrombosis and Haemostasis Unit, Melbourne, Victoria, Australia|ICIC, San Jose, Costa Rica|Hopital Cardio-vasculaire Louis Pradel; Hemostase clinique, Bron, France|CH de Bicetre; Centre de Traitement d' Hemophilie, Le Kremlin Bicetre, France|Hopital Cardiologique; Hematologie B, Lille, France|Groupe Hospitalier Necker Enfants Malades, Paris, France|Universitätsklinikum Bonn; Institut für Experimentelle Hämatologie und Transfusionsmedizin, Bonn, Germany|CTC North GmbH & Co. KG am Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany|Hämophilie-Zentrum Rhein Main GmbH, Mörfelden-Walldorf, Germany|IRCCS Ca' Granda Ospedale Maggiore Policlinico; Centro Emofilia e Trombosi ""Angelo Bianchi e Bonomi"", Milano, Lombardia, Italy|AOU Careggi; SOD Malattie Emorragiche, Firenze, Toscana, Italy|Nagoya University Hospital, Aichi, Japan|Hiroshima University Hospital, Hiroshima, Japan|Hyogo College of Medicine Hospital, Hyogo, Japan|St. Marianna University School of Medicine Hospital, Kanagawa, Japan|Hospital of the University of Occupational and Environmental Health,Japan, Kitakyushu-shi, Japan|Nara Medical University Hospital, Nara, Japan|Tokyo Medical University Hospital, Tokyo, Japan|Severance Hospital, Seoul, Korea, Republic of|Auckland City Hospital; Auckland Haemophilia Centre, Auckland, New Zealand|Uniwersyteckie Centrum Kliniczne; Klinika Hematologii i Transplantologii, Gdansk, Poland|SPSK Nr1 Klinika Hematoo&Transpl.Szpiku, Lublin, Poland|ALVAMED Lekarskie Gabinety Specjalistyczne, Poznań, Poland|Instytut Hematologii i Transfuzjologii; Klinika Zaburzeń Hemostazy i Chorób Wewnętrznych, Warsaw, Poland|Charlotte Maxeke Johannesburg Hospital; Haemophilia Comprehensive Care Center, Johannesburg, South Africa|Hospital Universitario la Paz; Servicio de Hematologia, Madrid, Spain|Hospital Universitario Virgen del Rocio; Servicio de Hematologia, Sevilla, Spain|Hospital Universitario la Fe; Servicio de Hematologia, Valencia, Spain|National Taiwan Uni Hospital, Taipei City, Taiwan|Cardiff and Vale NHS Trust, Cardiff, United Kingdom|St Thomas' Hospital; Haemostasis & Thromboisis Centre, London, United Kingdom|Oxford University Hospitals NHS Trust - Churchill Hospital, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02622321"
913,"NCT01826123","Point-of-Care Testing in Coagulopathic Patients Undergoing Cardiac Surgery - a Multicenter Study","MultiPOC","Unknown status","No Results Available","Coagulopathy During Cardiac Surgery","Device: Conventional laboratory testing (Central laboratory)|Device: POC testing","packed red blood cell concentrate (PRBC) transfusion rate|Transfusion rate of Fresh Frozen Plasma|Postoperative Blood loss|Duration of mechanical ventilation|Horovitz - indices|Incidence of acute renal failure|Duration of hospitalisation|rethoracotomies|Thromboembolic or allergic adverse events|Ventilator - associated pneumonia|Postoperative Sepsis|Transfusion rate of platelet concentrates|Age of each platelet concentrate|Amount of infused PCC|Amount of infused rVIIa|Amount of infused fibrinogen concentrate","Goethe University","All","18 Years to 99 Years   (Adult, Older Adult)","Not Applicable","160","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","343/12","July 2013","May 2019","May 2019","April 8, 2013",,"May 4, 2017","University of Linz, Linz, Oberösterreich, Austria|University of Heidelberg, Heidelberg, Baden Württemberg, Germany|Goethe - University, Frankfurt, Hessen, Germany|University of Rostock, Rostock, Mecklenburg Vorpommern, Germany",,"https://ClinicalTrials.gov/show/NCT01826123"
914,"NCT04159064","Impact of Cardiac Surgery With a Minimal Invasive Extracorporeal Circuit οn Coagulation: Data From Point of Care Devices",,"Completed","No Results Available","Extracorporeal Circulation; Complications|Coagulation Disorder|Extracorporeal Circulation of Blood; Thrombocytopenia","Diagnostic Test: Thromboelastometry, Impedance Aggregometry","Change of Clotting Time|Change of Maximum Clot Firmness|Change of Clot Formation Time|Change of ADPtest of Impedance Aggregometry|Change of TRAPtest of Impedance Aggregometry|Bleeding in the drainage at 12 hours postoperatively|Bleeding in the drainage at 24 hours postoperatively|Transfusion requirements|Mortality|Morbidity","AHEPA University Hospital","All","18 Years to 79 Years   (Adult, Older Adult)",,"57","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","49886/8.11.2018","December 1, 2018","April 30, 2019","April 30, 2019","November 12, 2019",,"November 13, 2019","AHEPA University Hospital, Thessaloniki, Greece",,"https://ClinicalTrials.gov/show/NCT04159064"
915,"NCT03504033","Xenon-anesthesia on Patients Undergoing Major Liver-resection","XeLiv","Withdrawn","No Results Available","Liver Function After Partial Liver Resection","Drug: Xenon|Drug: Desflurane","Time-course of postoperative liver injury and function|Intra- and postoperative blood loss|Quantity of intra- and postoperative infusions|Quantity of intra- and postoperative blood products|Quantity of intra- and postoperative coagulation products|Necessity and duration of surgical pringle maneuver|Necessity and duration of surgical total vascular occlusion|Surgery time|Fibrosis in the resected liver tissue|Number of hepatocytes in synthesis phase in the resected liver tissue|Number of macrophages in the resected liver tissue|Expression of Interleukin 6 (IL-6) in the resected liver tissue|Expression of tumor necrosis factor (TNF) in the resected liver tissue|Expression of hepatocyte growth factor (HGF) in the resected liver tissue|Expression of epidermal growth factor (EGF) in the resected liver tissue|Expression of fibroblast growth factor (FGF) in the resected liver tissue|Expression of insulin-like growth factors I/II (IGF-I/II) in the resected liver tissue|Weight of the resected liver tissue|Computer tomography-assisted planimetry of the resected liver tissue|Time-course of hemoglobin (Hb)|Time-course of platelet count|Time-course of prothrombin time (PT)|Time-course of partial thromboplastin time (PTT)|Time-course of bilirubin|Time-course of aspartate aminotransferase (ASAT)|Time-course of creatinine|Time-course of lactate|Time-course of albumin|Time-course of international normalized ratio (INR)|Postoperative peak of blood lactate|Length of ICU stay|Length of hospital stay|Postoperative mortality|Adverse events|Difference in mortality, assessed by 30 days follow up via phone|Difference in coagulation disorder, assessed by 30 days follow up via phone|Difference in re-admission to hospital, assessed by 30 days follow up via phone|Difference in other adverse events, assessed by 30 days follow up via phone","RWTH Aachen University","All","18 Years and older   (Adult, Older Adult)","Phase 4","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","15-163","April 11, 2018","September 27, 2019","September 27, 2019","April 20, 2018",,"October 29, 2019","University Hospital RWTH Aachen University, Department of Anesthesiology, Aachen, Germany",,"https://ClinicalTrials.gov/show/NCT03504033"
916,"NCT05049044","Observational Prospective Study of Quality of Life in Unresectable TNM Stage III NSCLC (OBSTINATE)","OBSTINATE","Recruiting","No Results Available","Non-Small Cell Lung Cancer","Other: Quality of Life Questionnaire-Core 30 (QLQ-C30)","QLQ-C30 (defined as the outcomes of a clinical intervention obtained by the patient)|QLQ-LC13 (defined as the outcomes of a clinical intervention obtained by the patient)|EQ5D-5L (defined as the outcomes of a clinical intervention obtained by the patient)|Baseline demographics|Tumor characteristics as defined by TNM stage|Tumor characteristics as defined by PD-L1 expression status|Tumor characteristics as defined by mutational status of driver genes|Time from diagnosis to treatment|Modality of follow-up|Median PFS|Median time to progression|Median OS (e.g. median PFS, median OS)|Treatment characteristics|Best response of treatment|Duration of response of treatment|Toxicity of treatment|Effective treatment compared to initial Multidisciplinary Tumor Board (MDTB) decision|Type of progression (local, loco-regional, metastatic)|Description of second line of treatment after disease progression|Change in patients' socio-economic and occupational outcomes using unique self questionnaire|Evaluate the cost-utility of the therapeutic strategy using Quality-Adjusted Life Years (QALYs)","Groupe Francais De Pneumo-Cancerologie|AstraZeneca","All","18 Years and older   (Adult, Older Adult)",,"150","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","GFPC 06-2019","December 18, 2020","June 30, 2027","June 30, 2027","September 17, 2021",,"September 17, 2021","Centre Hospitalier d'Aix en Provence, Aix En Provence, France|CHU Amiens-Picardie, Amiens, France|Centre Hospitalier Universitaire, Angers, France|Centre Hospitalier d'Annecy, Annecy, France|Hôpital Privé d'Antony, Antony, France|Centre Hospitalier du Morvan, Brest, France|Hôpital Paul d'Egine, Champigny-sur-Marne, France|Centre Hospitalier de Chauny, Chauny, France|Centre Hospitalier du Cotentin, Cherbourg, France|Centre Hospitalier Intercommunal de Créteil, Creteil, France|Centre Hospitalier d'Elbeuf - Pneumologie, Elbeuf, France|Centre Hospitalier Universitaire DUPUYTREN, Limoges, France|Hôpital du Scorff, Lorient, France|Hôpital Européen, Marseille, France|Hôpital Nord, Marseille, France|Hôpital de Meaux, Meaux, France|Centre Hospitalier Régional, Orléans, France|Centre Catalan d'Oncologie, Perpignan, France|Centre Hospitalier Intercommunal de Quimper, Quimper, France|CHU Ponchaillou, Rennes, France|Hôpital Charles Nicolle, Rouen, France|CHU La Réunion Site Nord, Saint-Denis, France|CHU La Réunion Site Sud, Saint-Pierre, France|Institut Lucien Neuwirth, Saint-Priest-en-Jarez, France|CHU Hôpital Nord, Saint-Étienne, France|CH de Bigorre Tarbes, Tarbes, France|Hôpital d'Instruction des Armées Ste Anne, Toulon, France|Centre Hospitalier de Villefranche sur Saone, Villefranche Sur Saone, France",,"https://ClinicalTrials.gov/show/NCT05049044"
917,"NCT04808050","Real-world Treatment Patterns and Associated Outcomes in Patients With Resectable Early-stage Non-small Cell Lung Cancer","THASSOS-INTL","Recruiting","No Results Available","Non-small Cell Lung Cancer",,"Proportion of patients per treatment modalities|Duration of treatment|Survival rate|Demographic characteristics|Eastern Cooperative Oncology performance status Group characteristics|Histological type|Clinical-pathological Tumor stage|TNM staging at index diagnosis|Genetic alterations|Survival rates at pre-defined landmark timepoints (other than 3-year)|Prevalence of EGFR mutations|Prevalence of PD-L1 expression","AstraZeneca","All","18 Years and older   (Adult, Older Adult)",,"400","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","D133FR00169","November 3, 2021","May 31, 2022","May 31, 2022","March 19, 2021",,"January 24, 2022","Research Site, Alexandria, Egypt|Research Site, Cairo, Egypt|Research Site, Giza, Egypt|Research Site, Hong Kong, Hong Kong",,"https://ClinicalTrials.gov/show/NCT04808050"
918,"NCT04586101","iT-based Sports Therapy Application in Haemophilia","iT-BaSTAH","Recruiting","No Results Available","Haemophilia|Sports Physical Therapy","Device: Trainings application","frequency of physical activity|duration of physical activity|score of subjective physical performance measured by the HEP-Test-Q|score of subjective quality of life measured by the SF36 Health Survey|pain intensity in score points measured by the German Pain Questionnaire|health-related physical activity presented as metabolic equivalents of tasks","Prof. Dr. Dr. Thomas Hilberg|Pfizer|University of Wuppertal","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","25","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","35318939","January 31, 2018","December 2021","December 2021","October 14, 2020",,"May 11, 2021","Department of Sports Medicine, University of Wuppertal, Wuppertal, North Rhine-Westphalia, Germany",,"https://ClinicalTrials.gov/show/NCT04586101"
919,"NCT03344003","Immune Tolerance Induction in Haemophilia A Patients Using Wilate or Nuwiq","PREVAIL","Terminated","No Results Available","Hemophilia A","Drug: Wilate or Nuwiq","Efficacy of Wilate or Nuwiq in achieving complete or partial immune tolerance induction (ITI) success in moderate and severe haemophilia A patients with inhibitors|Time necessary to achieve complete or partial ITI success|In case of complete or partial ITI success, duration of immune tolerance|Bleeding frequency while on Wilate or Nuwiq ITI treatment|Association of inhibitor titres with the probability of ITI success|Use of bypassing agents before and during ITI treatment with Wilate or Nuwiq|Use of emicizumab (Hemlibra) during ITI treatment with Wilate or Nuwiq|Relapse rate following complete or partial successful ITI using Wilate or Nuwiq|Time to relapse following complete or partial successful ITI using Wilate or Nuwiq|Adherence with the ITI regimen|Safety: adverse drug reactions (ADRs)|Safety: infection-related adverse events (AEs)","Octapharma","Male","Child, Adult, Older Adult",,"80","Industry","Observational","Observational Model: Cohort|Time Perspective: Other","WIL-26","June 28, 2018","November 20, 2020","November 20, 2020","November 17, 2017",,"February 23, 2021","Stollery children's hospital, University of Alberta, Edmonton, Alberta, Canada|Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada|Hamilton Health Science center, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03344003"
920,"NCT01678898","Dose-ranging Study of PRX-102 in Adult Fabry Disease Patients",,"Completed","Has Results","Fabry Disease","Drug: PRX-102","Adverse Events","Protalix","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","18","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PB-102-F01 & PB-102-F02","October 2012","March 6, 2016","March 6, 2016","September 5, 2012","January 27, 2020","January 27, 2020","UC Davis Medical Center, MIND Institute Department of Pediatrics, Section of Genetics, Sacramento, California, United States|Department of Human Genetics, Emory University School of Medicine, Atlanta, Georgia, United States|University of Iowa Health Clinics, Iowa City, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Johns Hopkins University School of Medicine, Baltimore, Maryland, United States|Duke University Medical Center, Durham, North Carolina, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|Research Baylor Institute of Metabolic Disease, Dallas, Texas, United States|O & O Alpan LLC, Fairfax, Virginia, United States|Royal Melbourne Hospital, Victoria Park, Australia|Hematology and Clinical Research Private Institute, Asuncion, Paraguay|Clinical Center of Serbia, Belgrade, Serbia|Hospital de Dia Quiron Zaragoza, Zaragoza, Spain|The Royal Free Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01678898"
921,"NCT04762550","Thrombin Generation in Liver Transplant Surgery",,"Recruiting","No Results Available","Liver Transplantation|Thrombin|Hemostasis, Surgical|Blood Coagulation Disorder Due to Liver Disease|Blood Coagulation Disorders",,"Thrombin Generation - Endogenous Thrombin Potential (nM*min)|Thrombin Generation - Lag Time (Seconds)|Thrombin Generation - Time to Peak (Seconds)|Thrombin Generation - Peak Height (nM)|Conventional Hemostatic Tests - Platelet Count|Conventional Hemostatic Tests - INR|Conventional Hemostatic Tests - aPTT|Conventional Hemostatic Tests - Fibrinogen Level|Viscoelastic Testing","University Health Network, Toronto","All","18 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20-5414.0","March 8, 2021","January 1, 2022","January 1, 2022","February 21, 2021",,"May 3, 2021","Toronto General Hospital - University Health Network, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04762550"
922,"NCT03991481","The Cryopreserved vs. Liquid Platelets Trial","CLIP II","Recruiting","No Results Available","Surgical Blood Loss|Hemorrhage","Biological: Cryopreserved platelets|Biological: Liquid-stored platelets","Volume of post-surgical bleeding in the first 24 hours|Total volume of post-surgical chest drain bleeding|Composite bleeding outcome using the BARC4 criteria|Number of units of Packed red blood cells transfused|Total number of units of Packed red blood cells transfused|Occurrence of any one of the following pre-specified potential complications","Australian and New Zealand Intensive Care Research Centre|Australian Red Cross","All","Child, Adult, Older Adult","Phase 3","808","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ANZIC-RC/MR002","August 17, 2021","June 2023","December 2023","June 19, 2019",,"August 31, 2021","Royal Prince Alfred Hospital, Sydney, New South Wales, Australia|The Prince Charles Hospital, Brisbane, Queensland, Australia",,"https://ClinicalTrials.gov/show/NCT03991481"
